<html>
    <head>
        <meta charset="utf-8">
        
            <script>function neighbourhoodHighlight(params) {
  // console.log("in nieghbourhoodhighlight");
  allNodes = nodes.get({ returnType: "Object" });
  // originalNodes = JSON.parse(JSON.stringify(allNodes));
  // if something is selected:
  if (params.nodes.length > 0) {
    highlightActive = true;
    var i, j;
    var selectedNode = params.nodes[0];
    var degrees = 2;

    // mark all nodes as hard to read.
    for (let nodeId in allNodes) {
      // nodeColors[nodeId] = allNodes[nodeId].color;
      allNodes[nodeId].color = "rgba(200,200,200,0.5)";
      if (allNodes[nodeId].hiddenLabel === undefined) {
        allNodes[nodeId].hiddenLabel = allNodes[nodeId].label;
        allNodes[nodeId].label = undefined;
      }
    }
    var connectedNodes = network.getConnectedNodes(selectedNode);
    var allConnectedNodes = [];

    // get the second degree nodes
    for (i = 1; i < degrees; i++) {
      for (j = 0; j < connectedNodes.length; j++) {
        allConnectedNodes = allConnectedNodes.concat(
          network.getConnectedNodes(connectedNodes[j])
        );
      }
    }

    // all second degree nodes get a different color and their label back
    for (i = 0; i < allConnectedNodes.length; i++) {
      // allNodes[allConnectedNodes[i]].color = "pink";
      allNodes[allConnectedNodes[i]].color = "rgba(150,150,150,0.75)";
      if (allNodes[allConnectedNodes[i]].hiddenLabel !== undefined) {
        allNodes[allConnectedNodes[i]].label =
          allNodes[allConnectedNodes[i]].hiddenLabel;
        allNodes[allConnectedNodes[i]].hiddenLabel = undefined;
      }
    }

    // all first degree nodes get their own color and their label back
    for (i = 0; i < connectedNodes.length; i++) {
      // allNodes[connectedNodes[i]].color = undefined;
      allNodes[connectedNodes[i]].color = nodeColors[connectedNodes[i]];
      if (allNodes[connectedNodes[i]].hiddenLabel !== undefined) {
        allNodes[connectedNodes[i]].label =
          allNodes[connectedNodes[i]].hiddenLabel;
        allNodes[connectedNodes[i]].hiddenLabel = undefined;
      }
    }

    // the main node gets its own color and its label back.
    // allNodes[selectedNode].color = undefined;
    allNodes[selectedNode].color = nodeColors[selectedNode];
    if (allNodes[selectedNode].hiddenLabel !== undefined) {
      allNodes[selectedNode].label = allNodes[selectedNode].hiddenLabel;
      allNodes[selectedNode].hiddenLabel = undefined;
    }
  } else if (highlightActive === true) {
    // console.log("highlightActive was true");
    // reset all nodes
    for (let nodeId in allNodes) {
      // allNodes[nodeId].color = "purple";
      allNodes[nodeId].color = nodeColors[nodeId];
      // delete allNodes[nodeId].color;
      if (allNodes[nodeId].hiddenLabel !== undefined) {
        allNodes[nodeId].label = allNodes[nodeId].hiddenLabel;
        allNodes[nodeId].hiddenLabel = undefined;
      }
    }
    highlightActive = false;
  }

  // transform the object into an array
  var updateArray = [];
  if (params.nodes.length > 0) {
    for (let nodeId in allNodes) {
      if (allNodes.hasOwnProperty(nodeId)) {
        // console.log(allNodes[nodeId]);
        updateArray.push(allNodes[nodeId]);
      }
    }
    nodes.update(updateArray);
  } else {
    // console.log("Nothing was selected");
    for (let nodeId in allNodes) {
      if (allNodes.hasOwnProperty(nodeId)) {
        // console.log(allNodes[nodeId]);
        // allNodes[nodeId].color = {};
        updateArray.push(allNodes[nodeId]);
      }
    }
    nodes.update(updateArray);
  }
}

function filterHighlight(params) {
  allNodes = nodes.get({ returnType: "Object" });
  // if something is selected:
  if (params.nodes.length > 0) {
    filterActive = true;
    let selectedNodes = params.nodes;

    // hiding all nodes and saving the label
    for (let nodeId in allNodes) {
      allNodes[nodeId].hidden = true;
      if (allNodes[nodeId].savedLabel === undefined) {
        allNodes[nodeId].savedLabel = allNodes[nodeId].label;
        allNodes[nodeId].label = undefined;
      }
    }

    for (let i=0; i < selectedNodes.length; i++) {
      allNodes[selectedNodes[i]].hidden = false;
      if (allNodes[selectedNodes[i]].savedLabel !== undefined) {
        allNodes[selectedNodes[i]].label = allNodes[selectedNodes[i]].savedLabel;
        allNodes[selectedNodes[i]].savedLabel = undefined;
      }
    }

  } else if (filterActive === true) {
    // reset all nodes
    for (let nodeId in allNodes) {
      allNodes[nodeId].hidden = false;
      if (allNodes[nodeId].savedLabel !== undefined) {
        allNodes[nodeId].label = allNodes[nodeId].savedLabel;
        allNodes[nodeId].savedLabel = undefined;
      }
    }
    filterActive = false;
  }

  // transform the object into an array
  var updateArray = [];
  if (params.nodes.length > 0) {
    for (let nodeId in allNodes) {
      if (allNodes.hasOwnProperty(nodeId)) {
        updateArray.push(allNodes[nodeId]);
      }
    }
    nodes.update(updateArray);
  } else {
    for (let nodeId in allNodes) {
      if (allNodes.hasOwnProperty(nodeId)) {
        updateArray.push(allNodes[nodeId]);
      }
    }
    nodes.update(updateArray);
  }
}

function selectNode(nodes) {
  network.selectNodes(nodes);
  neighbourhoodHighlight({ nodes: nodes });
  return nodes;
}

function selectNodes(nodes) {
  network.selectNodes(nodes);
  filterHighlight({nodes: nodes});
  return nodes;
}

function highlightFilter(filter) {
  let selectedNodes = []
  let selectedProp = filter['property']
  if (filter['item'] === 'node') {
    let allNodes = nodes.get({ returnType: "Object" });
    for (let nodeId in allNodes) {
      if (allNodes[nodeId][selectedProp] && filter['value'].includes((allNodes[nodeId][selectedProp]).toString())) {
        selectedNodes.push(nodeId)
      }
    }
  }
  else if (filter['item'] === 'edge'){
    let allEdges = edges.get({returnType: 'object'});
    // check if the selected property exists for selected edge and select the nodes connected to the edge
    for (let edge in allEdges) {
      if (allEdges[edge][selectedProp] && filter['value'].includes((allEdges[edge][selectedProp]).toString())) {
        selectedNodes.push(allEdges[edge]['from'])
        selectedNodes.push(allEdges[edge]['to'])
      }
    }
  }
  selectNodes(selectedNodes)
}</script>
            <style>.vis-overlay{bottom:0;left:0;position:absolute;right:0;top:0;z-index:10}.vis-active{box-shadow:0 0 10px #86d5f8}.vis [class*=span]{min-height:0;width:auto}div.vis-color-picker{background-color:#fff;border-radius:15px;box-shadow:0 0 10px 0 rgba(0,0,0,.5);display:none;height:444px;left:30px;margin-left:30px;margin-top:-140px;padding:10px;position:absolute;top:0;width:310px;z-index:1}div.vis-color-picker div.vis-arrow{left:5px;position:absolute;top:147px}div.vis-color-picker div.vis-arrow:after,div.vis-color-picker div.vis-arrow:before{border:solid transparent;content:" ";height:0;pointer-events:none;position:absolute;right:100%;top:50%;width:0}div.vis-color-picker div.vis-arrow:after{border-color:hsla(0,0%,100%,0) #fff hsla(0,0%,100%,0) hsla(0,0%,100%,0);border-width:30px;margin-top:-30px}div.vis-color-picker div.vis-color{cursor:pointer;height:289px;position:absolute;width:289px}div.vis-color-picker div.vis-brightness{position:absolute;top:313px}div.vis-color-picker div.vis-opacity{position:absolute;top:350px}div.vis-color-picker div.vis-selector{background:#4c4c4c;background:-moz-linear-gradient(top,#4c4c4c 0,#595959 12%,#666 25%,#474747 39%,#2c2c2c 50%,#000 51%,#111 60%,#2b2b2b 76%,#1c1c1c 91%,#131313 100%);background:-webkit-gradient(linear,left top,left bottom,color-stop(0,#4c4c4c),color-stop(12%,#595959),color-stop(25%,#666),color-stop(39%,#474747),color-stop(50%,#2c2c2c),color-stop(51%,#000),color-stop(60%,#111),color-stop(76%,#2b2b2b),color-stop(91%,#1c1c1c),color-stop(100%,#131313));background:-webkit-linear-gradient(top,#4c4c4c,#595959 12%,#666 25%,#474747 39%,#2c2c2c 50%,#000 51%,#111 60%,#2b2b2b 76%,#1c1c1c 91%,#131313);background:-o-linear-gradient(top,#4c4c4c 0,#595959 12%,#666 25%,#474747 39%,#2c2c2c 50%,#000 51%,#111 60%,#2b2b2b 76%,#1c1c1c 91%,#131313 100%);background:-ms-linear-gradient(top,#4c4c4c 0,#595959 12%,#666 25%,#474747 39%,#2c2c2c 50%,#000 51%,#111 60%,#2b2b2b 76%,#1c1c1c 91%,#131313 100%);background:linear-gradient(180deg,#4c4c4c 0,#595959 12%,#666 25%,#474747 39%,#2c2c2c 50%,#000 51%,#111 60%,#2b2b2b 76%,#1c1c1c 91%,#131313);border:1px solid #fff;border-radius:15px;filter:progid:DXImageTransform.Microsoft.gradient(startColorstr="#4c4c4c",endColorstr="#131313",GradientType=0);height:15px;left:137px;position:absolute;top:137px;width:15px}div.vis-color-picker div.vis-new-color{left:159px;padding-right:2px;text-align:right}div.vis-color-picker div.vis-initial-color,div.vis-color-picker div.vis-new-color{border:1px solid rgba(0,0,0,.1);border-radius:5px;color:rgba(0,0,0,.4);font-size:10px;height:20px;line-height:20px;position:absolute;top:380px;vertical-align:middle;width:140px}div.vis-color-picker div.vis-initial-color{left:10px;padding-left:2px;text-align:left}div.vis-color-picker div.vis-label{left:10px;position:absolute;width:300px}div.vis-color-picker div.vis-label.vis-brightness{top:300px}div.vis-color-picker div.vis-label.vis-opacity{top:338px}div.vis-color-picker div.vis-button{background-color:#f7f7f7;border:2px solid #d9d9d9;border-radius:10px;cursor:pointer;height:25px;line-height:25px;position:absolute;text-align:center;top:410px;vertical-align:middle;width:68px}div.vis-color-picker div.vis-button.vis-cancel{left:5px}div.vis-color-picker div.vis-button.vis-load{left:82px}div.vis-color-picker div.vis-button.vis-apply{left:159px}div.vis-color-picker div.vis-button.vis-save{left:236px}div.vis-color-picker input.vis-range{height:20px;width:290px}div.vis-configuration{display:block;float:left;font-size:12px;position:relative}div.vis-configuration-wrapper{display:block;width:700px}div.vis-configuration-wrapper:after{clear:both;content:"";display:block}div.vis-configuration.vis-config-option-container{background-color:#fff;border:2px solid #f7f8fa;border-radius:4px;display:block;left:10px;margin-top:20px;padding-left:5px;width:495px}div.vis-configuration.vis-config-button{background-color:#f7f8fa;border:2px solid #ceced0;border-radius:4px;cursor:pointer;display:block;height:25px;left:10px;line-height:25px;margin-bottom:30px;margin-top:20px;padding-left:5px;vertical-align:middle;width:495px}div.vis-configuration.vis-config-button.hover{background-color:#4588e6;border:2px solid #214373;color:#fff}div.vis-configuration.vis-config-item{display:block;float:left;height:25px;line-height:25px;vertical-align:middle;width:495px}div.vis-configuration.vis-config-item.vis-config-s2{background-color:#f7f8fa;border-radius:3px;left:10px;padding-left:5px}div.vis-configuration.vis-config-item.vis-config-s3{background-color:#e4e9f0;border-radius:3px;left:20px;padding-left:5px}div.vis-configuration.vis-config-item.vis-config-s4{background-color:#cfd8e6;border-radius:3px;left:30px;padding-left:5px}div.vis-configuration.vis-config-header{font-size:18px;font-weight:700}div.vis-configuration.vis-config-label{height:25px;line-height:25px;width:120px}div.vis-configuration.vis-config-label.vis-config-s3{width:110px}div.vis-configuration.vis-config-label.vis-config-s4{width:100px}div.vis-configuration.vis-config-colorBlock{border:1px solid #444;border-radius:2px;cursor:pointer;height:19px;margin:0;padding:0;top:1px;width:30px}input.vis-configuration.vis-config-checkbox{left:-5px}input.vis-configuration.vis-config-rangeinput{margin:0;padding:1px;pointer-events:none;position:relative;top:-5px;width:60px}input.vis-configuration.vis-config-range{-webkit-appearance:none;background-color:transparent;border:0 solid #fff;height:20px;width:300px}input.vis-configuration.vis-config-range::-webkit-slider-runnable-track{background:#dedede;background:-moz-linear-gradient(top,#dedede 0,#c8c8c8 99%);background:-webkit-gradient(linear,left top,left bottom,color-stop(0,#dedede),color-stop(99%,#c8c8c8));background:-webkit-linear-gradient(top,#dedede,#c8c8c8 99%);background:-o-linear-gradient(top,#dedede 0,#c8c8c8 99%);background:-ms-linear-gradient(top,#dedede 0,#c8c8c8 99%);background:linear-gradient(180deg,#dedede 0,#c8c8c8 99%);border:1px solid #999;border-radius:3px;box-shadow:0 0 3px 0 #aaa;filter:progid:DXImageTransform.Microsoft.gradient(startColorstr="#dedede",endColorstr="#c8c8c8",GradientType=0);height:5px;width:300px}input.vis-configuration.vis-config-range::-webkit-slider-thumb{-webkit-appearance:none;background:#3876c2;background:-moz-linear-gradient(top,#3876c2 0,#385380 100%);background:-webkit-gradient(linear,left top,left bottom,color-stop(0,#3876c2),color-stop(100%,#385380));background:-webkit-linear-gradient(top,#3876c2,#385380);background:-o-linear-gradient(top,#3876c2 0,#385380 100%);background:-ms-linear-gradient(top,#3876c2 0,#385380 100%);background:linear-gradient(180deg,#3876c2 0,#385380);border:1px solid #14334b;border-radius:50%;box-shadow:0 0 1px 0 #111927;filter:progid:DXImageTransform.Microsoft.gradient(startColorstr="#3876c2",endColorstr="#385380",GradientType=0);height:17px;margin-top:-7px;width:17px}input.vis-configuration.vis-config-range:focus{outline:none}input.vis-configuration.vis-config-range:focus::-webkit-slider-runnable-track{background:#9d9d9d;background:-moz-linear-gradient(top,#9d9d9d 0,#c8c8c8 99%);background:-webkit-gradient(linear,left top,left bottom,color-stop(0,#9d9d9d),color-stop(99%,#c8c8c8));background:-webkit-linear-gradient(top,#9d9d9d,#c8c8c8 99%);background:-o-linear-gradient(top,#9d9d9d 0,#c8c8c8 99%);background:-ms-linear-gradient(top,#9d9d9d 0,#c8c8c8 99%);background:linear-gradient(180deg,#9d9d9d 0,#c8c8c8 99%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr="#9d9d9d",endColorstr="#c8c8c8",GradientType=0)}input.vis-configuration.vis-config-range::-moz-range-track{background:#dedede;background:-moz-linear-gradient(top,#dedede 0,#c8c8c8 99%);background:-webkit-gradient(linear,left top,left bottom,color-stop(0,#dedede),color-stop(99%,#c8c8c8));background:-webkit-linear-gradient(top,#dedede,#c8c8c8 99%);background:-o-linear-gradient(top,#dedede 0,#c8c8c8 99%);background:-ms-linear-gradient(top,#dedede 0,#c8c8c8 99%);background:linear-gradient(180deg,#dedede 0,#c8c8c8 99%);border:1px solid #999;border-radius:3px;box-shadow:0 0 3px 0 #aaa;filter:progid:DXImageTransform.Microsoft.gradient(startColorstr="#dedede",endColorstr="#c8c8c8",GradientType=0);height:10px;width:300px}input.vis-configuration.vis-config-range::-moz-range-thumb{background:#385380;border:none;border-radius:50%;height:16px;width:16px}input.vis-configuration.vis-config-range:-moz-focusring{outline:1px solid #fff;outline-offset:-1px}input.vis-configuration.vis-config-range::-ms-track{background:transparent;border-color:transparent;border-width:6px 0;color:transparent;height:5px;width:300px}input.vis-configuration.vis-config-range::-ms-fill-lower{background:#777;border-radius:10px}input.vis-configuration.vis-config-range::-ms-fill-upper{background:#ddd;border-radius:10px}input.vis-configuration.vis-config-range::-ms-thumb{background:#385380;border:none;border-radius:50%;height:16px;width:16px}input.vis-configuration.vis-config-range:focus::-ms-fill-lower{background:#888}input.vis-configuration.vis-config-range:focus::-ms-fill-upper{background:#ccc}.vis-configuration-popup{background:rgba(57,76,89,.85);border:2px solid #f2faff;border-radius:4px;color:#fff;font-size:14px;height:30px;line-height:30px;position:absolute;text-align:center;-webkit-transition:opacity .3s ease-in-out;-moz-transition:opacity .3s ease-in-out;transition:opacity .3s ease-in-out;width:150px}.vis-configuration-popup:after,.vis-configuration-popup:before{border:solid transparent;content:" ";height:0;left:100%;pointer-events:none;position:absolute;top:50%;width:0}.vis-configuration-popup:after{border-color:rgba(136,183,213,0) rgba(136,183,213,0) rgba(136,183,213,0) rgba(57,76,89,.85);border-width:8px;margin-top:-8px}.vis-configuration-popup:before{border-color:rgba(194,225,245,0) rgba(194,225,245,0) rgba(194,225,245,0) #f2faff;border-width:12px;margin-top:-12px}div.vis-tooltip{background-color:#f5f4ed;border:1px solid #808074;-moz-border-radius:3px;-webkit-border-radius:3px;border-radius:3px;box-shadow:3px 3px 10px rgba(0,0,0,.2);color:#000;font-family:verdana;font-size:14px;padding:5px;pointer-events:none;position:absolute;visibility:hidden;white-space:nowrap;z-index:5}div.vis-network div.vis-navigation div.vis-button{-webkit-touch-callout:none;background-position:2px 2px;background-repeat:no-repeat;-moz-border-radius:17px;border-radius:17px;cursor:pointer;display:inline-block;height:34px;position:absolute;-webkit-user-select:none;-khtml-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:34px}div.vis-network div.vis-navigation div.vis-button:hover{box-shadow:0 0 3px 3px rgba(56,207,21,.3)}div.vis-network div.vis-navigation div.vis-button:active{box-shadow:0 0 1px 3px rgba(56,207,21,.95)}div.vis-network div.vis-navigation div.vis-button.vis-up{background-image:url("data:image/png;base64,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");bottom:50px;left:55px}div.vis-network div.vis-navigation div.vis-button.vis-down{background-image:url("data:image/png;base64,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");bottom:10px;left:55px}div.vis-network div.vis-navigation div.vis-button.vis-left{background-image:url("data:image/png;base64,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");bottom:10px;left:15px}div.vis-network div.vis-navigation div.vis-button.vis-right{background-image:url("data:image/png;base64,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");bottom:10px;left:95px}div.vis-network div.vis-navigation div.vis-button.vis-zoomIn{background-image:url("data:image/png;base64,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");bottom:10px;right:15px}div.vis-network div.vis-navigation div.vis-button.vis-zoomOut{background-image:url("data:image/png;base64,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");bottom:10px;right:55px}div.vis-network div.vis-navigation div.vis-button.vis-zoomExtends{background-image:url("data:image/png;base64,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");bottom:50px;right:15px}div.vis-network div.vis-manipulation{background:#fff;background:-moz-linear-gradient(top,#fff 0,#fcfcfc 48%,#fafafa 50%,#fcfcfc 100%);background:-webkit-gradient(linear,left top,left bottom,color-stop(0,#fff),color-stop(48%,#fcfcfc),color-stop(50%,#fafafa),color-stop(100%,#fcfcfc));background:-webkit-linear-gradient(top,#fff,#fcfcfc 48%,#fafafa 50%,#fcfcfc);background:-o-linear-gradient(top,#fff 0,#fcfcfc 48%,#fafafa 50%,#fcfcfc 100%);background:-ms-linear-gradient(top,#fff 0,#fcfcfc 48%,#fafafa 50%,#fcfcfc 100%);background:linear-gradient(180deg,#fff 0,#fcfcfc 48%,#fafafa 50%,#fcfcfc);border:0 solid #d6d9d8;border-bottom:1px;box-sizing:content-box;filter:progid:DXImageTransform.Microsoft.gradient(startColorstr="#ffffff",endColorstr="#fcfcfc",GradientType=0);height:28px;left:0;padding-top:4px;position:absolute;top:0;width:100%}div.vis-network button.vis-edit-mode,div.vis-network div.vis-edit-mode{height:30px;left:0;position:absolute;top:5px}div.vis-network button.vis-close{-webkit-touch-callout:none;background-color:transparent;background-image:url("data:image/png;base64,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");background-position:20px 3px;background-repeat:no-repeat;border:none;cursor:pointer;height:30px;position:absolute;right:0;top:0;-webkit-user-select:none;-khtml-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:30px}div.vis-network button.vis-close:hover{opacity:.6}div.vis-network div.vis-edit-mode button.vis-button,div.vis-network div.vis-manipulation button.vis-button{-webkit-touch-callout:none;background-color:transparent;background-position:0 0;background-repeat:no-repeat;border:none;-moz-border-radius:15px;border-radius:15px;box-sizing:content-box;cursor:pointer;float:left;font-family:verdana;font-size:12px;height:24px;margin-left:10px;padding:0 8px;-webkit-user-select:none;-khtml-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none}div.vis-network div.vis-manipulation button.vis-button:hover{box-shadow:1px 1px 8px rgba(0,0,0,.2)}div.vis-network div.vis-manipulation button.vis-button:active{box-shadow:1px 1px 8px rgba(0,0,0,.5)}div.vis-network div.vis-manipulation button.vis-button.vis-back{background-image:url("data:image/png;base64,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")}div.vis-network div.vis-manipulation div.vis-none:hover{box-shadow:1px 1px 8px transparent;cursor:default}div.vis-network div.vis-manipulation div.vis-none:active{box-shadow:1px 1px 8px transparent}div.vis-network div.vis-manipulation div.vis-none{line-height:23px;padding:0}div.vis-network div.vis-manipulation div.notification{font-weight:700;margin:2px}div.vis-network div.vis-manipulation button.vis-button.vis-add{background-image:url("data:image/png;base64,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")}div.vis-network div.vis-edit-mode button.vis-button.vis-edit,div.vis-network div.vis-manipulation button.vis-button.vis-edit{background-image:url("data:image/png;base64,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")}div.vis-network div.vis-edit-mode button.vis-button.vis-edit.vis-edit-mode{background-color:#fcfcfc;border:1px solid #ccc}div.vis-network div.vis-manipulation button.vis-button.vis-connect{background-image:url("data:image/png;base64,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")}div.vis-network div.vis-manipulation button.vis-button.vis-delete{background-image:url("data:image/png;base64,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")}div.vis-network div.vis-edit-mode div.vis-label,div.vis-network div.vis-manipulation div.vis-label{line-height:25px;margin:0 0 0 23px}div.vis-network div.vis-manipulation div.vis-separator-line{background-color:#bdbdbd;display:inline-block;float:left;height:21px;margin:0 7px 0 15px;width:1px}</style>
            <script>/**
 * vis-network
 * https://visjs.github.io/vis-network/
 *
 * A dynamic, browser-based visualization library.
 *
 * @version 9.1.2
 * @date    2022-03-28T20:17:35.342Z
 *
 * @copyright (c) 2011-2017 Almende B.V, http://almende.com
 * @copyright (c) 2017-2019 visjs contributors, https://github.com/visjs
 *
 * @license
 * vis.js is dual licensed under both
 *
 *   1. The Apache 2.0 License
 *      http://www.apache.org/licenses/LICENSE-2.0
 *
 *   and
 *
 *   2. The MIT License
 *      http://opensource.org/licenses/MIT
 *
 * vis.js may be distributed under either license.
 */
!function(t,e){"object"==typeof exports&&"undefined"!=typeof module?e(exports):"function"==typeof define&&define.amd?define(["exports"],e):e((t="undefined"!=typeof globalThis?globalThis:t||self).vis=t.vis||{})}(this,(function(t){"use strict";var e="undefined"!=typeof globalThis?globalThis:"undefined"!=typeof window?window:"undefined"!=typeof global?global:"undefined"!=typeof self?self:{},i=function(t){return t&&t.Math==Math&&t},n=i("object"==typeof globalThis&&globalThis)||i("object"==typeof window&&window)||i("object"==typeof self&&self)||i("object"==typeof e&&e)||function(){return this}()||Function("return this")(),o=function(t){try{return!!t()}catch(t){return!0}},r=!o((function(){var t=function(){}.bind();return"function"!=typeof t||t.hasOwnProperty("prototype")})),s=r,a=Function.prototype,h=a.apply,l=a.call,d="object"==typeof Reflect&&Reflect.apply||(s?l.bind(h):function(){return l.apply(h,arguments)}),c=r,u=Function.prototype,f=u.bind,p=u.call,v=c&&f.bind(p,p),g=c?function(t){return t&&v(t)}:function(t){return t&&function(){return p.apply(t,arguments)}},y=function(t){return"function"==typeof t},m={},b=!o((function(){return 7!=Object.defineProperty({},1,{get:function(){return 7}})[1]})),w=r,k=Function.prototype.call,_=w?k.bind(k):function(){return k.apply(k,arguments)},x={},E={}.propertyIsEnumerable,O=Object.getOwnPropertyDescriptor,C=O&&!E.call({1:2},1);x.f=C?function(t){var e=O(this,t);return!!e&&e.enumerable}:E;var S,T,M=function(t,e){return{enumerable:!(1&t),configurable:!(2&t),writable:!(4&t),value:e}},P=g,D=P({}.toString),I=P("".slice),B=function(t){return I(D(t),8,-1)},z=g,N=o,F=B,A=n.Object,j=z("".split),R=N((function(){return!A("z").propertyIsEnumerable(0)}))?function(t){return"String"==F(t)?j(t,""):A(t)}:A,L=n.TypeError,H=function(t){if(null==t)throw L("Can't call method on "+t);return t},W=R,q=H,V=function(t){return W(q(t))},U=y,Y=function(t){return"object"==typeof t?null!==t:U(t)},X={},G=X,K=n,$=y,Z=function(t){return $(t)?t:void 0},Q=function(t,e){return arguments.length<2?Z(G[t])||Z(K[t]):G[t]&&G[t][e]||K[t]&&K[t][e]},J=g({}.isPrototypeOf),tt=Q("navigator","userAgent")||"",et=n,it=tt,nt=et.process,ot=et.Deno,rt=nt&&nt.versions||ot&&ot.version,st=rt&&rt.v8;st&&(T=(S=st.split("."))[0]>0&&S[0]<4?1:+(S[0]+S[1])),!T&&it&&(!(S=it.match(/Edge\/(\d+)/))||S[1]>=74)&&(S=it.match(/Chrome\/(\d+)/))&&(T=+S[1]);var at=T,ht=at,lt=o,dt=!!Object.getOwnPropertySymbols&&!lt((function(){var t=Symbol();return!String(t)||!(Object(t)instanceof Symbol)||!Symbol.sham&&ht&&ht<41})),ct=dt&&!Symbol.sham&&"symbol"==typeof Symbol.iterator,ut=Q,ft=y,pt=J,vt=ct,gt=n.Object,yt=vt?function(t){return"symbol"==typeof t}:function(t){var e=ut("Symbol");return ft(e)&&pt(e.prototype,gt(t))},mt=n.String,bt=function(t){try{return mt(t)}catch(t){return"Object"}},wt=y,kt=bt,_t=n.TypeError,xt=function(t){if(wt(t))return t;throw _t(kt(t)+" is not a function")},Et=xt,Ot=function(t,e){var i=t[e];return null==i?void 0:Et(i)},Ct=_,St=y,Tt=Y,Mt=n.TypeError,Pt={exports:{}},Dt=n,It=Object.defineProperty,Bt=function(t,e){try{It(Dt,t,{value:e,configurable:!0,writable:!0})}catch(i){Dt[t]=e}return e},zt="__core-js_shared__",Nt=n[zt]||Bt(zt,{}),Ft=Nt;(Pt.exports=function(t,e){return Ft[t]||(Ft[t]=void 0!==e?e:{})})("versions",[]).push({version:"3.21.1",mode:"pure",copyright:"© 2014-2022 Denis Pushkarev (zloirock.ru)",license:"https://github.com/zloirock/core-js/blob/v3.21.1/LICENSE",source:"https://github.com/zloirock/core-js"});var At=H,jt=n.Object,Rt=function(t){return jt(At(t))},Lt=Rt,Ht=g({}.hasOwnProperty),Wt=Object.hasOwn||function(t,e){return Ht(Lt(t),e)},qt=g,Vt=0,Ut=Math.random(),Yt=qt(1..toString),Xt=function(t){return"Symbol("+(void 0===t?"":t)+")_"+Yt(++Vt+Ut,36)},Gt=n,Kt=Pt.exports,$t=Wt,Zt=Xt,Qt=dt,Jt=ct,te=Kt("wks"),ee=Gt.Symbol,ie=ee&&ee.for,ne=Jt?ee:ee&&ee.withoutSetter||Zt,oe=function(t){if(!$t(te,t)||!Qt&&"string"!=typeof te[t]){var e="Symbol."+t;Qt&&$t(ee,t)?te[t]=ee[t]:te[t]=Jt&&ie?ie(e):ne(e)}return te[t]},re=_,se=Y,ae=yt,he=Ot,le=function(t,e){var i,n;if("string"===e&&St(i=t.toString)&&!Tt(n=Ct(i,t)))return n;if(St(i=t.valueOf)&&!Tt(n=Ct(i,t)))return n;if("string"!==e&&St(i=t.toString)&&!Tt(n=Ct(i,t)))return n;throw Mt("Can't convert object to primitive value")},de=oe,ce=n.TypeError,ue=de("toPrimitive"),fe=function(t,e){if(!se(t)||ae(t))return t;var i,n=he(t,ue);if(n){if(void 0===e&&(e="default"),i=re(n,t,e),!se(i)||ae(i))return i;throw ce("Can't convert object to primitive value")}return void 0===e&&(e="number"),le(t,e)},pe=yt,ve=function(t){var e=fe(t,"string");return pe(e)?e:e+""},ge=Y,ye=n.document,me=ge(ye)&&ge(ye.createElement),be=function(t){return me?ye.createElement(t):{}},we=be,ke=!b&&!o((function(){return 7!=Object.defineProperty(we("div"),"a",{get:function(){return 7}}).a})),_e=b,xe=_,Ee=x,Oe=M,Ce=V,Se=ve,Te=Wt,Me=ke,Pe=Object.getOwnPropertyDescriptor;m.f=_e?Pe:function(t,e){if(t=Ce(t),e=Se(e),Me)try{return Pe(t,e)}catch(t){}if(Te(t,e))return Oe(!xe(Ee.f,t,e),t[e])};var De=o,Ie=y,Be=/#|\.prototype\./,ze=function(t,e){var i=Fe[Ne(t)];return i==je||i!=Ae&&(Ie(e)?De(e):!!e)},Ne=ze.normalize=function(t){return String(t).replace(Be,".").toLowerCase()},Fe=ze.data={},Ae=ze.NATIVE="N",je=ze.POLYFILL="P",Re=ze,Le=xt,He=r,We=g(g.bind),qe=function(t,e){return Le(t),void 0===e?t:He?We(t,e):function(){return t.apply(e,arguments)}},Ve={},Ue=b&&o((function(){return 42!=Object.defineProperty((function(){}),"prototype",{value:42,writable:!1}).prototype})),Ye=n,Xe=Y,Ge=Ye.String,Ke=Ye.TypeError,$e=function(t){if(Xe(t))return t;throw Ke(Ge(t)+" is not an object")},Ze=b,Qe=ke,Je=Ue,ti=$e,ei=ve,ii=n.TypeError,ni=Object.defineProperty,oi=Object.getOwnPropertyDescriptor,ri="enumerable",si="configurable",ai="writable";Ve.f=Ze?Je?function(t,e,i){if(ti(t),e=ei(e),ti(i),"function"==typeof t&&"prototype"===e&&"value"in i&&ai in i&&!i.writable){var n=oi(t,e);n&&n.writable&&(t[e]=i.value,i={configurable:si in i?i.configurable:n.configurable,enumerable:ri in i?i.enumerable:n.enumerable,writable:!1})}return ni(t,e,i)}:ni:function(t,e,i){if(ti(t),e=ei(e),ti(i),Qe)try{return ni(t,e,i)}catch(t){}if("get"in i||"set"in i)throw ii("Accessors not supported");return"value"in i&&(t[e]=i.value),t};var hi=Ve,li=M,di=b?function(t,e,i){return hi.f(t,e,li(1,i))}:function(t,e,i){return t[e]=i,t},ci=n,ui=d,fi=g,pi=y,vi=m.f,gi=Re,yi=X,mi=qe,bi=di,wi=Wt,ki=function(t){var e=function(i,n,o){if(this instanceof e){switch(arguments.length){case 0:return new t;case 1:return new t(i);case 2:return new t(i,n)}return new t(i,n,o)}return ui(t,this,arguments)};return e.prototype=t.prototype,e},_i=function(t,e){var i,n,o,r,s,a,h,l,d=t.target,c=t.global,u=t.stat,f=t.proto,p=c?ci:u?ci[d]:(ci[d]||{}).prototype,v=c?yi:yi[d]||bi(yi,d,{})[d],g=v.prototype;for(o in e)i=!gi(c?o:d+(u?".":"#")+o,t.forced)&&p&&wi(p,o),s=v[o],i&&(a=t.noTargetGet?(l=vi(p,o))&&l.value:p[o]),r=i&&a?a:e[o],i&&typeof s==typeof r||(h=t.bind&&i?mi(r,ci):t.wrap&&i?ki(r):f&&pi(r)?fi(r):r,(t.sham||r&&r.sham||s&&s.sham)&&bi(h,"sham",!0),bi(v,o,h),f&&(wi(yi,n=d+"Prototype")||bi(yi,n,{}),bi(yi[n],o,r),t.real&&g&&!g[o]&&bi(g,o,r)))},xi=Math.ceil,Ei=Math.floor,Oi=function(t){var e=+t;return e!=e||0===e?0:(e>0?Ei:xi)(e)},Ci=Oi,Si=Math.max,Ti=Math.min,Mi=function(t,e){var i=Ci(t);return i<0?Si(i+e,0):Ti(i,e)},Pi=Oi,Di=Math.min,Ii=function(t){return t>0?Di(Pi(t),9007199254740991):0},Bi=function(t){return Ii(t.length)},zi=V,Ni=Mi,Fi=Bi,Ai=function(t){return function(e,i,n){var o,r=zi(e),s=Fi(r),a=Ni(n,s);if(t&&i!=i){for(;s>a;)if((o=r[a++])!=o)return!0}else for(;s>a;a++)if((t||a in r)&&r[a]===i)return t||a||0;return!t&&-1}},ji={includes:Ai(!0),indexOf:Ai(!1)},Ri={},Li=Wt,Hi=V,Wi=ji.indexOf,qi=Ri,Vi=g([].push),Ui=function(t,e){var i,n=Hi(t),o=0,r=[];for(i in n)!Li(qi,i)&&Li(n,i)&&Vi(r,i);for(;e.length>o;)Li(n,i=e[o++])&&(~Wi(r,i)||Vi(r,i));return r},Yi=["constructor","hasOwnProperty","isPrototypeOf","propertyIsEnumerable","toLocaleString","toString","valueOf"],Xi=Ui,Gi=Yi,Ki=Object.keys||function(t){return Xi(t,Gi)},$i={};$i.f=Object.getOwnPropertySymbols;var Zi=b,Qi=g,Ji=_,tn=o,en=Ki,nn=$i,on=x,rn=Rt,sn=R,an=Object.assign,hn=Object.defineProperty,ln=Qi([].concat),dn=!an||tn((function(){if(Zi&&1!==an({b:1},an(hn({},"a",{enumerable:!0,get:function(){hn(this,"b",{value:3,enumerable:!1})}}),{b:2})).b)return!0;var t={},e={},i=Symbol(),n="abcdefghijklmnopqrst";return t[i]=7,n.split("").forEach((function(t){e[t]=t})),7!=an({},t)[i]||en(an({},e)).join("")!=n}))?function(t,e){for(var i=rn(t),n=arguments.length,o=1,r=nn.f,s=on.f;n>o;)for(var a,h=sn(arguments[o++]),l=r?ln(en(h),r(h)):en(h),d=l.length,c=0;d>c;)a=l[c++],Zi&&!Ji(s,h,a)||(i[a]=h[a]);return i}:an,cn=dn;_i({target:"Object",stat:!0,forced:Object.assign!==cn},{assign:cn});var un=X.Object.assign,fn=g([].slice),pn=g,vn=xt,gn=Y,yn=Wt,mn=fn,bn=r,wn=n.Function,kn=pn([].concat),_n=pn([].join),xn={},En=function(t,e,i){if(!yn(xn,e)){for(var n=[],o=0;o<e;o++)n[o]="a["+o+"]";xn[e]=wn("C,a","return new C("+_n(n,",")+")")}return xn[e](t,i)},On=bn?wn.bind:function(t){var e=vn(this),i=e.prototype,n=mn(arguments,1),o=function(){var i=kn(n,mn(arguments));return this instanceof o?En(e,i.length,i):e.apply(t,i)};return gn(i)&&(o.prototype=i),o},Cn=On;_i({target:"Function",proto:!0,forced:Function.bind!==Cn},{bind:Cn});var Sn=X,Tn=function(t){return Sn[t+"Prototype"]},Mn=Tn("Function").bind,Pn=J,Dn=Mn,In=Function.prototype,Bn=function(t){var e=t.bind;return t===In||Pn(In,t)&&e===In.bind?Dn:e},zn=Bn;function Nn(t,e,i,n){t.beginPath(),t.arc(e,i,n,0,2*Math.PI,!1),t.closePath()}function Fn(t,e,i,n,o,r){var s=Math.PI/180;n-2*r<0&&(r=n/2),o-2*r<0&&(r=o/2),t.beginPath(),t.moveTo(e+r,i),t.lineTo(e+n-r,i),t.arc(e+n-r,i+r,r,270*s,360*s,!1),t.lineTo(e+n,i+o-r),t.arc(e+n-r,i+o-r,r,0,90*s,!1),t.lineTo(e+r,i+o),t.arc(e+r,i+o-r,r,90*s,180*s,!1),t.lineTo(e,i+r),t.arc(e+r,i+r,r,180*s,270*s,!1),t.closePath()}function An(t,e,i,n,o){var r=.5522848,s=n/2*r,a=o/2*r,h=e+n,l=i+o,d=e+n/2,c=i+o/2;t.beginPath(),t.moveTo(e,c),t.bezierCurveTo(e,c-a,d-s,i,d,i),t.bezierCurveTo(d+s,i,h,c-a,h,c),t.bezierCurveTo(h,c+a,d+s,l,d,l),t.bezierCurveTo(d-s,l,e,c+a,e,c),t.closePath()}function jn(t,e,i,n,o){var r=o*(1/3),s=.5522848,a=n/2*s,h=r/2*s,l=e+n,d=i+r,c=e+n/2,u=i+r/2,f=i+(o-r/2),p=i+o;t.beginPath(),t.moveTo(l,u),t.bezierCurveTo(l,u+h,c+a,d,c,d),t.bezierCurveTo(c-a,d,e,u+h,e,u),t.bezierCurveTo(e,u-h,c-a,i,c,i),t.bezierCurveTo(c+a,i,l,u-h,l,u),t.lineTo(l,f),t.bezierCurveTo(l,f+h,c+a,p,c,p),t.bezierCurveTo(c-a,p,e,f+h,e,f),t.lineTo(e,u)}function Rn(t,e,i,n,o,r){t.beginPath(),t.moveTo(e,i);for(var s=r.length,a=n-e,h=o-i,l=h/a,d=Math.sqrt(a*a+h*h),c=0,u=!0,f=0,p=+r[0];d>=.1;)(p=+r[c++%s])>d&&(p=d),f=Math.sqrt(p*p/(1+l*l)),e+=f=a<0?-f:f,i+=l*f,!0===u?t.lineTo(e,i):t.moveTo(e,i),d-=p,u=!u}var Ln={circle:Nn,dashedLine:Rn,database:jn,diamond:function(t,e,i,n){t.beginPath(),t.lineTo(e,i+n),t.lineTo(e+n,i),t.lineTo(e,i-n),t.lineTo(e-n,i),t.closePath()},ellipse:An,ellipse_vis:An,hexagon:function(t,e,i,n){t.beginPath();var o=2*Math.PI/6;t.moveTo(e+n,i);for(var r=1;r<6;r++)t.lineTo(e+n*Math.cos(o*r),i+n*Math.sin(o*r));t.closePath()},roundRect:Fn,square:function(t,e,i,n){t.beginPath(),t.rect(e-n,i-n,2*n,2*n),t.closePath()},star:function(t,e,i,n){t.beginPath(),i+=.1*(n*=.82);for(var o=0;o<10;o++){var r=o%2==0?1.3*n:.5*n;t.lineTo(e+r*Math.sin(2*o*Math.PI/10),i-r*Math.cos(2*o*Math.PI/10))}t.closePath()},triangle:function(t,e,i,n){t.beginPath(),i+=.275*(n*=1.15);var o=2*n,r=o/2,s=Math.sqrt(3)/6*o,a=Math.sqrt(o*o-r*r);t.moveTo(e,i-(a-s)),t.lineTo(e+r,i+s),t.lineTo(e-r,i+s),t.lineTo(e,i-(a-s)),t.closePath()},triangleDown:function(t,e,i,n){t.beginPath(),i-=.275*(n*=1.15);var o=2*n,r=o/2,s=Math.sqrt(3)/6*o,a=Math.sqrt(o*o-r*r);t.moveTo(e,i+(a-s)),t.lineTo(e+r,i-s),t.lineTo(e-r,i-s),t.lineTo(e,i+(a-s)),t.closePath()}};var Hn={exports:{}};!function(t){function e(t){if(t)return function(t){for(var i in e.prototype)t[i]=e.prototype[i];return t}(t)}t.exports=e,e.prototype.on=e.prototype.addEventListener=function(t,e){return this._callbacks=this._callbacks||{},(this._callbacks["$"+t]=this._callbacks["$"+t]||[]).push(e),this},e.prototype.once=function(t,e){function i(){this.off(t,i),e.apply(this,arguments)}return i.fn=e,this.on(t,i),this},e.prototype.off=e.prototype.removeListener=e.prototype.removeAllListeners=e.prototype.removeEventListener=function(t,e){if(this._callbacks=this._callbacks||{},0==arguments.length)return this._callbacks={},this;var i,n=this._callbacks["$"+t];if(!n)return this;if(1==arguments.length)return delete this._callbacks["$"+t],this;for(var o=0;o<n.length;o++)if((i=n[o])===e||i.fn===e){n.splice(o,1);break}return 0===n.length&&delete this._callbacks["$"+t],this},e.prototype.emit=function(t){this._callbacks=this._callbacks||{};for(var e=new Array(arguments.length-1),i=this._callbacks["$"+t],n=1;n<arguments.length;n++)e[n-1]=arguments[n];if(i){n=0;for(var o=(i=i.slice(0)).length;n<o;++n)i[n].apply(this,e)}return this},e.prototype.listeners=function(t){return this._callbacks=this._callbacks||{},this._callbacks["$"+t]||[]},e.prototype.hasListeners=function(t){return!!this.listeners(t).length}}(Hn);var Wn=Hn.exports,qn={};qn[oe("toStringTag")]="z";var Vn="[object z]"===String(qn),Un=n,Yn=Vn,Xn=y,Gn=B,Kn=oe("toStringTag"),$n=Un.Object,Zn="Arguments"==Gn(function(){return arguments}()),Qn=Yn?Gn:function(t){var e,i,n;return void 0===t?"Undefined":null===t?"Null":"string"==typeof(i=function(t,e){try{return t[e]}catch(t){}}(e=$n(t),Kn))?i:Zn?Gn(e):"Object"==(n=Gn(e))&&Xn(e.callee)?"Arguments":n},Jn=Qn,to=n.String,eo=function(t){if("Symbol"===Jn(t))throw TypeError("Cannot convert a Symbol value to a string");return to(t)},io=g,no=Oi,oo=eo,ro=H,so=io("".charAt),ao=io("".charCodeAt),ho=io("".slice),lo=function(t){return function(e,i){var n,o,r=oo(ro(e)),s=no(i),a=r.length;return s<0||s>=a?t?"":void 0:(n=ao(r,s))<55296||n>56319||s+1===a||(o=ao(r,s+1))<56320||o>57343?t?so(r,s):n:t?ho(r,s,s+2):o-56320+(n-55296<<10)+65536}},co={codeAt:lo(!1),charAt:lo(!0)},uo=y,fo=Nt,po=g(Function.toString);uo(fo.inspectSource)||(fo.inspectSource=function(t){return po(t)});var vo,go,yo,mo=fo.inspectSource,bo=y,wo=mo,ko=n.WeakMap,_o=bo(ko)&&/native code/.test(wo(ko)),xo=Pt.exports,Eo=Xt,Oo=xo("keys"),Co=function(t){return Oo[t]||(Oo[t]=Eo(t))},So=_o,To=n,Mo=g,Po=Y,Do=di,Io=Wt,Bo=Nt,zo=Co,No=Ri,Fo="Object already initialized",Ao=To.TypeError,jo=To.WeakMap;if(So||Bo.state){var Ro=Bo.state||(Bo.state=new jo),Lo=Mo(Ro.get),Ho=Mo(Ro.has),Wo=Mo(Ro.set);vo=function(t,e){if(Ho(Ro,t))throw new Ao(Fo);return e.facade=t,Wo(Ro,t,e),e},go=function(t){return Lo(Ro,t)||{}},yo=function(t){return Ho(Ro,t)}}else{var qo=zo("state");No[qo]=!0,vo=function(t,e){if(Io(t,qo))throw new Ao(Fo);return e.facade=t,Do(t,qo,e),e},go=function(t){return Io(t,qo)?t[qo]:{}},yo=function(t){return Io(t,qo)}}var Vo={set:vo,get:go,has:yo,enforce:function(t){return yo(t)?go(t):vo(t,{})},getterFor:function(t){return function(e){var i;if(!Po(e)||(i=go(e)).type!==t)throw Ao("Incompatible receiver, "+t+" required");return i}}},Uo=b,Yo=Wt,Xo=Function.prototype,Go=Uo&&Object.getOwnPropertyDescriptor,Ko=Yo(Xo,"name"),$o={EXISTS:Ko,PROPER:Ko&&"something"===function(){}.name,CONFIGURABLE:Ko&&(!Uo||Uo&&Go(Xo,"name").configurable)},Zo={},Qo=b,Jo=Ue,tr=Ve,er=$e,ir=V,nr=Ki;Zo.f=Qo&&!Jo?Object.defineProperties:function(t,e){er(t);for(var i,n=ir(e),o=nr(e),r=o.length,s=0;r>s;)tr.f(t,i=o[s++],n[i]);return t};var or,rr=Q("document","documentElement"),sr=$e,ar=Zo,hr=Yi,lr=Ri,dr=rr,cr=be,ur=Co("IE_PROTO"),fr=function(){},pr=function(t){return"<script>"+t+"</"+"script>"},vr=function(t){t.write(pr("")),t.close();var e=t.parentWindow.Object;return t=null,e},gr=function(){try{or=new ActiveXObject("htmlfile")}catch(t){}var t,e;gr="undefined"!=typeof document?document.domain&&or?vr(or):((e=cr("iframe")).style.display="none",dr.appendChild(e),e.src=String("javascript:"),(t=e.contentWindow.document).open(),t.write(pr("document.F=Object")),t.close(),t.F):vr(or);for(var i=hr.length;i--;)delete gr.prototype[hr[i]];return gr()};lr[ur]=!0;var yr,mr,br,wr=Object.create||function(t,e){var i;return null!==t?(fr.prototype=sr(t),i=new fr,fr.prototype=null,i[ur]=t):i=gr(),void 0===e?i:ar.f(i,e)},kr=!o((function(){function t(){}return t.prototype.constructor=null,Object.getPrototypeOf(new t)!==t.prototype})),_r=n,xr=Wt,Er=y,Or=Rt,Cr=kr,Sr=Co("IE_PROTO"),Tr=_r.Object,Mr=Tr.prototype,Pr=Cr?Tr.getPrototypeOf:function(t){var e=Or(t);if(xr(e,Sr))return e[Sr];var i=e.constructor;return Er(i)&&e instanceof i?i.prototype:e instanceof Tr?Mr:null},Dr=di,Ir=function(t,e,i,n){n&&n.enumerable?t[e]=i:Dr(t,e,i)},Br=o,zr=y,Nr=wr,Fr=Pr,Ar=Ir,jr=oe("iterator"),Rr=!1;[].keys&&("next"in(br=[].keys())?(mr=Fr(Fr(br)))!==Object.prototype&&(yr=mr):Rr=!0);var Lr=null==yr||Br((function(){var t={};return yr[jr].call(t)!==t}));zr((yr=Lr?{}:Nr(yr))[jr])||Ar(yr,jr,(function(){return this}));var Hr={IteratorPrototype:yr,BUGGY_SAFARI_ITERATORS:Rr},Wr=Qn,qr=Vn?{}.toString:function(){return"[object "+Wr(this)+"]"},Vr=Vn,Ur=Ve.f,Yr=di,Xr=Wt,Gr=qr,Kr=oe("toStringTag"),$r=function(t,e,i,n){if(t){var o=i?t:t.prototype;Xr(o,Kr)||Ur(o,Kr,{configurable:!0,value:e}),n&&!Vr&&Yr(o,"toString",Gr)}},Zr={},Qr=Hr.IteratorPrototype,Jr=wr,ts=M,es=$r,is=Zr,ns=function(){return this},os=n,rs=y,ss=os.String,as=os.TypeError,hs=g,ls=$e,ds=function(t){if("object"==typeof t||rs(t))return t;throw as("Can't set "+ss(t)+" as a prototype")},cs=Object.setPrototypeOf||("__proto__"in{}?function(){var t,e=!1,i={};try{(t=hs(Object.getOwnPropertyDescriptor(Object.prototype,"__proto__").set))(i,[]),e=i instanceof Array}catch(t){}return function(i,n){return ls(i),ds(n),e?t(i,n):i.__proto__=n,i}}():void 0),us=_i,fs=_,ps=function(t,e,i,n){var o=e+" Iterator";return t.prototype=Jr(Qr,{next:ts(+!n,i)}),es(t,o,!1,!0),is[o]=ns,t},vs=Pr,gs=$r,ys=Ir,ms=Zr,bs=$o.PROPER,ws=Hr.BUGGY_SAFARI_ITERATORS,ks=oe("iterator"),_s="keys",xs="values",Es="entries",Os=function(){return this},Cs=function(t,e,i,n,o,r,s){ps(i,e,n);var a,h,l,d=function(t){if(t===o&&v)return v;if(!ws&&t in f)return f[t];switch(t){case _s:case xs:case Es:return function(){return new i(this,t)}}return function(){return new i(this)}},c=e+" Iterator",u=!1,f=t.prototype,p=f[ks]||f["@@iterator"]||o&&f[o],v=!ws&&p||d(o),g="Array"==e&&f.entries||p;if(g&&(a=vs(g.call(new t)))!==Object.prototype&&a.next&&(gs(a,c,!0,!0),ms[c]=Os),bs&&o==xs&&p&&p.name!==xs&&(u=!0,v=function(){return fs(p,this)}),o)if(h={values:d(xs),keys:r?v:d(_s),entries:d(Es)},s)for(l in h)(ws||u||!(l in f))&&ys(f,l,h[l]);else us({target:e,proto:!0,forced:ws||u},h);return s&&f[ks]!==v&&ys(f,ks,v,{name:o}),ms[e]=v,h},Ss=co.charAt,Ts=eo,Ms=Vo,Ps=Cs,Ds="String Iterator",Is=Ms.set,Bs=Ms.getterFor(Ds);Ps(String,"String",(function(t){Is(this,{type:Ds,string:Ts(t),index:0})}),(function(){var t,e=Bs(this),i=e.string,n=e.index;return n>=i.length?{value:void 0,done:!0}:(t=Ss(i,n),e.index+=t.length,{value:t,done:!1})}));var zs=_,Ns=$e,Fs=Ot,As=function(t,e,i){var n,o;Ns(t);try{if(!(n=Fs(t,"return"))){if("throw"===e)throw i;return i}n=zs(n,t)}catch(t){o=!0,n=t}if("throw"===e)throw i;if(o)throw n;return Ns(n),i},js=$e,Rs=As,Ls=Zr,Hs=oe("iterator"),Ws=Array.prototype,qs=function(t){return void 0!==t&&(Ls.Array===t||Ws[Hs]===t)},Vs=g,Us=o,Ys=y,Xs=Qn,Gs=mo,Ks=function(){},$s=[],Zs=Q("Reflect","construct"),Qs=/^\s*(?:class|function)\b/,Js=Vs(Qs.exec),ta=!Qs.exec(Ks),ea=function(t){if(!Ys(t))return!1;try{return Zs(Ks,$s,t),!0}catch(t){return!1}},ia=function(t){if(!Ys(t))return!1;switch(Xs(t)){case"AsyncFunction":case"GeneratorFunction":case"AsyncGeneratorFunction":return!1}try{return ta||!!Js(Qs,Gs(t))}catch(t){return!0}};ia.sham=!0;var na=!Zs||Us((function(){var t;return ea(ea.call)||!ea(Object)||!ea((function(){t=!0}))||t}))?ia:ea,oa=ve,ra=Ve,sa=M,aa=function(t,e,i){var n=oa(e);n in t?ra.f(t,n,sa(0,i)):t[n]=i},ha=Qn,la=Ot,da=Zr,ca=oe("iterator"),ua=function(t){if(null!=t)return la(t,ca)||la(t,"@@iterator")||da[ha(t)]},fa=_,pa=xt,va=$e,ga=bt,ya=ua,ma=n.TypeError,ba=function(t,e){var i=arguments.length<2?ya(t):e;if(pa(i))return va(fa(i,t));throw ma(ga(t)+" is not iterable")},wa=qe,ka=_,_a=Rt,xa=function(t,e,i,n){try{return n?e(js(i)[0],i[1]):e(i)}catch(e){Rs(t,"throw",e)}},Ea=qs,Oa=na,Ca=Bi,Sa=aa,Ta=ba,Ma=ua,Pa=n.Array,Da=oe("iterator"),Ia=!1;try{var Ba=0,za={next:function(){return{done:!!Ba++}},return:function(){Ia=!0}};za[Da]=function(){return this},Array.from(za,(function(){throw 2}))}catch(t){}var Na=function(t){var e=_a(t),i=Oa(this),n=arguments.length,o=n>1?arguments[1]:void 0,r=void 0!==o;r&&(o=wa(o,n>2?arguments[2]:void 0));var s,a,h,l,d,c,u=Ma(e),f=0;if(!u||this==Pa&&Ea(u))for(s=Ca(e),a=i?new this(s):Pa(s);s>f;f++)c=r?o(e[f],f):e[f],Sa(a,f,c);else for(d=(l=Ta(e,u)).next,a=i?new this:[];!(h=ka(d,l)).done;f++)c=r?xa(l,o,[h.value,f],!0):h.value,Sa(a,f,c);return a.length=f,a},Fa=function(t,e){if(!e&&!Ia)return!1;var i=!1;try{var n={};n[Da]=function(){return{next:function(){return{done:i=!0}}}},t(n)}catch(t){}return i};_i({target:"Array",stat:!0,forced:!Fa((function(t){Array.from(t)}))},{from:Na});var Aa=X.Array.from,ja=Aa,Ra=V,La=Zr,Ha=Vo;Ve.f;var Wa=Cs,qa="Array Iterator",Va=Ha.set,Ua=Ha.getterFor(qa);Wa(Array,"Array",(function(t,e){Va(this,{type:qa,target:Ra(t),index:0,kind:e})}),(function(){var t=Ua(this),e=t.target,i=t.kind,n=t.index++;return!e||n>=e.length?(t.target=void 0,{value:void 0,done:!0}):"keys"==i?{value:n,done:!1}:"values"==i?{value:e[n],done:!1}:{value:[n,e[n]],done:!1}}),"values"),La.Arguments=La.Array;var Ya=ua,Xa={CSSRuleList:0,CSSStyleDeclaration:0,CSSValueList:0,ClientRectList:0,DOMRectList:0,DOMStringList:0,DOMTokenList:1,DataTransferItemList:0,FileList:0,HTMLAllCollection:0,HTMLCollection:0,HTMLFormElement:0,HTMLSelectElement:0,MediaList:0,MimeTypeArray:0,NamedNodeMap:0,NodeList:1,PaintRequestList:0,Plugin:0,PluginArray:0,SVGLengthList:0,SVGNumberList:0,SVGPathSegList:0,SVGPointList:0,SVGStringList:0,SVGTransformList:0,SourceBufferList:0,StyleSheetList:0,TextTrackCueList:0,TextTrackList:0,TouchList:0},Ga=n,Ka=Qn,$a=di,Za=Zr,Qa=oe("toStringTag");for(var Ja in Xa){var th=Ga[Ja],eh=th&&th.prototype;eh&&Ka(eh)!==Qa&&$a(eh,Qa,Ja),Za[Ja]=Za.Array}var ih=Ya,nh=B,oh=Array.isArray||function(t){return"Array"==nh(t)},rh={},sh=Ui,ah=Yi.concat("length","prototype");rh.f=Object.getOwnPropertyNames||function(t){return sh(t,ah)};var hh={},lh=Mi,dh=Bi,ch=aa,uh=n.Array,fh=Math.max,ph=function(t,e,i){for(var n=dh(t),o=lh(e,n),r=lh(void 0===i?n:i,n),s=uh(fh(r-o,0)),a=0;o<r;o++,a++)ch(s,a,t[o]);return s.length=a,s},vh=B,gh=V,yh=rh.f,mh=ph,bh="object"==typeof window&&window&&Object.getOwnPropertyNames?Object.getOwnPropertyNames(window):[];hh.f=function(t){return bh&&"Window"==vh(t)?function(t){try{return yh(t)}catch(t){return mh(bh)}}(t):yh(gh(t))};var wh={},kh=oe;wh.f=kh;var _h=X,xh=Wt,Eh=wh,Oh=Ve.f,Ch=function(t){var e=_h.Symbol||(_h.Symbol={});xh(e,t)||Oh(e,t,{value:Eh.f(t)})},Sh=n,Th=oh,Mh=na,Ph=Y,Dh=oe("species"),Ih=Sh.Array,Bh=function(t){var e;return Th(t)&&(e=t.constructor,(Mh(e)&&(e===Ih||Th(e.prototype))||Ph(e)&&null===(e=e[Dh]))&&(e=void 0)),void 0===e?Ih:e},zh=function(t,e){return new(Bh(t))(0===e?0:e)},Nh=qe,Fh=R,Ah=Rt,jh=Bi,Rh=zh,Lh=g([].push),Hh=function(t){var e=1==t,i=2==t,n=3==t,o=4==t,r=6==t,s=7==t,a=5==t||r;return function(h,l,d,c){for(var u,f,p=Ah(h),v=Fh(p),g=Nh(l,d),y=jh(v),m=0,b=c||Rh,w=e?b(h,y):i||s?b(h,0):void 0;y>m;m++)if((a||m in v)&&(f=g(u=v[m],m,p),t))if(e)w[m]=f;else if(f)switch(t){case 3:return!0;case 5:return u;case 6:return m;case 2:Lh(w,u)}else switch(t){case 4:return!1;case 7:Lh(w,u)}return r?-1:n||o?o:w}},Wh={forEach:Hh(0),map:Hh(1),filter:Hh(2),some:Hh(3),every:Hh(4),find:Hh(5),findIndex:Hh(6),filterReject:Hh(7)},qh=_i,Vh=n,Uh=Q,Yh=d,Xh=_,Gh=g,Kh=b,$h=dt,Zh=o,Qh=Wt,Jh=oh,tl=y,el=Y,il=J,nl=yt,ol=$e,rl=Rt,sl=V,al=ve,hl=eo,ll=M,dl=wr,cl=Ki,ul=rh,fl=hh,pl=$i,vl=m,gl=Ve,yl=Zo,ml=x,bl=fn,wl=Ir,kl=Pt.exports,_l=Ri,xl=Xt,El=oe,Ol=wh,Cl=Ch,Sl=$r,Tl=Vo,Ml=Wh.forEach,Pl=Co("hidden"),Dl="Symbol",Il=El("toPrimitive"),Bl=Tl.set,zl=Tl.getterFor(Dl),Nl=Object.prototype,Fl=Vh.Symbol,Al=Fl&&Fl.prototype,jl=Vh.TypeError,Rl=Vh.QObject,Ll=Uh("JSON","stringify"),Hl=vl.f,Wl=gl.f,ql=fl.f,Vl=ml.f,Ul=Gh([].push),Yl=kl("symbols"),Xl=kl("op-symbols"),Gl=kl("string-to-symbol-registry"),Kl=kl("symbol-to-string-registry"),$l=kl("wks"),Zl=!Rl||!Rl.prototype||!Rl.prototype.findChild,Ql=Kh&&Zh((function(){return 7!=dl(Wl({},"a",{get:function(){return Wl(this,"a",{value:7}).a}})).a}))?function(t,e,i){var n=Hl(Nl,e);n&&delete Nl[e],Wl(t,e,i),n&&t!==Nl&&Wl(Nl,e,n)}:Wl,Jl=function(t,e){var i=Yl[t]=dl(Al);return Bl(i,{type:Dl,tag:t,description:e}),Kh||(i.description=e),i},td=function(t,e,i){t===Nl&&td(Xl,e,i),ol(t);var n=al(e);return ol(i),Qh(Yl,n)?(i.enumerable?(Qh(t,Pl)&&t[Pl][n]&&(t[Pl][n]=!1),i=dl(i,{enumerable:ll(0,!1)})):(Qh(t,Pl)||Wl(t,Pl,ll(1,{})),t[Pl][n]=!0),Ql(t,n,i)):Wl(t,n,i)},ed=function(t,e){ol(t);var i=sl(e),n=cl(i).concat(rd(i));return Ml(n,(function(e){Kh&&!Xh(id,i,e)||td(t,e,i[e])})),t},id=function(t){var e=al(t),i=Xh(Vl,this,e);return!(this===Nl&&Qh(Yl,e)&&!Qh(Xl,e))&&(!(i||!Qh(this,e)||!Qh(Yl,e)||Qh(this,Pl)&&this[Pl][e])||i)},nd=function(t,e){var i=sl(t),n=al(e);if(i!==Nl||!Qh(Yl,n)||Qh(Xl,n)){var o=Hl(i,n);return!o||!Qh(Yl,n)||Qh(i,Pl)&&i[Pl][n]||(o.enumerable=!0),o}},od=function(t){var e=ql(sl(t)),i=[];return Ml(e,(function(t){Qh(Yl,t)||Qh(_l,t)||Ul(i,t)})),i},rd=function(t){var e=t===Nl,i=ql(e?Xl:sl(t)),n=[];return Ml(i,(function(t){!Qh(Yl,t)||e&&!Qh(Nl,t)||Ul(n,Yl[t])})),n};if($h||(Fl=function(){if(il(Al,this))throw jl("Symbol is not a constructor");var t=arguments.length&&void 0!==arguments[0]?hl(arguments[0]):void 0,e=xl(t),i=function(t){this===Nl&&Xh(i,Xl,t),Qh(this,Pl)&&Qh(this[Pl],e)&&(this[Pl][e]=!1),Ql(this,e,ll(1,t))};return Kh&&Zl&&Ql(Nl,e,{configurable:!0,set:i}),Jl(e,t)},wl(Al=Fl.prototype,"toString",(function(){return zl(this).tag})),wl(Fl,"withoutSetter",(function(t){return Jl(xl(t),t)})),ml.f=id,gl.f=td,yl.f=ed,vl.f=nd,ul.f=fl.f=od,pl.f=rd,Ol.f=function(t){return Jl(El(t),t)},Kh&&Wl(Al,"description",{configurable:!0,get:function(){return zl(this).description}})),qh({global:!0,wrap:!0,forced:!$h,sham:!$h},{Symbol:Fl}),Ml(cl($l),(function(t){Cl(t)})),qh({target:Dl,stat:!0,forced:!$h},{for:function(t){var e=hl(t);if(Qh(Gl,e))return Gl[e];var i=Fl(e);return Gl[e]=i,Kl[i]=e,i},keyFor:function(t){if(!nl(t))throw jl(t+" is not a symbol");if(Qh(Kl,t))return Kl[t]},useSetter:function(){Zl=!0},useSimple:function(){Zl=!1}}),qh({target:"Object",stat:!0,forced:!$h,sham:!Kh},{create:function(t,e){return void 0===e?dl(t):ed(dl(t),e)},defineProperty:td,defineProperties:ed,getOwnPropertyDescriptor:nd}),qh({target:"Object",stat:!0,forced:!$h},{getOwnPropertyNames:od,getOwnPropertySymbols:rd}),qh({target:"Object",stat:!0,forced:Zh((function(){pl.f(1)}))},{getOwnPropertySymbols:function(t){return pl.f(rl(t))}}),Ll){var sd=!$h||Zh((function(){var t=Fl();return"[null]"!=Ll([t])||"{}"!=Ll({a:t})||"{}"!=Ll(Object(t))}));qh({target:"JSON",stat:!0,forced:sd},{stringify:function(t,e,i){var n=bl(arguments),o=e;if((el(e)||void 0!==t)&&!nl(t))return Jh(e)||(e=function(t,e){if(tl(o)&&(e=Xh(o,this,t,e)),!nl(e))return e}),n[1]=e,Yh(Ll,null,n)}})}if(!Al[Il]){var ad=Al.valueOf;wl(Al,Il,(function(t){return Xh(ad,this)}))}Sl(Fl,Dl),_l[Pl]=!0;var hd=X.Object.getOwnPropertySymbols,ld={exports:{}},dd=_i,cd=o,ud=V,fd=m.f,pd=b,vd=cd((function(){fd(1)}));dd({target:"Object",stat:!0,forced:!pd||vd,sham:!pd},{getOwnPropertyDescriptor:function(t,e){return fd(ud(t),e)}});var gd=X.Object,yd=ld.exports=function(t,e){return gd.getOwnPropertyDescriptor(t,e)};gd.getOwnPropertyDescriptor.sham&&(yd.sham=!0);var md=ld.exports,bd=md,wd=Q,kd=rh,_d=$i,xd=$e,Ed=g([].concat),Od=wd("Reflect","ownKeys")||function(t){var e=kd.f(xd(t)),i=_d.f;return i?Ed(e,i(t)):e},Cd=Od,Sd=V,Td=m,Md=aa;_i({target:"Object",stat:!0,sham:!b},{getOwnPropertyDescriptors:function(t){for(var e,i,n=Sd(t),o=Td.f,r=Cd(n),s={},a=0;r.length>a;)void 0!==(i=o(n,e=r[a++]))&&Md(s,e,i);return s}});var Pd=X.Object.getOwnPropertyDescriptors,Dd={exports:{}},Id=_i,Bd=b,zd=Zo.f;Id({target:"Object",stat:!0,forced:Object.defineProperties!==zd,sham:!Bd},{defineProperties:zd});var Nd=X.Object,Fd=Dd.exports=function(t,e){return Nd.defineProperties(t,e)};Nd.defineProperties.sham&&(Fd.sham=!0);var Ad=Dd.exports,jd={exports:{}},Rd=_i,Ld=b,Hd=Ve.f;Rd({target:"Object",stat:!0,forced:Object.defineProperty!==Hd,sham:!Ld},{defineProperty:Hd});var Wd=X.Object,qd=jd.exports=function(t,e,i){return Wd.defineProperty(t,e,i)};Wd.defineProperty.sham&&(qd.sham=!0);var Vd=jd.exports,Ud=Vd;function Yd(t,e){if(!(t instanceof e))throw new TypeError("Cannot call a class as a function")}var Xd=Vd;function Gd(t,e){for(var i=0;i<e.length;i++){var n=e[i];n.enumerable=n.enumerable||!1,n.configurable=!0,"value"in n&&(n.writable=!0),Xd(t,n.key,n)}}function Kd(t,e,i){return e&&Gd(t.prototype,e),i&&Gd(t,i),Xd(t,"prototype",{writable:!1}),t}function $d(t,e,i){return e in t?Xd(t,e,{value:i,enumerable:!0,configurable:!0,writable:!0}):t[e]=i,t}_i({target:"Array",stat:!0},{isArray:oh});var Zd=X.Array.isArray,Qd=Zd;var Jd=o,tc=at,ec=oe("species"),ic=function(t){return tc>=51||!Jd((function(){var e=[];return(e.constructor={})[ec]=function(){return{foo:1}},1!==e[t](Boolean).foo}))},nc=_i,oc=n,rc=o,sc=oh,ac=Y,hc=Rt,lc=Bi,dc=aa,cc=zh,uc=ic,fc=at,pc=oe("isConcatSpreadable"),vc=9007199254740991,gc="Maximum allowed index exceeded",yc=oc.TypeError,mc=fc>=51||!rc((function(){var t=[];return t[pc]=!1,t.concat()[0]!==t})),bc=uc("concat"),wc=function(t){if(!ac(t))return!1;var e=t[pc];return void 0!==e?!!e:sc(t)};nc({target:"Array",proto:!0,forced:!mc||!bc},{concat:function(t){var e,i,n,o,r,s=hc(this),a=cc(s,0),h=0;for(e=-1,n=arguments.length;e<n;e++)if(wc(r=-1===e?s:arguments[e])){if(h+(o=lc(r))>vc)throw yc(gc);for(i=0;i<o;i++,h++)i in r&&dc(a,h,r[i])}else{if(h>=vc)throw yc(gc);dc(a,h++,r)}return a.length=h,a}}),Ch("asyncIterator"),Ch("hasInstance"),Ch("isConcatSpreadable"),Ch("iterator"),Ch("match"),Ch("matchAll"),Ch("replace"),Ch("search"),Ch("species"),Ch("split"),Ch("toPrimitive"),Ch("toStringTag"),Ch("unscopables"),$r(n.JSON,"JSON",!0);var kc=X.Symbol,_c=kc;Ch("asyncDispose"),Ch("dispose"),Ch("matcher"),Ch("metadata"),Ch("observable"),Ch("patternMatch"),Ch("replaceAll");var xc=_c;var Ec=_i,Oc=n,Cc=oh,Sc=na,Tc=Y,Mc=Mi,Pc=Bi,Dc=V,Ic=aa,Bc=oe,zc=fn,Nc=ic("slice"),Fc=Bc("species"),Ac=Oc.Array,jc=Math.max;Ec({target:"Array",proto:!0,forced:!Nc},{slice:function(t,e){var i,n,o,r=Dc(this),s=Pc(r),a=Mc(t,s),h=Mc(void 0===e?s:e,s);if(Cc(r)&&(i=r.constructor,(Sc(i)&&(i===Ac||Cc(i.prototype))||Tc(i)&&null===(i=i[Fc]))&&(i=void 0),i===Ac||void 0===i))return zc(r,a,h);for(n=new(void 0===i?Ac:i)(jc(h-a,0)),o=0;a<h;a++,o++)a in r&&Ic(n,o,r[a]);return n.length=o,n}});var Rc=Tn("Array").slice,Lc=J,Hc=Rc,Wc=Array.prototype,qc=function(t){var e=t.slice;return t===Wc||Lc(Wc,t)&&e===Wc.slice?Hc:e},Vc=qc,Uc=Vc,Yc=Aa;function Xc(t,e){(null==e||e>t.length)&&(e=t.length);for(var i=0,n=new Array(e);i<e;i++)n[i]=t[i];return n}function Gc(t,e){var i;if(t){if("string"==typeof t)return Xc(t,e);var n=Uc(i=Object.prototype.toString.call(t)).call(i,8,-1);return"Object"===n&&t.constructor&&(n=t.constructor.name),"Map"===n||"Set"===n?Yc(t):"Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n)?Xc(t,e):void 0}}function Kc(t,e){return function(t){if(Qd(t))return t}(t)||function(t,e){var i=null==t?null:void 0!==xc&&ih(t)||t["@@iterator"];if(null!=i){var n,o,r=[],s=!0,a=!1;try{for(i=i.call(t);!(s=(n=i.next()).done)&&(r.push(n.value),!e||r.length!==e);s=!0);}catch(t){a=!0,o=t}finally{try{s||null==i.return||i.return()}finally{if(a)throw o}}return r}}(t,e)||Gc(t,e)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}var $c=wh.f("iterator"),Zc=$c;function Qc(t){return Qc="function"==typeof xc&&"symbol"==typeof Zc?function(t){return typeof t}:function(t){return t&&"function"==typeof xc&&t.constructor===xc&&t!==xc.prototype?"symbol":typeof t},Qc(t)}function Jc(t){return function(t){if(Qd(t))return Xc(t)}(t)||function(t){if(void 0!==xc&&null!=ih(t)||null!=t["@@iterator"])return Yc(t)}(t)||Gc(t)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}var tu=kc,eu=Tn("Array").concat,iu=J,nu=eu,ou=Array.prototype,ru=function(t){var e=t.concat;return t===ou||iu(ou,t)&&e===ou.concat?nu:e},su=ru,au=Vc;_i({target:"Reflect",stat:!0},{ownKeys:Od});var hu=X.Reflect.ownKeys,lu=Zd,du=Wh.map;_i({target:"Array",proto:!0,forced:!ic("map")},{map:function(t){return du(this,t,arguments.length>1?arguments[1]:void 0)}});var cu=Tn("Array").map,uu=J,fu=cu,pu=Array.prototype,vu=function(t){var e=t.map;return t===pu||uu(pu,t)&&e===pu.map?fu:e},gu=vu,yu=Rt,mu=Ki;_i({target:"Object",stat:!0,forced:o((function(){mu(1)}))},{keys:function(t){return mu(yu(t))}});var bu=X.Object.keys,wu=_i,ku=g,_u=n.Date,xu=ku(_u.prototype.getTime);wu({target:"Date",stat:!0},{now:function(){return xu(new _u)}});var Eu=X.Date.now,Ou=o,Cu=function(t,e){var i=[][t];return!!i&&Ou((function(){i.call(null,e||function(){return 1},1)}))},Su=Wh.forEach,Tu=Cu("forEach")?[].forEach:function(t){return Su(this,t,arguments.length>1?arguments[1]:void 0)};_i({target:"Array",proto:!0,forced:[].forEach!=Tu},{forEach:Tu});var Mu=Tn("Array").forEach,Pu=Qn,Du=Wt,Iu=J,Bu=Mu,zu=Array.prototype,Nu={DOMTokenList:!0,NodeList:!0},Fu=function(t){var e=t.forEach;return t===zu||Iu(zu,t)&&e===zu.forEach||Du(Nu,Pu(t))?Bu:e},Au=_i,ju=oh,Ru=g([].reverse),Lu=[1,2];Au({target:"Array",proto:!0,forced:String(Lu)===String(Lu.reverse())},{reverse:function(){return ju(this)&&(this.length=this.length),Ru(this)}});var Hu=Tn("Array").reverse,Wu=J,qu=Hu,Vu=Array.prototype,Uu=function(t){var e=t.reverse;return t===Vu||Wu(Vu,t)&&e===Vu.reverse?qu:e},Yu=Uu,Xu=_i,Gu=n,Ku=Mi,$u=Oi,Zu=Bi,Qu=Rt,Ju=zh,tf=aa,ef=ic("splice"),nf=Gu.TypeError,of=Math.max,rf=Math.min,sf=9007199254740991,af="Maximum allowed length exceeded";Xu({target:"Array",proto:!0,forced:!ef},{splice:function(t,e){var i,n,o,r,s,a,h=Qu(this),l=Zu(h),d=Ku(t,l),c=arguments.length;if(0===c?i=n=0:1===c?(i=0,n=l-d):(i=c-2,n=rf(of($u(e),0),l-d)),l+i-n>sf)throw nf(af);for(o=Ju(h,n),r=0;r<n;r++)(s=d+r)in h&&tf(o,r,h[s]);if(o.length=n,i<n){for(r=d;r<l-n;r++)a=r+i,(s=r+n)in h?h[a]=h[s]:delete h[a];for(r=l;r>l-n+i;r--)delete h[r-1]}else if(i>n)for(r=l-n;r>d;r--)a=r+i-1,(s=r+n-1)in h?h[a]=h[s]:delete h[a];for(r=0;r<i;r++)h[r+d]=arguments[r+2];return h.length=l-n+i,o}});var hf=Tn("Array").splice,lf=J,df=hf,cf=Array.prototype,uf=function(t){var e=t.splice;return t===cf||lf(cf,t)&&e===cf.splice?df:e},ff=uf,pf=ji.includes;_i({target:"Array",proto:!0},{includes:function(t){return pf(this,t,arguments.length>1?arguments[1]:void 0)}});var vf=Tn("Array").includes,gf=Y,yf=B,mf=oe("match"),bf=function(t){var e;return gf(t)&&(void 0!==(e=t[mf])?!!e:"RegExp"==yf(t))},wf=n.TypeError,kf=oe("match"),_f=_i,xf=function(t){if(bf(t))throw wf("The method doesn't accept regular expressions");return t},Ef=H,Of=eo,Cf=function(t){var e=/./;try{"/./"[t](e)}catch(i){try{return e[kf]=!1,"/./"[t](e)}catch(t){}}return!1},Sf=g("".indexOf);_f({target:"String",proto:!0,forced:!Cf("includes")},{includes:function(t){return!!~Sf(Of(Ef(this)),Of(xf(t)),arguments.length>1?arguments[1]:void 0)}});var Tf=Tn("String").includes,Mf=J,Pf=vf,Df=Tf,If=Array.prototype,Bf=String.prototype,zf=function(t){var e=t.includes;return t===If||Mf(If,t)&&e===If.includes?Pf:"string"==typeof t||t===Bf||Mf(Bf,t)&&e===Bf.includes?Df:e},Nf=zf,Ff=Rt,Af=Pr,jf=kr;_i({target:"Object",stat:!0,forced:o((function(){Af(1)})),sham:!jf},{getPrototypeOf:function(t){return Af(Ff(t))}});var Rf=X.Object.getPrototypeOf,Lf=Rf,Hf=Wh.filter;_i({target:"Array",proto:!0,forced:!ic("filter")},{filter:function(t){return Hf(this,t,arguments.length>1?arguments[1]:void 0)}});var Wf=Tn("Array").filter,qf=J,Vf=Wf,Uf=Array.prototype,Yf=function(t){var e=t.filter;return t===Uf||qf(Uf,t)&&e===Uf.filter?Vf:e},Xf=Yf,Gf=b,Kf=g,$f=Ki,Zf=V,Qf=Kf(x.f),Jf=Kf([].push),tp=function(t){return function(e){for(var i,n=Zf(e),o=$f(n),r=o.length,s=0,a=[];r>s;)i=o[s++],Gf&&!Qf(n,i)||Jf(a,t?[i,n[i]]:n[i]);return a}},ep={entries:tp(!0),values:tp(!1)}.values;_i({target:"Object",stat:!0},{values:function(t){return ep(t)}});var ip=X.Object.values,np="\t\n\v\f\r                　\u2028\u2029\ufeff",op=H,rp=eo,sp=g("".replace),ap="[\t\n\v\f\r                　\u2028\u2029\ufeff]",hp=RegExp("^"+ap+ap+"*"),lp=RegExp(ap+ap+"*$"),dp=function(t){return function(e){var i=rp(op(e));return 1&t&&(i=sp(i,hp,"")),2&t&&(i=sp(i,lp,"")),i}},cp={start:dp(1),end:dp(2),trim:dp(3)},up=n,fp=o,pp=g,vp=eo,gp=cp.trim,yp=np,mp=up.parseInt,bp=up.Symbol,wp=bp&&bp.iterator,kp=/^[+-]?0x/i,_p=pp(kp.exec),xp=8!==mp(yp+"08")||22!==mp(yp+"0x16")||wp&&!fp((function(){mp(Object(wp))}))?function(t,e){var i=gp(vp(t));return mp(i,e>>>0||(_p(kp,i)?16:10))}:mp;_i({global:!0,forced:parseInt!=xp},{parseInt:xp});var Ep=X.parseInt,Op=_i,Cp=ji.indexOf,Sp=Cu,Tp=g([].indexOf),Mp=!!Tp&&1/Tp([1],1,-0)<0,Pp=Sp("indexOf");Op({target:"Array",proto:!0,forced:Mp||!Pp},{indexOf:function(t){var e=arguments.length>1?arguments[1]:void 0;return Mp?Tp(this,t,e)||0:Cp(this,t,e)}});var Dp=Tn("Array").indexOf,Ip=J,Bp=Dp,zp=Array.prototype,Np=function(t){var e=t.indexOf;return t===zp||Ip(zp,t)&&e===zp.indexOf?Bp:e},Fp=Np,Ap=$o.PROPER,jp=o,Rp=np,Lp=cp.trim;_i({target:"String",proto:!0,forced:function(t){return jp((function(){return!!Rp[t]()||"​᠎"!=="​᠎"[t]()||Ap&&Rp[t].name!==t}))}("trim")},{trim:function(){return Lp(this)}});var Hp=Tn("String").trim,Wp=J,qp=Hp,Vp=String.prototype,Up=function(t){var e=t.trim;return"string"==typeof t||t===Vp||Wp(Vp,t)&&e===Vp.trim?qp:e},Yp=Up;_i({target:"Object",stat:!0,sham:!b},{create:wr});var Xp=X.Object,Gp=function(t,e){return Xp.create(t,e)},Kp=Gp,$p=_i,Zp=Q,Qp=d,Jp=g,tv=o,ev=n.Array,iv=Zp("JSON","stringify"),nv=Jp(/./.exec),ov=Jp("".charAt),rv=Jp("".charCodeAt),sv=Jp("".replace),av=Jp(1..toString),hv=/[\uD800-\uDFFF]/g,lv=/^[\uD800-\uDBFF]$/,dv=/^[\uDC00-\uDFFF]$/,cv=function(t,e,i){var n=ov(i,e-1),o=ov(i,e+1);return nv(lv,t)&&!nv(dv,o)||nv(dv,t)&&!nv(lv,n)?"\\u"+av(rv(t,0),16):t},uv=tv((function(){return'"\\udf06\\ud834"'!==iv("\udf06\ud834")||'"\\udead"'!==iv("\udead")}));iv&&$p({target:"JSON",stat:!0,forced:uv},{stringify:function(t,e,i){for(var n=0,o=arguments.length,r=ev(o);n<o;n++)r[n]=arguments[n];var s=Qp(iv,null,r);return"string"==typeof s?sv(s,hv,cv):s}});var fv=X,pv=d;fv.JSON||(fv.JSON={stringify:JSON.stringify});var vv=function(t,e,i){return pv(fv.JSON.stringify,null,arguments)},gv=vv,yv=n.TypeError,mv=_i,bv=n,wv=d,kv=y,_v=fn,xv=function(t,e){if(t<e)throw yv("Not enough arguments");return t},Ev=/MSIE .\./.test(tt),Ov=bv.Function,Cv=function(t){return function(e,i){var n=xv(arguments.length,1)>2,o=kv(e)?e:Ov(e),r=n?_v(arguments,2):void 0;return t(n?function(){wv(o,this,r)}:o,i)}};mv({global:!0,bind:!0,forced:Ev},{setTimeout:Cv(bv.setTimeout),setInterval:Cv(bv.setInterval)});var Sv=X.setTimeout,Tv=Rt,Mv=Mi,Pv=Bi,Dv=function(t){for(var e=Tv(this),i=Pv(e),n=arguments.length,o=Mv(n>1?arguments[1]:void 0,i),r=n>2?arguments[2]:void 0,s=void 0===r?i:Mv(r,i);s>o;)e[o++]=t;return e};_i({target:"Array",proto:!0},{fill:Dv});var Iv,Bv=Tn("Array").fill,zv=J,Nv=Bv,Fv=Array.prototype,Av=function(t){var e=t.fill;return t===Fv||zv(Fv,t)&&e===Fv.fill?Nv:e},jv=Av;function Rv(){return Rv=Object.assign||function(t){for(var e=1;e<arguments.length;e++){var i=arguments[e];for(var n in i)Object.prototype.hasOwnProperty.call(i,n)&&(t[n]=i[n])}return t},Rv.apply(this,arguments)}function Lv(t,e){t.prototype=Object.create(e.prototype),t.prototype.constructor=t,t.__proto__=e}function Hv(t){if(void 0===t)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return t}Iv="function"!=typeof Object.assign?function(t){if(null==t)throw new TypeError("Cannot convert undefined or null to object");for(var e=Object(t),i=1;i<arguments.length;i++){var n=arguments[i];if(null!=n)for(var o in n)n.hasOwnProperty(o)&&(e[o]=n[o])}return e}:Object.assign;var Wv,qv=Iv,Vv=["","webkit","Moz","MS","ms","o"],Uv="undefined"==typeof document?{style:{}}:document.createElement("div"),Yv=Math.round,Xv=Math.abs,Gv=Date.now;function Kv(t,e){for(var i,n,o=e[0].toUpperCase()+e.slice(1),r=0;r<Vv.length;){if((n=(i=Vv[r])?i+o:e)in t)return n;r++}}Wv="undefined"==typeof window?{}:window;var $v=Kv(Uv.style,"touchAction"),Zv=void 0!==$v;var Qv="compute",Jv="auto",tg="manipulation",eg="none",ig="pan-x",ng="pan-y",og=function(){if(!Zv)return!1;var t={},e=Wv.CSS&&Wv.CSS.supports;return["auto","manipulation","pan-y","pan-x","pan-x pan-y","none"].forEach((function(i){return t[i]=!e||Wv.CSS.supports("touch-action",i)})),t}(),rg="ontouchstart"in Wv,sg=void 0!==Kv(Wv,"PointerEvent"),ag=rg&&/mobile|tablet|ip(ad|hone|od)|android/i.test(navigator.userAgent),hg="touch",lg="mouse",dg=16,cg=24,ug=["x","y"],fg=["clientX","clientY"];function pg(t,e,i){var n;if(t)if(t.forEach)t.forEach(e,i);else if(void 0!==t.length)for(n=0;n<t.length;)e.call(i,t[n],n,t),n++;else for(n in t)t.hasOwnProperty(n)&&e.call(i,t[n],n,t)}function vg(t,e){return"function"==typeof t?t.apply(e&&e[0]||void 0,e):t}function gg(t,e){return t.indexOf(e)>-1}var yg=function(){function t(t,e){this.manager=t,this.set(e)}var e=t.prototype;return e.set=function(t){t===Qv&&(t=this.compute()),Zv&&this.manager.element.style&&og[t]&&(this.manager.element.style[$v]=t),this.actions=t.toLowerCase().trim()},e.update=function(){this.set(this.manager.options.touchAction)},e.compute=function(){var t=[];return pg(this.manager.recognizers,(function(e){vg(e.options.enable,[e])&&(t=t.concat(e.getTouchAction()))})),function(t){if(gg(t,eg))return eg;var e=gg(t,ig),i=gg(t,ng);return e&&i?eg:e||i?e?ig:ng:gg(t,tg)?tg:Jv}(t.join(" "))},e.preventDefaults=function(t){var e=t.srcEvent,i=t.offsetDirection;if(this.manager.session.prevented)e.preventDefault();else{var n=this.actions,o=gg(n,eg)&&!og.none,r=gg(n,ng)&&!og["pan-y"],s=gg(n,ig)&&!og["pan-x"];if(o){var a=1===t.pointers.length,h=t.distance<2,l=t.deltaTime<250;if(a&&h&&l)return}if(!s||!r)return o||r&&6&i||s&&i&cg?this.preventSrc(e):void 0}},e.preventSrc=function(t){this.manager.session.prevented=!0,t.preventDefault()},t}();function mg(t,e){for(;t;){if(t===e)return!0;t=t.parentNode}return!1}function bg(t){var e=t.length;if(1===e)return{x:Yv(t[0].clientX),y:Yv(t[0].clientY)};for(var i=0,n=0,o=0;o<e;)i+=t[o].clientX,n+=t[o].clientY,o++;return{x:Yv(i/e),y:Yv(n/e)}}function wg(t){for(var e=[],i=0;i<t.pointers.length;)e[i]={clientX:Yv(t.pointers[i].clientX),clientY:Yv(t.pointers[i].clientY)},i++;return{timeStamp:Gv(),pointers:e,center:bg(e),deltaX:t.deltaX,deltaY:t.deltaY}}function kg(t,e,i){i||(i=ug);var n=e[i[0]]-t[i[0]],o=e[i[1]]-t[i[1]];return Math.sqrt(n*n+o*o)}function _g(t,e,i){i||(i=ug);var n=e[i[0]]-t[i[0]],o=e[i[1]]-t[i[1]];return 180*Math.atan2(o,n)/Math.PI}function xg(t,e){return t===e?1:Xv(t)>=Xv(e)?t<0?2:4:e<0?8:dg}function Eg(t,e,i){return{x:e/t||0,y:i/t||0}}function Og(t,e){var i=t.session,n=e.pointers,o=n.length;i.firstInput||(i.firstInput=wg(e)),o>1&&!i.firstMultiple?i.firstMultiple=wg(e):1===o&&(i.firstMultiple=!1);var r=i.firstInput,s=i.firstMultiple,a=s?s.center:r.center,h=e.center=bg(n);e.timeStamp=Gv(),e.deltaTime=e.timeStamp-r.timeStamp,e.angle=_g(a,h),e.distance=kg(a,h),function(t,e){var i=e.center,n=t.offsetDelta||{},o=t.prevDelta||{},r=t.prevInput||{};1!==e.eventType&&4!==r.eventType||(o=t.prevDelta={x:r.deltaX||0,y:r.deltaY||0},n=t.offsetDelta={x:i.x,y:i.y}),e.deltaX=o.x+(i.x-n.x),e.deltaY=o.y+(i.y-n.y)}(i,e),e.offsetDirection=xg(e.deltaX,e.deltaY);var l,d,c=Eg(e.deltaTime,e.deltaX,e.deltaY);e.overallVelocityX=c.x,e.overallVelocityY=c.y,e.overallVelocity=Xv(c.x)>Xv(c.y)?c.x:c.y,e.scale=s?(l=s.pointers,kg((d=n)[0],d[1],fg)/kg(l[0],l[1],fg)):1,e.rotation=s?function(t,e){return _g(e[1],e[0],fg)+_g(t[1],t[0],fg)}(s.pointers,n):0,e.maxPointers=i.prevInput?e.pointers.length>i.prevInput.maxPointers?e.pointers.length:i.prevInput.maxPointers:e.pointers.length,function(t,e){var i,n,o,r,s=t.lastInterval||e,a=e.timeStamp-s.timeStamp;if(8!==e.eventType&&(a>25||void 0===s.velocity)){var h=e.deltaX-s.deltaX,l=e.deltaY-s.deltaY,d=Eg(a,h,l);n=d.x,o=d.y,i=Xv(d.x)>Xv(d.y)?d.x:d.y,r=xg(h,l),t.lastInterval=e}else i=s.velocity,n=s.velocityX,o=s.velocityY,r=s.direction;e.velocity=i,e.velocityX=n,e.velocityY=o,e.direction=r}(i,e);var u,f=t.element,p=e.srcEvent;mg(u=p.composedPath?p.composedPath()[0]:p.path?p.path[0]:p.target,f)&&(f=u),e.target=f}function Cg(t,e,i){var n=i.pointers.length,o=i.changedPointers.length,r=1&e&&n-o==0,s=12&e&&n-o==0;i.isFirst=!!r,i.isFinal=!!s,r&&(t.session={}),i.eventType=e,Og(t,i),t.emit("hammer.input",i),t.recognize(i),t.session.prevInput=i}function Sg(t){return t.trim().split(/\s+/g)}function Tg(t,e,i){pg(Sg(e),(function(e){t.addEventListener(e,i,!1)}))}function Mg(t,e,i){pg(Sg(e),(function(e){t.removeEventListener(e,i,!1)}))}function Pg(t){var e=t.ownerDocument||t;return e.defaultView||e.parentWindow||window}var Dg=function(){function t(t,e){var i=this;this.manager=t,this.callback=e,this.element=t.element,this.target=t.options.inputTarget,this.domHandler=function(e){vg(t.options.enable,[t])&&i.handler(e)},this.init()}var e=t.prototype;return e.handler=function(){},e.init=function(){this.evEl&&Tg(this.element,this.evEl,this.domHandler),this.evTarget&&Tg(this.target,this.evTarget,this.domHandler),this.evWin&&Tg(Pg(this.element),this.evWin,this.domHandler)},e.destroy=function(){this.evEl&&Mg(this.element,this.evEl,this.domHandler),this.evTarget&&Mg(this.target,this.evTarget,this.domHandler),this.evWin&&Mg(Pg(this.element),this.evWin,this.domHandler)},t}();function Ig(t,e,i){if(t.indexOf&&!i)return t.indexOf(e);for(var n=0;n<t.length;){if(i&&t[n][i]==e||!i&&t[n]===e)return n;n++}return-1}var Bg={pointerdown:1,pointermove:2,pointerup:4,pointercancel:8,pointerout:8},zg={2:hg,3:"pen",4:lg,5:"kinect"},Ng="pointerdown",Fg="pointermove pointerup pointercancel";Wv.MSPointerEvent&&!Wv.PointerEvent&&(Ng="MSPointerDown",Fg="MSPointerMove MSPointerUp MSPointerCancel");var Ag=function(t){function e(){var i,n=e.prototype;return n.evEl=Ng,n.evWin=Fg,(i=t.apply(this,arguments)||this).store=i.manager.session.pointerEvents=[],i}return Lv(e,t),e.prototype.handler=function(t){var e=this.store,i=!1,n=t.type.toLowerCase().replace("ms",""),o=Bg[n],r=zg[t.pointerType]||t.pointerType,s=r===hg,a=Ig(e,t.pointerId,"pointerId");1&o&&(0===t.button||s)?a<0&&(e.push(t),a=e.length-1):12&o&&(i=!0),a<0||(e[a]=t,this.callback(this.manager,o,{pointers:e,changedPointers:[t],pointerType:r,srcEvent:t}),i&&e.splice(a,1))},e}(Dg);function jg(t){return Array.prototype.slice.call(t,0)}function Rg(t,e,i){for(var n=[],o=[],r=0;r<t.length;){var s=e?t[r][e]:t[r];Ig(o,s)<0&&n.push(t[r]),o[r]=s,r++}return i&&(n=e?n.sort((function(t,i){return t[e]>i[e]})):n.sort()),n}var Lg={touchstart:1,touchmove:2,touchend:4,touchcancel:8},Hg="touchstart touchmove touchend touchcancel",Wg=function(t){function e(){var i;return e.prototype.evTarget=Hg,(i=t.apply(this,arguments)||this).targetIds={},i}return Lv(e,t),e.prototype.handler=function(t){var e=Lg[t.type],i=qg.call(this,t,e);i&&this.callback(this.manager,e,{pointers:i[0],changedPointers:i[1],pointerType:hg,srcEvent:t})},e}(Dg);function qg(t,e){var i,n,o=jg(t.touches),r=this.targetIds;if(3&e&&1===o.length)return r[o[0].identifier]=!0,[o,o];var s=jg(t.changedTouches),a=[],h=this.target;if(n=o.filter((function(t){return mg(t.target,h)})),1===e)for(i=0;i<n.length;)r[n[i].identifier]=!0,i++;for(i=0;i<s.length;)r[s[i].identifier]&&a.push(s[i]),12&e&&delete r[s[i].identifier],i++;return a.length?[Rg(n.concat(a),"identifier",!0),a]:void 0}var Vg={mousedown:1,mousemove:2,mouseup:4},Ug="mousedown",Yg="mousemove mouseup",Xg=function(t){function e(){var i,n=e.prototype;return n.evEl=Ug,n.evWin=Yg,(i=t.apply(this,arguments)||this).pressed=!1,i}return Lv(e,t),e.prototype.handler=function(t){var e=Vg[t.type];1&e&&0===t.button&&(this.pressed=!0),2&e&&1!==t.which&&(e=4),this.pressed&&(4&e&&(this.pressed=!1),this.callback(this.manager,e,{pointers:[t],changedPointers:[t],pointerType:lg,srcEvent:t}))},e}(Dg);function Gg(t){var e=t.changedPointers[0];if(e.identifier===this.primaryTouch){var i={x:e.clientX,y:e.clientY},n=this.lastTouches;this.lastTouches.push(i);setTimeout((function(){var t=n.indexOf(i);t>-1&&n.splice(t,1)}),2500)}}function Kg(t,e){1&t?(this.primaryTouch=e.changedPointers[0].identifier,Gg.call(this,e)):12&t&&Gg.call(this,e)}function $g(t){for(var e=t.srcEvent.clientX,i=t.srcEvent.clientY,n=0;n<this.lastTouches.length;n++){var o=this.lastTouches[n],r=Math.abs(e-o.x),s=Math.abs(i-o.y);if(r<=25&&s<=25)return!0}return!1}var Zg=function(){return function(t){function e(e,i){var n;return(n=t.call(this,e,i)||this).handler=function(t,e,i){var o=i.pointerType===hg,r=i.pointerType===lg;if(!(r&&i.sourceCapabilities&&i.sourceCapabilities.firesTouchEvents)){if(o)Kg.call(Hv(Hv(n)),e,i);else if(r&&$g.call(Hv(Hv(n)),i))return;n.callback(t,e,i)}},n.touch=new Wg(n.manager,n.handler),n.mouse=new Xg(n.manager,n.handler),n.primaryTouch=null,n.lastTouches=[],n}return Lv(e,t),e.prototype.destroy=function(){this.touch.destroy(),this.mouse.destroy()},e}(Dg)}();function Qg(t,e,i){return!!Array.isArray(t)&&(pg(t,i[e],i),!0)}var Jg=32,ty=1;function ey(t,e){var i=e.manager;return i?i.get(t):t}function iy(t){return 16&t?"cancel":8&t?"end":4&t?"move":2&t?"start":""}var ny=function(){function t(t){void 0===t&&(t={}),this.options=Rv({enable:!0},t),this.id=ty++,this.manager=null,this.state=1,this.simultaneous={},this.requireFail=[]}var e=t.prototype;return e.set=function(t){return qv(this.options,t),this.manager&&this.manager.touchAction.update(),this},e.recognizeWith=function(t){if(Qg(t,"recognizeWith",this))return this;var e=this.simultaneous;return e[(t=ey(t,this)).id]||(e[t.id]=t,t.recognizeWith(this)),this},e.dropRecognizeWith=function(t){return Qg(t,"dropRecognizeWith",this)||(t=ey(t,this),delete this.simultaneous[t.id]),this},e.requireFailure=function(t){if(Qg(t,"requireFailure",this))return this;var e=this.requireFail;return-1===Ig(e,t=ey(t,this))&&(e.push(t),t.requireFailure(this)),this},e.dropRequireFailure=function(t){if(Qg(t,"dropRequireFailure",this))return this;t=ey(t,this);var e=Ig(this.requireFail,t);return e>-1&&this.requireFail.splice(e,1),this},e.hasRequireFailures=function(){return this.requireFail.length>0},e.canRecognizeWith=function(t){return!!this.simultaneous[t.id]},e.emit=function(t){var e=this,i=this.state;function n(i){e.manager.emit(i,t)}i<8&&n(e.options.event+iy(i)),n(e.options.event),t.additionalEvent&&n(t.additionalEvent),i>=8&&n(e.options.event+iy(i))},e.tryEmit=function(t){if(this.canEmit())return this.emit(t);this.state=Jg},e.canEmit=function(){for(var t=0;t<this.requireFail.length;){if(!(33&this.requireFail[t].state))return!1;t++}return!0},e.recognize=function(t){var e=qv({},t);if(!vg(this.options.enable,[this,e]))return this.reset(),void(this.state=Jg);56&this.state&&(this.state=1),this.state=this.process(e),30&this.state&&this.tryEmit(e)},e.process=function(t){},e.getTouchAction=function(){},e.reset=function(){},t}(),oy=function(t){function e(e){var i;return void 0===e&&(e={}),(i=t.call(this,Rv({event:"tap",pointers:1,taps:1,interval:300,time:250,threshold:9,posThreshold:10},e))||this).pTime=!1,i.pCenter=!1,i._timer=null,i._input=null,i.count=0,i}Lv(e,t);var i=e.prototype;return i.getTouchAction=function(){return[tg]},i.process=function(t){var e=this,i=this.options,n=t.pointers.length===i.pointers,o=t.distance<i.threshold,r=t.deltaTime<i.time;if(this.reset(),1&t.eventType&&0===this.count)return this.failTimeout();if(o&&r&&n){if(4!==t.eventType)return this.failTimeout();var s=!this.pTime||t.timeStamp-this.pTime<i.interval,a=!this.pCenter||kg(this.pCenter,t.center)<i.posThreshold;if(this.pTime=t.timeStamp,this.pCenter=t.center,a&&s?this.count+=1:this.count=1,this._input=t,0===this.count%i.taps)return this.hasRequireFailures()?(this._timer=setTimeout((function(){e.state=8,e.tryEmit()}),i.interval),2):8}return Jg},i.failTimeout=function(){var t=this;return this._timer=setTimeout((function(){t.state=Jg}),this.options.interval),Jg},i.reset=function(){clearTimeout(this._timer)},i.emit=function(){8===this.state&&(this._input.tapCount=this.count,this.manager.emit(this.options.event,this._input))},e}(ny),ry=function(t){function e(e){return void 0===e&&(e={}),t.call(this,Rv({pointers:1},e))||this}Lv(e,t);var i=e.prototype;return i.attrTest=function(t){var e=this.options.pointers;return 0===e||t.pointers.length===e},i.process=function(t){var e=this.state,i=t.eventType,n=6&e,o=this.attrTest(t);return n&&(8&i||!o)?16|e:n||o?4&i?8|e:2&e?4|e:2:Jg},e}(ny);function sy(t){return t===dg?"down":8===t?"up":2===t?"left":4===t?"right":""}var ay=function(t){function e(e){var i;return void 0===e&&(e={}),(i=t.call(this,Rv({event:"pan",threshold:10,pointers:1,direction:30},e))||this).pX=null,i.pY=null,i}Lv(e,t);var i=e.prototype;return i.getTouchAction=function(){var t=this.options.direction,e=[];return 6&t&&e.push(ng),t&cg&&e.push(ig),e},i.directionTest=function(t){var e=this.options,i=!0,n=t.distance,o=t.direction,r=t.deltaX,s=t.deltaY;return o&e.direction||(6&e.direction?(o=0===r?1:r<0?2:4,i=r!==this.pX,n=Math.abs(t.deltaX)):(o=0===s?1:s<0?8:dg,i=s!==this.pY,n=Math.abs(t.deltaY))),t.direction=o,i&&n>e.threshold&&o&e.direction},i.attrTest=function(t){return ry.prototype.attrTest.call(this,t)&&(2&this.state||!(2&this.state)&&this.directionTest(t))},i.emit=function(e){this.pX=e.deltaX,this.pY=e.deltaY;var i=sy(e.direction);i&&(e.additionalEvent=this.options.event+i),t.prototype.emit.call(this,e)},e}(ry),hy=function(t){function e(e){return void 0===e&&(e={}),t.call(this,Rv({event:"swipe",threshold:10,velocity:.3,direction:30,pointers:1},e))||this}Lv(e,t);var i=e.prototype;return i.getTouchAction=function(){return ay.prototype.getTouchAction.call(this)},i.attrTest=function(e){var i,n=this.options.direction;return 30&n?i=e.overallVelocity:6&n?i=e.overallVelocityX:n&cg&&(i=e.overallVelocityY),t.prototype.attrTest.call(this,e)&&n&e.offsetDirection&&e.distance>this.options.threshold&&e.maxPointers===this.options.pointers&&Xv(i)>this.options.velocity&&4&e.eventType},i.emit=function(t){var e=sy(t.offsetDirection);e&&this.manager.emit(this.options.event+e,t),this.manager.emit(this.options.event,t)},e}(ry),ly=function(t){function e(e){return void 0===e&&(e={}),t.call(this,Rv({event:"pinch",threshold:0,pointers:2},e))||this}Lv(e,t);var i=e.prototype;return i.getTouchAction=function(){return[eg]},i.attrTest=function(e){return t.prototype.attrTest.call(this,e)&&(Math.abs(e.scale-1)>this.options.threshold||2&this.state)},i.emit=function(e){if(1!==e.scale){var i=e.scale<1?"in":"out";e.additionalEvent=this.options.event+i}t.prototype.emit.call(this,e)},e}(ry),dy=function(t){function e(e){return void 0===e&&(e={}),t.call(this,Rv({event:"rotate",threshold:0,pointers:2},e))||this}Lv(e,t);var i=e.prototype;return i.getTouchAction=function(){return[eg]},i.attrTest=function(e){return t.prototype.attrTest.call(this,e)&&(Math.abs(e.rotation)>this.options.threshold||2&this.state)},e}(ry),cy=function(t){function e(e){var i;return void 0===e&&(e={}),(i=t.call(this,Rv({event:"press",pointers:1,time:251,threshold:9},e))||this)._timer=null,i._input=null,i}Lv(e,t);var i=e.prototype;return i.getTouchAction=function(){return[Jv]},i.process=function(t){var e=this,i=this.options,n=t.pointers.length===i.pointers,o=t.distance<i.threshold,r=t.deltaTime>i.time;if(this._input=t,!o||!n||12&t.eventType&&!r)this.reset();else if(1&t.eventType)this.reset(),this._timer=setTimeout((function(){e.state=8,e.tryEmit()}),i.time);else if(4&t.eventType)return 8;return Jg},i.reset=function(){clearTimeout(this._timer)},i.emit=function(t){8===this.state&&(t&&4&t.eventType?this.manager.emit(this.options.event+"up",t):(this._input.timeStamp=Gv(),this.manager.emit(this.options.event,this._input)))},e}(ny),uy={domEvents:!1,touchAction:Qv,enable:!0,inputTarget:null,inputClass:null,cssProps:{userSelect:"none",touchSelect:"none",touchCallout:"none",contentZooming:"none",userDrag:"none",tapHighlightColor:"rgba(0,0,0,0)"}},fy=[[dy,{enable:!1}],[ly,{enable:!1},["rotate"]],[hy,{direction:6}],[ay,{direction:6},["swipe"]],[oy],[oy,{event:"doubletap",taps:2},["tap"]],[cy]];function py(t,e){var i,n=t.element;n.style&&(pg(t.options.cssProps,(function(o,r){i=Kv(n.style,r),e?(t.oldCssProps[i]=n.style[i],n.style[i]=o):n.style[i]=t.oldCssProps[i]||""})),e||(t.oldCssProps={}))}var vy=function(){function t(t,e){var i,n=this;this.options=qv({},uy,e||{}),this.options.inputTarget=this.options.inputTarget||t,this.handlers={},this.session={},this.recognizers=[],this.oldCssProps={},this.element=t,this.input=new((i=this).options.inputClass||(sg?Ag:ag?Wg:rg?Zg:Xg))(i,Cg),this.touchAction=new yg(this,this.options.touchAction),py(this,!0),pg(this.options.recognizers,(function(t){var e=n.add(new t[0](t[1]));t[2]&&e.recognizeWith(t[2]),t[3]&&e.requireFailure(t[3])}),this)}var e=t.prototype;return e.set=function(t){return qv(this.options,t),t.touchAction&&this.touchAction.update(),t.inputTarget&&(this.input.destroy(),this.input.target=t.inputTarget,this.input.init()),this},e.stop=function(t){this.session.stopped=t?2:1},e.recognize=function(t){var e=this.session;if(!e.stopped){var i;this.touchAction.preventDefaults(t);var n=this.recognizers,o=e.curRecognizer;(!o||o&&8&o.state)&&(e.curRecognizer=null,o=null);for(var r=0;r<n.length;)i=n[r],2===e.stopped||o&&i!==o&&!i.canRecognizeWith(o)?i.reset():i.recognize(t),!o&&14&i.state&&(e.curRecognizer=i,o=i),r++}},e.get=function(t){if(t instanceof ny)return t;for(var e=this.recognizers,i=0;i<e.length;i++)if(e[i].options.event===t)return e[i];return null},e.add=function(t){if(Qg(t,"add",this))return this;var e=this.get(t.options.event);return e&&this.remove(e),this.recognizers.push(t),t.manager=this,this.touchAction.update(),t},e.remove=function(t){if(Qg(t,"remove",this))return this;var e=this.get(t);if(t){var i=this.recognizers,n=Ig(i,e);-1!==n&&(i.splice(n,1),this.touchAction.update())}return this},e.on=function(t,e){if(void 0===t||void 0===e)return this;var i=this.handlers;return pg(Sg(t),(function(t){i[t]=i[t]||[],i[t].push(e)})),this},e.off=function(t,e){if(void 0===t)return this;var i=this.handlers;return pg(Sg(t),(function(t){e?i[t]&&i[t].splice(Ig(i[t],e),1):delete i[t]})),this},e.emit=function(t,e){this.options.domEvents&&function(t,e){var i=document.createEvent("Event");i.initEvent(t,!0,!0),i.gesture=e,e.target.dispatchEvent(i)}(t,e);var i=this.handlers[t]&&this.handlers[t].slice();if(i&&i.length){e.type=t,e.preventDefault=function(){e.srcEvent.preventDefault()};for(var n=0;n<i.length;)i[n](e),n++}},e.destroy=function(){this.element&&py(this,!1),this.handlers={},this.session={},this.input.destroy(),this.element=null},t}(),gy={touchstart:1,touchmove:2,touchend:4,touchcancel:8},yy="touchstart",my="touchstart touchmove touchend touchcancel",by=function(t){function e(){var i,n=e.prototype;return n.evTarget=yy,n.evWin=my,(i=t.apply(this,arguments)||this).started=!1,i}return Lv(e,t),e.prototype.handler=function(t){var e=gy[t.type];if(1===e&&(this.started=!0),this.started){var i=wy.call(this,t,e);12&e&&i[0].length-i[1].length==0&&(this.started=!1),this.callback(this.manager,e,{pointers:i[0],changedPointers:i[1],pointerType:hg,srcEvent:t})}},e}(Dg);function wy(t,e){var i=jg(t.touches),n=jg(t.changedTouches);return 12&e&&(i=Rg(i.concat(n),"identifier",!0)),[i,n]}function ky(t,e,i){var n="DEPRECATED METHOD: "+e+"\n"+i+" AT \n";return function(){var e=new Error("get-stack-trace"),i=e&&e.stack?e.stack.replace(/^[^\(]+?[\n$]/gm,"").replace(/^\s+at\s+/gm,"").replace(/^Object.<anonymous>\s*\(/gm,"{anonymous}()@"):"Unknown Stack Trace",o=window.console&&(window.console.warn||window.console.log);return o&&o.call(window.console,n,i),t.apply(this,arguments)}}var _y=ky((function(t,e,i){for(var n=Object.keys(e),o=0;o<n.length;)(!i||i&&void 0===t[n[o]])&&(t[n[o]]=e[n[o]]),o++;return t}),"extend","Use `assign`."),xy=ky((function(t,e){return _y(t,e,!0)}),"merge","Use `assign`.");function Ey(t,e,i){var n,o=e.prototype;(n=t.prototype=Object.create(o)).constructor=t,n._super=o,i&&qv(n,i)}function Oy(t,e){return function(){return t.apply(e,arguments)}}var Cy=function(){var t=function(t,e){return void 0===e&&(e={}),new vy(t,Rv({recognizers:fy.concat()},e))};return t.VERSION="2.0.17-rc",t.DIRECTION_ALL=30,t.DIRECTION_DOWN=dg,t.DIRECTION_LEFT=2,t.DIRECTION_RIGHT=4,t.DIRECTION_UP=8,t.DIRECTION_HORIZONTAL=6,t.DIRECTION_VERTICAL=cg,t.DIRECTION_NONE=1,t.DIRECTION_DOWN=dg,t.INPUT_START=1,t.INPUT_MOVE=2,t.INPUT_END=4,t.INPUT_CANCEL=8,t.STATE_POSSIBLE=1,t.STATE_BEGAN=2,t.STATE_CHANGED=4,t.STATE_ENDED=8,t.STATE_RECOGNIZED=8,t.STATE_CANCELLED=16,t.STATE_FAILED=Jg,t.Manager=vy,t.Input=Dg,t.TouchAction=yg,t.TouchInput=Wg,t.MouseInput=Xg,t.PointerEventInput=Ag,t.TouchMouseInput=Zg,t.SingleTouchInput=by,t.Recognizer=ny,t.AttrRecognizer=ry,t.Tap=oy,t.Pan=ay,t.Swipe=hy,t.Pinch=ly,t.Rotate=dy,t.Press=cy,t.on=Tg,t.off=Mg,t.each=pg,t.merge=xy,t.extend=_y,t.bindFn=Oy,t.assign=qv,t.inherit=Ey,t.bindFn=Oy,t.prefixed=Kv,t.toArray=jg,t.inArray=Ig,t.uniqueArray=Rg,t.splitStr=Sg,t.boolOrFn=vg,t.hasParent=mg,t.addEventListeners=Tg,t.removeEventListeners=Mg,t.defaults=qv({},uy,{preset:fy}),t}(),Sy=Cy;function Ty(t,e){var i=bu(t);if(hd){var n=hd(t);e&&(n=Xf(n).call(n,(function(e){return bd(t,e).enumerable}))),i.push.apply(i,n)}return i}function My(t){for(var e=1;e<arguments.length;e++){var i,n,o=null!=arguments[e]?arguments[e]:{};e%2?Fu(i=Ty(Object(o),!0)).call(i,(function(e){$d(t,e,o[e])})):Pd?Ad(t,Pd(o)):Fu(n=Ty(Object(o))).call(n,(function(e){Ud(t,e,bd(o,e))}))}return t}function Py(t,e){var i=void 0!==tu&&ih(t)||t["@@iterator"];if(!i){if(lu(t)||(i=function(t,e){var i;if(!t)return;if("string"==typeof t)return Dy(t,e);var n=au(i=Object.prototype.toString.call(t)).call(i,8,-1);"Object"===n&&t.constructor&&(n=t.constructor.name);if("Map"===n||"Set"===n)return ja(t);if("Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n))return Dy(t,e)}(t))||e&&t&&"number"==typeof t.length){i&&(t=i);var n=0,o=function(){};return{s:o,n:function(){return n>=t.length?{done:!0}:{done:!1,value:t[n++]}},e:function(t){throw t},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var r,s=!0,a=!1;return{s:function(){i=i.call(t)},n:function(){var t=i.next();return s=t.done,t},e:function(t){a=!0,r=t},f:function(){try{s||null==i.return||i.return()}finally{if(a)throw r}}}}function Dy(t,e){(null==e||e>t.length)&&(e=t.length);for(var i=0,n=new Array(e);i<e;i++)n[i]=t[i];return n}var Iy=tu("DELETE");function By(t){for(var e,i=arguments.length,n=new Array(i>1?i-1:0),o=1;o<i;o++)n[o-1]=arguments[o];return zy.apply(void 0,su(e=[{},t]).call(e,n))}function zy(){var t=Ny.apply(void 0,arguments);return Ay(t),t}function Ny(){for(var t=arguments.length,e=new Array(t),i=0;i<t;i++)e[i]=arguments[i];if(e.length<2)return e[0];var n;if(e.length>2)return Ny.apply(void 0,su(n=[zy(e[0],e[1])]).call(n,Jc(au(e).call(e,2))));var o,r=e[0],s=e[1],a=Py(hu(s));try{for(a.s();!(o=a.n()).done;){var h=o.value;Object.prototype.propertyIsEnumerable.call(s,h)&&(s[h]===Iy?delete r[h]:null===r[h]||null===s[h]||"object"!==Qc(r[h])||"object"!==Qc(s[h])||lu(r[h])||lu(s[h])?r[h]=Fy(s[h]):r[h]=Ny(r[h],s[h]))}}catch(t){a.e(t)}finally{a.f()}return r}function Fy(t){return lu(t)?gu(t).call(t,(function(t){return Fy(t)})):"object"===Qc(t)&&null!==t?Ny({},t):t}function Ay(t){for(var e=0,i=bu(t);e<i.length;e++){var n=i[e];t[n]===Iy?delete t[n]:"object"===Qc(t[n])&&null!==t[n]&&Ay(t[n])}}function jy(){for(var t=arguments.length,e=new Array(t),i=0;i<t;i++)e[i]=arguments[i];return Ry(e.length?e:[Eu()])}function Ry(t){var e=function(){for(var t=Ly(),e=t(" "),i=t(" "),n=t(" "),o=0;o<arguments.length;o++)(e-=t(o<0||arguments.length<=o?void 0:arguments[o]))<0&&(e+=1),(i-=t(o<0||arguments.length<=o?void 0:arguments[o]))<0&&(i+=1),(n-=t(o<0||arguments.length<=o?void 0:arguments[o]))<0&&(n+=1);return[e,i,n]}(t),i=Kc(e,3),n=i[0],o=i[1],r=i[2],s=1,a=function(){var t=2091639*n+2.3283064365386963e-10*s;return n=o,o=r,r=t-(s=0|t)};return a.uint32=function(){return 4294967296*a()},a.fract53=function(){return a()+11102230246251565e-32*(2097152*a()|0)},a.algorithm="Alea",a.seed=t,a.version="0.9",a}function Ly(){var t=4022871197;return function(e){for(var i=e.toString(),n=0;n<i.length;n++){var o=.02519603282416938*(t+=i.charCodeAt(n));o-=t=o>>>0,t=(o*=t)>>>0,t+=4294967296*(o-=t)}return 2.3283064365386963e-10*(t>>>0)}}var Hy="undefined"!=typeof window?window.Hammer||Sy:function(){return function(){var t=function(){};return{on:t,off:t,destroy:t,emit:t,get:function(){return{set:t}}}}()};function Wy(t){var e,i=this;this._cleanupQueue=[],this.active=!1,this._dom={container:t,overlay:document.createElement("div")},this._dom.overlay.classList.add("vis-overlay"),this._dom.container.appendChild(this._dom.overlay),this._cleanupQueue.push((function(){i._dom.overlay.parentNode.removeChild(i._dom.overlay)}));var n=Hy(this._dom.overlay);n.on("tap",zn(e=this._onTapOverlay).call(e,this)),this._cleanupQueue.push((function(){n.destroy()}));var o=["tap","doubletap","press","pinch","pan","panstart","panmove","panend"];Fu(o).call(o,(function(t){n.on(t,(function(t){t.srcEvent.stopPropagation()}))})),document&&document.body&&(this._onClick=function(e){(function(t,e){for(;t;){if(t===e)return!0;t=t.parentNode}return!1})(e.target,t)||i.deactivate()},document.body.addEventListener("click",this._onClick),this._cleanupQueue.push((function(){document.body.removeEventListener("click",i._onClick)}))),this._escListener=function(t){("key"in t?"Escape"===t.key:27===t.keyCode)&&i.deactivate()}}Wn(Wy.prototype),Wy.current=null,Wy.prototype.destroy=function(){var t,e;this.deactivate();var i,n=Py(Yu(t=ff(e=this._cleanupQueue).call(e,0)).call(t));try{for(n.s();!(i=n.n()).done;){(0,i.value)()}}catch(t){n.e(t)}finally{n.f()}},Wy.prototype.activate=function(){Wy.current&&Wy.current.deactivate(),Wy.current=this,this.active=!0,this._dom.overlay.style.display="none",this._dom.container.classList.add("vis-active"),this.emit("change"),this.emit("activate"),document.body.addEventListener("keydown",this._escListener)},Wy.prototype.deactivate=function(){this.active=!1,this._dom.overlay.style.display="block",this._dom.container.classList.remove("vis-active"),document.body.removeEventListener("keydown",this._escListener),this.emit("change"),this.emit("deactivate")},Wy.prototype._onTapOverlay=function(t){this.activate(),t.srcEvent.stopPropagation()};var qy=/^\/?Date\((-?\d+)/i,Vy=/^#?([a-f\d]{2})([a-f\d]{2})([a-f\d]{2})$/i,Uy=/^#?([a-f\d])([a-f\d])([a-f\d])$/i,Yy=/^rgb\( *(1?\d{1,2}|2[0-4]\d|25[0-5]) *, *(1?\d{1,2}|2[0-4]\d|25[0-5]) *, *(1?\d{1,2}|2[0-4]\d|25[0-5]) *\)$/i,Xy=/^rgba\( *(1?\d{1,2}|2[0-4]\d|25[0-5]) *, *(1?\d{1,2}|2[0-4]\d|25[0-5]) *, *(1?\d{1,2}|2[0-4]\d|25[0-5]) *, *([01]|0?\.\d+) *\)$/i;function Gy(t){return t instanceof Number||"number"==typeof t}function Ky(t){if(t)for(;!0===t.hasChildNodes();){var e=t.firstChild;e&&(Ky(e),t.removeChild(e))}}function $y(t){return t instanceof String||"string"==typeof t}function Zy(t){return"object"===Qc(t)&&null!==t}function Qy(t,e,i,n){var o=!1;!0===n&&(o=null===e[i]&&void 0!==t[i]),o?delete t[i]:t[i]=e[i]}function Jy(t,e){var i=arguments.length>2&&void 0!==arguments[2]&&arguments[2];for(var n in t)if(void 0!==e[n])if(null===e[n]||"object"!==Qc(e[n]))Qy(t,e,n,i);else{var o=t[n],r=e[n];Zy(o)&&Zy(r)&&Jy(o,r,i)}}var tm=un;function em(t,e,i){var n=arguments.length>3&&void 0!==arguments[3]&&arguments[3];if(lu(i))throw new TypeError("Arrays are not supported by deepExtend");for(var o=0;o<t.length;o++){var r=t[o];if(Object.prototype.hasOwnProperty.call(i,r))if(i[r]&&i[r].constructor===Object)void 0===e[r]&&(e[r]={}),e[r].constructor===Object?nm(e[r],i[r],!1,n):Qy(e,i,r,n);else{if(lu(i[r]))throw new TypeError("Arrays are not supported by deepExtend");Qy(e,i,r,n)}}return e}function im(t,e,i){var n=arguments.length>3&&void 0!==arguments[3]&&arguments[3];if(lu(i))throw new TypeError("Arrays are not supported by deepExtend");for(var o in i)if(Object.prototype.hasOwnProperty.call(i,o)&&!Nf(t).call(t,o))if(i[o]&&i[o].constructor===Object)void 0===e[o]&&(e[o]={}),e[o].constructor===Object?nm(e[o],i[o]):Qy(e,i,o,n);else if(lu(i[o])){e[o]=[];for(var r=0;r<i[o].length;r++)e[o].push(i[o][r])}else Qy(e,i,o,n);return e}function nm(t,e){var i=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3&&void 0!==arguments[3]&&arguments[3];for(var o in e)if(Object.prototype.hasOwnProperty.call(e,o)||!0===i)if("object"===Qc(e[o])&&null!==e[o]&&Lf(e[o])===Object.prototype)void 0===t[o]?t[o]=nm({},e[o],i):"object"===Qc(t[o])&&null!==t[o]&&Lf(t[o])===Object.prototype?nm(t[o],e[o],i):Qy(t,e,o,n);else if(lu(e[o])){var r;t[o]=au(r=e[o]).call(r)}else Qy(t,e,o,n);return t}function om(t,e){var i;return su(i=[]).call(i,Jc(t),[e])}function rm(t){return au(t).call(t)}function sm(t){return t.getBoundingClientRect().left}function am(t){return t.getBoundingClientRect().top}function hm(t,e){if(lu(t))for(var i=t.length,n=0;n<i;n++)e(t[n],n,t);else for(var o in t)Object.prototype.hasOwnProperty.call(t,o)&&e(t[o],o,t)}var lm=ip;function dm(t,e,i,n){var o;t.addEventListener?(void 0===n&&(n=!1),"mousewheel"===e&&Nf(o=navigator.userAgent).call(o,"Firefox")&&(e="DOMMouseScroll"),t.addEventListener(e,i,n)):t.attachEvent("on"+e,i)}function cm(t,e,i,n){var o;t.removeEventListener?(void 0===n&&(n=!1),"mousewheel"===e&&Nf(o=navigator.userAgent).call(o,"Firefox")&&(e="DOMMouseScroll"),t.removeEventListener(e,i,n)):t.detachEvent("on"+e,i)}var um={asBoolean:function(t,e){return"function"==typeof t&&(t=t()),null!=t?0!=t:e||null},asNumber:function(t,e){return"function"==typeof t&&(t=t()),null!=t?Number(t)||e||null:e||null},asString:function(t,e){return"function"==typeof t&&(t=t()),null!=t?String(t):e||null},asSize:function(t,e){return"function"==typeof t&&(t=t()),$y(t)?t:Gy(t)?t+"px":e||null},asElement:function(t,e){return"function"==typeof t&&(t=t()),t||e||null}};function fm(t){var e;switch(t.length){case 3:case 4:return(e=Uy.exec(t))?{r:Ep(e[1]+e[1],16),g:Ep(e[2]+e[2],16),b:Ep(e[3]+e[3],16)}:null;case 6:case 7:return(e=Vy.exec(t))?{r:Ep(e[1],16),g:Ep(e[2],16),b:Ep(e[3],16)}:null;default:return null}}function pm(t,e){if(Nf(t).call(t,"rgba"))return t;if(Nf(t).call(t,"rgb")){var i=t.substr(Fp(t).call(t,"(")+1).replace(")","").split(",");return"rgba("+i[0]+","+i[1]+","+i[2]+","+e+")"}var n=fm(t);return null==n?t:"rgba("+n.r+","+n.g+","+n.b+","+e+")"}function vm(t,e,i){var n;return"#"+au(n=((1<<24)+(t<<16)+(e<<8)+i).toString(16)).call(n,1)}function gm(t,e){if($y(t)){var i=t;if(Em(i)){var n,o=gu(n=i.substr(4).substr(0,i.length-5).split(",")).call(n,(function(t){return Ep(t)}));i=vm(o[0],o[1],o[2])}if(!0===xm(i)){var r=_m(i),s={h:r.h,s:.8*r.s,v:Math.min(1,1.02*r.v)},a={h:r.h,s:Math.min(1,1.25*r.s),v:.8*r.v},h=km(a.h,a.s,a.v),l=km(s.h,s.s,s.v);return{background:i,border:h,highlight:{background:l,border:h},hover:{background:l,border:h}}}return{background:i,border:i,highlight:{background:i,border:i},hover:{background:i,border:i}}}return e?{background:t.background||e.background,border:t.border||e.border,highlight:$y(t.highlight)?{border:t.highlight,background:t.highlight}:{background:t.highlight&&t.highlight.background||e.highlight.background,border:t.highlight&&t.highlight.border||e.highlight.border},hover:$y(t.hover)?{border:t.hover,background:t.hover}:{border:t.hover&&t.hover.border||e.hover.border,background:t.hover&&t.hover.background||e.hover.background}}:{background:t.background||void 0,border:t.border||void 0,highlight:$y(t.highlight)?{border:t.highlight,background:t.highlight}:{background:t.highlight&&t.highlight.background||void 0,border:t.highlight&&t.highlight.border||void 0},hover:$y(t.hover)?{border:t.hover,background:t.hover}:{border:t.hover&&t.hover.border||void 0,background:t.hover&&t.hover.background||void 0}}}function ym(t,e,i){t/=255,e/=255,i/=255;var n=Math.min(t,Math.min(e,i)),o=Math.max(t,Math.max(e,i));return n===o?{h:0,s:0,v:n}:{h:60*((t===n?3:i===n?1:5)-(t===n?e-i:i===n?t-e:i-t)/(o-n))/360,s:(o-n)/o,v:o}}var mm=function(t){var e,i={};return Fu(e=t.split(";")).call(e,(function(t){if(""!=Yp(t).call(t)){var e,n,o=t.split(":"),r=Yp(e=o[0]).call(e),s=Yp(n=o[1]).call(n);i[r]=s}})),i},bm=function(t){var e;return gu(e=bu(t)).call(e,(function(e){return e+": "+t[e]})).join("; ")};function wm(t,e,i){var n,o,r,s=Math.floor(6*t),a=6*t-s,h=i*(1-e),l=i*(1-a*e),d=i*(1-(1-a)*e);switch(s%6){case 0:n=i,o=d,r=h;break;case 1:n=l,o=i,r=h;break;case 2:n=h,o=i,r=d;break;case 3:n=h,o=l,r=i;break;case 4:n=d,o=h,r=i;break;case 5:n=i,o=h,r=l}return{r:Math.floor(255*n),g:Math.floor(255*o),b:Math.floor(255*r)}}function km(t,e,i){var n=wm(t,e,i);return vm(n.r,n.g,n.b)}function _m(t){var e=fm(t);if(!e)throw new TypeError("'".concat(t,"' is not a valid color."));return ym(e.r,e.g,e.b)}function xm(t){return/(^#[0-9A-F]{6}$)|(^#[0-9A-F]{3}$)/i.test(t)}function Em(t){return Yy.test(t)}function Om(t){return Xy.test(t)}function Cm(t){if(null===t||"object"!==Qc(t))return null;if(t instanceof Element)return t;var e=Kp(t);for(var i in t)Object.prototype.hasOwnProperty.call(t,i)&&"object"==Qc(t[i])&&(e[i]=Cm(t[i]));return e}function Sm(t,e,i){var n=arguments.length>3&&void 0!==arguments[3]?arguments[3]:{},o=function(t){return null!=t},r=function(t){return null!==t&&"object"===Qc(t)},s=function(t){for(var e in t)if(Object.prototype.hasOwnProperty.call(t,e))return!1;return!0};if(!r(t))throw new Error("Parameter mergeTarget must be an object");if(!r(e))throw new Error("Parameter options must be an object");if(!o(i))throw new Error("Parameter option must have a value");if(!r(n))throw new Error("Parameter globalOptions must be an object");var a=function(t,e,i){r(t[i])||(t[i]={});var n=e[i],o=t[i];for(var s in n)Object.prototype.hasOwnProperty.call(n,s)&&(o[s]=n[s])},h=e[i],l=r(n)&&!s(n),d=l?n[i]:void 0,c=d?d.enabled:void 0;if(void 0!==h){if("boolean"==typeof h)return r(t[i])||(t[i]={}),void(t[i].enabled=h);if(null===h&&!r(t[i])){if(!o(d))return;t[i]=Kp(d)}if(r(h)){var u=!0;void 0!==h.enabled?u=h.enabled:void 0!==c&&(u=d.enabled),a(t,e,i),t[i].enabled=u}}}var Tm={linear:function(t){return t},easeInQuad:function(t){return t*t},easeOutQuad:function(t){return t*(2-t)},easeInOutQuad:function(t){return t<.5?2*t*t:(4-2*t)*t-1},easeInCubic:function(t){return t*t*t},easeOutCubic:function(t){return--t*t*t+1},easeInOutCubic:function(t){return t<.5?4*t*t*t:(t-1)*(2*t-2)*(2*t-2)+1},easeInQuart:function(t){return t*t*t*t},easeOutQuart:function(t){return 1- --t*t*t*t},easeInOutQuart:function(t){return t<.5?8*t*t*t*t:1-8*--t*t*t*t},easeInQuint:function(t){return t*t*t*t*t},easeOutQuint:function(t){return 1+--t*t*t*t*t},easeInOutQuint:function(t){return t<.5?16*t*t*t*t*t:1+16*--t*t*t*t*t}};function Mm(t,e){var i;lu(e)||(e=[e]);var n,o=Py(t);try{for(o.s();!(n=o.n()).done;){var r=n.value;if(r){i=r[e[0]];for(var s=1;s<e.length;s++)i&&(i=i[e[s]]);if(void 0!==i)break}}}catch(t){o.e(t)}finally{o.f()}return i}var Pm={black:"#000000",navy:"#000080",darkblue:"#00008B",mediumblue:"#0000CD",blue:"#0000FF",darkgreen:"#006400",green:"#008000",teal:"#008080",darkcyan:"#008B8B",deepskyblue:"#00BFFF",darkturquoise:"#00CED1",mediumspringgreen:"#00FA9A",lime:"#00FF00",springgreen:"#00FF7F",aqua:"#00FFFF",cyan:"#00FFFF",midnightblue:"#191970",dodgerblue:"#1E90FF",lightseagreen:"#20B2AA",forestgreen:"#228B22",seagreen:"#2E8B57",darkslategray:"#2F4F4F",limegreen:"#32CD32",mediumseagreen:"#3CB371",turquoise:"#40E0D0",royalblue:"#4169E1",steelblue:"#4682B4",darkslateblue:"#483D8B",mediumturquoise:"#48D1CC",indigo:"#4B0082",darkolivegreen:"#556B2F",cadetblue:"#5F9EA0",cornflowerblue:"#6495ED",mediumaquamarine:"#66CDAA",dimgray:"#696969",slateblue:"#6A5ACD",olivedrab:"#6B8E23",slategray:"#708090",lightslategray:"#778899",mediumslateblue:"#7B68EE",lawngreen:"#7CFC00",chartreuse:"#7FFF00",aquamarine:"#7FFFD4",maroon:"#800000",purple:"#800080",olive:"#808000",gray:"#808080",skyblue:"#87CEEB",lightskyblue:"#87CEFA",blueviolet:"#8A2BE2",darkred:"#8B0000",darkmagenta:"#8B008B",saddlebrown:"#8B4513",darkseagreen:"#8FBC8F",lightgreen:"#90EE90",mediumpurple:"#9370D8",darkviolet:"#9400D3",palegreen:"#98FB98",darkorchid:"#9932CC",yellowgreen:"#9ACD32",sienna:"#A0522D",brown:"#A52A2A",darkgray:"#A9A9A9",lightblue:"#ADD8E6",greenyellow:"#ADFF2F",paleturquoise:"#AFEEEE",lightsteelblue:"#B0C4DE",powderblue:"#B0E0E6",firebrick:"#B22222",darkgoldenrod:"#B8860B",mediumorchid:"#BA55D3",rosybrown:"#BC8F8F",darkkhaki:"#BDB76B",silver:"#C0C0C0",mediumvioletred:"#C71585",indianred:"#CD5C5C",peru:"#CD853F",chocolate:"#D2691E",tan:"#D2B48C",lightgrey:"#D3D3D3",palevioletred:"#D87093",thistle:"#D8BFD8",orchid:"#DA70D6",goldenrod:"#DAA520",crimson:"#DC143C",gainsboro:"#DCDCDC",plum:"#DDA0DD",burlywood:"#DEB887",lightcyan:"#E0FFFF",lavender:"#E6E6FA",darksalmon:"#E9967A",violet:"#EE82EE",palegoldenrod:"#EEE8AA",lightcoral:"#F08080",khaki:"#F0E68C",aliceblue:"#F0F8FF",honeydew:"#F0FFF0",azure:"#F0FFFF",sandybrown:"#F4A460",wheat:"#F5DEB3",beige:"#F5F5DC",whitesmoke:"#F5F5F5",mintcream:"#F5FFFA",ghostwhite:"#F8F8FF",salmon:"#FA8072",antiquewhite:"#FAEBD7",linen:"#FAF0E6",lightgoldenrodyellow:"#FAFAD2",oldlace:"#FDF5E6",red:"#FF0000",fuchsia:"#FF00FF",magenta:"#FF00FF",deeppink:"#FF1493",orangered:"#FF4500",tomato:"#FF6347",hotpink:"#FF69B4",coral:"#FF7F50",darkorange:"#FF8C00",lightsalmon:"#FFA07A",orange:"#FFA500",lightpink:"#FFB6C1",pink:"#FFC0CB",gold:"#FFD700",peachpuff:"#FFDAB9",navajowhite:"#FFDEAD",moccasin:"#FFE4B5",bisque:"#FFE4C4",mistyrose:"#FFE4E1",blanchedalmond:"#FFEBCD",papayawhip:"#FFEFD5",lavenderblush:"#FFF0F5",seashell:"#FFF5EE",cornsilk:"#FFF8DC",lemonchiffon:"#FFFACD",floralwhite:"#FFFAF0",snow:"#FFFAFA",yellow:"#FFFF00",lightyellow:"#FFFFE0",ivory:"#FFFFF0",white:"#FFFFFF"},Dm=function(){function t(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:1;Yd(this,t),this.pixelRatio=e,this.generated=!1,this.centerCoordinates={x:144.5,y:144.5},this.r=289*.49,this.color={r:255,g:255,b:255,a:1},this.hueCircle=void 0,this.initialColor={r:255,g:255,b:255,a:1},this.previousColor=void 0,this.applied=!1,this.updateCallback=function(){},this.closeCallback=function(){},this._create()}return Kd(t,[{key:"insertTo",value:function(t){void 0!==this.hammer&&(this.hammer.destroy(),this.hammer=void 0),this.container=t,this.container.appendChild(this.frame),this._bindHammer(),this._setSize()}},{key:"setUpdateCallback",value:function(t){if("function"!=typeof t)throw new Error("Function attempted to set as colorPicker update callback is not a function.");this.updateCallback=t}},{key:"setCloseCallback",value:function(t){if("function"!=typeof t)throw new Error("Function attempted to set as colorPicker closing callback is not a function.");this.closeCallback=t}},{key:"_isColorString",value:function(t){if("string"==typeof t)return Pm[t]}},{key:"setColor",value:function(t){var e=!(arguments.length>1&&void 0!==arguments[1])||arguments[1];if("none"!==t){var i,n=this._isColorString(t);if(void 0!==n&&(t=n),!0===$y(t)){if(!0===Em(t)){var o=t.substr(4).substr(0,t.length-5).split(",");i={r:o[0],g:o[1],b:o[2],a:1}}else if(!0===Om(t)){var r=t.substr(5).substr(0,t.length-6).split(",");i={r:r[0],g:r[1],b:r[2],a:r[3]}}else if(!0===xm(t)){var s=fm(t);i={r:s.r,g:s.g,b:s.b,a:1}}}else if(t instanceof Object&&void 0!==t.r&&void 0!==t.g&&void 0!==t.b){var a=void 0!==t.a?t.a:"1.0";i={r:t.r,g:t.g,b:t.b,a:a}}if(void 0===i)throw new Error("Unknown color passed to the colorPicker. Supported are strings: rgb, hex, rgba. Object: rgb ({r:r,g:g,b:b,[a:a]}). Supplied: "+gv(t));this._setColor(i,e)}}},{key:"show",value:function(){void 0!==this.closeCallback&&(this.closeCallback(),this.closeCallback=void 0),this.applied=!1,this.frame.style.display="block",this._generateHueCircle()}},{key:"_hide",value:function(){var t=this,e=!(arguments.length>0&&void 0!==arguments[0])||arguments[0];!0===e&&(this.previousColor=un({},this.color)),!0===this.applied&&this.updateCallback(this.initialColor),this.frame.style.display="none",Sv((function(){void 0!==t.closeCallback&&(t.closeCallback(),t.closeCallback=void 0)}),0)}},{key:"_save",value:function(){this.updateCallback(this.color),this.applied=!1,this._hide()}},{key:"_apply",value:function(){this.applied=!0,this.updateCallback(this.color),this._updatePicker(this.color)}},{key:"_loadLast",value:function(){void 0!==this.previousColor?this.setColor(this.previousColor,!1):alert("There is no last color to load...")}},{key:"_setColor",value:function(t){var e=!(arguments.length>1&&void 0!==arguments[1])||arguments[1];!0===e&&(this.initialColor=un({},t)),this.color=t;var i=ym(t.r,t.g,t.b),n=2*Math.PI,o=this.r*i.s,r=this.centerCoordinates.x+o*Math.sin(n*i.h),s=this.centerCoordinates.y+o*Math.cos(n*i.h);this.colorPickerSelector.style.left=r-.5*this.colorPickerSelector.clientWidth+"px",this.colorPickerSelector.style.top=s-.5*this.colorPickerSelector.clientHeight+"px",this._updatePicker(t)}},{key:"_setOpacity",value:function(t){this.color.a=t/100,this._updatePicker(this.color)}},{key:"_setBrightness",value:function(t){var e=ym(this.color.r,this.color.g,this.color.b);e.v=t/100;var i=wm(e.h,e.s,e.v);i.a=this.color.a,this.color=i,this._updatePicker()}},{key:"_updatePicker",value:function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:this.color,e=ym(t.r,t.g,t.b),i=this.colorPickerCanvas.getContext("2d");void 0===this.pixelRation&&(this.pixelRatio=(window.devicePixelRatio||1)/(i.webkitBackingStorePixelRatio||i.mozBackingStorePixelRatio||i.msBackingStorePixelRatio||i.oBackingStorePixelRatio||i.backingStorePixelRatio||1)),i.setTransform(this.pixelRatio,0,0,this.pixelRatio,0,0);var n=this.colorPickerCanvas.clientWidth,o=this.colorPickerCanvas.clientHeight;i.clearRect(0,0,n,o),i.putImageData(this.hueCircle,0,0),i.fillStyle="rgba(0,0,0,"+(1-e.v)+")",i.circle(this.centerCoordinates.x,this.centerCoordinates.y,this.r),jv(i).call(i),this.brightnessRange.value=100*e.v,this.opacityRange.value=100*t.a,this.initialColorDiv.style.backgroundColor="rgba("+this.initialColor.r+","+this.initialColor.g+","+this.initialColor.b+","+this.initialColor.a+")",this.newColorDiv.style.backgroundColor="rgba("+this.color.r+","+this.color.g+","+this.color.b+","+this.color.a+")"}},{key:"_setSize",value:function(){this.colorPickerCanvas.style.width="100%",this.colorPickerCanvas.style.height="100%",this.colorPickerCanvas.width=289*this.pixelRatio,this.colorPickerCanvas.height=289*this.pixelRatio}},{key:"_create",value:function(){var t,e,i,n;if(this.frame=document.createElement("div"),this.frame.className="vis-color-picker",this.colorPickerDiv=document.createElement("div"),this.colorPickerSelector=document.createElement("div"),this.colorPickerSelector.className="vis-selector",this.colorPickerDiv.appendChild(this.colorPickerSelector),this.colorPickerCanvas=document.createElement("canvas"),this.colorPickerDiv.appendChild(this.colorPickerCanvas),this.colorPickerCanvas.getContext){var o=this.colorPickerCanvas.getContext("2d");this.pixelRatio=(window.devicePixelRatio||1)/(o.webkitBackingStorePixelRatio||o.mozBackingStorePixelRatio||o.msBackingStorePixelRatio||o.oBackingStorePixelRatio||o.backingStorePixelRatio||1),this.colorPickerCanvas.getContext("2d").setTransform(this.pixelRatio,0,0,this.pixelRatio,0,0)}else{var r=document.createElement("DIV");r.style.color="red",r.style.fontWeight="bold",r.style.padding="10px",r.innerText="Error: your browser does not support HTML canvas",this.colorPickerCanvas.appendChild(r)}this.colorPickerDiv.className="vis-color",this.opacityDiv=document.createElement("div"),this.opacityDiv.className="vis-opacity",this.brightnessDiv=document.createElement("div"),this.brightnessDiv.className="vis-brightness",this.arrowDiv=document.createElement("div"),this.arrowDiv.className="vis-arrow",this.opacityRange=document.createElement("input");try{this.opacityRange.type="range",this.opacityRange.min="0",this.opacityRange.max="100"}catch(t){}this.opacityRange.value="100",this.opacityRange.className="vis-range",this.brightnessRange=document.createElement("input");try{this.brightnessRange.type="range",this.brightnessRange.min="0",this.brightnessRange.max="100"}catch(t){}this.brightnessRange.value="100",this.brightnessRange.className="vis-range",this.opacityDiv.appendChild(this.opacityRange),this.brightnessDiv.appendChild(this.brightnessRange);var s=this;this.opacityRange.onchange=function(){s._setOpacity(this.value)},this.opacityRange.oninput=function(){s._setOpacity(this.value)},this.brightnessRange.onchange=function(){s._setBrightness(this.value)},this.brightnessRange.oninput=function(){s._setBrightness(this.value)},this.brightnessLabel=document.createElement("div"),this.brightnessLabel.className="vis-label vis-brightness",this.brightnessLabel.innerText="brightness:",this.opacityLabel=document.createElement("div"),this.opacityLabel.className="vis-label vis-opacity",this.opacityLabel.innerText="opacity:",this.newColorDiv=document.createElement("div"),this.newColorDiv.className="vis-new-color",this.newColorDiv.innerText="new",this.initialColorDiv=document.createElement("div"),this.initialColorDiv.className="vis-initial-color",this.initialColorDiv.innerText="initial",this.cancelButton=document.createElement("div"),this.cancelButton.className="vis-button vis-cancel",this.cancelButton.innerText="cancel",this.cancelButton.onclick=zn(t=this._hide).call(t,this,!1),this.applyButton=document.createElement("div"),this.applyButton.className="vis-button vis-apply",this.applyButton.innerText="apply",this.applyButton.onclick=zn(e=this._apply).call(e,this),this.saveButton=document.createElement("div"),this.saveButton.className="vis-button vis-save",this.saveButton.innerText="save",this.saveButton.onclick=zn(i=this._save).call(i,this),this.loadButton=document.createElement("div"),this.loadButton.className="vis-button vis-load",this.loadButton.innerText="load last",this.loadButton.onclick=zn(n=this._loadLast).call(n,this),this.frame.appendChild(this.colorPickerDiv),this.frame.appendChild(this.arrowDiv),this.frame.appendChild(this.brightnessLabel),this.frame.appendChild(this.brightnessDiv),this.frame.appendChild(this.opacityLabel),this.frame.appendChild(this.opacityDiv),this.frame.appendChild(this.newColorDiv),this.frame.appendChild(this.initialColorDiv),this.frame.appendChild(this.cancelButton),this.frame.appendChild(this.applyButton),this.frame.appendChild(this.saveButton),this.frame.appendChild(this.loadButton)}},{key:"_bindHammer",value:function(){var t=this;this.drag={},this.pinch={},this.hammer=new Hy(this.colorPickerCanvas),this.hammer.get("pinch").set({enable:!0}),this.hammer.on("hammer.input",(function(e){e.isFirst&&t._moveSelector(e)})),this.hammer.on("tap",(function(e){t._moveSelector(e)})),this.hammer.on("panstart",(function(e){t._moveSelector(e)})),this.hammer.on("panmove",(function(e){t._moveSelector(e)})),this.hammer.on("panend",(function(e){t._moveSelector(e)}))}},{key:"_generateHueCircle",value:function(){if(!1===this.generated){var t=this.colorPickerCanvas.getContext("2d");void 0===this.pixelRation&&(this.pixelRatio=(window.devicePixelRatio||1)/(t.webkitBackingStorePixelRatio||t.mozBackingStorePixelRatio||t.msBackingStorePixelRatio||t.oBackingStorePixelRatio||t.backingStorePixelRatio||1)),t.setTransform(this.pixelRatio,0,0,this.pixelRatio,0,0);var e,i,n,o,r=this.colorPickerCanvas.clientWidth,s=this.colorPickerCanvas.clientHeight;t.clearRect(0,0,r,s),this.centerCoordinates={x:.5*r,y:.5*s},this.r=.49*r;var a,h=2*Math.PI/360,l=1/this.r;for(n=0;n<360;n++)for(o=0;o<this.r;o++)e=this.centerCoordinates.x+o*Math.sin(h*n),i=this.centerCoordinates.y+o*Math.cos(h*n),a=wm(.002777777777777778*n,o*l,1),t.fillStyle="rgb("+a.r+","+a.g+","+a.b+")",t.fillRect(e-.5,i-.5,2,2);t.strokeStyle="rgba(0,0,0,1)",t.circle(this.centerCoordinates.x,this.centerCoordinates.y,this.r),t.stroke(),this.hueCircle=t.getImageData(0,0,r,s)}this.generated=!0}},{key:"_moveSelector",value:function(t){var e=this.colorPickerDiv.getBoundingClientRect(),i=t.center.x-e.left,n=t.center.y-e.top,o=.5*this.colorPickerDiv.clientHeight,r=.5*this.colorPickerDiv.clientWidth,s=i-r,a=n-o,h=Math.atan2(s,a),l=.98*Math.min(Math.sqrt(s*s+a*a),r),d=Math.cos(h)*l+o,c=Math.sin(h)*l+r;this.colorPickerSelector.style.top=d-.5*this.colorPickerSelector.clientHeight+"px",this.colorPickerSelector.style.left=c-.5*this.colorPickerSelector.clientWidth+"px";var u=h/(2*Math.PI);u=u<0?u+1:u;var f=l/this.r,p=ym(this.color.r,this.color.g,this.color.b);p.h=u,p.s=f;var v=wm(p.h,p.s,p.v);v.a=this.color.a,this.color=v,this.initialColorDiv.style.backgroundColor="rgba("+this.initialColor.r+","+this.initialColor.g+","+this.initialColor.b+","+this.initialColor.a+")",this.newColorDiv.style.backgroundColor="rgba("+this.color.r+","+this.color.g+","+this.color.b+","+this.color.a+")"}}]),t}();function Im(){for(var t=arguments.length,e=new Array(t),i=0;i<t;i++)e[i]=arguments[i];if(e.length<1)throw new TypeError("Invalid arguments.");if(1===e.length)return document.createTextNode(e[0]);var n=document.createElement(e[0]);return n.appendChild(Im.apply(void 0,Jc(au(e).call(e,1)))),n}var Bm,zm=function(){function t(e,i,n){var o=arguments.length>3&&void 0!==arguments[3]?arguments[3]:1,r=arguments.length>4&&void 0!==arguments[4]?arguments[4]:function(){return!1};Yd(this,t),this.parent=e,this.changedOptions=[],this.container=i,this.allowCreation=!1,this.hideOption=r,this.options={},this.initialized=!1,this.popupCounter=0,this.defaultOptions={enabled:!1,filter:!0,container:void 0,showButton:!0},un(this.options,this.defaultOptions),this.configureOptions=n,this.moduleOptions={},this.domElements=[],this.popupDiv={},this.popupLimit=5,this.popupHistory={},this.colorPicker=new Dm(o),this.wrapper=void 0}return Kd(t,[{key:"setOptions",value:function(t){if(void 0!==t){this.popupHistory={},this._removePopup();var e=!0;if("string"==typeof t)this.options.filter=t;else if(lu(t))this.options.filter=t.join();else if("object"===Qc(t)){if(null==t)throw new TypeError("options cannot be null");void 0!==t.container&&(this.options.container=t.container),void 0!==Xf(t)&&(this.options.filter=Xf(t)),void 0!==t.showButton&&(this.options.showButton=t.showButton),void 0!==t.enabled&&(e=t.enabled)}else"boolean"==typeof t?(this.options.filter=!0,e=t):"function"==typeof t&&(this.options.filter=t,e=!0);!1===Xf(this.options)&&(e=!1),this.options.enabled=e}this._clean()}},{key:"setModuleOptions",value:function(t){this.moduleOptions=t,!0===this.options.enabled&&(this._clean(),void 0!==this.options.container&&(this.container=this.options.container),this._create())}},{key:"_create",value:function(){this._clean(),this.changedOptions=[];var t=Xf(this.options),e=0,i=!1;for(var n in this.configureOptions)Object.prototype.hasOwnProperty.call(this.configureOptions,n)&&(this.allowCreation=!1,i=!1,"function"==typeof t?i=(i=t(n,[]))||this._handleObject(this.configureOptions[n],[n],!0):!0!==t&&-1===Fp(t).call(t,n)||(i=!0),!1!==i&&(this.allowCreation=!0,e>0&&this._makeItem([]),this._makeHeader(n),this._handleObject(this.configureOptions[n],[n])),e++);this._makeButton(),this._push()}},{key:"_push",value:function(){this.wrapper=document.createElement("div"),this.wrapper.className="vis-configuration-wrapper",this.container.appendChild(this.wrapper);for(var t=0;t<this.domElements.length;t++)this.wrapper.appendChild(this.domElements[t]);this._showPopupIfNeeded()}},{key:"_clean",value:function(){for(var t=0;t<this.domElements.length;t++)this.wrapper.removeChild(this.domElements[t]);void 0!==this.wrapper&&(this.container.removeChild(this.wrapper),this.wrapper=void 0),this.domElements=[],this._removePopup()}},{key:"_getValue",value:function(t){for(var e=this.moduleOptions,i=0;i<t.length;i++){if(void 0===e[t[i]]){e=void 0;break}e=e[t[i]]}return e}},{key:"_makeItem",value:function(t){if(!0===this.allowCreation){var e=document.createElement("div");e.className="vis-configuration vis-config-item vis-config-s"+t.length;for(var i=arguments.length,n=new Array(i>1?i-1:0),o=1;o<i;o++)n[o-1]=arguments[o];return Fu(n).call(n,(function(t){e.appendChild(t)})),this.domElements.push(e),this.domElements.length}return 0}},{key:"_makeHeader",value:function(t){var e=document.createElement("div");e.className="vis-configuration vis-config-header",e.innerText=t,this._makeItem([],e)}},{key:"_makeLabel",value:function(t,e){var i=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=document.createElement("div");if(n.className="vis-configuration vis-config-label vis-config-s"+e.length,!0===i){for(;n.firstChild;)n.removeChild(n.firstChild);n.appendChild(Im("i","b",t))}else n.innerText=t+":";return n}},{key:"_makeDropdown",value:function(t,e,i){var n=document.createElement("select");n.className="vis-configuration vis-config-select";var o=0;void 0!==e&&-1!==Fp(t).call(t,e)&&(o=Fp(t).call(t,e));for(var r=0;r<t.length;r++){var s=document.createElement("option");s.value=t[r],r===o&&(s.selected="selected"),s.innerText=t[r],n.appendChild(s)}var a=this;n.onchange=function(){a._update(this.value,i)};var h=this._makeLabel(i[i.length-1],i);this._makeItem(i,h,n)}},{key:"_makeRange",value:function(t,e,i){var n=t[0],o=t[1],r=t[2],s=t[3],a=document.createElement("input");a.className="vis-configuration vis-config-range";try{a.type="range",a.min=o,a.max=r}catch(t){}a.step=s;var h="",l=0;if(void 0!==e){var d=1.2;e<0&&e*d<o?(a.min=Math.ceil(e*d),l=a.min,h="range increased"):e/d<o&&(a.min=Math.ceil(e/d),l=a.min,h="range increased"),e*d>r&&1!==r&&(a.max=Math.ceil(e*d),l=a.max,h="range increased"),a.value=e}else a.value=n;var c=document.createElement("input");c.className="vis-configuration vis-config-rangeinput",c.value=a.value;var u=this;a.onchange=function(){c.value=this.value,u._update(Number(this.value),i)},a.oninput=function(){c.value=this.value};var f=this._makeLabel(i[i.length-1],i),p=this._makeItem(i,f,a,c);""!==h&&this.popupHistory[p]!==l&&(this.popupHistory[p]=l,this._setupPopup(h,p))}},{key:"_makeButton",value:function(){var t=this;if(!0===this.options.showButton){var e=document.createElement("div");e.className="vis-configuration vis-config-button",e.innerText="generate options",e.onclick=function(){t._printOptions()},e.onmouseover=function(){e.className="vis-configuration vis-config-button hover"},e.onmouseout=function(){e.className="vis-configuration vis-config-button"},this.optionsContainer=document.createElement("div"),this.optionsContainer.className="vis-configuration vis-config-option-container",this.domElements.push(this.optionsContainer),this.domElements.push(e)}}},{key:"_setupPopup",value:function(t,e){var i=this;if(!0===this.initialized&&!0===this.allowCreation&&this.popupCounter<this.popupLimit){var n=document.createElement("div");n.id="vis-configuration-popup",n.className="vis-configuration-popup",n.innerText=t,n.onclick=function(){i._removePopup()},this.popupCounter+=1,this.popupDiv={html:n,index:e}}}},{key:"_removePopup",value:function(){void 0!==this.popupDiv.html&&(this.popupDiv.html.parentNode.removeChild(this.popupDiv.html),clearTimeout(this.popupDiv.hideTimeout),clearTimeout(this.popupDiv.deleteTimeout),this.popupDiv={})}},{key:"_showPopupIfNeeded",value:function(){var t=this;if(void 0!==this.popupDiv.html){var e=this.domElements[this.popupDiv.index].getBoundingClientRect();this.popupDiv.html.style.left=e.left+"px",this.popupDiv.html.style.top=e.top-30+"px",document.body.appendChild(this.popupDiv.html),this.popupDiv.hideTimeout=Sv((function(){t.popupDiv.html.style.opacity=0}),1500),this.popupDiv.deleteTimeout=Sv((function(){t._removePopup()}),1800)}}},{key:"_makeCheckbox",value:function(t,e,i){var n=document.createElement("input");n.type="checkbox",n.className="vis-configuration vis-config-checkbox",n.checked=t,void 0!==e&&(n.checked=e,e!==t&&("object"===Qc(t)?e!==t.enabled&&this.changedOptions.push({path:i,value:e}):this.changedOptions.push({path:i,value:e})));var o=this;n.onchange=function(){o._update(this.checked,i)};var r=this._makeLabel(i[i.length-1],i);this._makeItem(i,r,n)}},{key:"_makeTextInput",value:function(t,e,i){var n=document.createElement("input");n.type="text",n.className="vis-configuration vis-config-text",n.value=e,e!==t&&this.changedOptions.push({path:i,value:e});var o=this;n.onchange=function(){o._update(this.value,i)};var r=this._makeLabel(i[i.length-1],i);this._makeItem(i,r,n)}},{key:"_makeColorField",value:function(t,e,i){var n=this,o=t[1],r=document.createElement("div");"none"!==(e=void 0===e?o:e)?(r.className="vis-configuration vis-config-colorBlock",r.style.backgroundColor=e):r.className="vis-configuration vis-config-colorBlock none",e=void 0===e?o:e,r.onclick=function(){n._showColorPicker(e,r,i)};var s=this._makeLabel(i[i.length-1],i);this._makeItem(i,s,r)}},{key:"_showColorPicker",value:function(t,e,i){var n=this;e.onclick=function(){},this.colorPicker.insertTo(e),this.colorPicker.show(),this.colorPicker.setColor(t),this.colorPicker.setUpdateCallback((function(t){var o="rgba("+t.r+","+t.g+","+t.b+","+t.a+")";e.style.backgroundColor=o,n._update(o,i)})),this.colorPicker.setCloseCallback((function(){e.onclick=function(){n._showColorPicker(t,e,i)}}))}},{key:"_handleObject",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:[],i=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=!1,o=Xf(this.options),r=!1;for(var s in t)if(Object.prototype.hasOwnProperty.call(t,s)){n=!0;var a=t[s],h=om(e,s);if("function"==typeof o&&!1===(n=o(s,e))&&!lu(a)&&"string"!=typeof a&&"boolean"!=typeof a&&a instanceof Object&&(this.allowCreation=!1,n=this._handleObject(a,h,!0),this.allowCreation=!1===i),!1!==n){r=!0;var l=this._getValue(h);if(lu(a))this._handleArray(a,l,h);else if("string"==typeof a)this._makeTextInput(a,l,h);else if("boolean"==typeof a)this._makeCheckbox(a,l,h);else if(a instanceof Object){if(!this.hideOption(e,s,this.moduleOptions))if(void 0!==a.enabled){var d=om(h,"enabled"),c=this._getValue(d);if(!0===c){var u=this._makeLabel(s,h,!0);this._makeItem(h,u),r=this._handleObject(a,h)||r}else this._makeCheckbox(a,c,h)}else{var f=this._makeLabel(s,h,!0);this._makeItem(h,f),r=this._handleObject(a,h)||r}}else console.error("dont know how to handle",a,s,h)}}return r}},{key:"_handleArray",value:function(t,e,i){"string"==typeof t[0]&&"color"===t[0]?(this._makeColorField(t,e,i),t[1]!==e&&this.changedOptions.push({path:i,value:e})):"string"==typeof t[0]?(this._makeDropdown(t,e,i),t[0]!==e&&this.changedOptions.push({path:i,value:e})):"number"==typeof t[0]&&(this._makeRange(t,e,i),t[0]!==e&&this.changedOptions.push({path:i,value:Number(e)}))}},{key:"_update",value:function(t,e){var i=this._constructOptions(t,e);this.parent.body&&this.parent.body.emitter&&this.parent.body.emitter.emit&&this.parent.body.emitter.emit("configChange",i),this.initialized=!0,this.parent.setOptions(i)}},{key:"_constructOptions",value:function(t,e){var i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{},n=i;t="false"!==(t="true"===t||t)&&t;for(var o=0;o<e.length;o++)"global"!==e[o]&&(void 0===n[e[o]]&&(n[e[o]]={}),o!==e.length-1?n=n[e[o]]:n[e[o]]=t);return i}},{key:"_printOptions",value:function(){for(var t=this.getOptions();this.optionsContainer.firstChild;)this.optionsContainer.removeChild(this.optionsContainer.firstChild);this.optionsContainer.appendChild(Im("pre","const options = "+gv(t,null,2)))}},{key:"getOptions",value:function(){for(var t={},e=0;e<this.changedOptions.length;e++)this._constructOptions(this.changedOptions[e].value,this.changedOptions[e].path,t);return t}}]),t}(),Nm=function(){function t(e,i){Yd(this,t),this.container=e,this.overflowMethod=i||"cap",this.x=0,this.y=0,this.padding=5,this.hidden=!1,this.frame=document.createElement("div"),this.frame.className="vis-tooltip",this.container.appendChild(this.frame)}return Kd(t,[{key:"setPosition",value:function(t,e){this.x=Ep(t),this.y=Ep(e)}},{key:"setText",value:function(t){if(t instanceof Element){for(;this.frame.firstChild;)this.frame.removeChild(this.frame.firstChild);this.frame.appendChild(t)}else this.frame.innerText=t}},{key:"show",value:function(t){if(void 0===t&&(t=!0),!0===t){var e=this.frame.clientHeight,i=this.frame.clientWidth,n=this.frame.parentNode.clientHeight,o=this.frame.parentNode.clientWidth,r=0,s=0;if("flip"==this.overflowMethod){var a=!1,h=!0;this.y-e<this.padding&&(h=!1),this.x+i>o-this.padding&&(a=!0),r=a?this.x-i:this.x,s=h?this.y-e:this.y}else(s=this.y-e)+e+this.padding>n&&(s=n-e-this.padding),s<this.padding&&(s=this.padding),(r=this.x)+i+this.padding>o&&(r=o-i-this.padding),r<this.padding&&(r=this.padding);this.frame.style.left=r+"px",this.frame.style.top=s+"px",this.frame.style.visibility="visible",this.hidden=!1}else this.hide()}},{key:"hide",value:function(){this.hidden=!0,this.frame.style.left="0",this.frame.style.top="0",this.frame.style.visibility="hidden"}},{key:"destroy",value:function(){this.frame.parentNode.removeChild(this.frame)}}]),t}(),Fm=!1,Am="background: #FFeeee; color: #dd0000",jm=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"validate",value:function(e,i,n){Fm=!1,Bm=i;var o=i;return void 0!==n&&(o=i[n]),t.parse(e,o,[]),Fm}},{key:"parse",value:function(e,i,n){for(var o in e)Object.prototype.hasOwnProperty.call(e,o)&&t.check(o,e,i,n)}},{key:"check",value:function(e,i,n,o){if(void 0!==n[e]||void 0!==n.__any__){var r=e,s=!0;void 0===n[e]&&void 0!==n.__any__&&(r="__any__",s="object"===t.getType(i[e]));var a=n[r];s&&void 0!==a.__type__&&(a=a.__type__),t.checkFields(e,i,n,r,a,o)}else t.getSuggestion(e,n,o)}},{key:"checkFields",value:function(e,i,n,o,r,s){var a=function(i){console.error("%c"+i+t.printLocation(s,e),Am)},h=t.getType(i[e]),l=r[h];void 0!==l?"array"===t.getType(l)&&-1===Fp(l).call(l,i[e])?(a('Invalid option detected in "'+e+'". Allowed values are:'+t.print(l)+' not "'+i[e]+'". '),Fm=!0):"object"===h&&"__any__"!==o&&(s=om(s,e),t.parse(i[e],n[o],s)):void 0===r.any&&(a('Invalid type received for "'+e+'". Expected: '+t.print(bu(r))+". Received ["+h+'] "'+i[e]+'"'),Fm=!0)}},{key:"getType",value:function(t){var e=Qc(t);return"object"===e?null===t?"null":t instanceof Boolean?"boolean":t instanceof Number?"number":t instanceof String?"string":lu(t)?"array":t instanceof Date?"date":void 0!==t.nodeType?"dom":!0===t._isAMomentObject?"moment":"object":"number"===e?"number":"boolean"===e?"boolean":"string"===e?"string":void 0===e?"undefined":e}},{key:"getSuggestion",value:function(e,i,n){var o,r=t.findInOptions(e,i,n,!1),s=t.findInOptions(e,Bm,[],!0);o=void 0!==r.indexMatch?" in "+t.printLocation(r.path,e,"")+'Perhaps it was incomplete? Did you mean: "'+r.indexMatch+'"?\n\n':s.distance<=4&&r.distance>s.distance?" in "+t.printLocation(r.path,e,"")+"Perhaps it was misplaced? Matching option found at: "+t.printLocation(s.path,s.closestMatch,""):r.distance<=8?'. Did you mean "'+r.closestMatch+'"?'+t.printLocation(r.path,e):". Did you mean one of these: "+t.print(bu(i))+t.printLocation(n,e),console.error('%cUnknown option detected: "'+e+'"'+o,Am),Fm=!0}},{key:"findInOptions",value:function(e,i,n){var o=arguments.length>3&&void 0!==arguments[3]&&arguments[3],r=1e9,s="",a=[],h=e.toLowerCase(),l=void 0;for(var d in i){var c=void 0;if(void 0!==i[d].__type__&&!0===o){var u=t.findInOptions(e,i[d],om(n,d));r>u.distance&&(s=u.closestMatch,a=u.path,r=u.distance,l=u.indexMatch)}else{var f;-1!==Fp(f=d.toLowerCase()).call(f,h)&&(l=d),r>(c=t.levenshteinDistance(e,d))&&(s=d,a=rm(n),r=c)}}return{closestMatch:s,path:a,distance:r,indexMatch:l}}},{key:"printLocation",value:function(t,e){for(var i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Problem value found at: \n",n="\n\n"+i+"options = {\n",o=0;o<t.length;o++){for(var r=0;r<o+1;r++)n+="  ";n+=t[o]+": {\n"}for(var s=0;s<t.length+1;s++)n+="  ";n+=e+"\n";for(var a=0;a<t.length+1;a++){for(var h=0;h<t.length-a;h++)n+="  ";n+="}\n"}return n+"\n\n"}},{key:"print",value:function(t){return gv(t).replace(/(")|(\[)|(\])|(,"__type__")/g,"").replace(/(,)/g,", ")}},{key:"levenshteinDistance",value:function(t,e){if(0===t.length)return e.length;if(0===e.length)return t.length;var i,n,o=[];for(i=0;i<=e.length;i++)o[i]=[i];for(n=0;n<=t.length;n++)o[0][n]=n;for(i=1;i<=e.length;i++)for(n=1;n<=t.length;n++)e.charAt(i-1)==t.charAt(n-1)?o[i][n]=o[i-1][n-1]:o[i][n]=Math.min(o[i-1][n-1]+1,Math.min(o[i][n-1]+1,o[i-1][n]+1));return o[e.length][t.length]}}]),t}(),Rm=Wy,Lm=Dm,Hm=zm,Wm=Hy,qm=Nm,Vm=Am,Um=jm,Ym=Object.freeze({__proto__:null,Activator:Rm,Alea:jy,ColorPicker:Lm,Configurator:Hm,DELETE:Iy,HSVToHex:km,HSVToRGB:wm,Hammer:Wm,Popup:qm,RGBToHSV:ym,RGBToHex:vm,VALIDATOR_PRINT_STYLE:Vm,Validator:Um,addClassName:function(t,e){var i=t.className.split(" "),n=e.split(" ");i=su(i).call(i,Xf(n).call(n,(function(t){return!Nf(i).call(i,t)}))),t.className=i.join(" ")},addCssText:function(t,e){var i=mm(t.style.cssText),n=mm(e),o=My(My({},i),n);t.style.cssText=bm(o)},addEventListener:dm,binarySearchCustom:function(t,e,i,n){for(var o=0,r=0,s=t.length-1;r<=s&&o<1e4;){var a=Math.floor((r+s)/2),h=t[a],l=e(void 0===n?h[i]:h[i][n]);if(0==l)return a;-1==l?r=a+1:s=a-1,o++}return-1},binarySearchValue:function(t,e,i,n,o){var r,s,a,h,l=0,d=0,c=t.length-1;for(o=null!=o?o:function(t,e){return t==e?0:t<e?-1:1};d<=c&&l<1e4;){if(h=Math.floor(.5*(c+d)),r=t[Math.max(0,h-1)][i],s=t[h][i],a=t[Math.min(t.length-1,h+1)][i],0==o(s,e))return h;if(o(r,e)<0&&o(s,e)>0)return"before"==n?Math.max(0,h-1):h;if(o(s,e)<0&&o(a,e)>0)return"before"==n?h:Math.min(t.length-1,h+1);o(s,e)<0?d=h+1:c=h-1,l++}return-1},bridgeObject:Cm,copyAndExtendArray:om,copyArray:rm,deepExtend:nm,deepObjectAssign:zy,easingFunctions:Tm,equalArray:function(t,e){if(t.length!==e.length)return!1;for(var i=0,n=t.length;i<n;i++)if(t[i]!=e[i])return!1;return!0},extend:tm,fillIfDefined:Jy,forEach:hm,getAbsoluteLeft:sm,getAbsoluteRight:function(t){return t.getBoundingClientRect().right},getAbsoluteTop:am,getScrollBarWidth:function(){var t=document.createElement("p");t.style.width="100%",t.style.height="200px";var e=document.createElement("div");e.style.position="absolute",e.style.top="0px",e.style.left="0px",e.style.visibility="hidden",e.style.width="200px",e.style.height="150px",e.style.overflow="hidden",e.appendChild(t),document.body.appendChild(e);var i=t.offsetWidth;e.style.overflow="scroll";var n=t.offsetWidth;return i==n&&(n=e.clientWidth),document.body.removeChild(e),i-n},getTarget:function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:window.event,e=null;return t&&(t.target?e=t.target:t.srcElement&&(e=t.srcElement)),e instanceof Element&&(null==e.nodeType||3!=e.nodeType||(e=e.parentNode)instanceof Element)?e:null},getType:function(t){var e=Qc(t);return"object"===e?null===t?"null":t instanceof Boolean?"Boolean":t instanceof Number?"Number":t instanceof String?"String":lu(t)?"Array":t instanceof Date?"Date":"Object":"number"===e?"Number":"boolean"===e?"Boolean":"string"===e?"String":void 0===e?"undefined":e},hasParent:function(t,e){for(var i=t;i;){if(i===e)return!0;if(!i.parentNode)return!1;i=i.parentNode}return!1},hexToHSV:_m,hexToRGB:fm,insertSort:function(t,e){for(var i=0;i<t.length;i++){var n=t[i],o=void 0;for(o=i;o>0&&e(n,t[o-1])<0;o--)t[o]=t[o-1];t[o]=n}return t},isDate:function(t){if(t instanceof Date)return!0;if($y(t)){if(qy.exec(t))return!0;if(!isNaN(Date.parse(t)))return!0}return!1},isNumber:Gy,isObject:Zy,isString:$y,isValidHex:xm,isValidRGB:Em,isValidRGBA:Om,mergeOptions:Sm,option:um,overrideOpacity:pm,parseColor:gm,preventDefault:function(t){t||(t=window.event),t&&(t.preventDefault?t.preventDefault():t.returnValue=!1)},pureDeepObjectAssign:By,recursiveDOMDelete:Ky,removeClassName:function(t,e){var i=t.className.split(" "),n=e.split(" ");i=Xf(i).call(i,(function(t){return!Nf(n).call(n,t)})),t.className=i.join(" ")},removeCssText:function(t,e){var i=mm(t.style.cssText),n=mm(e);for(var o in n)Object.prototype.hasOwnProperty.call(n,o)&&delete i[o];t.style.cssText=bm(i)},removeEventListener:cm,selectiveBridgeObject:function(t,e){if(null!==e&&"object"===Qc(e)){for(var i=Kp(e),n=0;n<t.length;n++)Object.prototype.hasOwnProperty.call(e,t[n])&&"object"==Qc(e[t[n]])&&(i[t[n]]=Cm(e[t[n]]));return i}return null},selectiveDeepExtend:em,selectiveExtend:function(t,e){if(!lu(t))throw new Error("Array with property names expected as first argument");for(var i=arguments.length,n=new Array(i>2?i-2:0),o=2;o<i;o++)n[o-2]=arguments[o];for(var r=0,s=n;r<s.length;r++)for(var a=s[r],h=0;h<t.length;h++){var l=t[h];a&&Object.prototype.hasOwnProperty.call(a,l)&&(e[l]=a[l])}return e},selectiveNotDeepExtend:im,throttle:function(t){var e=!1;return function(){e||(e=!0,requestAnimationFrame((function(){e=!1,t()})))}},toArray:lm,topMost:Mm,updateProperty:function(t,e,i){return t[e]!==i&&(t[e]=i,!0)}});function Xm(t){return eb=t,function(){var t={};ib=0,void(nb=eb.charAt(0)),pb(),"strict"===ob&&(t.strict=!0,pb());"graph"!==ob&&"digraph"!==ob||(t.type=ob,pb());rb===Qm&&(t.id=ob,pb());if("{"!=ob)throw wb("Angle bracket { expected");if(pb(),vb(t),"}"!=ob)throw wb("Angle bracket } expected");if(pb(),""!==ob)throw wb("End of file expected");return pb(),delete t.node,delete t.edge,delete t.graph,t}()}var Gm={fontsize:"font.size",fontcolor:"font.color",labelfontcolor:"font.color",fontname:"font.face",color:["color.border","color.background"],fillcolor:"color.background",tooltip:"title",labeltooltip:"title"},Km=Kp(Gm);Km.color="color.color",Km.style="dashes";var $m=0,Zm=1,Qm=2,Jm=3,tb={"{":!0,"}":!0,"[":!0,"]":!0,";":!0,"=":!0,",":!0,"->":!0,"--":!0},eb="",ib=0,nb="",ob="",rb=$m;function sb(){ib++,nb=eb.charAt(ib)}function ab(){return eb.charAt(ib+1)}function hb(t){var e=t.charCodeAt(0);return e<47?35===e||46===e:e<59?e>47:e<91?e>64:e<96?95===e:e<123&&e>96}function lb(t,e){if(t||(t={}),e)for(var i in e)e.hasOwnProperty(i)&&(t[i]=e[i]);return t}function db(t,e,i){for(var n=e.split("."),o=t;n.length;){var r=n.shift();n.length?(o[r]||(o[r]={}),o=o[r]):o[r]=i}}function cb(t,e){for(var i,n,o=null,r=[t],s=t;s.parent;)r.push(s.parent),s=s.parent;if(s.nodes)for(i=0,n=s.nodes.length;i<n;i++)if(e.id===s.nodes[i].id){o=s.nodes[i];break}for(o||(o={id:e.id},t.node&&(o.attr=lb(o.attr,t.node))),i=r.length-1;i>=0;i--){var a,h=r[i];h.nodes||(h.nodes=[]),-1===Fp(a=h.nodes).call(a,o)&&h.nodes.push(o)}e.attr&&(o.attr=lb(o.attr,e.attr))}function ub(t,e){if(t.edges||(t.edges=[]),t.edges.push(e),t.edge){var i=lb({},t.edge);e.attr=lb(i,e.attr)}}function fb(t,e,i,n,o){var r={from:e,to:i,type:n};return t.edge&&(r.attr=lb({},t.edge)),r.attr=lb(r.attr||{},o),null!=o&&o.hasOwnProperty("arrows")&&null!=o.arrows&&(r.arrows={to:{enabled:!0,type:o.arrows.type}},o.arrows=null),r}function pb(){for(rb=$m,ob="";" "===nb||"\t"===nb||"\n"===nb||"\r"===nb;)sb();do{var t=!1;if("#"===nb){for(var e=ib-1;" "===eb.charAt(e)||"\t"===eb.charAt(e);)e--;if("\n"===eb.charAt(e)||""===eb.charAt(e)){for(;""!=nb&&"\n"!=nb;)sb();t=!0}}if("/"===nb&&"/"===ab()){for(;""!=nb&&"\n"!=nb;)sb();t=!0}if("/"===nb&&"*"===ab()){for(;""!=nb;){if("*"===nb&&"/"===ab()){sb(),sb();break}sb()}t=!0}for(;" "===nb||"\t"===nb||"\n"===nb||"\r"===nb;)sb()}while(t);if(""!==nb){var i=nb+ab();if(tb[i])return rb=Zm,ob=i,sb(),void sb();if(tb[nb])return rb=Zm,ob=nb,void sb();if(hb(nb)||"-"===nb){for(ob+=nb,sb();hb(nb);)ob+=nb,sb();return"false"===ob?ob=!1:"true"===ob?ob=!0:isNaN(Number(ob))||(ob=Number(ob)),void(rb=Qm)}if('"'===nb){for(sb();""!=nb&&('"'!=nb||'"'===nb&&'"'===ab());)'"'===nb?(ob+=nb,sb()):"\\"===nb&&"n"===ab()?(ob+="\n",sb()):ob+=nb,sb();if('"'!=nb)throw wb('End of string " expected');return sb(),void(rb=Qm)}for(rb=Jm;""!=nb;)ob+=nb,sb();throw new SyntaxError('Syntax error in part "'+kb(ob,30)+'"')}rb=Zm}function vb(t){for(;""!==ob&&"}"!=ob;)gb(t),";"===ob&&pb()}function gb(t){var e=yb(t);if(e)mb(t,e);else{var i=function(t){if("node"===ob)return pb(),t.node=bb(),"node";if("edge"===ob)return pb(),t.edge=bb(),"edge";if("graph"===ob)return pb(),t.graph=bb(),"graph";return null}(t);if(!i){if(rb!=Qm)throw wb("Identifier expected");var n=ob;if(pb(),"="===ob){if(pb(),rb!=Qm)throw wb("Identifier expected");t[n]=ob,pb()}else!function(t,e){var i={id:e},n=bb();n&&(i.attr=n);cb(t,i),mb(t,e)}(t,n)}}}function yb(t){var e=null;if("subgraph"===ob&&((e={}).type="subgraph",pb(),rb===Qm&&(e.id=ob,pb())),"{"===ob){if(pb(),e||(e={}),e.parent=t,e.node=t.node,e.edge=t.edge,e.graph=t.graph,vb(e),"}"!=ob)throw wb("Angle bracket } expected");pb(),delete e.node,delete e.edge,delete e.graph,delete e.parent,t.subgraphs||(t.subgraphs=[]),t.subgraphs.push(e)}return e}function mb(t,e){for(;"->"===ob||"--"===ob;){var i,n=ob;pb();var o=yb(t);if(o)i=o;else{if(rb!=Qm)throw wb("Identifier or subgraph expected");cb(t,{id:i=ob}),pb()}ub(t,fb(t,e,i,n,bb())),e=i}}function bb(){for(var t,e,i=null,n={dashed:!0,solid:!1,dotted:[1,5]},o={dot:"circle",box:"box",crow:"crow",curve:"curve",icurve:"inv_curve",normal:"triangle",inv:"inv_triangle",diamond:"diamond",tee:"bar",vee:"vee"},r=new Array,s=new Array;"["===ob;){for(pb(),i={};""!==ob&&"]"!=ob;){if(rb!=Qm)throw wb("Attribute name expected");var a=ob;if(pb(),"="!=ob)throw wb("Equal sign = expected");if(pb(),rb!=Qm)throw wb("Attribute value expected");var h=ob;"style"===a&&(h=n[h]),"arrowhead"===a&&(a="arrows",h={to:{enabled:!0,type:o[h]}}),"arrowtail"===a&&(a="arrows",h={from:{enabled:!0,type:o[h]}}),r.push({attr:i,name:a,value:h}),s.push(a),pb(),","==ob&&pb()}if("]"!=ob)throw wb("Bracket ] expected");pb()}if(Nf(s).call(s,"dir")){var l={arrows:{}};for(t=0;t<r.length;t++)if("arrows"===r[t].name)if(null!=r[t].value.to)l.arrows.to=t;else{if(null==r[t].value.from)throw wb("Invalid value of arrows");l.arrows.from=t}else"dir"===r[t].name&&(l.dir=t);var d,c,u=r[l.dir].value;if(!Nf(s).call(s,"arrows"))if("both"===u)r.push({attr:r[l.dir].attr,name:"arrows",value:{to:{enabled:!0}}}),l.arrows.to=r.length-1,r.push({attr:r[l.dir].attr,name:"arrows",value:{from:{enabled:!0}}}),l.arrows.from=r.length-1;else if("forward"===u)r.push({attr:r[l.dir].attr,name:"arrows",value:{to:{enabled:!0}}}),l.arrows.to=r.length-1;else if("back"===u)r.push({attr:r[l.dir].attr,name:"arrows",value:{from:{enabled:!0}}}),l.arrows.from=r.length-1;else{if("none"!==u)throw wb('Invalid dir type "'+u+'"');r.push({attr:r[l.dir].attr,name:"arrows",value:""}),l.arrows.to=r.length-1}if("both"===u)l.arrows.to&&l.arrows.from?(c=r[l.arrows.to].value.to.type,d=r[l.arrows.from].value.from.type,r[l.arrows.to]={attr:r[l.arrows.to].attr,name:r[l.arrows.to].name,value:{to:{enabled:!0,type:c},from:{enabled:!0,type:d}}},ff(r).call(r,l.arrows.from,1)):l.arrows.to?(c=r[l.arrows.to].value.to.type,d="arrow",r[l.arrows.to]={attr:r[l.arrows.to].attr,name:r[l.arrows.to].name,value:{to:{enabled:!0,type:c},from:{enabled:!0,type:d}}}):l.arrows.from&&(c="arrow",d=r[l.arrows.from].value.from.type,r[l.arrows.from]={attr:r[l.arrows.from].attr,name:r[l.arrows.from].name,value:{to:{enabled:!0,type:c},from:{enabled:!0,type:d}}});else if("back"===u)l.arrows.to&&l.arrows.from?(c="",d=r[l.arrows.from].value.from.type,r[l.arrows.from]={attr:r[l.arrows.from].attr,name:r[l.arrows.from].name,value:{to:{enabled:!0,type:c},from:{enabled:!0,type:d}}}):l.arrows.to?(c="",d="arrow",l.arrows.from=l.arrows.to,r[l.arrows.from]={attr:r[l.arrows.from].attr,name:r[l.arrows.from].name,value:{to:{enabled:!0,type:c},from:{enabled:!0,type:d}}}):l.arrows.from&&(c="",d=r[l.arrows.from].value.from.type,r[l.arrows.to]={attr:r[l.arrows.from].attr,name:r[l.arrows.from].name,value:{to:{enabled:!0,type:c},from:{enabled:!0,type:d}}}),r[l.arrows.from]={attr:r[l.arrows.from].attr,name:r[l.arrows.from].name,value:{from:{enabled:!0,type:r[l.arrows.from].value.from.type}}};else if("none"===u){var f;r[f=l.arrows.to?l.arrows.to:l.arrows.from]={attr:r[f].attr,name:r[f].name,value:""}}else{if("forward"!==u)throw wb('Invalid dir type "'+u+'"');l.arrows.to&&l.arrows.from||l.arrows.to?(c=r[l.arrows.to].value.to.type,d="",r[l.arrows.to]={attr:r[l.arrows.to].attr,name:r[l.arrows.to].name,value:{to:{enabled:!0,type:c},from:{enabled:!0,type:d}}}):l.arrows.from&&(c="arrow",d="",l.arrows.to=l.arrows.from,r[l.arrows.to]={attr:r[l.arrows.to].attr,name:r[l.arrows.to].name,value:{to:{enabled:!0,type:c},from:{enabled:!0,type:d}}}),r[l.arrows.to]={attr:r[l.arrows.to].attr,name:r[l.arrows.to].name,value:{to:{enabled:!0,type:r[l.arrows.to].value.to.type}}}}ff(r).call(r,l.dir,1)}if(Nf(s).call(s,"penwidth")){var p=[];for(e=r.length,t=0;t<e;t++)"width"!==r[t].name&&("penwidth"===r[t].name&&(r[t].name="width"),p.push(r[t]));r=p}for(e=r.length,t=0;t<e;t++)db(r[t].attr,r[t].name,r[t].value);return i}function wb(t){return new SyntaxError(t+', got "'+kb(ob,30)+'" (char '+ib+")")}function kb(t,e){return t.length<=e?t:t.substr(0,27)+"..."}function _b(t,e,i){for(var n=e.split("."),o=n.pop(),r=t,s=0;s<n.length;s++){var a=n[s];a in r||(r[a]={}),r=r[a]}return r[o]=i,t}function xb(t,e){var i={};for(var n in t)if(t.hasOwnProperty(n)){var o=e[n];lu(o)?Fu(o).call(o,(function(e){_b(i,e,t[n])})):_b(i,"string"==typeof o?o:n,t[n])}return i}function Eb(t){var e,i=Xm(t),n={nodes:[],edges:[],options:{}};i.nodes&&Fu(e=i.nodes).call(e,(function(t){var e={id:t.id,label:String(t.label||t.id)};lb(e,xb(t.attr,Gm)),e.image&&(e.shape="image"),n.nodes.push(e)}));if(i.edges){var o,r=function(t){var e={from:t.from,to:t.to};return lb(e,xb(t.attr,Km)),null==e.arrows&&"->"===t.type&&(e.arrows="to"),e};Fu(o=i.edges).call(o,(function(t){var e,i,o,s,a,h,l;(e=t.from instanceof Object?t.from.nodes:{id:t.from},i=t.to instanceof Object?t.to.nodes:{id:t.to},t.from instanceof Object&&t.from.edges)&&Fu(o=t.from.edges).call(o,(function(t){var e=r(t);n.edges.push(e)}));(a=i,h=function(e,i){var o=fb(n,e.id,i.id,t.type,t.attr),s=r(o);n.edges.push(s)},lu(s=e)?Fu(s).call(s,(function(t){lu(a)?Fu(a).call(a,(function(e){h(t,e)})):h(t,a)})):lu(a)?Fu(a).call(a,(function(t){h(s,t)})):h(s,a),t.to instanceof Object&&t.to.edges)&&Fu(l=t.to.edges).call(l,(function(t){var e=r(t);n.edges.push(e)}))}))}return i.attr&&(n.options=i.attr),n}var Ob=Object.freeze({__proto__:null,parseDOT:Xm,DOTToGraph:Eb});function Cb(t,e){var i,n={edges:{inheritColor:!1},nodes:{fixed:!1,parseColor:!1}};null!=e&&(null!=e.fixed&&(n.nodes.fixed=e.fixed),null!=e.parseColor&&(n.nodes.parseColor=e.parseColor),null!=e.inheritColor&&(n.edges.inheritColor=e.inheritColor));var o=t.edges,r=gu(o).call(o,(function(t){var e={from:t.source,id:t.id,to:t.target};return null!=t.attributes&&(e.attributes=t.attributes),null!=t.label&&(e.label=t.label),null!=t.attributes&&null!=t.attributes.title&&(e.title=t.attributes.title),"Directed"===t.type&&(e.arrows="to"),t.color&&!1===n.edges.inheritColor&&(e.color=t.color),e}));return{nodes:gu(i=t.nodes).call(i,(function(t){var e={id:t.id,fixed:n.nodes.fixed&&null!=t.x&&null!=t.y};return null!=t.attributes&&(e.attributes=t.attributes),null!=t.label&&(e.label=t.label),null!=t.size&&(e.size=t.size),null!=t.attributes&&null!=t.attributes.title&&(e.title=t.attributes.title),null!=t.title&&(e.title=t.title),null!=t.x&&(e.x=t.x),null!=t.y&&(e.y=t.y),null!=t.color&&(!0===n.nodes.parseColor?e.color=t.color:e.color={background:t.color,border:t.color,highlight:{background:t.color,border:t.color},hover:{background:t.color,border:t.color}}),e})),edges:r}}var Sb=Object.freeze({__proto__:null,parseGephi:Cb}),Tb=Object.freeze({__proto__:null,en:{addDescription:"Click in an empty space to place a new node.",addEdge:"Add Edge",addNode:"Add Node",back:"Back",close:"Close",createEdgeError:"Cannot link edges to a cluster.",del:"Delete selected",deleteClusterError:"Clusters cannot be deleted.",edgeDescription:"Click on a node and drag the edge to another node to connect them.",edit:"Edit",editClusterError:"Clusters cannot be edited.",editEdge:"Edit Edge",editEdgeDescription:"Click on the control points and drag them to a node to connect to it.",editNode:"Edit Node"},de:{addDescription:"Klicke auf eine freie Stelle, um einen neuen Knoten zu plazieren.",addEdge:"Kante hinzufügen",addNode:"Knoten hinzufügen",back:"Zurück",close:"Schließen",createEdgeError:"Es ist nicht möglich, Kanten mit Clustern zu verbinden.",del:"Lösche Auswahl",deleteClusterError:"Cluster können nicht gelöscht werden.",edgeDescription:"Klicke auf einen Knoten und ziehe die Kante zu einem anderen Knoten, um diese zu verbinden.",edit:"Editieren",editClusterError:"Cluster können nicht editiert werden.",editEdge:"Kante editieren",editEdgeDescription:"Klicke auf die Verbindungspunkte und ziehe diese auf einen Knoten, um sie zu verbinden.",editNode:"Knoten editieren"},es:{addDescription:"Haga clic en un lugar vacío para colocar un nuevo nodo.",addEdge:"Añadir arista",addNode:"Añadir nodo",back:"Atrás",close:"Cerrar",createEdgeError:"No se puede conectar una arista a un grupo.",del:"Eliminar selección",deleteClusterError:"No es posible eliminar grupos.",edgeDescription:"Haga clic en un nodo y arrastre la arista hacia otro nodo para conectarlos.",edit:"Editar",editClusterError:"No es posible editar grupos.",editEdge:"Editar arista",editEdgeDescription:"Haga clic en un punto de control y arrastrelo a un nodo para conectarlo.",editNode:"Editar nodo"},it:{addDescription:"Clicca per aggiungere un nuovo nodo",addEdge:"Aggiungi un vertice",addNode:"Aggiungi un nodo",back:"Indietro",close:"Chiudere",createEdgeError:"Non si possono collegare vertici ad un cluster",del:"Cancella la selezione",deleteClusterError:"I cluster non possono essere cancellati",edgeDescription:"Clicca su un nodo e trascinalo ad un altro nodo per connetterli.",edit:"Modifica",editClusterError:"I clusters non possono essere modificati.",editEdge:"Modifica il vertice",editEdgeDescription:"Clicca sui Punti di controllo e trascinali ad un nodo per connetterli.",editNode:"Modifica il nodo"},nl:{addDescription:"Klik op een leeg gebied om een nieuwe node te maken.",addEdge:"Link toevoegen",addNode:"Node toevoegen",back:"Terug",close:"Sluiten",createEdgeError:"Kan geen link maken naar een cluster.",del:"Selectie verwijderen",deleteClusterError:"Clusters kunnen niet worden verwijderd.",edgeDescription:"Klik op een node en sleep de link naar een andere node om ze te verbinden.",edit:"Wijzigen",editClusterError:"Clusters kunnen niet worden aangepast.",editEdge:"Link wijzigen",editEdgeDescription:"Klik op de verbindingspunten en sleep ze naar een node om daarmee te verbinden.",editNode:"Node wijzigen"},pt:{addDescription:"Clique em um espaço em branco para adicionar um novo nó",addEdge:"Adicionar aresta",addNode:"Adicionar nó",back:"Voltar",close:"Fechar",createEdgeError:"Não foi possível linkar arestas a um cluster.",del:"Remover selecionado",deleteClusterError:"Clusters não puderam ser removidos.",edgeDescription:"Clique em um nó e arraste a aresta até outro nó para conectá-los",edit:"Editar",editClusterError:"Clusters não puderam ser editados.",editEdge:"Editar aresta",editEdgeDescription:"Clique nos pontos de controle e os arraste para um nó para conectá-los",editNode:"Editar nó"},ru:{addDescription:"Кликните в свободное место, чтобы добавить новый узел.",addEdge:"Добавить ребро",addNode:"Добавить узел",back:"Назад",close:"Закрывать",createEdgeError:"Невозможно соединить ребра в кластер.",del:"Удалить выбранное",deleteClusterError:"Кластеры не могут быть удалены",edgeDescription:"Кликните на узел и протяните ребро к другому узлу, чтобы соединить их.",edit:"Редактировать",editClusterError:"Кластеры недоступны для редактирования.",editEdge:"Редактировать ребро",editEdgeDescription:"Кликните на контрольные точки и перетащите их в узел, чтобы подключиться к нему.",editNode:"Редактировать узел"},cn:{addDescription:"单击空白处放置新节点。",addEdge:"添加连接线",addNode:"添加节点",back:"返回",close:"關閉",createEdgeError:"无法将连接线连接到群集。",del:"删除选定",deleteClusterError:"无法删除群集。",edgeDescription:"单击某个节点并将该连接线拖动到另一个节点以连接它们。",edit:"编辑",editClusterError:"无法编辑群集。",editEdge:"编辑连接线",editEdgeDescription:"单击控制节点并将它们拖到节点上连接。",editNode:"编辑节点"},uk:{addDescription:"Kлікніть на вільне місце, щоб додати новий вузол.",addEdge:"Додати край",addNode:"Додати вузол",back:"Назад",close:"Закрити",createEdgeError:"Не можливо об'єднати краї в групу.",del:"Видалити обране",deleteClusterError:"Групи не можуть бути видалені.",edgeDescription:"Клікніть на вузол і перетягніть край до іншого вузла, щоб їх з'єднати.",edit:"Редагувати",editClusterError:"Групи недоступні для редагування.",editEdge:"Редагувати край",editEdgeDescription:"Клікніть на контрольні точки і перетягніть їх у вузол, щоб підключитися до нього.",editNode:"Редагувати вузол"},fr:{addDescription:"Cliquez dans un endroit vide pour placer un nœud.",addEdge:"Ajouter un lien",addNode:"Ajouter un nœud",back:"Retour",close:"Fermer",createEdgeError:"Impossible de créer un lien vers un cluster.",del:"Effacer la sélection",deleteClusterError:"Les clusters ne peuvent pas être effacés.",edgeDescription:"Cliquez sur un nœud et glissez le lien vers un autre nœud pour les connecter.",edit:"Éditer",editClusterError:"Les clusters ne peuvent pas être édités.",editEdge:"Éditer le lien",editEdgeDescription:"Cliquez sur les points de contrôle et glissez-les pour connecter un nœud.",editNode:"Éditer le nœud"},cs:{addDescription:"Kluknutím do prázdného prostoru můžete přidat nový vrchol.",addEdge:"Přidat hranu",addNode:"Přidat vrchol",back:"Zpět",close:"Zavřít",createEdgeError:"Nelze připojit hranu ke shluku.",del:"Smazat výběr",deleteClusterError:"Nelze mazat shluky.",edgeDescription:"Přetažením z jednoho vrcholu do druhého můžete spojit tyto vrcholy novou hranou.",edit:"Upravit",editClusterError:"Nelze upravovat shluky.",editEdge:"Upravit hranu",editEdgeDescription:"Přetažením kontrolního vrcholu hrany ji můžete připojit k jinému vrcholu.",editNode:"Upravit vrchol"}});var Mb=function(){function t(){Yd(this,t),this.NUM_ITERATIONS=4,this.image=new Image,this.canvas=document.createElement("canvas")}return Kd(t,[{key:"init",value:function(){if(!this.initialized()){this.src=this.image.src;var t=this.image.width,e=this.image.height;this.width=t,this.height=e;var i=Math.floor(e/2),n=Math.floor(e/4),o=Math.floor(e/8),r=Math.floor(e/16),s=Math.floor(t/2),a=Math.floor(t/4),h=Math.floor(t/8),l=Math.floor(t/16);this.canvas.width=3*a,this.canvas.height=i,this.coordinates=[[0,0,s,i],[s,0,a,n],[s,n,h,o],[5*h,n,l,r]],this._fillMipMap()}}},{key:"initialized",value:function(){return void 0!==this.coordinates}},{key:"_fillMipMap",value:function(){var t=this.canvas.getContext("2d"),e=this.coordinates[0];t.drawImage(this.image,e[0],e[1],e[2],e[3]);for(var i=1;i<this.NUM_ITERATIONS;i++){var n=this.coordinates[i-1],o=this.coordinates[i];t.drawImage(this.canvas,n[0],n[1],n[2],n[3],o[0],o[1],o[2],o[3])}}},{key:"drawImageAtPosition",value:function(t,e,i,n,o,r){if(this.initialized())if(e>2){e*=.5;for(var s=0;e>2&&s<this.NUM_ITERATIONS;)e*=.5,s+=1;s>=this.NUM_ITERATIONS&&(s=this.NUM_ITERATIONS-1);var a=this.coordinates[s];t.drawImage(this.canvas,a[0],a[1],a[2],a[3],i,n,o,r)}else t.drawImage(this.image,i,n,o,r)}}]),t}(),Pb=function(){function t(e){Yd(this,t),this.images={},this.imageBroken={},this.callback=e}return Kd(t,[{key:"_tryloadBrokenUrl",value:function(t,e,i){void 0!==t&&void 0!==i&&(void 0!==e?(i.image.onerror=function(){console.error("Could not load brokenImage:",e)},i.image.src=e):console.warn("No broken url image defined"))}},{key:"_redrawWithImage",value:function(t){this.callback&&this.callback(t)}},{key:"load",value:function(t,e){var i=this,n=this.images[t];if(n)return n;var o=new Mb;return this.images[t]=o,o.image.onload=function(){i._fixImageCoordinates(o.image),o.init(),i._redrawWithImage(o)},o.image.onerror=function(){console.error("Could not load image:",t),i._tryloadBrokenUrl(t,e,o)},o.image.src=t,o}},{key:"_fixImageCoordinates",value:function(t){0===t.width&&(document.body.appendChild(t),t.width=t.offsetWidth,t.height=t.offsetHeight,document.body.removeChild(t))}}]),t}(),Db={exports:{}},Ib=o((function(){if("function"==typeof ArrayBuffer){var t=new ArrayBuffer(8);Object.isExtensible(t)&&Object.defineProperty(t,"a",{value:8})}})),Bb=o,zb=Y,Nb=B,Fb=Ib,Ab=Object.isExtensible,jb=Bb((function(){Ab(1)}))||Fb?function(t){return!!zb(t)&&((!Fb||"ArrayBuffer"!=Nb(t))&&(!Ab||Ab(t)))}:Ab,Rb=!o((function(){return Object.isExtensible(Object.preventExtensions({}))})),Lb=_i,Hb=g,Wb=Ri,qb=Y,Vb=Wt,Ub=Ve.f,Yb=rh,Xb=hh,Gb=jb,Kb=Rb,$b=!1,Zb=Xt("meta"),Qb=0,Jb=function(t){Ub(t,Zb,{value:{objectID:"O"+Qb++,weakData:{}}})},tw=Db.exports={enable:function(){tw.enable=function(){},$b=!0;var t=Yb.f,e=Hb([].splice),i={};i[Zb]=1,t(i).length&&(Yb.f=function(i){for(var n=t(i),o=0,r=n.length;o<r;o++)if(n[o]===Zb){e(n,o,1);break}return n},Lb({target:"Object",stat:!0,forced:!0},{getOwnPropertyNames:Xb.f}))},fastKey:function(t,e){if(!qb(t))return"symbol"==typeof t?t:("string"==typeof t?"S":"P")+t;if(!Vb(t,Zb)){if(!Gb(t))return"F";if(!e)return"E";Jb(t)}return t[Zb].objectID},getWeakData:function(t,e){if(!Vb(t,Zb)){if(!Gb(t))return!0;if(!e)return!1;Jb(t)}return t[Zb].weakData},onFreeze:function(t){return Kb&&$b&&Gb(t)&&!Vb(t,Zb)&&Jb(t),t}};Wb[Zb]=!0;var ew=qe,iw=_,nw=$e,ow=bt,rw=qs,sw=Bi,aw=J,hw=ba,lw=ua,dw=As,cw=n.TypeError,uw=function(t,e){this.stopped=t,this.result=e},fw=uw.prototype,pw=function(t,e,i){var n,o,r,s,a,h,l,d=i&&i.that,c=!(!i||!i.AS_ENTRIES),u=!(!i||!i.IS_ITERATOR),f=!(!i||!i.INTERRUPTED),p=ew(e,d),v=function(t){return n&&dw(n,"normal",t),new uw(!0,t)},g=function(t){return c?(nw(t),f?p(t[0],t[1],v):p(t[0],t[1])):f?p(t,v):p(t)};if(u)n=t;else{if(!(o=lw(t)))throw cw(ow(t)+" is not iterable");if(rw(o)){for(r=0,s=sw(t);s>r;r++)if((a=g(t[r]))&&aw(fw,a))return a;return new uw(!1)}n=hw(t,o)}for(h=n.next;!(l=iw(h,n)).done;){try{a=g(l.value)}catch(t){dw(n,"throw",t)}if("object"==typeof a&&a&&aw(fw,a))return a}return new uw(!1)},vw=J,gw=n.TypeError,yw=function(t,e){if(vw(e,t))return t;throw gw("Incorrect invocation")},mw=_i,bw=n,ww=Db.exports,kw=o,_w=di,xw=pw,Ew=yw,Ow=y,Cw=Y,Sw=$r,Tw=Ve.f,Mw=Wh.forEach,Pw=b,Dw=Vo.set,Iw=Vo.getterFor,Bw=function(t,e,i){var n,o=-1!==t.indexOf("Map"),r=-1!==t.indexOf("Weak"),s=o?"set":"add",a=bw[t],h=a&&a.prototype,l={};if(Pw&&Ow(a)&&(r||h.forEach&&!kw((function(){(new a).entries().next()})))){var d=(n=e((function(e,i){Dw(Ew(e,d),{type:t,collection:new a}),null!=i&&xw(i,e[s],{that:e,AS_ENTRIES:o})}))).prototype,c=Iw(t);Mw(["add","clear","delete","forEach","get","has","set","keys","values","entries"],(function(t){var e="add"==t||"set"==t;!(t in h)||r&&"clear"==t||_w(d,t,(function(i,n){var o=c(this).collection;if(!e&&r&&!Cw(i))return"get"==t&&void 0;var s=o[t](0===i?0:i,n);return e?this:s}))})),r||Tw(d,"size",{configurable:!0,get:function(){return c(this).collection.size}})}else n=i.getConstructor(e,t,o,s),ww.enable();return Sw(n,t,!1,!0),l[t]=n,mw({global:!0,forced:!0},l),r||i.setStrong(n,t,o),n},zw=Ir,Nw=function(t,e,i){for(var n in e)i&&i.unsafe&&t[n]?t[n]=e[n]:zw(t,n,e[n],i);return t},Fw=Q,Aw=Ve,jw=b,Rw=oe("species"),Lw=Ve.f,Hw=wr,Ww=Nw,qw=qe,Vw=yw,Uw=pw,Yw=Cs,Xw=function(t){var e=Fw(t),i=Aw.f;jw&&e&&!e[Rw]&&i(e,Rw,{configurable:!0,get:function(){return this}})},Gw=b,Kw=Db.exports.fastKey,$w=Vo.set,Zw=Vo.getterFor,Qw={getConstructor:function(t,e,i,n){var o=t((function(t,o){Vw(t,r),$w(t,{type:e,index:Hw(null),first:void 0,last:void 0,size:0}),Gw||(t.size=0),null!=o&&Uw(o,t[n],{that:t,AS_ENTRIES:i})})),r=o.prototype,s=Zw(e),a=function(t,e,i){var n,o,r=s(t),a=h(t,e);return a?a.value=i:(r.last=a={index:o=Kw(e,!0),key:e,value:i,previous:n=r.last,next:void 0,removed:!1},r.first||(r.first=a),n&&(n.next=a),Gw?r.size++:t.size++,"F"!==o&&(r.index[o]=a)),t},h=function(t,e){var i,n=s(t),o=Kw(e);if("F"!==o)return n.index[o];for(i=n.first;i;i=i.next)if(i.key==e)return i};return Ww(r,{clear:function(){for(var t=s(this),e=t.index,i=t.first;i;)i.removed=!0,i.previous&&(i.previous=i.previous.next=void 0),delete e[i.index],i=i.next;t.first=t.last=void 0,Gw?t.size=0:this.size=0},delete:function(t){var e=this,i=s(e),n=h(e,t);if(n){var o=n.next,r=n.previous;delete i.index[n.index],n.removed=!0,r&&(r.next=o),o&&(o.previous=r),i.first==n&&(i.first=o),i.last==n&&(i.last=r),Gw?i.size--:e.size--}return!!n},forEach:function(t){for(var e,i=s(this),n=qw(t,arguments.length>1?arguments[1]:void 0);e=e?e.next:i.first;)for(n(e.value,e.key,this);e&&e.removed;)e=e.previous},has:function(t){return!!h(this,t)}}),Ww(r,i?{get:function(t){var e=h(this,t);return e&&e.value},set:function(t,e){return a(this,0===t?0:t,e)}}:{add:function(t){return a(this,t=0===t?0:t,t)}}),Gw&&Lw(r,"size",{get:function(){return s(this).size}}),o},setStrong:function(t,e,i){var n=e+" Iterator",o=Zw(e),r=Zw(n);Yw(t,e,(function(t,e){$w(this,{type:n,target:t,state:o(t),kind:e,last:void 0})}),(function(){for(var t=r(this),e=t.kind,i=t.last;i&&i.removed;)i=i.previous;return t.target&&(t.last=i=i?i.next:t.state.first)?"keys"==e?{value:i.key,done:!1}:"values"==e?{value:i.value,done:!1}:{value:[i.key,i.value],done:!1}:(t.target=void 0,{value:void 0,done:!0})}),i?"entries":"values",!i,!0),Xw(e)}};Bw("Map",(function(t){return function(){return t(this,arguments.length?arguments[0]:void 0)}}),Qw);var Jw=X.Map,tk=function(){function t(){Yd(this,t),this.clear(),this._defaultIndex=0,this._groupIndex=0,this._defaultGroups=[{border:"#2B7CE9",background:"#97C2FC",highlight:{border:"#2B7CE9",background:"#D2E5FF"},hover:{border:"#2B7CE9",background:"#D2E5FF"}},{border:"#FFA500",background:"#FFFF00",highlight:{border:"#FFA500",background:"#FFFFA3"},hover:{border:"#FFA500",background:"#FFFFA3"}},{border:"#FA0A10",background:"#FB7E81",highlight:{border:"#FA0A10",background:"#FFAFB1"},hover:{border:"#FA0A10",background:"#FFAFB1"}},{border:"#41A906",background:"#7BE141",highlight:{border:"#41A906",background:"#A1EC76"},hover:{border:"#41A906",background:"#A1EC76"}},{border:"#E129F0",background:"#EB7DF4",highlight:{border:"#E129F0",background:"#F0B3F5"},hover:{border:"#E129F0",background:"#F0B3F5"}},{border:"#7C29F0",background:"#AD85E4",highlight:{border:"#7C29F0",background:"#D3BDF0"},hover:{border:"#7C29F0",background:"#D3BDF0"}},{border:"#C37F00",background:"#FFA807",highlight:{border:"#C37F00",background:"#FFCA66"},hover:{border:"#C37F00",background:"#FFCA66"}},{border:"#4220FB",background:"#6E6EFD",highlight:{border:"#4220FB",background:"#9B9BFD"},hover:{border:"#4220FB",background:"#9B9BFD"}},{border:"#FD5A77",background:"#FFC0CB",highlight:{border:"#FD5A77",background:"#FFD1D9"},hover:{border:"#FD5A77",background:"#FFD1D9"}},{border:"#4AD63A",background:"#C2FABC",highlight:{border:"#4AD63A",background:"#E6FFE3"},hover:{border:"#4AD63A",background:"#E6FFE3"}},{border:"#990000",background:"#EE0000",highlight:{border:"#BB0000",background:"#FF3333"},hover:{border:"#BB0000",background:"#FF3333"}},{border:"#FF6000",background:"#FF6000",highlight:{border:"#FF6000",background:"#FF6000"},hover:{border:"#FF6000",background:"#FF6000"}},{border:"#97C2FC",background:"#2B7CE9",highlight:{border:"#D2E5FF",background:"#2B7CE9"},hover:{border:"#D2E5FF",background:"#2B7CE9"}},{border:"#399605",background:"#255C03",highlight:{border:"#399605",background:"#255C03"},hover:{border:"#399605",background:"#255C03"}},{border:"#B70054",background:"#FF007E",highlight:{border:"#B70054",background:"#FF007E"},hover:{border:"#B70054",background:"#FF007E"}},{border:"#AD85E4",background:"#7C29F0",highlight:{border:"#D3BDF0",background:"#7C29F0"},hover:{border:"#D3BDF0",background:"#7C29F0"}},{border:"#4557FA",background:"#000EA1",highlight:{border:"#6E6EFD",background:"#000EA1"},hover:{border:"#6E6EFD",background:"#000EA1"}},{border:"#FFC0CB",background:"#FD5A77",highlight:{border:"#FFD1D9",background:"#FD5A77"},hover:{border:"#FFD1D9",background:"#FD5A77"}},{border:"#C2FABC",background:"#74D66A",highlight:{border:"#E6FFE3",background:"#74D66A"},hover:{border:"#E6FFE3",background:"#74D66A"}},{border:"#EE0000",background:"#990000",highlight:{border:"#FF3333",background:"#BB0000"},hover:{border:"#FF3333",background:"#BB0000"}}],this.options={},this.defaultOptions={useDefaultGroups:!0},un(this.options,this.defaultOptions)}return Kd(t,[{key:"setOptions",value:function(t){var e=["useDefaultGroups"];if(void 0!==t)for(var i in t)if(Object.prototype.hasOwnProperty.call(t,i)&&-1===Fp(e).call(e,i)){var n=t[i];this.add(i,n)}}},{key:"clear",value:function(){this._groups=new Jw,this._groupNames=[]}},{key:"get",value:function(t){var e=!(arguments.length>1&&void 0!==arguments[1])||arguments[1],i=this._groups.get(t);if(void 0===i&&e)if(!1===this.options.useDefaultGroups&&this._groupNames.length>0){var n=this._groupIndex%this._groupNames.length;++this._groupIndex,(i={}).color=this._groups.get(this._groupNames[n]),this._groups.set(t,i)}else{var o=this._defaultIndex%this._defaultGroups.length;this._defaultIndex++,(i={}).color=this._defaultGroups[o],this._groups.set(t,i)}return i}},{key:"add",value:function(t,e){return this._groups.has(t)||this._groupNames.push(t),this._groups.set(t,e),e}}]),t}();_i({target:"Number",stat:!0},{isNaN:function(t){return t!=t}});var ek=X.Number.isNaN,ik=n.isFinite,nk=Number.isFinite||function(t){return"number"==typeof t&&ik(t)};_i({target:"Number",stat:!0},{isFinite:nk});var ok=X.Number.isFinite,rk=Wh.some;_i({target:"Array",proto:!0,forced:!Cu("some")},{some:function(t){return rk(this,t,arguments.length>1?arguments[1]:void 0)}});var sk=Tn("Array").some,ak=J,hk=sk,lk=Array.prototype,dk=function(t){var e=t.some;return t===lk||ak(lk,t)&&e===lk.some?hk:e},ck=dk,uk=na,fk=bt,pk=n.TypeError,vk=_i,gk=d,yk=On,mk=function(t){if(uk(t))return t;throw pk(fk(t)+" is not a constructor")},bk=$e,wk=Y,kk=wr,_k=o,xk=Q("Reflect","construct"),Ek=Object.prototype,Ok=[].push,Ck=_k((function(){function t(){}return!(xk((function(){}),[],t)instanceof t)})),Sk=!_k((function(){xk((function(){}))})),Tk=Ck||Sk;vk({target:"Reflect",stat:!0,forced:Tk,sham:Tk},{construct:function(t,e){mk(t),bk(e);var i=arguments.length<3?t:mk(arguments[2]);if(Sk&&!Ck)return xk(t,e,i);if(t==i){switch(e.length){case 0:return new t;case 1:return new t(e[0]);case 2:return new t(e[0],e[1]);case 3:return new t(e[0],e[1],e[2]);case 4:return new t(e[0],e[1],e[2],e[3])}var n=[null];return gk(Ok,n,e),new(gk(yk,t,n))}var o=i.prototype,r=kk(wk(o)?o:Ek),s=gk(t,r,e);return wk(s)?s:r}});var Mk=X.Reflect.construct;function Pk(t){if(void 0===t)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return t}var Dk=Gp;_i({target:"Object",stat:!0},{setPrototypeOf:cs});var Ik=X.Object.setPrototypeOf;function Bk(t,e){return Bk=Ik||function(t,e){return t.__proto__=e,t},Bk(t,e)}function zk(t,e){if("function"!=typeof e&&null!==e)throw new TypeError("Super expression must either be null or a function");t.prototype=Dk(e&&e.prototype,{constructor:{value:t,writable:!0,configurable:!0}}),Xd(t,"prototype",{writable:!1}),e&&Bk(t,e)}function Nk(t,e){if(e&&("object"===Qc(e)||"function"==typeof e))return e;if(void 0!==e)throw new TypeError("Derived constructors may only return object or undefined");return Pk(t)}var Fk=Rf;function Ak(t){return Ak=Ik?Fk:function(t){return t.__proto__||Fk(t)},Ak(t)}var jk={exports:{}};!function(t){var e=function(t){var e,i=Object.prototype,n=i.hasOwnProperty,o="function"==typeof Symbol?Symbol:{},r=o.iterator||"@@iterator",s=o.asyncIterator||"@@asyncIterator",a=o.toStringTag||"@@toStringTag";function h(t,e,i){return Object.defineProperty(t,e,{value:i,enumerable:!0,configurable:!0,writable:!0}),t[e]}try{h({},"")}catch(t){h=function(t,e,i){return t[e]=i}}function l(t,e,i,n){var o=e&&e.prototype instanceof g?e:g,r=Object.create(o.prototype),s=new T(n||[]);return r._invoke=function(t,e,i){var n=c;return function(o,r){if(n===f)throw new Error("Generator is already running");if(n===p){if("throw"===o)throw r;return P()}for(i.method=o,i.arg=r;;){var s=i.delegate;if(s){var a=O(s,i);if(a){if(a===v)continue;return a}}if("next"===i.method)i.sent=i._sent=i.arg;else if("throw"===i.method){if(n===c)throw n=p,i.arg;i.dispatchException(i.arg)}else"return"===i.method&&i.abrupt("return",i.arg);n=f;var h=d(t,e,i);if("normal"===h.type){if(n=i.done?p:u,h.arg===v)continue;return{value:h.arg,done:i.done}}"throw"===h.type&&(n=p,i.method="throw",i.arg=h.arg)}}}(t,i,s),r}function d(t,e,i){try{return{type:"normal",arg:t.call(e,i)}}catch(t){return{type:"throw",arg:t}}}t.wrap=l;var c="suspendedStart",u="suspendedYield",f="executing",p="completed",v={};function g(){}function y(){}function m(){}var b={};h(b,r,(function(){return this}));var w=Object.getPrototypeOf,k=w&&w(w(M([])));k&&k!==i&&n.call(k,r)&&(b=k);var _=m.prototype=g.prototype=Object.create(b);function x(t){["next","throw","return"].forEach((function(e){h(t,e,(function(t){return this._invoke(e,t)}))}))}function E(t,e){function i(o,r,s,a){var h=d(t[o],t,r);if("throw"!==h.type){var l=h.arg,c=l.value;return c&&"object"==typeof c&&n.call(c,"__await")?e.resolve(c.__await).then((function(t){i("next",t,s,a)}),(function(t){i("throw",t,s,a)})):e.resolve(c).then((function(t){l.value=t,s(l)}),(function(t){return i("throw",t,s,a)}))}a(h.arg)}var o;this._invoke=function(t,n){function r(){return new e((function(e,o){i(t,n,e,o)}))}return o=o?o.then(r,r):r()}}function O(t,i){var n=t.iterator[i.method];if(n===e){if(i.delegate=null,"throw"===i.method){if(t.iterator.return&&(i.method="return",i.arg=e,O(t,i),"throw"===i.method))return v;i.method="throw",i.arg=new TypeError("The iterator does not provide a 'throw' method")}return v}var o=d(n,t.iterator,i.arg);if("throw"===o.type)return i.method="throw",i.arg=o.arg,i.delegate=null,v;var r=o.arg;return r?r.done?(i[t.resultName]=r.value,i.next=t.nextLoc,"return"!==i.method&&(i.method="next",i.arg=e),i.delegate=null,v):r:(i.method="throw",i.arg=new TypeError("iterator result is not an object"),i.delegate=null,v)}function C(t){var e={tryLoc:t[0]};1 in t&&(e.catchLoc=t[1]),2 in t&&(e.finallyLoc=t[2],e.afterLoc=t[3]),this.tryEntries.push(e)}function S(t){var e=t.completion||{};e.type="normal",delete e.arg,t.completion=e}function T(t){this.tryEntries=[{tryLoc:"root"}],t.forEach(C,this),this.reset(!0)}function M(t){if(t){var i=t[r];if(i)return i.call(t);if("function"==typeof t.next)return t;if(!isNaN(t.length)){var o=-1,s=function i(){for(;++o<t.length;)if(n.call(t,o))return i.value=t[o],i.done=!1,i;return i.value=e,i.done=!0,i};return s.next=s}}return{next:P}}function P(){return{value:e,done:!0}}return y.prototype=m,h(_,"constructor",m),h(m,"constructor",y),y.displayName=h(m,a,"GeneratorFunction"),t.isGeneratorFunction=function(t){var e="function"==typeof t&&t.constructor;return!!e&&(e===y||"GeneratorFunction"===(e.displayName||e.name))},t.mark=function(t){return Object.setPrototypeOf?Object.setPrototypeOf(t,m):(t.__proto__=m,h(t,a,"GeneratorFunction")),t.prototype=Object.create(_),t},t.awrap=function(t){return{__await:t}},x(E.prototype),h(E.prototype,s,(function(){return this})),t.AsyncIterator=E,t.async=function(e,i,n,o,r){void 0===r&&(r=Promise);var s=new E(l(e,i,n,o),r);return t.isGeneratorFunction(i)?s:s.next().then((function(t){return t.done?t.value:s.next()}))},x(_),h(_,a,"Generator"),h(_,r,(function(){return this})),h(_,"toString",(function(){return"[object Generator]"})),t.keys=function(t){var e=[];for(var i in t)e.push(i);return e.reverse(),function i(){for(;e.length;){var n=e.pop();if(n in t)return i.value=n,i.done=!1,i}return i.done=!0,i}},t.values=M,T.prototype={constructor:T,reset:function(t){if(this.prev=0,this.next=0,this.sent=this._sent=e,this.done=!1,this.delegate=null,this.method="next",this.arg=e,this.tryEntries.forEach(S),!t)for(var i in this)"t"===i.charAt(0)&&n.call(this,i)&&!isNaN(+i.slice(1))&&(this[i]=e)},stop:function(){this.done=!0;var t=this.tryEntries[0].completion;if("throw"===t.type)throw t.arg;return this.rval},dispatchException:function(t){if(this.done)throw t;var i=this;function o(n,o){return a.type="throw",a.arg=t,i.next=n,o&&(i.method="next",i.arg=e),!!o}for(var r=this.tryEntries.length-1;r>=0;--r){var s=this.tryEntries[r],a=s.completion;if("root"===s.tryLoc)return o("end");if(s.tryLoc<=this.prev){var h=n.call(s,"catchLoc"),l=n.call(s,"finallyLoc");if(h&&l){if(this.prev<s.catchLoc)return o(s.catchLoc,!0);if(this.prev<s.finallyLoc)return o(s.finallyLoc)}else if(h){if(this.prev<s.catchLoc)return o(s.catchLoc,!0)}else{if(!l)throw new Error("try statement without catch or finally");if(this.prev<s.finallyLoc)return o(s.finallyLoc)}}}},abrupt:function(t,e){for(var i=this.tryEntries.length-1;i>=0;--i){var o=this.tryEntries[i];if(o.tryLoc<=this.prev&&n.call(o,"finallyLoc")&&this.prev<o.finallyLoc){var r=o;break}}r&&("break"===t||"continue"===t)&&r.tryLoc<=e&&e<=r.finallyLoc&&(r=null);var s=r?r.completion:{};return s.type=t,s.arg=e,r?(this.method="next",this.next=r.finallyLoc,v):this.complete(s)},complete:function(t,e){if("throw"===t.type)throw t.arg;return"break"===t.type||"continue"===t.type?this.next=t.arg:"return"===t.type?(this.rval=this.arg=t.arg,this.method="return",this.next="end"):"normal"===t.type&&e&&(this.next=e),v},finish:function(t){for(var e=this.tryEntries.length-1;e>=0;--e){var i=this.tryEntries[e];if(i.finallyLoc===t)return this.complete(i.completion,i.afterLoc),S(i),v}},catch:function(t){for(var e=this.tryEntries.length-1;e>=0;--e){var i=this.tryEntries[e];if(i.tryLoc===t){var n=i.completion;if("throw"===n.type){var o=n.arg;S(i)}return o}}throw new Error("illegal catch attempt")},delegateYield:function(t,i,n){return this.delegate={iterator:M(t),resultName:i,nextLoc:n},"next"===this.method&&(this.arg=e),v}},t}(t.exports);try{regeneratorRuntime=e}catch(t){"object"==typeof globalThis?globalThis.regeneratorRuntime=e:Function("r","regeneratorRuntime = r")(e)}}(jk);var Rk=jk.exports,Lk=xt,Hk=Rt,Wk=R,qk=Bi,Vk=n.TypeError,Uk=function(t){return function(e,i,n,o){Lk(i);var r=Hk(e),s=Wk(r),a=qk(r),h=t?a-1:0,l=t?-1:1;if(n<2)for(;;){if(h in s){o=s[h],h+=l;break}if(h+=l,t?h<0:a<=h)throw Vk("Reduce of empty array with no initial value")}for(;t?h>=0:a>h;h+=l)h in s&&(o=i(o,s[h],h,r));return o}},Yk={left:Uk(!1),right:Uk(!0)},Xk="process"==B(n.process),Gk=Yk.left,Kk=at,$k=Xk;_i({target:"Array",proto:!0,forced:!Cu("reduce")||!$k&&Kk>79&&Kk<83},{reduce:function(t){var e=arguments.length;return Gk(this,t,e,e>1?arguments[1]:void 0)}});var Zk=Tn("Array").reduce,Qk=J,Jk=Zk,t_=Array.prototype,e_=function(t){var e=t.reduce;return t===t_||Qk(t_,t)&&e===t_.reduce?Jk:e},i_=e_,n_=oh,o_=Bi,r_=qe,s_=n.TypeError,a_=function(t,e,i,n,o,r,s,a){for(var h,l,d=o,c=0,u=!!s&&r_(s,a);c<n;){if(c in i){if(h=u?u(i[c],c,e):i[c],r>0&&n_(h))l=o_(h),d=a_(t,e,h,l,d,r-1)-1;else{if(d>=9007199254740991)throw s_("Exceed the acceptable array length");t[d]=h}d++}c++}return d},h_=a_,l_=xt,d_=Rt,c_=Bi,u_=zh;_i({target:"Array",proto:!0},{flatMap:function(t){var e,i=d_(this),n=c_(i);return l_(t),(e=u_(i,0)).length=h_(e,i,i,n,0,1,t,arguments.length>1?arguments[1]:void 0),e}});var f_=Tn("Array").flatMap,p_=J,v_=f_,g_=Array.prototype,y_=function(t){var e=t.flatMap;return t===g_||p_(g_,t)&&e===g_.flatMap?v_:e},m_=y_;Bw("Set",(function(t){return function(){return t(this,arguments.length?arguments[0]:void 0)}}),Qw);var b_=X.Set,w_=$c,k_=ba,__=ph,x_=Math.floor,E_=function(t,e){var i=t.length,n=x_(i/2);return i<8?O_(t,e):C_(t,E_(__(t,0,n),e),E_(__(t,n),e),e)},O_=function(t,e){for(var i,n,o=t.length,r=1;r<o;){for(n=r,i=t[r];n&&e(t[n-1],i)>0;)t[n]=t[--n];n!==r++&&(t[n]=i)}return t},C_=function(t,e,i,n){for(var o=e.length,r=i.length,s=0,a=0;s<o||a<r;)t[s+a]=s<o&&a<r?n(e[s],i[a])<=0?e[s++]:i[a++]:s<o?e[s++]:i[a++];return t},S_=E_,T_=tt.match(/firefox\/(\d+)/i),M_=!!T_&&+T_[1],P_=/MSIE|Trident/.test(tt),D_=tt.match(/AppleWebKit\/(\d+)\./),I_=!!D_&&+D_[1],B_=_i,z_=g,N_=xt,F_=Rt,A_=Bi,j_=eo,R_=o,L_=S_,H_=Cu,W_=M_,q_=P_,V_=at,U_=I_,Y_=[],X_=z_(Y_.sort),G_=z_(Y_.push),K_=R_((function(){Y_.sort(void 0)})),$_=R_((function(){Y_.sort(null)})),Z_=H_("sort"),Q_=!R_((function(){if(V_)return V_<70;if(!(W_&&W_>3)){if(q_)return!0;if(U_)return U_<603;var t,e,i,n,o="";for(t=65;t<76;t++){switch(e=String.fromCharCode(t),t){case 66:case 69:case 70:case 72:i=3;break;case 68:case 71:i=4;break;default:i=2}for(n=0;n<47;n++)Y_.push({k:e+n,v:i})}for(Y_.sort((function(t,e){return e.v-t.v})),n=0;n<Y_.length;n++)e=Y_[n].k.charAt(0),o.charAt(o.length-1)!==e&&(o+=e);return"DGBEFHACIJK"!==o}}));B_({target:"Array",proto:!0,forced:K_||!$_||!Z_||!Q_},{sort:function(t){void 0!==t&&N_(t);var e=F_(this);if(Q_)return void 0===t?X_(e):X_(e,t);var i,n,o=[],r=A_(e);for(n=0;n<r;n++)n in e&&G_(o,e[n]);for(L_(o,function(t){return function(e,i){return void 0===i?-1:void 0===e?1:void 0!==t?+t(e,i)||0:j_(e)>j_(i)?1:-1}}(t)),i=o.length,n=0;n<i;)e[n]=o[n++];for(;n<r;)delete e[n++];return e}});var J_,tx=Tn("Array").sort,ex=J,ix=tx,nx=Array.prototype,ox=function(t){var e=t.sort;return t===nx||ex(nx,t)&&e===nx.sort?ix:e},rx=ox,sx=Tn("Array").keys,ax=Qn,hx=Wt,lx=J,dx=sx,cx=Array.prototype,ux={DOMTokenList:!0,NodeList:!0},fx=function(t){var e=t.keys;return t===cx||lx(cx,t)&&e===cx.keys||hx(ux,ax(t))?dx:e},px=Tn("Array").values,vx=Qn,gx=Wt,yx=J,mx=px,bx=Array.prototype,wx={DOMTokenList:!0,NodeList:!0},kx=function(t){var e=t.values;return t===bx||yx(bx,t)&&e===bx.values||gx(wx,vx(t))?mx:e},_x=Tn("Array").entries,xx=Qn,Ex=Wt,Ox=J,Cx=_x,Sx=Array.prototype,Tx={DOMTokenList:!0,NodeList:!0},Mx=function(t){var e=t.entries;return t===Sx||Ox(Sx,t)&&e===Sx.entries||Ex(Tx,xx(t))?Cx:e},Px=new Uint8Array(16);function Dx(){if(!J_&&!(J_="undefined"!=typeof crypto&&crypto.getRandomValues&&crypto.getRandomValues.bind(crypto)||"undefined"!=typeof msCrypto&&"function"==typeof msCrypto.getRandomValues&&msCrypto.getRandomValues.bind(msCrypto)))throw new Error("crypto.getRandomValues() not supported. See https://github.com/uuidjs/uuid#getrandomvalues-not-supported");return J_(Px)}var Ix=/^(?:[0-9a-f]{8}-[0-9a-f]{4}-[1-5][0-9a-f]{3}-[89ab][0-9a-f]{3}-[0-9a-f]{12}|00000000-0000-0000-0000-000000000000)$/i;function Bx(t){return"string"==typeof t&&Ix.test(t)}for(var zx,Nx=[],Fx=0;Fx<256;++Fx)Nx.push((Fx+256).toString(16).substr(1));function Ax(t,e,i){var n=(t=t||{}).random||(t.rng||Dx)();if(n[6]=15&n[6]|64,n[8]=63&n[8]|128,e){i=i||0;for(var o=0;o<16;++o)e[i+o]=n[o];return e}return function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,i=(Nx[t[e+0]]+Nx[t[e+1]]+Nx[t[e+2]]+Nx[t[e+3]]+"-"+Nx[t[e+4]]+Nx[t[e+5]]+"-"+Nx[t[e+6]]+Nx[t[e+7]]+"-"+Nx[t[e+8]]+Nx[t[e+9]]+"-"+Nx[t[e+10]]+Nx[t[e+11]]+Nx[t[e+12]]+Nx[t[e+13]]+Nx[t[e+14]]+Nx[t[e+15]]).toLowerCase();if(!Bx(i))throw TypeError("Stringified UUID is invalid");return i}(n)}function jx(t,e){var i=bu(t);if(hd){var n=hd(t);e&&(n=Xf(n).call(n,(function(e){return bd(t,e).enumerable}))),i.push.apply(i,n)}return i}function Rx(t){for(var e=1;e<arguments.length;e++){var i,n,o=null!=arguments[e]?arguments[e]:{};e%2?Fu(i=jx(Object(o),!0)).call(i,(function(e){$d(t,e,o[e])})):Pd?Ad(t,Pd(o)):Fu(n=jx(Object(o))).call(n,(function(e){Ud(t,e,bd(o,e))}))}return t}function Lx(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}function Hx(t,e){var i=void 0!==tu&&ih(t)||t["@@iterator"];if(!i){if(lu(t)||(i=function(t,e){var i;if(!t)return;if("string"==typeof t)return Wx(t,e);var n=au(i=Object.prototype.toString.call(t)).call(i,8,-1);"Object"===n&&t.constructor&&(n=t.constructor.name);if("Map"===n||"Set"===n)return ja(t);if("Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n))return Wx(t,e)}(t))||e&&t&&"number"==typeof t.length){i&&(t=i);var n=0,o=function(){};return{s:o,n:function(){return n>=t.length?{done:!0}:{done:!1,value:t[n++]}},e:function(t){throw t},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var r,s=!0,a=!1;return{s:function(){i=i.call(t)},n:function(){var t=i.next();return s=t.done,t},e:function(t){a=!0,r=t},f:function(){try{s||null==i.return||i.return()}finally{if(a)throw r}}}}function Wx(t,e){(null==e||e>t.length)&&(e=t.length);for(var i=0,n=new Array(e);i<e;i++)n[i]=t[i];return n}var qx=function(){function t(e,i,n){var o,r,s;Yd(this,t),$d(this,"_source",void 0),$d(this,"_transformers",void 0),$d(this,"_target",void 0),$d(this,"_listeners",{add:zn(o=this._add).call(o,this),remove:zn(r=this._remove).call(r,this),update:zn(s=this._update).call(s,this)}),this._source=e,this._transformers=i,this._target=n}return Kd(t,[{key:"all",value:function(){return this._target.update(this._transformItems(this._source.get())),this}},{key:"start",value:function(){return this._source.on("add",this._listeners.add),this._source.on("remove",this._listeners.remove),this._source.on("update",this._listeners.update),this}},{key:"stop",value:function(){return this._source.off("add",this._listeners.add),this._source.off("remove",this._listeners.remove),this._source.off("update",this._listeners.update),this}},{key:"_transformItems",value:function(t){var e;return i_(e=this._transformers).call(e,(function(t,e){return e(t)}),t)}},{key:"_add",value:function(t,e){null!=e&&this._target.add(this._transformItems(this._source.get(e.items)))}},{key:"_update",value:function(t,e){null!=e&&this._target.update(this._transformItems(this._source.get(e.items)))}},{key:"_remove",value:function(t,e){null!=e&&this._target.remove(this._transformItems(e.oldData))}}]),t}(),Vx=function(){function t(e){Yd(this,t),$d(this,"_source",void 0),$d(this,"_transformers",[]),this._source=e}return Kd(t,[{key:"filter",value:function(t){return this._transformers.push((function(e){return Xf(e).call(e,t)})),this}},{key:"map",value:function(t){return this._transformers.push((function(e){return gu(e).call(e,t)})),this}},{key:"flatMap",value:function(t){return this._transformers.push((function(e){return m_(e).call(e,t)})),this}},{key:"to",value:function(t){return new qx(this._source,this._transformers,t)}}]),t}();function Ux(t){return"string"==typeof t||"number"==typeof t}var Yx=function(){function t(e){Yd(this,t),$d(this,"delay",void 0),$d(this,"max",void 0),$d(this,"_queue",[]),$d(this,"_timeout",null),$d(this,"_extended",null),this.delay=null,this.max=1/0,this.setOptions(e)}return Kd(t,[{key:"setOptions",value:function(t){t&&void 0!==t.delay&&(this.delay=t.delay),t&&void 0!==t.max&&(this.max=t.max),this._flushIfNeeded()}},{key:"destroy",value:function(){if(this.flush(),this._extended){for(var t=this._extended.object,e=this._extended.methods,i=0;i<e.length;i++){var n=e[i];n.original?t[n.name]=n.original:delete t[n.name]}this._extended=null}}},{key:"replace",value:function(t,e){var i=this,n=t[e];if(!n)throw new Error("Method "+e+" undefined");t[e]=function(){for(var t=arguments.length,e=new Array(t),o=0;o<t;o++)e[o]=arguments[o];i.queue({args:e,fn:n,context:this})}}},{key:"queue",value:function(t){"function"==typeof t?this._queue.push({fn:t}):this._queue.push(t),this._flushIfNeeded()}},{key:"_flushIfNeeded",value:function(){var t=this;this._queue.length>this.max&&this.flush(),null!=this._timeout&&(clearTimeout(this._timeout),this._timeout=null),this.queue.length>0&&"number"==typeof this.delay&&(this._timeout=Sv((function(){t.flush()}),this.delay))}},{key:"flush",value:function(){var t,e;Fu(t=ff(e=this._queue).call(e,0)).call(t,(function(t){t.fn.apply(t.context||t.fn,t.args||[])}))}}],[{key:"extend",value:function(e,i){var n=new t(i);if(void 0!==e.flush)throw new Error("Target object already has a property flush");e.flush=function(){n.flush()};var o=[{name:"flush",original:void 0}];if(i&&i.replace)for(var r=0;r<i.replace.length;r++){var s=i.replace[r];o.push({name:s,original:e[s]}),n.replace(e,s)}return n._extended={object:e,methods:o},n}}]),t}(),Xx=function(){function t(){Yd(this,t),$d(this,"_subscribers",{"*":[],add:[],remove:[],update:[]}),$d(this,"subscribe",t.prototype.on),$d(this,"unsubscribe",t.prototype.off)}return Kd(t,[{key:"_trigger",value:function(t,e,i){var n,o;if("*"===t)throw new Error("Cannot trigger event *");Fu(n=su(o=[]).call(o,Jc(this._subscribers[t]),Jc(this._subscribers["*"]))).call(n,(function(n){n(t,e,null!=i?i:null)}))}},{key:"on",value:function(t,e){"function"==typeof e&&this._subscribers[t].push(e)}},{key:"off",value:function(t,e){var i;this._subscribers[t]=Xf(i=this._subscribers[t]).call(i,(function(t){return t!==e}))}}]),t}();zx=w_;var Gx=function(){function t(e){Yd(this,t),$d(this,"_pairs",void 0),this._pairs=e}return Kd(t,[{key:zx,value:Rk.mark((function t(){var e,i,n,o,r;return Rk.wrap((function(t){for(;;)switch(t.prev=t.next){case 0:e=Hx(this._pairs),t.prev=1,e.s();case 3:if((i=e.n()).done){t.next=9;break}return n=Kc(i.value,2),o=n[0],r=n[1],t.next=7,[o,r];case 7:t.next=3;break;case 9:t.next=14;break;case 11:t.prev=11,t.t0=t.catch(1),e.e(t.t0);case 14:return t.prev=14,e.f(),t.finish(14);case 17:case"end":return t.stop()}}),t,this,[[1,11,14,17]])}))},{key:"entries",value:Rk.mark((function t(){var e,i,n,o,r;return Rk.wrap((function(t){for(;;)switch(t.prev=t.next){case 0:e=Hx(this._pairs),t.prev=1,e.s();case 3:if((i=e.n()).done){t.next=9;break}return n=Kc(i.value,2),o=n[0],r=n[1],t.next=7,[o,r];case 7:t.next=3;break;case 9:t.next=14;break;case 11:t.prev=11,t.t0=t.catch(1),e.e(t.t0);case 14:return t.prev=14,e.f(),t.finish(14);case 17:case"end":return t.stop()}}),t,this,[[1,11,14,17]])}))},{key:"keys",value:Rk.mark((function t(){var e,i,n,o;return Rk.wrap((function(t){for(;;)switch(t.prev=t.next){case 0:e=Hx(this._pairs),t.prev=1,e.s();case 3:if((i=e.n()).done){t.next=9;break}return n=Kc(i.value,1),o=n[0],t.next=7,o;case 7:t.next=3;break;case 9:t.next=14;break;case 11:t.prev=11,t.t0=t.catch(1),e.e(t.t0);case 14:return t.prev=14,e.f(),t.finish(14);case 17:case"end":return t.stop()}}),t,this,[[1,11,14,17]])}))},{key:"values",value:Rk.mark((function t(){var e,i,n,o;return Rk.wrap((function(t){for(;;)switch(t.prev=t.next){case 0:e=Hx(this._pairs),t.prev=1,e.s();case 3:if((i=e.n()).done){t.next=9;break}return n=Kc(i.value,2),o=n[1],t.next=7,o;case 7:t.next=3;break;case 9:t.next=14;break;case 11:t.prev=11,t.t0=t.catch(1),e.e(t.t0);case 14:return t.prev=14,e.f(),t.finish(14);case 17:case"end":return t.stop()}}),t,this,[[1,11,14,17]])}))},{key:"toIdArray",value:function(){var t;return gu(t=Jc(this._pairs)).call(t,(function(t){return t[0]}))}},{key:"toItemArray",value:function(){var t;return gu(t=Jc(this._pairs)).call(t,(function(t){return t[1]}))}},{key:"toEntryArray",value:function(){return Jc(this._pairs)}},{key:"toObjectMap",value:function(){var t,e=Kp(null),i=Hx(this._pairs);try{for(i.s();!(t=i.n()).done;){var n=Kc(t.value,2),o=n[0],r=n[1];e[o]=r}}catch(t){i.e(t)}finally{i.f()}return e}},{key:"toMap",value:function(){return new Jw(this._pairs)}},{key:"toIdSet",value:function(){return new b_(this.toIdArray())}},{key:"toItemSet",value:function(){return new b_(this.toItemArray())}},{key:"cache",value:function(){return new t(Jc(this._pairs))}},{key:"distinct",value:function(t){var e,i=new b_,n=Hx(this._pairs);try{for(n.s();!(e=n.n()).done;){var o=Kc(e.value,2),r=o[0],s=o[1];i.add(t(s,r))}}catch(t){n.e(t)}finally{n.f()}return i}},{key:"filter",value:function(e){var i=this._pairs;return new t($d({},w_,Rk.mark((function t(){var n,o,r,s,a;return Rk.wrap((function(t){for(;;)switch(t.prev=t.next){case 0:n=Hx(i),t.prev=1,n.s();case 3:if((o=n.n()).done){t.next=10;break}if(r=Kc(o.value,2),s=r[0],a=r[1],!e(a,s)){t.next=8;break}return t.next=8,[s,a];case 8:t.next=3;break;case 10:t.next=15;break;case 12:t.prev=12,t.t0=t.catch(1),n.e(t.t0);case 15:return t.prev=15,n.f(),t.finish(15);case 18:case"end":return t.stop()}}),t,null,[[1,12,15,18]])}))))}},{key:"forEach",value:function(t){var e,i=Hx(this._pairs);try{for(i.s();!(e=i.n()).done;){var n=Kc(e.value,2),o=n[0];t(n[1],o)}}catch(t){i.e(t)}finally{i.f()}}},{key:"map",value:function(e){var i=this._pairs;return new t($d({},w_,Rk.mark((function t(){var n,o,r,s,a;return Rk.wrap((function(t){for(;;)switch(t.prev=t.next){case 0:n=Hx(i),t.prev=1,n.s();case 3:if((o=n.n()).done){t.next=9;break}return r=Kc(o.value,2),s=r[0],a=r[1],t.next=7,[s,e(a,s)];case 7:t.next=3;break;case 9:t.next=14;break;case 11:t.prev=11,t.t0=t.catch(1),n.e(t.t0);case 14:return t.prev=14,n.f(),t.finish(14);case 17:case"end":return t.stop()}}),t,null,[[1,11,14,17]])}))))}},{key:"max",value:function(t){var e=k_(this._pairs),i=e.next();if(i.done)return null;for(var n=i.value[1],o=t(i.value[1],i.value[0]);!(i=e.next()).done;){var r=Kc(i.value,2),s=r[0],a=r[1],h=t(a,s);h>o&&(o=h,n=a)}return n}},{key:"min",value:function(t){var e=k_(this._pairs),i=e.next();if(i.done)return null;for(var n=i.value[1],o=t(i.value[1],i.value[0]);!(i=e.next()).done;){var r=Kc(i.value,2),s=r[0],a=r[1],h=t(a,s);h<o&&(o=h,n=a)}return n}},{key:"reduce",value:function(t,e){var i,n=Hx(this._pairs);try{for(n.s();!(i=n.n()).done;){var o=Kc(i.value,2),r=o[0];e=t(e,o[1],r)}}catch(t){n.e(t)}finally{n.f()}return e}},{key:"sort",value:function(e){var i=this;return new t($d({},w_,(function(){var t;return k_(rx(t=Jc(i._pairs)).call(t,(function(t,i){var n=Kc(t,2),o=n[0],r=n[1],s=Kc(i,2),a=s[0],h=s[1];return e(r,h,o,a)})))})))}}]),t}();var Kx=function(t){zk(i,t);var e=Lx(i);function i(t,n){var o;return Yd(this,i),$d(Pk(o=e.call(this)),"flush",void 0),$d(Pk(o),"length",void 0),$d(Pk(o),"_options",void 0),$d(Pk(o),"_data",void 0),$d(Pk(o),"_idProp",void 0),$d(Pk(o),"_queue",null),t&&!lu(t)&&(n=t,t=[]),o._options=n||{},o._data=new Jw,o.length=0,o._idProp=o._options.fieldId||"id",t&&t.length&&o.add(t),o.setOptions(n),o}return Kd(i,[{key:"idProp",get:function(){return this._idProp}},{key:"setOptions",value:function(t){t&&void 0!==t.queue&&(!1===t.queue?this._queue&&(this._queue.destroy(),this._queue=null):(this._queue||(this._queue=Yx.extend(this,{replace:["add","update","remove"]})),t.queue&&"object"===Qc(t.queue)&&this._queue.setOptions(t.queue)))}},{key:"add",value:function(t,e){var i,n=this,o=[];if(lu(t)){var r=gu(t).call(t,(function(t){return t[n._idProp]}));if(ck(r).call(r,(function(t){return n._data.has(t)})))throw new Error("A duplicate id was found in the parameter array.");for(var s=0,a=t.length;s<a;s++)i=this._addItem(t[s]),o.push(i)}else{if(!t||"object"!==Qc(t))throw new Error("Unknown dataType");i=this._addItem(t),o.push(i)}return o.length&&this._trigger("add",{items:o},e),o}},{key:"update",value:function(t,e){var i=this,n=[],o=[],r=[],s=[],a=this._idProp,h=function(t){var e=t[a];if(null!=e&&i._data.has(e)){var h=t,l=un({},i._data.get(e)),d=i._updateItem(h);o.push(d),s.push(h),r.push(l)}else{var c=i._addItem(t);n.push(c)}};if(lu(t))for(var l=0,d=t.length;l<d;l++)t[l]&&"object"===Qc(t[l])?h(t[l]):console.warn("Ignoring input item, which is not an object at index "+l);else{if(!t||"object"!==Qc(t))throw new Error("Unknown dataType");h(t)}if(n.length&&this._trigger("add",{items:n},e),o.length){var c={items:o,oldData:r,data:s};this._trigger("update",c,e)}return su(n).call(n,o)}},{key:"updateOnly",value:function(t,e){var i,n=this;lu(t)||(t=[t]);var o=gu(i=gu(t).call(t,(function(t){var e=n._data.get(t[n._idProp]);if(null==e)throw new Error("Updating non-existent items is not allowed.");return{oldData:e,update:t}}))).call(i,(function(t){var e=t.oldData,i=t.update,o=e[n._idProp],r=By(e,i);return n._data.set(o,r),{id:o,oldData:e,updatedData:r}}));if(o.length){var r={items:gu(o).call(o,(function(t){return t.id})),oldData:gu(o).call(o,(function(t){return t.oldData})),data:gu(o).call(o,(function(t){return t.updatedData}))};return this._trigger("update",r,e),r.items}return[]}},{key:"get",value:function(t,e){var i=void 0,n=void 0,o=void 0;Ux(t)?(i=t,o=e):lu(t)?(n=t,o=e):o=t;var r,s=o&&"Object"===o.returnType?"Object":"Array",a=o&&Xf(o),h=[],l=void 0,d=void 0,c=void 0;if(null!=i)(l=this._data.get(i))&&a&&!a(l)&&(l=void 0);else if(null!=n)for(var u=0,f=n.length;u<f;u++)null==(l=this._data.get(n[u]))||a&&!a(l)||h.push(l);else for(var p,v=0,g=(d=Jc(fx(p=this._data).call(p))).length;v<g;v++)c=d[v],null==(l=this._data.get(c))||a&&!a(l)||h.push(l);if(o&&o.order&&null==i&&this._sort(h,o.order),o&&o.fields){var y=o.fields;if(null!=i&&null!=l)l=this._filterFields(l,y);else for(var m=0,b=h.length;m<b;m++)h[m]=this._filterFields(h[m],y)}if("Object"==s){for(var w={},k=0,_=h.length;k<_;k++){var x=h[k];w[x[this._idProp]]=x}return w}return null!=i?null!==(r=l)&&void 0!==r?r:null:h}},{key:"getIds",value:function(t){var e=this._data,i=t&&Xf(t),n=t&&t.order,o=Jc(fx(e).call(e)),r=[];if(i)if(n){for(var s=[],a=0,h=o.length;a<h;a++){var l=o[a],d=this._data.get(l);null!=d&&i(d)&&s.push(d)}this._sort(s,n);for(var c=0,u=s.length;c<u;c++)r.push(s[c][this._idProp])}else for(var f=0,p=o.length;f<p;f++){var v=o[f],g=this._data.get(v);null!=g&&i(g)&&r.push(g[this._idProp])}else if(n){for(var y=[],m=0,b=o.length;m<b;m++){var w=o[m];y.push(e.get(w))}this._sort(y,n);for(var k=0,_=y.length;k<_;k++)r.push(y[k][this._idProp])}else for(var x=0,E=o.length;x<E;x++){var O=o[x],C=e.get(O);null!=C&&r.push(C[this._idProp])}return r}},{key:"getDataSet",value:function(){return this}},{key:"forEach",value:function(t,e){var i=e&&Xf(e),n=this._data,o=Jc(fx(n).call(n));if(e&&e.order)for(var r=this.get(e),s=0,a=r.length;s<a;s++){var h=r[s];t(h,h[this._idProp])}else for(var l=0,d=o.length;l<d;l++){var c=o[l],u=this._data.get(c);null==u||i&&!i(u)||t(u,c)}}},{key:"map",value:function(t,e){for(var i=e&&Xf(e),n=[],o=this._data,r=Jc(fx(o).call(o)),s=0,a=r.length;s<a;s++){var h=r[s],l=this._data.get(h);null==l||i&&!i(l)||n.push(t(l,h))}return e&&e.order&&this._sort(n,e.order),n}},{key:"_filterFields",value:function(t,e){var i;return t?i_(i=lu(e)?e:bu(e)).call(i,(function(e,i){return e[i]=t[i],e}),{}):t}},{key:"_sort",value:function(t,e){if("string"==typeof e){var i=e;rx(t).call(t,(function(t,e){var n=t[i],o=e[i];return n>o?1:n<o?-1:0}))}else{if("function"!=typeof e)throw new TypeError("Order must be a function or a string");rx(t).call(t,e)}}},{key:"remove",value:function(t,e){for(var i=[],n=[],o=lu(t)?t:[t],r=0,s=o.length;r<s;r++){var a=this._remove(o[r]);if(a){var h=a[this._idProp];null!=h&&(i.push(h),n.push(a))}}return i.length&&this._trigger("remove",{items:i,oldData:n},e),i}},{key:"_remove",value:function(t){var e;if(Ux(t)?e=t:t&&"object"===Qc(t)&&(e=t[this._idProp]),null!=e&&this._data.has(e)){var i=this._data.get(e)||null;return this._data.delete(e),--this.length,i}return null}},{key:"clear",value:function(t){for(var e,i=Jc(fx(e=this._data).call(e)),n=[],o=0,r=i.length;o<r;o++)n.push(this._data.get(i[o]));return this._data.clear(),this.length=0,this._trigger("remove",{items:i,oldData:n},t),i}},{key:"max",value:function(t){var e,i,n=null,o=null,r=Hx(kx(e=this._data).call(e));try{for(r.s();!(i=r.n()).done;){var s=i.value,a=s[t];"number"==typeof a&&(null==o||a>o)&&(n=s,o=a)}}catch(t){r.e(t)}finally{r.f()}return n||null}},{key:"min",value:function(t){var e,i,n=null,o=null,r=Hx(kx(e=this._data).call(e));try{for(r.s();!(i=r.n()).done;){var s=i.value,a=s[t];"number"==typeof a&&(null==o||a<o)&&(n=s,o=a)}}catch(t){r.e(t)}finally{r.f()}return n||null}},{key:"distinct",value:function(t){for(var e=this._data,i=Jc(fx(e).call(e)),n=[],o=0,r=0,s=i.length;r<s;r++){for(var a=i[r],h=e.get(a)[t],l=!1,d=0;d<o;d++)if(n[d]==h){l=!0;break}l||void 0===h||(n[o]=h,o++)}return n}},{key:"_addItem",value:function(t){var e=function(t,e){return null==t[e]&&(t[e]=Ax()),t}(t,this._idProp),i=e[this._idProp];if(this._data.has(i))throw new Error("Cannot add item: item with id "+i+" already exists");return this._data.set(i,e),++this.length,i}},{key:"_updateItem",value:function(t){var e=t[this._idProp];if(null==e)throw new Error("Cannot update item: item has no id (item: "+gv(t)+")");var i=this._data.get(e);if(!i)throw new Error("Cannot update item: no item with id "+e+" found");return this._data.set(e,Rx(Rx({},i),t)),e}},{key:"stream",value:function(t){if(t){var e=this._data;return new Gx($d({},w_,Rk.mark((function i(){var n,o,r,s;return Rk.wrap((function(i){for(;;)switch(i.prev=i.next){case 0:n=Hx(t),i.prev=1,n.s();case 3:if((o=n.n()).done){i.next=11;break}if(r=o.value,null==(s=e.get(r))){i.next=9;break}return i.next=9,[r,s];case 9:i.next=3;break;case 11:i.next=16;break;case 13:i.prev=13,i.t0=i.catch(1),n.e(i.t0);case 16:return i.prev=16,n.f(),i.finish(16);case 19:case"end":return i.stop()}}),i,null,[[1,13,16,19]])}))))}var i;return new Gx($d({},w_,zn(i=Mx(this._data)).call(i,this._data)))}}]),i}(Xx),$x=function(t){zk(i,t);var e=Lx(i);function i(t,n){var o,r;return Yd(this,i),$d(Pk(r=e.call(this)),"length",0),$d(Pk(r),"_listener",void 0),$d(Pk(r),"_data",void 0),$d(Pk(r),"_ids",new b_),$d(Pk(r),"_options",void 0),r._options=n||{},r._listener=zn(o=r._onEvent).call(o,Pk(r)),r.setData(t),r}return Kd(i,[{key:"idProp",get:function(){return this.getDataSet().idProp}},{key:"setData",value:function(t){if(this._data){this._data.off&&this._data.off("*",this._listener);var e=this._data.getIds({filter:Xf(this._options)}),i=this._data.get(e);this._ids.clear(),this.length=0,this._trigger("remove",{items:e,oldData:i})}if(null!=t){this._data=t;for(var n=this._data.getIds({filter:Xf(this._options)}),o=0,r=n.length;o<r;o++){var s=n[o];this._ids.add(s)}this.length=n.length,this._trigger("add",{items:n})}else this._data=new Kx;this._data.on&&this._data.on("*",this._listener)}},{key:"refresh",value:function(){for(var t=this._data.getIds({filter:Xf(this._options)}),e=Jc(this._ids),i={},n=[],o=[],r=[],s=0,a=t.length;s<a;s++){var h=t[s];i[h]=!0,this._ids.has(h)||(n.push(h),this._ids.add(h))}for(var l=0,d=e.length;l<d;l++){var c=e[l],u=this._data.get(c);null==u?console.error("If you see this, report it please."):i[c]||(o.push(c),r.push(u),this._ids.delete(c))}this.length+=n.length-o.length,n.length&&this._trigger("add",{items:n}),o.length&&this._trigger("remove",{items:o,oldData:r})}},{key:"get",value:function(t,e){if(null==this._data)return null;var i,n=null;Ux(t)||lu(t)?(n=t,i=e):i=t;var o=un({},this._options,i),r=Xf(this._options),s=i&&Xf(i);return r&&s&&(o.filter=function(t){return r(t)&&s(t)}),null==n?this._data.get(o):this._data.get(n,o)}},{key:"getIds",value:function(t){if(this._data.length){var e,i=Xf(this._options),n=null!=t?Xf(t):null;return e=n?i?function(t){return i(t)&&n(t)}:n:i,this._data.getIds({filter:e,order:t&&t.order})}return[]}},{key:"forEach",value:function(t,e){if(this._data){var i,n,o=Xf(this._options),r=e&&Xf(e);n=r?o?function(t){return o(t)&&r(t)}:r:o,Fu(i=this._data).call(i,t,{filter:n,order:e&&e.order})}}},{key:"map",value:function(t,e){if(this._data){var i,n,o=Xf(this._options),r=e&&Xf(e);return n=r?o?function(t){return o(t)&&r(t)}:r:o,gu(i=this._data).call(i,t,{filter:n,order:e&&e.order})}return[]}},{key:"getDataSet",value:function(){return this._data.getDataSet()}},{key:"stream",value:function(t){var e;return this._data.stream(t||$d({},w_,zn(e=fx(this._ids)).call(e,this._ids)))}},{key:"dispose",value:function(){var t;null!==(t=this._data)&&void 0!==t&&t.off&&this._data.off("*",this._listener);var e,n="This data view has already been disposed of.",o={get:function(){throw new Error(n)},set:function(){throw new Error(n)},configurable:!1},r=Hx(hu(i.prototype));try{for(r.s();!(e=r.n()).done;){var s=e.value;Ud(this,s,o)}}catch(t){r.e(t)}finally{r.f()}}},{key:"_onEvent",value:function(t,e,i){if(e&&e.items&&this._data){var n=e.items,o=[],r=[],s=[],a=[],h=[],l=[];switch(t){case"add":for(var d=0,c=n.length;d<c;d++){var u=n[d];this.get(u)&&(this._ids.add(u),o.push(u))}break;case"update":for(var f=0,p=n.length;f<p;f++){var v=n[f];this.get(v)?this._ids.has(v)?(r.push(v),h.push(e.data[f]),a.push(e.oldData[f])):(this._ids.add(v),o.push(v)):this._ids.has(v)&&(this._ids.delete(v),s.push(v),l.push(e.oldData[f]))}break;case"remove":for(var g=0,y=n.length;g<y;g++){var m=n[g];this._ids.has(m)&&(this._ids.delete(m),s.push(m),l.push(e.oldData[g]))}}this.length+=o.length-s.length,o.length&&this._trigger("add",{items:o},i),r.length&&this._trigger("update",{items:r,oldData:a,data:h},i),s.length&&this._trigger("remove",{items:s,oldData:l},i)}}}]),i}(Xx);function Zx(t,e){return"object"===Qc(e)&&null!==e&&t===e.idProp&&"function"==typeof e.add&&"function"==typeof e.clear&&"function"==typeof e.distinct&&"function"==typeof Fu(e)&&"function"==typeof e.get&&"function"==typeof e.getDataSet&&"function"==typeof e.getIds&&"number"==typeof e.length&&"function"==typeof gu(e)&&"function"==typeof e.max&&"function"==typeof e.min&&"function"==typeof e.off&&"function"==typeof e.on&&"function"==typeof e.remove&&"function"==typeof e.setOptions&&"function"==typeof e.stream&&"function"==typeof e.update&&"function"==typeof e.updateOnly}function Qx(t,e){return"object"===Qc(e)&&null!==e&&t===e.idProp&&"function"==typeof Fu(e)&&"function"==typeof e.get&&"function"==typeof e.getDataSet&&"function"==typeof e.getIds&&"number"==typeof e.length&&"function"==typeof gu(e)&&"function"==typeof e.off&&"function"==typeof e.on&&"function"==typeof e.stream&&Zx(t,e.getDataSet())}var Jx=Object.freeze({__proto__:null,DELETE:Iy,DataSet:Kx,DataStream:Gx,DataView:$x,Queue:Yx,createNewDataPipeFrom:function(t){return new Vx(t)},isDataSetLike:Zx,isDataViewLike:Qx}),tE=n,eE=o,iE=eo,nE=cp.trim,oE=g("".charAt),rE=tE.parseFloat,sE=tE.Symbol,aE=sE&&sE.iterator,hE=1/rE("\t\n\v\f\r                　\u2028\u2029\ufeff-0")!=-1/0||aE&&!eE((function(){rE(Object(aE))}))?function(t){var e=nE(iE(t)),i=rE(e);return 0===i&&"-"==oE(e,0)?-0:i}:rE;_i({global:!0,forced:parseFloat!=hE},{parseFloat:hE});var lE=X.parseFloat,dE=_i,cE=o,uE=hh.f;dE({target:"Object",stat:!0,forced:cE((function(){return!Object.getOwnPropertyNames(1)}))},{getOwnPropertyNames:uE});var fE=X.Object,pE=function(t){return fE.getOwnPropertyNames(t)},vE=pE;function gE(t,e){var i=["node","edge","label"],n=!0,o=Mm(e,"chosen");if("boolean"==typeof o)n=o;else if("object"===Qc(o)){if(-1===Fp(i).call(i,t))throw new Error("choosify: subOption '"+t+"' should be one of '"+i.join("', '")+"'");var r=Mm(e,["chosen",t]);"boolean"!=typeof r&&"function"!=typeof r||(n=r)}return n}function yE(t,e,i){if(t.width<=0||t.height<=0)return!1;if(void 0!==i){var n={x:e.x-i.x,y:e.y-i.y};if(0!==i.angle){var o=-i.angle;e={x:Math.cos(o)*n.x-Math.sin(o)*n.y,y:Math.sin(o)*n.x+Math.cos(o)*n.y}}else e=n}var r=t.x+t.width,s=t.y+t.width;return t.left<e.x&&r>e.x&&t.top<e.y&&s>e.y}function mE(t){return"string"==typeof t&&""!==t}function bE(t,e,i,n){var o=n.x,r=n.y;if("function"==typeof n.distanceToBorder){var s=n.distanceToBorder(t,e),a=Math.sin(e)*s,h=Math.cos(e)*s;h===s?(o+=s,r=n.y):a===s?(o=n.x,r-=s):(o+=h,r-=a)}else n.shape.width>n.shape.height?(o=n.x+.5*n.shape.width,r=n.y-i):(o=n.x+i,r=n.y-.5*n.shape.height);return{x:o,y:r}}var wE=function(){function t(e){Yd(this,t),this.measureText=e,this.current=0,this.width=0,this.height=0,this.lines=[]}return Kd(t,[{key:"_add",value:function(t,e){var i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"normal";void 0===this.lines[t]&&(this.lines[t]={width:0,height:0,blocks:[]});var n=e;void 0!==e&&""!==e||(n=" ");var o=this.measureText(n,i),r=un({},kx(o));r.text=e,r.width=o.width,r.mod=i,void 0!==e&&""!==e||(r.width=0),this.lines[t].blocks.push(r),this.lines[t].width+=r.width}},{key:"curWidth",value:function(){var t=this.lines[this.current];return void 0===t?0:t.width}},{key:"append",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"normal";this._add(this.current,t,e)}},{key:"newLine",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"normal";this._add(this.current,t,e),this.current++}},{key:"determineLineHeights",value:function(){for(var t=0;t<this.lines.length;t++){var e=this.lines[t],i=0;if(void 0!==e.blocks)for(var n=0;n<e.blocks.length;n++){var o=e.blocks[n];i<o.height&&(i=o.height)}e.height=i}}},{key:"determineLabelSize",value:function(){for(var t=0,e=0,i=0;i<this.lines.length;i++){var n=this.lines[i];n.width>t&&(t=n.width),e+=n.height}this.width=t,this.height=e}},{key:"removeEmptyBlocks",value:function(){for(var t=[],e=0;e<this.lines.length;e++){var i=this.lines[e];if(0!==i.blocks.length&&(e!==this.lines.length-1||0!==i.width)){var n={};un(n,i),n.blocks=[];for(var o=void 0,r=[],s=0;s<i.blocks.length;s++){var a=i.blocks[s];0!==a.width?r.push(a):void 0===o&&(o=a)}0===r.length&&void 0!==o&&r.push(o),n.blocks=r,t.push(n)}}return t}},{key:"finalize",value:function(){this.determineLineHeights(),this.determineLabelSize();var t=this.removeEmptyBlocks();return{width:this.width,height:this.height,lines:t}}}]),t}(),kE={"<b>":/<b>/,"<i>":/<i>/,"<code>":/<code>/,"</b>":/<\/b>/,"</i>":/<\/i>/,"</code>":/<\/code>/,"*":/\*/,_:/_/,"`":/`/,afterBold:/[^*]/,afterItal:/[^_]/,afterMono:/[^`]/},_E=function(){function t(e){Yd(this,t),this.text=e,this.bold=!1,this.ital=!1,this.mono=!1,this.spacing=!1,this.position=0,this.buffer="",this.modStack=[],this.blocks=[]}return Kd(t,[{key:"mod",value:function(){return 0===this.modStack.length?"normal":this.modStack[0]}},{key:"modName",value:function(){return 0===this.modStack.length?"normal":"mono"===this.modStack[0]?"mono":this.bold&&this.ital?"boldital":this.bold?"bold":this.ital?"ital":void 0}},{key:"emitBlock",value:function(){this.spacing&&(this.add(" "),this.spacing=!1),this.buffer.length>0&&(this.blocks.push({text:this.buffer,mod:this.modName()}),this.buffer="")}},{key:"add",value:function(t){" "===t&&(this.spacing=!0),this.spacing&&(this.buffer+=" ",this.spacing=!1)," "!=t&&(this.buffer+=t)}},{key:"parseWS",value:function(t){return!!/[ \t]/.test(t)&&(this.mono?this.add(t):this.spacing=!0,!0)}},{key:"setTag",value:function(t){this.emitBlock(),this[t]=!0,this.modStack.unshift(t)}},{key:"unsetTag",value:function(t){this.emitBlock(),this[t]=!1,this.modStack.shift()}},{key:"parseStartTag",value:function(t,e){return!(this.mono||this[t]||!this.match(e))&&(this.setTag(t),!0)}},{key:"match",value:function(t){var e=!(arguments.length>1&&void 0!==arguments[1])||arguments[1],i=this.prepareRegExp(t),n=Kc(i,2),o=n[0],r=n[1],s=o.test(this.text.substr(this.position,r));return s&&e&&(this.position+=r-1),s}},{key:"parseEndTag",value:function(t,e,i){var n=this.mod()===t;return!(!(n="mono"===t?n&&this.mono:n&&!this.mono)||!this.match(e))&&(void 0!==i?(this.position===this.text.length-1||this.match(i,!1))&&this.unsetTag(t):this.unsetTag(t),!0)}},{key:"replace",value:function(t,e){return!!this.match(t)&&(this.add(e),this.position+=length-1,!0)}},{key:"prepareRegExp",value:function(t){var e,i;if(t instanceof RegExp)i=t,e=1;else{var n=kE[t];i=void 0!==n?n:new RegExp(t),e=t.length}return[i,e]}}]),t}(),xE=function(){function t(e,i,n,o){var r=this;Yd(this,t),this.ctx=e,this.parent=i,this.selected=n,this.hover=o;this.lines=new wE((function(t,i){if(void 0===t)return 0;var s=r.parent.getFormattingValues(e,n,o,i),a=0;""!==t&&(a=r.ctx.measureText(t).width);return{width:a,values:s}}))}return Kd(t,[{key:"process",value:function(t){if(!mE(t))return this.lines.finalize();var e=this.parent.fontOptions;t=(t=t.replace(/\r\n/g,"\n")).replace(/\r/g,"\n");var i=String(t).split("\n"),n=i.length;if(e.multi)for(var o=0;o<n;o++){var r=this.splitBlocks(i[o],e.multi);if(void 0!==r)if(0!==r.length){if(e.maxWdt>0)for(var s=0;s<r.length;s++){var a=r[s].mod,h=r[s].text;this.splitStringIntoLines(h,a,!0)}else for(var l=0;l<r.length;l++){var d=r[l].mod,c=r[l].text;this.lines.append(c,d)}this.lines.newLine()}else this.lines.newLine("")}else if(e.maxWdt>0)for(var u=0;u<n;u++)this.splitStringIntoLines(i[u]);else for(var f=0;f<n;f++)this.lines.newLine(i[f]);return this.lines.finalize()}},{key:"decodeMarkupSystem",value:function(t){var e="none";return"markdown"===t||"md"===t?e="markdown":!0!==t&&"html"!==t||(e="html"),e}},{key:"splitHtmlBlocks",value:function(t){for(var e=new _E(t),i=function(t){return!!/&/.test(t)&&(e.replace(e.text,"&lt;","<")||e.replace(e.text,"&amp;","&")||e.add("&"),!0)};e.position<e.text.length;){var n=e.text.charAt(e.position);e.parseWS(n)||/</.test(n)&&(e.parseStartTag("bold","<b>")||e.parseStartTag("ital","<i>")||e.parseStartTag("mono","<code>")||e.parseEndTag("bold","</b>")||e.parseEndTag("ital","</i>")||e.parseEndTag("mono","</code>"))||i(n)||e.add(n),e.position++}return e.emitBlock(),e.blocks}},{key:"splitMarkdownBlocks",value:function(t){for(var e=this,i=new _E(t),n=!0,o=function(t){return!!/\\/.test(t)&&(i.position<e.text.length+1&&(i.position++,t=e.text.charAt(i.position),/ \t/.test(t)?i.spacing=!0:(i.add(t),n=!1)),!0)};i.position<i.text.length;){var r=i.text.charAt(i.position);i.parseWS(r)||o(r)||(n||i.spacing)&&(i.parseStartTag("bold","*")||i.parseStartTag("ital","_")||i.parseStartTag("mono","`"))||i.parseEndTag("bold","*","afterBold")||i.parseEndTag("ital","_","afterItal")||i.parseEndTag("mono","`","afterMono")||(i.add(r),n=!1),i.position++}return i.emitBlock(),i.blocks}},{key:"splitBlocks",value:function(t,e){var i=this.decodeMarkupSystem(e);return"none"===i?[{text:t,mod:"normal"}]:"markdown"===i?this.splitMarkdownBlocks(t):"html"===i?this.splitHtmlBlocks(t):void 0}},{key:"overMaxWidth",value:function(t){var e=this.ctx.measureText(t).width;return this.lines.curWidth()+e>this.parent.fontOptions.maxWdt}},{key:"getLongestFit",value:function(t){for(var e="",i=0;i<t.length;){var n=e+(""===e?"":" ")+t[i];if(this.overMaxWidth(n))break;e=n,i++}return i}},{key:"getLongestFitWord",value:function(t){for(var e=0;e<t.length&&!this.overMaxWidth(au(t).call(t,0,e));)e++;return e}},{key:"splitStringIntoLines",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"normal",i=arguments.length>2&&void 0!==arguments[2]&&arguments[2];this.parent.getFormattingValues(this.ctx,this.selected,this.hover,e);for(var n=(t=(t=t.replace(/^( +)/g,"$1\r")).replace(/([^\r][^ ]*)( +)/g,"$1\r$2\r")).split("\r");n.length>0;){var o=this.getLongestFit(n);if(0===o){var r=n[0],s=this.getLongestFitWord(r);this.lines.newLine(au(r).call(r,0,s),e),n[0]=au(r).call(r,s)}else{var a=o;" "===n[o-1]?o--:" "===n[a]&&a++;var h=au(n).call(n,0,o).join("");o==n.length&&i?this.lines.append(h,e):this.lines.newLine(h,e),n=au(n).call(n,a)}}}}]),t}(),EE=["bold","ital","boldital","mono"],OE=function(){function t(e,i){var n=arguments.length>2&&void 0!==arguments[2]&&arguments[2];Yd(this,t),this.body=e,this.pointToSelf=!1,this.baseSize=void 0,this.fontOptions={},this.setOptions(i),this.size={top:0,left:0,width:0,height:0,yLine:0},this.isEdgeLabel=n}return Kd(t,[{key:"setOptions",value:function(t){if(this.elementOptions=t,this.initFontOptions(t.font),mE(t.label)?this.labelDirty=!0:t.label=void 0,void 0!==t.font&&null!==t.font)if("string"==typeof t.font)this.baseSize=this.fontOptions.size;else if("object"===Qc(t.font)){var e=t.font.size;void 0!==e&&(this.baseSize=e)}}},{key:"initFontOptions",value:function(e){var i=this;hm(EE,(function(t){i.fontOptions[t]={}})),t.parseFontString(this.fontOptions,e)?this.fontOptions.vadjust=0:hm(e,(function(t,e){null!=t&&"object"!==Qc(t)&&(i.fontOptions[e]=t)}))}},{key:"constrain",value:function(t){var e={constrainWidth:!1,maxWdt:-1,minWdt:-1,constrainHeight:!1,minHgt:-1,valign:"middle"},i=Mm(t,"widthConstraint");if("number"==typeof i)e.maxWdt=Number(i),e.minWdt=Number(i);else if("object"===Qc(i)){var n=Mm(t,["widthConstraint","maximum"]);"number"==typeof n&&(e.maxWdt=Number(n));var o=Mm(t,["widthConstraint","minimum"]);"number"==typeof o&&(e.minWdt=Number(o))}var r=Mm(t,"heightConstraint");if("number"==typeof r)e.minHgt=Number(r);else if("object"===Qc(r)){var s=Mm(t,["heightConstraint","minimum"]);"number"==typeof s&&(e.minHgt=Number(s));var a=Mm(t,["heightConstraint","valign"]);"string"==typeof a&&("top"!==a&&"bottom"!==a||(e.valign=a))}return e}},{key:"update",value:function(t,e){this.setOptions(t,!0),this.propagateFonts(e),nm(this.fontOptions,this.constrain(e)),this.fontOptions.chooser=gE("label",e)}},{key:"adjustSizes",value:function(t){var e=t?t.right+t.left:0;this.fontOptions.constrainWidth&&(this.fontOptions.maxWdt-=e,this.fontOptions.minWdt-=e);var i=t?t.top+t.bottom:0;this.fontOptions.constrainHeight&&(this.fontOptions.minHgt-=i)}},{key:"addFontOptionsToPile",value:function(t,e){for(var i=0;i<e.length;++i)this.addFontToPile(t,e[i])}},{key:"addFontToPile",value:function(t,e){if(void 0!==e&&void 0!==e.font&&null!==e.font){var i=e.font;t.push(i)}}},{key:"getBasicOptions",value:function(e){for(var i={},n=0;n<e.length;++n){var o=e[n],r={};t.parseFontString(r,o)&&(o=r),hm(o,(function(t,e){void 0!==t&&(Object.prototype.hasOwnProperty.call(i,e)||(-1!==Fp(EE).call(EE,e)?i[e]={}:i[e]=t))}))}return i}},{key:"getFontOption",value:function(e,i,n){for(var o,r=0;r<e.length;++r){var s=e[r];if(Object.prototype.hasOwnProperty.call(s,i)){if(null==(o=s[i]))continue;var a={};if(t.parseFontString(a,o)&&(o=a),Object.prototype.hasOwnProperty.call(o,n))return o[n]}}if(Object.prototype.hasOwnProperty.call(this.fontOptions,n))return this.fontOptions[n];throw new Error("Did not find value for multi-font for property: '"+n+"'")}},{key:"getFontOptions",value:function(t,e){for(var i={},n=["color","size","face","mod","vadjust"],o=0;o<n.length;++o){var r=n[o];i[r]=this.getFontOption(t,e,r)}return i}},{key:"propagateFonts",value:function(t){var e=this,i=[];this.addFontOptionsToPile(i,t),this.fontOptions=this.getBasicOptions(i);for(var n=function(t){var n=EE[t],o=e.fontOptions[n];hm(e.getFontOptions(i,n),(function(t,e){o[e]=t})),o.size=Number(o.size),o.vadjust=Number(o.vadjust)},o=0;o<EE.length;++o)n(o)}},{key:"draw",value:function(t,e,i,n,o){var r=arguments.length>5&&void 0!==arguments[5]?arguments[5]:"middle";if(void 0!==this.elementOptions.label){var s=this.fontOptions.size*this.body.view.scale;this.elementOptions.label&&s<this.elementOptions.scaling.label.drawThreshold-1||(s>=this.elementOptions.scaling.label.maxVisible&&(s=Number(this.elementOptions.scaling.label.maxVisible)/this.body.view.scale),this.calculateLabelSize(t,n,o,e,i,r),this._drawBackground(t),this._drawText(t,e,this.size.yLine,r,s))}}},{key:"_drawBackground",value:function(t){if(void 0!==this.fontOptions.background&&"none"!==this.fontOptions.background){t.fillStyle=this.fontOptions.background;var e=this.getSize();t.fillRect(e.left,e.top,e.width,e.height)}}},{key:"_drawText",value:function(t,e,i){var n=arguments.length>3&&void 0!==arguments[3]?arguments[3]:"middle",o=arguments.length>4?arguments[4]:void 0,r=this._setAlignment(t,e,i,n),s=Kc(r,2);e=s[0],i=s[1],t.textAlign="left",e-=this.size.width/2,this.fontOptions.valign&&this.size.height>this.size.labelHeight&&("top"===this.fontOptions.valign&&(i-=(this.size.height-this.size.labelHeight)/2),"bottom"===this.fontOptions.valign&&(i+=(this.size.height-this.size.labelHeight)/2));for(var a=0;a<this.lineCount;a++){var h=this.lines[a];if(h&&h.blocks){var l=0;this.isEdgeLabel||"center"===this.fontOptions.align?l+=(this.size.width-h.width)/2:"right"===this.fontOptions.align&&(l+=this.size.width-h.width);for(var d=0;d<h.blocks.length;d++){var c=h.blocks[d];t.font=c.font;var u=this._getColor(c.color,o,c.strokeColor),f=Kc(u,2),p=f[0],v=f[1];c.strokeWidth>0&&(t.lineWidth=c.strokeWidth,t.strokeStyle=v,t.lineJoin="round"),t.fillStyle=p,c.strokeWidth>0&&t.strokeText(c.text,e+l,i+c.vadjust),t.fillText(c.text,e+l,i+c.vadjust),l+=c.width}i+=h.height}}}},{key:"_setAlignment",value:function(t,e,i,n){if(this.isEdgeLabel&&"horizontal"!==this.fontOptions.align&&!1===this.pointToSelf){e=0,i=0;"top"===this.fontOptions.align?(t.textBaseline="alphabetic",i-=4):"bottom"===this.fontOptions.align?(t.textBaseline="hanging",i+=4):t.textBaseline="middle"}else t.textBaseline=n;return[e,i]}},{key:"_getColor",value:function(t,e,i){var n=t||"#000000",o=i||"#ffffff";if(e<=this.elementOptions.scaling.label.drawThreshold){var r=Math.max(0,Math.min(1,1-(this.elementOptions.scaling.label.drawThreshold-e)));n=pm(n,r),o=pm(o,r)}return[n,o]}},{key:"getTextSize",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1],i=arguments.length>2&&void 0!==arguments[2]&&arguments[2];return this._processLabel(t,e,i),{width:this.size.width,height:this.size.height,lineCount:this.lineCount}}},{key:"getSize",value:function(){var t=this.size.left,e=this.size.top-1;if(this.isEdgeLabel){var i=.5*-this.size.width;switch(this.fontOptions.align){case"middle":t=i,e=.5*-this.size.height;break;case"top":t=i,e=-(this.size.height+2);break;case"bottom":t=i,e=2}}return{left:t,top:e,width:this.size.width,height:this.size.height}}},{key:"calculateLabelSize",value:function(t,e,i){var n=arguments.length>3&&void 0!==arguments[3]?arguments[3]:0,o=arguments.length>4&&void 0!==arguments[4]?arguments[4]:0,r=arguments.length>5&&void 0!==arguments[5]?arguments[5]:"middle";this._processLabel(t,e,i),this.size.left=n-.5*this.size.width,this.size.top=o-.5*this.size.height,this.size.yLine=o+.5*(1-this.lineCount)*this.fontOptions.size,"hanging"===r&&(this.size.top+=.5*this.fontOptions.size,this.size.top+=4,this.size.yLine+=4)}},{key:"getFormattingValues",value:function(t,e,i,n){var o=function(t,e,i){return"normal"===e?"mod"===i?"":t[i]:void 0!==t[e][i]?t[e][i]:t[i]},r={color:o(this.fontOptions,n,"color"),size:o(this.fontOptions,n,"size"),face:o(this.fontOptions,n,"face"),mod:o(this.fontOptions,n,"mod"),vadjust:o(this.fontOptions,n,"vadjust"),strokeWidth:this.fontOptions.strokeWidth,strokeColor:this.fontOptions.strokeColor};(e||i)&&("normal"===n&&!0===this.fontOptions.chooser&&this.elementOptions.labelHighlightBold?r.mod="bold":"function"==typeof this.fontOptions.chooser&&this.fontOptions.chooser(r,this.elementOptions.id,e,i));var s="";return void 0!==r.mod&&""!==r.mod&&(s+=r.mod+" "),s+=r.size+"px "+r.face,t.font=s.replace(/"/g,""),r.font=t.font,r.height=r.size,r}},{key:"differentState",value:function(t,e){return t!==this.selectedState||e!==this.hoverState}},{key:"_processLabelText",value:function(t,e,i,n){return new xE(t,this,e,i).process(n)}},{key:"_processLabel",value:function(t,e,i){if(!1!==this.labelDirty||this.differentState(e,i)){var n=this._processLabelText(t,e,i,this.elementOptions.label);this.fontOptions.minWdt>0&&n.width<this.fontOptions.minWdt&&(n.width=this.fontOptions.minWdt),this.size.labelHeight=n.height,this.fontOptions.minHgt>0&&n.height<this.fontOptions.minHgt&&(n.height=this.fontOptions.minHgt),this.lines=n.lines,this.lineCount=n.lines.length,this.size.width=n.width,this.size.height=n.height,this.selectedState=e,this.hoverState=i,this.labelDirty=!1}}},{key:"visible",value:function(){return 0!==this.size.width&&0!==this.size.height&&void 0!==this.elementOptions.label&&!(this.fontOptions.size*this.body.view.scale<this.elementOptions.scaling.label.drawThreshold-1)}}],[{key:"parseFontString",value:function(t,e){if(!e||"string"!=typeof e)return!1;var i=e.split(" ");return t.size=+i[0].replace("px",""),t.face=i[1],t.color=i[2],!0}}]),t}(),CE=function(){function t(e,i,n){Yd(this,t),this.body=i,this.labelModule=n,this.setOptions(e),this.top=void 0,this.left=void 0,this.height=void 0,this.width=void 0,this.radius=void 0,this.margin=void 0,this.refreshNeeded=!0,this.boundingBox={top:0,left:0,right:0,bottom:0}}return Kd(t,[{key:"setOptions",value:function(t){this.options=t}},{key:"_setMargins",value:function(t){this.margin={},this.options.margin&&("object"==Qc(this.options.margin)?(this.margin.top=this.options.margin.top,this.margin.right=this.options.margin.right,this.margin.bottom=this.options.margin.bottom,this.margin.left=this.options.margin.left):(this.margin.top=this.options.margin,this.margin.right=this.options.margin,this.margin.bottom=this.options.margin,this.margin.left=this.options.margin)),t.adjustSizes(this.margin)}},{key:"_distanceToBorder",value:function(t,e){var i=this.options.borderWidth;return t&&this.resize(t),Math.min(Math.abs(this.width/2/Math.cos(e)),Math.abs(this.height/2/Math.sin(e)))+i}},{key:"enableShadow",value:function(t,e){e.shadow&&(t.shadowColor=e.shadowColor,t.shadowBlur=e.shadowSize,t.shadowOffsetX=e.shadowX,t.shadowOffsetY=e.shadowY)}},{key:"disableShadow",value:function(t,e){e.shadow&&(t.shadowColor="rgba(0,0,0,0)",t.shadowBlur=0,t.shadowOffsetX=0,t.shadowOffsetY=0)}},{key:"enableBorderDashes",value:function(t,e){if(!1!==e.borderDashes)if(void 0!==t.setLineDash){var i=e.borderDashes;!0===i&&(i=[5,15]),t.setLineDash(i)}else console.warn("setLineDash is not supported in this browser. The dashed borders cannot be used."),this.options.shapeProperties.borderDashes=!1,e.borderDashes=!1}},{key:"disableBorderDashes",value:function(t,e){!1!==e.borderDashes&&(void 0!==t.setLineDash?t.setLineDash([0]):(console.warn("setLineDash is not supported in this browser. The dashed borders cannot be used."),this.options.shapeProperties.borderDashes=!1,e.borderDashes=!1))}},{key:"needsRefresh",value:function(t,e){return!0===this.refreshNeeded?(this.refreshNeeded=!1,!0):void 0===this.width||this.labelModule.differentState(t,e)}},{key:"initContextForDraw",value:function(t,e){var i=e.borderWidth/this.body.view.scale;t.lineWidth=Math.min(this.width,i),t.strokeStyle=e.borderColor,t.fillStyle=e.color}},{key:"performStroke",value:function(t,e){var i=e.borderWidth/this.body.view.scale;t.save(),i>0&&(this.enableBorderDashes(t,e),t.stroke(),this.disableBorderDashes(t,e)),t.restore()}},{key:"performFill",value:function(t,e){t.save(),t.fillStyle=e.color,this.enableShadow(t,e),jv(t).call(t),this.disableShadow(t,e),t.restore(),this.performStroke(t,e)}},{key:"_addBoundingBoxMargin",value:function(t){this.boundingBox.left-=t,this.boundingBox.top-=t,this.boundingBox.bottom+=t,this.boundingBox.right+=t}},{key:"_updateBoundingBox",value:function(t,e,i,n,o){void 0!==i&&this.resize(i,n,o),this.left=t-this.width/2,this.top=e-this.height/2,this.boundingBox.left=this.left,this.boundingBox.top=this.top,this.boundingBox.bottom=this.top+this.height,this.boundingBox.right=this.left+this.width}},{key:"updateBoundingBox",value:function(t,e,i,n,o){this._updateBoundingBox(t,e,i,n,o)}},{key:"getDimensionsFromLabel",value:function(t,e,i){this.textSize=this.labelModule.getTextSize(t,e,i);var n=this.textSize.width,o=this.textSize.height;return 0===n&&(n=14,o=14),{width:n,height:o}}}]),t}();function SE(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var TE=function(t){zk(i,t);var e=SE(i);function i(t,n,o){var r;return Yd(this,i),(r=e.call(this,t,n,o))._setMargins(o),r}return Kd(i,[{key:"resize",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:this.selected,i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:this.hover;if(this.needsRefresh(e,i)){var n=this.getDimensionsFromLabel(t,e,i);this.width=n.width+this.margin.right+this.margin.left,this.height=n.height+this.margin.top+this.margin.bottom,this.radius=this.width/2}}},{key:"draw",value:function(t,e,i,n,o,r){this.resize(t,n,o),this.left=e-this.width/2,this.top=i-this.height/2,this.initContextForDraw(t,r),Fn(t,this.left,this.top,this.width,this.height,r.borderRadius),this.performFill(t,r),this.updateBoundingBox(e,i,t,n,o),this.labelModule.draw(t,this.left+this.textSize.width/2+this.margin.left,this.top+this.textSize.height/2+this.margin.top,n,o)}},{key:"updateBoundingBox",value:function(t,e,i,n,o){this._updateBoundingBox(t,e,i,n,o);var r=this.options.shapeProperties.borderRadius;this._addBoundingBoxMargin(r)}},{key:"distanceToBorder",value:function(t,e){t&&this.resize(t);var i=this.options.borderWidth;return Math.min(Math.abs(this.width/2/Math.cos(e)),Math.abs(this.height/2/Math.sin(e)))+i}}]),i}(CE);function ME(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var PE=function(t){zk(i,t);var e=ME(i);function i(t,n,o){var r;return Yd(this,i),(r=e.call(this,t,n,o)).labelOffset=0,r.selected=!1,r}return Kd(i,[{key:"setOptions",value:function(t,e,i){this.options=t,void 0===e&&void 0===i||this.setImages(e,i)}},{key:"setImages",value:function(t,e){e&&this.selected?(this.imageObj=e,this.imageObjAlt=t):(this.imageObj=t,this.imageObjAlt=e)}},{key:"switchImages",value:function(t){var e=t&&!this.selected||!t&&this.selected;if(this.selected=t,void 0!==this.imageObjAlt&&e){var i=this.imageObj;this.imageObj=this.imageObjAlt,this.imageObjAlt=i}}},{key:"_getImagePadding",value:function(){var t={top:0,right:0,bottom:0,left:0};if(this.options.imagePadding){var e=this.options.imagePadding;"object"==Qc(e)?(t.top=e.top,t.right=e.right,t.bottom=e.bottom,t.left=e.left):(t.top=e,t.right=e,t.bottom=e,t.left=e)}return t}},{key:"_resizeImage",value:function(){var t,e;if(!1===this.options.shapeProperties.useImageSize){var i=1,n=1;this.imageObj.width&&this.imageObj.height&&(this.imageObj.width>this.imageObj.height?i=this.imageObj.width/this.imageObj.height:n=this.imageObj.height/this.imageObj.width),t=2*this.options.size*i,e=2*this.options.size*n}else{var o=this._getImagePadding();t=this.imageObj.width+o.left+o.right,e=this.imageObj.height+o.top+o.bottom}this.width=t,this.height=e,this.radius=.5*this.width}},{key:"_drawRawCircle",value:function(t,e,i,n){this.initContextForDraw(t,n),Nn(t,e,i,n.size),this.performFill(t,n)}},{key:"_drawImageAtPosition",value:function(t,e){if(0!=this.imageObj.width){t.globalAlpha=void 0!==e.opacity?e.opacity:1,this.enableShadow(t,e);var i=1;!0===this.options.shapeProperties.interpolation&&(i=this.imageObj.width/this.width/this.body.view.scale);var n=this._getImagePadding(),o=this.left+n.left,r=this.top+n.top,s=this.width-n.left-n.right,a=this.height-n.top-n.bottom;this.imageObj.drawImageAtPosition(t,i,o,r,s,a),this.disableShadow(t,e)}}},{key:"_drawImageLabel",value:function(t,e,i,n,o){var r=0;if(void 0!==this.height){r=.5*this.height;var s=this.labelModule.getTextSize(t,n,o);s.lineCount>=1&&(r+=s.height/2)}var a=i+r;this.options.label&&(this.labelOffset=r),this.labelModule.draw(t,e,a,n,o,"hanging")}}]),i}(CE);function DE(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var IE=function(t){zk(i,t);var e=DE(i);function i(t,n,o){var r;return Yd(this,i),(r=e.call(this,t,n,o))._setMargins(o),r}return Kd(i,[{key:"resize",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:this.selected,i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:this.hover;if(this.needsRefresh(e,i)){var n=this.getDimensionsFromLabel(t,e,i),o=Math.max(n.width+this.margin.right+this.margin.left,n.height+this.margin.top+this.margin.bottom);this.options.size=o/2,this.width=o,this.height=o,this.radius=this.width/2}}},{key:"draw",value:function(t,e,i,n,o,r){this.resize(t,n,o),this.left=e-this.width/2,this.top=i-this.height/2,this._drawRawCircle(t,e,i,r),this.updateBoundingBox(e,i),this.labelModule.draw(t,this.left+this.textSize.width/2+this.margin.left,i,n,o)}},{key:"updateBoundingBox",value:function(t,e){this.boundingBox.top=e-this.options.size,this.boundingBox.left=t-this.options.size,this.boundingBox.right=t+this.options.size,this.boundingBox.bottom=e+this.options.size}},{key:"distanceToBorder",value:function(t){return t&&this.resize(t),.5*this.width}}]),i}(PE);function BE(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var zE=function(t){zk(i,t);var e=BE(i);function i(t,n,o,r,s){var a;return Yd(this,i),(a=e.call(this,t,n,o)).setImages(r,s),a}return Kd(i,[{key:"resize",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:this.selected,i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:this.hover,n=void 0===this.imageObj.src||void 0===this.imageObj.width||void 0===this.imageObj.height;if(n){var o=2*this.options.size;return this.width=o,this.height=o,void(this.radius=.5*this.width)}this.needsRefresh(e,i)&&this._resizeImage()}},{key:"draw",value:function(t,e,i,n,o,r){this.switchImages(n),this.resize();var s=e,a=i;"top-left"===this.options.shapeProperties.coordinateOrigin?(this.left=e,this.top=i,s+=this.width/2,a+=this.height/2):(this.left=e-this.width/2,this.top=i-this.height/2),this._drawRawCircle(t,s,a,r),t.save(),t.clip(),this._drawImageAtPosition(t,r),t.restore(),this._drawImageLabel(t,s,a,n,o),this.updateBoundingBox(e,i)}},{key:"updateBoundingBox",value:function(t,e){"top-left"===this.options.shapeProperties.coordinateOrigin?(this.boundingBox.top=e,this.boundingBox.left=t,this.boundingBox.right=t+2*this.options.size,this.boundingBox.bottom=e+2*this.options.size):(this.boundingBox.top=e-this.options.size,this.boundingBox.left=t-this.options.size,this.boundingBox.right=t+this.options.size,this.boundingBox.bottom=e+this.options.size),this.boundingBox.left=Math.min(this.boundingBox.left,this.labelModule.size.left),this.boundingBox.right=Math.max(this.boundingBox.right,this.labelModule.size.left+this.labelModule.size.width),this.boundingBox.bottom=Math.max(this.boundingBox.bottom,this.boundingBox.bottom+this.labelOffset)}},{key:"distanceToBorder",value:function(t){return t&&this.resize(t),.5*this.width}}]),i}(PE);function NE(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var FE=function(t){zk(i,t);var e=NE(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"resize",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:this.selected,i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:this.hover,n=arguments.length>3&&void 0!==arguments[3]?arguments[3]:{size:this.options.size};if(this.needsRefresh(e,i)){var o,r;this.labelModule.getTextSize(t,e,i);var s=2*n.size;this.width=null!==(o=this.customSizeWidth)&&void 0!==o?o:s,this.height=null!==(r=this.customSizeHeight)&&void 0!==r?r:s,this.radius=.5*this.width}}},{key:"_drawShape",value:function(t,e,i,n,o,r,s,a){var h,l=this;return this.resize(t,r,s,a),this.left=n-this.width/2,this.top=o-this.height/2,this.initContextForDraw(t,a),(h=e,Object.prototype.hasOwnProperty.call(Ln,h)?Ln[h]:function(t){for(var e=arguments.length,i=new Array(e>1?e-1:0),n=1;n<e;n++)i[n-1]=arguments[n];CanvasRenderingContext2D.prototype[h].call(t,i)})(t,n,o,a.size),this.performFill(t,a),void 0!==this.options.icon&&void 0!==this.options.icon.code&&(t.font=(r?"bold ":"")+this.height/2+"px "+(this.options.icon.face||"FontAwesome"),t.fillStyle=this.options.icon.color||"black",t.textAlign="center",t.textBaseline="middle",t.fillText(this.options.icon.code,n,o)),{drawExternalLabel:function(){if(void 0!==l.options.label){l.labelModule.calculateLabelSize(t,r,s,n,o,"hanging");var e=o+.5*l.height+.5*l.labelModule.size.height;l.labelModule.draw(t,n,e,r,s,"hanging")}l.updateBoundingBox(n,o)}}}},{key:"updateBoundingBox",value:function(t,e){this.boundingBox.top=e-this.options.size,this.boundingBox.left=t-this.options.size,this.boundingBox.right=t+this.options.size,this.boundingBox.bottom=e+this.options.size,void 0!==this.options.label&&this.labelModule.size.width>0&&(this.boundingBox.left=Math.min(this.boundingBox.left,this.labelModule.size.left),this.boundingBox.right=Math.max(this.boundingBox.right,this.labelModule.size.left+this.labelModule.size.width),this.boundingBox.bottom=Math.max(this.boundingBox.bottom,this.boundingBox.bottom+this.labelModule.size.height))}}]),i}(CE);function AE(t,e){var i=bu(t);if(hd){var n=hd(t);e&&(n=Xf(n).call(n,(function(e){return bd(t,e).enumerable}))),i.push.apply(i,n)}return i}function jE(t){for(var e=1;e<arguments.length;e++){var i,n,o=null!=arguments[e]?arguments[e]:{};e%2?Fu(i=AE(Object(o),!0)).call(i,(function(e){$d(t,e,o[e])})):Pd?Ad(t,Pd(o)):Fu(n=AE(Object(o))).call(n,(function(e){Ud(t,e,bd(o,e))}))}return t}function RE(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var LE=function(t){zk(i,t);var e=RE(i);function i(t,n,o,r){var s;return Yd(this,i),(s=e.call(this,t,n,o,r)).ctxRenderer=r,s}return Kd(i,[{key:"draw",value:function(t,e,i,n,o,r){this.resize(t,n,o,r),this.left=e-this.width/2,this.top=i-this.height/2,t.save();var s=this.ctxRenderer({ctx:t,id:this.options.id,x:e,y:i,state:{selected:n,hover:o},style:jE({},r),label:this.options.label});if(null!=s.drawNode&&s.drawNode(),t.restore(),s.drawExternalLabel){var a=s.drawExternalLabel;s.drawExternalLabel=function(){t.save(),a(),t.restore()}}return s.nodeDimensions&&(this.customSizeWidth=s.nodeDimensions.width,this.customSizeHeight=s.nodeDimensions.height),s}},{key:"distanceToBorder",value:function(t,e){return this._distanceToBorder(t,e)}}]),i}(FE);function HE(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var WE=function(t){zk(i,t);var e=HE(i);function i(t,n,o){var r;return Yd(this,i),(r=e.call(this,t,n,o))._setMargins(o),r}return Kd(i,[{key:"resize",value:function(t,e,i){if(this.needsRefresh(e,i)){var n=this.getDimensionsFromLabel(t,e,i).width+this.margin.right+this.margin.left;this.width=n,this.height=n,this.radius=this.width/2}}},{key:"draw",value:function(t,e,i,n,o,r){this.resize(t,n,o),this.left=e-this.width/2,this.top=i-this.height/2,this.initContextForDraw(t,r),jn(t,e-this.width/2,i-this.height/2,this.width,this.height),this.performFill(t,r),this.updateBoundingBox(e,i,t,n,o),this.labelModule.draw(t,this.left+this.textSize.width/2+this.margin.left,this.top+this.textSize.height/2+this.margin.top,n,o)}},{key:"distanceToBorder",value:function(t,e){return this._distanceToBorder(t,e)}}]),i}(CE);function qE(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var VE=function(t){zk(i,t);var e=qE(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"draw",value:function(t,e,i,n,o,r){return this._drawShape(t,"diamond",4,e,i,n,o,r)}},{key:"distanceToBorder",value:function(t,e){return this._distanceToBorder(t,e)}}]),i}(FE);function UE(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var YE=function(t){zk(i,t);var e=UE(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"draw",value:function(t,e,i,n,o,r){return this._drawShape(t,"circle",2,e,i,n,o,r)}},{key:"distanceToBorder",value:function(t){return t&&this.resize(t),this.options.size}}]),i}(FE);function XE(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var GE=function(t){zk(i,t);var e=XE(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"resize",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:this.selected,i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:this.hover;if(this.needsRefresh(e,i)){var n=this.getDimensionsFromLabel(t,e,i);this.height=2*n.height,this.width=n.width+n.height,this.radius=.5*this.width}}},{key:"draw",value:function(t,e,i,n,o,r){this.resize(t,n,o),this.left=e-.5*this.width,this.top=i-.5*this.height,this.initContextForDraw(t,r),An(t,this.left,this.top,this.width,this.height),this.performFill(t,r),this.updateBoundingBox(e,i,t,n,o),this.labelModule.draw(t,e,i,n,o)}},{key:"distanceToBorder",value:function(t,e){t&&this.resize(t);var i=.5*this.width,n=.5*this.height,o=Math.sin(e)*i,r=Math.cos(e)*n;return i*n/Math.sqrt(o*o+r*r)}}]),i}(CE);function KE(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var $E=function(t){zk(i,t);var e=KE(i);function i(t,n,o){var r;return Yd(this,i),(r=e.call(this,t,n,o))._setMargins(o),r}return Kd(i,[{key:"resize",value:function(t,e,i){this.needsRefresh(e,i)&&(this.iconSize={width:Number(this.options.icon.size),height:Number(this.options.icon.size)},this.width=this.iconSize.width+this.margin.right+this.margin.left,this.height=this.iconSize.height+this.margin.top+this.margin.bottom,this.radius=.5*this.width)}},{key:"draw",value:function(t,e,i,n,o,r){var s=this;return this.resize(t,n,o),this.options.icon.size=this.options.icon.size||50,this.left=e-this.width/2,this.top=i-this.height/2,this._icon(t,e,i,n,o,r),{drawExternalLabel:function(){if(void 0!==s.options.label){s.labelModule.draw(t,s.left+s.iconSize.width/2+s.margin.left,i+s.height/2+5,n)}s.updateBoundingBox(e,i)}}}},{key:"updateBoundingBox",value:function(t,e){if(this.boundingBox.top=e-.5*this.options.icon.size,this.boundingBox.left=t-.5*this.options.icon.size,this.boundingBox.right=t+.5*this.options.icon.size,this.boundingBox.bottom=e+.5*this.options.icon.size,void 0!==this.options.label&&this.labelModule.size.width>0){this.boundingBox.left=Math.min(this.boundingBox.left,this.labelModule.size.left),this.boundingBox.right=Math.max(this.boundingBox.right,this.labelModule.size.left+this.labelModule.size.width),this.boundingBox.bottom=Math.max(this.boundingBox.bottom,this.boundingBox.bottom+this.labelModule.size.height+5)}}},{key:"_icon",value:function(t,e,i,n,o,r){var s=Number(this.options.icon.size);void 0!==this.options.icon.code?(t.font=[null!=this.options.icon.weight?this.options.icon.weight:n?"bold":"",(null!=this.options.icon.weight&&n?5:0)+s+"px",this.options.icon.face].join(" "),t.fillStyle=this.options.icon.color||"black",t.textAlign="center",t.textBaseline="middle",this.enableShadow(t,r),t.fillText(this.options.icon.code,e,i),this.disableShadow(t,r)):console.error("When using the icon shape, you need to define the code in the icon options object. This can be done per node or globally.")}},{key:"distanceToBorder",value:function(t,e){return this._distanceToBorder(t,e)}}]),i}(CE);function ZE(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var QE=function(t){zk(i,t);var e=ZE(i);function i(t,n,o,r,s){var a;return Yd(this,i),(a=e.call(this,t,n,o)).setImages(r,s),a}return Kd(i,[{key:"resize",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:this.selected,i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:this.hover,n=void 0===this.imageObj.src||void 0===this.imageObj.width||void 0===this.imageObj.height;if(n){var o=2*this.options.size;return this.width=o,void(this.height=o)}this.needsRefresh(e,i)&&this._resizeImage()}},{key:"draw",value:function(t,e,i,n,o,r){t.save(),this.switchImages(n),this.resize();var s=e,a=i;if("top-left"===this.options.shapeProperties.coordinateOrigin?(this.left=e,this.top=i,s+=this.width/2,a+=this.height/2):(this.left=e-this.width/2,this.top=i-this.height/2),!0===this.options.shapeProperties.useBorderWithImage){var h=this.options.borderWidth,l=this.options.borderWidthSelected||2*this.options.borderWidth,d=(n?l:h)/this.body.view.scale;t.lineWidth=Math.min(this.width,d),t.beginPath();var c=n?this.options.color.highlight.border:o?this.options.color.hover.border:this.options.color.border,u=n?this.options.color.highlight.background:o?this.options.color.hover.background:this.options.color.background;void 0!==r.opacity&&(c=pm(c,r.opacity),u=pm(u,r.opacity)),t.strokeStyle=c,t.fillStyle=u,t.rect(this.left-.5*t.lineWidth,this.top-.5*t.lineWidth,this.width+t.lineWidth,this.height+t.lineWidth),jv(t).call(t),this.performStroke(t,r),t.closePath()}this._drawImageAtPosition(t,r),this._drawImageLabel(t,s,a,n,o),this.updateBoundingBox(e,i),t.restore()}},{key:"updateBoundingBox",value:function(t,e){this.resize(),"top-left"===this.options.shapeProperties.coordinateOrigin?(this.left=t,this.top=e):(this.left=t-this.width/2,this.top=e-this.height/2),this.boundingBox.left=this.left,this.boundingBox.top=this.top,this.boundingBox.bottom=this.top+this.height,this.boundingBox.right=this.left+this.width,void 0!==this.options.label&&this.labelModule.size.width>0&&(this.boundingBox.left=Math.min(this.boundingBox.left,this.labelModule.size.left),this.boundingBox.right=Math.max(this.boundingBox.right,this.labelModule.size.left+this.labelModule.size.width),this.boundingBox.bottom=Math.max(this.boundingBox.bottom,this.boundingBox.bottom+this.labelOffset))}},{key:"distanceToBorder",value:function(t,e){return this._distanceToBorder(t,e)}}]),i}(PE);function JE(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var tO=function(t){zk(i,t);var e=JE(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"draw",value:function(t,e,i,n,o,r){return this._drawShape(t,"square",2,e,i,n,o,r)}},{key:"distanceToBorder",value:function(t,e){return this._distanceToBorder(t,e)}}]),i}(FE);function eO(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var iO=function(t){zk(i,t);var e=eO(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"draw",value:function(t,e,i,n,o,r){return this._drawShape(t,"hexagon",4,e,i,n,o,r)}},{key:"distanceToBorder",value:function(t,e){return this._distanceToBorder(t,e)}}]),i}(FE);function nO(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var oO=function(t){zk(i,t);var e=nO(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"draw",value:function(t,e,i,n,o,r){return this._drawShape(t,"star",4,e,i,n,o,r)}},{key:"distanceToBorder",value:function(t,e){return this._distanceToBorder(t,e)}}]),i}(FE);function rO(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var sO=function(t){zk(i,t);var e=rO(i);function i(t,n,o){var r;return Yd(this,i),(r=e.call(this,t,n,o))._setMargins(o),r}return Kd(i,[{key:"resize",value:function(t,e,i){this.needsRefresh(e,i)&&(this.textSize=this.labelModule.getTextSize(t,e,i),this.width=this.textSize.width+this.margin.right+this.margin.left,this.height=this.textSize.height+this.margin.top+this.margin.bottom,this.radius=.5*this.width)}},{key:"draw",value:function(t,e,i,n,o,r){this.resize(t,n,o),this.left=e-this.width/2,this.top=i-this.height/2,this.enableShadow(t,r),this.labelModule.draw(t,this.left+this.textSize.width/2+this.margin.left,this.top+this.textSize.height/2+this.margin.top,n,o),this.disableShadow(t,r),this.updateBoundingBox(e,i,t,n,o)}},{key:"distanceToBorder",value:function(t,e){return this._distanceToBorder(t,e)}}]),i}(CE);function aO(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var hO=function(t){zk(i,t);var e=aO(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"draw",value:function(t,e,i,n,o,r){return this._drawShape(t,"triangle",3,e,i,n,o,r)}},{key:"distanceToBorder",value:function(t,e){return this._distanceToBorder(t,e)}}]),i}(FE);function lO(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var dO=function(t){zk(i,t);var e=lO(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"draw",value:function(t,e,i,n,o,r){return this._drawShape(t,"triangleDown",3,e,i,n,o,r)}},{key:"distanceToBorder",value:function(t,e){return this._distanceToBorder(t,e)}}]),i}(FE);function cO(t,e){var i=bu(t);if(hd){var n=hd(t);e&&(n=Xf(n).call(n,(function(e){return bd(t,e).enumerable}))),i.push.apply(i,n)}return i}function uO(t){for(var e=1;e<arguments.length;e++){var i,n,o=null!=arguments[e]?arguments[e]:{};e%2?Fu(i=cO(Object(o),!0)).call(i,(function(e){$d(t,e,o[e])})):Pd?Ad(t,Pd(o)):Fu(n=cO(Object(o))).call(n,(function(e){Ud(t,e,bd(o,e))}))}return t}var fO=function(){function t(e,i,n,o,r,s){Yd(this,t),this.options=Cm(r),this.globalOptions=r,this.defaultOptions=s,this.body=i,this.edges=[],this.id=void 0,this.imagelist=n,this.grouplist=o,this.x=void 0,this.y=void 0,this.baseSize=this.options.size,this.baseFontSize=this.options.font.size,this.predefinedPosition=!1,this.selected=!1,this.hover=!1,this.labelModule=new OE(this.body,this.options,!1),this.setOptions(e)}return Kd(t,[{key:"attachEdge",value:function(t){var e;-1===Fp(e=this.edges).call(e,t)&&this.edges.push(t)}},{key:"detachEdge",value:function(t){var e,i,n=Fp(e=this.edges).call(e,t);-1!=n&&ff(i=this.edges).call(i,n,1)}},{key:"setOptions",value:function(e){var i=this.options.shape;if(e){if(void 0!==e.color&&(this._localColor=e.color),void 0!==e.id&&(this.id=e.id),void 0===this.id)throw new Error("Node must have an id");t.checkMass(e,this.id),void 0!==e.x&&(null===e.x?(this.x=void 0,this.predefinedPosition=!1):(this.x=Ep(e.x),this.predefinedPosition=!0)),void 0!==e.y&&(null===e.y?(this.y=void 0,this.predefinedPosition=!1):(this.y=Ep(e.y),this.predefinedPosition=!0)),void 0!==e.size&&(this.baseSize=e.size),void 0!==e.value&&(e.value=lE(e.value)),t.parseOptions(this.options,e,!0,this.globalOptions,this.grouplist);var n=[e,this.options,this.defaultOptions];return this.chooser=gE("node",n),this._load_images(),this.updateLabelModule(e),void 0!==e.opacity&&t.checkOpacity(e.opacity)&&(this.options.opacity=e.opacity),this.updateShape(i),void 0!==e.hidden||void 0!==e.physics}}},{key:"_load_images",value:function(){if(("circularImage"===this.options.shape||"image"===this.options.shape)&&void 0===this.options.image)throw new Error("Option image must be defined for node type '"+this.options.shape+"'");if(void 0!==this.options.image){if(void 0===this.imagelist)throw new Error("Internal Error: No images provided");if("string"==typeof this.options.image)this.imageObj=this.imagelist.load(this.options.image,this.options.brokenImage,this.id);else{if(void 0===this.options.image.unselected)throw new Error("No unselected image provided");this.imageObj=this.imagelist.load(this.options.image.unselected,this.options.brokenImage,this.id),void 0!==this.options.image.selected?this.imageObjAlt=this.imagelist.load(this.options.image.selected,this.options.brokenImage,this.id):this.imageObjAlt=void 0}}}},{key:"getFormattingValues",value:function(){var t={color:this.options.color.background,opacity:this.options.opacity,borderWidth:this.options.borderWidth,borderColor:this.options.color.border,size:this.options.size,borderDashes:this.options.shapeProperties.borderDashes,borderRadius:this.options.shapeProperties.borderRadius,shadow:this.options.shadow.enabled,shadowColor:this.options.shadow.color,shadowSize:this.options.shadow.size,shadowX:this.options.shadow.x,shadowY:this.options.shadow.y};if(this.selected||this.hover?!0===this.chooser?this.selected?(null!=this.options.borderWidthSelected?t.borderWidth=this.options.borderWidthSelected:t.borderWidth*=2,t.color=this.options.color.highlight.background,t.borderColor=this.options.color.highlight.border,t.shadow=this.options.shadow.enabled):this.hover&&(t.color=this.options.color.hover.background,t.borderColor=this.options.color.hover.border,t.shadow=this.options.shadow.enabled):"function"==typeof this.chooser&&(this.chooser(t,this.options.id,this.selected,this.hover),!1===t.shadow&&(t.shadowColor===this.options.shadow.color&&t.shadowSize===this.options.shadow.size&&t.shadowX===this.options.shadow.x&&t.shadowY===this.options.shadow.y||(t.shadow=!0))):t.shadow=this.options.shadow.enabled,void 0!==this.options.opacity){var e=this.options.opacity;t.borderColor=pm(t.borderColor,e),t.color=pm(t.color,e),t.shadowColor=pm(t.shadowColor,e)}return t}},{key:"updateLabelModule",value:function(e){void 0!==this.options.label&&null!==this.options.label||(this.options.label=""),t.updateGroupOptions(this.options,uO(uO({},e),{},{color:e&&e.color||this._localColor||void 0}),this.grouplist);var i=this.grouplist.get(this.options.group,!1),n=[e,this.options,i,this.globalOptions,this.defaultOptions];this.labelModule.update(this.options,n),void 0!==this.labelModule.baseSize&&(this.baseFontSize=this.labelModule.baseSize)}},{key:"updateShape",value:function(t){if(t===this.options.shape&&this.shape)this.shape.setOptions(this.options,this.imageObj,this.imageObjAlt);else switch(this.options.shape){case"box":this.shape=new TE(this.options,this.body,this.labelModule);break;case"circle":this.shape=new IE(this.options,this.body,this.labelModule);break;case"circularImage":this.shape=new zE(this.options,this.body,this.labelModule,this.imageObj,this.imageObjAlt);break;case"custom":this.shape=new LE(this.options,this.body,this.labelModule,this.options.ctxRenderer);break;case"database":this.shape=new WE(this.options,this.body,this.labelModule);break;case"diamond":this.shape=new VE(this.options,this.body,this.labelModule);break;case"dot":this.shape=new YE(this.options,this.body,this.labelModule);break;case"ellipse":default:this.shape=new GE(this.options,this.body,this.labelModule);break;case"icon":this.shape=new $E(this.options,this.body,this.labelModule);break;case"image":this.shape=new QE(this.options,this.body,this.labelModule,this.imageObj,this.imageObjAlt);break;case"square":this.shape=new tO(this.options,this.body,this.labelModule);break;case"hexagon":this.shape=new iO(this.options,this.body,this.labelModule);break;case"star":this.shape=new oO(this.options,this.body,this.labelModule);break;case"text":this.shape=new sO(this.options,this.body,this.labelModule);break;case"triangle":this.shape=new hO(this.options,this.body,this.labelModule);break;case"triangleDown":this.shape=new dO(this.options,this.body,this.labelModule)}this.needsRefresh()}},{key:"select",value:function(){this.selected=!0,this.needsRefresh()}},{key:"unselect",value:function(){this.selected=!1,this.needsRefresh()}},{key:"needsRefresh",value:function(){this.shape.refreshNeeded=!0}},{key:"getTitle",value:function(){return this.options.title}},{key:"distanceToBorder",value:function(t,e){return this.shape.distanceToBorder(t,e)}},{key:"isFixed",value:function(){return this.options.fixed.x&&this.options.fixed.y}},{key:"isSelected",value:function(){return this.selected}},{key:"getValue",value:function(){return this.options.value}},{key:"getLabelSize",value:function(){return this.labelModule.size()}},{key:"setValueRange",value:function(t,e,i){if(void 0!==this.options.value){var n=this.options.scaling.customScalingFunction(t,e,i,this.options.value),o=this.options.scaling.max-this.options.scaling.min;if(!0===this.options.scaling.label.enabled){var r=this.options.scaling.label.max-this.options.scaling.label.min;this.options.font.size=this.options.scaling.label.min+n*r}this.options.size=this.options.scaling.min+n*o}else this.options.size=this.baseSize,this.options.font.size=this.baseFontSize;this.updateLabelModule()}},{key:"draw",value:function(t){var e=this.getFormattingValues();return this.shape.draw(t,this.x,this.y,this.selected,this.hover,e)||{}}},{key:"updateBoundingBox",value:function(t){this.shape.updateBoundingBox(this.x,this.y,t)}},{key:"resize",value:function(t){var e=this.getFormattingValues();this.shape.resize(t,this.selected,this.hover,e)}},{key:"getItemsOnPoint",value:function(t){var e=[];return this.labelModule.visible()&&yE(this.labelModule.getSize(),t)&&e.push({nodeId:this.id,labelId:0}),yE(this.shape.boundingBox,t)&&e.push({nodeId:this.id}),e}},{key:"isOverlappingWith",value:function(t){return this.shape.left<t.right&&this.shape.left+this.shape.width>t.left&&this.shape.top<t.bottom&&this.shape.top+this.shape.height>t.top}},{key:"isBoundingBoxOverlappingWith",value:function(t){return this.shape.boundingBox.left<t.right&&this.shape.boundingBox.right>t.left&&this.shape.boundingBox.top<t.bottom&&this.shape.boundingBox.bottom>t.top}}],[{key:"checkOpacity",value:function(t){return 0<=t&&t<=1}},{key:"checkCoordinateOrigin",value:function(t){return void 0===t||"center"===t||"top-left"===t}},{key:"updateGroupOptions",value:function(e,i,n){var o;if(void 0!==n){var r=e.group;if(void 0!==i&&void 0!==i.group&&r!==i.group)throw new Error("updateGroupOptions: group values in options don't match.");if("number"==typeof r||"string"==typeof r&&""!=r){var s=n.get(r);void 0!==s.opacity&&void 0===i.opacity&&(t.checkOpacity(s.opacity)||(console.error("Invalid option for node opacity. Value must be between 0 and 1, found: "+s.opacity),s.opacity=void 0));var a=Xf(o=vE(i)).call(o,(function(t){return null!=i[t]}));a.push("font"),im(a,e,s),e.color=gm(e.color)}}}},{key:"parseOptions",value:function(e,i){var n=arguments.length>2&&void 0!==arguments[2]&&arguments[2],o=arguments.length>3&&void 0!==arguments[3]?arguments[3]:{},r=arguments.length>4?arguments[4]:void 0,s=["color","fixed","shadow"];if(im(s,e,i,n),t.checkMass(i),void 0!==e.opacity&&(t.checkOpacity(e.opacity)||(console.error("Invalid option for node opacity. Value must be between 0 and 1, found: "+e.opacity),e.opacity=void 0)),void 0!==i.opacity&&(t.checkOpacity(i.opacity)||(console.error("Invalid option for node opacity. Value must be between 0 and 1, found: "+i.opacity),i.opacity=void 0)),i.shapeProperties&&!t.checkCoordinateOrigin(i.shapeProperties.coordinateOrigin)&&console.error("Invalid option for node coordinateOrigin, found: "+i.shapeProperties.coordinateOrigin),Sm(e,i,"shadow",o),void 0!==i.color&&null!==i.color){var a=gm(i.color);Jy(e.color,a)}else!0===n&&null===i.color&&(e.color=Cm(o.color));void 0!==i.fixed&&null!==i.fixed&&("boolean"==typeof i.fixed?(e.fixed.x=i.fixed,e.fixed.y=i.fixed):(void 0!==i.fixed.x&&"boolean"==typeof i.fixed.x&&(e.fixed.x=i.fixed.x),void 0!==i.fixed.y&&"boolean"==typeof i.fixed.y&&(e.fixed.y=i.fixed.y))),!0===n&&null===i.font&&(e.font=Cm(o.font)),t.updateGroupOptions(e,i,r),void 0!==i.scaling&&Sm(e.scaling,i.scaling,"label",o.scaling)}},{key:"checkMass",value:function(t,e){if(void 0!==t.mass&&t.mass<=0){var i="";void 0!==e&&(i=" in node id: "+e),console.error("%cNegative or zero mass disallowed"+i+", setting mass to 1.",Vm),t.mass=1}}}]),t}();function pO(t,e){var i=void 0!==tu&&ih(t)||t["@@iterator"];if(!i){if(lu(t)||(i=function(t,e){var i;if(!t)return;if("string"==typeof t)return vO(t,e);var n=au(i=Object.prototype.toString.call(t)).call(i,8,-1);"Object"===n&&t.constructor&&(n=t.constructor.name);if("Map"===n||"Set"===n)return ja(t);if("Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n))return vO(t,e)}(t))||e&&t&&"number"==typeof t.length){i&&(t=i);var n=0,o=function(){};return{s:o,n:function(){return n>=t.length?{done:!0}:{done:!1,value:t[n++]}},e:function(t){throw t},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var r,s=!0,a=!1;return{s:function(){i=i.call(t)},n:function(){var t=i.next();return s=t.done,t},e:function(t){a=!0,r=t},f:function(){try{s||null==i.return||i.return()}finally{if(a)throw r}}}}function vO(t,e){(null==e||e>t.length)&&(e=t.length);for(var i=0,n=new Array(e);i<e;i++)n[i]=t[i];return n}var gO=function(){function t(e,i,n,o){var r,s=this;if(Yd(this,t),this.body=e,this.images=i,this.groups=n,this.layoutEngine=o,this.body.functions.createNode=zn(r=this.create).call(r,this),this.nodesListeners={add:function(t,e){s.add(e.items)},update:function(t,e){s.update(e.items,e.data,e.oldData)},remove:function(t,e){s.remove(e.items)}},this.defaultOptions={borderWidth:1,borderWidthSelected:void 0,brokenImage:void 0,color:{border:"#2B7CE9",background:"#97C2FC",highlight:{border:"#2B7CE9",background:"#D2E5FF"},hover:{border:"#2B7CE9",background:"#D2E5FF"}},opacity:void 0,fixed:{x:!1,y:!1},font:{color:"#343434",size:14,face:"arial",background:"none",strokeWidth:0,strokeColor:"#ffffff",align:"center",vadjust:0,multi:!1,bold:{mod:"bold"},boldital:{mod:"bold italic"},ital:{mod:"italic"},mono:{mod:"",size:15,face:"monospace",vadjust:2}},group:void 0,hidden:!1,icon:{face:"FontAwesome",code:void 0,size:50,color:"#2B7CE9"},image:void 0,imagePadding:{top:0,right:0,bottom:0,left:0},label:void 0,labelHighlightBold:!0,level:void 0,margin:{top:5,right:5,bottom:5,left:5},mass:1,physics:!0,scaling:{min:10,max:30,label:{enabled:!1,min:14,max:30,maxVisible:30,drawThreshold:5},customScalingFunction:function(t,e,i,n){if(e===t)return.5;var o=1/(e-t);return Math.max(0,(n-t)*o)}},shadow:{enabled:!1,color:"rgba(0,0,0,0.5)",size:10,x:5,y:5},shape:"ellipse",shapeProperties:{borderDashes:!1,borderRadius:6,interpolation:!0,useImageSize:!1,useBorderWithImage:!1,coordinateOrigin:"center"},size:25,title:void 0,value:void 0,x:void 0,y:void 0},this.defaultOptions.mass<=0)throw"Internal error: mass in defaultOptions of NodesHandler may not be zero or negative";this.options=Cm(this.defaultOptions),this.bindEventListeners()}return Kd(t,[{key:"bindEventListeners",value:function(){var t,e,i=this;this.body.emitter.on("refreshNodes",zn(t=this.refresh).call(t,this)),this.body.emitter.on("refresh",zn(e=this.refresh).call(e,this)),this.body.emitter.on("destroy",(function(){hm(i.nodesListeners,(function(t,e){i.body.data.nodes&&i.body.data.nodes.off(e,t)})),delete i.body.functions.createNode,delete i.nodesListeners.add,delete i.nodesListeners.update,delete i.nodesListeners.remove,delete i.nodesListeners}))}},{key:"setOptions",value:function(t){if(void 0!==t){if(fO.parseOptions(this.options,t),void 0!==t.opacity&&(ek(t.opacity)||!ok(t.opacity)||t.opacity<0||t.opacity>1?console.error("Invalid option for node opacity. Value must be between 0 and 1, found: "+t.opacity):this.options.opacity=t.opacity),void 0!==t.shape)for(var e in this.body.nodes)Object.prototype.hasOwnProperty.call(this.body.nodes,e)&&this.body.nodes[e].updateShape();if(void 0!==t.font||void 0!==t.widthConstraint||void 0!==t.heightConstraint)for(var i=0,n=bu(this.body.nodes);i<n.length;i++){var o=n[i];this.body.nodes[o].updateLabelModule(),this.body.nodes[o].needsRefresh()}if(void 0!==t.size)for(var r in this.body.nodes)Object.prototype.hasOwnProperty.call(this.body.nodes,r)&&this.body.nodes[r].needsRefresh();void 0===t.hidden&&void 0===t.physics||this.body.emitter.emit("_dataChanged")}}},{key:"setData",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1],i=this.body.data.nodes;if(Qx("id",t))this.body.data.nodes=t;else if(lu(t))this.body.data.nodes=new Kx,this.body.data.nodes.add(t);else{if(t)throw new TypeError("Array or DataSet expected");this.body.data.nodes=new Kx}if(i&&hm(this.nodesListeners,(function(t,e){i.off(e,t)})),this.body.nodes={},this.body.data.nodes){var n=this;hm(this.nodesListeners,(function(t,e){n.body.data.nodes.on(e,t)}));var o=this.body.data.nodes.getIds();this.add(o,!0)}!1===e&&this.body.emitter.emit("_dataChanged")}},{key:"add",value:function(t){for(var e,i=arguments.length>1&&void 0!==arguments[1]&&arguments[1],n=[],o=0;o<t.length;o++){e=t[o];var r=this.body.data.nodes.get(e),s=this.create(r);n.push(s),this.body.nodes[e]=s}this.layoutEngine.positionInitially(n),!1===i&&this.body.emitter.emit("_dataChanged")}},{key:"update",value:function(t,e,i){for(var n=this.body.nodes,o=!1,r=0;r<t.length;r++){var s=t[r],a=n[s],h=e[r];void 0!==a?a.setOptions(h)&&(o=!0):(o=!0,a=this.create(h),n[s]=a)}o||void 0===i||(o=ck(e).call(e,(function(t,e){var n=i[e];return n&&n.level!==t.level}))),!0===o?this.body.emitter.emit("_dataChanged"):this.body.emitter.emit("_dataUpdated")}},{key:"remove",value:function(t){for(var e=this.body.nodes,i=0;i<t.length;i++){delete e[t[i]]}this.body.emitter.emit("_dataChanged")}},{key:"create",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:fO;return new e(t,this.body,this.images,this.groups,this.options,this.defaultOptions)}},{key:"refresh",value:function(){var t=this,e=arguments.length>0&&void 0!==arguments[0]&&arguments[0];hm(this.body.nodes,(function(i,n){var o=t.body.data.nodes.get(n);void 0!==o&&(!0===e&&i.setOptions({x:null,y:null}),i.setOptions({fixed:!1}),i.setOptions(o))}))}},{key:"getPositions",value:function(t){var e={};if(void 0!==t){if(!0===lu(t)){for(var i=0;i<t.length;i++)if(void 0!==this.body.nodes[t[i]]){var n=this.body.nodes[t[i]];e[t[i]]={x:Math.round(n.x),y:Math.round(n.y)}}}else if(void 0!==this.body.nodes[t]){var o=this.body.nodes[t];e[t]={x:Math.round(o.x),y:Math.round(o.y)}}}else for(var r=0;r<this.body.nodeIndices.length;r++){var s=this.body.nodes[this.body.nodeIndices[r]];e[this.body.nodeIndices[r]]={x:Math.round(s.x),y:Math.round(s.y)}}return e}},{key:"getPosition",value:function(t){if(null==t)throw new TypeError("No id was specified for getPosition method.");if(null==this.body.nodes[t])throw new ReferenceError("NodeId provided for getPosition does not exist. Provided: ".concat(t));return{x:Math.round(this.body.nodes[t].x),y:Math.round(this.body.nodes[t].y)}}},{key:"storePositions",value:function(){var t,e=[],i=this.body.data.nodes.getDataSet(),n=pO(i.get());try{for(n.s();!(t=n.n()).done;){var o=t.value,r=o.id,s=this.body.nodes[r],a=Math.round(s.x),h=Math.round(s.y);o.x===a&&o.y===h||e.push({id:r,x:a,y:h})}}catch(t){n.e(t)}finally{n.f()}i.update(e)}},{key:"getBoundingBox",value:function(t){if(void 0!==this.body.nodes[t])return this.body.nodes[t].shape.boundingBox}},{key:"getConnectedNodes",value:function(t,e){var i=[];if(void 0!==this.body.nodes[t])for(var n=this.body.nodes[t],o={},r=0;r<n.edges.length;r++){var s=n.edges[r];"to"!==e&&s.toId==n.id?void 0===o[s.fromId]&&(i.push(s.fromId),o[s.fromId]=!0):"from"!==e&&s.fromId==n.id&&void 0===o[s.toId]&&(i.push(s.toId),o[s.toId]=!0)}return i}},{key:"getConnectedEdges",value:function(t){var e=[];if(void 0!==this.body.nodes[t])for(var i=this.body.nodes[t],n=0;n<i.edges.length;n++)e.push(i.edges[n].id);else console.error("NodeId provided for getConnectedEdges does not exist. Provided: ",t);return e}},{key:"moveNode",value:function(t,e,i){var n=this;void 0!==this.body.nodes[t]?(this.body.nodes[t].x=Number(e),this.body.nodes[t].y=Number(i),Sv((function(){n.body.emitter.emit("startSimulation")}),0)):console.error("Node id supplied to moveNode does not exist. Provided: ",t)}}]),t}(),yO=Wt,mO=_,bO=Y,wO=$e,kO=function(t){return void 0!==t&&(yO(t,"value")||yO(t,"writable"))},_O=m,xO=Pr;_i({target:"Reflect",stat:!0},{get:function t(e,i){var n,o,r=arguments.length<3?e:arguments[2];return wO(e)===r?e[i]:(n=_O.f(e,i))?kO(n)?n.value:void 0===n.get?void 0:mO(n.get,r):bO(o=xO(e))?t(o,i,r):void 0}});var EO=X.Reflect.get,OO=md;function CO(t,e){for(;!Object.prototype.hasOwnProperty.call(t,e)&&null!==(t=Ak(t)););return t}function SO(){return SO="undefined"!=typeof Reflect&&EO?EO:function(t,e,i){var n=CO(t,e);if(n){var o=OO(n,e);return o.get?o.get.call(arguments.length<3?t:i):o.value}},SO.apply(this,arguments)}var TO=_i,MO=Math.hypot,PO=Math.abs,DO=Math.sqrt;TO({target:"Math",stat:!0,forced:!!MO&&MO(1/0,NaN)!==1/0},{hypot:function(t,e){for(var i,n,o=0,r=0,s=arguments.length,a=0;r<s;)a<(i=PO(arguments[r++]))?(o=o*(n=a/i)*n+1,a=i):o+=i>0?(n=i/a)*n:i;return a===1/0?1/0:a*DO(o)}});var IO=X.Math.hypot;function BO(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var zO=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"transform",value:function(t,e){lu(t)||(t=[t]);for(var i=e.point.x,n=e.point.y,o=e.angle,r=e.length,s=0;s<t.length;++s){var a=t[s],h=a.x*Math.cos(o)-a.y*Math.sin(o),l=a.x*Math.sin(o)+a.y*Math.cos(o);a.x=i+r*h,a.y=n+r*l}}},{key:"drawPath",value:function(t,e){t.beginPath(),t.moveTo(e[0].x,e[0].y);for(var i=1;i<e.length;++i)t.lineTo(e[i].x,e[i].y);t.closePath()}}]),t}(),NO=function(t){zk(i,t);var e=BO(i);function i(){return Yd(this,i),e.apply(this,arguments)}return Kd(i,null,[{key:"draw",value:function(t,e){if(e.image){t.save(),t.translate(e.point.x,e.point.y),t.rotate(Math.PI/2+e.angle);var i=null!=e.imageWidth?e.imageWidth:e.image.width,n=null!=e.imageHeight?e.imageHeight:e.image.height;e.image.drawImageAtPosition(t,1,-i/2,0,i,n),t.restore()}return!1}}]),i}(zO),FO=function(t){zk(i,t);var e=BO(i);function i(){return Yd(this,i),e.apply(this,arguments)}return Kd(i,null,[{key:"draw",value:function(t,e){var i=[{x:0,y:0},{x:-1,y:.3},{x:-.9,y:0},{x:-1,y:-.3}];return zO.transform(i,e),zO.drawPath(t,i),!0}}]),i}(zO),AO=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"draw",value:function(t,e){var i=[{x:-1,y:0},{x:0,y:.3},{x:-.4,y:0},{x:0,y:-.3}];return zO.transform(i,e),zO.drawPath(t,i),!0}}]),t}(),jO=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"draw",value:function(t,e){var i={x:-.4,y:0};zO.transform(i,e),t.strokeStyle=t.fillStyle,t.fillStyle="rgba(0, 0, 0, 0)";var n=Math.PI,o=e.angle-n/2,r=e.angle+n/2;return t.beginPath(),t.arc(i.x,i.y,.4*e.length,o,r,!1),t.stroke(),!0}}]),t}(),RO=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"draw",value:function(t,e){var i={x:-.3,y:0};zO.transform(i,e),t.strokeStyle=t.fillStyle,t.fillStyle="rgba(0, 0, 0, 0)";var n=Math.PI,o=e.angle+n/2,r=e.angle+3*n/2;return t.beginPath(),t.arc(i.x,i.y,.4*e.length,o,r,!1),t.stroke(),!0}}]),t}(),LO=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"draw",value:function(t,e){var i=[{x:.02,y:0},{x:-1,y:.3},{x:-1,y:-.3}];return zO.transform(i,e),zO.drawPath(t,i),!0}}]),t}(),HO=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"draw",value:function(t,e){var i=[{x:0,y:.3},{x:0,y:-.3},{x:-1,y:0}];return zO.transform(i,e),zO.drawPath(t,i),!0}}]),t}(),WO=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"draw",value:function(t,e){var i={x:-.4,y:0};return zO.transform(i,e),Nn(t,i.x,i.y,.4*e.length),!0}}]),t}(),qO=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"draw",value:function(t,e){var i=[{x:0,y:.5},{x:0,y:-.5},{x:-.15,y:-.5},{x:-.15,y:.5}];return zO.transform(i,e),zO.drawPath(t,i),!0}}]),t}(),VO=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"draw",value:function(t,e){var i=[{x:0,y:.3},{x:0,y:-.3},{x:-.6,y:-.3},{x:-.6,y:.3}];return zO.transform(i,e),zO.drawPath(t,i),!0}}]),t}(),UO=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"draw",value:function(t,e){var i=[{x:0,y:0},{x:-.5,y:-.3},{x:-1,y:0},{x:-.5,y:.3}];return zO.transform(i,e),zO.drawPath(t,i),!0}}]),t}(),YO=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"draw",value:function(t,e){var i=[{x:-1,y:.3},{x:-.5,y:0},{x:-1,y:-.3},{x:0,y:0}];return zO.transform(i,e),zO.drawPath(t,i),!0}}]),t}(),XO=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"draw",value:function(t,e){var i;switch(e.type&&(i=e.type.toLowerCase()),i){case"image":return NO.draw(t,e);case"circle":return WO.draw(t,e);case"box":return VO.draw(t,e);case"crow":return AO.draw(t,e);case"curve":return jO.draw(t,e);case"diamond":return UO.draw(t,e);case"inv_curve":return RO.draw(t,e);case"triangle":return LO.draw(t,e);case"inv_triangle":return HO.draw(t,e);case"bar":return qO.draw(t,e);case"vee":return YO.draw(t,e);default:return FO.draw(t,e)}}}]),t}();function GO(t,e){var i=bu(t);if(hd){var n=hd(t);e&&(n=Xf(n).call(n,(function(e){return bd(t,e).enumerable}))),i.push.apply(i,n)}return i}function KO(t){for(var e=1;e<arguments.length;e++){var i,n,o=null!=arguments[e]?arguments[e]:{};e%2?Fu(i=GO(Object(o),!0)).call(i,(function(e){$d(t,e,o[e])})):Pd?Ad(t,Pd(o)):Fu(n=GO(Object(o))).call(n,(function(e){Ud(t,e,bd(o,e))}))}return t}var $O=function(){function t(e,i,n){Yd(this,t),this._body=i,this._labelModule=n,this.color={},this.colorDirty=!0,this.hoverWidth=1.5,this.selectionWidth=2,this.setOptions(e),this.fromPoint=this.from,this.toPoint=this.to}return Kd(t,[{key:"connect",value:function(){this.from=this._body.nodes[this.options.from],this.to=this._body.nodes[this.options.to]}},{key:"cleanup",value:function(){return!1}},{key:"setOptions",value:function(t){this.options=t,this.from=this._body.nodes[this.options.from],this.to=this._body.nodes[this.options.to],this.id=this.options.id}},{key:"drawLine",value:function(t,e,i,n){var o=arguments.length>4&&void 0!==arguments[4]?arguments[4]:this.getViaNode();t.strokeStyle=this.getColor(t,e),t.lineWidth=e.width,!1!==e.dashes?this._drawDashedLine(t,e,o):this._drawLine(t,e,o)}},{key:"_drawLine",value:function(t,e,i,n,o){if(this.from!=this.to)this._line(t,e,i,n,o);else{var r=Kc(this._getCircleData(t),3),s=r[0],a=r[1],h=r[2];this._circle(t,e,s,a,h)}}},{key:"_drawDashedLine",value:function(t,e,i,n,o){t.lineCap="round";var r=lu(e.dashes)?e.dashes:[5,5];if(void 0!==t.setLineDash){if(t.save(),t.setLineDash(r),t.lineDashOffset=0,this.from!=this.to)this._line(t,e,i);else{var s=Kc(this._getCircleData(t),3),a=s[0],h=s[1],l=s[2];this._circle(t,e,a,h,l)}t.setLineDash([0]),t.lineDashOffset=0,t.restore()}else{if(this.from!=this.to)Rn(t,this.from.x,this.from.y,this.to.x,this.to.y,r);else{var d=Kc(this._getCircleData(t),3),c=d[0],u=d[1],f=d[2];this._circle(t,e,c,u,f)}this.enableShadow(t,e),t.stroke(),this.disableShadow(t,e)}}},{key:"findBorderPosition",value:function(t,e,i){return this.from!=this.to?this._findBorderPosition(t,e,i):this._findBorderPositionCircle(t,e,i)}},{key:"findBorderPositions",value:function(t){if(this.from!=this.to)return{from:this._findBorderPosition(this.from,t),to:this._findBorderPosition(this.to,t)};var e,i=Kc(au(e=this._getCircleData(t)).call(e,0,2),2),n=i[0],o=i[1];return{from:this._findBorderPositionCircle(this.from,t,{x:n,y:o,low:.25,high:.6,direction:-1}),to:this._findBorderPositionCircle(this.from,t,{x:n,y:o,low:.6,high:.8,direction:1})}}},{key:"_getCircleData",value:function(t){var e=this.options.selfReference.size;void 0!==t&&void 0===this.from.shape.width&&this.from.shape.resize(t);var i=bE(t,this.options.selfReference.angle,e,this.from);return[i.x,i.y,e]}},{key:"_pointOnCircle",value:function(t,e,i,n){var o=2*n*Math.PI;return{x:t+i*Math.cos(o),y:e-i*Math.sin(o)}}},{key:"_findBorderPositionCircle",value:function(t,e,i){var n,o=i.x,r=i.y,s=i.low,a=i.high,h=i.direction,l=this.options.selfReference.size,d=.5*(s+a),c=0;!0===this.options.arrowStrikethrough&&(-1===h?c=this.options.endPointOffset.from:1===h&&(c=this.options.endPointOffset.to));var u=0;do{d=.5*(s+a),n=this._pointOnCircle(o,r,l,d);var f=Math.atan2(t.y-n.y,t.x-n.x),p=t.distanceToBorder(e,f)+c-Math.sqrt(Math.pow(n.x-t.x,2)+Math.pow(n.y-t.y,2));if(Math.abs(p)<.05)break;p>0?h>0?s=d:a=d:h>0?a=d:s=d,++u}while(s<=a&&u<10);return KO(KO({},n),{},{t:d})}},{key:"getLineWidth",value:function(t,e){return!0===t?Math.max(this.selectionWidth,.3/this._body.view.scale):!0===e?Math.max(this.hoverWidth,.3/this._body.view.scale):Math.max(this.options.width,.3/this._body.view.scale)}},{key:"getColor",value:function(t,e){if(!1!==e.inheritsColor){if("both"===e.inheritsColor&&this.from.id!==this.to.id){var i=t.createLinearGradient(this.from.x,this.from.y,this.to.x,this.to.y),n=this.from.options.color.highlight.border,o=this.to.options.color.highlight.border;return!1===this.from.selected&&!1===this.to.selected?(n=pm(this.from.options.color.border,e.opacity),o=pm(this.to.options.color.border,e.opacity)):!0===this.from.selected&&!1===this.to.selected?o=this.to.options.color.border:!1===this.from.selected&&!0===this.to.selected&&(n=this.from.options.color.border),i.addColorStop(0,n),i.addColorStop(1,o),i}return"to"===e.inheritsColor?pm(this.to.options.color.border,e.opacity):pm(this.from.options.color.border,e.opacity)}return pm(e.color,e.opacity)}},{key:"_circle",value:function(t,e,i,n,o){this.enableShadow(t,e);var r=0,s=2*Math.PI;if(!this.options.selfReference.renderBehindTheNode){var a=this.options.selfReference.angle,h=this.options.selfReference.angle+Math.PI,l=this._findBorderPositionCircle(this.from,t,{x:i,y:n,low:a,high:h,direction:-1}),d=this._findBorderPositionCircle(this.from,t,{x:i,y:n,low:a,high:h,direction:1});r=Math.atan2(l.y-n,l.x-i),s=Math.atan2(d.y-n,d.x-i)}t.beginPath(),t.arc(i,n,o,r,s,!1),t.stroke(),this.disableShadow(t,e)}},{key:"getDistanceToEdge",value:function(t,e,i,n,o,r){if(this.from!=this.to)return this._getDistanceToEdge(t,e,i,n,o,r);var s=Kc(this._getCircleData(void 0),3),a=s[0],h=s[1],l=s[2],d=a-o,c=h-r;return Math.abs(Math.sqrt(d*d+c*c)-l)}},{key:"_getDistanceToLine",value:function(t,e,i,n,o,r){var s=i-t,a=n-e,h=((o-t)*s+(r-e)*a)/(s*s+a*a);h>1?h=1:h<0&&(h=0);var l=t+h*s-o,d=e+h*a-r;return Math.sqrt(l*l+d*d)}},{key:"getArrowData",value:function(t,e,i,n,o,r){var s,a,h,l,d,c,u,f=r.width;"from"===e?(h=this.from,l=this.to,d=r.fromArrowScale<0,c=Math.abs(r.fromArrowScale),u=r.fromArrowType):"to"===e?(h=this.to,l=this.from,d=r.toArrowScale<0,c=Math.abs(r.toArrowScale),u=r.toArrowType):(h=this.to,l=this.from,d=r.middleArrowScale<0,c=Math.abs(r.middleArrowScale),u=r.middleArrowType);var p=15*c+3*f;if(h!=l){var v=p/IO(h.x-l.x,h.y-l.y);if("middle"!==e)if(!0===this.options.smooth.enabled){var g=this._findBorderPosition(h,t,{via:i}),y=this.getPoint(g.t+v*("from"===e?1:-1),i);s=Math.atan2(g.y-y.y,g.x-y.x),a=g}else s=Math.atan2(h.y-l.y,h.x-l.x),a=this._findBorderPosition(h,t);else{var m=(d?-v:v)/2,b=this.getPoint(.5+m,i),w=this.getPoint(.5-m,i);s=Math.atan2(b.y-w.y,b.x-w.x),a=this.getPoint(.5,i)}}else{var k=Kc(this._getCircleData(t),3),_=k[0],x=k[1],E=k[2];if("from"===e){var O=this.options.selfReference.angle,C=this.options.selfReference.angle+Math.PI,S=this._findBorderPositionCircle(this.from,t,{x:_,y:x,low:O,high:C,direction:-1});s=-2*S.t*Math.PI+1.5*Math.PI+.1*Math.PI,a=S}else if("to"===e){var T=this.options.selfReference.angle,M=this.options.selfReference.angle+Math.PI,P=this._findBorderPositionCircle(this.from,t,{x:_,y:x,low:T,high:M,direction:1});s=-2*P.t*Math.PI+1.5*Math.PI-1.1*Math.PI,a=P}else{var D=this.options.selfReference.angle/(2*Math.PI);a=this._pointOnCircle(_,x,E,D),s=-2*D*Math.PI+1.5*Math.PI+.1*Math.PI}}return{point:a,core:{x:a.x-.9*p*Math.cos(s),y:a.y-.9*p*Math.sin(s)},angle:s,length:p,type:u}}},{key:"drawArrowHead",value:function(t,e,i,n,o){t.strokeStyle=this.getColor(t,e),t.fillStyle=t.strokeStyle,t.lineWidth=e.width,XO.draw(t,o)&&(this.enableShadow(t,e),jv(t).call(t),this.disableShadow(t,e))}},{key:"enableShadow",value:function(t,e){!0===e.shadow&&(t.shadowColor=e.shadowColor,t.shadowBlur=e.shadowSize,t.shadowOffsetX=e.shadowX,t.shadowOffsetY=e.shadowY)}},{key:"disableShadow",value:function(t,e){!0===e.shadow&&(t.shadowColor="rgba(0,0,0,0)",t.shadowBlur=0,t.shadowOffsetX=0,t.shadowOffsetY=0)}},{key:"drawBackground",value:function(t,e){if(!1!==e.background){var i={strokeStyle:t.strokeStyle,lineWidth:t.lineWidth,dashes:t.dashes};t.strokeStyle=e.backgroundColor,t.lineWidth=e.backgroundSize,this.setStrokeDashed(t,e.backgroundDashes),t.stroke(),t.strokeStyle=i.strokeStyle,t.lineWidth=i.lineWidth,t.dashes=i.dashes,this.setStrokeDashed(t,e.dashes)}}},{key:"setStrokeDashed",value:function(t,e){if(!1!==e)if(void 0!==t.setLineDash){var i=lu(e)?e:[5,5];t.setLineDash(i)}else console.warn("setLineDash is not supported in this browser. The dashed stroke cannot be used.");else void 0!==t.setLineDash?t.setLineDash([]):console.warn("setLineDash is not supported in this browser. The dashed stroke cannot be used.")}}]),t}();function ZO(t,e){var i=bu(t);if(hd){var n=hd(t);e&&(n=Xf(n).call(n,(function(e){return bd(t,e).enumerable}))),i.push.apply(i,n)}return i}function QO(t){for(var e=1;e<arguments.length;e++){var i,n,o=null!=arguments[e]?arguments[e]:{};e%2?Fu(i=ZO(Object(o),!0)).call(i,(function(e){$d(t,e,o[e])})):Pd?Ad(t,Pd(o)):Fu(n=ZO(Object(o))).call(n,(function(e){Ud(t,e,bd(o,e))}))}return t}function JO(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var tC=function(t){zk(i,t);var e=JO(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"_findBorderPositionBezier",value:function(t,e){var i,n,o=arguments.length>2&&void 0!==arguments[2]?arguments[2]:this._getViaCoordinates(),r=10,s=.2,a=!1,h=1,l=0,d=this.to,c=this.options.endPointOffset?this.options.endPointOffset.to:0;t.id===this.from.id&&(d=this.from,a=!0,c=this.options.endPointOffset?this.options.endPointOffset.from:0),!1===this.options.arrowStrikethrough&&(c=0);var u=0;do{n=.5*(l+h),i=this.getPoint(n,o);var f=Math.atan2(d.y-i.y,d.x-i.x),p=d.distanceToBorder(e,f)+c,v=Math.sqrt(Math.pow(i.x-d.x,2)+Math.pow(i.y-d.y,2)),g=p-v;if(Math.abs(g)<s)break;g<0?!1===a?l=n:h=n:!1===a?h=n:l=n,++u}while(l<=h&&u<r);return QO(QO({},i),{},{t:n})}},{key:"_getDistanceToBezierEdge",value:function(t,e,i,n,o,r,s){var a,h,l,d,c,u=1e9,f=t,p=e;for(h=1;h<10;h++)l=.1*h,d=Math.pow(1-l,2)*t+2*l*(1-l)*s.x+Math.pow(l,2)*i,c=Math.pow(1-l,2)*e+2*l*(1-l)*s.y+Math.pow(l,2)*n,h>0&&(u=(a=this._getDistanceToLine(f,p,d,c,o,r))<u?a:u),f=d,p=c;return u}},{key:"_bezierCurve",value:function(t,e,i,n){t.beginPath(),t.moveTo(this.fromPoint.x,this.fromPoint.y),null!=i&&null!=i.x?null!=n&&null!=n.x?t.bezierCurveTo(i.x,i.y,n.x,n.y,this.toPoint.x,this.toPoint.y):t.quadraticCurveTo(i.x,i.y,this.toPoint.x,this.toPoint.y):t.lineTo(this.toPoint.x,this.toPoint.y),this.drawBackground(t,e),this.enableShadow(t,e),t.stroke(),this.disableShadow(t,e)}},{key:"getViaNode",value:function(){return this._getViaCoordinates()}}]),i}($O);function eC(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var iC=function(t){zk(i,t);var e=eC(i);function i(t,n,o){var r;return Yd(this,i),(r=e.call(this,t,n,o)).via=r.via,r._boundFunction=function(){r.positionBezierNode()},r._body.emitter.on("_repositionBezierNodes",r._boundFunction),r}return Kd(i,[{key:"setOptions",value:function(t){SO(Ak(i.prototype),"setOptions",this).call(this,t);var e=!1;this.options.physics!==t.physics&&(e=!0),this.options=t,this.id=this.options.id,this.from=this._body.nodes[this.options.from],this.to=this._body.nodes[this.options.to],this.setupSupportNode(),this.connect(),!0===e&&(this.via.setOptions({physics:this.options.physics}),this.positionBezierNode())}},{key:"connect",value:function(){this.from=this._body.nodes[this.options.from],this.to=this._body.nodes[this.options.to],void 0===this.from||void 0===this.to||!1===this.options.physics||this.from.id===this.to.id?this.via.setOptions({physics:!1}):this.via.setOptions({physics:!0})}},{key:"cleanup",value:function(){return this._body.emitter.off("_repositionBezierNodes",this._boundFunction),void 0!==this.via&&(delete this._body.nodes[this.via.id],this.via=void 0,!0)}},{key:"setupSupportNode",value:function(){if(void 0===this.via){var t="edgeId:"+this.id,e=this._body.functions.createNode({id:t,shape:"circle",physics:!0,hidden:!0});this._body.nodes[t]=e,this.via=e,this.via.parentEdgeId=this.id,this.positionBezierNode()}}},{key:"positionBezierNode",value:function(){void 0!==this.via&&void 0!==this.from&&void 0!==this.to?(this.via.x=.5*(this.from.x+this.to.x),this.via.y=.5*(this.from.y+this.to.y)):void 0!==this.via&&(this.via.x=0,this.via.y=0)}},{key:"_line",value:function(t,e,i){this._bezierCurve(t,e,i)}},{key:"_getViaCoordinates",value:function(){return this.via}},{key:"getViaNode",value:function(){return this.via}},{key:"getPoint",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:this.via;if(this.from===this.to){var i=this._getCircleData(),n=Kc(i,3),o=n[0],r=n[1],s=n[2],a=2*Math.PI*(1-t);return{x:o+s*Math.sin(a),y:r+s-s*(1-Math.cos(a))}}return{x:Math.pow(1-t,2)*this.fromPoint.x+2*t*(1-t)*e.x+Math.pow(t,2)*this.toPoint.x,y:Math.pow(1-t,2)*this.fromPoint.y+2*t*(1-t)*e.y+Math.pow(t,2)*this.toPoint.y}}},{key:"_findBorderPosition",value:function(t,e){return this._findBorderPositionBezier(t,e,this.via)}},{key:"_getDistanceToEdge",value:function(t,e,i,n,o,r){return this._getDistanceToBezierEdge(t,e,i,n,o,r,this.via)}}]),i}(tC);function nC(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var oC=function(t){zk(i,t);var e=nC(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"_line",value:function(t,e,i){this._bezierCurve(t,e,i)}},{key:"getViaNode",value:function(){return this._getViaCoordinates()}},{key:"_getViaCoordinates",value:function(){var t,e,i=this.options.smooth.roundness,n=this.options.smooth.type,o=Math.abs(this.from.x-this.to.x),r=Math.abs(this.from.y-this.to.y);if("discrete"===n||"diagonalCross"===n){var s,a;s=a=o<=r?i*r:i*o,this.from.x>this.to.x&&(s=-s),this.from.y>=this.to.y&&(a=-a);var h=this.from.x+s,l=this.from.y+a;return"discrete"===n&&(o<=r?h=o<i*r?this.from.x:h:l=r<i*o?this.from.y:l),{x:h,y:l}}if("straightCross"===n){var d=(1-i)*o,c=(1-i)*r;return o<=r?(d=0,this.from.y<this.to.y&&(c=-c)):(this.from.x<this.to.x&&(d=-d),c=0),{x:this.to.x+d,y:this.to.y+c}}if("horizontal"===n){var u=(1-i)*o;return this.from.x<this.to.x&&(u=-u),{x:this.to.x+u,y:this.from.y}}if("vertical"===n){var f=(1-i)*r;return this.from.y<this.to.y&&(f=-f),{x:this.from.x,y:this.to.y+f}}if("curvedCW"===n){o=this.to.x-this.from.x,r=this.from.y-this.to.y;var p=Math.sqrt(o*o+r*r),v=Math.PI,g=(Math.atan2(r,o)+(.5*i+.5)*v)%(2*v);return{x:this.from.x+(.5*i+.5)*p*Math.sin(g),y:this.from.y+(.5*i+.5)*p*Math.cos(g)}}if("curvedCCW"===n){o=this.to.x-this.from.x,r=this.from.y-this.to.y;var y=Math.sqrt(o*o+r*r),m=Math.PI,b=(Math.atan2(r,o)+(.5*-i+.5)*m)%(2*m);return{x:this.from.x+(.5*i+.5)*y*Math.sin(b),y:this.from.y+(.5*i+.5)*y*Math.cos(b)}}t=e=o<=r?i*r:i*o,this.from.x>this.to.x&&(t=-t),this.from.y>=this.to.y&&(e=-e);var w=this.from.x+t,k=this.from.y+e;return o<=r?w=this.from.x<=this.to.x?this.to.x<w?this.to.x:w:this.to.x>w?this.to.x:w:k=this.from.y>=this.to.y?this.to.y>k?this.to.y:k:this.to.y<k?this.to.y:k,{x:w,y:k}}},{key:"_findBorderPosition",value:function(t,e){var i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};return this._findBorderPositionBezier(t,e,i.via)}},{key:"_getDistanceToEdge",value:function(t,e,i,n,o,r){var s=arguments.length>6&&void 0!==arguments[6]?arguments[6]:this._getViaCoordinates();return this._getDistanceToBezierEdge(t,e,i,n,o,r,s)}},{key:"getPoint",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:this._getViaCoordinates(),i=t,n=Math.pow(1-i,2)*this.fromPoint.x+2*i*(1-i)*e.x+Math.pow(i,2)*this.toPoint.x,o=Math.pow(1-i,2)*this.fromPoint.y+2*i*(1-i)*e.y+Math.pow(i,2)*this.toPoint.y;return{x:n,y:o}}}]),i}(tC);function rC(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var sC=function(t){zk(i,t);var e=rC(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"_getDistanceToBezierEdge2",value:function(t,e,i,n,o,r,s,a){for(var h=1e9,l=t,d=e,c=[0,0,0,0],u=1;u<10;u++){var f=.1*u;c[0]=Math.pow(1-f,3),c[1]=3*f*Math.pow(1-f,2),c[2]=3*Math.pow(f,2)*(1-f),c[3]=Math.pow(f,3);var p=c[0]*t+c[1]*s.x+c[2]*a.x+c[3]*i,v=c[0]*e+c[1]*s.y+c[2]*a.y+c[3]*n;if(u>0){var g=this._getDistanceToLine(l,d,p,v,o,r);h=g<h?g:h}l=p,d=v}return h}}]),i}(tC);function aC(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var hC=function(t){zk(i,t);var e=aC(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"_line",value:function(t,e,i){var n=i[0],o=i[1];this._bezierCurve(t,e,n,o)}},{key:"_getViaCoordinates",value:function(){var t,e,i,n,o=this.from.x-this.to.x,r=this.from.y-this.to.y,s=this.options.smooth.roundness;return(Math.abs(o)>Math.abs(r)||!0===this.options.smooth.forceDirection||"horizontal"===this.options.smooth.forceDirection)&&"vertical"!==this.options.smooth.forceDirection?(e=this.from.y,n=this.to.y,t=this.from.x-s*o,i=this.to.x+s*o):(e=this.from.y-s*r,n=this.to.y+s*r,t=this.from.x,i=this.to.x),[{x:t,y:e},{x:i,y:n}]}},{key:"getViaNode",value:function(){return this._getViaCoordinates()}},{key:"_findBorderPosition",value:function(t,e){return this._findBorderPositionBezier(t,e)}},{key:"_getDistanceToEdge",value:function(t,e,i,n,o,r){var s=arguments.length>6&&void 0!==arguments[6]?arguments[6]:this._getViaCoordinates(),a=Kc(s,2),h=a[0],l=a[1];return this._getDistanceToBezierEdge2(t,e,i,n,o,r,h,l)}},{key:"getPoint",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:this._getViaCoordinates(),i=Kc(e,2),n=i[0],o=i[1],r=t,s=[Math.pow(1-r,3),3*r*Math.pow(1-r,2),3*Math.pow(r,2)*(1-r),Math.pow(r,3)],a=s[0]*this.fromPoint.x+s[1]*n.x+s[2]*o.x+s[3]*this.toPoint.x,h=s[0]*this.fromPoint.y+s[1]*n.y+s[2]*o.y+s[3]*this.toPoint.y;return{x:a,y:h}}}]),i}(sC);function lC(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var dC=function(t){zk(i,t);var e=lC(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"_line",value:function(t,e){t.beginPath(),t.moveTo(this.fromPoint.x,this.fromPoint.y),t.lineTo(this.toPoint.x,this.toPoint.y),this.enableShadow(t,e),t.stroke(),this.disableShadow(t,e)}},{key:"getViaNode",value:function(){}},{key:"getPoint",value:function(t){return{x:(1-t)*this.fromPoint.x+t*this.toPoint.x,y:(1-t)*this.fromPoint.y+t*this.toPoint.y}}},{key:"_findBorderPosition",value:function(t,e){var i=this.to,n=this.from;t.id===this.from.id&&(i=this.from,n=this.to);var o=Math.atan2(i.y-n.y,i.x-n.x),r=i.x-n.x,s=i.y-n.y,a=Math.sqrt(r*r+s*s),h=(a-t.distanceToBorder(e,o))/a;return{x:(1-h)*n.x+h*i.x,y:(1-h)*n.y+h*i.y,t:0}}},{key:"_getDistanceToEdge",value:function(t,e,i,n,o,r){return this._getDistanceToLine(t,e,i,n,o,r)}}]),i}($O),cC=function(){function t(e,i,n,o,r){if(Yd(this,t),void 0===i)throw new Error("No body provided");this.options=Cm(o),this.globalOptions=o,this.defaultOptions=r,this.body=i,this.imagelist=n,this.id=void 0,this.fromId=void 0,this.toId=void 0,this.selected=!1,this.hover=!1,this.labelDirty=!0,this.baseWidth=this.options.width,this.baseFontSize=this.options.font.size,this.from=void 0,this.to=void 0,this.edgeType=void 0,this.connected=!1,this.labelModule=new OE(this.body,this.options,!0),this.setOptions(e)}return Kd(t,[{key:"setOptions",value:function(e){if(e){var i=void 0!==e.physics&&this.options.physics!==e.physics||void 0!==e.hidden&&(this.options.hidden||!1)!==(e.hidden||!1)||void 0!==e.from&&this.options.from!==e.from||void 0!==e.to&&this.options.to!==e.to;t.parseOptions(this.options,e,!0,this.globalOptions),void 0!==e.id&&(this.id=e.id),void 0!==e.from&&(this.fromId=e.from),void 0!==e.to&&(this.toId=e.to),void 0!==e.title&&(this.title=e.title),void 0!==e.value&&(e.value=lE(e.value));var n=[e,this.options,this.defaultOptions];return this.chooser=gE("edge",n),this.updateLabelModule(e),i=this.updateEdgeType()||i,this._setInteractionWidths(),this.connect(),i}}},{key:"getFormattingValues",value:function(){var t=!0===this.options.arrows.to||!0===this.options.arrows.to.enabled,e=!0===this.options.arrows.from||!0===this.options.arrows.from.enabled,i=!0===this.options.arrows.middle||!0===this.options.arrows.middle.enabled,n=this.options.color.inherit,o={toArrow:t,toArrowScale:this.options.arrows.to.scaleFactor,toArrowType:this.options.arrows.to.type,toArrowSrc:this.options.arrows.to.src,toArrowImageWidth:this.options.arrows.to.imageWidth,toArrowImageHeight:this.options.arrows.to.imageHeight,middleArrow:i,middleArrowScale:this.options.arrows.middle.scaleFactor,middleArrowType:this.options.arrows.middle.type,middleArrowSrc:this.options.arrows.middle.src,middleArrowImageWidth:this.options.arrows.middle.imageWidth,middleArrowImageHeight:this.options.arrows.middle.imageHeight,fromArrow:e,fromArrowScale:this.options.arrows.from.scaleFactor,fromArrowType:this.options.arrows.from.type,fromArrowSrc:this.options.arrows.from.src,fromArrowImageWidth:this.options.arrows.from.imageWidth,fromArrowImageHeight:this.options.arrows.from.imageHeight,arrowStrikethrough:this.options.arrowStrikethrough,color:n?void 0:this.options.color.color,inheritsColor:n,opacity:this.options.color.opacity,hidden:this.options.hidden,length:this.options.length,shadow:this.options.shadow.enabled,shadowColor:this.options.shadow.color,shadowSize:this.options.shadow.size,shadowX:this.options.shadow.x,shadowY:this.options.shadow.y,dashes:this.options.dashes,width:this.options.width,background:this.options.background.enabled,backgroundColor:this.options.background.color,backgroundSize:this.options.background.size,backgroundDashes:this.options.background.dashes};if(this.selected||this.hover)if(!0===this.chooser){if(this.selected){var r=this.options.selectionWidth;"function"==typeof r?o.width=r(o.width):"number"==typeof r&&(o.width+=r),o.width=Math.max(o.width,.3/this.body.view.scale),o.color=this.options.color.highlight,o.shadow=this.options.shadow.enabled}else if(this.hover){var s=this.options.hoverWidth;"function"==typeof s?o.width=s(o.width):"number"==typeof s&&(o.width+=s),o.width=Math.max(o.width,.3/this.body.view.scale),o.color=this.options.color.hover,o.shadow=this.options.shadow.enabled}}else"function"==typeof this.chooser&&(this.chooser(o,this.options.id,this.selected,this.hover),void 0!==o.color&&(o.inheritsColor=!1),!1===o.shadow&&(o.shadowColor===this.options.shadow.color&&o.shadowSize===this.options.shadow.size&&o.shadowX===this.options.shadow.x&&o.shadowY===this.options.shadow.y||(o.shadow=!0)));else o.shadow=this.options.shadow.enabled,o.width=Math.max(o.width,.3/this.body.view.scale);return o}},{key:"updateLabelModule",value:function(t){var e=[t,this.options,this.globalOptions,this.defaultOptions];this.labelModule.update(this.options,e),void 0!==this.labelModule.baseSize&&(this.baseFontSize=this.labelModule.baseSize)}},{key:"updateEdgeType",value:function(){var t=this.options.smooth,e=!1,i=!0;return void 0!==this.edgeType&&((this.edgeType instanceof iC&&!0===t.enabled&&"dynamic"===t.type||this.edgeType instanceof hC&&!0===t.enabled&&"cubicBezier"===t.type||this.edgeType instanceof oC&&!0===t.enabled&&"dynamic"!==t.type&&"cubicBezier"!==t.type||this.edgeType instanceof dC&&!1===t.type.enabled)&&(i=!1),!0===i&&(e=this.cleanup())),!0===i?!0===t.enabled?"dynamic"===t.type?(e=!0,this.edgeType=new iC(this.options,this.body,this.labelModule)):"cubicBezier"===t.type?this.edgeType=new hC(this.options,this.body,this.labelModule):this.edgeType=new oC(this.options,this.body,this.labelModule):this.edgeType=new dC(this.options,this.body,this.labelModule):this.edgeType.setOptions(this.options),e}},{key:"connect",value:function(){this.disconnect(),this.from=this.body.nodes[this.fromId]||void 0,this.to=this.body.nodes[this.toId]||void 0,this.connected=void 0!==this.from&&void 0!==this.to,!0===this.connected?(this.from.attachEdge(this),this.to.attachEdge(this)):(this.from&&this.from.detachEdge(this),this.to&&this.to.detachEdge(this)),this.edgeType.connect()}},{key:"disconnect",value:function(){this.from&&(this.from.detachEdge(this),this.from=void 0),this.to&&(this.to.detachEdge(this),this.to=void 0),this.connected=!1}},{key:"getTitle",value:function(){return this.title}},{key:"isSelected",value:function(){return this.selected}},{key:"getValue",value:function(){return this.options.value}},{key:"setValueRange",value:function(t,e,i){if(void 0!==this.options.value){var n=this.options.scaling.customScalingFunction(t,e,i,this.options.value),o=this.options.scaling.max-this.options.scaling.min;if(!0===this.options.scaling.label.enabled){var r=this.options.scaling.label.max-this.options.scaling.label.min;this.options.font.size=this.options.scaling.label.min+n*r}this.options.width=this.options.scaling.min+n*o}else this.options.width=this.baseWidth,this.options.font.size=this.baseFontSize;this._setInteractionWidths(),this.updateLabelModule()}},{key:"_setInteractionWidths",value:function(){"function"==typeof this.options.hoverWidth?this.edgeType.hoverWidth=this.options.hoverWidth(this.options.width):this.edgeType.hoverWidth=this.options.hoverWidth+this.options.width,"function"==typeof this.options.selectionWidth?this.edgeType.selectionWidth=this.options.selectionWidth(this.options.width):this.edgeType.selectionWidth=this.options.selectionWidth+this.options.width}},{key:"draw",value:function(t){var e=this.getFormattingValues();if(!e.hidden){var i=this.edgeType.getViaNode();this.edgeType.drawLine(t,e,this.selected,this.hover,i),this.drawLabel(t,i)}}},{key:"drawArrows",value:function(t){var e=this.getFormattingValues();if(!e.hidden){var i=this.edgeType.getViaNode(),n={};this.edgeType.fromPoint=this.edgeType.from,this.edgeType.toPoint=this.edgeType.to,e.fromArrow&&(n.from=this.edgeType.getArrowData(t,"from",i,this.selected,this.hover,e),!1===e.arrowStrikethrough&&(this.edgeType.fromPoint=n.from.core),e.fromArrowSrc&&(n.from.image=this.imagelist.load(e.fromArrowSrc)),e.fromArrowImageWidth&&(n.from.imageWidth=e.fromArrowImageWidth),e.fromArrowImageHeight&&(n.from.imageHeight=e.fromArrowImageHeight)),e.toArrow&&(n.to=this.edgeType.getArrowData(t,"to",i,this.selected,this.hover,e),!1===e.arrowStrikethrough&&(this.edgeType.toPoint=n.to.core),e.toArrowSrc&&(n.to.image=this.imagelist.load(e.toArrowSrc)),e.toArrowImageWidth&&(n.to.imageWidth=e.toArrowImageWidth),e.toArrowImageHeight&&(n.to.imageHeight=e.toArrowImageHeight)),e.middleArrow&&(n.middle=this.edgeType.getArrowData(t,"middle",i,this.selected,this.hover,e),e.middleArrowSrc&&(n.middle.image=this.imagelist.load(e.middleArrowSrc)),e.middleArrowImageWidth&&(n.middle.imageWidth=e.middleArrowImageWidth),e.middleArrowImageHeight&&(n.middle.imageHeight=e.middleArrowImageHeight)),e.fromArrow&&this.edgeType.drawArrowHead(t,e,this.selected,this.hover,n.from),e.middleArrow&&this.edgeType.drawArrowHead(t,e,this.selected,this.hover,n.middle),e.toArrow&&this.edgeType.drawArrowHead(t,e,this.selected,this.hover,n.to)}}},{key:"drawLabel",value:function(t,e){if(void 0!==this.options.label){var i,n=this.from,o=this.to;if(this.labelModule.differentState(this.selected,this.hover)&&this.labelModule.getTextSize(t,this.selected,this.hover),n.id!=o.id){this.labelModule.pointToSelf=!1,i=this.edgeType.getPoint(.5,e),t.save();var r=this._getRotation(t);0!=r.angle&&(t.translate(r.x,r.y),t.rotate(r.angle)),this.labelModule.draw(t,i.x,i.y,this.selected,this.hover),t.restore()}else{this.labelModule.pointToSelf=!0;var s=bE(t,this.options.selfReference.angle,this.options.selfReference.size,n);i=this._pointOnCircle(s.x,s.y,this.options.selfReference.size,this.options.selfReference.angle),this.labelModule.draw(t,i.x,i.y,this.selected,this.hover)}}}},{key:"getItemsOnPoint",value:function(t){var e=[];if(this.labelModule.visible()){var i=this._getRotation();yE(this.labelModule.getSize(),t,i)&&e.push({edgeId:this.id,labelId:0})}var n={left:t.x,top:t.y};return this.isOverlappingWith(n)&&e.push({edgeId:this.id}),e}},{key:"isOverlappingWith",value:function(t){if(this.connected){var e=this.from.x,i=this.from.y,n=this.to.x,o=this.to.y,r=t.left,s=t.top;return this.edgeType.getDistanceToEdge(e,i,n,o,r,s)<10}return!1}},{key:"_getRotation",value:function(t){var e=this.edgeType.getViaNode(),i=this.edgeType.getPoint(.5,e);void 0!==t&&this.labelModule.calculateLabelSize(t,this.selected,this.hover,i.x,i.y);var n={x:i.x,y:this.labelModule.size.yLine,angle:0};if(!this.labelModule.visible())return n;if("horizontal"===this.options.font.align)return n;var o=this.from.y-this.to.y,r=this.from.x-this.to.x,s=Math.atan2(o,r);return(s<-1&&r<0||s>0&&r<0)&&(s+=Math.PI),n.angle=s,n}},{key:"_pointOnCircle",value:function(t,e,i,n){return{x:t+i*Math.cos(n),y:e-i*Math.sin(n)}}},{key:"select",value:function(){this.selected=!0}},{key:"unselect",value:function(){this.selected=!1}},{key:"cleanup",value:function(){return this.edgeType.cleanup()}},{key:"remove",value:function(){this.cleanup(),this.disconnect(),delete this.body.edges[this.id]}},{key:"endPointsValid",value:function(){return void 0!==this.body.nodes[this.fromId]&&void 0!==this.body.nodes[this.toId]}}],[{key:"parseOptions",value:function(t,e){var i=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3&&void 0!==arguments[3]?arguments[3]:{},o=arguments.length>4&&void 0!==arguments[4]&&arguments[4],r=["endPointOffset","arrowStrikethrough","id","from","hidden","hoverWidth","labelHighlightBold","length","line","opacity","physics","scaling","selectionWidth","selfReferenceSize","selfReference","to","title","value","width","font","chosen","widthConstraint"];if(em(r,t,e,i),void 0!==e.endPointOffset&&void 0!==e.endPointOffset.from&&(ok(e.endPointOffset.from)?t.endPointOffset.from=e.endPointOffset.from:(t.endPointOffset.from=void 0!==n.endPointOffset.from?n.endPointOffset.from:0,console.error("endPointOffset.from is not a valid number"))),void 0!==e.endPointOffset&&void 0!==e.endPointOffset.to&&(ok(e.endPointOffset.to)?t.endPointOffset.to=e.endPointOffset.to:(t.endPointOffset.to=void 0!==n.endPointOffset.to?n.endPointOffset.to:0,console.error("endPointOffset.to is not a valid number"))),mE(e.label)?t.label=e.label:mE(t.label)||(t.label=void 0),Sm(t,e,"smooth",n),Sm(t,e,"shadow",n),Sm(t,e,"background",n),void 0!==e.dashes&&null!==e.dashes?t.dashes=e.dashes:!0===i&&null===e.dashes&&(t.dashes=Kp(n.dashes)),void 0!==e.scaling&&null!==e.scaling?(void 0!==e.scaling.min&&(t.scaling.min=e.scaling.min),void 0!==e.scaling.max&&(t.scaling.max=e.scaling.max),Sm(t.scaling,e.scaling,"label",n.scaling)):!0===i&&null===e.scaling&&(t.scaling=Kp(n.scaling)),void 0!==e.arrows&&null!==e.arrows)if("string"==typeof e.arrows){var s=e.arrows.toLowerCase();t.arrows.to.enabled=-1!=Fp(s).call(s,"to"),t.arrows.middle.enabled=-1!=Fp(s).call(s,"middle"),t.arrows.from.enabled=-1!=Fp(s).call(s,"from")}else{if("object"!==Qc(e.arrows))throw new Error("The arrow newOptions can only be an object or a string. Refer to the documentation. You used:"+gv(e.arrows));Sm(t.arrows,e.arrows,"to",n.arrows),Sm(t.arrows,e.arrows,"middle",n.arrows),Sm(t.arrows,e.arrows,"from",n.arrows)}else!0===i&&null===e.arrows&&(t.arrows=Kp(n.arrows));if(void 0!==e.color&&null!==e.color){var a=$y(e.color)?{color:e.color,highlight:e.color,hover:e.color,inherit:!1,opacity:1}:e.color,h=t.color;if(o)nm(h,n.color,!1,i);else for(var l in h)Object.prototype.hasOwnProperty.call(h,l)&&delete h[l];if($y(h))h.color=h,h.highlight=h,h.hover=h,h.inherit=!1,void 0===a.opacity&&(h.opacity=1);else{var d=!1;void 0!==a.color&&(h.color=a.color,d=!0),void 0!==a.highlight&&(h.highlight=a.highlight,d=!0),void 0!==a.hover&&(h.hover=a.hover,d=!0),void 0!==a.inherit&&(h.inherit=a.inherit),void 0!==a.opacity&&(h.opacity=Math.min(1,Math.max(0,a.opacity))),!0===d?h.inherit=!1:void 0===h.inherit&&(h.inherit="from")}}else!0===i&&null===e.color&&(t.color=Cm(n.color));!0===i&&null===e.font&&(t.font=Cm(n.font)),Object.prototype.hasOwnProperty.call(e,"selfReferenceSize")&&(console.warn("The selfReferenceSize property has been deprecated. Please use selfReference property instead. The selfReference can be set like thise selfReference:{size:30, angle:Math.PI / 4}"),t.selfReference.size=e.selfReferenceSize)}}]),t}(),uC=function(){function t(e,i,n){var o,r=this;Yd(this,t),this.body=e,this.images=i,this.groups=n,this.body.functions.createEdge=zn(o=this.create).call(o,this),this.edgesListeners={add:function(t,e){r.add(e.items)},update:function(t,e){r.update(e.items)},remove:function(t,e){r.remove(e.items)}},this.options={},this.defaultOptions={arrows:{to:{enabled:!1,scaleFactor:1,type:"arrow"},middle:{enabled:!1,scaleFactor:1,type:"arrow"},from:{enabled:!1,scaleFactor:1,type:"arrow"}},endPointOffset:{from:0,to:0},arrowStrikethrough:!0,color:{color:"#848484",highlight:"#848484",hover:"#848484",inherit:"from",opacity:1},dashes:!1,font:{color:"#343434",size:14,face:"arial",background:"none",strokeWidth:2,strokeColor:"#ffffff",align:"horizontal",multi:!1,vadjust:0,bold:{mod:"bold"},boldital:{mod:"bold italic"},ital:{mod:"italic"},mono:{mod:"",size:15,face:"courier new",vadjust:2}},hidden:!1,hoverWidth:1.5,label:void 0,labelHighlightBold:!0,length:void 0,physics:!0,scaling:{min:1,max:15,label:{enabled:!0,min:14,max:30,maxVisible:30,drawThreshold:5},customScalingFunction:function(t,e,i,n){if(e===t)return.5;var o=1/(e-t);return Math.max(0,(n-t)*o)}},selectionWidth:1.5,selfReference:{size:20,angle:Math.PI/4,renderBehindTheNode:!0},shadow:{enabled:!1,color:"rgba(0,0,0,0.5)",size:10,x:5,y:5},background:{enabled:!1,color:"rgba(111,111,111,1)",size:10,dashes:!1},smooth:{enabled:!0,type:"dynamic",forceDirection:"none",roundness:.5},title:void 0,width:1,value:void 0},nm(this.options,this.defaultOptions),this.bindEventListeners()}return Kd(t,[{key:"bindEventListeners",value:function(){var t,e,i=this;this.body.emitter.on("_forceDisableDynamicCurves",(function(t){var e=!(arguments.length>1&&void 0!==arguments[1])||arguments[1];"dynamic"===t&&(t="continuous");var n=!1;for(var o in i.body.edges)if(Object.prototype.hasOwnProperty.call(i.body.edges,o)){var r=i.body.edges[o],s=i.body.data.edges.get(o);if(null!=s){var a=s.smooth;void 0!==a&&!0===a.enabled&&"dynamic"===a.type&&(void 0===t?r.setOptions({smooth:!1}):r.setOptions({smooth:{type:t}}),n=!0)}}!0===e&&!0===n&&i.body.emitter.emit("_dataChanged")})),this.body.emitter.on("_dataUpdated",(function(){i.reconnectEdges()})),this.body.emitter.on("refreshEdges",zn(t=this.refresh).call(t,this)),this.body.emitter.on("refresh",zn(e=this.refresh).call(e,this)),this.body.emitter.on("destroy",(function(){hm(i.edgesListeners,(function(t,e){i.body.data.edges&&i.body.data.edges.off(e,t)})),delete i.body.functions.createEdge,delete i.edgesListeners.add,delete i.edgesListeners.update,delete i.edgesListeners.remove,delete i.edgesListeners}))}},{key:"setOptions",value:function(t){if(void 0!==t){cC.parseOptions(this.options,t,!0,this.defaultOptions,!0);var e=!1;if(void 0!==t.smooth)for(var i in this.body.edges)Object.prototype.hasOwnProperty.call(this.body.edges,i)&&(e=this.body.edges[i].updateEdgeType()||e);if(void 0!==t.font)for(var n in this.body.edges)Object.prototype.hasOwnProperty.call(this.body.edges,n)&&this.body.edges[n].updateLabelModule();void 0===t.hidden&&void 0===t.physics&&!0!==e||this.body.emitter.emit("_dataChanged")}}},{key:"setData",value:function(t){var e=this,i=arguments.length>1&&void 0!==arguments[1]&&arguments[1],n=this.body.data.edges;if(Qx("id",t))this.body.data.edges=t;else if(lu(t))this.body.data.edges=new Kx,this.body.data.edges.add(t);else{if(t)throw new TypeError("Array or DataSet expected");this.body.data.edges=new Kx}if(n&&hm(this.edgesListeners,(function(t,e){n.off(e,t)})),this.body.edges={},this.body.data.edges){hm(this.edgesListeners,(function(t,i){e.body.data.edges.on(i,t)}));var o=this.body.data.edges.getIds();this.add(o,!0)}this.body.emitter.emit("_adjustEdgesForHierarchicalLayout"),!1===i&&this.body.emitter.emit("_dataChanged")}},{key:"add",value:function(t){for(var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1],i=this.body.edges,n=this.body.data.edges,o=0;o<t.length;o++){var r=t[o],s=i[r];s&&s.disconnect();var a=n.get(r,{showInternalIds:!0});i[r]=this.create(a)}this.body.emitter.emit("_adjustEdgesForHierarchicalLayout"),!1===e&&this.body.emitter.emit("_dataChanged")}},{key:"update",value:function(t){for(var e=this.body.edges,i=this.body.data.edges,n=!1,o=0;o<t.length;o++){var r=t[o],s=i.get(r),a=e[r];void 0!==a?(a.disconnect(),n=a.setOptions(s)||n,a.connect()):(this.body.edges[r]=this.create(s),n=!0)}!0===n?(this.body.emitter.emit("_adjustEdgesForHierarchicalLayout"),this.body.emitter.emit("_dataChanged")):this.body.emitter.emit("_dataUpdated")}},{key:"remove",value:function(t){var e=!(arguments.length>1&&void 0!==arguments[1])||arguments[1];if(0!==t.length){var i=this.body.edges;hm(t,(function(t){var e=i[t];void 0!==e&&e.remove()})),e&&this.body.emitter.emit("_dataChanged")}}},{key:"refresh",value:function(){var t=this;hm(this.body.edges,(function(e,i){var n=t.body.data.edges.get(i);void 0!==n&&e.setOptions(n)}))}},{key:"create",value:function(t){return new cC(t,this.body,this.images,this.options,this.defaultOptions)}},{key:"reconnectEdges",value:function(){var t,e=this.body.nodes,i=this.body.edges;for(t in e)Object.prototype.hasOwnProperty.call(e,t)&&(e[t].edges=[]);for(t in i)if(Object.prototype.hasOwnProperty.call(i,t)){var n=i[t];n.from=null,n.to=null,n.connect()}}},{key:"getConnectedNodes",value:function(t){var e=[];if(void 0!==this.body.edges[t]){var i=this.body.edges[t];void 0!==i.fromId&&e.push(i.fromId),void 0!==i.toId&&e.push(i.toId)}return e}},{key:"_updateState",value:function(){this._addMissingEdges(),this._removeInvalidEdges()}},{key:"_removeInvalidEdges",value:function(){var t=this,e=[];hm(this.body.edges,(function(i,n){var o=t.body.nodes[i.toId],r=t.body.nodes[i.fromId];void 0!==o&&!0===o.isCluster||void 0!==r&&!0===r.isCluster||void 0!==o&&void 0!==r||e.push(n)})),this.remove(e,!1)}},{key:"_addMissingEdges",value:function(){var t=this.body.data.edges;if(null!=t){var e=this.body.edges,i=[];Fu(t).call(t,(function(t,n){void 0===e[n]&&i.push(n)})),this.add(i,!0)}}}]),t}(),fC=function(){function t(e,i,n){Yd(this,t),this.body=e,this.physicsBody=i,this.barnesHutTree,this.setOptions(n),this._rng=jy("BARNES HUT SOLVER")}return Kd(t,[{key:"setOptions",value:function(t){this.options=t,this.thetaInversed=1/this.options.theta,this.overlapAvoidanceFactor=1-Math.max(0,Math.min(1,this.options.avoidOverlap))}},{key:"solve",value:function(){if(0!==this.options.gravitationalConstant&&this.physicsBody.physicsNodeIndices.length>0){var t,e=this.body.nodes,i=this.physicsBody.physicsNodeIndices,n=i.length,o=this._formBarnesHutTree(e,i);this.barnesHutTree=o;for(var r=0;r<n;r++)(t=e[i[r]]).options.mass>0&&this._getForceContributions(o.root,t)}}},{key:"_getForceContributions",value:function(t,e){this._getForceContribution(t.children.NW,e),this._getForceContribution(t.children.NE,e),this._getForceContribution(t.children.SW,e),this._getForceContribution(t.children.SE,e)}},{key:"_getForceContribution",value:function(t,e){if(t.childrenCount>0){var i=t.centerOfMass.x-e.x,n=t.centerOfMass.y-e.y,o=Math.sqrt(i*i+n*n);o*t.calcSize>this.thetaInversed?this._calculateForces(o,i,n,e,t):4===t.childrenCount?this._getForceContributions(t,e):t.children.data.id!=e.id&&this._calculateForces(o,i,n,e,t)}}},{key:"_calculateForces",value:function(t,e,i,n,o){0===t&&(e=t=.1),this.overlapAvoidanceFactor<1&&n.shape.radius&&(t=Math.max(.1+this.overlapAvoidanceFactor*n.shape.radius,t-n.shape.radius));var r=this.options.gravitationalConstant*o.mass*n.options.mass/Math.pow(t,3),s=e*r,a=i*r;this.physicsBody.forces[n.id].x+=s,this.physicsBody.forces[n.id].y+=a}},{key:"_formBarnesHutTree",value:function(t,e){for(var i,n=e.length,o=t[e[0]].x,r=t[e[0]].y,s=t[e[0]].x,a=t[e[0]].y,h=1;h<n;h++){var l=t[e[h]],d=l.x,c=l.y;l.options.mass>0&&(d<o&&(o=d),d>s&&(s=d),c<r&&(r=c),c>a&&(a=c))}var u=Math.abs(s-o)-Math.abs(a-r);u>0?(r-=.5*u,a+=.5*u):(o+=.5*u,s-=.5*u);var f=Math.max(1e-5,Math.abs(s-o)),p=.5*f,v=.5*(o+s),g=.5*(r+a),y={root:{centerOfMass:{x:0,y:0},mass:0,range:{minX:v-p,maxX:v+p,minY:g-p,maxY:g+p},size:f,calcSize:1/f,children:{data:null},maxWidth:0,level:0,childrenCount:4}};this._splitBranch(y.root);for(var m=0;m<n;m++)(i=t[e[m]]).options.mass>0&&this._placeInTree(y.root,i);return y}},{key:"_updateBranchMass",value:function(t,e){var i=t.centerOfMass,n=t.mass+e.options.mass,o=1/n;i.x=i.x*t.mass+e.x*e.options.mass,i.x*=o,i.y=i.y*t.mass+e.y*e.options.mass,i.y*=o,t.mass=n;var r=Math.max(Math.max(e.height,e.radius),e.width);t.maxWidth=t.maxWidth<r?r:t.maxWidth}},{key:"_placeInTree",value:function(t,e,i){1==i&&void 0!==i||this._updateBranchMass(t,e);var n,o=t.children.NW.range;n=o.maxX>e.x?o.maxY>e.y?"NW":"SW":o.maxY>e.y?"NE":"SE",this._placeInRegion(t,e,n)}},{key:"_placeInRegion",value:function(t,e,i){var n=t.children[i];switch(n.childrenCount){case 0:n.children.data=e,n.childrenCount=1,this._updateBranchMass(n,e);break;case 1:n.children.data.x===e.x&&n.children.data.y===e.y?(e.x+=this._rng(),e.y+=this._rng()):(this._splitBranch(n),this._placeInTree(n,e));break;case 4:this._placeInTree(n,e)}}},{key:"_splitBranch",value:function(t){var e=null;1===t.childrenCount&&(e=t.children.data,t.mass=0,t.centerOfMass.x=0,t.centerOfMass.y=0),t.childrenCount=4,t.children.data=null,this._insertRegion(t,"NW"),this._insertRegion(t,"NE"),this._insertRegion(t,"SW"),this._insertRegion(t,"SE"),null!=e&&this._placeInTree(t,e)}},{key:"_insertRegion",value:function(t,e){var i,n,o,r,s=.5*t.size;switch(e){case"NW":i=t.range.minX,n=t.range.minX+s,o=t.range.minY,r=t.range.minY+s;break;case"NE":i=t.range.minX+s,n=t.range.maxX,o=t.range.minY,r=t.range.minY+s;break;case"SW":i=t.range.minX,n=t.range.minX+s,o=t.range.minY+s,r=t.range.maxY;break;case"SE":i=t.range.minX+s,n=t.range.maxX,o=t.range.minY+s,r=t.range.maxY}t.children[e]={centerOfMass:{x:0,y:0},mass:0,range:{minX:i,maxX:n,minY:o,maxY:r},size:.5*t.size,calcSize:2*t.calcSize,children:{data:null},maxWidth:0,level:t.level+1,childrenCount:0}}},{key:"_debug",value:function(t,e){void 0!==this.barnesHutTree&&(t.lineWidth=1,this._drawBranch(this.barnesHutTree.root,t,e))}},{key:"_drawBranch",value:function(t,e,i){void 0===i&&(i="#FF0000"),4===t.childrenCount&&(this._drawBranch(t.children.NW,e),this._drawBranch(t.children.NE,e),this._drawBranch(t.children.SE,e),this._drawBranch(t.children.SW,e)),e.strokeStyle=i,e.beginPath(),e.moveTo(t.range.minX,t.range.minY),e.lineTo(t.range.maxX,t.range.minY),e.stroke(),e.beginPath(),e.moveTo(t.range.maxX,t.range.minY),e.lineTo(t.range.maxX,t.range.maxY),e.stroke(),e.beginPath(),e.moveTo(t.range.maxX,t.range.maxY),e.lineTo(t.range.minX,t.range.maxY),e.stroke(),e.beginPath(),e.moveTo(t.range.minX,t.range.maxY),e.lineTo(t.range.minX,t.range.minY),e.stroke()}}]),t}(),pC=function(){function t(e,i,n){Yd(this,t),this._rng=jy("REPULSION SOLVER"),this.body=e,this.physicsBody=i,this.setOptions(n)}return Kd(t,[{key:"setOptions",value:function(t){this.options=t}},{key:"solve",value:function(){for(var t,e,i,n,o,r,s,a,h=this.body.nodes,l=this.physicsBody.physicsNodeIndices,d=this.physicsBody.forces,c=this.options.nodeDistance,u=-2/3/c,f=0;f<l.length-1;f++){s=h[l[f]];for(var p=f+1;p<l.length;p++)t=(a=h[l[p]]).x-s.x,e=a.y-s.y,0===(i=Math.sqrt(t*t+e*e))&&(t=i=.1*this._rng()),i<2*c&&(r=i<.5*c?1:u*i+1.3333333333333333,n=t*(r/=i),o=e*r,d[s.id].x-=n,d[s.id].y-=o,d[a.id].x+=n,d[a.id].y+=o)}}}]),t}(),vC=function(){function t(e,i,n){Yd(this,t),this.body=e,this.physicsBody=i,this.setOptions(n)}return Kd(t,[{key:"setOptions",value:function(t){this.options=t,this.overlapAvoidanceFactor=Math.max(0,Math.min(1,this.options.avoidOverlap||0))}},{key:"solve",value:function(){for(var t=this.body.nodes,e=this.physicsBody.physicsNodeIndices,i=this.physicsBody.forces,n=this.options.nodeDistance,o=0;o<e.length-1;o++)for(var r=t[e[o]],s=o+1;s<e.length;s++){var a=t[e[s]];if(r.level===a.level){var h=n+this.overlapAvoidanceFactor*((r.shape.radius||0)/2+(a.shape.radius||0)/2),l=a.x-r.x,d=a.y-r.y,c=Math.sqrt(l*l+d*d),u=void 0;u=c<h?-Math.pow(.05*c,2)+Math.pow(.05*h,2):0,0!==c&&(u/=c);var f=l*u,p=d*u;i[r.id].x-=f,i[r.id].y-=p,i[a.id].x+=f,i[a.id].y+=p}}}}]),t}(),gC=function(){function t(e,i,n){Yd(this,t),this.body=e,this.physicsBody=i,this.setOptions(n)}return Kd(t,[{key:"setOptions",value:function(t){this.options=t}},{key:"solve",value:function(){for(var t,e,i,n,o,r=this.physicsBody.physicsEdgeIndices,s=this.body.edges,a=0;a<r.length;a++)!0===(e=s[r[a]]).connected&&e.toId!==e.fromId&&void 0!==this.body.nodes[e.toId]&&void 0!==this.body.nodes[e.fromId]&&(void 0!==e.edgeType.via?(t=void 0===e.options.length?this.options.springLength:e.options.length,i=e.to,n=e.edgeType.via,o=e.from,this._calculateSpringForce(i,n,.5*t),this._calculateSpringForce(n,o,.5*t)):(t=void 0===e.options.length?1.5*this.options.springLength:e.options.length,this._calculateSpringForce(e.from,e.to,t)))}},{key:"_calculateSpringForce",value:function(t,e,i){var n=t.x-e.x,o=t.y-e.y,r=Math.max(Math.sqrt(n*n+o*o),.01),s=this.options.springConstant*(i-r)/r,a=n*s,h=o*s;void 0!==this.physicsBody.forces[t.id]&&(this.physicsBody.forces[t.id].x+=a,this.physicsBody.forces[t.id].y+=h),void 0!==this.physicsBody.forces[e.id]&&(this.physicsBody.forces[e.id].x-=a,this.physicsBody.forces[e.id].y-=h)}}]),t}(),yC=function(){function t(e,i,n){Yd(this,t),this.body=e,this.physicsBody=i,this.setOptions(n)}return Kd(t,[{key:"setOptions",value:function(t){this.options=t}},{key:"solve",value:function(){for(var t,e,i,n,o,r,s,a,h,l,d=this.body.edges,c=.5,u=this.physicsBody.physicsEdgeIndices,f=this.physicsBody.physicsNodeIndices,p=this.physicsBody.forces,v=0;v<f.length;v++){var g=f[v];p[g].springFx=0,p[g].springFy=0}for(var y=0;y<u.length;y++)!0===(e=d[u[y]]).connected&&(t=void 0===e.options.length?this.options.springLength:e.options.length,i=e.from.x-e.to.x,n=e.from.y-e.to.y,a=0===(a=Math.sqrt(i*i+n*n))?.01:a,o=i*(s=this.options.springConstant*(t-a)/a),r=n*s,e.to.level!=e.from.level?(void 0!==p[e.toId]&&(p[e.toId].springFx-=o,p[e.toId].springFy-=r),void 0!==p[e.fromId]&&(p[e.fromId].springFx+=o,p[e.fromId].springFy+=r)):(void 0!==p[e.toId]&&(p[e.toId].x-=c*o,p[e.toId].y-=c*r),void 0!==p[e.fromId]&&(p[e.fromId].x+=c*o,p[e.fromId].y+=c*r)));s=1;for(var m=0;m<f.length;m++){var b=f[m];h=Math.min(s,Math.max(-s,p[b].springFx)),l=Math.min(s,Math.max(-s,p[b].springFy)),p[b].x+=h,p[b].y+=l}for(var w=0,k=0,_=0;_<f.length;_++){var x=f[_];w+=p[x].x,k+=p[x].y}for(var E=w/f.length,O=k/f.length,C=0;C<f.length;C++){var S=f[C];p[S].x-=E,p[S].y-=O}}}]),t}(),mC=function(){function t(e,i,n){Yd(this,t),this.body=e,this.physicsBody=i,this.setOptions(n)}return Kd(t,[{key:"setOptions",value:function(t){this.options=t}},{key:"solve",value:function(){for(var t,e,i,n,o=this.body.nodes,r=this.physicsBody.physicsNodeIndices,s=this.physicsBody.forces,a=0;a<r.length;a++){t=-(n=o[r[a]]).x,e=-n.y,i=Math.sqrt(t*t+e*e),this._calculateForces(i,t,e,s,n)}}},{key:"_calculateForces",value:function(t,e,i,n,o){var r=0===t?0:this.options.centralGravity/t;n[o.id].x=e*r,n[o.id].y=i*r}}]),t}();function bC(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var wC=function(t){zk(i,t);var e=bC(i);function i(t,n,o){var r;return Yd(this,i),(r=e.call(this,t,n,o))._rng=jy("FORCE ATLAS 2 BASED REPULSION SOLVER"),r}return Kd(i,[{key:"_calculateForces",value:function(t,e,i,n,o){0===t&&(e=t=.1*this._rng()),this.overlapAvoidanceFactor<1&&n.shape.radius&&(t=Math.max(.1+this.overlapAvoidanceFactor*n.shape.radius,t-n.shape.radius));var r=n.edges.length+1,s=this.options.gravitationalConstant*o.mass*n.options.mass*r/Math.pow(t,2),a=e*s,h=i*s;this.physicsBody.forces[n.id].x+=a,this.physicsBody.forces[n.id].y+=h}}]),i}(fC);function kC(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var _C=function(t){zk(i,t);var e=kC(i);function i(t,n,o){return Yd(this,i),e.call(this,t,n,o)}return Kd(i,[{key:"_calculateForces",value:function(t,e,i,n,o){if(t>0){var r=o.edges.length+1,s=this.options.centralGravity*r*o.options.mass;n[o.id].x=e*s,n[o.id].y=i*s}}}]),i}(mC),xC=function(){function t(e){Yd(this,t),this.body=e,this.physicsBody={physicsNodeIndices:[],physicsEdgeIndices:[],forces:{},velocities:{}},this.physicsEnabled=!0,this.simulationInterval=1e3/60,this.requiresTimeout=!0,this.previousStates={},this.referenceState={},this.freezeCache={},this.renderTimer=void 0,this.adaptiveTimestep=!1,this.adaptiveTimestepEnabled=!1,this.adaptiveCounter=0,this.adaptiveInterval=3,this.stabilized=!1,this.startedStabilization=!1,this.stabilizationIterations=0,this.ready=!1,this.options={},this.defaultOptions={enabled:!0,barnesHut:{theta:.5,gravitationalConstant:-2e3,centralGravity:.3,springLength:95,springConstant:.04,damping:.09,avoidOverlap:0},forceAtlas2Based:{theta:.5,gravitationalConstant:-50,centralGravity:.01,springConstant:.08,springLength:100,damping:.4,avoidOverlap:0},repulsion:{centralGravity:.2,springLength:200,springConstant:.05,nodeDistance:100,damping:.09,avoidOverlap:0},hierarchicalRepulsion:{centralGravity:0,springLength:100,springConstant:.01,nodeDistance:120,damping:.09},maxVelocity:50,minVelocity:.75,solver:"barnesHut",stabilization:{enabled:!0,iterations:1e3,updateInterval:50,onlyDynamicEdges:!1,fit:!0},timestep:.5,adaptiveTimestep:!0,wind:{x:0,y:0}},un(this.options,this.defaultOptions),this.timestep=.5,this.layoutFailed=!1,this.bindEventListeners()}return Kd(t,[{key:"bindEventListeners",value:function(){var t=this;this.body.emitter.on("initPhysics",(function(){t.initPhysics()})),this.body.emitter.on("_layoutFailed",(function(){t.layoutFailed=!0})),this.body.emitter.on("resetPhysics",(function(){t.stopSimulation(),t.ready=!1})),this.body.emitter.on("disablePhysics",(function(){t.physicsEnabled=!1,t.stopSimulation()})),this.body.emitter.on("restorePhysics",(function(){t.setOptions(t.options),!0===t.ready&&t.startSimulation()})),this.body.emitter.on("startSimulation",(function(){!0===t.ready&&t.startSimulation()})),this.body.emitter.on("stopSimulation",(function(){t.stopSimulation()})),this.body.emitter.on("destroy",(function(){t.stopSimulation(!1),t.body.emitter.off()})),this.body.emitter.on("_dataChanged",(function(){t.updatePhysicsData()}))}},{key:"setOptions",value:function(t){if(void 0!==t)if(!1===t)this.options.enabled=!1,this.physicsEnabled=!1,this.stopSimulation();else if(!0===t)this.options.enabled=!0,this.physicsEnabled=!0,this.startSimulation();else{this.physicsEnabled=!0,im(["stabilization"],this.options,t),Sm(this.options,t,"stabilization"),void 0===t.enabled&&(this.options.enabled=!0),!1===this.options.enabled&&(this.physicsEnabled=!1,this.stopSimulation());var e=this.options.wind;e&&(("number"!=typeof e.x||ek(e.x))&&(e.x=0),("number"!=typeof e.y||ek(e.y))&&(e.y=0)),this.timestep=this.options.timestep}this.init()}},{key:"init",value:function(){var t;"forceAtlas2Based"===this.options.solver?(t=this.options.forceAtlas2Based,this.nodesSolver=new wC(this.body,this.physicsBody,t),this.edgesSolver=new gC(this.body,this.physicsBody,t),this.gravitySolver=new _C(this.body,this.physicsBody,t)):"repulsion"===this.options.solver?(t=this.options.repulsion,this.nodesSolver=new pC(this.body,this.physicsBody,t),this.edgesSolver=new gC(this.body,this.physicsBody,t),this.gravitySolver=new mC(this.body,this.physicsBody,t)):"hierarchicalRepulsion"===this.options.solver?(t=this.options.hierarchicalRepulsion,this.nodesSolver=new vC(this.body,this.physicsBody,t),this.edgesSolver=new yC(this.body,this.physicsBody,t),this.gravitySolver=new mC(this.body,this.physicsBody,t)):(t=this.options.barnesHut,this.nodesSolver=new fC(this.body,this.physicsBody,t),this.edgesSolver=new gC(this.body,this.physicsBody,t),this.gravitySolver=new mC(this.body,this.physicsBody,t)),this.modelOptions=t}},{key:"initPhysics",value:function(){!0===this.physicsEnabled&&!0===this.options.enabled?!0===this.options.stabilization.enabled?this.stabilize():(this.stabilized=!1,this.ready=!0,this.body.emitter.emit("fit",{},this.layoutFailed),this.startSimulation()):(this.ready=!0,this.body.emitter.emit("fit"))}},{key:"startSimulation",value:function(){var t;!0===this.physicsEnabled&&!0===this.options.enabled?(this.stabilized=!1,this.adaptiveTimestep=!1,this.body.emitter.emit("_resizeNodes"),void 0===this.viewFunction&&(this.viewFunction=zn(t=this.simulationStep).call(t,this),this.body.emitter.on("initRedraw",this.viewFunction),this.body.emitter.emit("_startRendering"))):this.body.emitter.emit("_redraw")}},{key:"stopSimulation",value:function(){var t=!(arguments.length>0&&void 0!==arguments[0])||arguments[0];this.stabilized=!0,!0===t&&this._emitStabilized(),void 0!==this.viewFunction&&(this.body.emitter.off("initRedraw",this.viewFunction),this.viewFunction=void 0,!0===t&&this.body.emitter.emit("_stopRendering"))}},{key:"simulationStep",value:function(){var t=Eu();this.physicsTick(),(Eu()-t<.4*this.simulationInterval||!0===this.runDoubleSpeed)&&!1===this.stabilized&&(this.physicsTick(),this.runDoubleSpeed=!0),!0===this.stabilized&&this.stopSimulation()}},{key:"_emitStabilized",value:function(){var t=this,e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:this.stabilizationIterations;(this.stabilizationIterations>1||!0===this.startedStabilization)&&Sv((function(){t.body.emitter.emit("stabilized",{iterations:e}),t.startedStabilization=!1,t.stabilizationIterations=0}),0)}},{key:"physicsStep",value:function(){this.gravitySolver.solve(),this.nodesSolver.solve(),this.edgesSolver.solve(),this.moveNodes()}},{key:"adjustTimeStep",value:function(){!0===this._evaluateStepQuality()?this.timestep=1.2*this.timestep:this.timestep/1.2<this.options.timestep?this.timestep=this.options.timestep:(this.adaptiveCounter=-1,this.timestep=Math.max(this.options.timestep,this.timestep/1.2))}},{key:"physicsTick",value:function(){if(this._startStabilizing(),!0!==this.stabilized){if(!0===this.adaptiveTimestep&&!0===this.adaptiveTimestepEnabled)this.adaptiveCounter%this.adaptiveInterval==0?(this.timestep=2*this.timestep,this.physicsStep(),this.revert(),this.timestep=.5*this.timestep,this.physicsStep(),this.physicsStep(),this.adjustTimeStep()):this.physicsStep(),this.adaptiveCounter+=1;else this.timestep=this.options.timestep,this.physicsStep();!0===this.stabilized&&this.revert(),this.stabilizationIterations++}}},{key:"updatePhysicsData",value:function(){this.physicsBody.forces={},this.physicsBody.physicsNodeIndices=[],this.physicsBody.physicsEdgeIndices=[];var t=this.body.nodes,e=this.body.edges;for(var i in t)Object.prototype.hasOwnProperty.call(t,i)&&!0===t[i].options.physics&&this.physicsBody.physicsNodeIndices.push(t[i].id);for(var n in e)Object.prototype.hasOwnProperty.call(e,n)&&!0===e[n].options.physics&&this.physicsBody.physicsEdgeIndices.push(e[n].id);for(var o=0;o<this.physicsBody.physicsNodeIndices.length;o++){var r=this.physicsBody.physicsNodeIndices[o];this.physicsBody.forces[r]={x:0,y:0},void 0===this.physicsBody.velocities[r]&&(this.physicsBody.velocities[r]={x:0,y:0})}for(var s in this.physicsBody.velocities)void 0===t[s]&&delete this.physicsBody.velocities[s]}},{key:"revert",value:function(){var t=bu(this.previousStates),e=this.body.nodes,i=this.physicsBody.velocities;this.referenceState={};for(var n=0;n<t.length;n++){var o=t[n];void 0!==e[o]?!0===e[o].options.physics&&(this.referenceState[o]={positions:{x:e[o].x,y:e[o].y}},i[o].x=this.previousStates[o].vx,i[o].y=this.previousStates[o].vy,e[o].x=this.previousStates[o].x,e[o].y=this.previousStates[o].y):delete this.previousStates[o]}}},{key:"_evaluateStepQuality",value:function(){var t,e,i=this.body.nodes,n=this.referenceState;for(var o in this.referenceState)if(Object.prototype.hasOwnProperty.call(this.referenceState,o)&&void 0!==i[o]&&(t=i[o].x-n[o].positions.x,e=i[o].y-n[o].positions.y,Math.sqrt(Math.pow(t,2)+Math.pow(e,2))>.3))return!1;return!0}},{key:"moveNodes",value:function(){for(var t=this.physicsBody.physicsNodeIndices,e=0,i=0,n=0;n<t.length;n++){var o=t[n],r=this._performStep(o);e=Math.max(e,r),i+=r}this.adaptiveTimestepEnabled=i/t.length<5,this.stabilized=e<this.options.minVelocity}},{key:"calculateComponentVelocity",value:function(t,e,i){t+=(e-this.modelOptions.damping*t)/i*this.timestep;var n=this.options.maxVelocity||1e9;return Math.abs(t)>n&&(t=t>0?n:-n),t}},{key:"_performStep",value:function(t){var e=this.body.nodes[t],i=this.physicsBody.forces[t];this.options.wind&&(i.x+=this.options.wind.x,i.y+=this.options.wind.y);var n=this.physicsBody.velocities[t];return this.previousStates[t]={x:e.x,y:e.y,vx:n.x,vy:n.y},!1===e.options.fixed.x?(n.x=this.calculateComponentVelocity(n.x,i.x,e.options.mass),e.x+=n.x*this.timestep):(i.x=0,n.x=0),!1===e.options.fixed.y?(n.y=this.calculateComponentVelocity(n.y,i.y,e.options.mass),e.y+=n.y*this.timestep):(i.y=0,n.y=0),Math.sqrt(Math.pow(n.x,2)+Math.pow(n.y,2))}},{key:"_freezeNodes",value:function(){var t=this.body.nodes;for(var e in t)if(Object.prototype.hasOwnProperty.call(t,e)&&t[e].x&&t[e].y){var i=t[e].options.fixed;this.freezeCache[e]={x:i.x,y:i.y},i.x=!0,i.y=!0}}},{key:"_restoreFrozenNodes",value:function(){var t=this.body.nodes;for(var e in t)Object.prototype.hasOwnProperty.call(t,e)&&void 0!==this.freezeCache[e]&&(t[e].options.fixed.x=this.freezeCache[e].x,t[e].options.fixed.y=this.freezeCache[e].y);this.freezeCache={}}},{key:"stabilize",value:function(){var t=this,e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:this.options.stabilization.iterations;"number"!=typeof e&&(e=this.options.stabilization.iterations,console.error("The stabilize method needs a numeric amount of iterations. Switching to default: ",e)),0!==this.physicsBody.physicsNodeIndices.length?(this.adaptiveTimestep=this.options.adaptiveTimestep,this.body.emitter.emit("_resizeNodes"),this.stopSimulation(),this.stabilized=!1,this.body.emitter.emit("_blockRedraw"),this.targetIterations=e,!0===this.options.stabilization.onlyDynamicEdges&&this._freezeNodes(),this.stabilizationIterations=0,Sv((function(){return t._stabilizationBatch()}),0)):this.ready=!0}},{key:"_startStabilizing",value:function(){return!0!==this.startedStabilization&&(this.body.emitter.emit("startStabilizing"),this.startedStabilization=!0,!0)}},{key:"_stabilizationBatch",value:function(){var t=this,e=function(){return!1===t.stabilized&&t.stabilizationIterations<t.targetIterations},i=function(){t.body.emitter.emit("stabilizationProgress",{iterations:t.stabilizationIterations,total:t.targetIterations})};this._startStabilizing()&&i();for(var n,o=0;e()&&o<this.options.stabilization.updateInterval;)this.physicsTick(),o++;(i(),e())?Sv(zn(n=this._stabilizationBatch).call(n,this),0):this._finalizeStabilization()}},{key:"_finalizeStabilization",value:function(){this.body.emitter.emit("_allowRedraw"),!0===this.options.stabilization.fit&&this.body.emitter.emit("fit"),!0===this.options.stabilization.onlyDynamicEdges&&this._restoreFrozenNodes(),this.body.emitter.emit("stabilizationIterationsDone"),this.body.emitter.emit("_requestRedraw"),!0===this.stabilized?this._emitStabilized():this.startSimulation(),this.ready=!0}},{key:"_drawForces",value:function(t){for(var e=0;e<this.physicsBody.physicsNodeIndices.length;e++){var i=this.physicsBody.physicsNodeIndices[e],n=this.body.nodes[i],o=this.physicsBody.forces[i],r=Math.sqrt(Math.pow(o.x,2)+Math.pow(o.x,2)),s=Math.min(Math.max(5,r),15),a=3*s,h=km((180-180*Math.min(1,Math.max(0,.03*r)))/360,1,1),l={x:n.x+20*o.x,y:n.y+20*o.y};t.lineWidth=s,t.strokeStyle=h,t.beginPath(),t.moveTo(n.x,n.y),t.lineTo(l.x,l.y),t.stroke();var d=Math.atan2(o.y,o.x);t.fillStyle=h,XO.draw(t,{type:"arrow",point:l,angle:d,length:a}),jv(t).call(t)}}}]),t}(),EC=function(){function t(){Yd(this,t)}return Kd(t,null,[{key:"getRange",value:function(t){var e,i=arguments.length>1&&void 0!==arguments[1]?arguments[1]:[],n=1e9,o=-1e9,r=1e9,s=-1e9;if(i.length>0)for(var a=0;a<i.length;a++)r>(e=t[i[a]]).shape.boundingBox.left&&(r=e.shape.boundingBox.left),s<e.shape.boundingBox.right&&(s=e.shape.boundingBox.right),n>e.shape.boundingBox.top&&(n=e.shape.boundingBox.top),o<e.shape.boundingBox.bottom&&(o=e.shape.boundingBox.bottom);return 1e9===r&&-1e9===s&&1e9===n&&-1e9===o&&(n=0,o=0,r=0,s=0),{minX:r,maxX:s,minY:n,maxY:o}}},{key:"getRangeCore",value:function(t){var e,i=arguments.length>1&&void 0!==arguments[1]?arguments[1]:[],n=1e9,o=-1e9,r=1e9,s=-1e9;if(i.length>0)for(var a=0;a<i.length;a++)r>(e=t[i[a]]).x&&(r=e.x),s<e.x&&(s=e.x),n>e.y&&(n=e.y),o<e.y&&(o=e.y);return 1e9===r&&-1e9===s&&1e9===n&&-1e9===o&&(n=0,o=0,r=0,s=0),{minX:r,maxX:s,minY:n,maxY:o}}},{key:"findCenter",value:function(t){return{x:.5*(t.maxX+t.minX),y:.5*(t.maxY+t.minY)}}},{key:"cloneOptions",value:function(t,e){var i={};return void 0===e||"node"===e?(nm(i,t.options,!0),i.x=t.x,i.y=t.y,i.amountOfConnections=t.edges.length):nm(i,t.options,!0),i}}]),t}();function OC(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var CC=function(t){zk(i,t);var e=OC(i);function i(t,n,o,r,s,a){var h;return Yd(this,i),(h=e.call(this,t,n,o,r,s,a)).isCluster=!0,h.containedNodes={},h.containedEdges={},h}return Kd(i,[{key:"_openChildCluster",value:function(t){var e=this,i=this.body.nodes[t];if(void 0===this.containedNodes[t])throw new Error("node with id: "+t+" not in current cluster");if(!i.isCluster)throw new Error("node with id: "+t+" is not a cluster");delete this.containedNodes[t],hm(i.edges,(function(t){delete e.containedEdges[t.id]})),hm(i.containedNodes,(function(t,i){e.containedNodes[i]=t})),i.containedNodes={},hm(i.containedEdges,(function(t,i){e.containedEdges[i]=t})),i.containedEdges={},hm(i.edges,(function(t){hm(e.edges,(function(i){var n,o,r=Fp(n=i.clusteringEdgeReplacingIds).call(n,t.id);-1!==r&&(hm(t.clusteringEdgeReplacingIds,(function(t){i.clusteringEdgeReplacingIds.push(t),e.body.edges[t].edgeReplacedById=i.id})),ff(o=i.clusteringEdgeReplacingIds).call(o,r,1))}))})),i.edges=[]}}]),i}(fO),SC=function(){function t(e){var i=this;Yd(this,t),this.body=e,this.clusteredNodes={},this.clusteredEdges={},this.options={},this.defaultOptions={},un(this.options,this.defaultOptions),this.body.emitter.on("_resetData",(function(){i.clusteredNodes={},i.clusteredEdges={}}))}return Kd(t,[{key:"clusterByHubsize",value:function(t,e){void 0===t?t=this._getHubSize():"object"===Qc(t)&&(e=this._checkOptions(t),t=this._getHubSize());for(var i=[],n=0;n<this.body.nodeIndices.length;n++){var o=this.body.nodes[this.body.nodeIndices[n]];o.edges.length>=t&&i.push(o.id)}for(var r=0;r<i.length;r++)this.clusterByConnection(i[r],e,!0);this.body.emitter.emit("_dataChanged")}},{key:"cluster",value:function(){var t=this,e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},i=!(arguments.length>1&&void 0!==arguments[1])||arguments[1];if(void 0===e.joinCondition)throw new Error("Cannot call clusterByNodeData without a joinCondition function in the options.");e=this._checkOptions(e);var n={},o={};hm(this.body.nodes,(function(i,r){i.options&&!0===e.joinCondition(i.options)&&(n[r]=i,hm(i.edges,(function(e){void 0===t.clusteredEdges[e.id]&&(o[e.id]=e)})))})),this._cluster(n,o,e,i)}},{key:"clusterByEdgeCount",value:function(t,e){var i=this,n=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];e=this._checkOptions(e);for(var o,r,s,a=[],h={},l=function(n){var l={},d={},c=i.body.nodeIndices[n],u=i.body.nodes[c];if(void 0===h[c]){s=0,r=[];for(var f=0;f<u.edges.length;f++)o=u.edges[f],void 0===i.clusteredEdges[o.id]&&(o.toId!==o.fromId&&s++,r.push(o));if(s===t){for(var p=function(t){if(void 0===e.joinCondition||null===e.joinCondition)return!0;var i=EC.cloneOptions(t);return e.joinCondition(i)},v=!0,g=0;g<r.length;g++){o=r[g];var y=i._getConnectedId(o,c);if(!p(u)){v=!1;break}d[o.id]=o,l[c]=u,l[y]=i.body.nodes[y],h[c]=!0}if(bu(l).length>0&&bu(d).length>0&&!0===v){var m=function(){for(var t=0;t<a.length;++t)for(var e in l)if(void 0!==a[t].nodes[e])return a[t]}();if(void 0!==m){for(var b in l)void 0===m.nodes[b]&&(m.nodes[b]=l[b]);for(var w in d)void 0===m.edges[w]&&(m.edges[w]=d[w])}else a.push({nodes:l,edges:d})}}}},d=0;d<this.body.nodeIndices.length;d++)l(d);for(var c=0;c<a.length;c++)this._cluster(a[c].nodes,a[c].edges,e,!1);!0===n&&this.body.emitter.emit("_dataChanged")}},{key:"clusterOutliers",value:function(t){var e=!(arguments.length>1&&void 0!==arguments[1])||arguments[1];this.clusterByEdgeCount(1,t,e)}},{key:"clusterBridges",value:function(t){var e=!(arguments.length>1&&void 0!==arguments[1])||arguments[1];this.clusterByEdgeCount(2,t,e)}},{key:"clusterByConnection",value:function(t,e){var i,n=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(void 0===t)throw new Error("No nodeId supplied to clusterByConnection!");if(void 0===this.body.nodes[t])throw new Error("The nodeId given to clusterByConnection does not exist!");var o=this.body.nodes[t];void 0===(e=this._checkOptions(e,o)).clusterNodeProperties.x&&(e.clusterNodeProperties.x=o.x),void 0===e.clusterNodeProperties.y&&(e.clusterNodeProperties.y=o.y),void 0===e.clusterNodeProperties.fixed&&(e.clusterNodeProperties.fixed={},e.clusterNodeProperties.fixed.x=o.options.fixed.x,e.clusterNodeProperties.fixed.y=o.options.fixed.y);var r={},s={},a=o.id,h=EC.cloneOptions(o);r[a]=o;for(var l=0;l<o.edges.length;l++){var d=o.edges[l];if(void 0===this.clusteredEdges[d.id]){var c=this._getConnectedId(d,a);if(void 0===this.clusteredNodes[c])if(c!==a)if(void 0===e.joinCondition)s[d.id]=d,r[c]=this.body.nodes[c];else{var u=EC.cloneOptions(this.body.nodes[c]);!0===e.joinCondition(h,u)&&(s[d.id]=d,r[c]=this.body.nodes[c])}else s[d.id]=d}}var f=gu(i=bu(r)).call(i,(function(t){return r[t].id}));for(var p in r)if(Object.prototype.hasOwnProperty.call(r,p))for(var v=r[p],g=0;g<v.edges.length;g++){var y=v.edges[g];Fp(f).call(f,this._getConnectedId(y,v.id))>-1&&(s[y.id]=y)}this._cluster(r,s,e,n)}},{key:"_createClusterEdges",value:function(t,e,i,n){for(var o,r,s,a,h,l,d=bu(t),c=[],u=0;u<d.length;u++){s=t[r=d[u]];for(var f=0;f<s.edges.length;f++)o=s.edges[f],void 0===this.clusteredEdges[o.id]&&(o.toId==o.fromId?e[o.id]=o:o.toId==r?(a=i.id,l=h=o.fromId):(a=o.toId,h=i.id,l=a),void 0===t[l]&&c.push({edge:o,fromId:h,toId:a}))}for(var p=[],v=function(t){for(var e=0;e<p.length;e++){var i=p[e],n=t.fromId===i.fromId&&t.toId===i.toId,o=t.fromId===i.toId&&t.toId===i.fromId;if(n||o)return i}return null},g=0;g<c.length;g++){var y=c[g],m=y.edge,b=v(y);null===b?(b=this._createClusteredEdge(y.fromId,y.toId,m,n),p.push(b)):b.clusteringEdgeReplacingIds.push(m.id),this.body.edges[m.id].edgeReplacedById=b.id,this._backupEdgeOptions(m),m.setOptions({physics:!1})}}},{key:"_checkOptions",value:function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};return void 0===t.clusterEdgeProperties&&(t.clusterEdgeProperties={}),void 0===t.clusterNodeProperties&&(t.clusterNodeProperties={}),t}},{key:"_cluster",value:function(t,e,i){var n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3],o=[];for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&void 0!==this.clusteredNodes[r]&&o.push(r);for(var s=0;s<o.length;++s)delete t[o[s]];if(0!=bu(t).length&&(1!=bu(t).length||1==i.clusterNodeProperties.allowSingleNodeCluster)){var a=nm({},i.clusterNodeProperties);if(void 0!==i.processProperties){var h=[];for(var l in t)if(Object.prototype.hasOwnProperty.call(t,l)){var d=EC.cloneOptions(t[l]);h.push(d)}var c=[];for(var u in e)if(Object.prototype.hasOwnProperty.call(e,u)&&"clusterEdge:"!==u.substr(0,12)){var f=EC.cloneOptions(e[u],"edge");c.push(f)}if(!(a=i.processProperties(a,h,c)))throw new Error("The processProperties function does not return properties!")}void 0===a.id&&(a.id="cluster:"+Ax());var p=a.id;void 0===a.label&&(a.label="cluster");var v=void 0;void 0===a.x&&(v=this._getClusterPosition(t),a.x=v.x),void 0===a.y&&(void 0===v&&(v=this._getClusterPosition(t)),a.y=v.y),a.id=p;var g=this.body.functions.createNode(a,CC);g.containedNodes=t,g.containedEdges=e,g.clusterEdgeProperties=i.clusterEdgeProperties,this.body.nodes[a.id]=g,this._clusterEdges(t,e,a,i.clusterEdgeProperties),a.id=void 0,!0===n&&this.body.emitter.emit("_dataChanged")}}},{key:"_backupEdgeOptions",value:function(t){void 0===this.clusteredEdges[t.id]&&(this.clusteredEdges[t.id]={physics:t.options.physics})}},{key:"_restoreEdge",value:function(t){var e=this.clusteredEdges[t.id];void 0!==e&&(t.setOptions({physics:e.physics}),delete this.clusteredEdges[t.id])}},{key:"isCluster",value:function(t){return void 0!==this.body.nodes[t]?!0===this.body.nodes[t].isCluster:(console.error("Node does not exist."),!1)}},{key:"_getClusterPosition",value:function(t){for(var e,i=bu(t),n=t[i[0]].x,o=t[i[0]].x,r=t[i[0]].y,s=t[i[0]].y,a=1;a<i.length;a++)n=(e=t[i[a]]).x<n?e.x:n,o=e.x>o?e.x:o,r=e.y<r?e.y:r,s=e.y>s?e.y:s;return{x:.5*(n+o),y:.5*(r+s)}}},{key:"openCluster",value:function(t,e){var i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(void 0===t)throw new Error("No clusterNodeId supplied to openCluster.");var n=this.body.nodes[t];if(void 0===n)throw new Error("The clusterNodeId supplied to openCluster does not exist.");if(!0!==n.isCluster||void 0===n.containedNodes||void 0===n.containedEdges)throw new Error("The node:"+t+" is not a valid cluster.");var o=this.findNode(t),r=Fp(o).call(o,t)-1;if(r>=0){var s=o[r],a=this.body.nodes[s];return a._openChildCluster(t),delete this.body.nodes[t],void(!0===i&&this.body.emitter.emit("_dataChanged"))}var h=n.containedNodes,l=n.containedEdges;if(void 0!==e&&void 0!==e.releaseFunction&&"function"==typeof e.releaseFunction){var d={},c={x:n.x,y:n.y};for(var u in h)if(Object.prototype.hasOwnProperty.call(h,u)){var f=this.body.nodes[u];d[u]={x:f.x,y:f.y}}var p=e.releaseFunction(c,d);for(var v in h)if(Object.prototype.hasOwnProperty.call(h,v)){var g=this.body.nodes[v];void 0!==p[v]&&(g.x=void 0===p[v].x?n.x:p[v].x,g.y=void 0===p[v].y?n.y:p[v].y)}}else hm(h,(function(t){!1===t.options.fixed.x&&(t.x=n.x),!1===t.options.fixed.y&&(t.y=n.y)}));for(var y in h)if(Object.prototype.hasOwnProperty.call(h,y)){var m=this.body.nodes[y];m.vx=n.vx,m.vy=n.vy,m.setOptions({physics:!0}),delete this.clusteredNodes[y]}for(var b=[],w=0;w<n.edges.length;w++)b.push(n.edges[w]);for(var k=0;k<b.length;k++){for(var _=b[k],x=this._getConnectedId(_,t),E=this.clusteredNodes[x],O=0;O<_.clusteringEdgeReplacingIds.length;O++){var C=_.clusteringEdgeReplacingIds[O],S=this.body.edges[C];if(void 0!==S)if(void 0!==E){var T=this.body.nodes[E.clusterId];T.containedEdges[S.id]=S,delete l[S.id];var M=S.fromId,P=S.toId;S.toId==x?P=E.clusterId:M=E.clusterId,this._createClusteredEdge(M,P,S,T.clusterEdgeProperties,{hidden:!1,physics:!0})}else this._restoreEdge(S)}_.remove()}for(var D in l)Object.prototype.hasOwnProperty.call(l,D)&&this._restoreEdge(l[D]);delete this.body.nodes[t],!0===i&&this.body.emitter.emit("_dataChanged")}},{key:"getNodesInCluster",value:function(t){var e=[];if(!0===this.isCluster(t)){var i=this.body.nodes[t].containedNodes;for(var n in i)Object.prototype.hasOwnProperty.call(i,n)&&e.push(this.body.nodes[n].id)}return e}},{key:"findNode",value:function(t){for(var e,i=[],n=0;void 0!==this.clusteredNodes[t]&&n<100;){if(void 0===(e=this.body.nodes[t]))return[];i.push(e.id),t=this.clusteredNodes[t].clusterId,n++}return void 0===(e=this.body.nodes[t])?[]:(i.push(e.id),Yu(i).call(i),i)}},{key:"updateClusteredNode",value:function(t,e){if(void 0===t)throw new Error("No clusteredNodeId supplied to updateClusteredNode.");if(void 0===e)throw new Error("No newOptions supplied to updateClusteredNode.");if(void 0===this.body.nodes[t])throw new Error("The clusteredNodeId supplied to updateClusteredNode does not exist.");this.body.nodes[t].setOptions(e),this.body.emitter.emit("_dataChanged")}},{key:"updateEdge",value:function(t,e){if(void 0===t)throw new Error("No startEdgeId supplied to updateEdge.");if(void 0===e)throw new Error("No newOptions supplied to updateEdge.");if(void 0===this.body.edges[t])throw new Error("The startEdgeId supplied to updateEdge does not exist.");for(var i=this.getClusteredEdges(t),n=0;n<i.length;n++){this.body.edges[i[n]].setOptions(e)}this.body.emitter.emit("_dataChanged")}},{key:"getClusteredEdges",value:function(t){for(var e=[],i=0;void 0!==t&&void 0!==this.body.edges[t]&&i<100;)e.push(this.body.edges[t].id),t=this.body.edges[t].edgeReplacedById,i++;return Yu(e).call(e),e}},{key:"getBaseEdge",value:function(t){return this.getBaseEdges(t)[0]}},{key:"getBaseEdges",value:function(t){for(var e=[t],i=[],n=[],o=0;e.length>0&&o<100;){var r=e.pop();if(void 0!==r){var s=this.body.edges[r];if(void 0!==s){o++;var a=s.clusteringEdgeReplacingIds;if(void 0===a)n.push(r);else for(var h=0;h<a.length;++h){var l=a[h];-1===Fp(e).call(e,a)&&-1===Fp(i).call(i,a)&&e.push(l)}i.push(r)}}}return n}},{key:"_getConnectedId",value:function(t,e){return t.toId!=e?t.toId:(t.fromId,t.fromId)}},{key:"_getHubSize",value:function(){for(var t=0,e=0,i=0,n=0,o=0;o<this.body.nodeIndices.length;o++){var r=this.body.nodes[this.body.nodeIndices[o]];r.edges.length>n&&(n=r.edges.length),t+=r.edges.length,e+=Math.pow(r.edges.length,2),i+=1}t/=i;var s=(e/=i)-Math.pow(t,2),a=Math.sqrt(s),h=Math.floor(t+2*a);return h>n&&(h=n),h}},{key:"_createClusteredEdge",value:function(t,e,i,n,o){var r=EC.cloneOptions(i,"edge");nm(r,n),r.from=t,r.to=e,r.id="clusterEdge:"+Ax(),void 0!==o&&nm(r,o);var s=this.body.functions.createEdge(r);return s.clusteringEdgeReplacingIds=[i.id],s.connect(),this.body.edges[s.id]=s,s}},{key:"_clusterEdges",value:function(t,e,i,n){if(e instanceof cC){var o=e,r={};r[o.id]=o,e=r}if(t instanceof fO){var s=t,a={};a[s.id]=s,t=a}if(null==i)throw new Error("_clusterEdges: parameter clusterNode required");for(var h in void 0===n&&(n=i.clusterEdgeProperties),this._createClusterEdges(t,e,i,n),e)if(Object.prototype.hasOwnProperty.call(e,h)&&void 0!==this.body.edges[h]){var l=this.body.edges[h];this._backupEdgeOptions(l),l.setOptions({physics:!1})}for(var d in t)Object.prototype.hasOwnProperty.call(t,d)&&(this.clusteredNodes[d]={clusterId:i.id,node:this.body.nodes[d]},this.body.nodes[d].setOptions({physics:!1}))}},{key:"_getClusterNodeForNode",value:function(t){if(void 0!==t){var e=this.clusteredNodes[t];if(void 0!==e){var i=e.clusterId;if(void 0!==i)return this.body.nodes[i]}}}},{key:"_filter",value:function(t,e){var i=[];return hm(t,(function(t){e(t)&&i.push(t)})),i}},{key:"_updateState",value:function(){var t,e=this,i=[],n={},o=function(t){hm(e.body.nodes,(function(e){!0===e.isCluster&&t(e)}))};for(t in this.clusteredNodes){if(Object.prototype.hasOwnProperty.call(this.clusteredNodes,t))void 0===this.body.nodes[t]&&i.push(t)}o((function(t){for(var e=0;e<i.length;e++)delete t.containedNodes[i[e]]}));for(var r=0;r<i.length;r++)delete this.clusteredNodes[i[r]];hm(this.clusteredEdges,(function(t){var i=e.body.edges[t];void 0!==i&&i.endPointsValid()||(n[t]=t)})),o((function(t){hm(t.containedEdges,(function(t,e){t.endPointsValid()||n[e]||(n[e]=e)}))})),hm(this.body.edges,(function(t,i){var o=!0,r=t.clusteringEdgeReplacingIds;if(void 0!==r){var s=0;hm(r,(function(t){var i=e.body.edges[t];void 0!==i&&i.endPointsValid()&&(s+=1)})),o=s>0}t.endPointsValid()&&o||(n[i]=i)})),o((function(t){hm(n,(function(i){delete t.containedEdges[i],hm(t.edges,(function(o,r){o.id!==i?o.clusteringEdgeReplacingIds=e._filter(o.clusteringEdgeReplacingIds,(function(t){return!n[t]})):t.edges[r]=null})),t.edges=e._filter(t.edges,(function(t){return null!==t}))}))})),hm(n,(function(t){delete e.clusteredEdges[t]})),hm(n,(function(t){delete e.body.edges[t]})),hm(bu(this.body.edges),(function(t){var i=e.body.edges[t],n=e._isClusteredNode(i.fromId)||e._isClusteredNode(i.toId);if(n!==e._isClusteredEdge(i.id))if(n){var o=e._getClusterNodeForNode(i.fromId);void 0!==o&&e._clusterEdges(e.body.nodes[i.fromId],i,o);var r=e._getClusterNodeForNode(i.toId);void 0!==r&&e._clusterEdges(e.body.nodes[i.toId],i,r)}else delete e._clusterEdges[t],e._restoreEdge(i)}));for(var s=!1,a=!0,h=function(){var t=[];o((function(e){var i=bu(e.containedNodes).length,n=!0===e.options.allowSingleNodeCluster;(n&&i<1||!n&&i<2)&&t.push(e.id)}));for(var i=0;i<t.length;++i)e.openCluster(t[i],{},!1);a=t.length>0,s=s||a};a;)h();s&&this._updateState()}},{key:"_isClusteredNode",value:function(t){return void 0!==this.clusteredNodes[t]}},{key:"_isClusteredEdge",value:function(t){return void 0!==this.clusteredEdges[t]}}]),t}();function TC(t,e){var i=void 0!==tu&&ih(t)||t["@@iterator"];if(!i){if(lu(t)||(i=function(t,e){var i;if(!t)return;if("string"==typeof t)return MC(t,e);var n=au(i=Object.prototype.toString.call(t)).call(i,8,-1);"Object"===n&&t.constructor&&(n=t.constructor.name);if("Map"===n||"Set"===n)return ja(t);if("Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n))return MC(t,e)}(t))||e&&t&&"number"==typeof t.length){i&&(t=i);var n=0,o=function(){};return{s:o,n:function(){return n>=t.length?{done:!0}:{done:!1,value:t[n++]}},e:function(t){throw t},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var r,s=!0,a=!1;return{s:function(){i=i.call(t)},n:function(){var t=i.next();return s=t.done,t},e:function(t){a=!0,r=t},f:function(){try{s||null==i.return||i.return()}finally{if(a)throw r}}}}function MC(t,e){(null==e||e>t.length)&&(e=t.length);for(var i=0,n=new Array(e);i<e;i++)n[i]=t[i];return n}var PC=function(){function t(e,i){var n;Yd(this,t),void 0!==window&&(n=window.requestAnimationFrame||window.mozRequestAnimationFrame||window.webkitRequestAnimationFrame||window.msRequestAnimationFrame),window.requestAnimationFrame=void 0===n?function(t){t()}:n,this.body=e,this.canvas=i,this.redrawRequested=!1,this.renderTimer=void 0,this.requiresTimeout=!0,this.renderingActive=!1,this.renderRequests=0,this.allowRedraw=!0,this.dragging=!1,this.zooming=!1,this.options={},this.defaultOptions={hideEdgesOnDrag:!1,hideEdgesOnZoom:!1,hideNodesOnDrag:!1},un(this.options,this.defaultOptions),this._determineBrowserMethod(),this.bindEventListeners()}return Kd(t,[{key:"bindEventListeners",value:function(){var t,e=this;this.body.emitter.on("dragStart",(function(){e.dragging=!0})),this.body.emitter.on("dragEnd",(function(){e.dragging=!1})),this.body.emitter.on("zoom",(function(){e.zooming=!0,window.clearTimeout(e.zoomTimeoutId),e.zoomTimeoutId=Sv((function(){var t;e.zooming=!1,zn(t=e._requestRedraw).call(t,e)()}),250)})),this.body.emitter.on("_resizeNodes",(function(){e._resizeNodes()})),this.body.emitter.on("_redraw",(function(){!1===e.renderingActive&&e._redraw()})),this.body.emitter.on("_blockRedraw",(function(){e.allowRedraw=!1})),this.body.emitter.on("_allowRedraw",(function(){e.allowRedraw=!0,e.redrawRequested=!1})),this.body.emitter.on("_requestRedraw",zn(t=this._requestRedraw).call(t,this)),this.body.emitter.on("_startRendering",(function(){e.renderRequests+=1,e.renderingActive=!0,e._startRendering()})),this.body.emitter.on("_stopRendering",(function(){e.renderRequests-=1,e.renderingActive=e.renderRequests>0,e.renderTimer=void 0})),this.body.emitter.on("destroy",(function(){e.renderRequests=0,e.allowRedraw=!1,e.renderingActive=!1,!0===e.requiresTimeout?clearTimeout(e.renderTimer):window.cancelAnimationFrame(e.renderTimer),e.body.emitter.off()}))}},{key:"setOptions",value:function(t){if(void 0!==t){em(["hideEdgesOnDrag","hideEdgesOnZoom","hideNodesOnDrag"],this.options,t)}}},{key:"_requestNextFrame",value:function(t,e){if("undefined"!=typeof window){var i,n=window;return!0===this.requiresTimeout?i=Sv(t,e):n.requestAnimationFrame&&(i=n.requestAnimationFrame(t)),i}}},{key:"_startRendering",value:function(){var t;!0===this.renderingActive&&(void 0===this.renderTimer&&(this.renderTimer=this._requestNextFrame(zn(t=this._renderStep).call(t,this),this.simulationInterval)))}},{key:"_renderStep",value:function(){!0===this.renderingActive&&(this.renderTimer=void 0,!0===this.requiresTimeout&&this._startRendering(),this._redraw(),!1===this.requiresTimeout&&this._startRendering())}},{key:"redraw",value:function(){this.body.emitter.emit("setSize"),this._redraw()}},{key:"_requestRedraw",value:function(){var t=this;!0!==this.redrawRequested&&!1===this.renderingActive&&!0===this.allowRedraw&&(this.redrawRequested=!0,this._requestNextFrame((function(){t._redraw(!1)}),0))}},{key:"_redraw",value:function(){var t=arguments.length>0&&void 0!==arguments[0]&&arguments[0];if(!0===this.allowRedraw){this.body.emitter.emit("initRedraw"),this.redrawRequested=!1;var e={drawExternalLabels:null};0!==this.canvas.frame.canvas.width&&0!==this.canvas.frame.canvas.height||this.canvas.setSize(),this.canvas.setTransform();var i=this.canvas.getContext(),n=this.canvas.frame.canvas.clientWidth,o=this.canvas.frame.canvas.clientHeight;if(i.clearRect(0,0,n,o),0===this.canvas.frame.clientWidth)return;if(i.save(),i.translate(this.body.view.translation.x,this.body.view.translation.y),i.scale(this.body.view.scale,this.body.view.scale),i.beginPath(),this.body.emitter.emit("beforeDrawing",i),i.closePath(),!1===t&&(!1===this.dragging||!0===this.dragging&&!1===this.options.hideEdgesOnDrag)&&(!1===this.zooming||!0===this.zooming&&!1===this.options.hideEdgesOnZoom)&&this._drawEdges(i),!1===this.dragging||!0===this.dragging&&!1===this.options.hideNodesOnDrag){var r=this._drawNodes(i,t),s=r.drawExternalLabels;e.drawExternalLabels=s}!1===t&&(!1===this.dragging||!0===this.dragging&&!1===this.options.hideEdgesOnDrag)&&(!1===this.zooming||!0===this.zooming&&!1===this.options.hideEdgesOnZoom)&&this._drawArrows(i),null!=e.drawExternalLabels&&e.drawExternalLabels(),!1===t&&this._drawSelectionBox(i),i.beginPath(),this.body.emitter.emit("afterDrawing",i),i.closePath(),i.restore(),!0===t&&i.clearRect(0,0,n,o)}}},{key:"_resizeNodes",value:function(){this.canvas.setTransform();var t=this.canvas.getContext();t.save(),t.translate(this.body.view.translation.x,this.body.view.translation.y),t.scale(this.body.view.scale,this.body.view.scale);var e,i=this.body.nodes;for(var n in i)Object.prototype.hasOwnProperty.call(i,n)&&((e=i[n]).resize(t),e.updateBoundingBox(t,e.selected));t.restore()}},{key:"_drawNodes",value:function(t){for(var e,i,n=arguments.length>1&&void 0!==arguments[1]&&arguments[1],o=this.body.nodes,r=this.body.nodeIndices,s=[],a=[],h=20,l=this.canvas.DOMtoCanvas({x:-h,y:-h}),d=this.canvas.DOMtoCanvas({x:this.canvas.frame.canvas.clientWidth+h,y:this.canvas.frame.canvas.clientHeight+h}),c={top:l.y,left:l.x,bottom:d.y,right:d.x},u=[],f=0;f<r.length;f++)if((e=o[r[f]]).hover)a.push(r[f]);else if(e.isSelected())s.push(r[f]);else if(!0===n){var p=e.draw(t);null!=p.drawExternalLabel&&u.push(p.drawExternalLabel)}else if(!0===e.isBoundingBoxOverlappingWith(c)){var v=e.draw(t);null!=v.drawExternalLabel&&u.push(v.drawExternalLabel)}else e.updateBoundingBox(t,e.selected);var g=s.length,y=a.length;for(i=0;i<g;i++){var m=(e=o[s[i]]).draw(t);null!=m.drawExternalLabel&&u.push(m.drawExternalLabel)}for(i=0;i<y;i++){var b=(e=o[a[i]]).draw(t);null!=b.drawExternalLabel&&u.push(b.drawExternalLabel)}return{drawExternalLabels:function(){var t,e=TC(u);try{for(e.s();!(t=e.n()).done;){(0,t.value)()}}catch(t){e.e(t)}finally{e.f()}}}}},{key:"_drawEdges",value:function(t){for(var e=this.body.edges,i=this.body.edgeIndices,n=0;n<i.length;n++){var o=e[i[n]];!0===o.connected&&o.draw(t)}}},{key:"_drawArrows",value:function(t){for(var e=this.body.edges,i=this.body.edgeIndices,n=0;n<i.length;n++){var o=e[i[n]];!0===o.connected&&o.drawArrows(t)}}},{key:"_determineBrowserMethod",value:function(){if("undefined"!=typeof window){var t=navigator.userAgent.toLowerCase();this.requiresTimeout=!1,(-1!=Fp(t).call(t,"msie 9.0")||-1!=Fp(t).call(t,"safari")&&Fp(t).call(t,"chrome")<=-1)&&(this.requiresTimeout=!0)}else this.requiresTimeout=!0}},{key:"_drawSelectionBox",value:function(t){if(this.body.selectionBox.show){t.beginPath();var e=this.body.selectionBox.position.end.x-this.body.selectionBox.position.start.x,i=this.body.selectionBox.position.end.y-this.body.selectionBox.position.start.y;t.rect(this.body.selectionBox.position.start.x,this.body.selectionBox.position.start.y,e,i),t.fillStyle="rgba(151, 194, 252, 0.2)",t.fillRect(this.body.selectionBox.position.start.x,this.body.selectionBox.position.start.y,e,i),t.strokeStyle="rgba(151, 194, 252, 1)",t.stroke()}else t.closePath()}}]),t}(),DC=X.setInterval;function IC(t,e){e.inputHandler=function(t){t.isFirst&&e(t)},t.on("hammer.input",e.inputHandler)}function BC(t,e){return e.inputHandler=function(t){t.isFinal&&e(t)},t.on("hammer.input",e.inputHandler)}var zC=function(){function t(e){Yd(this,t),this.body=e,this.pixelRatio=1,this.cameraState={},this.initialized=!1,this.canvasViewCenter={},this._cleanupCallbacks=[],this.options={},this.defaultOptions={autoResize:!0,height:"100%",width:"100%"},un(this.options,this.defaultOptions),this.bindEventListeners()}return Kd(t,[{key:"bindEventListeners",value:function(){var t,e=this;this.body.emitter.once("resize",(function(t){0!==t.width&&(e.body.view.translation.x=.5*t.width),0!==t.height&&(e.body.view.translation.y=.5*t.height)})),this.body.emitter.on("setSize",zn(t=this.setSize).call(t,this)),this.body.emitter.on("destroy",(function(){e.hammerFrame.destroy(),e.hammer.destroy(),e._cleanUp()}))}},{key:"setOptions",value:function(t){var e=this;if(void 0!==t){em(["width","height","autoResize"],this.options,t)}if(this._cleanUp(),!0===this.options.autoResize){var i;if(window.ResizeObserver){var n=new ResizeObserver((function(){!0===e.setSize()&&e.body.emitter.emit("_requestRedraw")})),o=this.frame;n.observe(o),this._cleanupCallbacks.push((function(){n.unobserve(o)}))}else{var r=DC((function(){!0===e.setSize()&&e.body.emitter.emit("_requestRedraw")}),1e3);this._cleanupCallbacks.push((function(){clearInterval(r)}))}var s=zn(i=this._onResize).call(i,this);dm(window,"resize",s),this._cleanupCallbacks.push((function(){cm(window,"resize",s)}))}}},{key:"_cleanUp",value:function(){var t,e,i;Fu(t=Yu(e=ff(i=this._cleanupCallbacks).call(i,0)).call(e)).call(t,(function(t){try{t()}catch(t){console.error(t)}}))}},{key:"_onResize",value:function(){this.setSize(),this.body.emitter.emit("_redraw")}},{key:"_getCameraState",value:function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:this.pixelRatio;!0===this.initialized&&(this.cameraState.previousWidth=this.frame.canvas.width/t,this.cameraState.previousHeight=this.frame.canvas.height/t,this.cameraState.scale=this.body.view.scale,this.cameraState.position=this.DOMtoCanvas({x:.5*this.frame.canvas.width/t,y:.5*this.frame.canvas.height/t}))}},{key:"_setCameraState",value:function(){if(void 0!==this.cameraState.scale&&0!==this.frame.canvas.clientWidth&&0!==this.frame.canvas.clientHeight&&0!==this.pixelRatio&&this.cameraState.previousWidth>0&&this.cameraState.previousHeight>0){var t=this.frame.canvas.width/this.pixelRatio/this.cameraState.previousWidth,e=this.frame.canvas.height/this.pixelRatio/this.cameraState.previousHeight,i=this.cameraState.scale;1!=t&&1!=e?i=.5*this.cameraState.scale*(t+e):1!=t?i=this.cameraState.scale*t:1!=e&&(i=this.cameraState.scale*e),this.body.view.scale=i;var n=this.DOMtoCanvas({x:.5*this.frame.canvas.clientWidth,y:.5*this.frame.canvas.clientHeight}),o={x:n.x-this.cameraState.position.x,y:n.y-this.cameraState.position.y};this.body.view.translation.x+=o.x*this.body.view.scale,this.body.view.translation.y+=o.y*this.body.view.scale}}},{key:"_prepareValue",value:function(t){if("number"==typeof t)return t+"px";if("string"==typeof t){if(-1!==Fp(t).call(t,"%")||-1!==Fp(t).call(t,"px"))return t;if(-1===Fp(t).call(t,"%"))return t+"px"}throw new Error("Could not use the value supplied for width or height:"+t)}},{key:"_create",value:function(){for(;this.body.container.hasChildNodes();)this.body.container.removeChild(this.body.container.firstChild);if(this.frame=document.createElement("div"),this.frame.className="vis-network",this.frame.style.position="relative",this.frame.style.overflow="hidden",this.frame.tabIndex=0,this.frame.canvas=document.createElement("canvas"),this.frame.canvas.style.position="relative",this.frame.appendChild(this.frame.canvas),this.frame.canvas.getContext)this._setPixelRatio(),this.setTransform();else{var t=document.createElement("DIV");t.style.color="red",t.style.fontWeight="bold",t.style.padding="10px",t.innerText="Error: your browser does not support HTML canvas",this.frame.canvas.appendChild(t)}this.body.container.appendChild(this.frame),this.body.view.scale=1,this.body.view.translation={x:.5*this.frame.canvas.clientWidth,y:.5*this.frame.canvas.clientHeight},this._bindHammer()}},{key:"_bindHammer",value:function(){var t=this;void 0!==this.hammer&&this.hammer.destroy(),this.drag={},this.pinch={},this.hammer=new Wm(this.frame.canvas),this.hammer.get("pinch").set({enable:!0}),this.hammer.get("pan").set({threshold:5,direction:Wm.DIRECTION_ALL}),IC(this.hammer,(function(e){t.body.eventListeners.onTouch(e)})),this.hammer.on("tap",(function(e){t.body.eventListeners.onTap(e)})),this.hammer.on("doubletap",(function(e){t.body.eventListeners.onDoubleTap(e)})),this.hammer.on("press",(function(e){t.body.eventListeners.onHold(e)})),this.hammer.on("panstart",(function(e){t.body.eventListeners.onDragStart(e)})),this.hammer.on("panmove",(function(e){t.body.eventListeners.onDrag(e)})),this.hammer.on("panend",(function(e){t.body.eventListeners.onDragEnd(e)})),this.hammer.on("pinch",(function(e){t.body.eventListeners.onPinch(e)})),this.frame.canvas.addEventListener("wheel",(function(e){t.body.eventListeners.onMouseWheel(e)})),this.frame.canvas.addEventListener("mousemove",(function(e){t.body.eventListeners.onMouseMove(e)})),this.frame.canvas.addEventListener("contextmenu",(function(e){t.body.eventListeners.onContext(e)})),this.hammerFrame=new Wm(this.frame),BC(this.hammerFrame,(function(e){t.body.eventListeners.onRelease(e)}))}},{key:"setSize",value:function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:this.options.width,e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:this.options.height;t=this._prepareValue(t),e=this._prepareValue(e);var i=!1,n=this.frame.canvas.width,o=this.frame.canvas.height,r=this.pixelRatio;if(this._setPixelRatio(),t!=this.options.width||e!=this.options.height||this.frame.style.width!=t||this.frame.style.height!=e)this._getCameraState(r),this.frame.style.width=t,this.frame.style.height=e,this.frame.canvas.style.width="100%",this.frame.canvas.style.height="100%",this.frame.canvas.width=Math.round(this.frame.canvas.clientWidth*this.pixelRatio),this.frame.canvas.height=Math.round(this.frame.canvas.clientHeight*this.pixelRatio),this.options.width=t,this.options.height=e,this.canvasViewCenter={x:.5*this.frame.clientWidth,y:.5*this.frame.clientHeight},i=!0;else{var s=Math.round(this.frame.canvas.clientWidth*this.pixelRatio),a=Math.round(this.frame.canvas.clientHeight*this.pixelRatio);this.frame.canvas.width===s&&this.frame.canvas.height===a||this._getCameraState(r),this.frame.canvas.width!==s&&(this.frame.canvas.width=s,i=!0),this.frame.canvas.height!==a&&(this.frame.canvas.height=a,i=!0)}return!0===i&&(this.body.emitter.emit("resize",{width:Math.round(this.frame.canvas.width/this.pixelRatio),height:Math.round(this.frame.canvas.height/this.pixelRatio),oldWidth:Math.round(n/this.pixelRatio),oldHeight:Math.round(o/this.pixelRatio)}),this._setCameraState()),this.initialized=!0,i}},{key:"getContext",value:function(){return this.frame.canvas.getContext("2d")}},{key:"_determinePixelRatio",value:function(){var t=this.getContext();if(void 0===t)throw new Error("Could not get canvax context");var e=1;return"undefined"!=typeof window&&(e=window.devicePixelRatio||1),e/(t.webkitBackingStorePixelRatio||t.mozBackingStorePixelRatio||t.msBackingStorePixelRatio||t.oBackingStorePixelRatio||t.backingStorePixelRatio||1)}},{key:"_setPixelRatio",value:function(){this.pixelRatio=this._determinePixelRatio()}},{key:"setTransform",value:function(){var t=this.getContext();if(void 0===t)throw new Error("Could not get canvax context");t.setTransform(this.pixelRatio,0,0,this.pixelRatio,0,0)}},{key:"_XconvertDOMtoCanvas",value:function(t){return(t-this.body.view.translation.x)/this.body.view.scale}},{key:"_XconvertCanvasToDOM",value:function(t){return t*this.body.view.scale+this.body.view.translation.x}},{key:"_YconvertDOMtoCanvas",value:function(t){return(t-this.body.view.translation.y)/this.body.view.scale}},{key:"_YconvertCanvasToDOM",value:function(t){return t*this.body.view.scale+this.body.view.translation.y}},{key:"canvasToDOM",value:function(t){return{x:this._XconvertCanvasToDOM(t.x),y:this._YconvertCanvasToDOM(t.y)}}},{key:"DOMtoCanvas",value:function(t){return{x:this._XconvertDOMtoCanvas(t.x),y:this._YconvertDOMtoCanvas(t.y)}}}]),t}();function NC(t,e){var i=un({nodes:e,minZoomLevel:Number.MIN_VALUE,maxZoomLevel:1},null!=t?t:{});if(!lu(i.nodes))throw new TypeError("Nodes has to be an array of ids.");if(0===i.nodes.length&&(i.nodes=e),!("number"==typeof i.minZoomLevel&&i.minZoomLevel>0))throw new TypeError("Min zoom level has to be a number higher than zero.");if(!("number"==typeof i.maxZoomLevel&&i.minZoomLevel<=i.maxZoomLevel))throw new TypeError("Max zoom level has to be a number higher than min zoom level.");return i}var FC=function(){function t(e,i){var n,o,r=this;Yd(this,t),this.body=e,this.canvas=i,this.animationSpeed=1/this.renderRefreshRate,this.animationEasingFunction="easeInOutQuint",this.easingTime=0,this.sourceScale=0,this.targetScale=0,this.sourceTranslation=0,this.targetTranslation=0,this.lockedOnNodeId=void 0,this.lockedOnNodeOffset=void 0,this.touchTime=0,this.viewFunction=void 0,this.body.emitter.on("fit",zn(n=this.fit).call(n,this)),this.body.emitter.on("animationFinished",(function(){r.body.emitter.emit("_stopRendering")})),this.body.emitter.on("unlockNode",zn(o=this.releaseNode).call(o,this))}return Kd(t,[{key:"setOptions",value:function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};this.options=t}},{key:"fit",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];t=NC(t,this.body.nodeIndices);var i,n,o=this.canvas.frame.canvas.clientWidth,r=this.canvas.frame.canvas.clientHeight;if(0===o||0===r)n=1,i=EC.getRange(this.body.nodes,t.nodes);else if(!0===e){var s=0;for(var a in this.body.nodes)if(Object.prototype.hasOwnProperty.call(this.body.nodes,a)){var h=this.body.nodes[a];!0===h.predefinedPosition&&(s+=1)}if(s>.5*this.body.nodeIndices.length)return void this.fit(t,!1);i=EC.getRange(this.body.nodes,t.nodes);var l=this.body.nodeIndices.length;n=12.662/(l+7.4147)+.0964822;var d=Math.min(o/600,r/600);n*=d}else{this.body.emitter.emit("_resizeNodes"),i=EC.getRange(this.body.nodes,t.nodes);var c=1.1*Math.abs(i.maxX-i.minX),u=1.1*Math.abs(i.maxY-i.minY),f=o/c,p=r/u;n=f<=p?f:p}n>t.maxZoomLevel?n=t.maxZoomLevel:n<t.minZoomLevel&&(n=t.minZoomLevel);var v=EC.findCenter(i),g={position:v,scale:n,animation:t.animation};this.moveTo(g)}},{key:"focus",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};if(void 0!==this.body.nodes[t]){var i={x:this.body.nodes[t].x,y:this.body.nodes[t].y};e.position=i,e.lockedOnNode=t,this.moveTo(e)}else console.error("Node: "+t+" cannot be found.")}},{key:"moveTo",value:function(t){if(void 0!==t){if(null!=t.offset){if(null!=t.offset.x){if(t.offset.x=+t.offset.x,!ok(t.offset.x))throw new TypeError('The option "offset.x" has to be a finite number.')}else t.offset.x=0;if(null!=t.offset.y){if(t.offset.y=+t.offset.y,!ok(t.offset.y))throw new TypeError('The option "offset.y" has to be a finite number.')}else t.offset.x=0}else t.offset={x:0,y:0};if(null!=t.position){if(null!=t.position.x){if(t.position.x=+t.position.x,!ok(t.position.x))throw new TypeError('The option "position.x" has to be a finite number.')}else t.position.x=0;if(null!=t.position.y){if(t.position.y=+t.position.y,!ok(t.position.y))throw new TypeError('The option "position.y" has to be a finite number.')}else t.position.x=0}else t.position=this.getViewPosition();if(null!=t.scale){if(t.scale=+t.scale,!(t.scale>0))throw new TypeError('The option "scale" has to be a number greater than zero.')}else t.scale=this.body.view.scale;void 0===t.animation&&(t.animation={duration:0}),!1===t.animation&&(t.animation={duration:0}),!0===t.animation&&(t.animation={}),void 0===t.animation.duration&&(t.animation.duration=1e3),void 0===t.animation.easingFunction&&(t.animation.easingFunction="easeInOutQuad"),this.animateView(t)}else t={}}},{key:"animateView",value:function(t){if(void 0!==t){this.animationEasingFunction=t.animation.easingFunction,this.releaseNode(),!0===t.locked&&(this.lockedOnNodeId=t.lockedOnNode,this.lockedOnNodeOffset=t.offset),0!=this.easingTime&&this._transitionRedraw(!0),this.sourceScale=this.body.view.scale,this.sourceTranslation=this.body.view.translation,this.targetScale=t.scale,this.body.view.scale=this.targetScale;var e,i,n=this.canvas.DOMtoCanvas({x:.5*this.canvas.frame.canvas.clientWidth,y:.5*this.canvas.frame.canvas.clientHeight}),o=n.x-t.position.x,r=n.y-t.position.y;if(this.targetTranslation={x:this.sourceTranslation.x+o*this.targetScale+t.offset.x,y:this.sourceTranslation.y+r*this.targetScale+t.offset.y},0===t.animation.duration)if(null!=this.lockedOnNodeId)this.viewFunction=zn(e=this._lockedRedraw).call(e,this),this.body.emitter.on("initRedraw",this.viewFunction);else this.body.view.scale=this.targetScale,this.body.view.translation=this.targetTranslation,this.body.emitter.emit("_requestRedraw");else this.animationSpeed=1/(60*t.animation.duration*.001)||1/60,this.animationEasingFunction=t.animation.easingFunction,this.viewFunction=zn(i=this._transitionRedraw).call(i,this),this.body.emitter.on("initRedraw",this.viewFunction),this.body.emitter.emit("_startRendering")}}},{key:"_lockedRedraw",value:function(){var t=this.body.nodes[this.lockedOnNodeId].x,e=this.body.nodes[this.lockedOnNodeId].y,i=this.canvas.DOMtoCanvas({x:.5*this.canvas.frame.canvas.clientWidth,y:.5*this.canvas.frame.canvas.clientHeight}),n=i.x-t,o=i.y-e,r=this.body.view.translation,s={x:r.x+n*this.body.view.scale+this.lockedOnNodeOffset.x,y:r.y+o*this.body.view.scale+this.lockedOnNodeOffset.y};this.body.view.translation=s}},{key:"releaseNode",value:function(){void 0!==this.lockedOnNodeId&&void 0!==this.viewFunction&&(this.body.emitter.off("initRedraw",this.viewFunction),this.lockedOnNodeId=void 0,this.lockedOnNodeOffset=void 0)}},{key:"_transitionRedraw",value:function(){var t=arguments.length>0&&void 0!==arguments[0]&&arguments[0];this.easingTime+=this.animationSpeed,this.easingTime=!0===t?1:this.easingTime;var e=Tm[this.animationEasingFunction](this.easingTime);if(this.body.view.scale=this.sourceScale+(this.targetScale-this.sourceScale)*e,this.body.view.translation={x:this.sourceTranslation.x+(this.targetTranslation.x-this.sourceTranslation.x)*e,y:this.sourceTranslation.y+(this.targetTranslation.y-this.sourceTranslation.y)*e},this.easingTime>=1){var i;if(this.body.emitter.off("initRedraw",this.viewFunction),this.easingTime=0,null!=this.lockedOnNodeId)this.viewFunction=zn(i=this._lockedRedraw).call(i,this),this.body.emitter.on("initRedraw",this.viewFunction);this.body.emitter.emit("animationFinished")}}},{key:"getScale",value:function(){return this.body.view.scale}},{key:"getViewPosition",value:function(){return this.canvas.DOMtoCanvas({x:.5*this.canvas.frame.canvas.clientWidth,y:.5*this.canvas.frame.canvas.clientHeight})}}]),t}();function AC(t){var e,i=t&&t.preventDefault||!1,n=t&&t.container||window,o={},r={keydown:{},keyup:{}},s={};for(e=97;e<=122;e++)s[String.fromCharCode(e)]={code:e-97+65,shift:!1};for(e=65;e<=90;e++)s[String.fromCharCode(e)]={code:e,shift:!0};for(e=0;e<=9;e++)s[""+e]={code:48+e,shift:!1};for(e=1;e<=12;e++)s["F"+e]={code:111+e,shift:!1};for(e=0;e<=9;e++)s["num"+e]={code:96+e,shift:!1};s["num*"]={code:106,shift:!1},s["num+"]={code:107,shift:!1},s["num-"]={code:109,shift:!1},s["num/"]={code:111,shift:!1},s["num."]={code:110,shift:!1},s.left={code:37,shift:!1},s.up={code:38,shift:!1},s.right={code:39,shift:!1},s.down={code:40,shift:!1},s.space={code:32,shift:!1},s.enter={code:13,shift:!1},s.shift={code:16,shift:void 0},s.esc={code:27,shift:!1},s.backspace={code:8,shift:!1},s.tab={code:9,shift:!1},s.ctrl={code:17,shift:!1},s.alt={code:18,shift:!1},s.delete={code:46,shift:!1},s.pageup={code:33,shift:!1},s.pagedown={code:34,shift:!1},s["="]={code:187,shift:!1},s["-"]={code:189,shift:!1},s["]"]={code:221,shift:!1},s["["]={code:219,shift:!1};var a=function(t){l(t,"keydown")},h=function(t){l(t,"keyup")},l=function(t,e){if(void 0!==r[e][t.keyCode]){for(var n=r[e][t.keyCode],o=0;o<n.length;o++)(void 0===n[o].shift||1==n[o].shift&&1==t.shiftKey||0==n[o].shift&&0==t.shiftKey)&&n[o].fn(t);1==i&&t.preventDefault()}};return o.bind=function(t,e,i){if(void 0===i&&(i="keydown"),void 0===s[t])throw new Error("unsupported key: "+t);void 0===r[i][s[t].code]&&(r[i][s[t].code]=[]),r[i][s[t].code].push({fn:e,shift:s[t].shift})},o.bindAll=function(t,e){for(var i in void 0===e&&(e="keydown"),s)s.hasOwnProperty(i)&&o.bind(i,t,e)},o.getKey=function(t){for(var e in s)if(s.hasOwnProperty(e)){if(1==t.shiftKey&&1==s[e].shift&&t.keyCode==s[e].code)return e;if(0==t.shiftKey&&0==s[e].shift&&t.keyCode==s[e].code)return e;if(t.keyCode==s[e].code&&"shift"==e)return e}return"unknown key, currently not supported"},o.unbind=function(t,e,i){if(void 0===i&&(i="keydown"),void 0===s[t])throw new Error("unsupported key: "+t);if(void 0!==e){var n=[],o=r[i][s[t].code];if(void 0!==o)for(var a=0;a<o.length;a++)o[a].fn==e&&o[a].shift==s[t].shift||n.push(r[i][s[t].code][a]);r[i][s[t].code]=n}else r[i][s[t].code]=[]},o.reset=function(){r={keydown:{},keyup:{}}},o.destroy=function(){r={keydown:{},keyup:{}},n.removeEventListener("keydown",a,!0),n.removeEventListener("keyup",h,!0)},n.addEventListener("keydown",a,!0),n.addEventListener("keyup",h,!0),o}var jC=Object.freeze({__proto__:null,default:AC}),RC=function(){function t(e,i){var n=this;Yd(this,t),this.body=e,this.canvas=i,this.iconsCreated=!1,this.navigationHammers=[],this.boundFunctions={},this.touchTime=0,this.activated=!1,this.body.emitter.on("activate",(function(){n.activated=!0,n.configureKeyboardBindings()})),this.body.emitter.on("deactivate",(function(){n.activated=!1,n.configureKeyboardBindings()})),this.body.emitter.on("destroy",(function(){void 0!==n.keycharm&&n.keycharm.destroy()})),this.options={}}return Kd(t,[{key:"setOptions",value:function(t){void 0!==t&&(this.options=t,this.create())}},{key:"create",value:function(){!0===this.options.navigationButtons?!1===this.iconsCreated&&this.loadNavigationElements():!0===this.iconsCreated&&this.cleanNavigation(),this.configureKeyboardBindings()}},{key:"cleanNavigation",value:function(){if(0!=this.navigationHammers.length){for(var t=0;t<this.navigationHammers.length;t++)this.navigationHammers[t].destroy();this.navigationHammers=[]}this.navigationDOM&&this.navigationDOM.wrapper&&this.navigationDOM.wrapper.parentNode&&this.navigationDOM.wrapper.parentNode.removeChild(this.navigationDOM.wrapper),this.iconsCreated=!1}},{key:"loadNavigationElements",value:function(){var t=this;this.cleanNavigation(),this.navigationDOM={};var e=["up","down","left","right","zoomIn","zoomOut","zoomExtends"],i=["_moveUp","_moveDown","_moveLeft","_moveRight","_zoomIn","_zoomOut","_fit"];this.navigationDOM.wrapper=document.createElement("div"),this.navigationDOM.wrapper.className="vis-navigation",this.canvas.frame.appendChild(this.navigationDOM.wrapper);for(var n=0;n<e.length;n++){this.navigationDOM[e[n]]=document.createElement("div"),this.navigationDOM[e[n]].className="vis-button vis-"+e[n],this.navigationDOM.wrapper.appendChild(this.navigationDOM[e[n]]);var o,r,s=new Wm(this.navigationDOM[e[n]]);if("_fit"===i[n])IC(s,zn(o=this._fit).call(o,this));else IC(s,zn(r=this.bindToRedraw).call(r,this,i[n]));this.navigationHammers.push(s)}var a=new Wm(this.canvas.frame);BC(a,(function(){t._stopMovement()})),this.navigationHammers.push(a),this.iconsCreated=!0}},{key:"bindToRedraw",value:function(t){var e;void 0===this.boundFunctions[t]&&(this.boundFunctions[t]=zn(e=this[t]).call(e,this),this.body.emitter.on("initRedraw",this.boundFunctions[t]),this.body.emitter.emit("_startRendering"))}},{key:"unbindFromRedraw",value:function(t){void 0!==this.boundFunctions[t]&&(this.body.emitter.off("initRedraw",this.boundFunctions[t]),this.body.emitter.emit("_stopRendering"),delete this.boundFunctions[t])}},{key:"_fit",value:function(){(new Date).valueOf()-this.touchTime>700&&(this.body.emitter.emit("fit",{duration:700}),this.touchTime=(new Date).valueOf())}},{key:"_stopMovement",value:function(){for(var t in this.boundFunctions)Object.prototype.hasOwnProperty.call(this.boundFunctions,t)&&(this.body.emitter.off("initRedraw",this.boundFunctions[t]),this.body.emitter.emit("_stopRendering"));this.boundFunctions={}}},{key:"_moveUp",value:function(){this.body.view.translation.y+=this.options.keyboard.speed.y}},{key:"_moveDown",value:function(){this.body.view.translation.y-=this.options.keyboard.speed.y}},{key:"_moveLeft",value:function(){this.body.view.translation.x+=this.options.keyboard.speed.x}},{key:"_moveRight",value:function(){this.body.view.translation.x-=this.options.keyboard.speed.x}},{key:"_zoomIn",value:function(){var t=this.body.view.scale,e=this.body.view.scale*(1+this.options.keyboard.speed.zoom),i=this.body.view.translation,n=e/t,o=(1-n)*this.canvas.canvasViewCenter.x+i.x*n,r=(1-n)*this.canvas.canvasViewCenter.y+i.y*n;this.body.view.scale=e,this.body.view.translation={x:o,y:r},this.body.emitter.emit("zoom",{direction:"+",scale:this.body.view.scale,pointer:null})}},{key:"_zoomOut",value:function(){var t=this.body.view.scale,e=this.body.view.scale/(1+this.options.keyboard.speed.zoom),i=this.body.view.translation,n=e/t,o=(1-n)*this.canvas.canvasViewCenter.x+i.x*n,r=(1-n)*this.canvas.canvasViewCenter.y+i.y*n;this.body.view.scale=e,this.body.view.translation={x:o,y:r},this.body.emitter.emit("zoom",{direction:"-",scale:this.body.view.scale,pointer:null})}},{key:"configureKeyboardBindings",value:function(){var t,e,i,n,o,r,s,a,h,l,d,c,u,f,p,v,g,y,m,b,w,k,_,x,E=this;(void 0!==this.keycharm&&this.keycharm.destroy(),!0===this.options.keyboard.enabled)&&(!0===this.options.keyboard.bindToWindow?this.keycharm=AC({container:window,preventDefault:!0}):this.keycharm=AC({container:this.canvas.frame,preventDefault:!0}),this.keycharm.reset(),!0===this.activated&&(zn(t=this.keycharm).call(t,"up",(function(){E.bindToRedraw("_moveUp")}),"keydown"),zn(e=this.keycharm).call(e,"down",(function(){E.bindToRedraw("_moveDown")}),"keydown"),zn(i=this.keycharm).call(i,"left",(function(){E.bindToRedraw("_moveLeft")}),"keydown"),zn(n=this.keycharm).call(n,"right",(function(){E.bindToRedraw("_moveRight")}),"keydown"),zn(o=this.keycharm).call(o,"=",(function(){E.bindToRedraw("_zoomIn")}),"keydown"),zn(r=this.keycharm).call(r,"num+",(function(){E.bindToRedraw("_zoomIn")}),"keydown"),zn(s=this.keycharm).call(s,"num-",(function(){E.bindToRedraw("_zoomOut")}),"keydown"),zn(a=this.keycharm).call(a,"-",(function(){E.bindToRedraw("_zoomOut")}),"keydown"),zn(h=this.keycharm).call(h,"[",(function(){E.bindToRedraw("_zoomOut")}),"keydown"),zn(l=this.keycharm).call(l,"]",(function(){E.bindToRedraw("_zoomIn")}),"keydown"),zn(d=this.keycharm).call(d,"pageup",(function(){E.bindToRedraw("_zoomIn")}),"keydown"),zn(c=this.keycharm).call(c,"pagedown",(function(){E.bindToRedraw("_zoomOut")}),"keydown"),zn(u=this.keycharm).call(u,"up",(function(){E.unbindFromRedraw("_moveUp")}),"keyup"),zn(f=this.keycharm).call(f,"down",(function(){E.unbindFromRedraw("_moveDown")}),"keyup"),zn(p=this.keycharm).call(p,"left",(function(){E.unbindFromRedraw("_moveLeft")}),"keyup"),zn(v=this.keycharm).call(v,"right",(function(){E.unbindFromRedraw("_moveRight")}),"keyup"),zn(g=this.keycharm).call(g,"=",(function(){E.unbindFromRedraw("_zoomIn")}),"keyup"),zn(y=this.keycharm).call(y,"num+",(function(){E.unbindFromRedraw("_zoomIn")}),"keyup"),zn(m=this.keycharm).call(m,"num-",(function(){E.unbindFromRedraw("_zoomOut")}),"keyup"),zn(b=this.keycharm).call(b,"-",(function(){E.unbindFromRedraw("_zoomOut")}),"keyup"),zn(w=this.keycharm).call(w,"[",(function(){E.unbindFromRedraw("_zoomOut")}),"keyup"),zn(k=this.keycharm).call(k,"]",(function(){E.unbindFromRedraw("_zoomIn")}),"keyup"),zn(_=this.keycharm).call(_,"pageup",(function(){E.unbindFromRedraw("_zoomIn")}),"keyup"),zn(x=this.keycharm).call(x,"pagedown",(function(){E.unbindFromRedraw("_zoomOut")}),"keyup")))}}]),t}();function LC(t,e){var i=void 0!==tu&&ih(t)||t["@@iterator"];if(!i){if(lu(t)||(i=function(t,e){var i;if(!t)return;if("string"==typeof t)return HC(t,e);var n=au(i=Object.prototype.toString.call(t)).call(i,8,-1);"Object"===n&&t.constructor&&(n=t.constructor.name);if("Map"===n||"Set"===n)return ja(t);if("Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n))return HC(t,e)}(t))||e&&t&&"number"==typeof t.length){i&&(t=i);var n=0,o=function(){};return{s:o,n:function(){return n>=t.length?{done:!0}:{done:!1,value:t[n++]}},e:function(t){throw t},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var r,s=!0,a=!1;return{s:function(){i=i.call(t)},n:function(){var t=i.next();return s=t.done,t},e:function(t){a=!0,r=t},f:function(){try{s||null==i.return||i.return()}finally{if(a)throw r}}}}function HC(t,e){(null==e||e>t.length)&&(e=t.length);for(var i=0,n=new Array(e);i<e;i++)n[i]=t[i];return n}var WC=function(){function t(e,i,n){var o,r,s,a,h,l,d,c,u,f,p,v,g;Yd(this,t),this.body=e,this.canvas=i,this.selectionHandler=n,this.navigationHandler=new RC(e,i),this.body.eventListeners.onTap=zn(o=this.onTap).call(o,this),this.body.eventListeners.onTouch=zn(r=this.onTouch).call(r,this),this.body.eventListeners.onDoubleTap=zn(s=this.onDoubleTap).call(s,this),this.body.eventListeners.onHold=zn(a=this.onHold).call(a,this),this.body.eventListeners.onDragStart=zn(h=this.onDragStart).call(h,this),this.body.eventListeners.onDrag=zn(l=this.onDrag).call(l,this),this.body.eventListeners.onDragEnd=zn(d=this.onDragEnd).call(d,this),this.body.eventListeners.onMouseWheel=zn(c=this.onMouseWheel).call(c,this),this.body.eventListeners.onPinch=zn(u=this.onPinch).call(u,this),this.body.eventListeners.onMouseMove=zn(f=this.onMouseMove).call(f,this),this.body.eventListeners.onRelease=zn(p=this.onRelease).call(p,this),this.body.eventListeners.onContext=zn(v=this.onContext).call(v,this),this.touchTime=0,this.drag={},this.pinch={},this.popup=void 0,this.popupObj=void 0,this.popupTimer=void 0,this.body.functions.getPointer=zn(g=this.getPointer).call(g,this),this.options={},this.defaultOptions={dragNodes:!0,dragView:!0,hover:!1,keyboard:{enabled:!1,speed:{x:10,y:10,zoom:.02},bindToWindow:!0,autoFocus:!0},navigationButtons:!1,tooltipDelay:300,zoomView:!0,zoomSpeed:1},un(this.options,this.defaultOptions),this.bindEventListeners()}return Kd(t,[{key:"bindEventListeners",value:function(){var t=this;this.body.emitter.on("destroy",(function(){clearTimeout(t.popupTimer),delete t.body.functions.getPointer}))}},{key:"setOptions",value:function(t){if(void 0!==t){im(["hideEdgesOnDrag","hideEdgesOnZoom","hideNodesOnDrag","keyboard","multiselect","selectable","selectConnectedEdges"],this.options,t),Sm(this.options,t,"keyboard"),t.tooltip&&(un(this.options.tooltip,t.tooltip),t.tooltip.color&&(this.options.tooltip.color=gm(t.tooltip.color)))}this.navigationHandler.setOptions(this.options)}},{key:"getPointer",value:function(t){return{x:t.x-sm(this.canvas.frame.canvas),y:t.y-am(this.canvas.frame.canvas)}}},{key:"onTouch",value:function(t){(new Date).valueOf()-this.touchTime>50&&(this.drag.pointer=this.getPointer(t.center),this.drag.pinched=!1,this.pinch.scale=this.body.view.scale,this.touchTime=(new Date).valueOf())}},{key:"onTap",value:function(t){var e=this.getPointer(t.center),i=this.selectionHandler.options.multiselect&&(t.changedPointers[0].ctrlKey||t.changedPointers[0].metaKey);this.checkSelectionChanges(e,i),this.selectionHandler.commitAndEmit(e,t),this.selectionHandler.generateClickEvent("click",t,e)}},{key:"onDoubleTap",value:function(t){var e=this.getPointer(t.center);this.selectionHandler.generateClickEvent("doubleClick",t,e)}},{key:"onHold",value:function(t){var e=this.getPointer(t.center),i=this.selectionHandler.options.multiselect;this.checkSelectionChanges(e,i),this.selectionHandler.commitAndEmit(e,t),this.selectionHandler.generateClickEvent("click",t,e),this.selectionHandler.generateClickEvent("hold",t,e)}},{key:"onRelease",value:function(t){if((new Date).valueOf()-this.touchTime>10){var e=this.getPointer(t.center);this.selectionHandler.generateClickEvent("release",t,e),this.touchTime=(new Date).valueOf()}}},{key:"onContext",value:function(t){var e=this.getPointer({x:t.clientX,y:t.clientY});this.selectionHandler.generateClickEvent("oncontext",t,e)}},{key:"checkSelectionChanges",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];!0===e?this.selectionHandler.selectAdditionalOnPoint(t):this.selectionHandler.selectOnPoint(t)}},{key:"_determineDifference",value:function(t,e){var i=function(t,e){for(var i=[],n=0;n<t.length;n++){var o=t[n];-1===Fp(e).call(e,o)&&i.push(o)}return i};return{nodes:i(t.nodes,e.nodes),edges:i(t.edges,e.edges)}}},{key:"onDragStart",value:function(t){if(!this.drag.dragging){void 0===this.drag.pointer&&this.onTouch(t);var e=this.selectionHandler.getNodeAt(this.drag.pointer);if(this.drag.dragging=!0,this.drag.selection=[],this.drag.translation=un({},this.body.view.translation),this.drag.nodeId=void 0,t.srcEvent.shiftKey){this.body.selectionBox.show=!0;var i=this.getPointer(t.center);this.body.selectionBox.position.start={x:this.canvas._XconvertDOMtoCanvas(i.x),y:this.canvas._YconvertDOMtoCanvas(i.y)},this.body.selectionBox.position.end={x:this.canvas._XconvertDOMtoCanvas(i.x),y:this.canvas._YconvertDOMtoCanvas(i.y)}}if(void 0!==e&&!0===this.options.dragNodes){this.drag.nodeId=e.id,!1===e.isSelected()&&this.selectionHandler.setSelection({nodes:[e.id]}),this.selectionHandler.generateClickEvent("dragStart",t,this.drag.pointer);var n,o=LC(this.selectionHandler.getSelectedNodes());try{for(o.s();!(n=o.n()).done;){var r=n.value,s={id:r.id,node:r,x:r.x,y:r.y,xFixed:r.options.fixed.x,yFixed:r.options.fixed.y};r.options.fixed.x=!0,r.options.fixed.y=!0,this.drag.selection.push(s)}}catch(t){o.e(t)}finally{o.f()}}else this.selectionHandler.generateClickEvent("dragStart",t,this.drag.pointer,void 0,!0)}}},{key:"onDrag",value:function(t){var e=this;if(!0!==this.drag.pinched){this.body.emitter.emit("unlockNode");var i=this.getPointer(t.center),n=this.drag.selection;if(n&&n.length&&!0===this.options.dragNodes){this.selectionHandler.generateClickEvent("dragging",t,i);var o=i.x-this.drag.pointer.x,r=i.y-this.drag.pointer.y;Fu(n).call(n,(function(t){var i=t.node;!1===t.xFixed&&(i.x=e.canvas._XconvertDOMtoCanvas(e.canvas._XconvertCanvasToDOM(t.x)+o)),!1===t.yFixed&&(i.y=e.canvas._YconvertDOMtoCanvas(e.canvas._YconvertCanvasToDOM(t.y)+r))})),this.body.emitter.emit("startSimulation")}else{if(t.srcEvent.shiftKey){if(this.selectionHandler.generateClickEvent("dragging",t,i,void 0,!0),void 0===this.drag.pointer)return void this.onDragStart(t);this.body.selectionBox.position.end={x:this.canvas._XconvertDOMtoCanvas(i.x),y:this.canvas._YconvertDOMtoCanvas(i.y)},this.body.emitter.emit("_requestRedraw")}if(!0===this.options.dragView&&!t.srcEvent.shiftKey){if(this.selectionHandler.generateClickEvent("dragging",t,i,void 0,!0),void 0===this.drag.pointer)return void this.onDragStart(t);var s=i.x-this.drag.pointer.x,a=i.y-this.drag.pointer.y;this.body.view.translation={x:this.drag.translation.x+s,y:this.drag.translation.y+a},this.body.emitter.emit("_requestRedraw")}}}}},{key:"onDragEnd",value:function(t){var e=this;if(this.drag.dragging=!1,this.body.selectionBox.show){var i;this.body.selectionBox.show=!1;var n=this.body.selectionBox.position,o={minX:Math.min(n.start.x,n.end.x),minY:Math.min(n.start.y,n.end.y),maxX:Math.max(n.start.x,n.end.x),maxY:Math.max(n.start.y,n.end.y)},r=Xf(i=this.body.nodeIndices).call(i,(function(t){var i=e.body.nodes[t];return i.x>=o.minX&&i.x<=o.maxX&&i.y>=o.minY&&i.y<=o.maxY}));Fu(r).call(r,(function(t){return e.selectionHandler.selectObject(e.body.nodes[t])}));var s=this.getPointer(t.center);this.selectionHandler.commitAndEmit(s,t),this.selectionHandler.generateClickEvent("dragEnd",t,this.getPointer(t.center),void 0,!0),this.body.emitter.emit("_requestRedraw")}else{var a=this.drag.selection;a&&a.length?(Fu(a).call(a,(function(t){t.node.options.fixed.x=t.xFixed,t.node.options.fixed.y=t.yFixed})),this.selectionHandler.generateClickEvent("dragEnd",t,this.getPointer(t.center)),this.body.emitter.emit("startSimulation")):(this.selectionHandler.generateClickEvent("dragEnd",t,this.getPointer(t.center),void 0,!0),this.body.emitter.emit("_requestRedraw"))}}},{key:"onPinch",value:function(t){var e=this.getPointer(t.center);this.drag.pinched=!0,void 0===this.pinch.scale&&(this.pinch.scale=1);var i=this.pinch.scale*t.scale;this.zoom(i,e)}},{key:"zoom",value:function(t,e){if(!0===this.options.zoomView){var i=this.body.view.scale;t<1e-5&&(t=1e-5),t>10&&(t=10);var n=void 0;void 0!==this.drag&&!0===this.drag.dragging&&(n=this.canvas.DOMtoCanvas(this.drag.pointer));var o=this.body.view.translation,r=t/i,s=(1-r)*e.x+o.x*r,a=(1-r)*e.y+o.y*r;if(this.body.view.scale=t,this.body.view.translation={x:s,y:a},null!=n){var h=this.canvas.canvasToDOM(n);this.drag.pointer.x=h.x,this.drag.pointer.y=h.y}this.body.emitter.emit("_requestRedraw"),i<t?this.body.emitter.emit("zoom",{direction:"+",scale:this.body.view.scale,pointer:e}):this.body.emitter.emit("zoom",{direction:"-",scale:this.body.view.scale,pointer:e})}}},{key:"onMouseWheel",value:function(t){if(!0===this.options.zoomView){if(0!==t.deltaY){var e=this.body.view.scale;e*=1+(t.deltaY<0?1:-1)*(.1*this.options.zoomSpeed);var i=this.getPointer({x:t.clientX,y:t.clientY});this.zoom(e,i)}t.preventDefault()}}},{key:"onMouseMove",value:function(t){var e=this,i=this.getPointer({x:t.clientX,y:t.clientY}),n=!1;void 0!==this.popup&&(!1===this.popup.hidden&&this._checkHidePopup(i),!1===this.popup.hidden&&(n=!0,this.popup.setPosition(i.x+3,i.y-5),this.popup.show())),this.options.keyboard.autoFocus&&!1===this.options.keyboard.bindToWindow&&!0===this.options.keyboard.enabled&&this.canvas.frame.focus(),!1===n&&(void 0!==this.popupTimer&&(clearInterval(this.popupTimer),this.popupTimer=void 0),this.drag.dragging||(this.popupTimer=Sv((function(){return e._checkShowPopup(i)}),this.options.tooltipDelay))),!0===this.options.hover&&this.selectionHandler.hoverObject(t,i)}},{key:"_checkShowPopup",value:function(t){var e=this.canvas._XconvertDOMtoCanvas(t.x),i=this.canvas._YconvertDOMtoCanvas(t.y),n={left:e,top:i,right:e,bottom:i},o=void 0===this.popupObj?void 0:this.popupObj.id,r=!1,s="node";if(void 0===this.popupObj){for(var a,h=this.body.nodeIndices,l=this.body.nodes,d=[],c=0;c<h.length;c++)!0===(a=l[h[c]]).isOverlappingWith(n)&&(r=!0,void 0!==a.getTitle()&&d.push(h[c]));d.length>0&&(this.popupObj=l[d[d.length-1]],r=!0)}if(void 0===this.popupObj&&!1===r){for(var u,f=this.body.edgeIndices,p=this.body.edges,v=[],g=0;g<f.length;g++)!0===(u=p[f[g]]).isOverlappingWith(n)&&!0===u.connected&&void 0!==u.getTitle()&&v.push(f[g]);v.length>0&&(this.popupObj=p[v[v.length-1]],s="edge")}void 0!==this.popupObj?this.popupObj.id!==o&&(void 0===this.popup&&(this.popup=new qm(this.canvas.frame)),this.popup.popupTargetType=s,this.popup.popupTargetId=this.popupObj.id,this.popup.setPosition(t.x+3,t.y-5),this.popup.setText(this.popupObj.getTitle()),this.popup.show(),this.body.emitter.emit("showPopup",this.popupObj.id)):void 0!==this.popup&&(this.popup.hide(),this.body.emitter.emit("hidePopup"))}},{key:"_checkHidePopup",value:function(t){var e=this.selectionHandler._pointerToPositionObject(t),i=!1;if("node"===this.popup.popupTargetType){if(void 0!==this.body.nodes[this.popup.popupTargetId]&&!0===(i=this.body.nodes[this.popup.popupTargetId].isOverlappingWith(e))){var n=this.selectionHandler.getNodeAt(t);i=void 0!==n&&n.id===this.popup.popupTargetId}}else void 0===this.selectionHandler.getNodeAt(t)&&void 0!==this.body.edges[this.popup.popupTargetId]&&(i=this.body.edges[this.popup.popupTargetId].isOverlappingWith(e));!1===i&&(this.popupObj=void 0,this.popup.hide(),this.body.emitter.emit("hidePopup"))}}]),t}(),qC=g,VC=Nw,UC=Db.exports.getWeakData,YC=$e,XC=Y,GC=yw,KC=pw,$C=Wt,ZC=Vo.set,QC=Vo.getterFor,JC=Wh.find,tS=Wh.findIndex,eS=qC([].splice),iS=0,nS=function(t){return t.frozen||(t.frozen=new oS)},oS=function(){this.entries=[]},rS=function(t,e){return JC(t.entries,(function(t){return t[0]===e}))};oS.prototype={get:function(t){var e=rS(this,t);if(e)return e[1]},has:function(t){return!!rS(this,t)},set:function(t,e){var i=rS(this,t);i?i[1]=e:this.entries.push([t,e])},delete:function(t){var e=tS(this.entries,(function(e){return e[0]===t}));return~e&&eS(this.entries,e,1),!!~e}};var sS,aS={getConstructor:function(t,e,i,n){var o=t((function(t,o){GC(t,r),ZC(t,{type:e,id:iS++,frozen:void 0}),null!=o&&KC(o,t[n],{that:t,AS_ENTRIES:i})})),r=o.prototype,s=QC(e),a=function(t,e,i){var n=s(t),o=UC(YC(e),!0);return!0===o?nS(n).set(e,i):o[n.id]=i,t};return VC(r,{delete:function(t){var e=s(this);if(!XC(t))return!1;var i=UC(t);return!0===i?nS(e).delete(t):i&&$C(i,e.id)&&delete i[e.id]},has:function(t){var e=s(this);if(!XC(t))return!1;var i=UC(t);return!0===i?nS(e).has(t):i&&$C(i,e.id)}}),VC(r,i?{get:function(t){var e=s(this);if(XC(t)){var i=UC(t);return!0===i?nS(e).get(t):i?i[e.id]:void 0}},set:function(t,e){return a(this,t,e)}}:{add:function(t){return a(this,t,!0)}}),o}},hS=n,lS=g,dS=Nw,cS=Db.exports,uS=Bw,fS=aS,pS=Y,vS=jb,gS=Vo.enforce,yS=_o,mS=!hS.ActiveXObject&&"ActiveXObject"in hS,bS=function(t){return function(){return t(this,arguments.length?arguments[0]:void 0)}},wS=uS("WeakMap",bS,fS);if(yS&&mS){sS=fS.getConstructor(bS,"WeakMap",!0),cS.enable();var kS=wS.prototype,_S=lS(kS.delete),xS=lS(kS.has),ES=lS(kS.get),OS=lS(kS.set);dS(kS,{delete:function(t){if(pS(t)&&!vS(t)){var e=gS(this);return e.frozen||(e.frozen=new sS),_S(this,t)||e.frozen.delete(t)}return _S(this,t)},has:function(t){if(pS(t)&&!vS(t)){var e=gS(this);return e.frozen||(e.frozen=new sS),xS(this,t)||e.frozen.has(t)}return xS(this,t)},get:function(t){if(pS(t)&&!vS(t)){var e=gS(this);return e.frozen||(e.frozen=new sS),xS(this,t)?ES(this,t):e.frozen.get(t)}return ES(this,t)},set:function(t,e){if(pS(t)&&!vS(t)){var i=gS(this);i.frozen||(i.frozen=new sS),xS(this,t)?OS(this,t,e):i.frozen.set(t,e)}else OS(this,t,e);return this}})}var CS,SS,TS,MS,PS,DS=X.WeakMap;function IS(t,e,i,n){if("a"===i&&!n)throw new TypeError("Private accessor was defined without a getter");if("function"==typeof e?t!==e||!n:!e.has(t))throw new TypeError("Cannot read private member from an object whose class did not declare it");return"m"===i?n:"a"===i?n.call(t):n?n.value:e.get(t)}function BS(t,e,i,n,o){if("m"===n)throw new TypeError("Private method is not writable");if("a"===n&&!o)throw new TypeError("Private accessor was defined without a setter");if("function"==typeof e?t!==e||!o:!e.has(t))throw new TypeError("Cannot write private member to an object whose class did not declare it");return"a"===n?o.call(t,i):o?o.value=i:e.set(t,i),i}function zS(t,e){var i=void 0!==tu&&ih(t)||t["@@iterator"];if(!i){if(lu(t)||(i=function(t,e){var i;if(!t)return;if("string"==typeof t)return NS(t,e);var n=au(i=Object.prototype.toString.call(t)).call(i,8,-1);"Object"===n&&t.constructor&&(n=t.constructor.name);if("Map"===n||"Set"===n)return ja(t);if("Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n))return NS(t,e)}(t))||e&&t&&"number"==typeof t.length){i&&(t=i);var n=0,o=function(){};return{s:o,n:function(){return n>=t.length?{done:!0}:{done:!1,value:t[n++]}},e:function(t){throw t},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var r,s=!0,a=!1;return{s:function(){i=i.call(t)},n:function(){var t=i.next();return s=t.done,t},e:function(t){a=!0,r=t},f:function(){try{s||null==i.return||i.return()}finally{if(a)throw r}}}}function NS(t,e){(null==e||e>t.length)&&(e=t.length);for(var i=0,n=new Array(e);i<e;i++)n[i]=t[i];return n}function FS(t,e){var i,n=new b_,o=zS(e);try{for(o.s();!(i=o.n()).done;){var r=i.value;t.has(r)||n.add(r)}}catch(t){o.e(t)}finally{o.f()}return n}var AS=function(){function t(){Yd(this,t),CS.set(this,new b_),SS.set(this,new b_)}return Kd(t,[{key:"size",get:function(){return IS(this,SS,"f").size}},{key:"add",value:function(){for(var t=arguments.length,e=new Array(t),i=0;i<t;i++)e[i]=arguments[i];for(var n=0,o=e;n<o.length;n++){var r=o[n];IS(this,SS,"f").add(r)}}},{key:"delete",value:function(){for(var t=arguments.length,e=new Array(t),i=0;i<t;i++)e[i]=arguments[i];for(var n=0,o=e;n<o.length;n++){var r=o[n];IS(this,SS,"f").delete(r)}}},{key:"clear",value:function(){IS(this,SS,"f").clear()}},{key:"getSelection",value:function(){return Jc(IS(this,SS,"f"))}},{key:"getChanges",value:function(){return{added:Jc(FS(IS(this,CS,"f"),IS(this,SS,"f"))),deleted:Jc(FS(IS(this,SS,"f"),IS(this,CS,"f"))),previous:Jc(new b_(IS(this,CS,"f"))),current:Jc(new b_(IS(this,SS,"f")))}}},{key:"commit",value:function(){var t=this.getChanges();BS(this,CS,IS(this,SS,"f"),"f"),BS(this,SS,new b_(IS(this,CS,"f")),"f");var e,i=zS(t.added);try{for(i.s();!(e=i.n()).done;){e.value.select()}}catch(t){i.e(t)}finally{i.f()}var n,o=zS(t.deleted);try{for(o.s();!(n=o.n()).done;){n.value.unselect()}}catch(t){o.e(t)}finally{o.f()}return t}}]),t}();CS=new DS,SS=new DS;var jS=function(){function t(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:function(){};Yd(this,t),TS.set(this,new AS),MS.set(this,new AS),PS.set(this,void 0),BS(this,PS,e,"f")}return Kd(t,[{key:"sizeNodes",get:function(){return IS(this,TS,"f").size}},{key:"sizeEdges",get:function(){return IS(this,MS,"f").size}},{key:"getNodes",value:function(){return IS(this,TS,"f").getSelection()}},{key:"getEdges",value:function(){return IS(this,MS,"f").getSelection()}},{key:"addNodes",value:function(){var t;(t=IS(this,TS,"f")).add.apply(t,arguments)}},{key:"addEdges",value:function(){var t;(t=IS(this,MS,"f")).add.apply(t,arguments)}},{key:"deleteNodes",value:function(t){IS(this,TS,"f").delete(t)}},{key:"deleteEdges",value:function(t){IS(this,MS,"f").delete(t)}},{key:"clear",value:function(){IS(this,TS,"f").clear(),IS(this,MS,"f").clear()}},{key:"commit",value:function(){for(var t,e,i={nodes:IS(this,TS,"f").commit(),edges:IS(this,MS,"f").commit()},n=arguments.length,o=new Array(n),r=0;r<n;r++)o[r]=arguments[r];return(t=IS(this,PS,"f")).call.apply(t,su(e=[this,i]).call(e,o)),i}}]),t}();function RS(t,e){var i=void 0!==tu&&ih(t)||t["@@iterator"];if(!i){if(lu(t)||(i=function(t,e){var i;if(!t)return;if("string"==typeof t)return LS(t,e);var n=au(i=Object.prototype.toString.call(t)).call(i,8,-1);"Object"===n&&t.constructor&&(n=t.constructor.name);if("Map"===n||"Set"===n)return ja(t);if("Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n))return LS(t,e)}(t))||e&&t&&"number"==typeof t.length){i&&(t=i);var n=0,o=function(){};return{s:o,n:function(){return n>=t.length?{done:!0}:{done:!1,value:t[n++]}},e:function(t){throw t},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var r,s=!0,a=!1;return{s:function(){i=i.call(t)},n:function(){var t=i.next();return s=t.done,t},e:function(t){a=!0,r=t},f:function(){try{s||null==i.return||i.return()}finally{if(a)throw r}}}}function LS(t,e){(null==e||e>t.length)&&(e=t.length);for(var i=0,n=new Array(e);i<e;i++)n[i]=t[i];return n}TS=new DS,MS=new DS,PS=new DS;var HS=function(){function t(e,i){var n=this;Yd(this,t),this.body=e,this.canvas=i,this._selectionAccumulator=new jS,this.hoverObj={nodes:{},edges:{}},this.options={},this.defaultOptions={multiselect:!1,selectable:!0,selectConnectedEdges:!0,hoverConnectedEdges:!0},un(this.options,this.defaultOptions),this.body.emitter.on("_dataChanged",(function(){n.updateSelection()}))}return Kd(t,[{key:"setOptions",value:function(t){if(void 0!==t){em(["multiselect","hoverConnectedEdges","selectable","selectConnectedEdges"],this.options,t)}}},{key:"selectOnPoint",value:function(t){var e=!1;if(!0===this.options.selectable){var i=this.getNodeAt(t)||this.getEdgeAt(t);this.unselectAll(),void 0!==i&&(e=this.selectObject(i)),this.body.emitter.emit("_requestRedraw")}return e}},{key:"selectAdditionalOnPoint",value:function(t){var e=!1;if(!0===this.options.selectable){var i=this.getNodeAt(t)||this.getEdgeAt(t);void 0!==i&&(e=!0,!0===i.isSelected()?this.deselectObject(i):this.selectObject(i),this.body.emitter.emit("_requestRedraw"))}return e}},{key:"_initBaseEvent",value:function(t,e){var i={};return i.pointer={DOM:{x:e.x,y:e.y},canvas:this.canvas.DOMtoCanvas(e)},i.event=t,i}},{key:"generateClickEvent",value:function(t,e,i,n){var o=arguments.length>4&&void 0!==arguments[4]&&arguments[4],r=this._initBaseEvent(e,i);if(!0===o)r.nodes=[],r.edges=[];else{var s=this.getSelection();r.nodes=s.nodes,r.edges=s.edges}void 0!==n&&(r.previousSelection=n),"click"==t&&(r.items=this.getClickedItems(i)),void 0!==e.controlEdge&&(r.controlEdge=e.controlEdge),this.body.emitter.emit(t,r)}},{key:"selectObject",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:this.options.selectConnectedEdges;if(void 0!==t){if(t instanceof fO){var i;if(!0===e)(i=this._selectionAccumulator).addEdges.apply(i,Jc(t.edges));this._selectionAccumulator.addNodes(t)}else this._selectionAccumulator.addEdges(t);return!0}return!1}},{key:"deselectObject",value:function(t){!0===t.isSelected()&&(t.selected=!1,this._removeFromSelection(t))}},{key:"_getAllNodesOverlappingWith",value:function(t){for(var e=[],i=this.body.nodes,n=0;n<this.body.nodeIndices.length;n++){var o=this.body.nodeIndices[n];i[o].isOverlappingWith(t)&&e.push(o)}return e}},{key:"_pointerToPositionObject",value:function(t){var e=this.canvas.DOMtoCanvas(t);return{left:e.x-1,top:e.y+1,right:e.x+1,bottom:e.y-1}}},{key:"getNodeAt",value:function(t){var e=!(arguments.length>1&&void 0!==arguments[1])||arguments[1],i=this._pointerToPositionObject(t),n=this._getAllNodesOverlappingWith(i);return n.length>0?!0===e?this.body.nodes[n[n.length-1]]:n[n.length-1]:void 0}},{key:"_getEdgesOverlappingWith",value:function(t,e){for(var i=this.body.edges,n=0;n<this.body.edgeIndices.length;n++){var o=this.body.edgeIndices[n];i[o].isOverlappingWith(t)&&e.push(o)}}},{key:"_getAllEdgesOverlappingWith",value:function(t){var e=[];return this._getEdgesOverlappingWith(t,e),e}},{key:"getEdgeAt",value:function(t){for(var e=!(arguments.length>1&&void 0!==arguments[1])||arguments[1],i=this.canvas.DOMtoCanvas(t),n=10,o=null,r=this.body.edges,s=0;s<this.body.edgeIndices.length;s++){var a=this.body.edgeIndices[s],h=r[a];if(h.connected){var l=h.from.x,d=h.from.y,c=h.to.x,u=h.to.y,f=h.edgeType.getDistanceToEdge(l,d,c,u,i.x,i.y);f<n&&(o=a,n=f)}}return null!==o?!0===e?this.body.edges[o]:o:void 0}},{key:"_addToHover",value:function(t){t instanceof fO?this.hoverObj.nodes[t.id]=t:this.hoverObj.edges[t.id]=t}},{key:"_removeFromSelection",value:function(t){var e;t instanceof fO?(this._selectionAccumulator.deleteNodes(t),(e=this._selectionAccumulator).deleteEdges.apply(e,Jc(t.edges))):this._selectionAccumulator.deleteEdges(t)}},{key:"unselectAll",value:function(){this._selectionAccumulator.clear()}},{key:"getSelectedNodeCount",value:function(){return this._selectionAccumulator.sizeNodes}},{key:"getSelectedEdgeCount",value:function(){return this._selectionAccumulator.sizeEdges}},{key:"_hoverConnectedEdges",value:function(t){for(var e=0;e<t.edges.length;e++){var i=t.edges[e];i.hover=!0,this._addToHover(i)}}},{key:"emitBlurEvent",value:function(t,e,i){var n=this._initBaseEvent(t,e);!0===i.hover&&(i.hover=!1,i instanceof fO?(n.node=i.id,this.body.emitter.emit("blurNode",n)):(n.edge=i.id,this.body.emitter.emit("blurEdge",n)))}},{key:"emitHoverEvent",value:function(t,e,i){var n=this._initBaseEvent(t,e),o=!1;return!1===i.hover&&(i.hover=!0,this._addToHover(i),o=!0,i instanceof fO?(n.node=i.id,this.body.emitter.emit("hoverNode",n)):(n.edge=i.id,this.body.emitter.emit("hoverEdge",n))),o}},{key:"hoverObject",value:function(t,e){var i=this.getNodeAt(e);void 0===i&&(i=this.getEdgeAt(e));var n=!1;for(var o in this.hoverObj.nodes)Object.prototype.hasOwnProperty.call(this.hoverObj.nodes,o)&&(void 0===i||i instanceof fO&&i.id!=o||i instanceof cC)&&(this.emitBlurEvent(t,e,this.hoverObj.nodes[o]),delete this.hoverObj.nodes[o],n=!0);for(var r in this.hoverObj.edges)Object.prototype.hasOwnProperty.call(this.hoverObj.edges,r)&&(!0===n?(this.hoverObj.edges[r].hover=!1,delete this.hoverObj.edges[r]):(void 0===i||i instanceof cC&&i.id!=r||i instanceof fO&&!i.hover)&&(this.emitBlurEvent(t,e,this.hoverObj.edges[r]),delete this.hoverObj.edges[r],n=!0));if(void 0!==i){var s=bu(this.hoverObj.edges).length,a=bu(this.hoverObj.nodes).length;(n||i instanceof cC&&0===s&&0===a||i instanceof fO&&0===s&&0===a)&&(n=this.emitHoverEvent(t,e,i)),i instanceof fO&&!0===this.options.hoverConnectedEdges&&this._hoverConnectedEdges(i)}!0===n&&this.body.emitter.emit("_requestRedraw")}},{key:"commitWithoutEmitting",value:function(){this._selectionAccumulator.commit()}},{key:"commitAndEmit",value:function(t,e){var i=!1,n=this._selectionAccumulator.commit(),o={nodes:n.nodes.previous,edges:n.edges.previous};n.edges.deleted.length>0&&(this.generateClickEvent("deselectEdge",e,t,o),i=!0),n.nodes.deleted.length>0&&(this.generateClickEvent("deselectNode",e,t,o),i=!0),n.nodes.added.length>0&&(this.generateClickEvent("selectNode",e,t),i=!0),n.edges.added.length>0&&(this.generateClickEvent("selectEdge",e,t),i=!0),!0===i&&this.generateClickEvent("select",e,t)}},{key:"getSelection",value:function(){return{nodes:this.getSelectedNodeIds(),edges:this.getSelectedEdgeIds()}}},{key:"getSelectedNodes",value:function(){return this._selectionAccumulator.getNodes()}},{key:"getSelectedEdges",value:function(){return this._selectionAccumulator.getEdges()}},{key:"getSelectedNodeIds",value:function(){var t;return gu(t=this._selectionAccumulator.getNodes()).call(t,(function(t){return t.id}))}},{key:"getSelectedEdgeIds",value:function(){var t;return gu(t=this._selectionAccumulator.getEdges()).call(t,(function(t){return t.id}))}},{key:"setSelection",value:function(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};if(!t||!t.nodes&&!t.edges)throw new TypeError("Selection must be an object with nodes and/or edges properties");if((e.unselectAll||void 0===e.unselectAll)&&this.unselectAll(),t.nodes){var i,n=RS(t.nodes);try{for(n.s();!(i=n.n()).done;){var o=i.value,r=this.body.nodes[o];if(!r)throw new RangeError('Node with id "'+o+'" not found');this.selectObject(r,e.highlightEdges)}}catch(t){n.e(t)}finally{n.f()}}if(t.edges){var s,a=RS(t.edges);try{for(a.s();!(s=a.n()).done;){var h=s.value,l=this.body.edges[h];if(!l)throw new RangeError('Edge with id "'+h+'" not found');this.selectObject(l)}}catch(t){a.e(t)}finally{a.f()}}this.body.emitter.emit("_requestRedraw"),this._selectionAccumulator.commit()}},{key:"selectNodes",value:function(t){var e=!(arguments.length>1&&void 0!==arguments[1])||arguments[1];if(!t||void 0===t.length)throw"Selection must be an array with ids";this.setSelection({nodes:t},{highlightEdges:e})}},{key:"selectEdges",value:function(t){if(!t||void 0===t.length)throw"Selection must be an array with ids";this.setSelection({edges:t})}},{key:"updateSelection",value:function(){for(var t in this._selectionAccumulator.getNodes())Object.prototype.hasOwnProperty.call(this.body.nodes,t.id)||this._selectionAccumulator.deleteNodes(t);for(var e in this._selectionAccumulator.getEdges())Object.prototype.hasOwnProperty.call(this.body.edges,e.id)||this._selectionAccumulator.deleteEdges(e)}},{key:"getClickedItems",value:function(t){for(var e=this.canvas.DOMtoCanvas(t),i=[],n=this.body.nodeIndices,o=this.body.nodes,r=n.length-1;r>=0;r--){var s=o[n[r]].getItemsOnPoint(e);i.push.apply(i,s)}for(var a=this.body.edgeIndices,h=this.body.edges,l=a.length-1;l>=0;l--){var d=h[a[l]].getItemsOnPoint(e);i.push.apply(i,d)}return i}}]),t}(),WS={};!function(t){!function(t){function e(t,e){if(!(t instanceof e))throw new TypeError("Cannot call a class as a function")}t.__esModule=!0,t.sort=v;var i=32,n=7,o=256,r=[1,10,100,1e3,1e4,1e5,1e6,1e7,1e8,1e9];function s(t){return t<1e5?t<100?t<10?0:1:t<1e4?t<1e3?2:3:4:t<1e7?t<1e6?5:6:t<1e9?t<1e8?7:8:9}function a(t,e){if(t===e)return 0;if(~~t===t&&~~e===e){if(0===t||0===e)return t<e?-1:1;if(t<0||e<0){if(e>=0)return-1;if(t>=0)return 1;t=-t,e=-e}var i=s(t),n=s(e),o=0;return i<n?(t*=r[n-i-1],e/=10,o=-1):i>n&&(e*=r[i-n-1],t/=10,o=1),t===e?o:t<e?-1:1}var a=String(t),h=String(e);return a===h?0:a<h?-1:1}function h(t){for(var e=0;t>=i;)e|=1&t,t>>=1;return t+e}function l(t,e,i,n){var o=e+1;if(o===i)return 1;if(n(t[o++],t[e])<0){for(;o<i&&n(t[o],t[o-1])<0;)o++;d(t,e,o)}else for(;o<i&&n(t[o],t[o-1])>=0;)o++;return o-e}function d(t,e,i){for(i--;e<i;){var n=t[e];t[e++]=t[i],t[i--]=n}}function c(t,e,i,n,o){for(n===e&&n++;n<i;n++){for(var r=t[n],s=e,a=n;s<a;){var h=s+a>>>1;o(r,t[h])<0?a=h:s=h+1}var l=n-s;switch(l){case 3:t[s+3]=t[s+2];case 2:t[s+2]=t[s+1];case 1:t[s+1]=t[s];break;default:for(;l>0;)t[s+l]=t[s+l-1],l--}t[s]=r}}function u(t,e,i,n,o,r){var s=0,a=0,h=1;if(r(t,e[i+o])>0){for(a=n-o;h<a&&r(t,e[i+o+h])>0;)s=h,(h=1+(h<<1))<=0&&(h=a);h>a&&(h=a),s+=o,h+=o}else{for(a=o+1;h<a&&r(t,e[i+o-h])<=0;)s=h,(h=1+(h<<1))<=0&&(h=a);h>a&&(h=a);var l=s;s=o-h,h=o-l}for(s++;s<h;){var d=s+(h-s>>>1);r(t,e[i+d])>0?s=d+1:h=d}return h}function f(t,e,i,n,o,r){var s=0,a=0,h=1;if(r(t,e[i+o])<0){for(a=o+1;h<a&&r(t,e[i+o-h])<0;)s=h,(h=1+(h<<1))<=0&&(h=a);h>a&&(h=a);var l=s;s=o-h,h=o-l}else{for(a=n-o;h<a&&r(t,e[i+o+h])>=0;)s=h,(h=1+(h<<1))<=0&&(h=a);h>a&&(h=a),s+=o,h+=o}for(s++;s<h;){var d=s+(h-s>>>1);r(t,e[i+d])<0?h=d:s=d+1}return h}var p=function(){function t(i,r){e(this,t),this.array=null,this.compare=null,this.minGallop=n,this.length=0,this.tmpStorageLength=o,this.stackLength=0,this.runStart=null,this.runLength=null,this.stackSize=0,this.array=i,this.compare=r,this.length=i.length,this.length<2*o&&(this.tmpStorageLength=this.length>>>1),this.tmp=new Array(this.tmpStorageLength),this.stackLength=this.length<120?5:this.length<1542?10:this.length<119151?19:40,this.runStart=new Array(this.stackLength),this.runLength=new Array(this.stackLength)}return t.prototype.pushRun=function(t,e){this.runStart[this.stackSize]=t,this.runLength[this.stackSize]=e,this.stackSize+=1},t.prototype.mergeRuns=function(){for(;this.stackSize>1;){var t=this.stackSize-2;if(t>=1&&this.runLength[t-1]<=this.runLength[t]+this.runLength[t+1]||t>=2&&this.runLength[t-2]<=this.runLength[t]+this.runLength[t-1])this.runLength[t-1]<this.runLength[t+1]&&t--;else if(this.runLength[t]>this.runLength[t+1])break;this.mergeAt(t)}},t.prototype.forceMergeRuns=function(){for(;this.stackSize>1;){var t=this.stackSize-2;t>0&&this.runLength[t-1]<this.runLength[t+1]&&t--,this.mergeAt(t)}},t.prototype.mergeAt=function(t){var e=this.compare,i=this.array,n=this.runStart[t],o=this.runLength[t],r=this.runStart[t+1],s=this.runLength[t+1];this.runLength[t]=o+s,t===this.stackSize-3&&(this.runStart[t+1]=this.runStart[t+2],this.runLength[t+1]=this.runLength[t+2]),this.stackSize--;var a=f(i[r],i,n,o,0,e);n+=a,0!=(o-=a)&&0!==(s=u(i[n+o-1],i,r,s,s-1,e))&&(o<=s?this.mergeLow(n,o,r,s):this.mergeHigh(n,o,r,s))},t.prototype.mergeLow=function(t,e,i,o){var r=this.compare,s=this.array,a=this.tmp,h=0;for(h=0;h<e;h++)a[h]=s[t+h];var l=0,d=i,c=t;if(s[c++]=s[d++],0!=--o)if(1!==e){for(var p=this.minGallop;;){var v=0,g=0,y=!1;do{if(r(s[d],a[l])<0){if(s[c++]=s[d++],g++,v=0,0==--o){y=!0;break}}else if(s[c++]=a[l++],v++,g=0,1==--e){y=!0;break}}while((v|g)<p);if(y)break;do{if(0!==(v=f(s[d],a,l,e,0,r))){for(h=0;h<v;h++)s[c+h]=a[l+h];if(c+=v,l+=v,(e-=v)<=1){y=!0;break}}if(s[c++]=s[d++],0==--o){y=!0;break}if(0!==(g=u(a[l],s,d,o,0,r))){for(h=0;h<g;h++)s[c+h]=s[d+h];if(c+=g,d+=g,0==(o-=g)){y=!0;break}}if(s[c++]=a[l++],1==--e){y=!0;break}p--}while(v>=n||g>=n);if(y)break;p<0&&(p=0),p+=2}if(this.minGallop=p,p<1&&(this.minGallop=1),1===e){for(h=0;h<o;h++)s[c+h]=s[d+h];s[c+o]=a[l]}else{if(0===e)throw new Error("mergeLow preconditions were not respected");for(h=0;h<e;h++)s[c+h]=a[l+h]}}else{for(h=0;h<o;h++)s[c+h]=s[d+h];s[c+o]=a[l]}else for(h=0;h<e;h++)s[c+h]=a[l+h]},t.prototype.mergeHigh=function(t,e,i,o){var r=this.compare,s=this.array,a=this.tmp,h=0;for(h=0;h<o;h++)a[h]=s[i+h];var l=t+e-1,d=o-1,c=i+o-1,p=0,v=0;if(s[c--]=s[l--],0!=--e)if(1!==o){for(var g=this.minGallop;;){var y=0,m=0,b=!1;do{if(r(a[d],s[l])<0){if(s[c--]=s[l--],y++,m=0,0==--e){b=!0;break}}else if(s[c--]=a[d--],m++,y=0,1==--o){b=!0;break}}while((y|m)<g);if(b)break;do{if(0!=(y=e-f(a[d],s,t,e,e-1,r))){for(e-=y,v=1+(c-=y),p=1+(l-=y),h=y-1;h>=0;h--)s[v+h]=s[p+h];if(0===e){b=!0;break}}if(s[c--]=a[d--],1==--o){b=!0;break}if(0!=(m=o-u(s[l],a,0,o,o-1,r))){for(o-=m,v=1+(c-=m),p=1+(d-=m),h=0;h<m;h++)s[v+h]=a[p+h];if(o<=1){b=!0;break}}if(s[c--]=s[l--],0==--e){b=!0;break}g--}while(y>=n||m>=n);if(b)break;g<0&&(g=0),g+=2}if(this.minGallop=g,g<1&&(this.minGallop=1),1===o){for(v=1+(c-=e),p=1+(l-=e),h=e-1;h>=0;h--)s[v+h]=s[p+h];s[c]=a[d]}else{if(0===o)throw new Error("mergeHigh preconditions were not respected");for(p=c-(o-1),h=0;h<o;h++)s[p+h]=a[h]}}else{for(v=1+(c-=e),p=1+(l-=e),h=e-1;h>=0;h--)s[v+h]=s[p+h];s[c]=a[d]}else for(p=c-(o-1),h=0;h<o;h++)s[p+h]=a[h]},t}();function v(t,e,n,o){if(!Array.isArray(t))throw new TypeError("Can only sort arrays");e?"function"!=typeof e&&(o=n,n=e,e=a):e=a,n||(n=0),o||(o=t.length);var r=o-n;if(!(r<2)){var s=0;if(r<i)c(t,n,o,n+(s=l(t,n,o,e)),e);else{var d=new p(t,e),u=h(r);do{if((s=l(t,n,o,e))<u){var f=r;f>u&&(f=u),c(t,n,n+f,n+s,e),s=f}d.pushRun(n,s),d.mergeRuns(),r-=s,n+=s}while(0!==r);d.forceMergeRuns()}}}}(t)}(WS);var qS=WS;function VS(t){var e=function(){if("undefined"==typeof Reflect||!Mk)return!1;if(Mk.sham)return!1;if("function"==typeof Proxy)return!0;try{return Boolean.prototype.valueOf.call(Mk(Boolean,[],(function(){}))),!0}catch(t){return!1}}();return function(){var i,n=Ak(t);if(e){var o=Ak(this).constructor;i=Mk(n,arguments,o)}else i=n.apply(this,arguments);return Nk(this,i)}}var US=function(){function t(){Yd(this,t)}return Kd(t,[{key:"abstract",value:function(){throw new Error("Can't instantiate abstract class!")}},{key:"fake_use",value:function(){}},{key:"curveType",value:function(){return this.abstract()}},{key:"getPosition",value:function(t){return this.fake_use(t),this.abstract()}},{key:"setPosition",value:function(t,e){var i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:void 0;this.fake_use(t,e,i),this.abstract()}},{key:"getTreeSize",value:function(t){return this.fake_use(t),this.abstract()}},{key:"sort",value:function(t){this.fake_use(t),this.abstract()}},{key:"fix",value:function(t,e){this.fake_use(t,e),this.abstract()}},{key:"shift",value:function(t,e){this.fake_use(t,e),this.abstract()}}]),t}(),YS=function(t){zk(i,t);var e=VS(i);function i(t){var n;return Yd(this,i),(n=e.call(this)).layout=t,n}return Kd(i,[{key:"curveType",value:function(){return"horizontal"}},{key:"getPosition",value:function(t){return t.x}},{key:"setPosition",value:function(t,e){var i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:void 0;void 0!==i&&this.layout.hierarchical.addToOrdering(t,i),t.x=e}},{key:"getTreeSize",value:function(t){var e=this.layout.hierarchical.getTreeSize(this.layout.body.nodes,t);return{min:e.min_x,max:e.max_x}}},{key:"sort",value:function(t){qS.sort(t,(function(t,e){return t.x-e.x}))}},{key:"fix",value:function(t,e){t.y=this.layout.options.hierarchical.levelSeparation*e,t.options.fixed.y=!0}},{key:"shift",value:function(t,e){this.layout.body.nodes[t].x+=e}}]),i}(US),XS=function(t){zk(i,t);var e=VS(i);function i(t){var n;return Yd(this,i),(n=e.call(this)).layout=t,n}return Kd(i,[{key:"curveType",value:function(){return"vertical"}},{key:"getPosition",value:function(t){return t.y}},{key:"setPosition",value:function(t,e){var i=arguments.length>2&&void 0!==arguments[2]?arguments[2]:void 0;void 0!==i&&this.layout.hierarchical.addToOrdering(t,i),t.y=e}},{key:"getTreeSize",value:function(t){var e=this.layout.hierarchical.getTreeSize(this.layout.body.nodes,t);return{min:e.min_y,max:e.max_y}}},{key:"sort",value:function(t){qS.sort(t,(function(t,e){return t.y-e.y}))}},{key:"fix",value:function(t,e){t.x=this.layout.options.hierarchical.levelSeparation*e,t.options.fixed.x=!0}},{key:"shift",value:function(t,e){this.layout.body.nodes[t].y+=e}}]),i}(US),GS=Wh.every;_i({target:"Array",proto:!0,forced:!Cu("every")},{every:function(t){return GS(this,t,arguments.length>1?arguments[1]:void 0)}});var KS=Tn("Array").every,$S=J,ZS=KS,QS=Array.prototype,JS=function(t){var e=t.every;return t===QS||$S(QS,t)&&e===QS.every?ZS:e},tT=JS;function eT(t,e){var i=void 0!==tu&&ih(t)||t["@@iterator"];if(!i){if(lu(t)||(i=function(t,e){var i;if(!t)return;if("string"==typeof t)return iT(t,e);var n=au(i=Object.prototype.toString.call(t)).call(i,8,-1);"Object"===n&&t.constructor&&(n=t.constructor.name);if("Map"===n||"Set"===n)return ja(t);if("Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n))return iT(t,e)}(t))||e&&t&&"number"==typeof t.length){i&&(t=i);var n=0,o=function(){};return{s:o,n:function(){return n>=t.length?{done:!0}:{done:!1,value:t[n++]}},e:function(t){throw t},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var r,s=!0,a=!1;return{s:function(){i=i.call(t)},n:function(){var t=i.next();return s=t.done,t},e:function(t){a=!0,r=t},f:function(){try{s||null==i.return||i.return()}finally{if(a)throw r}}}}function iT(t,e){(null==e||e>t.length)&&(e=t.length);for(var i=0,n=new Array(e);i<e;i++)n[i]=t[i];return n}function nT(t,e){var i=new b_;return Fu(t).call(t,(function(t){var e;Fu(e=t.edges).call(e,(function(t){t.connected&&i.add(t)}))})),Fu(i).call(i,(function(t){var i=t.from.id,n=t.to.id;null==e[i]&&(e[i]=0),(null==e[n]||e[i]>=e[n])&&(e[n]=e[i]+1)})),e}function oT(t,e,i,n){var o,r,s=Kp(null),a=i_(o=Jc(kx(n).call(n))).call(o,(function(t,e){return t+1+e.edges.length}),0),h=i+"Id",l="to"===i?1:-1,d=eT(n);try{var c=function(){var o=Kc(r.value,2),d=o[0],c=o[1];if(!n.has(d)||!t(c))return"continue";s[d]=0;for(var u=[c],f=0,p=void 0,v=function(){var t,o;if(!n.has(d))return"continue";var r=s[p.id]+l;if(Fu(t=Xf(o=p.edges).call(o,(function(t){return t.connected&&t.to!==t.from&&t[i]!==p&&n.has(t.toId)&&n.has(t.fromId)}))).call(t,(function(t){var n=t[h],o=s[n];(null==o||e(r,o))&&(s[n]=r,u.push(t[i]))})),f>a)return{v:{v:nT(n,s)}};++f};p=u.pop();){var g=v();if("continue"!==g&&"object"===Qc(g))return g.v}};for(d.s();!(r=d.n()).done;){var u=c();if("continue"!==u&&"object"===Qc(u))return u.v}}catch(t){d.e(t)}finally{d.f()}return s}var rT=function(){function t(){Yd(this,t),this.childrenReference={},this.parentReference={},this.trees={},this.distributionOrdering={},this.levels={},this.distributionIndex={},this.isTree=!1,this.treeIndex=-1}return Kd(t,[{key:"addRelation",value:function(t,e){void 0===this.childrenReference[t]&&(this.childrenReference[t]=[]),this.childrenReference[t].push(e),void 0===this.parentReference[e]&&(this.parentReference[e]=[]),this.parentReference[e].push(t)}},{key:"checkIfTree",value:function(){for(var t in this.parentReference)if(this.parentReference[t].length>1)return void(this.isTree=!1);this.isTree=!0}},{key:"numTrees",value:function(){return this.treeIndex+1}},{key:"setTreeIndex",value:function(t,e){void 0!==e&&void 0===this.trees[t.id]&&(this.trees[t.id]=e,this.treeIndex=Math.max(e,this.treeIndex))}},{key:"ensureLevel",value:function(t){void 0===this.levels[t]&&(this.levels[t]=0)}},{key:"getMaxLevel",value:function(t){var e=this,i={};return function t(n){if(void 0!==i[n])return i[n];var o=e.levels[n];if(e.childrenReference[n]){var r=e.childrenReference[n];if(r.length>0)for(var s=0;s<r.length;s++)o=Math.max(o,t(r[s]))}return i[n]=o,o}(t)}},{key:"levelDownstream",value:function(t,e){void 0===this.levels[e.id]&&(void 0===this.levels[t.id]&&(this.levels[t.id]=0),this.levels[e.id]=this.levels[t.id]+1)}},{key:"setMinLevelToZero",value:function(t){var e=1e9;for(var i in t)Object.prototype.hasOwnProperty.call(t,i)&&void 0!==this.levels[i]&&(e=Math.min(this.levels[i],e));for(var n in t)Object.prototype.hasOwnProperty.call(t,n)&&void 0!==this.levels[n]&&(this.levels[n]-=e)}},{key:"getTreeSize",value:function(t,e){var i=1e9,n=-1e9,o=1e9,r=-1e9;for(var s in this.trees)if(Object.prototype.hasOwnProperty.call(this.trees,s)&&this.trees[s]===e){var a=t[s];i=Math.min(a.x,i),n=Math.max(a.x,n),o=Math.min(a.y,o),r=Math.max(a.y,r)}return{min_x:i,max_x:n,min_y:o,max_y:r}}},{key:"hasSameParent",value:function(t,e){var i=this.parentReference[t.id],n=this.parentReference[e.id];if(void 0===i||void 0===n)return!1;for(var o=0;o<i.length;o++)for(var r=0;r<n.length;r++)if(i[o]==n[r])return!0;return!1}},{key:"inSameSubNetwork",value:function(t,e){return this.trees[t.id]===this.trees[e.id]}},{key:"getLevels",value:function(){return bu(this.distributionOrdering)}},{key:"addToOrdering",value:function(t,e){void 0===this.distributionOrdering[e]&&(this.distributionOrdering[e]=[]);var i=!1,n=this.distributionOrdering[e];for(var o in n)if(n[o]===t){i=!0;break}i||(this.distributionOrdering[e].push(t),this.distributionIndex[t.id]=this.distributionOrdering[e].length-1)}}]),t}(),sT=function(){function t(e){Yd(this,t),this.body=e,this._resetRNG(Math.random()+":"+Eu()),this.setPhysics=!1,this.options={},this.optionsBackup={physics:{}},this.defaultOptions={randomSeed:void 0,improvedLayout:!0,clusterThreshold:150,hierarchical:{enabled:!1,levelSeparation:150,nodeSpacing:100,treeSpacing:200,blockShifting:!0,edgeMinimization:!0,parentCentralization:!0,direction:"UD",sortMethod:"hubsize"}},un(this.options,this.defaultOptions),this.bindEventListeners()}return Kd(t,[{key:"bindEventListeners",value:function(){var t=this;this.body.emitter.on("_dataChanged",(function(){t.setupHierarchicalLayout()})),this.body.emitter.on("_dataLoaded",(function(){t.layoutNetwork()})),this.body.emitter.on("_resetHierarchicalLayout",(function(){t.setupHierarchicalLayout()})),this.body.emitter.on("_adjustEdgesForHierarchicalLayout",(function(){if(!0===t.options.hierarchical.enabled){var e=t.direction.curveType();t.body.emitter.emit("_forceDisableDynamicCurves",e,!1)}}))}},{key:"setOptions",value:function(t,e){if(void 0!==t){var i=this.options.hierarchical,n=i.enabled;if(em(["randomSeed","improvedLayout","clusterThreshold"],this.options,t),Sm(this.options,t,"hierarchical"),void 0!==t.randomSeed&&this._resetRNG(t.randomSeed),!0===i.enabled)return!0===n&&this.body.emitter.emit("refresh",!0),"RL"===i.direction||"DU"===i.direction?i.levelSeparation>0&&(i.levelSeparation*=-1):i.levelSeparation<0&&(i.levelSeparation*=-1),this.setDirectionStrategy(),this.body.emitter.emit("_resetHierarchicalLayout"),this.adaptAllOptionsForHierarchicalLayout(e);if(!0===n)return this.body.emitter.emit("refresh"),nm(e,this.optionsBackup)}return e}},{key:"_resetRNG",value:function(t){this.initialRandomSeed=t,this._rng=jy(this.initialRandomSeed)}},{key:"adaptAllOptionsForHierarchicalLayout",value:function(t){if(!0===this.options.hierarchical.enabled){var e=this.optionsBackup.physics;void 0===t.physics||!0===t.physics?(t.physics={enabled:void 0===e.enabled||e.enabled,solver:"hierarchicalRepulsion"},e.enabled=void 0===e.enabled||e.enabled,e.solver=e.solver||"barnesHut"):"object"===Qc(t.physics)?(e.enabled=void 0===t.physics.enabled||t.physics.enabled,e.solver=t.physics.solver||"barnesHut",t.physics.solver="hierarchicalRepulsion"):!1!==t.physics&&(e.solver="barnesHut",t.physics={solver:"hierarchicalRepulsion"});var i=this.direction.curveType();if(void 0===t.edges)this.optionsBackup.edges={smooth:{enabled:!0,type:"dynamic"}},t.edges={smooth:!1};else if(void 0===t.edges.smooth)this.optionsBackup.edges={smooth:{enabled:!0,type:"dynamic"}},t.edges.smooth=!1;else if("boolean"==typeof t.edges.smooth)this.optionsBackup.edges={smooth:t.edges.smooth},t.edges.smooth={enabled:t.edges.smooth,type:i};else{var n=t.edges.smooth;void 0!==n.type&&"dynamic"!==n.type&&(i=n.type),this.optionsBackup.edges={smooth:{enabled:void 0===n.enabled||n.enabled,type:void 0===n.type?"dynamic":n.type,roundness:void 0===n.roundness?.5:n.roundness,forceDirection:void 0!==n.forceDirection&&n.forceDirection}},t.edges.smooth={enabled:void 0===n.enabled||n.enabled,type:i,roundness:void 0===n.roundness?.5:n.roundness,forceDirection:void 0!==n.forceDirection&&n.forceDirection}}this.body.emitter.emit("_forceDisableDynamicCurves",i)}return t}},{key:"positionInitially",value:function(t){if(!0!==this.options.hierarchical.enabled){this._resetRNG(this.initialRandomSeed);for(var e=t.length+50,i=0;i<t.length;i++){var n=t[i],o=2*Math.PI*this._rng();void 0===n.x&&(n.x=e*Math.cos(o)),void 0===n.y&&(n.y=e*Math.sin(o))}}}},{key:"layoutNetwork",value:function(){if(!0!==this.options.hierarchical.enabled&&!0===this.options.improvedLayout){for(var t=this.body.nodeIndices,e=0,i=0;i<t.length;i++){!0===this.body.nodes[t[i]].predefinedPosition&&(e+=1)}if(e<.5*t.length){var n=0,o=this.options.clusterThreshold,r={clusterNodeProperties:{shape:"ellipse",label:"",group:"",font:{multi:!1}},clusterEdgeProperties:{label:"",font:{multi:!1},smooth:{enabled:!1}}};if(t.length>o){for(var s=t.length;t.length>o&&n<=10;){n+=1;var a=t.length;if(n%3==0?this.body.modules.clustering.clusterBridges(r):this.body.modules.clustering.clusterOutliers(r),a==t.length&&n%3!=0)return this._declusterAll(),this.body.emitter.emit("_layoutFailed"),void console.info("This network could not be positioned by this version of the improved layout algorithm. Please disable improvedLayout for better performance.")}this.body.modules.kamadaKawai.setOptions({springLength:Math.max(150,2*s)})}n>10&&console.info("The clustering didn't succeed within the amount of interations allowed, progressing with partial result."),this.body.modules.kamadaKawai.solve(t,this.body.edgeIndices,!0),this._shiftToCenter();for(var h=0;h<t.length;h++){var l=this.body.nodes[t[h]];!1===l.predefinedPosition&&(l.x+=70*(.5-this._rng()),l.y+=70*(.5-this._rng()))}this._declusterAll(),this.body.emitter.emit("_repositionBezierNodes")}}}},{key:"_shiftToCenter",value:function(){for(var t=EC.getRangeCore(this.body.nodes,this.body.nodeIndices),e=EC.findCenter(t),i=0;i<this.body.nodeIndices.length;i++){var n=this.body.nodes[this.body.nodeIndices[i]];n.x-=e.x,n.y-=e.y}}},{key:"_declusterAll",value:function(){for(var t=!0;!0===t;){t=!1;for(var e=0;e<this.body.nodeIndices.length;e++)!0===this.body.nodes[this.body.nodeIndices[e]].isCluster&&(t=!0,this.body.modules.clustering.openCluster(this.body.nodeIndices[e],{},!1));!0===t&&this.body.emitter.emit("_dataChanged")}}},{key:"getSeed",value:function(){return this.initialRandomSeed}},{key:"setupHierarchicalLayout",value:function(){if(!0===this.options.hierarchical.enabled&&this.body.nodeIndices.length>0){var t,e,i=!1,n=!1;for(e in this.lastNodeOnLevel={},this.hierarchical=new rT,this.body.nodes)Object.prototype.hasOwnProperty.call(this.body.nodes,e)&&(void 0!==(t=this.body.nodes[e]).options.level?(i=!0,this.hierarchical.levels[e]=t.options.level):n=!0);if(!0===n&&!0===i)throw new Error("To use the hierarchical layout, nodes require either no predefined levels or levels have to be defined for all nodes.");if(!0===n){var o=this.options.hierarchical.sortMethod;"hubsize"===o?this._determineLevelsByHubsize():"directed"===o?this._determineLevelsDirected():"custom"===o&&this._determineLevelsCustomCallback()}for(var r in this.body.nodes)Object.prototype.hasOwnProperty.call(this.body.nodes,r)&&this.hierarchical.ensureLevel(r);var s=this._getDistribution();this._generateMap(),this._placeNodesByHierarchy(s),this._condenseHierarchy(),this._shiftToCenter()}}},{key:"_condenseHierarchy",value:function(){var t=this,e=!1,i={},n=function(e,i){var n=t.hierarchical.trees;for(var o in n)Object.prototype.hasOwnProperty.call(n,o)&&n[o]===e&&t.direction.shift(o,i)},o=function(){for(var e=[],i=0;i<t.hierarchical.numTrees();i++)e.push(t.direction.getTreeSize(i));return e},r=function e(i,n){if(!n[i.id]&&(n[i.id]=!0,t.hierarchical.childrenReference[i.id])){var o=t.hierarchical.childrenReference[i.id];if(o.length>0)for(var r=0;r<o.length;r++)e(t.body.nodes[o[r]],n)}},s=function(e){var i=arguments.length>1&&void 0!==arguments[1]?arguments[1]:1e9,n=1e9,o=1e9,r=1e9,s=-1e9;for(var a in e)if(Object.prototype.hasOwnProperty.call(e,a)){var h=t.body.nodes[a],l=t.hierarchical.levels[h.id],d=t.direction.getPosition(h),c=t._getSpaceAroundNode(h,e),u=Kc(c,2),f=u[0],p=u[1];n=Math.min(f,n),o=Math.min(p,o),l<=i&&(r=Math.min(d,r),s=Math.max(d,s))}return[r,s,n,o]},a=function(e,i){var n=t.hierarchical.getMaxLevel(e.id),o=t.hierarchical.getMaxLevel(i.id);return Math.min(n,o)},h=function(e,i,n){for(var o=t.hierarchical,r=0;r<i.length;r++){var s=i[r],a=o.distributionOrdering[s];if(a.length>1)for(var h=0;h<a.length-1;h++){var l=a[h],d=a[h+1];o.hasSameParent(l,d)&&o.inSameSubNetwork(l,d)&&e(l,d,n)}}},l=function(i,n){var o=arguments.length>2&&void 0!==arguments[2]&&arguments[2],h=t.direction.getPosition(i),l=t.direction.getPosition(n),d=Math.abs(l-h),c=t.options.hierarchical.nodeSpacing;if(d>c){var u={},f={};r(i,u),r(n,f);var p=a(i,n),v=s(u,p),g=s(f,p),y=v[1],m=g[0],b=g[2],w=Math.abs(y-m);if(w>c){var k=y-m+c;k<-b+c&&(k=-b+c),k<0&&(t._shiftBlock(n.id,k),e=!0,!0===o&&t._centerParent(n))}}},d=function(n,o){for(var a=o.id,h=o.edges,l=t.hierarchical.levels[o.id],d=t.options.hierarchical.levelSeparation*t.options.hierarchical.levelSeparation,c={},u=[],f=0;f<h.length;f++){var p=h[f];if(p.toId!=p.fromId){var v=p.toId==a?p.from:p.to;c[h[f].id]=v,t.hierarchical.levels[v.id]<l&&u.push(p)}}var g=function(e,i){for(var n=0,o=0;o<i.length;o++)if(void 0!==c[i[o].id]){var r=t.direction.getPosition(c[i[o].id])-e;n+=r/Math.sqrt(r*r+d)}return n},y=function(e,i){for(var n=0,o=0;o<i.length;o++)if(void 0!==c[i[o].id]){var r=t.direction.getPosition(c[i[o].id])-e;n-=d*Math.pow(r*r+d,-1.5)}return n},m=function(e,i){for(var n=t.direction.getPosition(o),r={},s=0;s<e;s++){var a=g(n,i),h=y(n,i);if(void 0!==r[n-=Math.max(-40,Math.min(40,Math.round(a/h)))])break;r[n]=s}return n},b=m(n,u);!function(n){var a=t.direction.getPosition(o);if(void 0===i[o.id]){var h={};r(o,h),i[o.id]=h}var l=s(i[o.id]),d=l[2],c=l[3],u=n-a,f=0;u>0?f=Math.min(u,c-t.options.hierarchical.nodeSpacing):u<0&&(f=-Math.min(-u,d-t.options.hierarchical.nodeSpacing)),0!=f&&(t._shiftBlock(o.id,f),e=!0)}(b),function(i){var n=t.direction.getPosition(o),r=Kc(t._getSpaceAroundNode(o),2),s=r[0],a=r[1],h=i-n,l=n;h>0?l=Math.min(n+(a-t.options.hierarchical.nodeSpacing),i):h<0&&(l=Math.max(n-(s-t.options.hierarchical.nodeSpacing),i)),l!==n&&(t.direction.setPosition(o,l),e=!0)}(b=m(n,h))};!0===this.options.hierarchical.blockShifting&&(function(i){var n=t.hierarchical.getLevels();n=Yu(n).call(n);for(var o=0;o<i&&(e=!1,h(l,n,!0),!0===e);o++);}(5),function(){for(var e in t.body.nodes)Object.prototype.hasOwnProperty.call(t.body.nodes,e)&&t._centerParent(t.body.nodes[e])}()),!0===this.options.hierarchical.edgeMinimization&&function(i){var n=t.hierarchical.getLevels();n=Yu(n).call(n);for(var o=0;o<i;o++){e=!1;for(var r=0;r<n.length;r++)for(var s=n[r],a=t.hierarchical.distributionOrdering[s],h=0;h<a.length;h++)d(1e3,a[h]);if(!0!==e)break}}(20),!0===this.options.hierarchical.parentCentralization&&function(){var e=t.hierarchical.getLevels();e=Yu(e).call(e);for(var i=0;i<e.length;i++)for(var n=e[i],o=t.hierarchical.distributionOrdering[n],r=0;r<o.length;r++)t._centerParent(o[r])}(),function(){for(var e=o(),i=0,r=0;r<e.length-1;r++){i+=e[r].max-e[r+1].min+t.options.hierarchical.treeSpacing,n(r+1,i)}}()}},{key:"_getSpaceAroundNode",value:function(t,e){var i=!0;void 0===e&&(i=!1);var n=this.hierarchical.levels[t.id];if(void 0!==n){var o=this.hierarchical.distributionIndex[t.id],r=this.direction.getPosition(t),s=this.hierarchical.distributionOrdering[n],a=1e9,h=1e9;if(0!==o){var l=s[o-1];if(!0===i&&void 0===e[l.id]||!1===i)a=r-this.direction.getPosition(l)}if(o!=s.length-1){var d=s[o+1];if(!0===i&&void 0===e[d.id]||!1===i){var c=this.direction.getPosition(d);h=Math.min(h,c-r)}}return[a,h]}return[0,0]}},{key:"_centerParent",value:function(t){if(this.hierarchical.parentReference[t.id])for(var e=this.hierarchical.parentReference[t.id],i=0;i<e.length;i++){var n=e[i],o=this.body.nodes[n],r=this.hierarchical.childrenReference[n];if(void 0!==r){var s=this._getCenterPosition(r),a=this.direction.getPosition(o),h=Kc(this._getSpaceAroundNode(o),2),l=h[0],d=h[1],c=a-s;(c<0&&Math.abs(c)<d-this.options.hierarchical.nodeSpacing||c>0&&Math.abs(c)<l-this.options.hierarchical.nodeSpacing)&&this.direction.setPosition(o,s)}}}},{key:"_placeNodesByHierarchy",value:function(t){for(var e in this.positionedNodes={},t)if(Object.prototype.hasOwnProperty.call(t,e)){var i,n=bu(t[e]);n=this._indexArrayToNodes(n),rx(i=this.direction).call(i,n);for(var o=0,r=0;r<n.length;r++){var s=n[r];if(void 0===this.positionedNodes[s.id]){var a=this.options.hierarchical.nodeSpacing,h=a*o;o>0&&(h=this.direction.getPosition(n[r-1])+a),this.direction.setPosition(s,h,e),this._validatePositionAndContinue(s,e,h),o++}}}}},{key:"_placeBranchNodes",value:function(t,e){var i,n=this.hierarchical.childrenReference[t];if(void 0!==n){for(var o=[],r=0;r<n.length;r++)o.push(this.body.nodes[n[r]]);rx(i=this.direction).call(i,o);for(var s=0;s<o.length;s++){var a=o[s],h=this.hierarchical.levels[a.id];if(!(h>e&&void 0===this.positionedNodes[a.id]))return;var l=this.options.hierarchical.nodeSpacing,d=void 0;d=0===s?this.direction.getPosition(this.body.nodes[t]):this.direction.getPosition(o[s-1])+l,this.direction.setPosition(a,d,h),this._validatePositionAndContinue(a,h,d)}var c=this._getCenterPosition(o);this.direction.setPosition(this.body.nodes[t],c,e)}}},{key:"_validatePositionAndContinue",value:function(t,e,i){if(this.hierarchical.isTree){if(void 0!==this.lastNodeOnLevel[e]){var n=this.direction.getPosition(this.body.nodes[this.lastNodeOnLevel[e]]);if(i-n<this.options.hierarchical.nodeSpacing){var o=n+this.options.hierarchical.nodeSpacing-i,r=this._findCommonParent(this.lastNodeOnLevel[e],t.id);this._shiftBlock(r.withChild,o)}}this.lastNodeOnLevel[e]=t.id,this.positionedNodes[t.id]=!0,this._placeBranchNodes(t.id,e)}}},{key:"_indexArrayToNodes",value:function(t){for(var e=[],i=0;i<t.length;i++)e.push(this.body.nodes[t[i]]);return e}},{key:"_getDistribution",value:function(){var t,e,i={};for(t in this.body.nodes)if(Object.prototype.hasOwnProperty.call(this.body.nodes,t)){e=this.body.nodes[t];var n=void 0===this.hierarchical.levels[t]?0:this.hierarchical.levels[t];this.direction.fix(e,n),void 0===i[n]&&(i[n]={}),i[n][t]=e}return i}},{key:"_getActiveEdges",value:function(t){var e=this,i=[];return hm(t.edges,(function(t){var n;-1!==Fp(n=e.body.edgeIndices).call(n,t.id)&&i.push(t)})),i}},{key:"_getHubSizes",value:function(){var t=this,e={};hm(this.body.nodeIndices,(function(i){var n=t.body.nodes[i],o=t._getActiveEdges(n).length;e[o]=!0}));var i=[];return hm(e,(function(t){i.push(Number(t))})),rx(qS).call(qS,i,(function(t,e){return e-t})),i}},{key:"_determineLevelsByHubsize",value:function(){for(var t=this,e=function(e,i){t.hierarchical.levelDownstream(e,i)},i=this._getHubSizes(),n=function(n){var o=i[n];if(0===o)return"break";hm(t.body.nodeIndices,(function(i){var n=t.body.nodes[i];o===t._getActiveEdges(n).length&&t._crawlNetwork(e,i)}))},o=0;o<i.length;++o){if("break"===n(o))break}}},{key:"_determineLevelsCustomCallback",value:function(){var t=this;this._crawlNetwork((function(e,i,n){var o=t.hierarchical.levels[e.id];void 0===o&&(o=t.hierarchical.levels[e.id]=1e5);var r=(EC.cloneOptions(e,"node"),EC.cloneOptions(i,"node"),void EC.cloneOptions(n,"edge"));t.hierarchical.levels[i.id]=o+r})),this.hierarchical.setMinLevelToZero(this.body.nodes)}},{key:"_determineLevelsDirected",value:function(){var t,e=this,i=i_(t=this.body.nodeIndices).call(t,(function(t,i){return t.set(i,e.body.nodes[i]),t}),new Jw);"roots"===this.options.hierarchical.shakeTowards?this.hierarchical.levels=function(t){return oT((function(e){var i,n;return tT(i=Xf(n=e.edges).call(n,(function(e){return t.has(e.toId)}))).call(i,(function(t){return t.from===e}))}),(function(t,e){return e<t}),"to",t)}(i):this.hierarchical.levels=function(t){return oT((function(e){var i,n;return tT(i=Xf(n=e.edges).call(n,(function(e){return t.has(e.toId)}))).call(i,(function(t){return t.to===e}))}),(function(t,e){return e>t}),"from",t)}(i),this.hierarchical.setMinLevelToZero(this.body.nodes)}},{key:"_generateMap",value:function(){var t=this;this._crawlNetwork((function(e,i){t.hierarchical.levels[i.id]>t.hierarchical.levels[e.id]&&t.hierarchical.addRelation(e.id,i.id)})),this.hierarchical.checkIfTree()}},{key:"_crawlNetwork",value:function(){var t=this,e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:function(){},i=arguments.length>1?arguments[1]:void 0,n={},o=function i(o,r){if(void 0===n[o.id]){var s;t.hierarchical.setTreeIndex(o,r),n[o.id]=!0;for(var a=t._getActiveEdges(o),h=0;h<a.length;h++){var l=a[h];!0===l.connected&&(s=l.toId==o.id?l.from:l.to,o.id!=s.id&&(e(o,s,l),i(s,r)))}}};if(void 0===i)for(var r=0,s=0;s<this.body.nodeIndices.length;s++){var a=this.body.nodeIndices[s];if(void 0===n[a]){var h=this.body.nodes[a];o(h,r),r+=1}}else{var l=this.body.nodes[i];if(void 0===l)return void console.error("Node not found:",i);o(l)}}},{key:"_shiftBlock",value:function(t,e){var i=this,n={};!function t(o){if(!n[o]){n[o]=!0,i.direction.shift(o,e);var r=i.hierarchical.childrenReference[o];if(void 0!==r)for(var s=0;s<r.length;s++)t(r[s])}}(t)}},{key:"_findCommonParent",value:function(t,e){var i=this,n={};return function t(e,n){var o=i.hierarchical.parentReference[n];if(void 0!==o)for(var r=0;r<o.length;r++){var s=o[r];e[s]=!0,t(e,s)}}(n,t),function t(e,n){var o=i.hierarchical.parentReference[n];if(void 0!==o)for(var r=0;r<o.length;r++){var s=o[r];if(void 0!==e[s])return{foundParent:s,withChild:n};var a=t(e,s);if(null!==a.foundParent)return a}return{foundParent:null,withChild:n}}(n,e)}},{key:"setDirectionStrategy",value:function(){var t="UD"===this.options.hierarchical.direction||"DU"===this.options.hierarchical.direction;this.direction=t?new YS(this):new XS(this)}},{key:"_getCenterPosition",value:function(t){for(var e=1e9,i=-1e9,n=0;n<t.length;n++){var o=void 0;if(void 0!==t[n].id)o=t[n];else{var r=t[n];o=this.body.nodes[r]}var s=this.direction.getPosition(o);e=Math.min(e,s),i=Math.max(i,s)}return.5*(e+i)}}]),t}();function aT(t,e){var i=void 0!==tu&&ih(t)||t["@@iterator"];if(!i){if(lu(t)||(i=function(t,e){var i;if(!t)return;if("string"==typeof t)return hT(t,e);var n=au(i=Object.prototype.toString.call(t)).call(i,8,-1);"Object"===n&&t.constructor&&(n=t.constructor.name);if("Map"===n||"Set"===n)return ja(t);if("Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n))return hT(t,e)}(t))||e&&t&&"number"==typeof t.length){i&&(t=i);var n=0,o=function(){};return{s:o,n:function(){return n>=t.length?{done:!0}:{done:!1,value:t[n++]}},e:function(t){throw t},f:o}}throw new TypeError("Invalid attempt to iterate non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}var r,s=!0,a=!1;return{s:function(){i=i.call(t)},n:function(){var t=i.next();return s=t.done,t},e:function(t){a=!0,r=t},f:function(){try{s||null==i.return||i.return()}finally{if(a)throw r}}}}function hT(t,e){(null==e||e>t.length)&&(e=t.length);for(var i=0,n=new Array(e);i<e;i++)n[i]=t[i];return n}var lT=function(){function t(e,i,n,o){var r,s,a=this;Yd(this,t),this.body=e,this.canvas=i,this.selectionHandler=n,this.interactionHandler=o,this.editMode=!1,this.manipulationDiv=void 0,this.editModeDiv=void 0,this.closeDiv=void 0,this._domEventListenerCleanupQueue=[],this.temporaryUIFunctions={},this.temporaryEventFunctions=[],this.touchTime=0,this.temporaryIds={nodes:[],edges:[]},this.guiEnabled=!1,this.inMode=!1,this.selectedControlNode=void 0,this.options={},this.defaultOptions={enabled:!1,initiallyActive:!1,addNode:!0,addEdge:!0,editNode:void 0,editEdge:!0,deleteNode:!0,deleteEdge:!0,controlNodeStyle:{shape:"dot",size:6,color:{background:"#ff0000",border:"#3c3c3c",highlight:{background:"#07f968",border:"#3c3c3c"}},borderWidth:2,borderWidthSelected:2}},un(this.options,this.defaultOptions),this.body.emitter.on("destroy",(function(){a._clean()})),this.body.emitter.on("_dataChanged",zn(r=this._restore).call(r,this)),this.body.emitter.on("_resetData",zn(s=this._restore).call(s,this))}return Kd(t,[{key:"_restore",value:function(){!1!==this.inMode&&(!0===this.options.initiallyActive?this.enableEditMode():this.disableEditMode())}},{key:"setOptions",value:function(t,e,i){void 0!==e&&(void 0!==e.locale?this.options.locale=e.locale:this.options.locale=i.locale,void 0!==e.locales?this.options.locales=e.locales:this.options.locales=i.locales),void 0!==t&&("boolean"==typeof t?this.options.enabled=t:(this.options.enabled=!0,nm(this.options,t)),!0===this.options.initiallyActive&&(this.editMode=!0),this._setup())}},{key:"toggleEditMode",value:function(){!0===this.editMode?this.disableEditMode():this.enableEditMode()}},{key:"enableEditMode",value:function(){this.editMode=!0,this._clean(),!0===this.guiEnabled&&(this.manipulationDiv.style.display="block",this.closeDiv.style.display="block",this.editModeDiv.style.display="none",this.showManipulatorToolbar())}},{key:"disableEditMode",value:function(){this.editMode=!1,this._clean(),!0===this.guiEnabled&&(this.manipulationDiv.style.display="none",this.closeDiv.style.display="none",this.editModeDiv.style.display="block",this._createEditButton())}},{key:"showManipulatorToolbar",value:function(){if(this._clean(),this.manipulationDOM={},!0===this.guiEnabled){var t,e;this.editMode=!0,this.manipulationDiv.style.display="block",this.closeDiv.style.display="block";var i=this.selectionHandler.getSelectedNodeCount(),n=this.selectionHandler.getSelectedEdgeCount(),o=i+n,r=this.options.locales[this.options.locale],s=!1;!1!==this.options.addNode&&(this._createAddNodeButton(r),s=!0),!1!==this.options.addEdge&&(!0===s?this._createSeperator(1):s=!0,this._createAddEdgeButton(r)),1===i&&"function"==typeof this.options.editNode?(!0===s?this._createSeperator(2):s=!0,this._createEditNodeButton(r)):1===n&&0===i&&!1!==this.options.editEdge&&(!0===s?this._createSeperator(3):s=!0,this._createEditEdgeButton(r)),0!==o&&(i>0&&!1!==this.options.deleteNode||0===i&&!1!==this.options.deleteEdge)&&(!0===s&&this._createSeperator(4),this._createDeleteButton(r)),this._bindElementEvents(this.closeDiv,zn(t=this.toggleEditMode).call(t,this)),this._temporaryBindEvent("select",zn(e=this.showManipulatorToolbar).call(e,this))}this.body.emitter.emit("_redraw")}},{key:"addNodeMode",value:function(){var t;if(!0!==this.editMode&&this.enableEditMode(),this._clean(),this.inMode="addNode",!0===this.guiEnabled){var e,i=this.options.locales[this.options.locale];this.manipulationDOM={},this._createBackButton(i),this._createSeperator(),this._createDescription(i.addDescription||this.options.locales.en.addDescription),this._bindElementEvents(this.closeDiv,zn(e=this.toggleEditMode).call(e,this))}this._temporaryBindEvent("click",zn(t=this._performAddNode).call(t,this))}},{key:"editNode",value:function(){var t=this;!0!==this.editMode&&this.enableEditMode(),this._clean();var e=this.selectionHandler.getSelectedNodes()[0];if(void 0!==e){if(this.inMode="editNode","function"!=typeof this.options.editNode)throw new Error("No function has been configured to handle the editing of nodes.");if(!0!==e.isCluster){var i=nm({},e.options,!1);if(i.x=e.x,i.y=e.y,2!==this.options.editNode.length)throw new Error("The function for edit does not support two arguments (data, callback)");this.options.editNode(i,(function(e){null!=e&&"editNode"===t.inMode&&t.body.data.nodes.getDataSet().update(e),t.showManipulatorToolbar()}))}else alert(this.options.locales[this.options.locale].editClusterError||this.options.locales.en.editClusterError)}else this.showManipulatorToolbar()}},{key:"addEdgeMode",value:function(){var t,e,i,n,o;if(!0!==this.editMode&&this.enableEditMode(),this._clean(),this.inMode="addEdge",!0===this.guiEnabled){var r,s=this.options.locales[this.options.locale];this.manipulationDOM={},this._createBackButton(s),this._createSeperator(),this._createDescription(s.edgeDescription||this.options.locales.en.edgeDescription),this._bindElementEvents(this.closeDiv,zn(r=this.toggleEditMode).call(r,this))}this._temporaryBindUI("onTouch",zn(t=this._handleConnect).call(t,this)),this._temporaryBindUI("onDragEnd",zn(e=this._finishConnect).call(e,this)),this._temporaryBindUI("onDrag",zn(i=this._dragControlNode).call(i,this)),this._temporaryBindUI("onRelease",zn(n=this._finishConnect).call(n,this)),this._temporaryBindUI("onDragStart",zn(o=this._dragStartEdge).call(o,this)),this._temporaryBindUI("onHold",(function(){}))}},{key:"editEdgeMode",value:function(){if(!0!==this.editMode&&this.enableEditMode(),this._clean(),this.inMode="editEdge","object"!==Qc(this.options.editEdge)||"function"!=typeof this.options.editEdge.editWithoutDrag||(this.edgeBeingEditedId=this.selectionHandler.getSelectedEdgeIds()[0],void 0===this.edgeBeingEditedId)){if(!0===this.guiEnabled){var t,e=this.options.locales[this.options.locale];this.manipulationDOM={},this._createBackButton(e),this._createSeperator(),this._createDescription(e.editEdgeDescription||this.options.locales.en.editEdgeDescription),this._bindElementEvents(this.closeDiv,zn(t=this.toggleEditMode).call(t,this))}if(this.edgeBeingEditedId=this.selectionHandler.getSelectedEdgeIds()[0],void 0!==this.edgeBeingEditedId){var i,n,o,r,s=this.body.edges[this.edgeBeingEditedId],a=this._getNewTargetNode(s.from.x,s.from.y),h=this._getNewTargetNode(s.to.x,s.to.y);this.temporaryIds.nodes.push(a.id),this.temporaryIds.nodes.push(h.id),this.body.nodes[a.id]=a,this.body.nodeIndices.push(a.id),this.body.nodes[h.id]=h,this.body.nodeIndices.push(h.id),this._temporaryBindUI("onTouch",zn(i=this._controlNodeTouch).call(i,this)),this._temporaryBindUI("onTap",(function(){})),this._temporaryBindUI("onHold",(function(){})),this._temporaryBindUI("onDragStart",zn(n=this._controlNodeDragStart).call(n,this)),this._temporaryBindUI("onDrag",zn(o=this._controlNodeDrag).call(o,this)),this._temporaryBindUI("onDragEnd",zn(r=this._controlNodeDragEnd).call(r,this)),this._temporaryBindUI("onMouseMove",(function(){})),this._temporaryBindEvent("beforeDrawing",(function(t){var e=s.edgeType.findBorderPositions(t);!1===a.selected&&(a.x=e.from.x,a.y=e.from.y),!1===h.selected&&(h.x=e.to.x,h.y=e.to.y)})),this.body.emitter.emit("_redraw")}else this.showManipulatorToolbar()}else{var l=this.body.edges[this.edgeBeingEditedId];this._performEditEdge(l.from.id,l.to.id)}}},{key:"deleteSelected",value:function(){var t=this;!0!==this.editMode&&this.enableEditMode(),this._clean(),this.inMode="delete";var e=this.selectionHandler.getSelectedNodeIds(),i=this.selectionHandler.getSelectedEdgeIds(),n=void 0;if(e.length>0){for(var o=0;o<e.length;o++)if(!0===this.body.nodes[e[o]].isCluster)return void alert(this.options.locales[this.options.locale].deleteClusterError||this.options.locales.en.deleteClusterError);"function"==typeof this.options.deleteNode&&(n=this.options.deleteNode)}else i.length>0&&"function"==typeof this.options.deleteEdge&&(n=this.options.deleteEdge);if("function"==typeof n){var r={nodes:e,edges:i};if(2!==n.length)throw new Error("The function for delete does not support two arguments (data, callback)");n(r,(function(e){null!=e&&"delete"===t.inMode?(t.body.data.edges.getDataSet().remove(e.edges),t.body.data.nodes.getDataSet().remove(e.nodes),t.body.emitter.emit("startSimulation"),t.showManipulatorToolbar()):(t.body.emitter.emit("startSimulation"),t.showManipulatorToolbar())}))}else this.body.data.edges.getDataSet().remove(i),this.body.data.nodes.getDataSet().remove(e),this.body.emitter.emit("startSimulation"),this.showManipulatorToolbar()}},{key:"_setup",value:function(){!0===this.options.enabled?(this.guiEnabled=!0,this._createWrappers(),!1===this.editMode?this._createEditButton():this.showManipulatorToolbar()):(this._removeManipulationDOM(),this.guiEnabled=!1)}},{key:"_createWrappers",value:function(){var t,e;(void 0===this.manipulationDiv&&(this.manipulationDiv=document.createElement("div"),this.manipulationDiv.className="vis-manipulation",!0===this.editMode?this.manipulationDiv.style.display="block":this.manipulationDiv.style.display="none",this.canvas.frame.appendChild(this.manipulationDiv)),void 0===this.editModeDiv&&(this.editModeDiv=document.createElement("div"),this.editModeDiv.className="vis-edit-mode",!0===this.editMode?this.editModeDiv.style.display="none":this.editModeDiv.style.display="block",this.canvas.frame.appendChild(this.editModeDiv)),void 0===this.closeDiv)&&(this.closeDiv=document.createElement("button"),this.closeDiv.className="vis-close",this.closeDiv.setAttribute("aria-label",null!==(t=null===(e=this.options.locales[this.options.locale])||void 0===e?void 0:e.close)&&void 0!==t?t:this.options.locales.en.close),this.closeDiv.style.display=this.manipulationDiv.style.display,this.canvas.frame.appendChild(this.closeDiv))}},{key:"_getNewTargetNode",value:function(t,e){var i=nm({},this.options.controlNodeStyle);i.id="targetNode"+Ax(),i.hidden=!1,i.physics=!1,i.x=t,i.y=e;var n=this.body.functions.createNode(i);return n.shape.boundingBox={left:t,right:t,top:e,bottom:e},n}},{key:"_createEditButton",value:function(){var t;this._clean(),this.manipulationDOM={},Ky(this.editModeDiv);var e=this.options.locales[this.options.locale],i=this._createButton("editMode","vis-edit vis-edit-mode",e.edit||this.options.locales.en.edit);this.editModeDiv.appendChild(i),this._bindElementEvents(i,zn(t=this.toggleEditMode).call(t,this))}},{key:"_clean",value:function(){this.inMode=!1,!0===this.guiEnabled&&(Ky(this.editModeDiv),Ky(this.manipulationDiv),this._cleanupDOMEventListeners()),this._cleanupTemporaryNodesAndEdges(),this._unbindTemporaryUIs(),this._unbindTemporaryEvents(),this.body.emitter.emit("restorePhysics")}},{key:"_cleanupDOMEventListeners",value:function(){var t,e,i=aT(ff(t=this._domEventListenerCleanupQueue).call(t,0));try{for(i.s();!(e=i.n()).done;){(0,e.value)()}}catch(t){i.e(t)}finally{i.f()}}},{key:"_removeManipulationDOM",value:function(){this._clean(),Ky(this.manipulationDiv),Ky(this.editModeDiv),Ky(this.closeDiv),this.manipulationDiv&&this.canvas.frame.removeChild(this.manipulationDiv),this.editModeDiv&&this.canvas.frame.removeChild(this.editModeDiv),this.closeDiv&&this.canvas.frame.removeChild(this.closeDiv),this.manipulationDiv=void 0,this.editModeDiv=void 0,this.closeDiv=void 0}},{key:"_createSeperator",value:function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:1;this.manipulationDOM["seperatorLineDiv"+t]=document.createElement("div"),this.manipulationDOM["seperatorLineDiv"+t].className="vis-separator-line",this.manipulationDiv.appendChild(this.manipulationDOM["seperatorLineDiv"+t])}},{key:"_createAddNodeButton",value:function(t){var e,i=this._createButton("addNode","vis-add",t.addNode||this.options.locales.en.addNode);this.manipulationDiv.appendChild(i),this._bindElementEvents(i,zn(e=this.addNodeMode).call(e,this))}},{key:"_createAddEdgeButton",value:function(t){var e,i=this._createButton("addEdge","vis-connect",t.addEdge||this.options.locales.en.addEdge);this.manipulationDiv.appendChild(i),this._bindElementEvents(i,zn(e=this.addEdgeMode).call(e,this))}},{key:"_createEditNodeButton",value:function(t){var e,i=this._createButton("editNode","vis-edit",t.editNode||this.options.locales.en.editNode);this.manipulationDiv.appendChild(i),this._bindElementEvents(i,zn(e=this.editNode).call(e,this))}},{key:"_createEditEdgeButton",value:function(t){var e,i=this._createButton("editEdge","vis-edit",t.editEdge||this.options.locales.en.editEdge);this.manipulationDiv.appendChild(i),this._bindElementEvents(i,zn(e=this.editEdgeMode).call(e,this))}},{key:"_createDeleteButton",value:function(t){var e,i;i=this.options.rtl?"vis-delete-rtl":"vis-delete";var n=this._createButton("delete",i,t.del||this.options.locales.en.del);this.manipulationDiv.appendChild(n),this._bindElementEvents(n,zn(e=this.deleteSelected).call(e,this))}},{key:"_createBackButton",value:function(t){var e,i=this._createButton("back","vis-back",t.back||this.options.locales.en.back);this.manipulationDiv.appendChild(i),this._bindElementEvents(i,zn(e=this.showManipulatorToolbar).call(e,this))}},{key:"_createButton",value:function(t,e,i){var n=arguments.length>3&&void 0!==arguments[3]?arguments[3]:"vis-label";return this.manipulationDOM[t+"Div"]=document.createElement("button"),this.manipulationDOM[t+"Div"].className="vis-button "+e,this.manipulationDOM[t+"Label"]=document.createElement("div"),this.manipulationDOM[t+"Label"].className=n,this.manipulationDOM[t+"Label"].innerText=i,this.manipulationDOM[t+"Div"].appendChild(this.manipulationDOM[t+"Label"]),this.manipulationDOM[t+"Div"]}},{key:"_createDescription",value:function(t){this.manipulationDOM.descriptionLabel=document.createElement("div"),this.manipulationDOM.descriptionLabel.className="vis-none",this.manipulationDOM.descriptionLabel.innerText=t,this.manipulationDiv.appendChild(this.manipulationDOM.descriptionLabel)}},{key:"_temporaryBindEvent",value:function(t,e){this.temporaryEventFunctions.push({event:t,boundFunction:e}),this.body.emitter.on(t,e)}},{key:"_temporaryBindUI",value:function(t,e){if(void 0===this.body.eventListeners[t])throw new Error("This UI function does not exist. Typo? You tried: "+t+" possible are: "+gv(bu(this.body.eventListeners)));this.temporaryUIFunctions[t]=this.body.eventListeners[t],this.body.eventListeners[t]=e}},{key:"_unbindTemporaryUIs",value:function(){for(var t in this.temporaryUIFunctions)Object.prototype.hasOwnProperty.call(this.temporaryUIFunctions,t)&&(this.body.eventListeners[t]=this.temporaryUIFunctions[t],delete this.temporaryUIFunctions[t]);this.temporaryUIFunctions={}}},{key:"_unbindTemporaryEvents",value:function(){for(var t=0;t<this.temporaryEventFunctions.length;t++){var e=this.temporaryEventFunctions[t].event,i=this.temporaryEventFunctions[t].boundFunction;this.body.emitter.off(e,i)}this.temporaryEventFunctions=[]}},{key:"_bindElementEvents",value:function(t,e){var i=new Wm(t,{});IC(i,e),this._domEventListenerCleanupQueue.push((function(){i.destroy()}));var n=function(t){var i=t.keyCode,n=t.key;"Enter"!==n&&" "!==n&&13!==i&&32!==i||e()};t.addEventListener("keyup",n,!1),this._domEventListenerCleanupQueue.push((function(){t.removeEventListener("keyup",n,!1)}))}},{key:"_cleanupTemporaryNodesAndEdges",value:function(){for(var t=0;t<this.temporaryIds.edges.length;t++){var e;this.body.edges[this.temporaryIds.edges[t]].disconnect(),delete this.body.edges[this.temporaryIds.edges[t]];var i,n=Fp(e=this.body.edgeIndices).call(e,this.temporaryIds.edges[t]);if(-1!==n)ff(i=this.body.edgeIndices).call(i,n,1)}for(var o=0;o<this.temporaryIds.nodes.length;o++){var r;delete this.body.nodes[this.temporaryIds.nodes[o]];var s,a=Fp(r=this.body.nodeIndices).call(r,this.temporaryIds.nodes[o]);if(-1!==a)ff(s=this.body.nodeIndices).call(s,a,1)}this.temporaryIds={nodes:[],edges:[]}}},{key:"_controlNodeTouch",value:function(t){this.selectionHandler.unselectAll(),this.lastTouch=this.body.functions.getPointer(t.center),this.lastTouch.translation=un({},this.body.view.translation)}},{key:"_controlNodeDragStart",value:function(){var t=this.lastTouch,e=this.selectionHandler._pointerToPositionObject(t),i=this.body.nodes[this.temporaryIds.nodes[0]],n=this.body.nodes[this.temporaryIds.nodes[1]],o=this.body.edges[this.edgeBeingEditedId];this.selectedControlNode=void 0;var r=i.isOverlappingWith(e),s=n.isOverlappingWith(e);!0===r?(this.selectedControlNode=i,o.edgeType.from=i):!0===s&&(this.selectedControlNode=n,o.edgeType.to=n),void 0!==this.selectedControlNode&&this.selectionHandler.selectObject(this.selectedControlNode),this.body.emitter.emit("_redraw")}},{key:"_controlNodeDrag",value:function(t){this.body.emitter.emit("disablePhysics");var e=this.body.functions.getPointer(t.center),i=this.canvas.DOMtoCanvas(e);void 0!==this.selectedControlNode?(this.selectedControlNode.x=i.x,this.selectedControlNode.y=i.y):this.interactionHandler.onDrag(t),this.body.emitter.emit("_redraw")}},{key:"_controlNodeDragEnd",value:function(t){var e=this.body.functions.getPointer(t.center),i=this.selectionHandler._pointerToPositionObject(e),n=this.body.edges[this.edgeBeingEditedId];if(void 0!==this.selectedControlNode){this.selectionHandler.unselectAll();for(var o=this.selectionHandler._getAllNodesOverlappingWith(i),r=void 0,s=o.length-1;s>=0;s--)if(o[s]!==this.selectedControlNode.id){r=this.body.nodes[o[s]];break}if(void 0!==r&&void 0!==this.selectedControlNode)if(!0===r.isCluster)alert(this.options.locales[this.options.locale].createEdgeError||this.options.locales.en.createEdgeError);else{var a=this.body.nodes[this.temporaryIds.nodes[0]];this.selectedControlNode.id===a.id?this._performEditEdge(r.id,n.to.id):this._performEditEdge(n.from.id,r.id)}else n.updateEdgeType(),this.body.emitter.emit("restorePhysics");this.body.emitter.emit("_redraw")}}},{key:"_handleConnect",value:function(t){if((new Date).valueOf()-this.touchTime>100){this.lastTouch=this.body.functions.getPointer(t.center),this.lastTouch.translation=un({},this.body.view.translation),this.interactionHandler.drag.pointer=this.lastTouch,this.interactionHandler.drag.translation=this.lastTouch.translation;var e=this.lastTouch,i=this.selectionHandler.getNodeAt(e);if(void 0!==i)if(!0===i.isCluster)alert(this.options.locales[this.options.locale].createEdgeError||this.options.locales.en.createEdgeError);else{var n=this._getNewTargetNode(i.x,i.y);this.body.nodes[n.id]=n,this.body.nodeIndices.push(n.id);var o=this.body.functions.createEdge({id:"connectionEdge"+Ax(),from:i.id,to:n.id,physics:!1,smooth:{enabled:!0,type:"continuous",roundness:.5}});this.body.edges[o.id]=o,this.body.edgeIndices.push(o.id),this.temporaryIds.nodes.push(n.id),this.temporaryIds.edges.push(o.id)}this.touchTime=(new Date).valueOf()}}},{key:"_dragControlNode",value:function(t){var e=this.body.functions.getPointer(t.center),i=this.selectionHandler._pointerToPositionObject(e),n=void 0;void 0!==this.temporaryIds.edges[0]&&(n=this.body.edges[this.temporaryIds.edges[0]].fromId);for(var o=this.selectionHandler._getAllNodesOverlappingWith(i),r=void 0,s=o.length-1;s>=0;s--){var a;if(-1===Fp(a=this.temporaryIds.nodes).call(a,o[s])){r=this.body.nodes[o[s]];break}}if(t.controlEdge={from:n,to:r?r.id:void 0},this.selectionHandler.generateClickEvent("controlNodeDragging",t,e),void 0!==this.temporaryIds.nodes[0]){var h=this.body.nodes[this.temporaryIds.nodes[0]];h.x=this.canvas._XconvertDOMtoCanvas(e.x),h.y=this.canvas._YconvertDOMtoCanvas(e.y),this.body.emitter.emit("_redraw")}else this.interactionHandler.onDrag(t)}},{key:"_finishConnect",value:function(t){var e=this.body.functions.getPointer(t.center),i=this.selectionHandler._pointerToPositionObject(e),n=void 0;void 0!==this.temporaryIds.edges[0]&&(n=this.body.edges[this.temporaryIds.edges[0]].fromId);for(var o=this.selectionHandler._getAllNodesOverlappingWith(i),r=void 0,s=o.length-1;s>=0;s--){var a;if(-1===Fp(a=this.temporaryIds.nodes).call(a,o[s])){r=this.body.nodes[o[s]];break}}this._cleanupTemporaryNodesAndEdges(),void 0!==r&&(!0===r.isCluster?alert(this.options.locales[this.options.locale].createEdgeError||this.options.locales.en.createEdgeError):void 0!==this.body.nodes[n]&&void 0!==this.body.nodes[r.id]&&this._performAddEdge(n,r.id)),t.controlEdge={from:n,to:r?r.id:void 0},this.selectionHandler.generateClickEvent("controlNodeDragEnd",t,e),this.body.emitter.emit("_redraw")}},{key:"_dragStartEdge",value:function(t){var e=this.lastTouch;this.selectionHandler.generateClickEvent("dragStart",t,e,void 0,!0)}},{key:"_performAddNode",value:function(t){var e=this,i={id:Ax(),x:t.pointer.canvas.x,y:t.pointer.canvas.y,label:"new"};if("function"==typeof this.options.addNode){if(2!==this.options.addNode.length)throw this.showManipulatorToolbar(),new Error("The function for add does not support two arguments (data,callback)");this.options.addNode(i,(function(t){null!=t&&"addNode"===e.inMode&&e.body.data.nodes.getDataSet().add(t),e.showManipulatorToolbar()}))}else this.body.data.nodes.getDataSet().add(i),this.showManipulatorToolbar()}},{key:"_performAddEdge",value:function(t,e){var i=this,n={from:t,to:e};if("function"==typeof this.options.addEdge){if(2!==this.options.addEdge.length)throw new Error("The function for connect does not support two arguments (data,callback)");this.options.addEdge(n,(function(t){null!=t&&"addEdge"===i.inMode&&(i.body.data.edges.getDataSet().add(t),i.selectionHandler.unselectAll(),i.showManipulatorToolbar())}))}else this.body.data.edges.getDataSet().add(n),this.selectionHandler.unselectAll(),this.showManipulatorToolbar()}},{key:"_performEditEdge",value:function(t,e){var i=this,n={id:this.edgeBeingEditedId,from:t,to:e,label:this.body.data.edges.get(this.edgeBeingEditedId).label},o=this.options.editEdge;if("object"===Qc(o)&&(o=o.editWithoutDrag),"function"==typeof o){if(2!==o.length)throw new Error("The function for edit does not support two arguments (data, callback)");o(n,(function(t){null==t||"editEdge"!==i.inMode?(i.body.edges[n.id].updateEdgeType(),i.body.emitter.emit("_redraw"),i.showManipulatorToolbar()):(i.body.data.edges.getDataSet().update(t),i.selectionHandler.unselectAll(),i.showManipulatorToolbar())}))}else this.body.data.edges.getDataSet().update(n),this.selectionHandler.unselectAll(),this.showManipulatorToolbar()}}]),t}(),dT="string",cT="boolean",uT="number",fT="array",pT="object",vT=["arrow","bar","box","circle","crow","curve","diamond","image","inv_curve","inv_triangle","triangle","vee"],gT={borderWidth:{number:uT},borderWidthSelected:{number:uT,undefined:"undefined"},brokenImage:{string:dT,undefined:"undefined"},chosen:{label:{boolean:cT,function:"function"},node:{boolean:cT,function:"function"},__type__:{object:pT,boolean:cT}},color:{border:{string:dT},background:{string:dT},highlight:{border:{string:dT},background:{string:dT},__type__:{object:pT,string:dT}},hover:{border:{string:dT},background:{string:dT},__type__:{object:pT,string:dT}},__type__:{object:pT,string:dT}},opacity:{number:uT,undefined:"undefined"},fixed:{x:{boolean:cT},y:{boolean:cT},__type__:{object:pT,boolean:cT}},font:{align:{string:dT},color:{string:dT},size:{number:uT},face:{string:dT},background:{string:dT},strokeWidth:{number:uT},strokeColor:{string:dT},vadjust:{number:uT},multi:{boolean:cT,string:dT},bold:{color:{string:dT},size:{number:uT},face:{string:dT},mod:{string:dT},vadjust:{number:uT},__type__:{object:pT,string:dT}},boldital:{color:{string:dT},size:{number:uT},face:{string:dT},mod:{string:dT},vadjust:{number:uT},__type__:{object:pT,string:dT}},ital:{color:{string:dT},size:{number:uT},face:{string:dT},mod:{string:dT},vadjust:{number:uT},__type__:{object:pT,string:dT}},mono:{color:{string:dT},size:{number:uT},face:{string:dT},mod:{string:dT},vadjust:{number:uT},__type__:{object:pT,string:dT}},__type__:{object:pT,string:dT}},group:{string:dT,number:uT,undefined:"undefined"},heightConstraint:{minimum:{number:uT},valign:{string:dT},__type__:{object:pT,boolean:cT,number:uT}},hidden:{boolean:cT},icon:{face:{string:dT},code:{string:dT},size:{number:uT},color:{string:dT},weight:{string:dT,number:uT},__type__:{object:pT}},id:{string:dT,number:uT},image:{selected:{string:dT,undefined:"undefined"},unselected:{string:dT,undefined:"undefined"},__type__:{object:pT,string:dT}},imagePadding:{top:{number:uT},right:{number:uT},bottom:{number:uT},left:{number:uT},__type__:{object:pT,number:uT}},label:{string:dT,undefined:"undefined"},labelHighlightBold:{boolean:cT},level:{number:uT,undefined:"undefined"},margin:{top:{number:uT},right:{number:uT},bottom:{number:uT},left:{number:uT},__type__:{object:pT,number:uT}},mass:{number:uT},physics:{boolean:cT},scaling:{min:{number:uT},max:{number:uT},label:{enabled:{boolean:cT},min:{number:uT},max:{number:uT},maxVisible:{number:uT},drawThreshold:{number:uT},__type__:{object:pT,boolean:cT}},customScalingFunction:{function:"function"},__type__:{object:pT}},shadow:{enabled:{boolean:cT},color:{string:dT},size:{number:uT},x:{number:uT},y:{number:uT},__type__:{object:pT,boolean:cT}},shape:{string:["custom","ellipse","circle","database","box","text","image","circularImage","diamond","dot","star","triangle","triangleDown","square","icon","hexagon"]},ctxRenderer:{function:"function"},shapeProperties:{borderDashes:{boolean:cT,array:fT},borderRadius:{number:uT},interpolation:{boolean:cT},useImageSize:{boolean:cT},useBorderWithImage:{boolean:cT},coordinateOrigin:{string:["center","top-left"]},__type__:{object:pT}},size:{number:uT},title:{string:dT,dom:"dom",undefined:"undefined"},value:{number:uT,undefined:"undefined"},widthConstraint:{minimum:{number:uT},maximum:{number:uT},__type__:{object:pT,boolean:cT,number:uT}},x:{number:uT},y:{number:uT},__type__:{object:pT}},yT={configure:{enabled:{boolean:cT},filter:{boolean:cT,string:dT,array:fT,function:"function"},container:{dom:"dom"},showButton:{boolean:cT},__type__:{object:pT,boolean:cT,string:dT,array:fT,function:"function"}},edges:{arrows:{to:{enabled:{boolean:cT},scaleFactor:{number:uT},type:{string:vT},imageHeight:{number:uT},imageWidth:{number:uT},src:{string:dT},__type__:{object:pT,boolean:cT}},middle:{enabled:{boolean:cT},scaleFactor:{number:uT},type:{string:vT},imageWidth:{number:uT},imageHeight:{number:uT},src:{string:dT},__type__:{object:pT,boolean:cT}},from:{enabled:{boolean:cT},scaleFactor:{number:uT},type:{string:vT},imageWidth:{number:uT},imageHeight:{number:uT},src:{string:dT},__type__:{object:pT,boolean:cT}},__type__:{string:["from","to","middle"],object:pT}},endPointOffset:{from:{number:uT},to:{number:uT},__type__:{object:pT,number:uT}},arrowStrikethrough:{boolean:cT},background:{enabled:{boolean:cT},color:{string:dT},size:{number:uT},dashes:{boolean:cT,array:fT},__type__:{object:pT,boolean:cT}},chosen:{label:{boolean:cT,function:"function"},edge:{boolean:cT,function:"function"},__type__:{object:pT,boolean:cT}},color:{color:{string:dT},highlight:{string:dT},hover:{string:dT},inherit:{string:["from","to","both"],boolean:cT},opacity:{number:uT},__type__:{object:pT,string:dT}},dashes:{boolean:cT,array:fT},font:{color:{string:dT},size:{number:uT},face:{string:dT},background:{string:dT},strokeWidth:{number:uT},strokeColor:{string:dT},align:{string:["horizontal","top","middle","bottom"]},vadjust:{number:uT},multi:{boolean:cT,string:dT},bold:{color:{string:dT},size:{number:uT},face:{string:dT},mod:{string:dT},vadjust:{number:uT},__type__:{object:pT,string:dT}},boldital:{color:{string:dT},size:{number:uT},face:{string:dT},mod:{string:dT},vadjust:{number:uT},__type__:{object:pT,string:dT}},ital:{color:{string:dT},size:{number:uT},face:{string:dT},mod:{string:dT},vadjust:{number:uT},__type__:{object:pT,string:dT}},mono:{color:{string:dT},size:{number:uT},face:{string:dT},mod:{string:dT},vadjust:{number:uT},__type__:{object:pT,string:dT}},__type__:{object:pT,string:dT}},hidden:{boolean:cT},hoverWidth:{function:"function",number:uT},label:{string:dT,undefined:"undefined"},labelHighlightBold:{boolean:cT},length:{number:uT,undefined:"undefined"},physics:{boolean:cT},scaling:{min:{number:uT},max:{number:uT},label:{enabled:{boolean:cT},min:{number:uT},max:{number:uT},maxVisible:{number:uT},drawThreshold:{number:uT},__type__:{object:pT,boolean:cT}},customScalingFunction:{function:"function"},__type__:{object:pT}},selectionWidth:{function:"function",number:uT},selfReferenceSize:{number:uT},selfReference:{size:{number:uT},angle:{number:uT},renderBehindTheNode:{boolean:cT},__type__:{object:pT}},shadow:{enabled:{boolean:cT},color:{string:dT},size:{number:uT},x:{number:uT},y:{number:uT},__type__:{object:pT,boolean:cT}},smooth:{enabled:{boolean:cT},type:{string:["dynamic","continuous","discrete","diagonalCross","straightCross","horizontal","vertical","curvedCW","curvedCCW","cubicBezier"]},roundness:{number:uT},forceDirection:{string:["horizontal","vertical","none"],boolean:cT},__type__:{object:pT,boolean:cT}},title:{string:dT,undefined:"undefined"},width:{number:uT},widthConstraint:{maximum:{number:uT},__type__:{object:pT,boolean:cT,number:uT}},value:{number:uT,undefined:"undefined"},__type__:{object:pT}},groups:{useDefaultGroups:{boolean:cT},__any__:gT,__type__:{object:pT}},interaction:{dragNodes:{boolean:cT},dragView:{boolean:cT},hideEdgesOnDrag:{boolean:cT},hideEdgesOnZoom:{boolean:cT},hideNodesOnDrag:{boolean:cT},hover:{boolean:cT},keyboard:{enabled:{boolean:cT},speed:{x:{number:uT},y:{number:uT},zoom:{number:uT},__type__:{object:pT}},bindToWindow:{boolean:cT},autoFocus:{boolean:cT},__type__:{object:pT,boolean:cT}},multiselect:{boolean:cT},navigationButtons:{boolean:cT},selectable:{boolean:cT},selectConnectedEdges:{boolean:cT},hoverConnectedEdges:{boolean:cT},tooltipDelay:{number:uT},zoomView:{boolean:cT},zoomSpeed:{number:uT},__type__:{object:pT}},layout:{randomSeed:{undefined:"undefined",number:uT,string:dT},improvedLayout:{boolean:cT},clusterThreshold:{number:uT},hierarchical:{enabled:{boolean:cT},levelSeparation:{number:uT},nodeSpacing:{number:uT},treeSpacing:{number:uT},blockShifting:{boolean:cT},edgeMinimization:{boolean:cT},parentCentralization:{boolean:cT},direction:{string:["UD","DU","LR","RL"]},sortMethod:{string:["hubsize","directed"]},shakeTowards:{string:["leaves","roots"]},__type__:{object:pT,boolean:cT}},__type__:{object:pT}},manipulation:{enabled:{boolean:cT},initiallyActive:{boolean:cT},addNode:{boolean:cT,function:"function"},addEdge:{boolean:cT,function:"function"},editNode:{function:"function"},editEdge:{editWithoutDrag:{function:"function"},__type__:{object:pT,boolean:cT,function:"function"}},deleteNode:{boolean:cT,function:"function"},deleteEdge:{boolean:cT,function:"function"},controlNodeStyle:gT,__type__:{object:pT,boolean:cT}},nodes:gT,physics:{enabled:{boolean:cT},barnesHut:{theta:{number:uT},gravitationalConstant:{number:uT},centralGravity:{number:uT},springLength:{number:uT},springConstant:{number:uT},damping:{number:uT},avoidOverlap:{number:uT},__type__:{object:pT}},forceAtlas2Based:{theta:{number:uT},gravitationalConstant:{number:uT},centralGravity:{number:uT},springLength:{number:uT},springConstant:{number:uT},damping:{number:uT},avoidOverlap:{number:uT},__type__:{object:pT}},repulsion:{centralGravity:{number:uT},springLength:{number:uT},springConstant:{number:uT},nodeDistance:{number:uT},damping:{number:uT},__type__:{object:pT}},hierarchicalRepulsion:{centralGravity:{number:uT},springLength:{number:uT},springConstant:{number:uT},nodeDistance:{number:uT},damping:{number:uT},avoidOverlap:{number:uT},__type__:{object:pT}},maxVelocity:{number:uT},minVelocity:{number:uT},solver:{string:["barnesHut","repulsion","hierarchicalRepulsion","forceAtlas2Based"]},stabilization:{enabled:{boolean:cT},iterations:{number:uT},updateInterval:{number:uT},onlyDynamicEdges:{boolean:cT},fit:{boolean:cT},__type__:{object:pT,boolean:cT}},timestep:{number:uT},adaptiveTimestep:{boolean:cT},wind:{x:{number:uT},y:{number:uT},__type__:{object:pT}},__type__:{object:pT,boolean:cT}},autoResize:{boolean:cT},clickToUse:{boolean:cT},locale:{string:dT},locales:{__any__:{any:"any"},__type__:{object:pT}},height:{string:dT},width:{string:dT},__type__:{object:pT}},mT={nodes:{borderWidth:[1,0,10,1],borderWidthSelected:[2,0,10,1],color:{border:["color","#2B7CE9"],background:["color","#97C2FC"],highlight:{border:["color","#2B7CE9"],background:["color","#D2E5FF"]},hover:{border:["color","#2B7CE9"],background:["color","#D2E5FF"]}},opacity:[0,0,1,.1],fixed:{x:!1,y:!1},font:{color:["color","#343434"],size:[14,0,100,1],face:["arial","verdana","tahoma"],background:["color","none"],strokeWidth:[0,0,50,1],strokeColor:["color","#ffffff"]},hidden:!1,labelHighlightBold:!0,physics:!0,scaling:{min:[10,0,200,1],max:[30,0,200,1],label:{enabled:!1,min:[14,0,200,1],max:[30,0,200,1],maxVisible:[30,0,200,1],drawThreshold:[5,0,20,1]}},shadow:{enabled:!1,color:"rgba(0,0,0,0.5)",size:[10,0,20,1],x:[5,-30,30,1],y:[5,-30,30,1]},shape:["ellipse","box","circle","database","diamond","dot","square","star","text","triangle","triangleDown","hexagon"],shapeProperties:{borderDashes:!1,borderRadius:[6,0,20,1],interpolation:!0,useImageSize:!1},size:[25,0,200,1]},edges:{arrows:{to:{enabled:!1,scaleFactor:[1,0,3,.05],type:"arrow"},middle:{enabled:!1,scaleFactor:[1,0,3,.05],type:"arrow"},from:{enabled:!1,scaleFactor:[1,0,3,.05],type:"arrow"}},endPointOffset:{from:[0,-10,10,1],to:[0,-10,10,1]},arrowStrikethrough:!0,color:{color:["color","#848484"],highlight:["color","#848484"],hover:["color","#848484"],inherit:["from","to","both",!0,!1],opacity:[1,0,1,.05]},dashes:!1,font:{color:["color","#343434"],size:[14,0,100,1],face:["arial","verdana","tahoma"],background:["color","none"],strokeWidth:[2,0,50,1],strokeColor:["color","#ffffff"],align:["horizontal","top","middle","bottom"]},hidden:!1,hoverWidth:[1.5,0,5,.1],labelHighlightBold:!0,physics:!0,scaling:{min:[1,0,100,1],max:[15,0,100,1],label:{enabled:!0,min:[14,0,200,1],max:[30,0,200,1],maxVisible:[30,0,200,1],drawThreshold:[5,0,20,1]}},selectionWidth:[1.5,0,5,.1],selfReferenceSize:[20,0,200,1],selfReference:{size:[20,0,200,1],angle:[Math.PI/2,-6*Math.PI,6*Math.PI,Math.PI/8],renderBehindTheNode:!0},shadow:{enabled:!1,color:"rgba(0,0,0,0.5)",size:[10,0,20,1],x:[5,-30,30,1],y:[5,-30,30,1]},smooth:{enabled:!0,type:["dynamic","continuous","discrete","diagonalCross","straightCross","horizontal","vertical","curvedCW","curvedCCW","cubicBezier"],forceDirection:["horizontal","vertical","none"],roundness:[.5,0,1,.05]},width:[1,0,30,1]},layout:{hierarchical:{enabled:!1,levelSeparation:[150,20,500,5],nodeSpacing:[100,20,500,5],treeSpacing:[200,20,500,5],blockShifting:!0,edgeMinimization:!0,parentCentralization:!0,direction:["UD","DU","LR","RL"],sortMethod:["hubsize","directed"],shakeTowards:["leaves","roots"]}},interaction:{dragNodes:!0,dragView:!0,hideEdgesOnDrag:!1,hideEdgesOnZoom:!1,hideNodesOnDrag:!1,hover:!1,keyboard:{enabled:!1,speed:{x:[10,0,40,1],y:[10,0,40,1],zoom:[.02,0,.1,.005]},bindToWindow:!0,autoFocus:!0},multiselect:!1,navigationButtons:!1,selectable:!0,selectConnectedEdges:!0,hoverConnectedEdges:!0,tooltipDelay:[300,0,1e3,25],zoomView:!0,zoomSpeed:[1,.1,2,.1]},manipulation:{enabled:!1,initiallyActive:!1},physics:{enabled:!0,barnesHut:{theta:[.5,.1,1,.05],gravitationalConstant:[-2e3,-3e4,0,50],centralGravity:[.3,0,10,.05],springLength:[95,0,500,5],springConstant:[.04,0,1.2,.005],damping:[.09,0,1,.01],avoidOverlap:[0,0,1,.01]},forceAtlas2Based:{theta:[.5,.1,1,.05],gravitationalConstant:[-50,-500,0,1],centralGravity:[.01,0,1,.005],springLength:[95,0,500,5],springConstant:[.08,0,1.2,.005],damping:[.4,0,1,.01],avoidOverlap:[0,0,1,.01]},repulsion:{centralGravity:[.2,0,10,.05],springLength:[200,0,500,5],springConstant:[.05,0,1.2,.005],nodeDistance:[100,0,500,5],damping:[.09,0,1,.01]},hierarchicalRepulsion:{centralGravity:[.2,0,10,.05],springLength:[100,0,500,5],springConstant:[.01,0,1.2,.005],nodeDistance:[120,0,500,5],damping:[.09,0,1,.01],avoidOverlap:[0,0,1,.01]},maxVelocity:[50,0,150,1],minVelocity:[.1,.01,.5,.01],solver:["barnesHut","forceAtlas2Based","repulsion","hierarchicalRepulsion"],timestep:[.5,.01,1,.01],wind:{x:[0,-10,10,.1],y:[0,-10,10,.1]}}},bT=function(t,e,i){var n;return!(!Nf(t).call(t,"physics")||!Nf(n=mT.physics.solver).call(n,e)||i.physics.solver===e||"wind"===e)},wT=Object.freeze({__proto__:null,configuratorHideOption:bT,allOptions:yT,configureOptions:mT}),kT=function(){function t(){Yd(this,t)}return Kd(t,[{key:"getDistances",value:function(t,e,i){for(var n={},o=t.edges,r=0;r<e.length;r++){var s={};n[e[r]]=s;for(var a=0;a<e.length;a++)s[e[a]]=r==a?0:1e9}for(var h=0;h<i.length;h++){var l=o[i[h]];!0===l.connected&&void 0!==n[l.fromId]&&void 0!==n[l.toId]&&(n[l.fromId][l.toId]=1,n[l.toId][l.fromId]=1)}for(var d=e.length,c=0;c<d;c++)for(var u=e[c],f=n[u],p=0;p<d-1;p++)for(var v=e[p],g=n[v],y=p+1;y<d;y++){var m=e[y],b=n[m],w=Math.min(g[m],g[u]+f[m]);g[m]=w,b[v]=w}return n}}]),t}(),_T=function(){function t(e,i,n){Yd(this,t),this.body=e,this.springLength=i,this.springConstant=n,this.distanceSolver=new kT}return Kd(t,[{key:"setOptions",value:function(t){t&&(t.springLength&&(this.springLength=t.springLength),t.springConstant&&(this.springConstant=t.springConstant))}},{key:"solve",value:function(t,e){var i=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=this.distanceSolver.getDistances(this.body,t,e);this._createL_matrix(n),this._createK_matrix(n),this._createE_matrix();for(var o=.01,r=1,s=0,a=Math.max(1e3,Math.min(10*this.body.nodeIndices.length,6e3)),h=5,l=1e9,d=0,c=0,u=0,f=0,p=0;l>o&&s<a;){s+=1;var v=this._getHighestEnergyNode(i),g=Kc(v,4);for(d=g[0],l=g[1],c=g[2],u=g[3],f=l,p=0;f>r&&p<h;){p+=1,this._moveNode(d,c,u);var y=this._getEnergy(d),m=Kc(y,3);f=m[0],c=m[1],u=m[2]}}}},{key:"_getHighestEnergyNode",value:function(t){for(var e=this.body.nodeIndices,i=this.body.nodes,n=0,o=e[0],r=0,s=0,a=0;a<e.length;a++){var h=e[a];if(!0!==i[h].predefinedPosition||!0===i[h].isCluster&&!0===t||!0!==i[h].options.fixed.x||!0!==i[h].options.fixed.y){var l=Kc(this._getEnergy(h),3),d=l[0],c=l[1],u=l[2];n<d&&(n=d,o=h,r=c,s=u)}}return[o,n,r,s]}},{key:"_getEnergy",value:function(t){var e=Kc(this.E_sums[t],2),i=e[0],n=e[1];return[Math.sqrt(Math.pow(i,2)+Math.pow(n,2)),i,n]}},{key:"_moveNode",value:function(t,e,i){for(var n=this.body.nodeIndices,o=this.body.nodes,r=0,s=0,a=0,h=o[t].x,l=o[t].y,d=this.K_matrix[t],c=this.L_matrix[t],u=0;u<n.length;u++){var f=n[u];if(f!==t){var p=o[f].x,v=o[f].y,g=d[f],y=c[f],m=1/Math.pow(Math.pow(h-p,2)+Math.pow(l-v,2),1.5);r+=g*(1-y*Math.pow(l-v,2)*m),s+=g*(y*(h-p)*(l-v)*m),a+=g*(1-y*Math.pow(h-p,2)*m)}}var b=(e/r+i/s)/(s/r-a/s),w=-(s*b+e)/r;o[t].x+=w,o[t].y+=b,this._updateE_matrix(t)}},{key:"_createL_matrix",value:function(t){var e=this.body.nodeIndices,i=this.springLength;this.L_matrix=[];for(var n=0;n<e.length;n++){this.L_matrix[e[n]]={};for(var o=0;o<e.length;o++)this.L_matrix[e[n]][e[o]]=i*t[e[n]][e[o]]}}},{key:"_createK_matrix",value:function(t){var e=this.body.nodeIndices,i=this.springConstant;this.K_matrix=[];for(var n=0;n<e.length;n++){this.K_matrix[e[n]]={};for(var o=0;o<e.length;o++)this.K_matrix[e[n]][e[o]]=i*Math.pow(t[e[n]][e[o]],-2)}}},{key:"_createE_matrix",value:function(){var t=this.body.nodeIndices,e=this.body.nodes;this.E_matrix={},this.E_sums={};for(var i=0;i<t.length;i++)this.E_matrix[t[i]]=[];for(var n=0;n<t.length;n++){for(var o=t[n],r=e[o].x,s=e[o].y,a=0,h=0,l=n;l<t.length;l++){var d=t[l];if(d!==o){var c=e[d].x,u=e[d].y,f=1/Math.sqrt(Math.pow(r-c,2)+Math.pow(s-u,2));this.E_matrix[o][l]=[this.K_matrix[o][d]*(r-c-this.L_matrix[o][d]*(r-c)*f),this.K_matrix[o][d]*(s-u-this.L_matrix[o][d]*(s-u)*f)],this.E_matrix[d][n]=this.E_matrix[o][l],a+=this.E_matrix[o][l][0],h+=this.E_matrix[o][l][1]}}this.E_sums[o]=[a,h]}}},{key:"_updateE_matrix",value:function(t){for(var e=this.body.nodeIndices,i=this.body.nodes,n=this.E_matrix[t],o=this.K_matrix[t],r=this.L_matrix[t],s=i[t].x,a=i[t].y,h=0,l=0,d=0;d<e.length;d++){var c=e[d];if(c!==t){var u=n[d],f=u[0],p=u[1],v=i[c].x,g=i[c].y,y=1/Math.sqrt(Math.pow(s-v,2)+Math.pow(a-g,2)),m=o[c]*(s-v-r[c]*(s-v)*y),b=o[c]*(a-g-r[c]*(a-g)*y);n[d]=[m,b],h+=m,l+=b;var w=this.E_sums[c];w[0]+=m-f,w[1]+=b-p}}this.E_sums[t]=[h,l]}}]),t}();function xT(t,e,i){var n,o,r,s,a=this;if(!(this instanceof xT))throw new SyntaxError("Constructor must be called with the new operator");this.options={},this.defaultOptions={locale:"en",locales:Tb,clickToUse:!1},un(this.options,this.defaultOptions),this.body={container:t,nodes:{},nodeIndices:[],edges:{},edgeIndices:[],emitter:{on:zn(n=this.on).call(n,this),off:zn(o=this.off).call(o,this),emit:zn(r=this.emit).call(r,this),once:zn(s=this.once).call(s,this)},eventListeners:{onTap:function(){},onTouch:function(){},onDoubleTap:function(){},onHold:function(){},onDragStart:function(){},onDrag:function(){},onDragEnd:function(){},onMouseWheel:function(){},onPinch:function(){},onMouseMove:function(){},onRelease:function(){},onContext:function(){}},data:{nodes:null,edges:null},functions:{createNode:function(){},createEdge:function(){},getPointer:function(){}},modules:{},view:{scale:1,translation:{x:0,y:0}},selectionBox:{show:!1,position:{start:{x:0,y:0},end:{x:0,y:0}}}},this.bindEventListeners(),this.images=new Pb((function(){return a.body.emitter.emit("_requestRedraw")})),this.groups=new tk,this.canvas=new zC(this.body),this.selectionHandler=new HS(this.body,this.canvas),this.interactionHandler=new WC(this.body,this.canvas,this.selectionHandler),this.view=new FC(this.body,this.canvas),this.renderer=new PC(this.body,this.canvas),this.physics=new xC(this.body),this.layoutEngine=new sT(this.body),this.clustering=new SC(this.body),this.manipulation=new lT(this.body,this.canvas,this.selectionHandler,this.interactionHandler),this.nodesHandler=new gO(this.body,this.images,this.groups,this.layoutEngine),this.edgesHandler=new uC(this.body,this.images,this.groups),this.body.modules.kamadaKawai=new _T(this.body,150,.05),this.body.modules.clustering=this.clustering,this.canvas._create(),this.setOptions(i),this.setData(e)}function ET(t){for(var e in t)Object.prototype.hasOwnProperty.call(t,e)&&(t[e].redundant=t[e].used,t[e].used=[])}function OT(t){for(var e in t)if(Object.prototype.hasOwnProperty.call(t,e)&&t[e].redundant){for(var i=0;i<t[e].redundant.length;i++)t[e].redundant[i].parentNode.removeChild(t[e].redundant[i]);t[e].redundant=[]}}function CT(t,e,i){var n;return Object.prototype.hasOwnProperty.call(e,t)?e[t].redundant.length>0?(n=e[t].redundant[0],e[t].redundant.shift()):(n=document.createElementNS("http://www.w3.org/2000/svg",t),i.appendChild(n)):(n=document.createElementNS("http://www.w3.org/2000/svg",t),e[t]={used:[],redundant:[]},i.appendChild(n)),e[t].used.push(n),n}Wn(xT.prototype),xT.prototype.setOptions=function(t){var e=this;if(null===t&&(t=void 0),void 0!==t){!0===Um.validate(t,yT)&&console.error("%cErrors have been found in the supplied options object.",Vm);if(em(["locale","locales","clickToUse"],this.options,t),void 0!==t.locale&&(t.locale=function(t,e){try{var i=Kc(e.split(/[-_ /]/,2),2),n=i[0],o=i[1],r=null!=n?n.toLowerCase():null,s=null!=o?o.toUpperCase():null;if(r&&s){var a,h=r+"-"+s;if(Object.prototype.hasOwnProperty.call(t,h))return h;console.warn(su(a="Unknown variant ".concat(s," of language ")).call(a,r,"."))}if(r){var l=r;if(Object.prototype.hasOwnProperty.call(t,l))return l;console.warn("Unknown language ".concat(r))}return console.warn("Unknown locale ".concat(e,", falling back to English.")),"en"}catch(t){return console.error(t),console.warn("Unexpected error while normalizing locale ".concat(e,", falling back to English.")),"en"}}(t.locales||this.options.locales,t.locale)),t=this.layoutEngine.setOptions(t.layout,t),this.canvas.setOptions(t),this.groups.setOptions(t.groups),this.nodesHandler.setOptions(t.nodes),this.edgesHandler.setOptions(t.edges),this.physics.setOptions(t.physics),this.manipulation.setOptions(t.manipulation,t,this.options),this.interactionHandler.setOptions(t.interaction),this.renderer.setOptions(t.interaction),this.selectionHandler.setOptions(t.interaction),void 0!==t.groups&&this.body.emitter.emit("refreshNodes"),"configure"in t&&(this.configurator||(this.configurator=new Hm(this,this.body.container,mT,this.canvas.pixelRatio,bT)),this.configurator.setOptions(t.configure)),this.configurator&&!0===this.configurator.options.enabled){var i={nodes:{},edges:{},layout:{},interaction:{},manipulation:{},physics:{},global:{}};nm(i.nodes,this.nodesHandler.options),nm(i.edges,this.edgesHandler.options),nm(i.layout,this.layoutEngine.options),nm(i.interaction,this.selectionHandler.options),nm(i.interaction,this.renderer.options),nm(i.interaction,this.interactionHandler.options),nm(i.manipulation,this.manipulation.options),nm(i.physics,this.physics.options),nm(i.global,this.canvas.options),nm(i.global,this.options),this.configurator.setModuleOptions(i)}void 0!==t.clickToUse?!0===t.clickToUse?void 0===this.activator&&(this.activator=new Rm(this.canvas.frame),this.activator.on("change",(function(){e.body.emitter.emit("activate")}))):(void 0!==this.activator&&(this.activator.destroy(),delete this.activator),this.body.emitter.emit("activate")):this.body.emitter.emit("activate"),this.canvas.setSize(),this.body.emitter.emit("startSimulation")}},xT.prototype._updateVisibleIndices=function(){var t=this.body.nodes,e=this.body.edges;for(var i in this.body.nodeIndices=[],this.body.edgeIndices=[],t)Object.prototype.hasOwnProperty.call(t,i)&&(this.clustering._isClusteredNode(i)||!1!==t[i].options.hidden||this.body.nodeIndices.push(t[i].id));for(var n in e)if(Object.prototype.hasOwnProperty.call(e,n)){var o=e[n],r=t[o.fromId],s=t[o.toId],a=void 0!==r&&void 0!==s;!this.clustering._isClusteredEdge(n)&&!1===o.options.hidden&&a&&!1===r.options.hidden&&!1===s.options.hidden&&this.body.edgeIndices.push(o.id)}},xT.prototype.bindEventListeners=function(){var t=this;this.body.emitter.on("_dataChanged",(function(){t.edgesHandler._updateState(),t.body.emitter.emit("_dataUpdated")})),this.body.emitter.on("_dataUpdated",(function(){t.clustering._updateState(),t._updateVisibleIndices(),t._updateValueRange(t.body.nodes),t._updateValueRange(t.body.edges),t.body.emitter.emit("startSimulation"),t.body.emitter.emit("_requestRedraw")}))},xT.prototype.setData=function(t){if(this.body.emitter.emit("resetPhysics"),this.body.emitter.emit("_resetData"),this.selectionHandler.unselectAll(),t&&t.dot&&(t.nodes||t.edges))throw new SyntaxError('Data must contain either parameter "dot" or  parameter pair "nodes" and "edges", but not both.');if(this.setOptions(t&&t.options),t&&t.dot){console.warn("The dot property has been deprecated. Please use the static convertDot method to convert DOT into vis.network format and use the normal data format with nodes and edges. This converter is used like this: var data = vis.network.convertDot(dotString);");var e=Eb(t.dot);this.setData(e)}else if(t&&t.gephi){console.warn("The gephi property has been deprecated. Please use the static convertGephi method to convert gephi into vis.network format and use the normal data format with nodes and edges. This converter is used like this: var data = vis.network.convertGephi(gephiJson);");var i=Cb(t.gephi);this.setData(i)}else this.nodesHandler.setData(t&&t.nodes,!0),this.edgesHandler.setData(t&&t.edges,!0),this.body.emitter.emit("_dataChanged"),this.body.emitter.emit("_dataLoaded"),this.body.emitter.emit("initPhysics")},xT.prototype.destroy=function(){for(var t in this.body.emitter.emit("destroy"),this.body.emitter.off(),this.off(),delete this.groups,delete this.canvas,delete this.selectionHandler,delete this.interactionHandler,delete this.view,delete this.renderer,delete this.physics,delete this.layoutEngine,delete this.clustering,delete this.manipulation,delete this.nodesHandler,delete this.edgesHandler,delete this.configurator,delete this.images,this.body.nodes)Object.prototype.hasOwnProperty.call(this.body.nodes,t)&&delete this.body.nodes[t];for(var e in this.body.edges)Object.prototype.hasOwnProperty.call(this.body.edges,e)&&delete this.body.edges[e];Ky(this.body.container)},xT.prototype._updateValueRange=function(t){var e,i=void 0,n=void 0,o=0;for(e in t)if(Object.prototype.hasOwnProperty.call(t,e)){var r=t[e].getValue();void 0!==r&&(i=void 0===i?r:Math.min(r,i),n=void 0===n?r:Math.max(r,n),o+=r)}if(void 0!==i&&void 0!==n)for(e in t)Object.prototype.hasOwnProperty.call(t,e)&&t[e].setValueRange(i,n,o)},xT.prototype.isActive=function(){return!this.activator||this.activator.active},xT.prototype.setSize=function(){return this.canvas.setSize.apply(this.canvas,arguments)},xT.prototype.canvasToDOM=function(){return this.canvas.canvasToDOM.apply(this.canvas,arguments)},xT.prototype.DOMtoCanvas=function(){return this.canvas.DOMtoCanvas.apply(this.canvas,arguments)},xT.prototype.findNode=function(){return this.clustering.findNode.apply(this.clustering,arguments)},xT.prototype.isCluster=function(){return this.clustering.isCluster.apply(this.clustering,arguments)},xT.prototype.openCluster=function(){return this.clustering.openCluster.apply(this.clustering,arguments)},xT.prototype.cluster=function(){return this.clustering.cluster.apply(this.clustering,arguments)},xT.prototype.getNodesInCluster=function(){return this.clustering.getNodesInCluster.apply(this.clustering,arguments)},xT.prototype.clusterByConnection=function(){return this.clustering.clusterByConnection.apply(this.clustering,arguments)},xT.prototype.clusterByHubsize=function(){return this.clustering.clusterByHubsize.apply(this.clustering,arguments)},xT.prototype.updateClusteredNode=function(){return this.clustering.updateClusteredNode.apply(this.clustering,arguments)},xT.prototype.getClusteredEdges=function(){return this.clustering.getClusteredEdges.apply(this.clustering,arguments)},xT.prototype.getBaseEdge=function(){return this.clustering.getBaseEdge.apply(this.clustering,arguments)},xT.prototype.getBaseEdges=function(){return this.clustering.getBaseEdges.apply(this.clustering,arguments)},xT.prototype.updateEdge=function(){return this.clustering.updateEdge.apply(this.clustering,arguments)},xT.prototype.clusterOutliers=function(){return this.clustering.clusterOutliers.apply(this.clustering,arguments)},xT.prototype.getSeed=function(){return this.layoutEngine.getSeed.apply(this.layoutEngine,arguments)},xT.prototype.enableEditMode=function(){return this.manipulation.enableEditMode.apply(this.manipulation,arguments)},xT.prototype.disableEditMode=function(){return this.manipulation.disableEditMode.apply(this.manipulation,arguments)},xT.prototype.addNodeMode=function(){return this.manipulation.addNodeMode.apply(this.manipulation,arguments)},xT.prototype.editNode=function(){return this.manipulation.editNode.apply(this.manipulation,arguments)},xT.prototype.editNodeMode=function(){return console.warn("Deprecated: Please use editNode instead of editNodeMode."),this.manipulation.editNode.apply(this.manipulation,arguments)},xT.prototype.addEdgeMode=function(){return this.manipulation.addEdgeMode.apply(this.manipulation,arguments)},xT.prototype.editEdgeMode=function(){return this.manipulation.editEdgeMode.apply(this.manipulation,arguments)},xT.prototype.deleteSelected=function(){return this.manipulation.deleteSelected.apply(this.manipulation,arguments)},xT.prototype.getPositions=function(){return this.nodesHandler.getPositions.apply(this.nodesHandler,arguments)},xT.prototype.getPosition=function(){return this.nodesHandler.getPosition.apply(this.nodesHandler,arguments)},xT.prototype.storePositions=function(){return this.nodesHandler.storePositions.apply(this.nodesHandler,arguments)},xT.prototype.moveNode=function(){return this.nodesHandler.moveNode.apply(this.nodesHandler,arguments)},xT.prototype.getBoundingBox=function(){return this.nodesHandler.getBoundingBox.apply(this.nodesHandler,arguments)},xT.prototype.getConnectedNodes=function(t){return void 0!==this.body.nodes[t]?this.nodesHandler.getConnectedNodes.apply(this.nodesHandler,arguments):this.edgesHandler.getConnectedNodes.apply(this.edgesHandler,arguments)},xT.prototype.getConnectedEdges=function(){return this.nodesHandler.getConnectedEdges.apply(this.nodesHandler,arguments)},xT.prototype.startSimulation=function(){return this.physics.startSimulation.apply(this.physics,arguments)},xT.prototype.stopSimulation=function(){return this.physics.stopSimulation.apply(this.physics,arguments)},xT.prototype.stabilize=function(){return this.physics.stabilize.apply(this.physics,arguments)},xT.prototype.getSelection=function(){return this.selectionHandler.getSelection.apply(this.selectionHandler,arguments)},xT.prototype.setSelection=function(){return this.selectionHandler.setSelection.apply(this.selectionHandler,arguments)},xT.prototype.getSelectedNodes=function(){return this.selectionHandler.getSelectedNodeIds.apply(this.selectionHandler,arguments)},xT.prototype.getSelectedEdges=function(){return this.selectionHandler.getSelectedEdgeIds.apply(this.selectionHandler,arguments)},xT.prototype.getNodeAt=function(){var t=this.selectionHandler.getNodeAt.apply(this.selectionHandler,arguments);return void 0!==t&&void 0!==t.id?t.id:t},xT.prototype.getEdgeAt=function(){var t=this.selectionHandler.getEdgeAt.apply(this.selectionHandler,arguments);return void 0!==t&&void 0!==t.id?t.id:t},xT.prototype.selectNodes=function(){return this.selectionHandler.selectNodes.apply(this.selectionHandler,arguments)},xT.prototype.selectEdges=function(){return this.selectionHandler.selectEdges.apply(this.selectionHandler,arguments)},xT.prototype.unselectAll=function(){this.selectionHandler.unselectAll.apply(this.selectionHandler,arguments),this.selectionHandler.commitWithoutEmitting.apply(this.selectionHandler),this.redraw()},xT.prototype.redraw=function(){return this.renderer.redraw.apply(this.renderer,arguments)},xT.prototype.getScale=function(){return this.view.getScale.apply(this.view,arguments)},xT.prototype.getViewPosition=function(){return this.view.getViewPosition.apply(this.view,arguments)},xT.prototype.fit=function(){return this.view.fit.apply(this.view,arguments)},xT.prototype.moveTo=function(){return this.view.moveTo.apply(this.view,arguments)},xT.prototype.focus=function(){return this.view.focus.apply(this.view,arguments)},xT.prototype.releaseNode=function(){return this.view.releaseNode.apply(this.view,arguments)},xT.prototype.getOptionsFromConfigurator=function(){var t={};return this.configurator&&(t=this.configurator.getOptions.apply(this.configurator)),t};var ST=Object.freeze({__proto__:null,prepareElements:ET,cleanupElements:OT,resetElements:function(t){ET(t),OT(t),ET(t)},getSVGElement:CT,getDOMElement:function(t,e,i,n){var o;return Object.prototype.hasOwnProperty.call(e,t)?e[t].redundant.length>0?(o=e[t].redundant[0],e[t].redundant.shift()):(o=document.createElement(t),void 0!==n?i.insertBefore(o,n):i.appendChild(o)):(o=document.createElement(t),e[t]={used:[],redundant:[]},void 0!==n?i.insertBefore(o,n):i.appendChild(o)),e[t].used.push(o),o},drawPoint:function(t,e,i,n,o,r){var s;if("circle"==i.style?((s=CT("circle",n,o)).setAttributeNS(null,"cx",t),s.setAttributeNS(null,"cy",e),s.setAttributeNS(null,"r",.5*i.size)):((s=CT("rect",n,o)).setAttributeNS(null,"x",t-.5*i.size),s.setAttributeNS(null,"y",e-.5*i.size),s.setAttributeNS(null,"width",i.size),s.setAttributeNS(null,"height",i.size)),void 0!==i.styles&&s.setAttributeNS(null,"style",i.styles),s.setAttributeNS(null,"class",i.className+" vis-point"),r){var a=CT("text",n,o);r.xOffset&&(t+=r.xOffset),r.yOffset&&(e+=r.yOffset),r.content&&(a.textContent=r.content),r.className&&a.setAttributeNS(null,"class",r.className+" vis-label"),a.setAttributeNS(null,"x",t),a.setAttributeNS(null,"y",e)}return s},drawBar:function(t,e,i,n,o,r,s,a){if(0!=n){n<0&&(e-=n*=-1);var h=CT("rect",r,s);h.setAttributeNS(null,"x",t-.5*i),h.setAttributeNS(null,"y",e),h.setAttributeNS(null,"width",i),h.setAttributeNS(null,"height",n),h.setAttributeNS(null,"class",o),a&&h.setAttributeNS(null,"style",a)}}}),TT={Images:Pb,dotparser:Ob,gephiParser:Sb,allOptions:wT,convertDot:Eb,convertGephi:Cb},MT=Object.freeze({__proto__:null,network:TT,DOMutil:ST,util:Ym,data:Jx,Hammer:Wm,keycharm:jC,DataSet:Kx,DataView:$x,Queue:Yx,Network:xT});t.DOMutil=ST,t.DataSet=Kx,t.DataView=$x,t.Hammer=Wm,t.Network=xT,t.Queue=Yx,t.data=Jx,t.default=MT,t.keycharm=jC,t.network=TT,t.util=Ym,Object.defineProperty(t,"__esModule",{value:!0})}));
//# sourceMappingURL=vis-network.min.js.map</script>
            
        
<center>
<h1></h1>
</center>

<!-- <link rel="stylesheet" href="../node_modules/vis/dist/vis.min.css" type="text/css" />
<script type="text/javascript" src="../node_modules/vis/dist/vis.js"> </script>-->
        <link
          href="https://cdn.jsdelivr.net/npm/bootstrap@5.0.0-beta3/dist/css/bootstrap.min.css"
          rel="stylesheet"
          integrity="sha384-eOJMYsd53ii+scO/bJGFsiCZc+5NDVN2yr8+0RDqr0Ql0h+rP48ckxlpbzKgwra6"
          crossorigin="anonymous"
        />
        <script
          src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.0-beta3/dist/js/bootstrap.bundle.min.js"
          integrity="sha384-JEW9xMcG8R+pH31jmWH6WWP0WintQrMb4s7ZOdauHnUtxwoG2vI5DkLtS3qm9Ekf"
          crossorigin="anonymous"
        ></script>


        <center>
          <h1></h1>
        </center>
        <style type="text/css">

             #mynetwork {
                 width: 100%;
                 height: 600px;
                 background-color: #ffffff;
                 border: 1px solid lightgray;
                 position: relative;
                 float: left;
             }

             
             #loadingBar {
                 position:absolute;
                 top:0px;
                 left:0px;
                 width: 100%;
                 height: 600px;
                 background-color:rgba(200,200,200,0.8);
                 -webkit-transition: all 0.5s ease;
                 -moz-transition: all 0.5s ease;
                 -ms-transition: all 0.5s ease;
                 -o-transition: all 0.5s ease;
                 transition: all 0.5s ease;
                 opacity:1;
             }

             #bar {
                 position:absolute;
                 top:0px;
                 left:0px;
                 width:20px;
                 height:20px;
                 margin:auto auto auto auto;
                 border-radius:11px;
                 border:2px solid rgba(30,30,30,0.05);
                 background: rgb(0, 173, 246); /* Old browsers */
                 box-shadow: 2px 0px 4px rgba(0,0,0,0.4);
             }

             #border {
                 position:absolute;
                 top:10px;
                 left:10px;
                 width:500px;
                 height:23px;
                 margin:auto auto auto auto;
                 box-shadow: 0px 0px 4px rgba(0,0,0,0.2);
                 border-radius:10px;
             }

             #text {
                 position:absolute;
                 top:8px;
                 left:530px;
                 width:30px;
                 height:50px;
                 margin:auto auto auto auto;
                 font-size:22px;
                 color: #000000;
             }

             div.outerBorder {
                 position:relative;
                 top:400px;
                 width:600px;
                 height:44px;
                 margin:auto auto auto auto;
                 border:8px solid rgba(0,0,0,0.1);
                 background: rgb(252,252,252); /* Old browsers */
                 background: -moz-linear-gradient(top,  rgba(252,252,252,1) 0%, rgba(237,237,237,1) 100%); /* FF3.6+ */
                 background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,rgba(252,252,252,1)), color-stop(100%,rgba(237,237,237,1))); /* Chrome,Safari4+ */
                 background: -webkit-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* Chrome10+,Safari5.1+ */
                 background: -o-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* Opera 11.10+ */
                 background: -ms-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* IE10+ */
                 background: linear-gradient(to bottom,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* W3C */
                 filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#fcfcfc', endColorstr='#ededed',GradientType=0 ); /* IE6-9 */
                 border-radius:72px;
                 box-shadow: 0px 0px 10px rgba(0,0,0,0.2);
             }
             

             

             
        </style>
    </head>


    <body>
        <div class="card" style="width: 100%">
            
            
            <div id="mynetwork" class="card-body"></div>
        </div>

        
            <div id="loadingBar">
              <div class="outerBorder">
                <div id="text">0%</div>
                <div id="border">
                  <div id="bar"></div>
                </div>
              </div>
            </div>
        
        

        <script type="text/javascript">

              // initialize global variables.
              var edges;
              var nodes;
              var allNodes;
              var allEdges;
              var nodeColors;
              var originalNodes;
              var network;
              var container;
              var options, data;
              var filter = {
                  item : '',
                  property : '',
                  value : []
              };

              

              

              // This method is responsible for drawing the graph, returns the drawn network
              function drawGraph() {
                  var container = document.getElementById('mynetwork');

                  

                  // parsing and collecting nodes and edges from the python
                  nodes = new vis.DataSet([{"color": "blue", "id": "CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O", "label": "CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ibalizumab, optimized background regimen", "label": "ibalizumab, optimized background regimen", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nevirapine ir, nevirapine xr", "label": "nevirapine ir, nevirapine xr", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednevirapine ir, nevirapine xr_hiv infections", "label": "completednevirapine ir, nevirapine xr_hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtrabectedin_sarcoma", "label": "completedtrabectedin_sarcoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "sarcoma", "label": "sarcoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "qva149, umeclidinium/vilanterol, placebo (umeclidinium/vilanterol ), placebo (qva149)", "label": "qva149, umeclidinium/vilanterol, placebo (umeclidinium/vilanterol ), placebo (qva149)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedqva149, umeclidinium/vilanterol, placebo (umeclidinium/vilanterol ), placebo (qva149)_chronic obstructive pulmonary disease", "label": "completedqva149, umeclidinium/vilanterol, placebo (umeclidinium/vilanterol ), placebo (qva149)_chronic obstructive pulmonary disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatednexium, placebo_exercise triggered asthma, gastroesophageal reflux", "label": "terminatednexium, placebo_exercise triggered asthma, gastroesophageal reflux", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "exercise triggered asthma, gastroesophageal reflux", "label": "exercise triggered asthma, gastroesophageal reflux", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "duloxetine, propranolol, placebo treatment", "label": "duloxetine, propranolol, placebo treatment", "shape": "dot", "size": 10}, {"color": "green", "id": "low back pain", "label": "low back pain", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "udca, sitagliptin", "label": "udca, sitagliptin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusudca, sitagliptin_type 2 diabetes mellitus, chronic liver disease", "label": "unknown statusudca, sitagliptin_type 2 diabetes mellitus, chronic liver disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "capecitabine, oxaliplatin", "label": "capecitabine, oxaliplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuscapecitabine, oxaliplatin_colorectal neoplasms, liver metastases", "label": "unknown statuscapecitabine, oxaliplatin_colorectal neoplasms, liver metastases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcapecitabine, oxaliplatin_gastric cancer", "label": "completedcapecitabine, oxaliplatin_gastric cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "insulin glargine, inhaled insulin (exubera)", "label": "insulin glargine, inhaled insulin (exubera)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin glargine, inhaled insulin (exubera)_diabetes mellitus, type 2", "label": "completedinsulin glargine, inhaled insulin (exubera)_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cbsst + oxytocin, cbsst + placebo", "label": "cbsst + oxytocin, cbsst + placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcbsst + oxytocin, cbsst + placebo_schizophrenia, schizoaffective disorder", "label": "completedcbsst + oxytocin, cbsst + placebo_schizophrenia, schizoaffective disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "g-csf plus plerixafor, g-csf plus plerixafor", "label": "g-csf plus plerixafor, g-csf plus plerixafor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedg-csf plus plerixafor, g-csf plus plerixafor_non-hodgkin lymphoma, hodgkin disease", "label": "completedg-csf plus plerixafor, g-csf plus plerixafor_non-hodgkin lymphoma, hodgkin disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "clopidogrel, cilostazol", "label": "clopidogrel, cilostazol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cerebral infarction, atherosclerosis", "label": "cerebral infarction, atherosclerosis", "shape": "dot", "size": 10}, {"color": "red", "id": "hydroxychloroquine (hc)", "label": "hydroxychloroquine (hc)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedhydroxychloroquine (hc)_renal cell carcinoma", "label": "terminatedhydroxychloroquine (hc)_renal cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus", "label": "cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus_adult acute lymphoblastic leukemia in complete remission, acute myeloid leukemia in remission, previously treated myelodysplastic syndrome, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, childhood acute lymphoblastic leukemia in complete remission", "label": "active, not recruitingcyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus_adult acute lymphoblastic leukemia in complete remission, acute myeloid leukemia in remission, previously treated myelodysplastic syndrome, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, childhood acute lymphoblastic leukemia in complete remission", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "eszopiclone, placebo", "label": "eszopiclone, placebo", "shape": "dot", "size": 10}, {"color": "green", "id": "sleep initiation and maintenance disorders", "label": "sleep initiation and maintenance disorders", "shape": "dot", "size": 10}, {"color": "red", "id": "hsp90 inhibitor sta-9090", "label": "hsp90 inhibitor sta-9090", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adenocarcinoma of the prostate, hormone-resistant prostate cancer, recurrent prostate cancer, stage iv prostate cancer", "label": "adenocarcinoma of the prostate, hormone-resistant prostate cancer, recurrent prostate cancer, stage iv prostate cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "clofarabine, cytarabine", "label": "clofarabine, cytarabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedclofarabine, cytarabine_acute myelogenous leukemia", "label": "terminatedclofarabine, cytarabine_acute myelogenous leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcisplatin, fluorouracil_anal cancer", "label": "active, not recruitingcisplatin, fluorouracil_anal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "anal cancer", "label": "anal cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "etoposide, mitoxantrone hydrochloride, prednisone, vinorelbine tartrate", "label": "etoposide, mitoxantrone hydrochloride, prednisone, vinorelbine tartrate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedetoposide, mitoxantrone hydrochloride, prednisone, vinorelbine tartrate_prostate cancer", "label": "completedetoposide, mitoxantrone hydrochloride, prednisone, vinorelbine tartrate_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mycophenolate mofetil, mycofenolate mofetil (mmf), placebo", "label": "mycophenolate mofetil, mycofenolate mofetil (mmf), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "interstitial cystitis, painful bladder syndrome", "label": "interstitial cystitis, painful bladder syndrome", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "umeclidinium/vilanterol 62.5/25 mcg, tiotropium 18 mcg", "label": "umeclidinium/vilanterol 62.5/25 mcg, tiotropium 18 mcg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedumeclidinium/vilanterol 62.5/25 mcg, tiotropium 18 mcg_pulmonary disease, chronic obstructive", "label": "completedumeclidinium/vilanterol 62.5/25 mcg, tiotropium 18 mcg_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tmc125, darunavir; ritonavir", "label": "tmc125, darunavir; ritonavir", "shape": "dot", "size": 10}, {"color": "green", "id": "hiv", "label": "hiv", "shape": "dot", "size": 10}, {"color": "red", "id": "oral azacitidine", "label": "oral azacitidine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedoral azacitidine_myelodysplastic syndromes, chronic myelomonocytic leukemia, acute myeloid leukemia, multiple myeloma, non-hodgkin lymphoma, hodgkin lymphoma", "label": "terminatedoral azacitidine_myelodysplastic syndromes, chronic myelomonocytic leukemia, acute myeloid leukemia, multiple myeloma, non-hodgkin lymphoma, hodgkin lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "zgn-440 for injectable suspension, zgn-440 placebo for injectable suspension", "label": "zgn-440 for injectable suspension, zgn-440 placebo for injectable suspension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "prader-willi syndrome, obesity", "label": "prader-willi syndrome, obesity", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "olaratumab, doxorubicin, placebo", "label": "olaratumab, doxorubicin, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingolaratumab, doxorubicin, placebo_soft tissue sarcoma", "label": "active, not recruitingolaratumab, doxorubicin, placebo_soft tissue sarcoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dasatinib, rituximab, fludarabine", "label": "dasatinib, rituximab, fludarabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic lymphocytic leukemia, small lymphocytic lymphoma", "label": "chronic lymphocytic leukemia, small lymphocytic lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": "tipifarnib", "label": "tipifarnib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adult acute megakaryoblastic leukemia, adult acute monoblastic leukemia, adult acute monocytic leukemia, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with maturation, adult acute myeloid leukemia with minimal differentiation, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll, adult acute myeloid leukemia without maturation, adult acute myelomonocytic leukemia, adult erythroleukemia, adult pure erythroid leukemia, alkylating agent-related acute myeloid leukemia, secondary acute myeloid leukemia, untreated adult acute myeloid leukemia", "label": "adult acute megakaryoblastic leukemia, adult acute monoblastic leukemia, adult acute monocytic leukemia, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with maturation, adult acute myeloid leukemia with minimal differentiation, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll, adult acute myeloid leukemia without maturation, adult acute myelomonocytic leukemia, adult erythroleukemia, adult pure erythroid leukemia, alkylating agent-related acute myeloid leukemia, secondary acute myeloid leukemia, untreated adult acute myeloid leukemia", "shape": "dot", "size": 10}, {"color": "red", "id": "pazopanib and paclitaxel", "label": "pazopanib and paclitaxel", "shape": "dot", "size": 10}, {"color": "green", "id": "ovarian neoplasm", "label": "ovarian neoplasm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hld200 methylphenidate hydrochloride (mph) capsules, placebo", "label": "hld200 methylphenidate hydrochloride (mph) capsules, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedhld200 methylphenidate hydrochloride (mph) capsules, placebo_attention deficit hyperactivity disorder", "label": "completedhld200 methylphenidate hydrochloride (mph) capsules, placebo_attention deficit hyperactivity disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO", "label": "OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ipragliflozin, alpha glucosidase inhibitor", "label": "ipragliflozin, alpha glucosidase inhibitor", "shape": "dot", "size": 10}, {"color": "red", "id": "letrozole; avastin", "label": "letrozole; avastin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedletrozole; avastin_breast cancer, cancer of the breast, breast neoplasm", "label": "completedletrozole; avastin_breast cancer, cancer of the breast, breast neoplasm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pt001 mdi, tiotropium bromide, pt001 placebo mdi", "label": "pt001 mdi, tiotropium bromide, pt001 placebo mdi", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O, S1SSSSSSS1", "label": "CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O, S1SSSSSSS1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "edoxaban tosylate, enoxaparin/unfractionated heparin, warfarin", "label": "edoxaban tosylate, enoxaparin/unfractionated heparin, warfarin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClC1=CC(Cl)=C(C=C1)C(=O)NS(=O)(=O)C1=CC=C(Br)S1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "label": "ClC1=CC(Cl)=C(C=C1)C(=O)NS(=O)(=O)C1=CC=C(Br)S1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tasisulam-sodium, paclitaxel", "label": "tasisulam-sodium, paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, vanquix auto-injector (diazepam injection)", "label": "placebo, vanquix auto-injector (diazepam injection)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "seizures, epilepsies, partial, epilepsy, complex partial, epilepsy, generalized, epilepsy", "label": "seizures, epilepsies, partial, epilepsy, complex partial, epilepsy, generalized, epilepsy", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "label": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "shape": "dot", "size": 10}, {"color": "red", "id": "topotecan and taxotere", "label": "topotecan and taxotere", "shape": "dot", "size": 10}, {"color": "red", "id": "opc-41061(tolvaptan)", "label": "opc-41061(tolvaptan)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "heart failure, congestive, edema", "label": "heart failure, congestive, edema", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "label": "CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "du-176b 15mg, du-176b 30mg, enoxaparin sodium 20 mg (=2000iu)", "label": "du-176b 15mg, du-176b 30mg, enoxaparin sodium 20 mg (=2000iu)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo + methotrexate (mtx) (group 1), ustekinumab + mtx (group 2), ustekinumab + mtx (group 3), cnto 1959 + mtx (group 4), cnto 1959 + mtx (group 5)", "label": "placebo + methotrexate (mtx) (group 1), ustekinumab + mtx (group 2), ustekinumab + mtx (group 3), cnto 1959 + mtx (group 4), cnto 1959 + mtx (group 5)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo + methotrexate (mtx) (group 1), ustekinumab + mtx (group 2), ustekinumab + mtx (group 3), cnto 1959 + mtx (group 4), cnto 1959 + mtx (group 5)_arthritis, rheumatoid", "label": "completedplacebo + methotrexate (mtx) (group 1), ustekinumab + mtx (group 2), ustekinumab + mtx (group 3), cnto 1959 + mtx (group 4), cnto 1959 + mtx (group 5)_arthritis, rheumatoid", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddoxorubicin hydrochloride_sarcoma", "label": "completeddoxorubicin hydrochloride_sarcoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "atomoxetine, other standard therapy for adhd", "label": "atomoxetine, other standard therapy for adhd", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedatomoxetine, other standard therapy for adhd_attention deficit hyperactivity disorder", "label": "completedatomoxetine, other standard therapy for adhd_attention deficit hyperactivity disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingenzalutamide, bicalutamide, leuprolide acetate, goserelin acetate_adenocarcinoma of the prostate, recurrent prostate cancer, stage iv prostate cancer", "label": "active, not recruitingenzalutamide, bicalutamide, leuprolide acetate, goserelin acetate_adenocarcinoma of the prostate, recurrent prostate cancer, stage iv prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adenocarcinoma of the prostate, recurrent prostate cancer, stage iv prostate cancer", "label": "adenocarcinoma of the prostate, recurrent prostate cancer, stage iv prostate cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "tozadenant", "label": "tozadenant", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtozadenant_idiopathic parkinson disease", "label": "terminatedtozadenant_idiopathic parkinson disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nemonoxacin, nemonoxacin, tavanic, tavanic, placebo (250 ml), placebo (100 ml)", "label": "nemonoxacin, nemonoxacin, tavanic, tavanic, placebo (250 ml), placebo (100 ml)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednemonoxacin, nemonoxacin, tavanic, tavanic, placebo (250 ml), placebo (100 ml)_pneumonia, bacterial", "label": "completednemonoxacin, nemonoxacin, tavanic, tavanic, placebo (250 ml), placebo (100 ml)_pneumonia, bacterial", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lidocaine hydrochloride, ketorolac tromethamine", "label": "lidocaine hydrochloride, ketorolac tromethamine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuslidocaine hydrochloride, ketorolac tromethamine_anesthesia", "label": "unknown statuslidocaine hydrochloride, ketorolac tromethamine_anesthesia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "anti-il-20, placebo", "label": "anti-il-20, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedanti-il-20, placebo_inflammation, rheumatoid arthritis", "label": "completedanti-il-20, placebo_inflammation, rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedvalganciclovir, ganciclovir_cytomegalovirus infections", "label": "terminatedvalganciclovir, ganciclovir_cytomegalovirus infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "cytomegalovirus infections", "label": "cytomegalovirus infections", "shape": "dot", "size": 10}, {"color": "blue", "id": "[K+]", "label": "[K+]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bexxar (tositumomab), potassium iodide (ki)", "label": "bexxar (tositumomab), potassium iodide (ki)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aspirin (acetylsalicylic acid, baye4465), placebo", "label": "aspirin (acetylsalicylic acid, baye4465), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaspirin (acetylsalicylic acid, baye4465), placebo_moderate risk of cvd", "label": "completedaspirin (acetylsalicylic acid, baye4465), placebo_moderate risk of cvd", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaspirin (acetylsalicylic acid, baye4465), placebo_common cold", "label": "completedaspirin (acetylsalicylic acid, baye4465), placebo_common cold", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "label": "FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "5-fluorouracil, capecitabine, cyclophosphamide, docetaxel, epirubicin", "label": "5-fluorouracil, capecitabine, cyclophosphamide, docetaxel, epirubicin", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1", "label": "NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "xl281, famotidine", "label": "xl281, famotidine", "shape": "dot", "size": 10}, {"color": "red", "id": "gsk1363089 (foretinib)", "label": "gsk1363089 (foretinib)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "neoplasms, head and neck", "label": "neoplasms, head and neck", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpf-04494700 - low dose arm, pf-04494700 - high dose arm, placebo comparator_alzheimer disease", "label": "completedpf-04494700 - low dose arm, pf-04494700 - high dose arm, placebo comparator_alzheimer disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "alzheimer disease", "label": "alzheimer disease", "shape": "dot", "size": 10}, {"color": "red", "id": "intraventricular rituximab plus mtx", "label": "intraventricular rituximab plus mtx", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "central nervous system lymphoma, intraocular lymphoma", "label": "central nervous system lymphoma, intraocular lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbnc210, placebo_post-traumatic stress disorder", "label": "completedbnc210, placebo_post-traumatic stress disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "post-traumatic stress disorder", "label": "post-traumatic stress disorder", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "prasugrel, clopidogrel", "label": "prasugrel, clopidogrel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedprasugrel, clopidogrel_thrombosis, coronary artery disease", "label": "terminatedprasugrel, clopidogrel_thrombosis, coronary artery disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mometasone furoate, nortriptyline hcl, vehicle (placebo)", "label": "mometasone furoate, nortriptyline hcl, vehicle (placebo)", "shape": "dot", "size": 10}, {"color": "green", "id": "plaque psoriasis", "label": "plaque psoriasis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbosentan_idiopathic pulmonary fibrosis", "label": "completedbosentan_idiopathic pulmonary fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "idiopathic pulmonary fibrosis", "label": "idiopathic pulmonary fibrosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CSCC[C@H](N)C(O)=O", "label": "CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CSCC[C@H](N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ertugliflozin 5 mg, ertugliflozin 15 mg, placebo to ertugliflozin, placebo to glimepiride, metformin", "label": "ertugliflozin 5 mg, ertugliflozin 15 mg, placebo to ertugliflozin, placebo to glimepiride, metformin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawneverolimus_peutz-jeghers syndrome, neoplastic processes, neoplasm metastasis", "label": "withdrawneverolimus_peutz-jeghers syndrome, neoplastic processes, neoplasm metastasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "peutz-jeghers syndrome, neoplastic processes, neoplasm metastasis", "label": "peutz-jeghers syndrome, neoplastic processes, neoplasm metastasis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "5 fluorouracil, irinotecan, levo- leucovorin, sunitinib, 5 fluorouracil, irinotecan, levo- leucovorin, placebo", "label": "5 fluorouracil, irinotecan, levo- leucovorin, sunitinib, 5 fluorouracil, irinotecan, levo- leucovorin, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completed5 fluorouracil, irinotecan, levo- leucovorin, sunitinib, 5 fluorouracil, irinotecan, levo- leucovorin, placebo_metastatic colorectal cancer", "label": "completed5 fluorouracil, irinotecan, levo- leucovorin, sunitinib, 5 fluorouracil, irinotecan, levo- leucovorin, placebo_metastatic colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbrentuximab vedotin, methotrexate, bexarotene_primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, cutaneous t-cell lymphoma", "label": "completedbrentuximab vedotin, methotrexate, bexarotene_primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, cutaneous t-cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, cutaneous t-cell lymphoma", "label": "primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, cutaneous t-cell lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbetrixaban, enoxaparin_venous thromboembolism (vte)", "label": "completedbetrixaban, enoxaparin_venous thromboembolism (vte)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "venous thromboembolism (vte)", "label": "venous thromboembolism (vte)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oral vinorelbine, cisplatin, maintenance with metronomic oral vinorelbine, pemetrexed, cisplatin, maintenance with pemetrexed", "label": "oral vinorelbine, cisplatin, maintenance with metronomic oral vinorelbine, pemetrexed, cisplatin, maintenance with pemetrexed", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carcinoma, non-small-cell lung, secondary, advanced stage iiib, high thymidylate synthase expression", "label": "carcinoma, non-small-cell lung, secondary, advanced stage iiib, high thymidylate synthase expression", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "neonatal morphine solution, methadone, phenobarbital", "label": "neonatal morphine solution, methadone, phenobarbital", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedneonatal morphine solution, methadone, phenobarbital_neonatal abstinence syndrome, neonatal opioid withdrawal", "label": "completedneonatal morphine solution, methadone, phenobarbital_neonatal abstinence syndrome, neonatal opioid withdrawal", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, varenicline tartrate, bupropion hydrochloride, nicotine replacement therapy patch_smoking cessation", "label": "completedplacebo, varenicline tartrate, bupropion hydrochloride, nicotine replacement therapy patch_smoking cessation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "smoking cessation", "label": "smoking cessation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tenofovir, placebo", "label": "tenofovir, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic hepatitis b, hepatocellular carcinoma", "label": "chronic hepatitis b, hepatocellular carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedoros hydromorphone hci sr (slow release)_low back pain", "label": "completedoros hydromorphone hci sr (slow release)_low back pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "abt-199", "label": "abt-199", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic lymphocytic leukemia, 17 p deletion, cancer of the blood and bone marrow", "label": "chronic lymphocytic leukemia, 17 p deletion, cancer of the blood and bone marrow", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completed100 mg sumatriptan tablet and optinose placebo delivered nasally, optinose sumatriptan delivered nasally and placebo tablet_migraine, headaches", "label": "completed100 mg sumatriptan tablet and optinose placebo delivered nasally, optinose sumatriptan delivered nasally and placebo tablet_migraine, headaches", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "migraine, headaches", "label": "migraine, headaches", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "busulfan, cytarabine, daunorubicin hydrochloride, decitabine, etoposide", "label": "busulfan, cytarabine, daunorubicin hydrochloride, decitabine, etoposide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acute myeloid leukemia, acute myeloid leukemia with myelodysplasia-related changes, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22.3;q23.3); mllt3-kmt2a, untreated adult acute myeloid leukemia", "label": "acute myeloid leukemia, acute myeloid leukemia with myelodysplasia-related changes, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22.3;q23.3); mllt3-kmt2a, untreated adult acute myeloid leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnsorafenib_medullary thyroid carcinoma", "label": "withdrawnsorafenib_medullary thyroid carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "medullary thyroid carcinoma", "label": "medullary thyroid carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedivabradine, placebo_coronary disease, ventricular dysfunction, left", "label": "completedivabradine, placebo_coronary disease, ventricular dysfunction, left", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "coronary disease, ventricular dysfunction, left", "label": "coronary disease, ventricular dysfunction, left", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carvedilol controlled release/lisinopril, lisinopril + placebo", "label": "carvedilol controlled release/lisinopril, lisinopril + placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarvedilol controlled release/lisinopril, lisinopril + placebo_hypertension", "label": "completedcarvedilol controlled release/lisinopril, lisinopril + placebo_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcariprazine_bipolar i disorder", "label": "completedcariprazine_bipolar i disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "bipolar i disorder", "label": "bipolar i disorder", "shape": "dot", "size": 10}, {"color": "red", "id": "capecitabine", "label": "capecitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuscapecitabine_rectal carcinoma", "label": "unknown statuscapecitabine_rectal carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O", "label": "CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O", "shape": "dot", "size": 10}, {"color": "red", "id": "ar antagonist (bms-641988)", "label": "ar antagonist (bms-641988)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "r-hlh + r-hfsh, r-hfsh, recombinant human choriogonadotropin (r-hcg), gnrh antagonist", "label": "r-hlh + r-hfsh, r-hfsh, recombinant human choriogonadotropin (r-hcg), gnrh antagonist", "shape": "dot", "size": 10}, {"color": "red", "id": "everolimus and intravesical gemcitabine", "label": "everolimus and intravesical gemcitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedeverolimus and intravesical gemcitabine_bladder cancer", "label": "completedeverolimus and intravesical gemcitabine_bladder cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completederlotinib hydrochloride, sorafenib tosylate_extrahepatic bile duct adenocarcinoma, gallbladder adenocarcinoma, gallbladder adenocarcinoma with squamous metaplasia, hilar cholangiocarcinoma, recurrent extrahepatic bile duct carcinoma, recurrent gallbladder carcinoma, undifferentiated gallbladder carcinoma, unresectable extrahepatic bile duct carcinoma, unresectable gallbladder carcinoma", "label": "completederlotinib hydrochloride, sorafenib tosylate_extrahepatic bile duct adenocarcinoma, gallbladder adenocarcinoma, gallbladder adenocarcinoma with squamous metaplasia, hilar cholangiocarcinoma, recurrent extrahepatic bile duct carcinoma, recurrent gallbladder carcinoma, undifferentiated gallbladder carcinoma, unresectable extrahepatic bile duct carcinoma, unresectable gallbladder carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "extrahepatic bile duct adenocarcinoma, gallbladder adenocarcinoma, gallbladder adenocarcinoma with squamous metaplasia, hilar cholangiocarcinoma, recurrent extrahepatic bile duct carcinoma, recurrent gallbladder carcinoma, undifferentiated gallbladder carcinoma, unresectable extrahepatic bile duct carcinoma, unresectable gallbladder carcinoma", "label": "extrahepatic bile duct adenocarcinoma, gallbladder adenocarcinoma, gallbladder adenocarcinoma with squamous metaplasia, hilar cholangiocarcinoma, recurrent extrahepatic bile duct carcinoma, recurrent gallbladder carcinoma, undifferentiated gallbladder carcinoma, unresectable extrahepatic bile duct carcinoma, unresectable gallbladder carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "abiraterone acetate, placebo, prednisone", "label": "abiraterone acetate, placebo, prednisone", "shape": "dot", "size": 10}, {"color": "green", "id": "prostate neoplasms", "label": "prostate neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedabiraterone acetate, placebo, prednisone_prostate neoplasms", "label": "completedabiraterone acetate, placebo, prednisone_prostate neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C", "label": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone furoate/vilanterol 100/25 mcg via ellipta inhaler, placebo inhalation powders via ellipta inhaler, fluticasone propionate/salmeterol 250/50 mcg via accuhaler/diskus inhaler, placebo inhalation powder via accuhaler/diskus inhaler, fluticasone propionate 250 mcg via accuhaler/diskus inhaler", "label": "fluticasone furoate/vilanterol 100/25 mcg via ellipta inhaler, placebo inhalation powders via ellipta inhaler, fluticasone propionate/salmeterol 250/50 mcg via accuhaler/diskus inhaler, placebo inhalation powder via accuhaler/diskus inhaler, fluticasone propionate 250 mcg via accuhaler/diskus inhaler", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "inhaled td139, placebo", "label": "inhaled td139, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "perampanel", "label": "perampanel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedperampanel_parkinson\u0027s disease", "label": "terminatedperampanel_parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "umeclidinium bromide/vilanterol, placebo accuhaler/diskus, fluticasone propionate/salmeterol, placebo ndpi", "label": "umeclidinium bromide/vilanterol, placebo accuhaler/diskus, fluticasone propionate/salmeterol, placebo ndpi", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ibrutinib, bendamustine hydrochloride, rituximab, placebo", "label": "ibrutinib, bendamustine hydrochloride, rituximab, placebo", "shape": "dot", "size": 10}, {"color": "blue", "id": "C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN", "label": "C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN", "shape": "dot", "size": 10}, {"color": "red", "id": "ldx treatment", "label": "ldx treatment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedexparel 266 mg, placebo_posterolateral thoracotomy, postoperative pain", "label": "completedexparel 266 mg, placebo_posterolateral thoracotomy, postoperative pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "posterolateral thoracotomy, postoperative pain", "label": "posterolateral thoracotomy, postoperative pain", "shape": "dot", "size": 10}, {"color": "red", "id": "e7080 capsule", "label": "e7080 capsule", "shape": "dot", "size": 10}, {"color": "green", "id": "thyroid cancer", "label": "thyroid cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1", "label": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, fludarabine, alemtuzumab, rituximab", "label": "cyclophosphamide, fludarabine, alemtuzumab, rituximab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fludarabine, cyclophosphamide, alemtuzumab, rituximab", "label": "fludarabine, cyclophosphamide, alemtuzumab, rituximab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O, CC1=CC(O)=CC(C)=C1Cl", "label": "COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "apixaban, placebo drug", "label": "apixaban, placebo drug", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "label": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "shape": "dot", "size": 10}, {"color": "red", "id": "combination therapy using decitabine and midostaurin", "label": "combination therapy using decitabine and midostaurin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=CC(C(O)=O)=C(O)C=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "NC1=CC(C(O)=O)=C(O)C=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mesalazine, iv corticosteroid, oral corticosteroids", "label": "mesalazine, iv corticosteroid, oral corticosteroids", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "octreotide, dg3173", "label": "octreotide, dg3173", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedoctreotide, dg3173_acromegaly", "label": "completedoctreotide, dg3173_acromegaly", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bevacizumab, temsirolimus", "label": "bevacizumab, temsirolimus", "shape": "dot", "size": 10}, {"color": "green", "id": "kidney cancer", "label": "kidney cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ogx-427 600 mg, ogx-427 1000 mg, placebo, gemcitabine, cisplatin, carboplatin", "label": "ogx-427 600 mg, ogx-427 1000 mg, placebo, gemcitabine, cisplatin, carboplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedogx-427 600 mg, ogx-427 1000 mg, placebo, gemcitabine, cisplatin, carboplatin_urologic neoplasms, metastatic bladder cancer, urinary tract neoplasms", "label": "completedogx-427 600 mg, ogx-427 1000 mg, placebo, gemcitabine, cisplatin, carboplatin_urologic neoplasms, metastatic bladder cancer, urinary tract neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "brimonidine, brimonidine mono therapy, sodium carboxymethylcellulose, corticosteroid eye drop", "label": "brimonidine, brimonidine mono therapy, sodium carboxymethylcellulose, corticosteroid eye drop", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbrimonidine, brimonidine mono therapy, sodium carboxymethylcellulose, corticosteroid eye drop_dry eye", "label": "completedbrimonidine, brimonidine mono therapy, sodium carboxymethylcellulose, corticosteroid eye drop_dry eye", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedallopurinol, placebo_pre-hypertension, jnc 7 stage i hypertension", "label": "completedallopurinol, placebo_pre-hypertension, jnc 7 stage i hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pre-hypertension, jnc 7 stage i hypertension", "label": "pre-hypertension, jnc 7 stage i hypertension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statustriptolide, cart, placebo_hiv", "label": "unknown statustriptolide, cart, placebo_hiv", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "pm01183", "label": "pm01183", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpm01183_breast cancer", "label": "completedpm01183_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1, [H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O, OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O, CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1", "label": "[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1, [H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O, OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O, CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ceftazidime - avibactam ( caz-avi), doripenem, either switch to oral therapy: 500 mg of ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)", "label": "ceftazidime - avibactam ( caz-avi), doripenem, either switch to oral therapy: 500 mg of ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "somatropin, placebo", "label": "somatropin, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic kidney disease, end-stage renal disease", "label": "chronic kidney disease, end-stage renal disease", "shape": "dot", "size": 10}, {"color": "blue", "id": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "label": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "pegylated interferon alpha2a", "label": "pegylated interferon alpha2a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gemcitabine, capecitabine and sorafenib (6 cycles)", "label": "gemcitabine, capecitabine and sorafenib (6 cycles)", "shape": "dot", "size": 10}, {"color": "red", "id": "pegylated interferon alpha-2a", "label": "pegylated interferon alpha-2a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sorafenib, bavituximab", "label": "sorafenib, bavituximab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnsorafenib, bavituximab_hepatocellular carcinoma, unresectable hepatocellular carcinoma, liver cancer", "label": "withdrawnsorafenib, bavituximab_hepatocellular carcinoma, unresectable hepatocellular carcinoma, liver cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1", "label": "CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1", "shape": "dot", "size": 10}, {"color": "red", "id": "rosiglitazone therapy", "label": "rosiglitazone therapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsb-705498_irritable colon", "label": "terminatedsb-705498_irritable colon", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "irritable colon", "label": "irritable colon", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O", "label": "CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gnrh antagonist (cetrorelix), conventional gnrh agonist (triptorelin)", "label": "gnrh antagonist (cetrorelix), conventional gnrh agonist (triptorelin)", "shape": "dot", "size": 10}, {"color": "blue", "id": "O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O", "label": "O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "iron isomaltoside/ferric derisomaltose, iron sucrose", "label": "iron isomaltoside/ferric derisomaltose, iron sucrose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "doxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, vinblastine sulfate, vincristine sulfate", "label": "doxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, vinblastine sulfate, vincristine sulfate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddoxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, vinblastine sulfate, vincristine sulfate_lymphoma", "label": "completeddoxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, vinblastine sulfate, vincristine sulfate_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedux007_glucose transporter type 1 deficiency syndrome", "label": "terminatedux007_glucose transporter type 1 deficiency syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "glucose transporter type 1 deficiency syndrome", "label": "glucose transporter type 1 deficiency syndrome", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedamg 706_thyroid cancer", "label": "completedamg 706_thyroid cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rivaroxaban (xarelto, bay59-7939), enoxaparin followed by vka", "label": "rivaroxaban (xarelto, bay59-7939), enoxaparin followed by vka", "shape": "dot", "size": 10}, {"color": "green", "id": "venous thrombosis", "label": "venous thrombosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbortezomib_sarcoma", "label": "completedbortezomib_sarcoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "raltegravir (mk-0518), nevirapine, lamivudine, tenofovir, emtricitabine, lopinavir, ritonavir, atazanavir, darunavir", "label": "raltegravir (mk-0518), nevirapine, lamivudine, tenofovir, emtricitabine, lopinavir, ritonavir, atazanavir, darunavir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedraltegravir (mk-0518), nevirapine, lamivudine, tenofovir, emtricitabine, lopinavir, ritonavir, atazanavir, darunavir_hiv infections", "label": "terminatedraltegravir (mk-0518), nevirapine, lamivudine, tenofovir, emtricitabine, lopinavir, ritonavir, atazanavir, darunavir_hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[f-18]-5-fluoro-2\u0027-deoxycytidine, tetrahydrouridine intravenous (iv), tetrahydrouridine (oral)", "label": "[f-18]-5-fluoro-2\u0027-deoxycytidine, tetrahydrouridine intravenous (iv), tetrahydrouridine (oral)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "head and neck neoplasms, lung neoplasms, urinary bladder neoplasms, breast neoplasms", "label": "head and neck neoplasms, lung neoplasms, urinary bladder neoplasms, breast neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bevacizumab, rad001", "label": "bevacizumab, rad001", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedescitalopram, placebo_generalized anxiety disorder", "label": "completedescitalopram, placebo_generalized anxiety disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "generalized anxiety disorder", "label": "generalized anxiety disorder", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, buprenorphine transdermal system", "label": "placebo, buprenorphine transdermal system", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, buprenorphine transdermal system_low back pain", "label": "completedplacebo, buprenorphine transdermal system_low back pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsuboxone, rbp-6000, placebo_opioid dependence, opioid related disorders", "label": "completedsuboxone, rbp-6000, placebo_opioid dependence, opioid related disorders", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "opioid dependence, opioid related disorders", "label": "opioid dependence, opioid related disorders", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1", "label": "CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "bisoprolol", "label": "bisoprolol", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1", "label": "CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsorafenib, tegafur/uracil (ufur\u00ae)_hepatocellular carcinoma", "label": "completedsorafenib, tegafur/uracil (ufur\u00ae)_hepatocellular carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "hepatocellular carcinoma", "label": "hepatocellular carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "anb020, placebo", "label": "anb020, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedanb020, placebo_eosinophilic asthma", "label": "completedanb020, placebo_eosinophilic asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pf-04991532, placebo", "label": "pf-04991532, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpf-04991532, placebo_diabetes mellitus, diabetes mellitus, type 2, glucose metabolism disorders", "label": "completedpf-04991532, placebo_diabetes mellitus, diabetes mellitus, type 2, glucose metabolism disorders", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "label": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "doxorubicin hydrochloride, sunitinib malate", "label": "doxorubicin hydrochloride, sunitinib malate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "roflumilast, pioglitazone, placebo, placebo", "label": "roflumilast, pioglitazone, placebo, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedroflumilast, pioglitazone, placebo, placebo_nonalcoholic steatohapatitis", "label": "terminatedroflumilast, pioglitazone, placebo, placebo_nonalcoholic steatohapatitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "label": "CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "perifosine, imatinib mesylate", "label": "perifosine, imatinib mesylate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaprepitant, placebo_chemotherapy induced nausea and vomiting", "label": "completedaprepitant, placebo_chemotherapy induced nausea and vomiting", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "chemotherapy induced nausea and vomiting", "label": "chemotherapy induced nausea and vomiting", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azd3480, donepezil", "label": "azd3480, donepezil", "shape": "dot", "size": 10}, {"color": "red", "id": "imexon", "label": "imexon", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedimexon_follicular lymphoma, small lymphocytic lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, diffuse large b cell lymphoma, mantle cell lymphoma, burkitt\u0027s lymphoma", "label": "completedimexon_follicular lymphoma, small lymphocytic lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, diffuse large b cell lymphoma, mantle cell lymphoma, burkitt\u0027s lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lurasidone, placebo", "label": "lurasidone, placebo", "shape": "dot", "size": 10}, {"color": "green", "id": "major depressive disorder with mixed features", "label": "major depressive disorder with mixed features", "shape": "dot", "size": 10}, {"color": "red", "id": "irinotecan hydrochloride", "label": "irinotecan hydrochloride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adenocarcinoma of the colon, adenocarcinoma of the rectum, recurrent colon cancer, recurrent rectal cancer, stage iii colon cancer, stage iii rectal cancer, stage iv colon cancer, stage iv rectal cancer", "label": "adenocarcinoma of the colon, adenocarcinoma of the rectum, recurrent colon cancer, recurrent rectal cancer, stage iii colon cancer, stage iii rectal cancer, stage iv colon cancer, stage iv rectal cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnirinotecan hydrochloride_central nervous system metastases, male breast cancer, recurrent breast cancer, stage iv breast cancer", "label": "withdrawnirinotecan hydrochloride_central nervous system metastases, male breast cancer, recurrent breast cancer, stage iv breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "goserelin acetate, letrozole, anastrozole, chemotherapy", "label": "goserelin acetate, letrozole, anastrozole, chemotherapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "estrogen receptor-positive breast cancer, her2-negative breast cancer, stage ii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer", "label": "estrogen receptor-positive breast cancer, her2-negative breast cancer, stage ii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1, [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1, [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fx006 32 mg, tca ir 40", "label": "fx006 32 mg, tca ir 40", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1", "label": "NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1", "shape": "dot", "size": 10}, {"color": "red", "id": "ganciclovir", "label": "ganciclovir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNC(=O)C1=CC=C(C=C1F)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2N=C1, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "label": "CNC(=O)C1=CC=C(C=C1F)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2N=C1, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "inc280, gefitinib", "label": "inc280, gefitinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatediv meropenem, i.v. meropenem, parenteral aminoglycoside; tobramycin for injection usp or gentamicin sulfate injection solution concentrate 5mg.kg iv q24h; amikacin sulfate injection usp 20 mg/kg iv q24h, linezolid or vancomycin (per institutional guidelines) will be available for mrsa coverage._bacterial pneumonia", "label": "terminatediv meropenem, i.v. meropenem, parenteral aminoglycoside; tobramycin for injection usp or gentamicin sulfate injection solution concentrate 5mg.kg iv q24h; amikacin sulfate injection usp 20 mg/kg iv q24h, linezolid or vancomycin (per institutional guidelines) will be available for mrsa coverage._bacterial pneumonia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "bacterial pneumonia", "label": "bacterial pneumonia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbest available therapy, ruxolitinib_polycythemia vera", "label": "completedbest available therapy, ruxolitinib_polycythemia vera", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "polycythemia vera", "label": "polycythemia vera", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ff inhalation powder, ff/gw642444 inhalation powder, gw642444 inhalation powder, placebo", "label": "ff inhalation powder, ff/gw642444 inhalation powder, gw642444 inhalation powder, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedff inhalation powder, ff/gw642444 inhalation powder, gw642444 inhalation powder, placebo_pulmonary disease, chronic obstructive", "label": "completedff inhalation powder, ff/gw642444 inhalation powder, gw642444 inhalation powder, placebo_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carboplatin, celecoxib, gemcitabine hydrochloride, pemetrexed disodium", "label": "carboplatin, celecoxib, gemcitabine hydrochloride, pemetrexed disodium", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcarboplatin, celecoxib, gemcitabine hydrochloride, pemetrexed disodium_lung cancer", "label": "terminatedcarboplatin, celecoxib, gemcitabine hydrochloride, pemetrexed disodium_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "axs-05, bupropion sr", "label": "axs-05, bupropion sr", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaxs-05, bupropion sr_smoking cessation, smoking, cigarette, nicotine dependence", "label": "completedaxs-05, bupropion sr_smoking cessation, smoking, cigarette, nicotine dependence", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "inhaled fluticasone propionate", "label": "inhaled fluticasone propionate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "asthma, chronic obstructive pulmonary disease, obstructive sleep apnea", "label": "asthma, chronic obstructive pulmonary disease, obstructive sleep apnea", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "netupitant and palonosetron, palonosetron, dexamethasone", "label": "netupitant and palonosetron, palonosetron, dexamethasone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednetupitant and palonosetron, palonosetron, dexamethasone_chemotherapy-induced nausea and vomiting", "label": "completednetupitant and palonosetron, palonosetron, dexamethasone_chemotherapy-induced nausea and vomiting", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oral ftc/tdf (daily emtricitabine/tenofovir disoproxil fumarate tablet), rectal daily tfv rg 1% gel (rectally applied tenofovir reduced glycerin 1% gel), rectal rai-associated tfv rg 1% gel (receptive anal intercourse associated rectally applied tenofovir reduced glycerin 1% gel)", "label": "oral ftc/tdf (daily emtricitabine/tenofovir disoproxil fumarate tablet), rectal daily tfv rg 1% gel (rectally applied tenofovir reduced glycerin 1% gel), rectal rai-associated tfv rg 1% gel (receptive anal intercourse associated rectally applied tenofovir reduced glycerin 1% gel)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pemetrexed disodium, sunitinib malate", "label": "pemetrexed disodium, sunitinib malate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recurrent non-small cell lung carcinoma, stage iiib non-small cell lung cancer ajcc v7, stage iv non-small cell lung cancer ajcc v7", "label": "recurrent non-small cell lung carcinoma, stage iiib non-small cell lung cancer ajcc v7, stage iv non-small cell lung cancer ajcc v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedezetimibe + statin (simvastatin, atorvastatin, or pravastatin), double statin (simvastatin, atorvastatin, or pravastatin)_hypercholesterolemia", "label": "completedezetimibe + statin (simvastatin, atorvastatin, or pravastatin), double statin (simvastatin, atorvastatin, or pravastatin)_hypercholesterolemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "hypercholesterolemia", "label": "hypercholesterolemia", "shape": "dot", "size": 10}, {"color": "red", "id": "olanzapine", "label": "olanzapine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hematopoietic/lymphoid cancer, pain, unspecified adult solid tumor, protocol specific", "label": "hematopoietic/lymphoid cancer, pain, unspecified adult solid tumor, protocol specific", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmemantine, placebo pill_alzheimer disease", "label": "completedmemantine, placebo pill_alzheimer disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ly2940680", "label": "ly2940680", "shape": "dot", "size": 10}, {"color": "green", "id": "neoplasm metastasis", "label": "neoplasm metastasis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo capsule, 10 mg natura-alpha capsule and 10 mg placebo capsule, 2 x 10 mg natura-alpha capsules", "label": "placebo capsule, 10 mg natura-alpha capsule and 10 mg placebo capsule, 2 x 10 mg natura-alpha capsules", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusplacebo capsule, 10 mg natura-alpha capsule and 10 mg placebo capsule, 2 x 10 mg natura-alpha capsules_ulcerative colitis", "label": "unknown statusplacebo capsule, 10 mg natura-alpha capsule and 10 mg placebo capsule, 2 x 10 mg natura-alpha capsules_ulcerative colitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=CC(F)=CC=C1F, CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=CC(F)=CC=C1F, CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1, CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1", "label": "CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=CC(F)=CC=C1F, CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=CC(F)=CC=C1F, CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1, CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "omarigliptin, placebo to omarigliptin, glipizide, placebo to glipizide", "label": "omarigliptin, placebo to omarigliptin, glipizide, placebo to glipizide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alendronate, denosumab, placebo", "label": "alendronate, denosumab, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalendronate, denosumab, placebo_postmenopausal osteoporosis", "label": "completedalendronate, denosumab, placebo_postmenopausal osteoporosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "olaparib, physician\u0027s choice chemotherapy", "label": "olaparib, physician\u0027s choice chemotherapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "breast cancer metastatic, brca 1 gene mutation, brca 2 gene mutation", "label": "breast cancer metastatic, brca 1 gene mutation, brca 2 gene mutation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bortezomib, rituximab", "label": "bortezomib, rituximab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedbortezomib, rituximab_lymphoma", "label": "terminatedbortezomib, rituximab_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sunitinib (sutent), taxotere", "label": "sunitinib (sutent), taxotere", "shape": "dot", "size": 10}, {"color": "green", "id": "breast neoplasms", "label": "breast neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cisplatin, panitumumab", "label": "cisplatin, panitumumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "head and neck cancer, squamous cell carcinoma", "label": "head and neck cancer, squamous cell carcinoma", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "red", "id": "budesonide and formoterol bid", "label": "budesonide and formoterol bid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedgalantamine_schizophrenia, psychotic disorder", "label": "terminatedgalantamine_schizophrenia, psychotic disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "schizophrenia, psychotic disorder", "label": "schizophrenia, psychotic disorder", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hydromorphone er, sugar pill", "label": "hydromorphone er, sugar pill", "shape": "dot", "size": 10}, {"color": "red", "id": "pioglitazone", "label": "pioglitazone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "depressive disorder, major, metabolic syndrome x", "label": "depressive disorder, major, metabolic syndrome x", "shape": "dot", "size": 10}, {"color": "red", "id": "hsp90 inhibitor auy922", "label": "hsp90 inhibitor auy922", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unspecified adult solid tumor, protocol specific", "label": "unspecified adult solid tumor, protocol specific", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedezetimibe, placebo_hypercholesterolemia, atherosclerosis", "label": "terminatedezetimibe, placebo_hypercholesterolemia, atherosclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hypercholesterolemia, atherosclerosis", "label": "hypercholesterolemia, atherosclerosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, oros (methylphenidate hcl), ritalin (methylphenidate)", "label": "placebo, oros (methylphenidate hcl), ritalin (methylphenidate)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, oros (methylphenidate hcl), ritalin (methylphenidate)_attention deficit hyperactivity disorder", "label": "completedplacebo, oros (methylphenidate hcl), ritalin (methylphenidate)_attention deficit hyperactivity disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dacomitinib, pemetrexed", "label": "dacomitinib, pemetrexed", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddacomitinib, pemetrexed_non small cell lung cancer", "label": "terminateddacomitinib, pemetrexed_non small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hqk-1001, placebo", "label": "hqk-1001, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedhqk-1001, placebo_sickle cell disease, sickle cell anemia, sickle cell disorders, hemoglobin s disease, sickling disorder due to hemoglobin s", "label": "terminatedhqk-1001, placebo_sickle cell disease, sickle cell anemia, sickle cell disorders, hemoglobin s disease, sickling disorder due to hemoglobin s", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "abiraterone acetate, prednisone, abiraterone acetate placebo, prednisone placebo", "label": "abiraterone acetate, prednisone, abiraterone acetate placebo, prednisone placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "corticosteroids, cyclophosphamide, mycophenolate mofetil, ocrelizumab, placebo, azathioprine", "label": "corticosteroids, cyclophosphamide, mycophenolate mofetil, ocrelizumab, placebo, azathioprine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lupus nephritis, systemic lupus erythematosus", "label": "lupus nephritis, systemic lupus erythematosus", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsecukinumab 150 mg s.c., secukinumab 300 mg s.c., placebo_plaque psoriasis", "label": "completedsecukinumab 150 mg s.c., secukinumab 300 mg s.c., placebo_plaque psoriasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chemotherapy, gemcitabine, irinotecan, leucovorin, 5-fluorouracil, pembrolizumab", "label": "chemotherapy, gemcitabine, irinotecan, leucovorin, 5-fluorouracil, pembrolizumab", "shape": "dot", "size": 10}, {"color": "green", "id": "pancreatic adenocarcinoma", "label": "pancreatic adenocarcinoma", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(O)(P(O)(O)=O)P(O)(O)=O", "label": "CC(O)(P(O)(O)=O)P(O)(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": "iv bisphosphonate q 4 weeks", "label": "iv bisphosphonate q 4 weeks", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmilnacipran, placebo_autism spectrum disorder, asperger syndrome, aspergers syndrome", "label": "completedmilnacipran, placebo_autism spectrum disorder, asperger syndrome, aspergers syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "autism spectrum disorder, asperger syndrome, aspergers syndrome", "label": "autism spectrum disorder, asperger syndrome, aspergers syndrome", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tozadenant (syn115) 60 mg bid, placebo, levodopa (l-dopa), tozadenant (syn115) 120 mg bid, tozadenant (syn115) 180 mg bid, tozadenant (syn115) 240 mg bid", "label": "tozadenant (syn115) 60 mg bid, placebo, levodopa (l-dopa), tozadenant (syn115) 120 mg bid, tozadenant (syn115) 180 mg bid, tozadenant (syn115) 240 mg bid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtozadenant (syn115) 60 mg bid, placebo, levodopa (l-dopa), tozadenant (syn115) 120 mg bid, tozadenant (syn115) 180 mg bid, tozadenant (syn115) 240 mg bid_parkinson\u0027s disease", "label": "completedtozadenant (syn115) 60 mg bid, placebo, levodopa (l-dopa), tozadenant (syn115) 120 mg bid, tozadenant (syn115) 180 mg bid, tozadenant (syn115) 240 mg bid_parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin", "label": "ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic hepatitis c, decompensated cirrhosis, hepatitis c virus", "label": "chronic hepatitis c, decompensated cirrhosis, hepatitis c virus", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H], CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "label": "[H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H], CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "at-101, topotecan", "label": "at-101, topotecan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrivastigmine 5 cm^2, rivastigmine 10 cm^2, rivastigmine 15 cm^2, placebo to 15 cm^2 patch, placebo to 10 cm^2 patch_alzheimer disease", "label": "completedrivastigmine 5 cm^2, rivastigmine 10 cm^2, rivastigmine 15 cm^2, placebo to 15 cm^2 patch, placebo to 10 cm^2 patch_alzheimer disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedduloxetine, pregabalin, placebo_diabetic peripheral neuropathic pain", "label": "completedduloxetine, pregabalin, placebo_diabetic peripheral neuropathic pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "diabetic peripheral neuropathic pain", "label": "diabetic peripheral neuropathic pain", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O", "label": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitinghigh dose methylprednisolone (hdmp), ofatumumab, lenalidomide_chronic lymphocytic leukemia, small lymphocytic lymphoma", "label": "active, not recruitinghigh dose methylprednisolone (hdmp), ofatumumab, lenalidomide_chronic lymphocytic leukemia, small lymphocytic lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "label": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dasatinib, imatinib", "label": "dasatinib, imatinib", "shape": "dot", "size": 10}, {"color": "red", "id": "vitamin d3 cholecalciferol", "label": "vitamin d3 cholecalciferol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vitamin d deficiency, insulin resistance", "label": "vitamin d deficiency, insulin resistance", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "captopril, enalapril, lisinopril, ramipril, trandolapril, bisoprolol, carvedilol, metoprolol succinate, candesartan, valsartan, eplerenone, spironolactone, diuretics, hf treatment according to swedish guidelines", "label": "captopril, enalapril, lisinopril, ramipril, trandolapril, bisoprolol, carvedilol, metoprolol succinate, candesartan, valsartan, eplerenone, spironolactone, diuretics, hf treatment according to swedish guidelines", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "heart failure, ventricular dysfunction, left", "label": "heart failure, ventricular dysfunction, left", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedku-0059436 (azd2281)(parp inhibitor), ku-0059436 (azd2281)(parp inhibitor)_ovarian neoplasm", "label": "completedku-0059436 (azd2281)(parp inhibitor), ku-0059436 (azd2281)(parp inhibitor)_ovarian neoplasm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlenvatinib, placebo, lenvatinib_thyroid cancer", "label": "completedlenvatinib, placebo, lenvatinib_thyroid cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "insulin glulisine, insulin glargine", "label": "insulin glulisine, insulin glargine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin glulisine, insulin glargine_diabetes mellitus, type 1", "label": "completedinsulin glulisine, insulin glargine_diabetes mellitus, type 1", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ibudilast, placebo oral capsule", "label": "ibudilast, placebo oral capsule", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedibudilast, placebo oral capsule_multiple sclerosis, primary progressive, multiple sclerosis, secondary progressive", "label": "completedibudilast, placebo oral capsule_multiple sclerosis, primary progressive, multiple sclerosis, secondary progressive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib", "label": "akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedakt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib_pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma, recurrent pancreatic carcinoma, stage iv pancreatic cancer", "label": "completedakt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib_pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma, recurrent pancreatic carcinoma, stage iv pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, bi 10773, placebo, placebo, placebo, bi 10773", "label": "placebo, bi 10773, placebo, placebo, placebo, bi 10773", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glimepiride and metformin hydrochloride combination (hoe490), glimepiride (hoe490)", "label": "glimepiride and metformin hydrochloride combination (hoe490), glimepiride (hoe490)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedglimepiride and metformin hydrochloride combination (hoe490), glimepiride (hoe490)_type 2 diabetes mellitus", "label": "completedglimepiride and metformin hydrochloride combination (hoe490), glimepiride (hoe490)_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "quetiapine fumarate, escitalopram oxylate", "label": "quetiapine fumarate, escitalopram oxylate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(=O)OC1=CC=CC=C1C(O)=O", "label": "CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(=O)OC1=CC=CC=C1C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tapentadol er (100 to 250 mg twice daily), matching placebo (twice daily), oxycodone cr (20 to 50 mg twice daily)", "label": "tapentadol er (100 to 250 mg twice daily), matching placebo (twice daily), oxycodone cr (20 to 50 mg twice daily)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cep-701, high-dose cytarabine, mitozantrone, etoposide, cytarabine (combination chemotherapy)", "label": "cep-701, high-dose cytarabine, mitozantrone, etoposide, cytarabine (combination chemotherapy)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcep-701, high-dose cytarabine, mitozantrone, etoposide, cytarabine (combination chemotherapy)_acute myeloid leukemia", "label": "completedcep-701, high-dose cytarabine, mitozantrone, etoposide, cytarabine (combination chemotherapy)_acute myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtemozolomide_colorectal neoplasm, head and neck neoplasm, carcinoma, non-small-cell lung, esophageal neoplasm", "label": "terminatedtemozolomide_colorectal neoplasm, head and neck neoplasm, carcinoma, non-small-cell lung, esophageal neoplasm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "colorectal neoplasm, head and neck neoplasm, carcinoma, non-small-cell lung, esophageal neoplasm", "label": "colorectal neoplasm, head and neck neoplasm, carcinoma, non-small-cell lung, esophageal neoplasm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rg7388, pegasys", "label": "rg7388, pegasys", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrg7388, pegasys_polycythemia vera, essential thrombocythemia", "label": "completedrg7388, pegasys_polycythemia vera, essential thrombocythemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine hydrochloride, triapine_anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, intraocular lymphoma, nodal marginal zone b-cell lymphoma, primary central nervous system hodgkin lymphoma, primary central nervous system non-hodgkin lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, small intestine lymphoma, splenic marginal zone lymphoma, stage iii adult burkitt lymphoma, stage iii adult diffuse large cell lymphoma, stage iii adult diffuse mixed cell lymphoma, stage iii adult diffuse small cleaved cell lymphoma, stage iii adult hodgkin lymphoma, stage iii adult immunoblastic large cell lymphoma, stage iii adult lymphoblastic lymphoma, stage iii adult t-cell leukemia/lymphoma, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iii marginal zone lymphoma, stage iii mycosis fungoides/sezary syndrome, stage iii small lymphocytic lymphoma, stage iv adult burkitt lymphoma, stage iv adult diffuse large cell lymphoma, stage iv adult diffuse mixed cell lymphoma, stage iv adult diffuse small cleaved cell lymphoma, stage iv adult hodgkin lymphoma, stage iv adult immunoblastic large cell lymphoma, stage iv adult lymphoblastic lymphoma, stage iv adult t-cell leukemia/lymphoma, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma, stage iv marginal zone lymphoma, stage iv mycosis fungoides/sezary syndrome, stage iv small lymphocytic lymphoma, unspecified adult solid tumor, protocol specific, waldenstr\u00f6m macroglobulinemia", "label": "completedgemcitabine hydrochloride, triapine_anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, intraocular lymphoma, nodal marginal zone b-cell lymphoma, primary central nervous system hodgkin lymphoma, primary central nervous system non-hodgkin lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, small intestine lymphoma, splenic marginal zone lymphoma, stage iii adult burkitt lymphoma, stage iii adult diffuse large cell lymphoma, stage iii adult diffuse mixed cell lymphoma, stage iii adult diffuse small cleaved cell lymphoma, stage iii adult hodgkin lymphoma, stage iii adult immunoblastic large cell lymphoma, stage iii adult lymphoblastic lymphoma, stage iii adult t-cell leukemia/lymphoma, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iii marginal zone lymphoma, stage iii mycosis fungoides/sezary syndrome, stage iii small lymphocytic lymphoma, stage iv adult burkitt lymphoma, stage iv adult diffuse large cell lymphoma, stage iv adult diffuse mixed cell lymphoma, stage iv adult diffuse small cleaved cell lymphoma, stage iv adult hodgkin lymphoma, stage iv adult immunoblastic large cell lymphoma, stage iv adult lymphoblastic lymphoma, stage iv adult t-cell leukemia/lymphoma, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma, stage iv marginal zone lymphoma, stage iv mycosis fungoides/sezary syndrome, stage iv small lymphocytic lymphoma, unspecified adult solid tumor, protocol specific, waldenstr\u00f6m macroglobulinemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, intraocular lymphoma, nodal marginal zone b-cell lymphoma, primary central nervous system hodgkin lymphoma, primary central nervous system non-hodgkin lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, small intestine lymphoma, splenic marginal zone lymphoma, stage iii adult burkitt lymphoma, stage iii adult diffuse large cell lymphoma, stage iii adult diffuse mixed cell lymphoma, stage iii adult diffuse small cleaved cell lymphoma, stage iii adult hodgkin lymphoma, stage iii adult immunoblastic large cell lymphoma, stage iii adult lymphoblastic lymphoma, stage iii adult t-cell leukemia/lymphoma, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iii marginal zone lymphoma, stage iii mycosis fungoides/sezary syndrome, stage iii small lymphocytic lymphoma, stage iv adult burkitt lymphoma, stage iv adult diffuse large cell lymphoma, stage iv adult diffuse mixed cell lymphoma, stage iv adult diffuse small cleaved cell lymphoma, stage iv adult hodgkin lymphoma, stage iv adult immunoblastic large cell lymphoma, stage iv adult lymphoblastic lymphoma, stage iv adult t-cell leukemia/lymphoma, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma, stage iv marginal zone lymphoma, stage iv mycosis fungoides/sezary syndrome, stage iv small lymphocytic lymphoma, unspecified adult solid tumor, protocol specific, waldenstr\u00f6m macroglobulinemia", "label": "anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, intraocular lymphoma, nodal marginal zone b-cell lymphoma, primary central nervous system hodgkin lymphoma, primary central nervous system non-hodgkin lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, small intestine lymphoma, splenic marginal zone lymphoma, stage iii adult burkitt lymphoma, stage iii adult diffuse large cell lymphoma, stage iii adult diffuse mixed cell lymphoma, stage iii adult diffuse small cleaved cell lymphoma, stage iii adult hodgkin lymphoma, stage iii adult immunoblastic large cell lymphoma, stage iii adult lymphoblastic lymphoma, stage iii adult t-cell leukemia/lymphoma, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iii marginal zone lymphoma, stage iii mycosis fungoides/sezary syndrome, stage iii small lymphocytic lymphoma, stage iv adult burkitt lymphoma, stage iv adult diffuse large cell lymphoma, stage iv adult diffuse mixed cell lymphoma, stage iv adult diffuse small cleaved cell lymphoma, stage iv adult hodgkin lymphoma, stage iv adult immunoblastic large cell lymphoma, stage iv adult lymphoblastic lymphoma, stage iv adult t-cell leukemia/lymphoma, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma, stage iv marginal zone lymphoma, stage iv mycosis fungoides/sezary syndrome, stage iv small lymphocytic lymphoma, unspecified adult solid tumor, protocol specific, waldenstr\u00f6m macroglobulinemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, placebo", "label": "tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, placebo_acute coronary syndrome", "label": "completedtak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, placebo_acute coronary syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmedi8897, placebo_respiratory syncytial virus infections", "label": "completedmedi8897, placebo_respiratory syncytial virus infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "respiratory syncytial virus infections", "label": "respiratory syncytial virus infections", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ranibizumab 0.5mg, thr-317 8mg, sham injection", "label": "ranibizumab 0.5mg, thr-317 8mg, sham injection", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "diabetes mellitus, diabetic retinopathy, macular edema", "label": "diabetes mellitus, diabetic retinopathy, macular edema", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pn400 (vimovo), pn 400 (vimovo)", "label": "pn400 (vimovo), pn 400 (vimovo)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpn400 (vimovo), pn 400 (vimovo)_gastric ulcer", "label": "completedpn400 (vimovo), pn 400 (vimovo)_gastric ulcer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nivolumab, bevacizumab", "label": "nivolumab, bevacizumab", "shape": "dot", "size": 10}, {"color": "red", "id": "systemic chemotherapy (folfox)", "label": "systemic chemotherapy (folfox)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "colorectal cancer, colorectal carcinoma, liver metastases", "label": "colorectal cancer, colorectal carcinoma, liver metastases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "omarigliptin, sitagliptin, placebo to omarigliptin, placebo to sitagliptin, open-label metformin, open-label glimepiride", "label": "omarigliptin, sitagliptin, placebo to omarigliptin, placebo to sitagliptin, open-label metformin, open-label glimepiride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedomarigliptin, sitagliptin, placebo to omarigliptin, placebo to sitagliptin, open-label metformin, open-label glimepiride_type 2 diabetes", "label": "completedomarigliptin, sitagliptin, placebo to omarigliptin, placebo to sitagliptin, open-label metformin, open-label glimepiride_type 2 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "oral glycopyrrolate liquid", "label": "oral glycopyrrolate liquid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedoral glycopyrrolate liquid_cerebral palsy, neurological conditions, mental retardation, sialorrhea", "label": "completedoral glycopyrrolate liquid_cerebral palsy, neurological conditions, mental retardation, sialorrhea", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C=NC2=C1C=C(C(O)=NOCCO)C(NC1=C(Cl)C=C(Br)C=C1)=C2F, [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1", "label": "CN1C=NC2=C1C=C(C(O)=NOCCO)C(NC1=C(Cl)C=C(Br)C=C1)=C2F, [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel and azd6244, docetaxel and placebo", "label": "docetaxel and azd6244, docetaxel and placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednintedanib, placebo, sildenafil_idiopathic pulmonary fibrosis", "label": "completednintedanib, placebo, sildenafil_idiopathic pulmonary fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azathioprine, infliximab, prednisolon", "label": "azathioprine, infliximab, prednisolon", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedazathioprine, infliximab, prednisolon_crohn\u0027s disease", "label": "terminatedazathioprine, infliximab, prednisolon_crohn\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddarunavir, ritonavir and rilpivirine_hiv", "label": "completeddarunavir, ritonavir and rilpivirine_hiv", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedetc-1002, placebo_hypercholesterolemia", "label": "completedetc-1002, placebo_hypercholesterolemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rvt-101 35 mg, placebo", "label": "rvt-101 35 mg, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alzheimer\u0027s disease, dementia with lewy bodies, parkinson\u0027s disease dementia", "label": "alzheimer\u0027s disease, dementia with lewy bodies, parkinson\u0027s disease dementia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tocilizumab, adalimumab, placebo to tocilizumab, placebo to adalimumab", "label": "tocilizumab, adalimumab, placebo to tocilizumab, placebo to adalimumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtocilizumab, adalimumab, placebo to tocilizumab, placebo to adalimumab_rheumatoid arthritis", "label": "completedtocilizumab, adalimumab, placebo to tocilizumab, placebo to adalimumab_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone 250/formoterol 10, fluticasone 250/salmeterol 25, fluticasone 125/formoterol 5", "label": "fluticasone 250/formoterol 10, fluticasone 250/salmeterol 25, fluticasone 125/formoterol 5", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfluticasone 250/formoterol 10, fluticasone 250/salmeterol 25, fluticasone 125/formoterol 5_asthma", "label": "completedfluticasone 250/formoterol 10, fluticasone 250/salmeterol 25, fluticasone 125/formoterol 5_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "iron (ferrous sulfate)", "label": "iron (ferrous sulfate)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawniron (ferrous sulfate)_anemia", "label": "withdrawniron (ferrous sulfate)_anemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC[C@H]1CC[C@@H](CC1)C(O)=O, NCCCCCC(O)=O", "label": "NC[C@H]1CC[C@@H](CC1)C(O)=O, NCCCCCC(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oral tranexamic acid, oral aminocaproic acid", "label": "oral tranexamic acid, oral aminocaproic acid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtrastuzumab (9 weeks) + docetaxel, trastuzumab (9 weeks) + docetaxel + cef + trastuzumab (up to 51 weeks)_breast neoplasms", "label": "completedtrastuzumab (9 weeks) + docetaxel, trastuzumab (9 weeks) + docetaxel + cef + trastuzumab (up to 51 weeks)_breast neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcapecitabine, sunitinib malate_breast neoplasms", "label": "terminatedcapecitabine, sunitinib malate_breast neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawngabapentin, placebo_fabry disease, neuropathic pain", "label": "withdrawngabapentin, placebo_fabry disease, neuropathic pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fabry disease, neuropathic pain", "label": "fabry disease, neuropathic pain", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbi 409306, placebo, bi 409306, placebo, placebo, bi 409306, bi 409306, placebo, placebo_alzheimer disease", "label": "completedbi 409306, placebo, bi 409306, placebo, placebo, bi 409306, bi 409306, placebo, placebo_alzheimer disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "firategrast 150 mg, firategrast 300 mg", "label": "firategrast 150 mg, firategrast 300 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfirategrast 150 mg, firategrast 300 mg_multiple sclerosis", "label": "completedfirategrast 150 mg, firategrast 300 mg_multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlatanoprost 0.005% eye drops and brimonidine 0.1% eye drops, latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops_glaucoma, ocular hypertension", "label": "completedlatanoprost 0.005% eye drops and brimonidine 0.1% eye drops, latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops_glaucoma, ocular hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glaucoma, ocular hypertension", "label": "glaucoma, ocular hypertension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpf-04457845, placebo_post-traumatic stress disorder", "label": "terminatedpf-04457845, placebo_post-traumatic stress disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1", "label": "NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1", "shape": "dot", "size": 10}, {"color": "red", "id": "abacavir sulfate", "label": "abacavir sulfate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dapagliflozin, dapagliflozin, metformin, dapagliflozin placebo, pioglitazone", "label": "dapagliflozin, dapagliflozin, metformin, dapagliflozin placebo, pioglitazone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tocilizumab [roactemra/actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate", "label": "tocilizumab [roactemra/actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtocilizumab [roactemra/actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate_rheumatoid arthritis", "label": "terminatedtocilizumab [roactemra/actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddocetaxel_breast neoplasms", "label": "completeddocetaxel_breast neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@]([H])(C=C1)[C@@H]([C@@H]2NC1=C(F)C=NC(NC2=CC=C(N3CCN(C)CC3)C(C)=C2)=N1)C(N)=O, [H][C@@]12C[C@@]([H])(C=C1)[C@@H]([C@@H]2NC1=C(F)C=NC(NC2=CC=C(N3CCN(C)CC3)C(C)=C2)=N1)C(N)=O", "label": "[H][C@@]12C[C@@]([H])(C=C1)[C@@H]([C@@H]2NC1=C(F)C=NC(NC2=CC=C(N3CCN(C)CC3)C(C)=C2)=N1)C(N)=O, [H][C@@]12C[C@@]([H])(C=C1)[C@@H]([C@@H]2NC1=C(F)C=NC(NC2=CC=C(N3CCN(C)CC3)C(C)=C2)=N1)C(N)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "as703569/gemcitabine, as703569/gemcitabine", "label": "as703569/gemcitabine, as703569/gemcitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddocetaxel, doxorubicin, carboplatin, cyclophosphamide, trastuzumab, bevacizumab_breast neoplasms", "label": "completeddocetaxel, doxorubicin, carboplatin, cyclophosphamide, trastuzumab, bevacizumab_breast neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlde225_advanced solid tumor cancers, medulloblastoma, basal cell carcinoma", "label": "completedlde225_advanced solid tumor cancers, medulloblastoma, basal cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "advanced solid tumor cancers, medulloblastoma, basal cell carcinoma", "label": "advanced solid tumor cancers, medulloblastoma, basal cell carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpreladenant, placebo, anticholinergic agents or propanolol, haloperidol_akathisia, drug-induced, antipsychotic agents, movement disorders", "label": "terminatedpreladenant, placebo, anticholinergic agents or propanolol, haloperidol_akathisia, drug-induced, antipsychotic agents, movement disorders", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "akathisia, drug-induced, antipsychotic agents, movement disorders", "label": "akathisia, drug-induced, antipsychotic agents, movement disorders", "shape": "dot", "size": 10}, {"color": "red", "id": "bi 201335", "label": "bi 201335", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbi 201335_hepatitis c, liver cirrhosis", "label": "completedbi 201335_hepatitis c, liver cirrhosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1", "label": "NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[s,s]-reboxetine + pregabalin, pregabalin", "label": "[s,s]-reboxetine + pregabalin, pregabalin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pramipexole 0.125 mg tablet, pramipexole 0.5 mg tablet", "label": "pramipexole 0.125 mg tablet, pramipexole 0.5 mg tablet", "shape": "dot", "size": 10}, {"color": "green", "id": "idiopathic restless legs syndrome", "label": "idiopathic restless legs syndrome", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedabiraterone acetate, glucocorticoid_prostate neoplasms", "label": "completedabiraterone acetate, glucocorticoid_prostate neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "marcaine", "label": "marcaine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "femoral fractures, pain, postoperative", "label": "femoral fractures, pain, postoperative", "shape": "dot", "size": 10}, {"color": "red", "id": "topiramate", "label": "topiramate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtopiramate_obesity", "label": "completedtopiramate_obesity", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "epilepsy, seizures, epilepsies, partial, epilepsy, generalized, seizures, tonic-clonic", "label": "epilepsy, seizures, epilepsies, partial, epilepsy, generalized, seizures, tonic-clonic", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, NC(=O)NO", "label": "ClCCN(CCCl)P1(=O)NCCCO1, NC(=O)NO", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cytarabine, hydroxyurea", "label": "cytarabine, hydroxyurea", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddexamethasone, trabectedin_breast neoplasms", "label": "completeddexamethasone, trabectedin_breast neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "niacin extended-release and simvastatin tablets", "label": "niacin extended-release and simvastatin tablets", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedniacin extended-release and simvastatin tablets_hypercholesterolemia", "label": "completedniacin extended-release and simvastatin tablets_hypercholesterolemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedclarithromycin, placebo_cachexia, lung cancer", "label": "terminatedclarithromycin, placebo_cachexia, lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cachexia, lung cancer", "label": "cachexia, lung cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mometasone furoate nasal spray (mfns), placebo nasal spray", "label": "mometasone furoate nasal spray (mfns), placebo nasal spray", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmometasone furoate nasal spray (mfns), placebo nasal spray_allergic rhinitis, asthma", "label": "completedmometasone furoate nasal spray (mfns), placebo nasal spray_allergic rhinitis, asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "poly-iclc, temozolomide", "label": "poly-iclc, temozolomide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glioblastoma multiforme, astrocytoma, grade iv", "label": "glioblastoma multiforme, astrocytoma, grade iv", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1, CC1=CC(O)=CC(C)=C1Cl", "label": "ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "5-mg desloratadine, placebo tablet", "label": "5-mg desloratadine, placebo tablet", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, celecoxib", "label": "cyclophosphamide, celecoxib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcyclophosphamide, celecoxib_fallopian tube cancer, peritoneal cavity cancer, recurrent ovarian epithelial cancer", "label": "active, not recruitingcyclophosphamide, celecoxib_fallopian tube cancer, peritoneal cavity cancer, recurrent ovarian epithelial cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sarcoma, melanoma, epithelial malignancies, pleural malignancies", "label": "sarcoma, melanoma, epithelial malignancies, pleural malignancies", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "arq-151 cream 0.3%, arq-151 cream 0.15%, arq-151 vehicle cream", "label": "arq-151 cream 0.3%, arq-151 cream 0.15%, arq-151 vehicle cream", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H]\\C(=C(\\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC, [H]\\C(=C(\\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H]\\C(=C(\\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC, [H]\\C(=C(\\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "istradefylline, istradefylline, placebo", "label": "istradefylline, istradefylline, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azd2820, placebo", "label": "azd2820, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedazd2820, placebo_obesity", "label": "terminatedazd2820, placebo_obesity", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "baclofen/amitriptyline/ketamine gel", "label": "baclofen/amitriptyline/ketamine gel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic myeloproliferative disorders, leukemia, lymphoma, lymphoproliferative disorder, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, neurotoxicity, pain, unspecified adult solid tumor, protocol specific", "label": "chronic myeloproliferative disorders, leukemia, lymphoma, lymphoproliferative disorder, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, neurotoxicity, pain, unspecified adult solid tumor, protocol specific", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C", "label": "CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tolterodine er, placebo, fesoterodine", "label": "tolterodine er, placebo, fesoterodine", "shape": "dot", "size": 10}, {"color": "red", "id": "maraviroc", "label": "maraviroc", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmaraviroc_acquired immunodeficiency syndrome, hiv infection", "label": "completedmaraviroc_acquired immunodeficiency syndrome, hiv infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "human immunodeficiency virus (hiv), hiv associated neurocognitive disorders (hand)", "label": "human immunodeficiency virus (hiv), hiv associated neurocognitive disorders (hand)", "shape": "dot", "size": 10}, {"color": "red", "id": "tg-873870 (nemonoxacin)", "label": "tg-873870 (nemonoxacin)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtg-873870 (nemonoxacin)_diabetic foot infections", "label": "completedtg-873870 (nemonoxacin)_diabetic foot infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "haemocomplettan p, placebo", "label": "haemocomplettan p, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hemorrhage, thoracic aneurysm", "label": "hemorrhage, thoracic aneurysm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedhaemocomplettan p, placebo_hemorrhage, thoracic aneurysm", "label": "terminatedhaemocomplettan p, placebo_hemorrhage, thoracic aneurysm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpemetrexed_sarcoma", "label": "completedpemetrexed_sarcoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedadalimumab, placebo_ulcerative colitis, pouchitis", "label": "completedadalimumab, placebo_ulcerative colitis, pouchitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ulcerative colitis, pouchitis", "label": "ulcerative colitis, pouchitis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recombinant human growth hormone, recombinant human igf-1", "label": "recombinant human growth hormone, recombinant human igf-1", "shape": "dot", "size": 10}, {"color": "green", "id": "growth hormone deficiency", "label": "growth hormone deficiency", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(NC2=CC(F)=CC=C12)C1=C(C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)C2=CC=C(F)C=C2N1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(NC2=CC(F)=CC=C12)C1=C(C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)C2=CC=C(F)C=C2N1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "birinapant, azacitidine, placebo", "label": "birinapant, azacitidine, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "perifosine", "label": "perifosine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "endometrial cancer, sarcoma", "label": "endometrial cancer, sarcoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adenocarcinoma of the prostate, recurrent prostate cancer, stage iib prostate cancer, stage iii prostate cancer, stage iv prostate cancer", "label": "adenocarcinoma of the prostate, recurrent prostate cancer, stage iib prostate cancer, stage iii prostate cancer, stage iv prostate cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddcvax-001, poly-iclc, placebo_hiv-1 infection, hiv infection, healthy volunteers", "label": "completeddcvax-001, poly-iclc, placebo_hiv-1 infection, hiv infection, healthy volunteers", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hiv-1 infection, hiv infection, healthy volunteers", "label": "hiv-1 infection, hiv infection, healthy volunteers", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCC(=O)OCOC(=O)C(C)(C)C", "label": "CCCC(=O)OCOC(=O)C(C)(C)C", "shape": "dot", "size": 10}, {"color": "red", "id": "pivanex", "label": "pivanex", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedepirubicin, cyclophosphamide and docetaxel, docetaxel, cyclophosphamide_breast neoplasms", "label": "completedepirubicin, cyclophosphamide and docetaxel, docetaxel, cyclophosphamide_breast neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "erlotinib, bevacizumab, gemcitabine, cisplatin", "label": "erlotinib, bevacizumab, gemcitabine, cisplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completederlotinib, bevacizumab, gemcitabine, cisplatin_carcinoma, non-small-cell lung", "label": "completederlotinib, bevacizumab, gemcitabine, cisplatin_carcinoma, non-small-cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "raltegravir, tenofovir, emtricitabine", "label": "raltegravir, tenofovir, emtricitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "epacadostat, pembrolizumab", "label": "epacadostat, pembrolizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingepacadostat, pembrolizumab_sarcoma", "label": "active, not recruitingepacadostat, pembrolizumab_sarcoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "desloratadine 5 mg, placebo", "label": "desloratadine 5 mg, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddesloratadine 5 mg, placebo_perennial allergic rhinitis", "label": "completeddesloratadine 5 mg, placebo_perennial allergic rhinitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedibrutinib_lymphoma, mantle-cell", "label": "completedibrutinib_lymphoma, mantle-cell", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lymphoma, mantle-cell", "label": "lymphoma, mantle-cell", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "decadron\u00ae, benadryl\u00ae, ativan\u00ae, ondansetron hydrochloride", "label": "decadron\u00ae, benadryl\u00ae, ativan\u00ae, ondansetron hydrochloride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddecadron\u00ae, benadryl\u00ae, ativan\u00ae, ondansetron hydrochloride_nausea, vomiting, unspecified childhood solid tumor, protocol specific", "label": "terminateddecadron\u00ae, benadryl\u00ae, ativan\u00ae, ondansetron hydrochloride_nausea, vomiting, unspecified childhood solid tumor, protocol specific", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NS(=O)(=O)C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "NS(=O)(=O)C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "e7070, idarubicin, cytarabine, dexamethasone", "label": "e7070, idarubicin, cytarabine, dexamethasone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedixekizumab, guselkumab, placebo_plaque psoriasis", "label": "completedixekizumab, guselkumab, placebo_plaque psoriasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "triptorelin (decapeptyl\u00ae)", "label": "triptorelin (decapeptyl\u00ae)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtriptorelin (decapeptyl\u00ae)_prostate cancer", "label": "completedtriptorelin (decapeptyl\u00ae)_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C, NC[C@H]1CC[C@@H](CC1)C(O)=O", "label": "CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C, NC[C@H]1CC[C@@H](CC1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vitamin d (cholecalciferol) and pba (sodium phenylbutyrate), placebo tablets", "label": "vitamin d (cholecalciferol) and pba (sodium phenylbutyrate), placebo tablets", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "label": "[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cetuximab, cisplatin, docetaxel, cisplatin", "label": "cetuximab, cisplatin, docetaxel, cisplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "shape": "dot", "size": 10}, {"color": "red", "id": "nanoparticulate paclitaxel", "label": "nanoparticulate paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednanoparticulate paclitaxel_peritoneal neoplasms", "label": "completednanoparticulate paclitaxel_peritoneal neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpregabalin, placebo_generalized anxiety disorder", "label": "completedpregabalin, placebo_generalized anxiety disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedintravenous ferric carboxymaltose_iron deficiency, anaemia", "label": "completedintravenous ferric carboxymaltose_iron deficiency, anaemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "iron deficiency, anaemia", "label": "iron deficiency, anaemia", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oncaspar, doxil, decadron", "label": "oncaspar, doxil, decadron", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ramosetron, aprepitant, dexamethasone", "label": "ramosetron, aprepitant, dexamethasone", "shape": "dot", "size": 10}, {"color": "red", "id": "ozurdex implant", "label": "ozurdex implant", "shape": "dot", "size": 10}, {"color": "red", "id": "vlx1570 and dexamethasone", "label": "vlx1570 and dexamethasone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bcd chemotherapy (bendamustine, carboplatin, dexamethasone)", "label": "bcd chemotherapy (bendamustine, carboplatin, dexamethasone)", "shape": "dot", "size": 10}, {"color": "red", "id": "decitabine", "label": "decitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddecitabine_acute myelogenous leukemia", "label": "completeddecitabine_acute myelogenous leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddecitabine_unspecified adult solid tumor, protocol specific", "label": "terminateddecitabine_unspecified adult solid tumor, protocol specific", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusdecitabine_untreated adult acute myeloid leukemia, effect of drugs, drug safety", "label": "unknown statusdecitabine_untreated adult acute myeloid leukemia, effect of drugs, drug safety", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "atezolizumab, topotecan, carboplatin, etoposide", "label": "atezolizumab, topotecan, carboplatin, etoposide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedatezolizumab, topotecan, carboplatin, etoposide_small cell lung cancer, small cell lung cancer limited stage, small cell lung cancer extensive stage", "label": "completedatezolizumab, topotecan, carboplatin, etoposide_small cell lung cancer, small cell lung cancer limited stage, small cell lung cancer extensive stage", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, xolair", "label": "placebo, xolair", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, xolair_asthma", "label": "completedplacebo, xolair_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "paclitaxel for injection\uff08albumin bound\uff09, carboplatin", "label": "paclitaxel for injection\uff08albumin bound\uff09, carboplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine, capecitabine and sorafenib (6 cycles)_carcinoma, renal cell", "label": "completedgemcitabine, capecitabine and sorafenib (6 cycles)_carcinoma, renal cell", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1", "label": "[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "linagliptin, linagliptin", "label": "linagliptin, linagliptin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "etelcalcetide, placebo", "label": "etelcalcetide, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hyperparathyroidism, secondary", "label": "hyperparathyroidism, secondary", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddasatinib_chronic myelogenous leukemia, philadelphia chromosome positive acute lymphoblastic leukemia", "label": "completeddasatinib_chronic myelogenous leukemia, philadelphia chromosome positive acute lymphoblastic leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic myelogenous leukemia, philadelphia chromosome positive acute lymphoblastic leukemia", "label": "chronic myelogenous leukemia, philadelphia chromosome positive acute lymphoblastic leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsta363, placebo_low back pain", "label": "completedsta363, placebo_low back pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC1=CNC(=O)NC1=O", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC1=CNC(=O)NC1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gm1, placebo, mfolfox6 or xelox", "label": "gm1, placebo, mfolfox6 or xelox", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "erismodegib, placebo", "label": "erismodegib, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedezetimibe + simvastatin, simvastatin, placebo_hypercholesterolemia, atherosclerosis", "label": "terminatedezetimibe + simvastatin, simvastatin, placebo_hypercholesterolemia, atherosclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NCCCNCCSP(O)(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "label": "NCCCNCCSP(O)(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "amifostine trihydrate, fluorouracil, cisplatin", "label": "amifostine trihydrate, fluorouracil, cisplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gtx-024, placebo", "label": "gtx-024, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "muscle wasting, non-small cell lung cancer", "label": "muscle wasting, non-small cell lung cancer", "shape": "dot", "size": 10}, {"color": "blue", "id": "CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O", "label": "CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": "fondaparinux", "label": "fondaparinux", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oral casopitant (gw679769), iv casopitant (gw679769), iv ondansetron hydrochloride, oral dexamethasone", "label": "oral casopitant (gw679769), iv casopitant (gw679769), iv ondansetron hydrochloride, oral dexamethasone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedoral casopitant (gw679769), iv casopitant (gw679769), iv ondansetron hydrochloride, oral dexamethasone_nausea and vomiting, chemotherapy-induced", "label": "completedoral casopitant (gw679769), iv casopitant (gw679769), iv ondansetron hydrochloride, oral dexamethasone_nausea and vomiting, chemotherapy-induced", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O", "label": "CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "red", "id": "irinotecan plus capecitabine", "label": "irinotecan plus capecitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completede7070, idarubicin, cytarabine, dexamethasone_leukemia", "label": "completede7070, idarubicin, cytarabine, dexamethasone_leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedly2127399, placebo every 2 weeks, placebo every 4 weeks, standard of care_systemic lupus erythematosus, connective tissue disease, autoimmune disease", "label": "completedly2127399, placebo every 2 weeks, placebo every 4 weeks, standard of care_systemic lupus erythematosus, connective tissue disease, autoimmune disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "systemic lupus erythematosus, connective tissue disease, autoimmune disease", "label": "systemic lupus erythematosus, connective tissue disease, autoimmune disease", "shape": "dot", "size": 10}, {"color": "red", "id": "gm-csf", "label": "gm-csf", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedgm-csf_myeloma", "label": "terminatedgm-csf_myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtopotecan and taxotere_ovarian neoplasms, uterine neoplasms", "label": "completedtopotecan and taxotere_ovarian neoplasms, uterine neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mt-1303-low, mt-1303-middle, mt-1303-high, placebo", "label": "mt-1303-low, mt-1303-middle, mt-1303-high, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmt-1303-low, mt-1303-middle, mt-1303-high, placebo_relapsing-remitting multiple sclerosis", "label": "completedmt-1303-low, mt-1303-middle, mt-1303-high, placebo_relapsing-remitting multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtamsulosin hcl controlled release capsules, matching placebo capsule_prostatic hyperplasia", "label": "completedtamsulosin hcl controlled release capsules, matching placebo capsule_prostatic hyperplasia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "prostatic hyperplasia", "label": "prostatic hyperplasia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC1=CC(O)=CC(C)=C1Cl, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1", "label": "O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC1=CC(O)=CC(C)=C1Cl, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ezetimibe (+) simvastatin, simvastatin, atorvastatin", "label": "ezetimibe (+) simvastatin, simvastatin, atorvastatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "everolimus, sunitinib", "label": "everolimus, sunitinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedeverolimus, sunitinib_advanced non-clear cell renal cell carcinoma", "label": "completedeverolimus, sunitinib_advanced non-clear cell renal cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ombitasvir/paritaprevir/ritonavir, dasabuvir", "label": "ombitasvir/paritaprevir/ritonavir, dasabuvir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedombitasvir/paritaprevir/ritonavir, dasabuvir_chronic hepatitis c infection, compensated cirrhosis", "label": "completedombitasvir/paritaprevir/ritonavir, dasabuvir_chronic hepatitis c infection, compensated cirrhosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sm-13496 40mg, sm-13496 80mg, placebo", "label": "sm-13496 40mg, sm-13496 80mg, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lurasidone 40 mg, lurasidone 80 mg, placebo 40 or 80 mg", "label": "lurasidone 40 mg, lurasidone 80 mg, placebo 40 or 80 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gamma delta tocotrienols - low dose, gamma delta tocotrienols - high dose, sugar pill", "label": "gamma delta tocotrienols - low dose, gamma delta tocotrienols - high dose, sugar pill", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "label": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pemetrexed, gemcitabine, carboplatin, pemetrexed", "label": "pemetrexed, gemcitabine, carboplatin, pemetrexed", "shape": "dot", "size": 10}, {"color": "red", "id": "gsk2118436", "label": "gsk2118436", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgsk2118436_cancer", "label": "completedgsk2118436_cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "filgrastim, pegfilgrastim, etoposide, cisplatin", "label": "filgrastim, pegfilgrastim, etoposide, cisplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfilgrastim, pegfilgrastim, etoposide, cisplatin_lung cancer", "label": "completedfilgrastim, pegfilgrastim, etoposide, cisplatin_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgabapentin/b-complex, pregabalin_diabetic peripheral neuropathic pain", "label": "completedgabapentin/b-complex, pregabalin_diabetic peripheral neuropathic pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lapatinib oral tablets, radiotherapy, cisplatin chemotherapy", "label": "lapatinib oral tablets, radiotherapy, cisplatin chemotherapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "volinanserin, placebo", "label": "volinanserin, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, OC(=O)C1=CN=CC=C1, NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1, CC(=O)OC1=CC=CC=C1C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, OC(=O)C1=CN=CC=C1, NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1, CC(=O)OC1=CC=CC=C1C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ezetimibe, niaspan, statin therapy, aspirin, clopidogrel, placebo niaspan, placebo ezetimibe", "label": "ezetimibe, niaspan, statin therapy, aspirin, clopidogrel, placebo niaspan, placebo ezetimibe", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddecitabine, fludarabine phosphate, busulfan, cyclophosphamide, tacrolimus, mycophenolate mofetil_acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia", "label": "completeddecitabine, fludarabine phosphate, busulfan, cyclophosphamide, tacrolimus, mycophenolate mofetil_acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia", "label": "acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "exemestane, everolimus (rad001)", "label": "exemestane, everolimus (rad001)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedexemestane, everolimus (rad001)_metastatic breast cancer", "label": "completedexemestane, everolimus (rad001)_metastatic breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcisplatin, paclitaxel_ovarian cancer, peritoneal cancer, fallopian tube cancer, bowel obstruction", "label": "terminatedcisplatin, paclitaxel_ovarian cancer, peritoneal cancer, fallopian tube cancer, bowel obstruction", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ovarian cancer, peritoneal cancer, fallopian tube cancer, bowel obstruction", "label": "ovarian cancer, peritoneal cancer, fallopian tube cancer, bowel obstruction", "shape": "dot", "size": 10}, {"color": "red", "id": "risperidone", "label": "risperidone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "depressive disorder, depressive disorder, major, depression", "label": "depressive disorder, depressive disorder, major, depression", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nnc109-0012, placebo", "label": "nnc109-0012, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednnc109-0012, placebo_inflammation, rheumatoid arthritis", "label": "completednnc109-0012, placebo_inflammation, rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedeviplera_hiv", "label": "completedeviplera_hiv", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pembrolizumab, azacitidine", "label": "pembrolizumab, azacitidine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpembrolizumab, azacitidine_metastatic colorectal cancer", "label": "completedpembrolizumab, azacitidine_metastatic colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "bosentan", "label": "bosentan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "b/f/taf, f/taf, dtg, dtg placebo, f/taf placebo, b/f/taf placebo", "label": "b/f/taf, f/taf, dtg, dtg placebo, f/taf placebo, b/f/taf placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingb/f/taf, f/taf, dtg, dtg placebo, f/taf placebo, b/f/taf placebo_hiv-1-infection", "label": "active, not recruitingb/f/taf, f/taf, dtg, dtg placebo, f/taf placebo, b/f/taf placebo_hiv-1-infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "azathioprine (aza) or 6-mercaptopurine (6-mp)", "label": "azathioprine (aza) or 6-mercaptopurine (6-mp)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazathioprine (aza) or 6-mercaptopurine (6-mp)_inflammatory bowel diseases, crohn disease, ulcerative colitis", "label": "completedazathioprine (aza) or 6-mercaptopurine (6-mp)_inflammatory bowel diseases, crohn disease, ulcerative colitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedacetyl-l-carnitine, placebo_carpal tunnel syndrome, compression neuropathy", "label": "completedacetyl-l-carnitine, placebo_carpal tunnel syndrome, compression neuropathy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carpal tunnel syndrome, compression neuropathy", "label": "carpal tunnel syndrome, compression neuropathy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "candesartan, placebo", "label": "candesartan, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcandesartan, placebo_glucose intolerance, obesity", "label": "terminatedcandesartan, placebo_glucose intolerance, obesity", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusprednisone, vincristine, daunorubicin , cyclophosphamide , l.-asparaginase, cytosine-arabinoside, methotrexate, etoposide_lymphoblastic lymphoma", "label": "unknown statusprednisone, vincristine, daunorubicin , cyclophosphamide , l.-asparaginase, cytosine-arabinoside, methotrexate, etoposide_lymphoblastic lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "lymphoblastic lymphoma", "label": "lymphoblastic lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "r932333, placebo", "label": "r932333, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedr932333, placebo_lupus erythematosus, discoid, lupus erythematosus, systemic", "label": "completedr932333, placebo_lupus erythematosus, discoid, lupus erythematosus, systemic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednilotinib, imatinib_myelogenous leukemia, chronic", "label": "completednilotinib, imatinib_myelogenous leukemia, chronic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "myelogenous leukemia, chronic", "label": "myelogenous leukemia, chronic", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "opk-88003, placebo", "label": "opk-88003, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedopk-88003, placebo_type 2 diabetes mellitus", "label": "completedopk-88003, placebo_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dlbs1033, placebo", "label": "dlbs1033, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddlbs1033, placebo_healthy", "label": "completeddlbs1033, placebo_healthy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddlbs1033, placebo_diabetes, peripheral arterial disease", "label": "terminateddlbs1033, placebo_diabetes, peripheral arterial disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1", "label": "[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgs-9450, gs-9450 placebo_hcv infection", "label": "completedgs-9450, gs-9450 placebo_hcv infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "hcv infection", "label": "hcv infection", "shape": "dot", "size": 10}, {"color": "red", "id": "pregabalin", "label": "pregabalin", "shape": "dot", "size": 10}, {"color": "green", "id": "post-herpetic neuralgia", "label": "post-herpetic neuralgia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpregabalin_epilepsy", "label": "completedpregabalin_epilepsy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "herpes zoster, postherpetic neuralgia", "label": "herpes zoster, postherpetic neuralgia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfec-docgemzar adjuvant chemotherapy, fec-doc adjuvant chemotherapy, zoledronic acid i.v. 2 years, zoledronic acid i.v. 5 years_breast neoplasms", "label": "completedfec-docgemzar adjuvant chemotherapy, fec-doc adjuvant chemotherapy, zoledronic acid i.v. 2 years, zoledronic acid i.v. 5 years_breast neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dapagliflozin, placebo matching with dapagliflozin, saxagliptin, metformin immediate release (ir)", "label": "dapagliflozin, placebo matching with dapagliflozin, saxagliptin, metformin immediate release (ir)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddapagliflozin, placebo matching with dapagliflozin, saxagliptin, metformin immediate release (ir)_type 2 diabetes", "label": "completeddapagliflozin, placebo matching with dapagliflozin, saxagliptin, metformin immediate release (ir)_type 2 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)C1=C(C)N=CN=C1C)C1=CC=C(C=C1)C(F)(F)F, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "label": "COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)C1=C(C)N=CN=C1C)C1=CC=C(C=C1)C(F)(F)F, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vicriviroc, emtricitabine and tenofovir disoproxil fumarate", "label": "vicriviroc, emtricitabine and tenofovir disoproxil fumarate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bhr-200 (0.36% transdermal 17\u03b2-estradiol gel), placebo", "label": "bhr-200 (0.36% transdermal 17\u03b2-estradiol gel), placebo", "shape": "dot", "size": 10}, {"color": "green", "id": "cancer of the prostate", "label": "cancer of the prostate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pregabalin, placebo", "label": "pregabalin, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpregabalin, placebo_neuropathic pain", "label": "completedpregabalin, placebo_neuropathic pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpregabalin, placebo_dry eye", "label": "completedpregabalin, placebo_dry eye", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1, CC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1, CC1=CC(O)=CC(C)=C1Cl", "label": "CC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1, CC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ot-551, ot-551, vehicle placebo", "label": "ot-551, ot-551, vehicle placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "mitomycin -c", "label": "mitomycin -c", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "laryngeal stenosis, subglottic stenosis, tracheal stenosis", "label": "laryngeal stenosis, subglottic stenosis, tracheal stenosis", "shape": "dot", "size": 10}, {"color": "blue", "id": "O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1", "label": "O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C", "label": "CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C", "shape": "dot", "size": 10}, {"color": "red", "id": "liposomal bupivacaine (lb)", "label": "liposomal bupivacaine (lb)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone", "label": "bortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedbortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone_non-hodgkin\u0027s lymphoma", "label": "terminatedbortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone_non-hodgkin\u0027s lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1", "label": "CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fimasartan , amlodipine, placebo", "label": "fimasartan , amlodipine, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "umec/vi, umec/vi matching placebo, tiotropium, tiotropium matching placebo, indacaterol, indacaterol matching placebo, albuterol/salbutamol metered dose inhaler (mdi)", "label": "umec/vi, umec/vi matching placebo, tiotropium, tiotropium matching placebo, indacaterol, indacaterol matching placebo, albuterol/salbutamol metered dose inhaler (mdi)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedumec/vi, umec/vi matching placebo, tiotropium, tiotropium matching placebo, indacaterol, indacaterol matching placebo, albuterol/salbutamol metered dose inhaler (mdi)_pulmonary disease, chronic obstructive", "label": "completedumec/vi, umec/vi matching placebo, tiotropium, tiotropium matching placebo, indacaterol, indacaterol matching placebo, albuterol/salbutamol metered dose inhaler (mdi)_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "prednisone, cyclophosphamide, doxorubicin, vincristine", "label": "prednisone, cyclophosphamide, doxorubicin, vincristine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "contiguous stage ii adult diffuse large cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone b-cell lymphoma, noncontiguous stage ii adult diffuse large cell lymphoma, splenic marginal zone lymphoma, stage i adult diffuse large cell lymphoma, testicular lymphoma, waldenstr\u00f6m macroglobulinemia", "label": "contiguous stage ii adult diffuse large cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone b-cell lymphoma, noncontiguous stage ii adult diffuse large cell lymphoma, splenic marginal zone lymphoma, stage i adult diffuse large cell lymphoma, testicular lymphoma, waldenstr\u00f6m macroglobulinemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pro 140 (humanized monoclonal antibody to ccr5), placebo comparator", "label": "pro 140 (humanized monoclonal antibody to ccr5), placebo comparator", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpro 140 (humanized monoclonal antibody to ccr5), placebo comparator_hiv -1 infection, hiv infections", "label": "completedpro 140 (humanized monoclonal antibody to ccr5), placebo comparator_hiv -1 infection, hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aripiprazole, placebo, lithium, valproate", "label": "aripiprazole, placebo, lithium, valproate", "shape": "dot", "size": 10}, {"color": "green", "id": "bipolar disorder mania", "label": "bipolar disorder mania", "shape": "dot", "size": 10}, {"color": "red", "id": "lenalidomide + plerixafor (+ rituximab)", "label": "lenalidomide + plerixafor (+ rituximab)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "leukemia, lymphocytic, chronic, b-cell", "label": "leukemia, lymphocytic, chronic, b-cell", "shape": "dot", "size": 10}, {"color": "red", "id": "lcz696 (sacubitril/valsartan)", "label": "lcz696 (sacubitril/valsartan)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlcz696 (sacubitril/valsartan)_heart failure", "label": "completedlcz696 (sacubitril/valsartan)_heart failure", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "escitalopram, pindolol, escitalopram, escitalopram", "label": "escitalopram, pindolol, escitalopram, escitalopram", "shape": "dot", "size": 10}, {"color": "green", "id": "unipolar depression", "label": "unipolar depression", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ruxolitinib, hydroxyurea (hu), hu-placebo, ruxolitinib-placebo", "label": "ruxolitinib, hydroxyurea (hu), hu-placebo, ruxolitinib-placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "label": "ClCCN(CCCl)P1(=O)NCCCO1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bendamustin, bortezomib, lenalidomide", "label": "bendamustin, bortezomib, lenalidomide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oregano extract cream, hydrocortisone", "label": "oregano extract cream, hydrocortisone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedoregano extract cream, hydrocortisone_atopic dermatitis", "label": "terminatedoregano extract cream, hydrocortisone_atopic dermatitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "pitavastatin", "label": "pitavastatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpitavastatin_hypercholesterolemia, dyslipidemias", "label": "completedpitavastatin_hypercholesterolemia, dyslipidemias", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "td-4208, tiotropium", "label": "td-4208, tiotropium", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtd-4208, tiotropium_chronic obstructive pulmonary disease (copd)", "label": "completedtd-4208, tiotropium_chronic obstructive pulmonary disease (copd)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "cyclosporine a versus mycophenolate mofetil for psoriasis", "label": "cyclosporine a versus mycophenolate mofetil for psoriasis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuscyclosporine a versus mycophenolate mofetil for psoriasis_psoriasis", "label": "unknown statuscyclosporine a versus mycophenolate mofetil for psoriasis_psoriasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, combination product (sumatriptan succinate/naproxen sodium)", "label": "placebo, combination product (sumatriptan succinate/naproxen sodium)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, combination product (sumatriptan succinate/naproxen sodium)_migraine disorders", "label": "completedplacebo, combination product (sumatriptan succinate/naproxen sodium)_migraine disorders", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedduloxetine hydrochloride_major depressive disorder, idiopathic parkinson disease", "label": "completedduloxetine hydrochloride_major depressive disorder, idiopathic parkinson disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "major depressive disorder, idiopathic parkinson disease", "label": "major depressive disorder, idiopathic parkinson disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cisplatin, fluorouracil, leucovorin calcium", "label": "cisplatin, fluorouracil, leucovorin calcium", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adenocarcinoma of the gastroesophageal junction, gastric cancer", "label": "adenocarcinoma of the gastroesophageal junction, gastric cancer", "shape": "dot", "size": 10}, {"color": "blue", "id": "[Fe++].NCC([O-])=O.NCC([O-])=O.OS(O)(=O)=O", "label": "[Fe++].NCC([O-])=O.NCC([O-])=O.OS(O)(=O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ferrous bis-glycinate, ferrous glycine sulphate", "label": "ferrous bis-glycinate, ferrous glycine sulphate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "enzalutamide, bicalutamide, leuprolide acetate, goserelin acetate", "label": "enzalutamide, bicalutamide, leuprolide acetate, goserelin acetate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddesipramine hcl_small cell lung cancer (sclc), neuroendocrine tumors", "label": "terminateddesipramine hcl_small cell lung cancer (sclc), neuroendocrine tumors", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "small cell lung cancer (sclc), neuroendocrine tumors", "label": "small cell lung cancer (sclc), neuroendocrine tumors", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "insulin lispro, insulin aspart", "label": "insulin lispro, insulin aspart", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin lispro, insulin aspart_type 2 diabetes mellitus", "label": "completedinsulin lispro, insulin aspart_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "label": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "shape": "dot", "size": 10}, {"color": "red", "id": "non pegylated liposomal doxorubicin and docetaxel", "label": "non pegylated liposomal doxorubicin and docetaxel", "shape": "dot", "size": 10}, {"color": "red", "id": "liposomal doxorubicin", "label": "liposomal doxorubicin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aprepitant 125 mg, aprepitant 80 mg, aprepitant powder for suspension (pfs), ondansetron, placebo for aprepitant 125 mg, placebo for aprepitant 80 mg, placebo for aprepitant pfs, emetogenic chemotherapy", "label": "aprepitant 125 mg, aprepitant 80 mg, aprepitant powder for suspension (pfs), ondansetron, placebo for aprepitant 125 mg, placebo for aprepitant 80 mg, placebo for aprepitant pfs, emetogenic chemotherapy", "shape": "dot", "size": 10}, {"color": "red", "id": "axitinib (ag-013736)", "label": "axitinib (ag-013736)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gemcitabine, cisplatin, gefitinib", "label": "gemcitabine, cisplatin, gefitinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpeg-p-ifn-alpha-2b (aop2014), hydroxyurea_polycythemia vera", "label": "completedpeg-p-ifn-alpha-2b (aop2014), hydroxyurea_polycythemia vera", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "leukine, dexamethasone", "label": "leukine, dexamethasone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnleukine, dexamethasone_renal cell carcinoma", "label": "withdrawnleukine, dexamethasone_renal cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC(=O)C1=CC=C2C(NC(=O)\\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1", "label": "COC(=O)C1=CC=C2C(NC(=O)\\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "microgynon, nintedanib", "label": "microgynon, nintedanib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cisplatin, ifosfamide, paclitaxel", "label": "cisplatin, ifosfamide, paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcisplatin, ifosfamide, paclitaxel_bladder cancer, urethral cancer", "label": "completedcisplatin, ifosfamide, paclitaxel_bladder cancer, urethral cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sbi-087, sbi-087, sbi-087, sbi-087, placebo", "label": "sbi-087, sbi-087, sbi-087, sbi-087, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsbi-087, sbi-087, sbi-087, sbi-087, placebo_active rheumatoid arthritis", "label": "completedsbi-087, sbi-087, sbi-087, sbi-087, placebo_active rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C", "label": "COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "verteporfin photodynamic therapy (low fluence) and bevacizumab, verteporfin photodynamic therapy (very low fluence) and bevacizumab, verteporfin photodynamic therapy (sham) and bevacizumab", "label": "verteporfin photodynamic therapy (low fluence) and bevacizumab, verteporfin photodynamic therapy (very low fluence) and bevacizumab, verteporfin photodynamic therapy (sham) and bevacizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcelecoxib, doxorubicin hydrochloride_metastatic cancer, prostate cancer", "label": "terminatedcelecoxib, doxorubicin hydrochloride_metastatic cancer, prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "metastatic cancer, prostate cancer", "label": "metastatic cancer, prostate cancer", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12", "label": "CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ribavirin, ribavirin + pegylated interferon-alpha", "label": "ribavirin, ribavirin + pegylated interferon-alpha", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedribavirin, ribavirin + pegylated interferon-alpha_hepatitis c", "label": "terminatedribavirin, ribavirin + pegylated interferon-alpha_hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ecf, ic, folfox", "label": "ecf, ic, folfox", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsimvastatin_alzheimer disease", "label": "completedsimvastatin_alzheimer disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "O", "label": "O", "shape": "dot", "size": 10}, {"color": "red", "id": "enbrel (etanercept)", "label": "enbrel (etanercept)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "t0001, t0001, t0001, t0001, enbrel", "label": "t0001, t0001, t0001, t0001, enbrel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tlc599 ld group, normal saline, tlc599 hd group", "label": "tlc599 ld group, normal saline, tlc599 hd group", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1", "label": "COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "budesonide/formoterol, fluticasone/salmeterol, albuterol", "label": "budesonide/formoterol, fluticasone/salmeterol, albuterol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateditv depocyt + temozolomide_glioblastoma multiforme, glioma, astrocytoma, brain tumor", "label": "terminateditv depocyt + temozolomide_glioblastoma multiforme, glioma, astrocytoma, brain tumor", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glioblastoma multiforme, glioma, astrocytoma, brain tumor", "label": "glioblastoma multiforme, glioma, astrocytoma, brain tumor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsimvastatin (+) ezetimibe, comparator: atorvastatin_hypercholesterolemia", "label": "completedsimvastatin (+) ezetimibe, comparator: atorvastatin_hypercholesterolemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1C=NC=C1[C@@](N)(C1=CC=C(Cl)C=C1)C1=CC2=C(C=C1)N(C)C(=O)C=C2C1=CC(Cl)=CC=C1", "label": "CN1C=NC=C1[C@@](N)(C1=CC=C(Cl)C=C1)C1=CC2=C(C=C1)N(C)C(=O)C=C2C1=CC(Cl)=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO, CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F", "label": "CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO, CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mek-162, nilotinib", "label": "mek-162, nilotinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gsk573719 125mcg, gsk573719 250mcg, gsk573719 500mcg, placebo", "label": "gsk573719 125mcg, gsk573719 250mcg, gsk573719 500mcg, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "mgcd0103", "label": "mgcd0103", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmgcd0103_myelodysplastic syndrome, acute myelogenous leukemia", "label": "completedmgcd0103_myelodysplastic syndrome, acute myelogenous leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "label": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "calcium sensing receptor agonist", "label": "calcium sensing receptor agonist", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedromidepsin, poly iclc_cutaneous t-cell lymphoma", "label": "terminatedromidepsin, poly iclc_cutaneous t-cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "cutaneous t-cell lymphoma", "label": "cutaneous t-cell lymphoma", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "label": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "shape": "dot", "size": 10}, {"color": "red", "id": "enoxaparin sodium", "label": "enoxaparin sodium", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "paclitaxel, cisplatin, pegfilgrastim", "label": "paclitaxel, cisplatin, pegfilgrastim", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel, cisplatin, fluorouracil, bevacizumab, leucovorin", "label": "docetaxel, cisplatin, fluorouracil, bevacizumab, leucovorin", "shape": "dot", "size": 10}, {"color": "red", "id": "chemotherapy following concurrent chemoradiotherapy", "label": "chemotherapy following concurrent chemoradiotherapy", "shape": "dot", "size": 10}, {"color": "red", "id": "gemcitabine and cisplatin (induction chemotherapy)", "label": "gemcitabine and cisplatin (induction chemotherapy)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bi 2536, pemetrexed", "label": "bi 2536, pemetrexed", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "enoxaparin sodium 40 mg/0.2 ml subcutaneous injectable, chemotherapeutic combinations", "label": "enoxaparin sodium 40 mg/0.2 ml subcutaneous injectable, chemotherapeutic combinations", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CO)C(O)=O, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, CCO", "label": "N[C@@H](CO)C(O)=O, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, CCO", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dolutegravir, lamivudine, continue current antiretroviral regimen", "label": "dolutegravir, lamivudine, continue current antiretroviral regimen", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "valsartan + hctz, valsartan, hctz", "label": "valsartan + hctz, valsartan, hctz", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvalsartan + hctz, valsartan, hctz_hypertension", "label": "completedvalsartan + hctz, valsartan, hctz_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1, CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1", "label": "CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1, CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedapo866_cutaneous t-cell lymphoma", "label": "completedapo866_cutaneous t-cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "abiraterone acetate", "label": "abiraterone acetate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedabiraterone acetate_prostate cancer", "label": "completedabiraterone acetate_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "efavirenz, tenofovir /emtricitabine, tenofovir/lamivudine, lamivudine/zidovudine", "label": "efavirenz, tenofovir /emtricitabine, tenofovir/lamivudine, lamivudine/zidovudine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "re-021 (sparsentan), irbesartan", "label": "re-021 (sparsentan), irbesartan", "shape": "dot", "size": 10}, {"color": "green", "id": "focal segmental glomerulosclerosis", "label": "focal segmental glomerulosclerosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carfilzomib, melphalan, prednisone", "label": "carfilzomib, melphalan, prednisone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarfilzomib, melphalan, prednisone_myeloma", "label": "completedcarfilzomib, melphalan, prednisone_myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingabemaciclib, fulvestrant, placebo_breast neoplasms", "label": "active, not recruitingabemaciclib, fulvestrant, placebo_breast neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC1=CC(=CC=C1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1C1=CC=CC(Cl)=C1F)C1=CC=C(Cl)C=C1F)C(O)=O", "label": "COC1=CC(=CC=C1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1C1=CC=CC(Cl)=C1F)C1=CC=C(Cl)C=C1F)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tremelimumab, durvalumab", "label": "tremelimumab, durvalumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingtremelimumab, durvalumab_colorectal cancer", "label": "active, not recruitingtremelimumab, durvalumab_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "irbesartan/hydrochlorothiazide, irbesartan", "label": "irbesartan/hydrochlorothiazide, irbesartan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedirbesartan/hydrochlorothiazide, irbesartan_hypertension", "label": "completedirbesartan/hydrochlorothiazide, irbesartan_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedleuprolide acetate_alzheimer disease", "label": "completedleuprolide acetate_alzheimer disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlebrikizumab, pirfenidone, placebo_idiopathic pulmonary fibrosis", "label": "completedlebrikizumab, pirfenidone, placebo_idiopathic pulmonary fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "label": "[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "efavirenz (efv), emtricitabine (ftc), tenofovir df (tdf)", "label": "efavirenz (efv), emtricitabine (ftc), tenofovir df (tdf)", "shape": "dot", "size": 10}, {"color": "red", "id": "atripla (atr) consisting of efv 600 mg/ftc 200 mg/tdf 300 mg", "label": "atripla (atr) consisting of efv 600 mg/ftc 200 mg/tdf 300 mg", "shape": "dot", "size": 10}, {"color": "red", "id": "entecavir + tenofovir (mdr group)", "label": "entecavir + tenofovir (mdr group)", "shape": "dot", "size": 10}, {"color": "red", "id": "tenofovir/emtricitabine", "label": "tenofovir/emtricitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddocetaxel, vandetanib_non-small cell lung cancer, lung cancer", "label": "completeddocetaxel, vandetanib_non-small cell lung cancer, lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "non-small cell lung cancer, lung cancer", "label": "non-small cell lung cancer, lung cancer", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "label": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "shape": "dot", "size": 10}, {"color": "red", "id": "lapatinib in tandem with capecitabine", "label": "lapatinib in tandem with capecitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O[C@H](\\C=C\\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C)C1CC1, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C, O[C@H](\\C=C\\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C)C1CC1", "label": "O[C@H](\\C=C\\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C)C1CC1, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C, O[C@H](\\C=C\\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C)C1CC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "calcipotriol plus hydrocortisone ointment vehicle, tacalcitol ointment, calcipotriol plus hydrocortisone ointment", "label": "calcipotriol plus hydrocortisone ointment vehicle, tacalcitol ointment, calcipotriol plus hydrocortisone ointment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcapecitabine, celecoxib_unspecified adult solid tumor, protocol specific", "label": "terminatedcapecitabine, celecoxib_unspecified adult solid tumor, protocol specific", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "label": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lapatinib, trastuzumab, aromatase inhibitor, lapatinib", "label": "lapatinib, trastuzumab, aromatase inhibitor, lapatinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmipomersen sodium, placebo_heterozygous familial hypercholesterolemia, coronary artery disease", "label": "completedmipomersen sodium, placebo_heterozygous familial hypercholesterolemia, coronary artery disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "heterozygous familial hypercholesterolemia, coronary artery disease", "label": "heterozygous familial hypercholesterolemia, coronary artery disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedminoxidil, hydralazine_treatment induced hypertension", "label": "terminatedminoxidil, hydralazine_treatment induced hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "treatment induced hypertension", "label": "treatment induced hypertension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1, CC(C)CC1=CC=C(C=C1)C(C)C(O)=O", "label": "COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1, CC(C)CC1=CC=C(C=C1)C(C)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lacosamide, levetiracetam", "label": "lacosamide, levetiracetam", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pr-104, docetaxel, gemcitabine hydrochloride", "label": "pr-104, docetaxel, gemcitabine hydrochloride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtivantinib, placebo, erlotinib_non squamous, non-small-cell lung cancer", "label": "terminatedtivantinib, placebo, erlotinib_non squamous, non-small-cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "non squamous, non-small-cell lung cancer", "label": "non squamous, non-small-cell lung cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "rilpivirine", "label": "rilpivirine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnmorphine sulfate, placebo_chronic obstructive pulmonary disease, dyspnea", "label": "withdrawnmorphine sulfate, placebo_chronic obstructive pulmonary disease, dyspnea", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic obstructive pulmonary disease, dyspnea", "label": "chronic obstructive pulmonary disease, dyspnea", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluocinolone acetonide, fluocinolone acetonide", "label": "fluocinolone acetonide, fluocinolone acetonide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfluocinolone acetonide, fluocinolone acetonide_diabetic macular edema", "label": "completedfluocinolone acetonide, fluocinolone acetonide_diabetic macular edema", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rhumab-vegf, docetaxel", "label": "rhumab-vegf, docetaxel", "shape": "dot", "size": 10}, {"color": "red", "id": "oxaliplatin + docetaxel", "label": "oxaliplatin + docetaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "androgen-deprivation therapy, docetaxel", "label": "androgen-deprivation therapy, docetaxel", "shape": "dot", "size": 10}, {"color": "red", "id": "s-1", "label": "s-1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "trastuzumab, pf03512676", "label": "trastuzumab, pf03512676", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "trastuzumab qw, trastuzumab q3w", "label": "trastuzumab qw, trastuzumab q3w", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vb-111, bevacizumab", "label": "vb-111, bevacizumab", "shape": "dot", "size": 10}, {"color": "red", "id": "abt-888 and mfolfox-6", "label": "abt-888 and mfolfox-6", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "luteinizing hormone-releasing hormone (lhrh), docetaxel", "label": "luteinizing hormone-releasing hormone (lhrh), docetaxel", "shape": "dot", "size": 10}, {"color": "red", "id": "capecitabine plus oxaliplatin", "label": "capecitabine plus oxaliplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mk-3475, docetaxel", "label": "mk-3475, docetaxel", "shape": "dot", "size": 10}, {"color": "red", "id": "interferon-gamma and nivolumab", "label": "interferon-gamma and nivolumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedimo-8400 regimen 1, imo-8400 regimen 2, imo-8400 regimen 3, saline placebo, imo-8400 regimen 4_plaque psoriasis", "label": "completedimo-8400 regimen 1, imo-8400 regimen 2, imo-8400 regimen 3, saline placebo, imo-8400 regimen 4_plaque psoriasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpegfilgrastim_breast cancer, chemotherapy, febrile neutropenia", "label": "completedpegfilgrastim_breast cancer, chemotherapy, febrile neutropenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "breast cancer, chemotherapy, febrile neutropenia", "label": "breast cancer, chemotherapy, febrile neutropenia", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "label": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lenalidomide, bortezomib", "label": "lenalidomide, bortezomib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bendamustine, rituximab, lenalidomide", "label": "bendamustine, rituximab, lenalidomide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lenalidomide, epoetin beta", "label": "lenalidomide, epoetin beta", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddocetaxel, 5-fluorouracil, doxorubicin, cyclophosphamide_breast neoplasms", "label": "completeddocetaxel, 5-fluorouracil, doxorubicin, cyclophosphamide_breast neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ecc, folfiri", "label": "ecc, folfiri", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedecc, folfiri_stomach cancer, neoplasm metastasis", "label": "completedecc, folfiri_stomach cancer, neoplasm metastasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedly2127399, placebo_systemic lupus erythematosus, connective tissue disease, autoimmune disease", "label": "terminatedly2127399, placebo_systemic lupus erythematosus, connective tissue disease, autoimmune disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1CCC[C@H]1C1=CN=CC=C1, [H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN1CCC[C@H]1C1=CN=CC=C1, [H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nicotine nasal spray, varenicline, placebo nasal spray, placebo varenicline", "label": "nicotine nasal spray, varenicline, placebo nasal spray, placebo varenicline", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedhki-272, paclitaxel_advanced breast cancer, advanced malignant solid tumors, breast neoplasms", "label": "completedhki-272, paclitaxel_advanced breast cancer, advanced malignant solid tumors, breast neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "advanced breast cancer, advanced malignant solid tumors, breast neoplasms", "label": "advanced breast cancer, advanced malignant solid tumors, breast neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cisplatin, docetaxel, fluorouracil, cetuximab", "label": "cisplatin, docetaxel, fluorouracil, cetuximab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "xyrem, xyrem placebo, modafinil at established dose, modafinil (placebo)", "label": "xyrem, xyrem placebo, modafinil at established dose, modafinil (placebo)", "shape": "dot", "size": 10}, {"color": "green", "id": "narcolepsy", "label": "narcolepsy", "shape": "dot", "size": 10}, {"color": "red", "id": "tesetaxel", "label": "tesetaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statustesetaxel_adenocarcinoma of the stomach, adenocarcinoma of esophagogastric junction", "label": "unknown statustesetaxel_adenocarcinoma of the stomach, adenocarcinoma of esophagogastric junction", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpresatovir, presatovir placebo_respiratory syncytial virus infection", "label": "completedpresatovir, presatovir placebo_respiratory syncytial virus infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "respiratory syncytial virus infection", "label": "respiratory syncytial virus infection", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedetanercept, chs-0214_plaque psoriasis", "label": "completedetanercept, chs-0214_plaque psoriasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3", "label": "[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3", "shape": "dot", "size": 10}, {"color": "red", "id": "galantamine hydrobromide", "label": "galantamine hydrobromide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gemcitabine hydrochloride, imatinib mesylate", "label": "gemcitabine hydrochloride, imatinib mesylate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedezetimibe (+) simvastatin_hypercholesterolemia", "label": "completedezetimibe (+) simvastatin_hypercholesterolemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "risperidone ism 75 mg, risperidone ism 100 mg, placebo of risperidone ism", "label": "risperidone ism 75 mg, risperidone ism 100 mg, placebo of risperidone ism", "shape": "dot", "size": 10}, {"color": "red", "id": "ipilimumab", "label": "ipilimumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedipilimumab_melanoma, brain metastases", "label": "completedipilimumab_melanoma, brain metastases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingipilimumab_malignant melanoma", "label": "active, not recruitingipilimumab_malignant melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1N=NC2=C(N=CN2C1=O)C(N)=O", "label": "CN1N=NC2=C(N=CN2C1=O)C(N)=O", "shape": "dot", "size": 10}, {"color": "red", "id": "bevacizumab and temozolomide", "label": "bevacizumab and temozolomide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carboplatin, nab-paclitaxel, mk-3475 (phase i), mk-3475 (phase ii)", "label": "carboplatin, nab-paclitaxel, mk-3475 (phase i), mk-3475 (phase ii)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcarboplatin, nab-paclitaxel, mk-3475 (phase i), mk-3475 (phase ii)_non-small cell lung cancer", "label": "active, not recruitingcarboplatin, nab-paclitaxel, mk-3475 (phase i), mk-3475 (phase ii)_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "neoadjuvant chemotherapy with gemcitabine/oxaliplatin, adjuvant chemotherapy with gemcitabine", "label": "neoadjuvant chemotherapy with gemcitabine/oxaliplatin, adjuvant chemotherapy with gemcitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedneoadjuvant chemotherapy with gemcitabine/oxaliplatin, adjuvant chemotherapy with gemcitabine_pancreatic cancer", "label": "terminatedneoadjuvant chemotherapy with gemcitabine/oxaliplatin, adjuvant chemotherapy with gemcitabine_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3", "label": "[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "esterified estrogens 1.25mg and methyltestosterone 2.5mg, esterified estrogens 1.25 mg", "label": "esterified estrogens 1.25mg and methyltestosterone 2.5mg, esterified estrogens 1.25 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gsk2838232, placebo, ritonavir", "label": "gsk2838232, placebo, ritonavir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedgsk2838232, placebo, ritonavir_infection, human immunodeficiency virus", "label": "terminatedgsk2838232, placebo, ritonavir_infection, human immunodeficiency virus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sunitinib, paclitaxel, bevacizumab, paclitaxel", "label": "sunitinib, paclitaxel, bevacizumab, paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aliskiren, amlodipine, placebo aliskiren, placebo amlodipine", "label": "aliskiren, amlodipine, placebo aliskiren, placebo amlodipine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "high blood pressure, metabolic syndrome, insulin resistance, endothelial dysfunction", "label": "high blood pressure, metabolic syndrome, insulin resistance, endothelial dysfunction", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CCNC(=O)C1=NOC(=C1C1=CC=C(CN2CCOCC2)C=C1)C1=CC(=C(O)C=C1O)C(C)(C)C", "label": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CCNC(=O)C1=NOC(=C1C1=CC=C(CN2CCOCC2)C=C1)C1=CC(=C(O)C=C1O)C(C)(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "erlotinib hydrochloride, hsp90 inhibitor auy922", "label": "erlotinib hydrochloride, hsp90 inhibitor auy922", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bevacizumab, irinotecan, oxaliplatin, 5-fluorouracil/leucovorin", "label": "bevacizumab, irinotecan, oxaliplatin, 5-fluorouracil/leucovorin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbevacizumab, irinotecan, oxaliplatin, 5-fluorouracil/leucovorin_colorectal cancer metastatic", "label": "completedbevacizumab, irinotecan, oxaliplatin, 5-fluorouracil/leucovorin_colorectal cancer metastatic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1", "label": "NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "angiotensin receptor blockers, \u03b2-blockers, thiazide diuretics", "label": "angiotensin receptor blockers, \u03b2-blockers, thiazide diuretics", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pitolisant, placebo", "label": "pitolisant, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "narcolepsy with cataplexy, excessive daytime sleepiness", "label": "narcolepsy with cataplexy, excessive daytime sleepiness", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "knee osteoarthritis, blood clot, transfusion related complication, blood loss", "label": "knee osteoarthritis, blood clot, transfusion related complication, blood loss", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedglargine insulin_diabetes", "label": "completedglargine insulin_diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "diabetes", "label": "diabetes", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawndoxorubicin, cisplatin_hepatocellular carcinoma", "label": "withdrawndoxorubicin, cisplatin_hepatocellular carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbicalutamide, flutamide, goserelin acetate, ipilimumab, leuprolide acetate_prostate adenocarcinoma, prostate carcinoma, recurrent prostate carcinoma, stage iii prostate cancer, stage iv prostate cancer", "label": "completedbicalutamide, flutamide, goserelin acetate, ipilimumab, leuprolide acetate_prostate adenocarcinoma, prostate carcinoma, recurrent prostate carcinoma, stage iii prostate cancer, stage iv prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "prostate adenocarcinoma, prostate carcinoma, recurrent prostate carcinoma, stage iii prostate cancer, stage iv prostate cancer", "label": "prostate adenocarcinoma, prostate carcinoma, recurrent prostate carcinoma, stage iii prostate cancer, stage iv prostate cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N", "label": "CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glimepiride/metformin fixed combination, metformin hcl", "label": "glimepiride/metformin fixed combination, metformin hcl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dapagliflozin, placebo-matching dapagliflozin", "label": "dapagliflozin, placebo-matching dapagliflozin", "shape": "dot", "size": 10}, {"color": "red", "id": "adjunctive asenapine", "label": "adjunctive asenapine", "shape": "dot", "size": 10}, {"color": "green", "id": "posttraumatic stress disorder", "label": "posttraumatic stress disorder", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcinacalcet_chronic kidney disease, end stage renal disease, coronary artery calcification, vascular calcification, calcification, cardiovascular disease, chronic renal failure, hyperparathyroidism, kidney disease, nephrology, secondary hyperparathyroidism", "label": "completedcinacalcet_chronic kidney disease, end stage renal disease, coronary artery calcification, vascular calcification, calcification, cardiovascular disease, chronic renal failure, hyperparathyroidism, kidney disease, nephrology, secondary hyperparathyroidism", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic kidney disease, end stage renal disease, coronary artery calcification, vascular calcification, calcification, cardiovascular disease, chronic renal failure, hyperparathyroidism, kidney disease, nephrology, secondary hyperparathyroidism", "label": "chronic kidney disease, end stage renal disease, coronary artery calcification, vascular calcification, calcification, cardiovascular disease, chronic renal failure, hyperparathyroidism, kidney disease, nephrology, secondary hyperparathyroidism", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "truvada qd, maraviroc 300 qd", "label": "truvada qd, maraviroc 300 qd", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=C(C)C2=C(C=C1)C(=O)C1=CC=CC(CC(O)=O)=C1O2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "label": "CC1=C(C)C2=C(C=C1)C(=O)C1=CC=CC(CC(O)=O)=C1O2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "asa404, placebo, carboplatin, paclitaxel", "label": "asa404, placebo, carboplatin, paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedil2, zoledronic acid_kidney cancer", "label": "terminatedil2, zoledronic acid_kidney cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel, prednisone", "label": "docetaxel, prednisone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawndocetaxel, prednisone_prostate cancer, adenocarcinoma of the prostate, stage i prostate cancer, stage ii prostate cancer", "label": "withdrawndocetaxel, prednisone_prostate cancer, adenocarcinoma of the prostate, stage i prostate cancer, stage ii prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedganaxolone, placebo_depression, depressive disorder, depression, postpartum, behavioral symptoms, mood disorders, mental disorders, puerperal disorders, pregnancy complications, postpartum, ppd", "label": "completedganaxolone, placebo_depression, depressive disorder, depression, postpartum, behavioral symptoms, mood disorders, mental disorders, puerperal disorders, pregnancy complications, postpartum, ppd", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "depression, depressive disorder, depression, postpartum, behavioral symptoms, mood disorders, mental disorders, puerperal disorders, pregnancy complications, postpartum, ppd", "label": "depression, depressive disorder, depression, postpartum, behavioral symptoms, mood disorders, mental disorders, puerperal disorders, pregnancy complications, postpartum, ppd", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "netupitant and palonosetron, aprepitant, palonosetron, dexamethasone", "label": "netupitant and palonosetron, aprepitant, palonosetron, dexamethasone", "shape": "dot", "size": 10}, {"color": "red", "id": "terlipressin acetate continuous infusion", "label": "terlipressin acetate continuous infusion", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedterlipressin acetate continuous infusion_cirrhosis, ascites hepatic", "label": "completedterlipressin acetate continuous infusion_cirrhosis, ascites hepatic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedirinotecan plus capecitabine_carcinoma, hepatocellular", "label": "completedirinotecan plus capecitabine_carcinoma, hepatocellular", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "latanoprostene bunod", "label": "latanoprostene bunod", "shape": "dot", "size": 10}, {"color": "red", "id": "carbamazepine er (equetro)", "label": "carbamazepine er (equetro)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarbamazepine er (equetro)_bipolar disorder, mania", "label": "completedcarbamazepine er (equetro)_bipolar disorder, mania", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "avelumab, m9241, avelumab (once weekly), m9241 (mtd), avelumab (expansion cohort)", "label": "avelumab, m9241, avelumab (once weekly), m9241 (mtd), avelumab (expansion cohort)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedavelumab, m9241, avelumab (once weekly), m9241 (mtd), avelumab (expansion cohort)_advanced solid tumors", "label": "terminatedavelumab, m9241, avelumab (once weekly), m9241 (mtd), avelumab (expansion cohort)_advanced solid tumors", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "reldesemtiv, placebo", "label": "reldesemtiv, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedreldesemtiv, placebo_amyotrophic lateral sclerosis", "label": "completedreldesemtiv, placebo_amyotrophic lateral sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCN(CC)CC(=O)NC1=C(C)C=CC=C1C, OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1", "label": "CCN(CC)CC(=O)NC1=C(C)C=CC=C1C, OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "amg 162, placebo", "label": "amg 162, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cnto148, placebo", "label": "cnto148, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gi262570 0.5 mg, gi262570 1.0 mg, placebo", "label": "gi262570 0.5 mg, gi262570 1.0 mg, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "alogliptin", "label": "alogliptin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fermagate, placebo", "label": "fermagate, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "omega-3 fatty acid administration, placebo", "label": "omega-3 fatty acid administration, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "canakinumab, placebo", "label": "canakinumab, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "atacicept, atacicept, atacicept, placebo matched to atacicept", "label": "atacicept, atacicept, atacicept, placebo matched to atacicept", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pancrecarb\u00ae (pancrelipase), placebo", "label": "pancrecarb\u00ae (pancrelipase), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "palifermin before only, placebo, palifermin before and after", "label": "palifermin before only, placebo, palifermin before and after", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mrx-801, placebo", "label": "mrx-801, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tocilizumab, placebo, permitted dmards", "label": "tocilizumab, placebo, permitted dmards", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "0.135mg map0010, 0.25mg map0010, placebo", "label": "0.135mg map0010, 0.25mg map0010, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "d9421-c, 9mg, d9421-c, 15mg, placebo", "label": "d9421-c, 9mg, d9421-c, 15mg, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "abciximab, abciximab placebo", "label": "abciximab, abciximab placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "eptifibatide, placebo", "label": "eptifibatide, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bms-791325, placebo", "label": "bms-791325, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "1.5 mg or 2.0 mg cjc-1134-pc, placebo", "label": "1.5 mg or 2.0 mg cjc-1134-pc, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azli 75 mg three times daily (tid), placebo three times daily (tid)", "label": "azli 75 mg three times daily (tid), placebo three times daily (tid)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sun13834, placebo", "label": "sun13834, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sarilumab, placebo", "label": "sarilumab, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tbr-652, tbr-652 matching placebo, tbr-652 50 mg, tbr-652 75 mg, tbr-652 100 mg, tbr-652 150 mg", "label": "tbr-652, tbr-652 matching placebo, tbr-652 50 mg, tbr-652 75 mg, tbr-652 100 mg, tbr-652 150 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "amg 827 350 mg, amg 827 210 mg, amg 827 700 mg, placebo", "label": "amg 827 350 mg, amg 827 210 mg, amg 827 700 mg, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vedolizumab, placebo", "label": "vedolizumab, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "namilumab (mt203), placebo", "label": "namilumab (mt203), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pth analog, placebo, forsteo (teriparatide)", "label": "pth analog, placebo, forsteo (teriparatide)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glpg0778, placebo", "label": "glpg0778, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "spd557, placebo", "label": "spd557, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "75 mg lx4211, 200 mg lx4211, 400 mg lx4211, 200 mg lx4211, placebo", "label": "75 mg lx4211, 200 mg lx4211, 400 mg lx4211, 200 mg lx4211, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "blisibimod, placebo", "label": "blisibimod, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ferrisat, placebo", "label": "ferrisat, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vr506, placebo", "label": "vr506, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "amg 827 140, placebo, amg 827 280, amg 827 210", "label": "amg 827 140, placebo, amg 827 280, amg 827 210", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "octohydroaminoacridine succinate tablets, octohydroaminoacridine succinate tablets, octohydroaminoacridine succinate tablets, placebo", "label": "octohydroaminoacridine succinate tablets, octohydroaminoacridine succinate tablets, octohydroaminoacridine succinate tablets, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, r940343 1mg, r940343 2mg", "label": "placebo, r940343 1mg, r940343 2mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "saf312, placebo to saf312", "label": "saf312, placebo to saf312", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, mk-8237 6 du, mk-8237 12 du", "label": "placebo, mk-8237 6 du, mk-8237 12 du", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ttp054, placebo", "label": "ttp054, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, gevokizumab", "label": "placebo, gevokizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "iw-9179, placebo", "label": "iw-9179, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cov155, placebo", "label": "cov155, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "syl1001, placebo", "label": "syl1001, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bay85-8501, placebo", "label": "bay85-8501, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chr-5154, placebo", "label": "chr-5154, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pf-02545920, placebo, pf-02545920", "label": "pf-02545920, placebo, pf-02545920", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cnto 6785, placebo", "label": "cnto 6785, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bococizumab (pf-04950615), placebo", "label": "bococizumab (pf-04950615), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dp-b99, placebo", "label": "dp-b99, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rikkunshito, rikkunshito placebo", "label": "rikkunshito, rikkunshito placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "opa-15406, placebo", "label": "opa-15406, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ain457 300 mg, ustekinumab 45/90 mg, placebo secukinumab", "label": "ain457 300 mg, ustekinumab 45/90 mg, placebo secukinumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "t-817ma-h, t-817ma-l, placebo", "label": "t-817ma-h, t-817ma-l, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sb012, placebo", "label": "sb012, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "s -equol, placebo", "label": "s -equol, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vay736, placebo", "label": "vay736, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cxl-1427, placebo", "label": "cxl-1427, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bi 1744 cl, placebo", "label": "bi 1744 cl, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chf 5259, placebo", "label": "chf 5259, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "r-verapamil 75 mg tablet, placebo", "label": "r-verapamil 75 mg tablet, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "p-321 ophthalmic solution, p-321 ophthalmic solution placebo", "label": "p-321 ophthalmic solution, p-321 ophthalmic solution placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tlpldc, placebo", "label": "tlpldc, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, alirocumab", "label": "placebo, alirocumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "qge031, placebo", "label": "qge031, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cs-3150, placebo", "label": "cs-3150, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "erythropoietin, placebo", "label": "erythropoietin, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bms-986036, bms-986036, placebo", "label": "bms-986036, bms-986036, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "jkb-121: 5 mg twice daily, jkb-121: 10 mg twice daily, placebo", "label": "jkb-121: 5 mg twice daily, jkb-121: 10 mg twice daily, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "jnj-42847922, placebo", "label": "jnj-42847922, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vis410, placebo", "label": "vis410, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ipp-201101, placebo", "label": "ipp-201101, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "guselkumab, placebo", "label": "guselkumab, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mdco-216, placebo", "label": "mdco-216, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "risankizumab, placebo for risankizumab", "label": "risankizumab, placebo for risankizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "miv-711, placebo", "label": "miv-711, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "secukinumab and placebo", "label": "secukinumab and placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gsk3179106, placebo", "label": "gsk3179106, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pf-04965842, pf-04965842, pf-04965842, pf-04965842, placebo", "label": "pf-04965842, pf-04965842, pf-04965842, pf-04965842, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gsp 301 ns, gom-ns, gmm-2 ns, gsp 301 placebo ns", "label": "gsp 301 ns, gom-ns, gmm-2 ns, gsp 301 placebo ns", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "f-627, placebo", "label": "f-627, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, abbv-8e12", "label": "placebo, abbv-8e12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bhv-0223, placebo", "label": "bhv-0223, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "broncho-vaxom, placebo - cap", "label": "broncho-vaxom, placebo - cap", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "php-201 0.25% ophthalmic solution, php-201 0.5% ophthalmic solution, placebo ophthalmic solution", "label": "php-201 0.25% ophthalmic solution, php-201 0.5% ophthalmic solution, placebo ophthalmic solution", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sm04690, placebo", "label": "sm04690, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, jnj-42847922", "label": "placebo, jnj-42847922", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "al-794, placebo", "label": "al-794, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ppc-06 400 mg qd, ppc-06 400 mg bid, ppc-06 600 mg, placebo", "label": "ppc-06 400 mg qd, ppc-06 400 mg bid, ppc-06 600 mg, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, e2730", "label": "placebo, e2730", "shape": "dot", "size": 10}, {"color": "red", "id": "artemether/lumefantrine (al)", "label": "artemether/lumefantrine (al)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hiv infection, malaria", "label": "hiv infection, malaria", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC(=O)NO, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "label": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC(=O)NO, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, 250 mg ck-2017357, 500 mg ck-2017357", "label": "placebo, 250 mg ck-2017357, 500 mg ck-2017357", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ticagrelor, clopidogrel, aspirin", "label": "ticagrelor, clopidogrel, aspirin", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC1=CC=CC(=C1)C(\\N)=N/O)NS(=O)(=O)C1=C(C=C(C=C1C(C)C)C(C)C)C(C)C", "label": "CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC1=CC=CC(=C1)C(\\N)=N/O)NS(=O)(=O)C1=C(C=C(C=C1C(C)C)C(C)C)C(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedipilimumab, 3 mg, ipilimumab, 10 mg, paclitaxel, carboplatin_non-small cell lung cancer", "label": "completedipilimumab, 3 mg, ipilimumab, 10 mg, paclitaxel, carboplatin_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedask8007, placebo_rheumatoid arthritis", "label": "completedask8007, placebo_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "xerostomia, sjogren\u0027s syndrome", "label": "xerostomia, sjogren\u0027s syndrome", "shape": "dot", "size": 10}, {"color": "red", "id": "nolasiban 900mg", "label": "nolasiban 900mg", "shape": "dot", "size": 10}, {"color": "red", "id": " endocrine", "label": " endocrine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chiglitazar, sitagliptin", "label": "chiglitazar, sitagliptin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedipilimumab, placebo, paclitaxel, carboplatin_lung cancer - non small cell squamous", "label": "completedipilimumab, placebo, paclitaxel, carboplatin_lung cancer - non small cell squamous", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtolvaptan_hyponatremia", "label": "completedtolvaptan_hyponatremia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " basiliximab", "label": " basiliximab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "red", "id": " fosfomycin trometamol-placebo", "label": " fosfomycin trometamol-placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "mp-376", "label": "mp-376", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bevacizumab, everolimus and lbh589", "label": "bevacizumab, everolimus and lbh589", "shape": "dot", "size": 10}, {"color": "red", "id": " solifenacin 10 mg matching placebo", "label": " solifenacin 10 mg matching placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " head and neck", "label": " head and neck", "shape": "dot", "size": 10}, {"color": "red", "id": " cozaar\u00ae plus pro tab", "label": " cozaar\u00ae plus pro tab", "shape": "dot", "size": 10}, {"color": "red", "id": " tegafur/uracil (ufur\u00ae)", "label": " tegafur/uracil (ufur\u00ae)", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iib pancreatic cancer", "label": " stage iib pancreatic cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pro-netupitant/palonosetron, netupitant/palonosetron, dexamethasone", "label": "pro-netupitant/palonosetron, netupitant/palonosetron, dexamethasone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedakn-028_acute myeloid leukemia", "label": "terminatedakn-028_acute myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo_diabetes mellitus, type 2", "label": "terminatedpf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " reflex sympathetic dystrophy", "label": " reflex sympathetic dystrophy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, omalizumab, immunotherapy, immunotherapy_allergic asthma", "label": "completedplacebo, omalizumab, immunotherapy, immunotherapy_allergic asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ly3009104", "label": "ly3009104", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "label": "C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "shape": "dot", "size": 10}, {"color": "green", "id": " stage i adult soft tissue sarcoma ajcc v7", "label": " stage i adult soft tissue sarcoma ajcc v7", "shape": "dot", "size": 10}, {"color": "red", "id": " 0.1% azelastine hydrochloride", "label": " 0.1% azelastine hydrochloride", "shape": "dot", "size": 10}, {"color": "green", "id": " childhood alveolar rhabdomyosarcoma", "label": " childhood alveolar rhabdomyosarcoma", "shape": "dot", "size": 10}, {"color": "red", "id": " vorapaxar 1 mg", "label": " vorapaxar 1 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rad001, carboplatin", "label": "rad001, carboplatin", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo (for otamixaban)", "label": " placebo (for otamixaban)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "radium-223 dichloride (xofigo, bay88-8223), placebo, best standard of care (bsoc)", "label": "radium-223 dichloride (xofigo, bay88-8223), placebo, best standard of care (bsoc)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "darunavir, ritonavir", "label": "darunavir, ritonavir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtak-058, ondansetron, tak-058 placebo, ondansetron placebo_schizophrenia", "label": "terminatedtak-058, ondansetron, tak-058 placebo, ondansetron placebo_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " ann arbor stage iii diffuse large b-cell lymphoma", "label": " ann arbor stage iii diffuse large b-cell lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": "hld200 methylphenidate hydrochloride (mph) capsules", "label": "hld200 methylphenidate hydrochloride (mph) capsules", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpimavanserin_treatment of depression in adults with parkinson\u0027s disease (pd)", "label": "completedpimavanserin_treatment of depression in adults with parkinson\u0027s disease (pd)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingmk-3475, gemcitabine_carcinoma, non-small-cell lung", "label": "active, not recruitingmk-3475, gemcitabine_carcinoma, non-small-cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "overactive bladder, urinary incontinence", "label": "overactive bladder, urinary incontinence", "shape": "dot", "size": 10}, {"color": "red", "id": "talabostat", "label": "talabostat", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "avelumab, cetuximab", "label": "avelumab, cetuximab", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent gliosarcoma", "label": " recurrent gliosarcoma", "shape": "dot", "size": 10}, {"color": "red", "id": " naproxen + esomeprazole", "label": " naproxen + esomeprazole", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawngleevec (imatinib), valproic acid_chronic myelogenous leukemia", "label": "withdrawngleevec (imatinib), valproic acid_chronic myelogenous leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "liraglutide, sitagliptin, placebo, placebo", "label": "liraglutide, sitagliptin, placebo, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " matching placebo twice daily (bid)", "label": " matching placebo twice daily (bid)", "shape": "dot", "size": 10}, {"color": "green", "id": " urinary bladder diseases", "label": " urinary bladder diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cancer, pain, constipation", "label": "cancer, pain, constipation", "shape": "dot", "size": 10}, {"color": "green", "id": " metastatic squamous cell carcinoma of the head or neck", "label": " metastatic squamous cell carcinoma of the head or neck", "shape": "dot", "size": 10}, {"color": "red", "id": "(+)- epicatechin", "label": "(+)- epicatechin", "shape": "dot", "size": 10}, {"color": "green", "id": " laryngeal cancer", "label": " laryngeal cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo ointment (vehicle)", "label": " placebo ointment (vehicle)", "shape": "dot", "size": 10}, {"color": "red", "id": "idalopirdine 60 mg", "label": "idalopirdine 60 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "clopidogrel, aspirin", "label": "clopidogrel, aspirin", "shape": "dot", "size": 10}, {"color": "green", "id": "metastatic renal cell cancer", "label": "metastatic renal cell cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " oxy combination: mometasone furoate nasal spray (mfns) and oxymetazoline nasal spray (oxy)", "label": " oxy combination: mometasone furoate nasal spray (mfns) and oxymetazoline nasal spray (oxy)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "asp8232, ranibizumab, placebo", "label": "asp8232, ranibizumab, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "leflunomide, azathioprine", "label": "leflunomide, azathioprine", "shape": "dot", "size": 10}, {"color": "red", "id": " insulin lispro premix (mid-mixture and low-mixture)", "label": " insulin lispro premix (mid-mixture and low-mixture)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine, dexamethasone, cisplatin, romidepsin_peripheral t-cell lymphoma, diffuse large b-cell lymphoma", "label": "completedgemcitabine, dexamethasone, cisplatin, romidepsin_peripheral t-cell lymphoma, diffuse large b-cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sunitinib malate continuous daily dosing, sunitinib malate schedule 4/2", "label": "sunitinib malate continuous daily dosing, sunitinib malate schedule 4/2", "shape": "dot", "size": 10}, {"color": "red", "id": " iron dextran injection", "label": " iron dextran injection", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "label": "[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": "repaglinide", "label": "repaglinide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bevacizumab, docetaxel, erlotinib, pemetrexed", "label": "bevacizumab, docetaxel, erlotinib, pemetrexed", "shape": "dot", "size": 10}, {"color": "red", "id": "inhaled iloprost (5 \u03bcg)", "label": "inhaled iloprost (5 \u03bcg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedglpg2222 50 mg, glpg2222 100 mg, placebo, glpg2222 200 mg, glpg2222 400 mg_cystic fibrosis", "label": "completedglpg2222 50 mg, glpg2222 100 mg, placebo, glpg2222 200 mg, glpg2222 400 mg_cystic fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "essential thrombocythemia, polycythemia vera, primary myelofibrosis", "label": "essential thrombocythemia, polycythemia vera, primary myelofibrosis", "shape": "dot", "size": 10}, {"color": "red", "id": "sibutramine hydrochloride", "label": "sibutramine hydrochloride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcisplatin_head and neck cancer", "label": "completedcisplatin_head and neck cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcytarabine, dasatinib, daunorubicin hydrochloride_acute myeloid leukemia, acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1, core binding factor acute myeloid leukemia, secondary acute myeloid leukemia, therapy-related acute myeloid leukemia", "label": "active, not recruitingcytarabine, dasatinib, daunorubicin hydrochloride_acute myeloid leukemia, acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1, core binding factor acute myeloid leukemia, secondary acute myeloid leukemia, therapy-related acute myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " sodium thiosulfate", "label": " sodium thiosulfate", "shape": "dot", "size": 10}, {"color": "green", "id": " foot ulcers", "label": " foot ulcers", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsingle subcutaneous dose (part a) of pb1023 or placebo (0.9% nacl), multiple (four weekly) subcutaneous injections (part b) of pb1023 or placebo (0.9% nacl)_diabetes mellitus, type 2", "label": "completedsingle subcutaneous dose (part a) of pb1023 or placebo (0.9% nacl), multiple (four weekly) subcutaneous injections (part b) of pb1023 or placebo (0.9% nacl)_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " 5fu", "label": " 5fu", "shape": "dot", "size": 10}, {"color": "red", "id": "315", "label": "315", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfremanezumab, placebo_episodic cluster headache", "label": "terminatedfremanezumab, placebo_episodic cluster headache", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "neurogenic orthostatic hypotension", "label": "neurogenic orthostatic hypotension", "shape": "dot", "size": 10}, {"color": "red", "id": " daunorubicin hydrochloride", "label": " daunorubicin hydrochloride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alemtuzumab, fludarabine, cyclophosphamide", "label": "alemtuzumab, fludarabine, cyclophosphamide", "shape": "dot", "size": 10}, {"color": "red", "id": " asa 100 mg", "label": " asa 100 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawneslicarbazepine acetate_epilepsy", "label": "withdrawneslicarbazepine acetate_epilepsy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " bi 660848", "label": " bi 660848", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "olodaterol, tiotropium, placebo", "label": "olodaterol, tiotropium, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlosartan potassium (+) hydrochlorothiazide_hypertension, metabolic disorder", "label": "completedlosartan potassium (+) hydrochlorothiazide_hypertension, metabolic disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgsk679586, placebo_asthma", "label": "completedgsk679586, placebo_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "red", "id": "arm a: folfiri or folfox + bevacizumab", "label": "arm a: folfiri or folfox + bevacizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "continuing aspirin, stopping aspirin", "label": "continuing aspirin, stopping aspirin", "shape": "dot", "size": 10}, {"color": "green", "id": "pulmonary fibrosis", "label": "pulmonary fibrosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=CC(O)=CC(C)=C1Cl, CN\\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O", "label": "CC1=CC(O)=CC(C)=C1Cl, CN\\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O", "shape": "dot", "size": 10}, {"color": "red", "id": " febuxostat 40 mg", "label": " febuxostat 40 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedngx-4010_peripheral nervous system diseases, pain, neuralgia, herpes zoster, shingles", "label": "completedngx-4010_peripheral nervous system diseases, pain, neuralgia, herpes zoster, shingles", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "erlotinib [tarceva], placebo, gemcitabine, cisplatin, carboplatin", "label": "erlotinib [tarceva], placebo, gemcitabine, cisplatin, carboplatin", "shape": "dot", "size": 10}, {"color": "red", "id": "dose-matched placebo", "label": "dose-matched placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "gwp42006", "label": "gwp42006", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmacitentan_portopulmonary hypertension", "label": "completedmacitentan_portopulmonary hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, N1C=CN=C1", "label": "CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, N1C=CN=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedregn910-3, intravitreal aflibercept injection (iai)_diabetic macular edema", "label": "completedregn910-3, intravitreal aflibercept injection (iai)_diabetic macular edema", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "C#CCN[C@@H]1CCC2=CC=CC=C12", "label": "C#CCN[C@@H]1CCC2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "valsartan + amlodipine 40/2.5 mg, valsartan + amlodipine 40/5 mg, valsartan + amlodipine 80/2.5 mg, valsartan + amlodipine 80/5 mg, valsartan 40 mg, valsartan 80 mg, amlodipine 2.5 mg, amlodipine 5 mg, placebo", "label": "valsartan + amlodipine 40/2.5 mg, valsartan + amlodipine 40/5 mg, valsartan + amlodipine 80/2.5 mg, valsartan + amlodipine 80/5 mg, valsartan 40 mg, valsartan 80 mg, amlodipine 2.5 mg, amlodipine 5 mg, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2", "label": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedwbi-1001_psoriasis", "label": "completedwbi-1001_psoriasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtelaprevir, boceprevir, peg-ifn, ribavirin_hepatitis c, chronic, cirrhosis", "label": "completedtelaprevir, boceprevir, peg-ifn, ribavirin_hepatitis c, chronic, cirrhosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, [H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2", "label": "[H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, [H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "endometrial adenocarcinoma, stage ia uterine corpus cancer, stage ib uterine corpus cancer, stage ii uterine corpus cancer, stage iiia uterine corpus cancer, stage iiib uterine corpus cancer, stage iiic uterine corpus cancer, stage iva uterine corpus cancer, stage ivb uterine corpus cancer", "label": "endometrial adenocarcinoma, stage ia uterine corpus cancer, stage ib uterine corpus cancer, stage ii uterine corpus cancer, stage iiia uterine corpus cancer, stage iiib uterine corpus cancer, stage iiic uterine corpus cancer, stage iva uterine corpus cancer, stage ivb uterine corpus cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin degludec/insulin aspart, insulin glargine_diabetes, diabetes mellitus, type 2", "label": "completedinsulin degludec/insulin aspart, insulin glargine_diabetes, diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " tca ir", "label": " tca ir", "shape": "dot", "size": 10}, {"color": "green", "id": " other inherited or acquired anaemia", "label": " other inherited or acquired anaemia", "shape": "dot", "size": 10}, {"color": "red", "id": "cc10004", "label": "cc10004", "shape": "dot", "size": 10}, {"color": "green", "id": " mild cognitive impairment", "label": " mild cognitive impairment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplerixafor gz316455, filgrastim_lymphoma", "label": "completedplerixafor gz316455, filgrastim_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrivaroxaban (xarelto, bay59-7939), vitamin k antagonist (vka)_atrial fibrillation", "label": "completedrivaroxaban (xarelto, bay59-7939), vitamin k antagonist (vka)_atrial fibrillation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpf-06291874, placebo_type 2 diabetes mellitus", "label": "completedpf-06291874, placebo_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedquetiapine fumarate or valproate_bipolar disorder", "label": "completedquetiapine fumarate or valproate_bipolar disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "telmisartan+amlodipine, amlodipine", "label": "telmisartan+amlodipine, amlodipine", "shape": "dot", "size": 10}, {"color": "green", "id": "constipation - functional", "label": "constipation - functional", "shape": "dot", "size": 10}, {"color": "red", "id": " desonide 0.1% cream", "label": " desonide 0.1% cream", "shape": "dot", "size": 10}, {"color": "green", "id": "pneumonia due to staphylococcus aureus", "label": "pneumonia due to staphylococcus aureus", "shape": "dot", "size": 10}, {"color": "red", "id": " inspra (eplerenone)", "label": " inspra (eplerenone)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedomacetaxine mepesuccinate_chronic myeloid leukemia", "label": "terminatedomacetaxine mepesuccinate_chronic myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " calcifediol", "label": " calcifediol", "shape": "dot", "size": 10}, {"color": "green", "id": " prostate ductal adenocarcinoma", "label": " prostate ductal adenocarcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN\\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O", "label": "CN\\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtreat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms_gastroesophageal reflux disease, eosinophilic esophagitis", "label": "terminatedtreat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms_gastroesophageal reflux disease, eosinophilic esophagitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "losartan potassium", "label": "losartan potassium", "shape": "dot", "size": 10}, {"color": "red", "id": "folfiri", "label": "folfiri", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsunitinib malate_metastatic squamous neck cancer with occult primary squamous cell carcinoma, recurrent metastatic squamous neck cancer with occult primary, recurrent squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the larynx, recurrent squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the nasopharynx, recurrent squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity, stage iv squamous cell carcinoma of the hypopharynx, stage iv squamous cell carcinoma of the larynx, stage iv squamous cell carcinoma of the lip and oral cavity, stage iv squamous cell carcinoma of the nasopharynx, stage iv squamous cell carcinoma of the oropharynx, stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity", "label": "completedsunitinib malate_metastatic squamous neck cancer with occult primary squamous cell carcinoma, recurrent metastatic squamous neck cancer with occult primary, recurrent squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the larynx, recurrent squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the nasopharynx, recurrent squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity, stage iv squamous cell carcinoma of the hypopharynx, stage iv squamous cell carcinoma of the larynx, stage iv squamous cell carcinoma of the lip and oral cavity, stage iv squamous cell carcinoma of the nasopharynx, stage iv squamous cell carcinoma of the oropharynx, stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedclazakizumab, placebo (matching with clazakizumab)_rheumatoid arthritis", "label": "completedclazakizumab, placebo (matching with clazakizumab)_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlenalidomide_multiple myeloma and plasma cell neoplasm", "label": "terminatedlenalidomide_multiple myeloma and plasma cell neoplasm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedrivaroxaban (xarelto, bay59-7939), acetylsalicylic acid (asa), clopidogrel, rivaroxaban (xarelto, bay59-7939), vitamin k antagonist (vka)_transcatheter aortic valve replacement", "label": "terminatedrivaroxaban (xarelto, bay59-7939), acetylsalicylic acid (asa), clopidogrel, rivaroxaban (xarelto, bay59-7939), vitamin k antagonist (vka)_transcatheter aortic valve replacement", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedolopatadine hydrochloride nasal spray 0.6%, vehicle_seasonal allergic rhinitis", "label": "completedolopatadine hydrochloride nasal spray 0.6%, vehicle_seasonal allergic rhinitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12, CCNC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)CCC1=CC=CC=C1", "label": "BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12, CCNC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)CCC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\\C=C\\C1=CC=C(OCCN(C)C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\\C=C\\C1=CC=C(OCCN(C)C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lenalidomide, dexamethasone, aspirin", "label": "lenalidomide, dexamethasone, aspirin", "shape": "dot", "size": 10}, {"color": "red", "id": " docetaxel 75 mg/m2", "label": " docetaxel 75 mg/m2", "shape": "dot", "size": 10}, {"color": "green", "id": " dermatitis atopic", "label": " dermatitis atopic", "shape": "dot", "size": 10}, {"color": "red", "id": "cr845 0.25 mg", "label": "cr845 0.25 mg", "shape": "dot", "size": 10}, {"color": "green", "id": " palb2 gene mutation", "label": " palb2 gene mutation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "clear cell renal cell carcinoma, recurrent renal cell cancer, stage i renal cell cancer, stage ii renal cell cancer, stage iii renal cell cancer, stage iv renal cell cancer, unspecified adult solid tumor, protocol specific", "label": "clear cell renal cell carcinoma, recurrent renal cell cancer, stage i renal cell cancer, stage ii renal cell cancer, stage iii renal cell cancer, stage iv renal cell cancer, unspecified adult solid tumor, protocol specific", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rapamycin, tacrolimus", "label": "rapamycin, tacrolimus", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddronabinol, placebo_irritable bowel syndrome", "label": "completeddronabinol, placebo_irritable bowel syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedletrozole, zoledronic acid_breast cancer, osteoporosis", "label": "completedletrozole, zoledronic acid_breast cancer, osteoporosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpemetrexed, carboplatin, gemcitabine, vinorelbine_breast cancer", "label": "completedpemetrexed, carboplatin, gemcitabine, vinorelbine_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedserdolect, placebo_schizophrenia", "label": "completedserdolect, placebo_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "cabazitaxel 10mg/m2", "label": "cabazitaxel 10mg/m2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedeverolimus 10mg daily_squamous cell carcinoma of the head and neck", "label": "terminatedeverolimus 10mg daily_squamous cell carcinoma of the head and neck", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "label": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbisoprolol, atenolol_hypertension", "label": "completedbisoprolol, atenolol_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedipilimumab, paclitaxel, cisplatin, carboplatin_non small cell lung cancer", "label": "completedipilimumab, paclitaxel, cisplatin, carboplatin_non small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "OC1=CC=C(\\C=C\\C2=CC(O)=CC(O)=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "abemaciclib, anastrozole, letrozole, placebo", "label": "abemaciclib, anastrozole, letrozole, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "iv abatacept", "label": "iv abatacept", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedindacaterol 300\u03bcg, placebo_chronic obstructive pulmonary disease", "label": "completedindacaterol 300\u03bcg, placebo_chronic obstructive pulmonary disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sorafenib tosylate, sunitinib malate", "label": "sorafenib tosylate, sunitinib malate", "shape": "dot", "size": 10}, {"color": "green", "id": "nicotine addiction", "label": "nicotine addiction", "shape": "dot", "size": 10}, {"color": "red", "id": " ifosfamide-based chemotherapy (ai)", "label": " ifosfamide-based chemotherapy (ai)", "shape": "dot", "size": 10}, {"color": "red", "id": "azithromycin", "label": "azithromycin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin glargine, insulin glulisine_diabetes mellitus", "label": "completedinsulin glargine, insulin glulisine_diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "idp-122 vehicle lotion", "label": "idp-122 vehicle lotion", "shape": "dot", "size": 10}, {"color": "red", "id": "ged-0507-34-levo 80 mg", "label": "ged-0507-34-levo 80 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "multiple myeloma, autologous stem cell transplant", "label": "multiple myeloma, autologous stem cell transplant", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtrastuzumab injectable solution, trastuzumab injectable product, trastuzumab injection_breast cancer", "label": "completedtrastuzumab injectable solution, trastuzumab injectable product, trastuzumab injection_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " type2 diabetes", "label": " type2 diabetes", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbortezomib, lenalidomide, dexamethasone_multiple myeloma", "label": "completedbortezomib, lenalidomide, dexamethasone_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcelecoxib, diclofenac_osteoarthritis, rheumatoid arthritis", "label": "completedcelecoxib, diclofenac_osteoarthritis, rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " racemic albuterol followed by levalbuterol hfa mdi", "label": " racemic albuterol followed by levalbuterol hfa mdi", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcyclosporine, fludarabine phosphate, mycophenolate mofetil_atypical chronic myeloid leukemia, bcr-abl1 negative, chronic myelomonocytic leukemia, de novo myelodysplastic syndrome, essential thrombocythemia, myeloproliferative neoplasm, paroxysmal nocturnal hemoglobinuria, polycythemia vera, polycythemia vera, post-polycythemic myelofibrosis phase, primary myelofibrosis, refractory anemia, refractory anemia with excess blasts, refractory anemia with ring sideroblasts, refractory cytopenia with multilineage dysplasia, refractory cytopenia with multilineage dysplasia and ring sideroblasts", "label": "completedcyclosporine, fludarabine phosphate, mycophenolate mofetil_atypical chronic myeloid leukemia, bcr-abl1 negative, chronic myelomonocytic leukemia, de novo myelodysplastic syndrome, essential thrombocythemia, myeloproliferative neoplasm, paroxysmal nocturnal hemoglobinuria, polycythemia vera, polycythemia vera, post-polycythemic myelofibrosis phase, primary myelofibrosis, refractory anemia, refractory anemia with excess blasts, refractory anemia with ring sideroblasts, refractory cytopenia with multilineage dysplasia, refractory cytopenia with multilineage dysplasia and ring sideroblasts", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo tablets (2) (am)", "label": " placebo tablets (2) (am)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingetoposide, cyclophosphamide, cisplatin, carboplatin, thiotepa, methotrexate, leucovorin calcium, vincristine sulfate_untreated childhood medulloblastoma, untreated childhood supratentorial primitive neuroectodermal tumor", "label": "active, not recruitingetoposide, cyclophosphamide, cisplatin, carboplatin, thiotepa, methotrexate, leucovorin calcium, vincristine sulfate_untreated childhood medulloblastoma, untreated childhood supratentorial primitive neuroectodermal tumor", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpaclitaxel (genexol\u00ae), paclitaxel loaded polymeric micelle (genexol-pm\u00ae)_non small cell lung cancer", "label": "completedpaclitaxel (genexol\u00ae), paclitaxel loaded polymeric micelle (genexol-pm\u00ae)_non small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " NC[C@@H](F)CP(O)=O", "label": " NC[C@@H](F)CP(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "laba, corticosteroids, prednisolone", "label": "laba, corticosteroids, prednisolone", "shape": "dot", "size": 10}, {"color": "green", "id": " aghbs negativation", "label": " aghbs negativation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlapatinib, capecitabine_metastatic colorectal cancer", "label": "completedlapatinib, capecitabine_metastatic colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedwarfarin, innohep\u00ae_venous thromboembolism", "label": "completedwarfarin, innohep\u00ae_venous thromboembolism", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "nwp09", "label": "nwp09", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcomparator: montelukast sodium, comparator: comparator: placebo (unspecified)_exercise-induced bronchoconstriction (eib)", "label": "completedcomparator: montelukast sodium, comparator: comparator: placebo (unspecified)_exercise-induced bronchoconstriction (eib)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "cardiothoracic surgery", "label": "cardiothoracic surgery", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C", "label": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedzometa, zometa, zometa_prostate cancer", "label": "completedzometa, zometa, zometa_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " acute lymphoblastic leukemia (philadelphia chromosome positive)", "label": " acute lymphoblastic leukemia (philadelphia chromosome positive)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalisporivir, peginterferon alfa-2a, ribavirin, placebo_hepatitis c", "label": "completedalisporivir, peginterferon alfa-2a, ribavirin, placebo_hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "infant, newborn, diseases, sepsis, puerperal infection", "label": "infant, newborn, diseases, sepsis, puerperal infection", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvelcade_multiple myeloma", "label": "completedvelcade_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedquetiapine sr, quetiapine sr placebo_bipolar disorder", "label": "completedquetiapine sr, quetiapine sr placebo_bipolar disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "mrx34", "label": "mrx34", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ro5083945, cisplatin, gemcitabine, pemetrexed", "label": "ro5083945, cisplatin, gemcitabine, pemetrexed", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ascorbic acid, placebo: 5% dextrose in water", "label": "ascorbic acid, placebo: 5% dextrose in water", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmirabegron, placebo, tamsulosin hydrochloride_benign prostatic hyperplasia, overactive bladder", "label": "completedmirabegron, placebo, tamsulosin hydrochloride_benign prostatic hyperplasia, overactive bladder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcetuximab, docetaxel_breast cancer", "label": "completedcetuximab, docetaxel_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "non-small-cell lung cancer, squamous cell carcinoma, adenocarcinoma of the lung", "label": "non-small-cell lung cancer, squamous cell carcinoma, adenocarcinoma of the lung", "shape": "dot", "size": 10}, {"color": "green", "id": " stage i multiple myeloma", "label": " stage i multiple myeloma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completed6,8-bis(benzylthio)octanoic acid_recurrent small cell lung cancer", "label": "completed6,8-bis(benzylthio)octanoic acid_recurrent small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcapsaicin dermal patch_hiv infections, peripheral nervous system diseases, pain", "label": "completedcapsaicin dermal patch_hiv infections, peripheral nervous system diseases, pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " ischemia", "label": " ischemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedbortezomib 1.3 mg/m2, bortezomib 1.6 mg/m2, bortezomib 1.8 mg/m2, carboplatin auc 6, bevacizumab, taxotere_lung cancer", "label": "terminatedbortezomib 1.3 mg/m2, bortezomib 1.6 mg/m2, bortezomib 1.8 mg/m2, carboplatin auc 6, bevacizumab, taxotere_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1CCN(CC1)C1=CC=C2N=C(NC2=C1)C1=C(N)C2=C(NC1=O)C=CC=C2F", "label": "CN1CCN(CC1)C1=CC=C2N=C(NC2=C1)C1=C(N)C2=C(NC1=O)C=CC=C2F", "shape": "dot", "size": 10}, {"color": "green", "id": "stage i breast cancer", "label": "stage i breast cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " tecemotide (l-blp25)", "label": " tecemotide (l-blp25)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alogliptin, glipizide", "label": "alogliptin, glipizide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedglycopyrrolate, glycopyrrolate, glycopyrrolate, comparator_pulmonary disease, chronic obstructive", "label": "completedglycopyrrolate, glycopyrrolate, glycopyrrolate, comparator_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O", "label": "N[C@@H](CC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrituxan, 1018 iss_non-hodgkin\u0027s lymphoma", "label": "completedrituxan, 1018 iss_non-hodgkin\u0027s lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvalproate, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone_diffuse large b-cell lymphoma", "label": "completedvalproate, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone_diffuse large b-cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "tenofovir/emtricitabine (truvada) and nevirapine", "label": "tenofovir/emtricitabine (truvada) and nevirapine", "shape": "dot", "size": 10}, {"color": "red", "id": "pi-88", "label": "pi-88", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mp-376, placebo", "label": "mp-376, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pramlintide acetate, metreleptin, placebo-p, placebo-m", "label": "pramlintide acetate, metreleptin, placebo-p, placebo-m", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "label": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " ketotifen fumarate dry syrup", "label": " ketotifen fumarate dry syrup", "shape": "dot", "size": 10}, {"color": "red", "id": "oral sufentanil", "label": "oral sufentanil", "shape": "dot", "size": 10}, {"color": "red", "id": "definity", "label": "definity", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpeginterferon alpha-2a_hepatitis c, cirrhosis, fibrosis", "label": "completedpeginterferon alpha-2a_hepatitis c, cirrhosis, fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H]\\C(C1=CC=C(C=C1)C(C)C(O)=O)=C1\\CCCCC1=O, CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F", "label": "[H]\\C(C1=CC=C(C=C1)C(C)C(O)=O)=C1\\CCCCC1=O, CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "brain and central nervous system tumors, extragonadal germ cell tumor, ovarian cancer, testicular germ cell tumor", "label": "brain and central nervous system tumors, extragonadal germ cell tumor, ovarian cancer, testicular germ cell tumor", "shape": "dot", "size": 10}, {"color": "red", "id": "thymosin beta 4", "label": "thymosin beta 4", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "doxorubicin hydrochloride, methylprednisolone", "label": "doxorubicin hydrochloride, methylprednisolone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "biphasic insulin aspart, insulin detemir, insulin aspart", "label": "biphasic insulin aspart, insulin detemir, insulin aspart", "shape": "dot", "size": 10}, {"color": "green", "id": "cervical dystonia", "label": "cervical dystonia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbudesonide/formoterol turbuhaler vs conventional best asthma therapy_asthma", "label": "completedbudesonide/formoterol turbuhaler vs conventional best asthma therapy_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rucaparib, nivolumab", "label": "rucaparib, nivolumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedabatacept, adalimumab, methotrexate_rheumatoid arthritis", "label": "completedabatacept, adalimumab, methotrexate_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "rescue medication: self-injectable epinephrine", "label": "rescue medication: self-injectable epinephrine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O", "label": "CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedplacebo, pf-06649751 low dose (1 mg qd), pf-06649751 middle dose 1 (3 mg qd), pf-06649751 middle dose 2 (7 mg qd), pf-06649751 high dose (15 mg qd)_parkinson disease", "label": "terminatedplacebo, pf-06649751 low dose (1 mg qd), pf-06649751 middle dose 1 (3 mg qd), pf-06649751 middle dose 2 (7 mg qd), pf-06649751 high dose (15 mg qd)_parkinson disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "pramipexole extended release", "label": "pramipexole extended release", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completededotecarin_breast cancer", "label": "completededotecarin_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " cisplatinum or carboplatin and e.g.etoposide+enoxaparin", "label": " cisplatinum or carboplatin and e.g.etoposide+enoxaparin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedranolazine_ischemic cardiomyopathy, nonischemic cardiomyopathy, heart failure", "label": "completedranolazine_ischemic cardiomyopathy, nonischemic cardiomyopathy, heart failure", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcer-001, placebo_acute coronary syndromes", "label": "completedcer-001, placebo_acute coronary syndromes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfosaprepitant dimeglumine, systemic chemotherapy_breakthrough nausea and vomiting, unspecified adult solid tumor, protocol specific", "label": "terminatedfosaprepitant dimeglumine, systemic chemotherapy_breakthrough nausea and vomiting, unspecified adult solid tumor, protocol specific", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcobimetinib, atezolizumab, pembrolizumab_advanced brafv600 wild-type melanoma", "label": "active, not recruitingcobimetinib, atezolizumab, pembrolizumab_advanced brafv600 wild-type melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "green", "id": " aids-related peripheral/systemic lymphoma", "label": " aids-related peripheral/systemic lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rbp-7000, placebo, risperidone", "label": "rbp-7000, placebo, risperidone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddexamethasone, doxorubicin hydrochloride, valspodar, vincristine sulfate_multiple myeloma and plasma cell neoplasm", "label": "completeddexamethasone, doxorubicin hydrochloride, valspodar, vincristine sulfate_multiple myeloma and plasma cell neoplasm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue", "label": " extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lenalidomide (revlimid), melphalan, dexamethasone", "label": "lenalidomide (revlimid), melphalan, dexamethasone", "shape": "dot", "size": 10}, {"color": "green", "id": " chronic kidney disease", "label": " chronic kidney disease", "shape": "dot", "size": 10}, {"color": "red", "id": " bi 207127", "label": " bi 207127", "shape": "dot", "size": 10}, {"color": "green", "id": "joint damage", "label": "joint damage", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpf-3512676 + erlotinib, erlotinib_carcinoma, non-small-cell lung", "label": "completedpf-3512676 + erlotinib, erlotinib_carcinoma, non-small-cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " metastatic esophageal squamous cell carcinoma", "label": " metastatic esophageal squamous cell carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedretapamulin, retapamulin, placebo_infections, bacterial", "label": "completedretapamulin, retapamulin, placebo_infections, bacterial", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "benzalkonium chloride-benzocaine topical, placebo oral tablet", "label": "benzalkonium chloride-benzocaine topical, placebo oral tablet", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "benign prostatic hyperplasia, chronic prostatitis", "label": "benign prostatic hyperplasia, chronic prostatitis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbevacizumab_metastatic melanoma", "label": "completedbevacizumab_metastatic melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " low-dose dexamethasone", "label": " low-dose dexamethasone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1, CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O", "label": "CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1, CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride, dexamethasone", "label": "fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride, dexamethasone", "shape": "dot", "size": 10}, {"color": "green", "id": " postpartum blues", "label": " postpartum blues", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bevacizumab, capecitabine, cisplatin, placebo, 5-fluorouracil", "label": "bevacizumab, capecitabine, cisplatin, placebo, 5-fluorouracil", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "label": "OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completed2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab_diabetic macular edema", "label": "completed2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab_diabetic macular edema", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnnebivolol, lisinopril_hypertension", "label": "withdrawnnebivolol, lisinopril_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedatomoxetine_attention-deficit/hyperactivity disorder", "label": "completedatomoxetine_attention-deficit/hyperactivity disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "gsk1325756 (danirixin)", "label": "gsk1325756 (danirixin)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cisplatin, gemcitabine", "label": "cisplatin, gemcitabine", "shape": "dot", "size": 10}, {"color": "green", "id": "progressive supranuclear palsy (psp)", "label": "progressive supranuclear palsy (psp)", "shape": "dot", "size": 10}, {"color": "green", "id": " ovarian", "label": " ovarian", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmontelukast_seasonal allergic rhinitis, allergic conjunctivitis, atopic eczema, asthma", "label": "completedmontelukast_seasonal allergic rhinitis, allergic conjunctivitis, atopic eczema, asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " a-cq 100", "label": " a-cq 100", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC[C@H]1\\C=C(C)\\[C@@H](O)C\\C=C\\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)[C@H](O)[C@@H]2OC)\\C(=O)OC(C\\C=C(/C)\\C=C(C)\\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O", "label": " CC[C@H]1\\C=C(C)\\[C@@H](O)C\\C=C\\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)[C@H](O)[C@@H]2OC)\\C(=O)OC(C\\C=C(/C)\\C=C(C)\\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedanlotinib_cancer", "label": "completedanlotinib_cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel, doxorubicin, cyclophosphamide, docetaxel,doxorubicin, cyclophosphamide", "label": "docetaxel, doxorubicin, cyclophosphamide, docetaxel,doxorubicin, cyclophosphamide", "shape": "dot", "size": 10}, {"color": "red", "id": "relaxin", "label": "relaxin", "shape": "dot", "size": 10}, {"color": "red", "id": "cyclosporine a microemulsion", "label": "cyclosporine a microemulsion", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bipolar depression, suicidal ideas, suicidal ideation, suicide, attempted", "label": "bipolar depression, suicidal ideas, suicidal ideation, suicide, attempted", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carboplatin, etoposide \u0026 thalidomide, carboplatin, etoposide \u0026 placebo", "label": "carboplatin, etoposide \u0026 thalidomide, carboplatin, etoposide \u0026 placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "bms-986001", "label": "bms-986001", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC(CNCCC2CCOCC2)=CC=C1OC1=CN=C(C=N1)C(N)=O", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC(CNCCC2CCOCC2)=CC=C1OC1=CN=C(C=N1)C(N)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbeclometasone dipropionate 100 \u00b5g + formoterol fumarate 6 \u00b5g, beclometasone dipropionate 200 \u00b5g + formoterol fumarate 6 \u00b5g, placebo_asthma", "label": "completedbeclometasone dipropionate 100 \u00b5g + formoterol fumarate 6 \u00b5g, beclometasone dipropionate 200 \u00b5g + formoterol fumarate 6 \u00b5g, placebo_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " chronic myeloproliferative disorders", "label": " chronic myeloproliferative disorders", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vitamin d, calcitriol, placebo", "label": "vitamin d, calcitriol, placebo", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1", "label": " CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "label": "CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedezetimibe (+) simvastatin, comparator: placebo_aortic stenosis", "label": "completedezetimibe (+) simvastatin, comparator: placebo_aortic stenosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "relapsing remitting multiple sclerosis, sleep initiation and maintenance disorders, fatigue", "label": "relapsing remitting multiple sclerosis, sleep initiation and maintenance disorders, fatigue", "shape": "dot", "size": 10}, {"color": "red", "id": " weekly paclitaxel and carboplatin", "label": " weekly paclitaxel and carboplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuscyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil_breast cancer, cardiac toxicity, perioperative/postoperative complications", "label": "unknown statuscyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil_breast cancer, cardiac toxicity, perioperative/postoperative complications", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " fluticasone propionate nasal spray placebo", "label": " fluticasone propionate nasal spray placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcapsaicin dermal patch_hiv infections, peripheral nervous system diseases, pain", "label": "terminatedcapsaicin dermal patch_hiv infections, peripheral nervous system diseases, pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcisplatin, carboplatin, pemetrexed, dexamethasone 4 mg, saline solution_non-small-cell lung carcinoma", "label": "active, not recruitingcisplatin, carboplatin, pemetrexed, dexamethasone 4 mg, saline solution_non-small-cell lung carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "000 mg/m^2", "label": "000 mg/m^2", "shape": "dot", "size": 10}, {"color": "red", "id": "vay736", "label": "vay736", "shape": "dot", "size": 10}, {"color": "red", "id": " testosterone only gel", "label": " testosterone only gel", "shape": "dot", "size": 10}, {"color": "red", "id": " pemetrexed and cisplatin", "label": " pemetrexed and cisplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedeverolimus_breast cancer", "label": "completedeverolimus_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedproellex 25 mg, placebo, proellex 50 mg_endometriosis", "label": "terminatedproellex 25 mg, placebo, proellex 50 mg_endometriosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "sumatriptan/naproxen sodium", "label": "sumatriptan/naproxen sodium", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "stage iiia non-small cell lung cancer, stage iiib non-small cell lung cancer, stage iv non-small cell lung cancer", "label": "stage iiia non-small cell lung cancer, stage iiib non-small cell lung cancer, stage iv non-small cell lung cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statushigh dose ivig and b cell depleting agents_end stage renal disease", "label": "unknown statushigh dose ivig and b cell depleting agents_end stage renal disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruiting6,8-bis(benzylthio)octanoic acid, fluorouracil_mucinous adenocarcinoma of the colon, mucinous adenocarcinoma of the rectum, recurrent colon cancer, recurrent rectal cancer, signet ring adenocarcinoma of the colon, signet ring adenocarcinoma of the rectum, stage iiia colon cancer, stage iiia rectal cancer, stage iiib colon cancer, stage iiib rectal cancer, stage iiic colon cancer, stage iiic rectal cancer, stage iva colon cancer, stage iva rectal cancer, stage ivb colon cancer, stage ivb rectal cancer", "label": "active, not recruiting6,8-bis(benzylthio)octanoic acid, fluorouracil_mucinous adenocarcinoma of the colon, mucinous adenocarcinoma of the rectum, recurrent colon cancer, recurrent rectal cancer, signet ring adenocarcinoma of the colon, signet ring adenocarcinoma of the rectum, stage iiia colon cancer, stage iiia rectal cancer, stage iiib colon cancer, stage iiib rectal cancer, stage iiic colon cancer, stage iiic rectal cancer, stage iva colon cancer, stage iva rectal cancer, stage ivb colon cancer, stage ivb rectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbrinzolamide 1.0%_primary open angle glaucoma, ocular hypertension", "label": "completedbrinzolamide 1.0%_primary open angle glaucoma, ocular hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " primary brain tumor", "label": " primary brain tumor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrad001 (everolimus), ptk787 (vatalanib)_kidney cancer, unspecified adult solid tumor, protocol specific", "label": "completedrad001 (everolimus), ptk787 (vatalanib)_kidney cancer, unspecified adult solid tumor, protocol specific", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O", "label": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedescitalopram_obsessive compulsive disorder", "label": "completedescitalopram_obsessive compulsive disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mesalamine 2400 mg (5-asa), mesalamine 1200 mg", "label": "mesalamine 2400 mg (5-asa), mesalamine 1200 mg", "shape": "dot", "size": 10}, {"color": "red", "id": "plx3397", "label": "plx3397", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@H](NC(=O)C(=O)NC1=CC=CC=C1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "C[C@H](NC(=O)C(=O)NC1=CC=CC=C1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "omalizumab (xolair)", "label": "omalizumab (xolair)", "shape": "dot", "size": 10}, {"color": "red", "id": " quinacrine dihydrochloride - escalation dose", "label": " quinacrine dihydrochloride - escalation dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcntx-4975-05, qutenza, lidocaine (without epinephrine)_knee osteoarthritis", "label": "completedcntx-4975-05, qutenza, lidocaine (without epinephrine)_knee osteoarthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cancer, myeloma, multiple myeloma", "label": "cancer, myeloma, multiple myeloma", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": " [H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedact-541468 5 mg, act-541468 10 mg, act-541468 25 mg, zolpidem, placebo 1, placebo 2_insomnia disorder", "label": "completedact-541468 5 mg, act-541468 10 mg, act-541468 25 mg, zolpidem, placebo 1, placebo 2_insomnia disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "itraconazole", "label": "itraconazole", "shape": "dot", "size": 10}, {"color": "red", "id": " pis (amp", "label": " pis (amp", "shape": "dot", "size": 10}, {"color": "red", "id": "crown", "label": "crown", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone propionate/salmeterol xinofoate 250/50 mcg bid, fluticasone propionate 250 mcg bid", "label": "fluticasone propionate/salmeterol xinofoate 250/50 mcg bid, fluticasone propionate 250 mcg bid", "shape": "dot", "size": 10}, {"color": "red", "id": "toremifene citrate", "label": "toremifene citrate", "shape": "dot", "size": 10}, {"color": "red", "id": "pasireotide lar 60 mg", "label": "pasireotide lar 60 mg", "shape": "dot", "size": 10}, {"color": "red", "id": "faster-acting insulin aspart", "label": "faster-acting insulin aspart", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpd 0332991, letrozole, letrozole_breast cancer", "label": "completedpd 0332991, letrozole, letrozole_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " enoxaparin-matching placebo", "label": " enoxaparin-matching placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=C(C\\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2", "label": "COC1=C(C\\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2", "shape": "dot", "size": 10}, {"color": "green", "id": " dyslexia", "label": " dyslexia", "shape": "dot", "size": 10}, {"color": "blue", "id": "O=C(NCC#N)C1=CC=C(C=C1)C1=CC=NC(NC2=CC=C(C=C2)N2CCOCC2)=N1", "label": "O=C(NCC#N)C1=CC=C(C=C1)C1=CC=NC(NC2=CC=C(C=C2)N2CCOCC2)=N1", "shape": "dot", "size": 10}, {"color": "red", "id": " irinotecan/docetaxel", "label": " irinotecan/docetaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfluocinolone acetonide_diabetic macular edema", "label": "completedfluocinolone acetonide_diabetic macular edema", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " idh2 gene mutation", "label": " idh2 gene mutation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfenretinide_head and neck cancer", "label": "terminatedfenretinide_head and neck cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo (double-blind)", "label": " placebo (double-blind)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vinorelbine, vandetanib", "label": "vinorelbine, vandetanib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedoravescent fentanyl_pain", "label": "completedoravescent fentanyl_pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1", "label": " OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1", "shape": "dot", "size": 10}, {"color": "red", "id": "cp-751", "label": "cp-751", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carboplatin, pazopanib", "label": "carboplatin, pazopanib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedoseltamivir [tamiflu]_influenza", "label": "completedoseltamivir [tamiflu]_influenza", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "investigator\u00b4s choice of chemotherapy", "label": "investigator\u00b4s choice of chemotherapy", "shape": "dot", "size": 10}, {"color": "green", "id": "heroin dependence", "label": "heroin dependence", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alzheimer disease, dementia, alzheimer type", "label": "alzheimer disease, dementia, alzheimer type", "shape": "dot", "size": 10}, {"color": "red", "id": " fluticasone propionate_6", "label": " fluticasone propionate_6", "shape": "dot", "size": 10}, {"color": "green", "id": " lymphoproliferative disorders", "label": " lymphoproliferative disorders", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fenofibrate, simvastatin", "label": "fenofibrate, simvastatin", "shape": "dot", "size": 10}, {"color": "red", "id": "tgr-1202", "label": "tgr-1202", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "indacaterol, tiotropium, placebo", "label": "indacaterol, tiotropium, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "olanzapine, aprepitant pill, ondansetron, dexamethasone", "label": "olanzapine, aprepitant pill, ondansetron, dexamethasone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmtx_rheumatoid arthritis (ra)", "label": "completedmtx_rheumatoid arthritis (ra)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hat1 topical cream, vehicle cream", "label": "hat1 topical cream, vehicle cream", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarboplatin_glioblastoma, glioma, brain tumor", "label": "completedcarboplatin_glioblastoma, glioma, brain tumor", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "acute bronchitis", "label": "acute bronchitis", "shape": "dot", "size": 10}, {"color": "red", "id": " ospemifene 60 mg", "label": " ospemifene 60 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazd2171_gastrointestinal stromal tumors, soft tissue sarcomas", "label": "completedazd2171_gastrointestinal stromal tumors, soft tissue sarcomas", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "epirubicin, cisplatin, capecitabine, panitumumab, epirubicin, cisplatin, capecitabine", "label": "epirubicin, cisplatin, capecitabine, panitumumab, epirubicin, cisplatin, capecitabine", "shape": "dot", "size": 10}, {"color": "red", "id": "carboplatin plus irinotecan vs carboplatin plus etoposide", "label": "carboplatin plus irinotecan vs carboplatin plus etoposide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtreatment with entecavir(baraclude\u00ae)_hepatitis b, chronic, liver fibrosis", "label": "terminatedtreatment with entecavir(baraclude\u00ae)_hepatitis b, chronic, liver fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "hand osteoarthritis", "label": "hand osteoarthritis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "capecitabine, trastuzumab, paclitaxel", "label": "capecitabine, trastuzumab, paclitaxel", "shape": "dot", "size": 10}, {"color": "green", "id": " ohss", "label": " ohss", "shape": "dot", "size": 10}, {"color": "red", "id": "etravirine (tmc125)", "label": "etravirine (tmc125)", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@]1(CO)O[C@]([H])(OC2=C(C=C(CCCCCCC3=CC(=C(O[C@@]4([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@]4([H])O)C=C3)C3=CC=CC(CC(O)=O)=C3)C=C2)C2=CC=CC(CC(O)=O)=C2)[C@@]([H])(O)[C@@]([H])(O)[C@]1([H])O", "label": "[H][C@]1(CO)O[C@]([H])(OC2=C(C=C(CCCCCCC3=CC(=C(O[C@@]4([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@]4([H])O)C=C3)C3=CC=CC(CC(O)=O)=C3)C=C2)C2=CC=CC(CC(O)=O)=C2)[C@@]([H])(O)[C@@]([H])(O)[C@]1([H])O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddocetaxel and cisplatin_esophageal cancer", "label": "completeddocetaxel and cisplatin_esophageal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuscisplatin_cervical cancer", "label": "unknown statuscisplatin_cervical cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C", "label": "CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "belatacept, cyclosporine a, tacrolimus", "label": "belatacept, cyclosporine a, tacrolimus", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusvitamin d_restless legs syndrome", "label": "unknown statusvitamin d_restless legs syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo am", "label": " placebo am", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "psi-7977, daclatasvir, ribavirin", "label": "psi-7977, daclatasvir, ribavirin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oxybutynin extended release, placebo", "label": "oxybutynin extended release, placebo", "shape": "dot", "size": 10}, {"color": "green", "id": "anti-retroviral agents", "label": "anti-retroviral agents", "shape": "dot", "size": 10}, {"color": "green", "id": "transitional cell carcinoma of the urothelial tract", "label": "transitional cell carcinoma of the urothelial tract", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "levetiracetam 1 g iv + lorazepam 2 mg iv, placebo + lorazepam 3 mg iv", "label": "levetiracetam 1 g iv + lorazepam 2 mg iv, placebo + lorazepam 3 mg iv", "shape": "dot", "size": 10}, {"color": "red", "id": "activated recombinant human factor vii", "label": "activated recombinant human factor vii", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedipi-926 plus gemcitabine, placebo plus gemcitabine_metastatic pancreatic cancer", "label": "completedipi-926 plus gemcitabine, placebo plus gemcitabine_metastatic pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " bi 10773 / bi 1356", "label": " bi 10773 / bi 1356", "shape": "dot", "size": 10}, {"color": "red", "id": " crixotinib 250 mg and sunitinib cohort 2", "label": " crixotinib 250 mg and sunitinib cohort 2", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=CC(F)=CC=C1C1=C2C=CC(=O)N(C2=NC(NC(CO)CO)=N1)C1=C(F)C=CC=C1F", "label": "CC1=CC(F)=CC=C1C1=C2C=CC(=O)N(C2=NC(NC(CO)CO)=N1)C1=C(F)C=CC=C1F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1, COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1", "label": "COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1, COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CN(C)C(=N)NC(N)=N", "label": "[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CN(C)C(=N)NC(N)=N", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dabrafenib, trametinib", "label": "dabrafenib, trametinib", "shape": "dot", "size": 10}, {"color": "green", "id": " squamous cell non-metastatic non-small cell lung cancer", "label": " squamous cell non-metastatic non-small cell lung cancer", "shape": "dot", "size": 10}, {"color": "green", "id": " mucinous adenocarcinoma", "label": " mucinous adenocarcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carboplatin, paclitaxel, lapatinib, cisplatin, cisplatin", "label": "carboplatin, paclitaxel, lapatinib, cisplatin, cisplatin", "shape": "dot", "size": 10}, {"color": "red", "id": "aclidinium 400 \u03bcg / formoterol 12 \u03bcg", "label": "aclidinium 400 \u03bcg / formoterol 12 \u03bcg", "shape": "dot", "size": 10}, {"color": "red", "id": " rebamipide-placebo", "label": " rebamipide-placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "chondroitin sulphate (condrosan\u00ae)", "label": "chondroitin sulphate (condrosan\u00ae)", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C", "label": " [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ac regimen, cyclophosphamide, doxorubicin hydrochloride", "label": "ac regimen, cyclophosphamide, doxorubicin hydrochloride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "viramidine, peginterferon alfa-2b", "label": "viramidine, peginterferon alfa-2b", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vildagliptin 100 mg qd, metformin 1500 mg daily", "label": "vildagliptin 100 mg qd, metformin 1500 mg daily", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "valsartan, non-arb", "label": "valsartan, non-arb", "shape": "dot", "size": 10}, {"color": "blue", "id": "C[C@]12CC[C@@H]([C@@H](CN)[C@@H]1CCC2=C)[C@@]1(C)CC[C@H](O)C[C@@H]1CO", "label": "C[C@]12CC[C@@H]([C@@H](CN)[C@@H]1CCC2=C)[C@@]1(C)CC[C@H](O)C[C@@H]1CO", "shape": "dot", "size": 10}, {"color": "red", "id": "paquinimod", "label": "paquinimod", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bicalutamide, docetaxel, gnrh analog", "label": "bicalutamide, docetaxel, gnrh analog", "shape": "dot", "size": 10}, {"color": "red", "id": "crd007", "label": "crd007", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "concurrent, sequential", "label": "concurrent, sequential", "shape": "dot", "size": 10}, {"color": "green", "id": " gastroesophageal junction neoplasms", "label": " gastroesophageal junction neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpaclitaxel, gemcitabine_non-small cell lung cancer", "label": "completedpaclitaxel, gemcitabine_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC[C@H]1\\C=C(C)\\[C@@H](O)C\\C=C\\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)[C@H](O)[C@@H]2OC)\\C(=O)OC(C\\C=C(/C)\\C=C(C)\\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O", "label": "CC[C@H]1\\C=C(C)\\[C@@H](O)C\\C=C\\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)[C@H](O)[C@@H]2OC)\\C(=O)OC(C\\C=C(/C)\\C=C(C)\\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@@H](O)[C@@H](C)OC1=C(C=NC(NC2=CC=C(C=C2)[S@](=N)(=O)C2CC2)=N1)C(F)(F)F, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "C[C@@H](O)[C@@H](C)OC1=C(C=NC(NC2=CC=C(C=C2)[S@](=N)(=O)C2CC2)=N1)C(F)(F)F, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "spd602 (fbs0701, ssp-004184)", "label": "spd602 (fbs0701, ssp-004184)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedindacaterol, placebo to indacaterol_persistent asthma", "label": "completedindacaterol, placebo to indacaterol_persistent asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo (for atg)", "label": " placebo (for atg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "inflammatory bowel disease, crohn\u0027s disease, ulcerative colitis", "label": "inflammatory bowel disease, crohn\u0027s disease, ulcerative colitis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedevolocumab, placebo_diabetes mellitus, type 2, dyslipidemia associated with type ii diabetes mellitus, percutaneous coronary intervention", "label": "terminatedevolocumab, placebo_diabetes mellitus, type 2, dyslipidemia associated with type ii diabetes mellitus, percutaneous coronary intervention", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedreslizumab, placebo, non-oral corticosteroid (non-ocs) asthma medication, oral corticosteroid (ocs)_asthma, elevated blood eosinophils, oral corticosteroid dependence", "label": "completedreslizumab, placebo, non-oral corticosteroid (non-ocs) asthma medication, oral corticosteroid (ocs)_asthma, elevated blood eosinophils, oral corticosteroid dependence", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl, FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl, COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1", "label": "FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl, FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl, COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, sildenafil citrate, 25 mg, 3 times a day., sildenafil citrate 50 mg, 3 times a day", "label": "placebo, sildenafil citrate, 25 mg, 3 times a day., sildenafil citrate 50 mg, 3 times a day", "shape": "dot", "size": 10}, {"color": "red", "id": " dovonex\u00ae = calcipotriol", "label": " dovonex\u00ae = calcipotriol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completede/c/f/tdf, e/c/f/taf placebo, e/c/f/taf, e/c/f/tdf placebo_acquired immunodeficiency syndrome, hiv infections", "label": "completede/c/f/tdf, e/c/f/taf placebo, e/c/f/taf, e/c/f/tdf placebo_acquired immunodeficiency syndrome, hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "impaired cognition", "label": "impaired cognition", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mk-2206, paclitaxel, trastuzumab", "label": "mk-2206, paclitaxel, trastuzumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "eyp001a, placebo, entecavir, peg-interferon alfa-2a", "label": "eyp001a, placebo, entecavir, peg-interferon alfa-2a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "exenatide, insulin glargine", "label": "exenatide, insulin glargine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNC[C@H](O)C1=CC(O)=C(O)C=C1, NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1, CNC[C@H](O)C1=CC(O)=C(O)C=C1", "label": "CNC[C@H](O)C1=CC(O)=C(O)C=C1, NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1, CNC[C@H](O)C1=CC(O)=C(O)C=C1", "shape": "dot", "size": 10}, {"color": "blue", "id": "OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(O)=O", "label": "OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarboplatin, gemcitabine hydrochloride_leydig cell tumor, ovarian sarcoma, ovarian stromal cancer, pseudomyxoma peritonei, recurrent cervical cancer, recurrent endometrial carcinoma, recurrent fallopian tube cancer, recurrent ovarian epithelial cancer, recurrent ovarian germ cell tumor, recurrent primary peritoneal cavity cancer, recurrent uterine sarcoma, recurrent vaginal cancer, recurrent vulvar cancer", "label": "completedcarboplatin, gemcitabine hydrochloride_leydig cell tumor, ovarian sarcoma, ovarian stromal cancer, pseudomyxoma peritonei, recurrent cervical cancer, recurrent endometrial carcinoma, recurrent fallopian tube cancer, recurrent ovarian epithelial cancer, recurrent ovarian germ cell tumor, recurrent primary peritoneal cavity cancer, recurrent uterine sarcoma, recurrent vaginal cancer, recurrent vulvar cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "octaplaslg\u00ae", "label": "octaplaslg\u00ae", "shape": "dot", "size": 10}, {"color": "red", "id": " ranibizumab 2.0mg (monthly)", "label": " ranibizumab 2.0mg (monthly)", "shape": "dot", "size": 10}, {"color": "red", "id": "ibandronate", "label": "ibandronate", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2C3=C(CCC4=C2C(Br)=CC(Cl)=C4)C=C(Br)C=N3)CC1", "label": "NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2C3=C(CCC4=C2C(Br)=CC(Cl)=C4)C=C(Br)C=N3)CC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingjbt-101, placebo, part b open-label extension_diffuse cutaneous systemic sclerosis", "label": "active, not recruitingjbt-101, placebo, part b open-label extension_diffuse cutaneous systemic sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@@H]5C[N@@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O", "label": " [H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@@H]5C[N@@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1", "label": "CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedabt-126, abt-126, placebo_schizophrenia", "label": "completedabt-126, abt-126, placebo_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1", "label": " CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedglecaprevir (300mg)/pibrentasvir (120mg)_hepatitis c, chronic", "label": "completedglecaprevir (300mg)/pibrentasvir (120mg)_hepatitis c, chronic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " contiguous stage ii grade 3 follicular lymphoma", "label": " contiguous stage ii grade 3 follicular lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dupilumab, placebo (for dupilumab)", "label": "dupilumab, placebo (for dupilumab)", "shape": "dot", "size": 10}, {"color": "red", "id": " gdc -0941", "label": " gdc -0941", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednva237, placebo, tiotropium_chronic obstructive pulmonary disease", "label": "completednva237, placebo, tiotropium_chronic obstructive pulmonary disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcabozantinib capsules, cabozantinib tablets_solid tumors, cancer, nsclc", "label": "completedcabozantinib capsules, cabozantinib tablets_solid tumors, cancer, nsclc", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedidelalisib_chronic lymphocytic leukemia, indolent non-hodgkin lymphoma, follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma (with or without waldenstrom macroglobulinemia), marginal zone lymphoma", "label": "completedidelalisib_chronic lymphocytic leukemia, indolent non-hodgkin lymphoma, follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma (with or without waldenstrom macroglobulinemia), marginal zone lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "levodopa carbidopa intestinal gel (lcig)", "label": "levodopa carbidopa intestinal gel (lcig)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alk3831, olanzapine, placebo", "label": "alk3831, olanzapine, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingandrogen blockade_prostate cancer", "label": "active, not recruitingandrogen blockade_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " benadryl\u00ae", "label": " benadryl\u00ae", "shape": "dot", "size": 10}, {"color": "red", "id": "dronedarone (sr33589)", "label": "dronedarone (sr33589)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NS(=O)(=O)NCCNC1=NON=C1\\C(NC1=CC(Br)=C(F)C=C1)=N\\O, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2", "label": "NS(=O)(=O)NCCNC1=NON=C1\\C(NC1=CC(Br)=C(F)C=C1)=N\\O, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2", "shape": "dot", "size": 10}, {"color": "red", "id": "romidepsin", "label": "romidepsin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gemcitabine, carboplatin, bevacizumab", "label": "gemcitabine, carboplatin, bevacizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ertugliflozin 5 mg, placebo 5 mg, ertugliflozin 10 mg, placebo 10 mg", "label": "ertugliflozin 5 mg, placebo 5 mg, ertugliflozin 10 mg, placebo 10 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " pac-14028 cream 0.3%", "label": " pac-14028 cream 0.3%", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "comparator: fosaprepitant dimeglumine, comparator: aprepitant, dexamethasone, dexamethasone, ondansetron", "label": "comparator: fosaprepitant dimeglumine, comparator: aprepitant, dexamethasone, dexamethasone, ondansetron", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcapecitabine, celecoxib_colorectal cancer", "label": "terminatedcapecitabine, celecoxib_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "castration levels of testosterone", "label": "castration levels of testosterone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "male breast cancer, stage ii breast cancer, stage iiia breast cancer, stage iiib breast cancer", "label": "male breast cancer, stage ii breast cancer, stage iiia breast cancer, stage iiib breast cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic hepatitis c, evidence of liver transplantation", "label": "chronic hepatitis c, evidence of liver transplantation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcapecitabine [xeloda], taxotere, herceptin (her2-neu positive patients only), capecitabine [xeloda], taxotere_breast cancer", "label": "completedcapecitabine [xeloda], taxotere, herceptin (her2-neu positive patients only), capecitabine [xeloda], taxotere_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, OC(=O)C1=CC=CC=C1O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, OC(=O)C1=CC=CC=C1O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mpc-7869, mpc-7869", "label": "mpc-7869, mpc-7869", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "metformin, placebo (for metformin)", "label": "metformin, placebo (for metformin)", "shape": "dot", "size": 10}, {"color": "red", "id": " las100977 2.5 \u03bcg", "label": " las100977 2.5 \u03bcg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O", "label": "[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aplindore, placebo", "label": "aplindore, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gastric cancer, gastric adenocarcinoma", "label": "gastric cancer, gastric adenocarcinoma", "shape": "dot", "size": 10}, {"color": "green", "id": " bone neoplasm", "label": " bone neoplasm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1", "label": "CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbazedoxifene acetate_osteoporosis", "label": "completedbazedoxifene acetate_osteoporosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " crushed alo-02 40 mg/4.8 mg", "label": " crushed alo-02 40 mg/4.8 mg", "shape": "dot", "size": 10}, {"color": "red", "id": "vincristine sulfate liposome injection plus rituximab", "label": "vincristine sulfate liposome injection plus rituximab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedranibizumab_diabetic macular edema", "label": "completedranibizumab_diabetic macular edema", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " atorvastatin 20 mg", "label": " atorvastatin 20 mg", "shape": "dot", "size": 10}, {"color": "red", "id": "azd7624 1.0 mg", "label": "azd7624 1.0 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "iron deficiency, anemia, kidney disease", "label": "iron deficiency, anemia, kidney disease", "shape": "dot", "size": 10}, {"color": "red", "id": " concerta\u00ae", "label": " concerta\u00ae", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddexamethasone_arthritis, gouty", "label": "completeddexamethasone_arthritis, gouty", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " gw642444", "label": " gw642444", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbevacizumab_malignant glioma", "label": "completedbevacizumab_malignant glioma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "myeloma, plasma-cell, lymphoma, malignant", "label": "myeloma, plasma-cell, lymphoma, malignant", "shape": "dot", "size": 10}, {"color": "green", "id": " metastatic renal cell cancer", "label": " metastatic renal cell cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " bay86-5321)", "label": " bay86-5321)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcilostazol 200mg, sumatriptan 6 mg/ml, placebo_migraine", "label": "completedcilostazol 200mg, sumatriptan 6 mg/ml, placebo_migraine", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddabigatran, acetylsalicylic acid_transient ischemic attack, minor ischemic stroke", "label": "completeddabigatran, acetylsalicylic acid_transient ischemic attack, minor ischemic stroke", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "label": "ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " rad54l gene mutation", "label": " rad54l gene mutation", "shape": "dot", "size": 10}, {"color": "blue", "id": "NCCCC(O)(P(O)(O)=O)P(O)(O)=O", "label": "NCCCC(O)(P(O)(O)=O)P(O)(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedabraxane, bevacizumab_ovarian cancer, peritoneal cancer", "label": "terminatedabraxane, bevacizumab_ovarian cancer, peritoneal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " dymista nasal spray", "label": " dymista nasal spray", "shape": "dot", "size": 10}, {"color": "red", "id": " doxorubicin/placebo", "label": " doxorubicin/placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfludarabine phosphate, cyclophosphamide, cyclosporine, mycophenolate mofetil_accelerated phase chronic myelogenous leukemia, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), childhood acute lymphoblastic leukemia in remission, childhood acute myeloid leukemia in remission, childhood chronic myelogenous leukemia, childhood myelodysplastic syndromes, chronic phase chronic myelogenous leukemia, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, refractory anemia, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, relapsing chronic myelogenous leukemia, secondary myelodysplastic syndromes", "label": "completedfludarabine phosphate, cyclophosphamide, cyclosporine, mycophenolate mofetil_accelerated phase chronic myelogenous leukemia, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), childhood acute lymphoblastic leukemia in remission, childhood acute myeloid leukemia in remission, childhood chronic myelogenous leukemia, childhood myelodysplastic syndromes, chronic phase chronic myelogenous leukemia, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, refractory anemia, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, relapsing chronic myelogenous leukemia, secondary myelodysplastic syndromes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CC1=C(CC2=CC=C3C=CC=CC3=N2)C2=CC(F)=CC=C2N1CC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaliskiren /amlodipine/hydrochlorothiazide_essential hypertension", "label": "completedaliskiren /amlodipine/hydrochlorothiazide_essential hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " alfacalcidol placebo", "label": " alfacalcidol placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "label": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "joint pain, musculoskeletal pain, stiffness, soft tissue inflammation in designated target area(s)", "label": "joint pain, musculoskeletal pain, stiffness, soft tissue inflammation in designated target area(s)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbrivaracetam 2.5 mg, brivaracetam 10 mg, brivaracetam 25 mg_epilepsy", "label": "completedbrivaracetam 2.5 mg, brivaracetam 10 mg, brivaracetam 25 mg_epilepsy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " cxl-1020 doses for echo cohort b", "label": " cxl-1020 doses for echo cohort b", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@]1(CCCN1C(O)=NC1=NC(C)=C(S1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F)C(O)=N", "label": "[H][C@]1(CCCN1C(O)=NC1=NC(C)=C(S1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F)C(O)=N", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcontrol solution_heart failure, cardiomyopathy, ventricular dysfunction", "label": "completedcontrol solution_heart failure, cardiomyopathy, ventricular dysfunction", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "oxycodone cr", "label": "oxycodone cr", "shape": "dot", "size": 10}, {"color": "red", "id": "ciprofloxacin (bayq3939) dry powder for inhalation", "label": "ciprofloxacin (bayq3939) dry powder for inhalation", "shape": "dot", "size": 10}, {"color": "red", "id": "ly2510924", "label": "ly2510924", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcytarabine, daunorubicin, midostaurin, dexamethasone acetate_leukemia", "label": "active, not recruitingcytarabine, daunorubicin, midostaurin, dexamethasone acetate_leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " regional gastrointestinal carcinoid tumor", "label": " regional gastrointestinal carcinoid tumor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rosiglitazone-metformin fixed dose combination, metformin + glimepiride", "label": "rosiglitazone-metformin fixed dose combination, metformin + glimepiride", "shape": "dot", "size": 10}, {"color": "red", "id": " dorzolamide/timolol and latanoprost", "label": " dorzolamide/timolol and latanoprost", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedly2090314_leukemia", "label": "completedly2090314_leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " atypical chronic myeloid leukemia", "label": " atypical chronic myeloid leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "label": "OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "shape": "dot", "size": 10}, {"color": "red", "id": " idraparinux sodium", "label": " idraparinux sodium", "shape": "dot", "size": 10}, {"color": "green", "id": " extramedullary plasmacytoma", "label": " extramedullary plasmacytoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedzushima plaster with high dose, zushima plaster with low dose, indometacin cataplasms_osteoarthritis", "label": "completedzushima plaster with high dose, zushima plaster with low dose, indometacin cataplasms_osteoarthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12", "label": " CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgranulocyte colony-stimulating factor plus plerixafor, granulocyte colony-stimulating factor plus placebo_multiple myeloma", "label": "completedgranulocyte colony-stimulating factor plus plerixafor, granulocyte colony-stimulating factor plus placebo_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " sage-547 60 \u03bcg/kg/h", "label": " sage-547 60 \u03bcg/kg/h", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgefitinib_breast cancer", "label": "completedgefitinib_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "recurrent prostate cancer", "label": "recurrent prostate cancer", "shape": "dot", "size": 10}, {"color": "green", "id": " adult t-cell leukemia", "label": " adult t-cell leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "capecitabine, fluorouracil, leucovorin calcium, oxaliplatin", "label": "capecitabine, fluorouracil, leucovorin calcium, oxaliplatin", "shape": "dot", "size": 10}, {"color": "red", "id": " bimatoprost ophthalmic solution 0.01%", "label": " bimatoprost ophthalmic solution 0.01%", "shape": "dot", "size": 10}, {"color": "red", "id": "aliskiren 150/300 mg", "label": "aliskiren 150/300 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnepacadostat_extensive stage small cell lung carcinoma", "label": "withdrawnepacadostat_extensive stage small cell lung carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC1=CC=C(C=C1)N(C)C1=NC(C)=NC2=C1C=CC=C2", "label": "COC1=CC=C(C=C1)N(C)C1=NC(C)=NC2=C1C=CC=C2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1, CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl", "label": "CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1, CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "emricasan (5 mg), emricasan (50 mg), placebo", "label": "emricasan (5 mg), emricasan (50 mg), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "5-fu, carboplatin, cisplatin, mehd7945a, paclitaxel", "label": "5-fu, carboplatin, cisplatin, mehd7945a, paclitaxel", "shape": "dot", "size": 10}, {"color": "green", "id": " shingles", "label": " shingles", "shape": "dot", "size": 10}, {"color": "red", "id": "ipi-145", "label": "ipi-145", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dulaglutide, placebo, insulin glargine, metformin", "label": "dulaglutide, placebo, insulin glargine, metformin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedwarfarin_cardiovascular diseases, heart diseases, peripheral vascular diseases, thromboembolism, vascular diseases, venous thromboembolism", "label": "completedwarfarin_cardiovascular diseases, heart diseases, peripheral vascular diseases, thromboembolism, vascular diseases, venous thromboembolism", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcefiderocol, meropenem, linezolid_healthcare-associated pneumonia (hcap), hospital acquired pneumonia (hap), ventilator associated pneumonia (vap)", "label": "completedcefiderocol, meropenem, linezolid_healthcare-associated pneumonia (hcap), hospital acquired pneumonia (hap), ventilator associated pneumonia (vap)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsorafenib_small cell lung cancer", "label": "terminatedsorafenib_small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O", "label": " [H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO", "label": "CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO", "shape": "dot", "size": 10}, {"color": "red", "id": "berodual\u00ae via respimat\u00ae", "label": "berodual\u00ae via respimat\u00ae", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnchondroitin sulfate_crohn\u0027s disease", "label": "withdrawnchondroitin sulfate_crohn\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "lotemax", "label": "lotemax", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1, O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1, O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1", "label": "O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1, O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1, O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "bicifadine", "label": "bicifadine", "shape": "dot", "size": 10}, {"color": "red", "id": " ridaforolimus", "label": " ridaforolimus", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carboplatin, irinotecan hydrochloride", "label": "carboplatin, irinotecan hydrochloride", "shape": "dot", "size": 10}, {"color": "red", "id": "nitric oxide", "label": "nitric oxide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "celecoxib, cyclophosphamide", "label": "celecoxib, cyclophosphamide", "shape": "dot", "size": 10}, {"color": "red", "id": "osi-906", "label": "osi-906", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ranolazine, ranolazine placebo", "label": "ranolazine, ranolazine placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "non-hodgkins lymphoma, chronic lymphocytic leukemia", "label": "non-hodgkins lymphoma, chronic lymphocytic leukemia", "shape": "dot", "size": 10}, {"color": "red", "id": " low dose grt6005", "label": " low dose grt6005", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingdocetaxel + trastuzumab sc + pertuzumab, trastuzumab emtansin_early-stage breast carcinoma, her-2 positive breast cancer", "label": "active, not recruitingdocetaxel + trastuzumab sc + pertuzumab, trastuzumab emtansin_early-stage breast carcinoma, her-2 positive breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ee/ne placebo", "label": " ee/ne placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "rapamune\u00ae (sirolimus)", "label": "rapamune\u00ae (sirolimus)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "red", "id": " ertugliflozin 1 mg", "label": " ertugliflozin 1 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "edoxaban, dalteparin, low molecular weight heparin", "label": "edoxaban, dalteparin, low molecular weight heparin", "shape": "dot", "size": 10}, {"color": "red", "id": "abt-751 and carboplatin", "label": "abt-751 and carboplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F, CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F", "label": "CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F, CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "blue", "id": " COC1=CC(\\C=C\\C(=O)CC(=O)\\C=C\\C2=CC(OC)=C(O)C=C2)=CC=C1O", "label": " COC1=CC(\\C=C\\C(=O)CC(=O)\\C=C\\C2=CC(OC)=C(O)C=C2)=CC=C1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completederibulin mesylate, gemcitabine hydrochloride_metastatic ureter carcinoma, metastatic urethral carcinoma, stage iii bladder urothelial carcinoma ajcc v6 and v7, stage iii ureter cancer ajcc v7, stage iii urethral cancer ajcc v7, stage iv bladder urothelial carcinoma ajcc v7, stage iv ureter cancer ajcc v7, stage iv urethral cancer ajcc v7, ureter urothelial carcinoma, urethral urothelial carcinoma", "label": "completederibulin mesylate, gemcitabine hydrochloride_metastatic ureter carcinoma, metastatic urethral carcinoma, stage iii bladder urothelial carcinoma ajcc v6 and v7, stage iii ureter cancer ajcc v7, stage iii urethral cancer ajcc v7, stage iv bladder urothelial carcinoma ajcc v7, stage iv ureter cancer ajcc v7, stage iv urethral cancer ajcc v7, ureter urothelial carcinoma, urethral urothelial carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, laquinimod, placebo_primary progressive multiple sclerosis", "label": "completedplacebo, laquinimod, placebo_primary progressive multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "90y-hpam4, 90y-hpam4, 90y-hpam4 + gemcitabine", "label": "90y-hpam4, 90y-hpam4, 90y-hpam4 + gemcitabine", "shape": "dot", "size": 10}, {"color": "red", "id": "injectafer", "label": "injectafer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmbx-8025 50 mg (dose escalation period 1), mbx-8025 50 mg or 100 mg (dose escalation period 2), mbx-8025 50 mg, 100 mg or 200 mg (dose escalation period 3)_homozygous familial hypercholesterolemia", "label": "completedmbx-8025 50 mg (dose escalation period 1), mbx-8025 50 mg or 100 mg (dose escalation period 2), mbx-8025 50 mg, 100 mg or 200 mg (dose escalation period 3)_homozygous familial hypercholesterolemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)C1=COC=C1", "label": " C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)C1=COC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " dtic", "label": " dtic", "shape": "dot", "size": 10}, {"color": "green", "id": " bone marrow diseases", "label": " bone marrow diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnpaclitaxel_breast cancer", "label": "withdrawnpaclitaxel_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlyso-thermosensitive liposomal doxorubicin(thermodox)_breast cancer", "label": "terminatedlyso-thermosensitive liposomal doxorubicin(thermodox)_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1, FC1=CNC(=O)NC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC1=CNC(=O)NC1=O", "label": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1, FC1=CNC(=O)NC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC1=CNC(=O)NC1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "xl147 (sar245408), xl765 (sar245409), letrozole (femara)", "label": "xl147 (sar245408), xl765 (sar245409), letrozole (femara)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedirbesartan/amlodipine (150/5mg), irbesartan/amlodipine (150/10mg), irbesartan/amlodipine (300/5mg), irbesartan/amlodipine (300/10mg)_hypertension", "label": "completedirbesartan/amlodipine (150/5mg), irbesartan/amlodipine (150/10mg), irbesartan/amlodipine (300/5mg), irbesartan/amlodipine (300/10mg)_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cytarabine, idarubicin, etoposide, all-trans retinoic acid, pegfilgrastim", "label": "cytarabine, idarubicin, etoposide, all-trans retinoic acid, pegfilgrastim", "shape": "dot", "size": 10}, {"color": "red", "id": " antidepressant therapy (adt)", "label": " antidepressant therapy (adt)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlapatinib, lapatinib-placebo_breast cancer", "label": "completedlapatinib, lapatinib-placebo_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsertraline, placebo_depression, postpartum", "label": "terminatedsertraline, placebo_depression, postpartum", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo to ertuglilflozin 1 or 5 mg, ertugliflozin 1 mg, ertugliflozin 5 mg, ertugliflozin 25 mg, hctz 12.5mg, placebo to hctz, placebo to ertuglilflozin 25 mg", "label": "placebo to ertuglilflozin 1 or 5 mg, ertugliflozin 1 mg, ertugliflozin 5 mg, ertugliflozin 25 mg, hctz 12.5mg, placebo to hctz, placebo to ertuglilflozin 25 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "green", "id": " salivary gland adenocarcinoma", "label": " salivary gland adenocarcinoma", "shape": "dot", "size": 10}, {"color": "red", "id": "oral nicotine", "label": "oral nicotine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1", "label": "CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1", "shape": "dot", "size": 10}, {"color": "red", "id": " aclidinium bromide 200 \u03bcg bid", "label": " aclidinium bromide 200 \u03bcg bid", "shape": "dot", "size": 10}, {"color": "red", "id": " tiotropium respimat\u00ae low dose", "label": " tiotropium respimat\u00ae low dose", "shape": "dot", "size": 10}, {"color": "red", "id": " victoza (liraglutide)", "label": " victoza (liraglutide)", "shape": "dot", "size": 10}, {"color": "red", "id": " vancomycin / linezolid", "label": " vancomycin / linezolid", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl", "label": " CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glucobay (acarbose), januvia (sitagliptin), verapamil hexal (verapamil), victoza (liraglutide), signifor (pasireotide)", "label": "glucobay (acarbose), januvia (sitagliptin), verapamil hexal (verapamil), victoza (liraglutide), signifor (pasireotide)", "shape": "dot", "size": 10}, {"color": "green", "id": " major depressive disorder", "label": " major depressive disorder", "shape": "dot", "size": 10}, {"color": "green", "id": "tumor", "label": "tumor", "shape": "dot", "size": 10}, {"color": "red", "id": "at-101 and docetaxel", "label": "at-101 and docetaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "caelyx, paclitaxel hcl", "label": "caelyx, paclitaxel hcl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tuberculosis, human immunodeficiency virus infections", "label": "tuberculosis, human immunodeficiency virus infections", "shape": "dot", "size": 10}, {"color": "red", "id": " docetaxel and capecitabine", "label": " docetaxel and capecitabine", "shape": "dot", "size": 10}, {"color": "red", "id": "valsartan + amlodipine", "label": "valsartan + amlodipine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvicriviroc maleate 20 mg, vicriviroc maleate 30 mg, placebo_hiv infections", "label": "completedvicriviroc maleate 20 mg, vicriviroc maleate 30 mg, placebo_hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "iti-214 dose a", "label": "iti-214 dose a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedveliparib (abt-888), placebo_breast cancer, ovarian cancer, colon cancer, lung cancer, gastric cancer, solid tumors", "label": "completedveliparib (abt-888), placebo_breast cancer, ovarian cancer, colon cancer, lung cancer, gastric cancer, solid tumors", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfremanezumab, placebo_migraine prophylaxis", "label": "completedfremanezumab, placebo_migraine prophylaxis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingolaparib, enzalutamide, abiraterone acetate, abiraterone acetate, enzalutamide_metastatic castration-resistant prostate cancer", "label": "active, not recruitingolaparib, enzalutamide, abiraterone acetate, abiraterone acetate, enzalutamide_metastatic castration-resistant prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbbi608, paclitaxel_gastric cancer, gastroesophageal junction cancer", "label": "completedbbi608, paclitaxel_gastric cancer, gastroesophageal junction cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to match sel 6 mg", "label": " placebo to match sel 6 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " loratadine and placebo", "label": " loratadine and placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)C(=N)NC(N)=N, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F", "label": "CN(C)C(=N)NC(N)=N, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, dexamethasone, bortezomib", "label": "placebo, dexamethasone, bortezomib", "shape": "dot", "size": 10}, {"color": "green", "id": " catheter-related infections", "label": " catheter-related infections", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcisplatin, doxorubicin hydrochloride, fosbretabulin disodium_head and neck cancer", "label": "terminatedcisplatin, doxorubicin hydrochloride, fosbretabulin disodium_head and neck cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " prophylaxis", "label": " prophylaxis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alogliptin, insulin", "label": "alogliptin, insulin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "brivaracetam tablets, brivaracetam bolus, brivaracetam infusion", "label": "brivaracetam tablets, brivaracetam bolus, brivaracetam infusion", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedazacitidine_leukemia, myeloid, acute, myelodysplastic syndromes, precursor cell lymphoblastic leukemia-lymphoma", "label": "terminatedazacitidine_leukemia, myeloid, acute, myelodysplastic syndromes, precursor cell lymphoblastic leukemia-lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ff", "label": " ff", "shape": "dot", "size": 10}, {"color": "red", "id": " basal insulin (lantus\u00ae [insulin glargine]", "label": " basal insulin (lantus\u00ae [insulin glargine]", "shape": "dot", "size": 10}, {"color": "red", "id": "axs-02 (oral zoledronate)", "label": "axs-02 (oral zoledronate)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1", "label": "[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "intravitreal ranibizumab 0.3 mg", "label": "intravitreal ranibizumab 0.3 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lymphoma, non hodgkin\u0027s lymphoma", "label": "lymphoma, non hodgkin\u0027s lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnbicalutamide, leuprolide acetate, squalamine lactate_prostate cancer", "label": "withdrawnbicalutamide, leuprolide acetate, squalamine lactate_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "viaject\u00ae25, viaject\u00ae7, insulin lispro", "label": "viaject\u00ae25, viaject\u00ae7, insulin lispro", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcarboplatin, cisplatin_cervical cancer", "label": "terminatedcarboplatin, cisplatin_cervical cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " fluticasone propionate 250 mcg via accuhaler/diskus inhaler", "label": " fluticasone propionate 250 mcg via accuhaler/diskus inhaler", "shape": "dot", "size": 10}, {"color": "green", "id": " substance use disorders", "label": " substance use disorders", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedinhaled nitric oxide 75 mcg/kg ibw/hr, placebo_pulmonary arterial hypertension", "label": "terminatedinhaled nitric oxide 75 mcg/kg ibw/hr, placebo_pulmonary arterial hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " adv group", "label": " adv group", "shape": "dot", "size": 10}, {"color": "red", "id": " da", "label": " da", "shape": "dot", "size": 10}, {"color": "green", "id": " estrogen receptor negative", "label": " estrogen receptor negative", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Na+].CC([O-])=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "label": "[Na+].CC([O-])=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvox, sof/vel_hepatitis c virus infection", "label": "completedvox, sof/vel_hepatitis c virus infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "pancrease mt 10.5", "label": "pancrease mt 10.5", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedescitalopram, placebo, escitalopram_major depressive disorder", "label": "completedescitalopram, placebo, escitalopram_major depressive disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "umec/vi 62.5/25 mcg via ellipta, umec 62.5 mcg via ellipta, salmeterol 50 mcg via diskus, placebo via ellipta, placebo via diskus", "label": "umec/vi 62.5/25 mcg via ellipta, umec 62.5 mcg via ellipta, salmeterol 50 mcg via diskus, placebo via ellipta, placebo via diskus", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedclofarabine_b-cell lymphoma", "label": "completedclofarabine_b-cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iiib gallbladder cancer ajcc v7", "label": " stage iiib gallbladder cancer ajcc v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplerixafor_myeloma, lymphoma", "label": "completedplerixafor_myeloma, lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedjte-051, placebo_plaque psoriasis, skin diseases", "label": "terminatedjte-051, placebo_plaque psoriasis, skin diseases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ku-0059436 (azd2281)(parp inhibitor)", "label": " ku-0059436 (azd2281)(parp inhibitor)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1CCC(CCCNC2=NC=C(C3=NC4=C(C)C=C(C)C=C4N3)C(C)=N2)CC1, CN1CCC(CCCNC2=NC=C(C3=NC4=C(C)C=C(C)C=C4N3)C(C)=N2)CC1, CN1CCC(CCCNC2=NC=C(C3=NC4=C(C)C=C(C)C=C4N3)C(C)=N2)CC1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1CCC(CCCNC2=NC=C(C3=NC4=C(C)C=C(C)C=C4N3)C(C)=N2)CC1, CN1CCC(CCCNC2=NC=C(C3=NC4=C(C)C=C(C)C=C4N3)C(C)=N2)CC1, CN1CCC(CCCNC2=NC=C(C3=NC4=C(C)C=C(C)C=C4N3)C(C)=N2)CC1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sevelamer hydrochloride, calcium carbonate", "label": "sevelamer hydrochloride, calcium carbonate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpf-00489791, pf-00489791, pf-00489791, pf-00489791, pf-00489791, pf-00489791, pf-00489791, pf-00489791_raynaud\u0027s disease, peripheral vascular disease", "label": "completedpf-00489791, pf-00489791, pf-00489791, pf-00489791, pf-00489791, pf-00489791, pf-00489791, pf-00489791_raynaud\u0027s disease, peripheral vascular disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "ischemia-reperfusion injury", "label": "ischemia-reperfusion injury", "shape": "dot", "size": 10}, {"color": "red", "id": " pyridoxine", "label": " pyridoxine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "e7820, e7820", "label": "e7820, e7820", "shape": "dot", "size": 10}, {"color": "red", "id": "etanercept or adalimumab", "label": "etanercept or adalimumab", "shape": "dot", "size": 10}, {"color": "green", "id": " hyperphosphatemic", "label": " hyperphosphatemic", "shape": "dot", "size": 10}, {"color": "red", "id": " chemotherapy", "label": " chemotherapy", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo matching bms-986184", "label": " placebo matching bms-986184", "shape": "dot", "size": 10}, {"color": "red", "id": " insulin nph", "label": " insulin nph", "shape": "dot", "size": 10}, {"color": "blue", "id": " COC1=C(OC)C(=O)C(CCCCCCCCCCCCO)=C(C)C1=O", "label": " COC1=C(OC)C(=O)C(CCCCCCCCCCCCO)=C(C)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carboplatin, bevacizumab and pemetrexed", "label": "carboplatin, bevacizumab and pemetrexed", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sof/vel/vox, placebo", "label": "sof/vel/vox, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " latanoprost ophthalmic solution", "label": " latanoprost ophthalmic solution", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bl - 1020, bl - 1020, placebo, risperidone", "label": "bl - 1020, bl - 1020, placebo, risperidone", "shape": "dot", "size": 10}, {"color": "red", "id": "nva237 100 \u00b5g", "label": "nva237 100 \u00b5g", "shape": "dot", "size": 10}, {"color": "red", "id": "istradefylline (kw-6002)", "label": "istradefylline (kw-6002)", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC=CC1=C3CCNC(C)C)C2=O", "label": " CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC=CC1=C3CCNC(C)C)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sinusitis, cystic fibrosis", "label": "sinusitis, cystic fibrosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcorifollitropin alfa, follitropin beta_infertility", "label": "completedcorifollitropin alfa, follitropin beta_infertility", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "placebo (pbs-20% sucrose)", "label": "placebo (pbs-20% sucrose)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "copanlisib (aliqopa, bay80-6946)", "label": "copanlisib (aliqopa, bay80-6946)", "shape": "dot", "size": 10}, {"color": "red", "id": "r788", "label": "r788", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedispinesib_recurrent renal cell cancer, stage iii renal cell cancer, stage iv renal cell cancer", "label": "completedispinesib_recurrent renal cell cancer, stage iii renal cell cancer, stage iv renal cell cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedchlorogenic acid_advanced cancer", "label": "completedchlorogenic acid_advanced cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "osteoarthritis, cardiovascular disease", "label": "osteoarthritis, cardiovascular disease", "shape": "dot", "size": 10}, {"color": "red", "id": " clomiphene citrate", "label": " clomiphene citrate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1", "label": "FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " relapsing chronic myelogenous leukemia", "label": " relapsing chronic myelogenous leukemia", "shape": "dot", "size": 10}, {"color": "red", "id": "ogx-427 600 mg", "label": "ogx-427 600 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo (0", "label": " placebo (0", "shape": "dot", "size": 10}, {"color": "red", "id": " ustekinumab 90 mg sc q12w", "label": " ustekinumab 90 mg sc q12w", "shape": "dot", "size": 10}, {"color": "red", "id": "folfox regimen", "label": "folfox regimen", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedkeppra xr, keppra xr_epilepsy", "label": "completedkeppra xr, keppra xr_epilepsy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlansoprazole, rebamipide, rebamipide-placebo_gastroesophageal reflux", "label": "completedlansoprazole, rebamipide, rebamipide-placebo_gastroesophageal reflux", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " excessive daytime somnolence", "label": " excessive daytime somnolence", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, ipratropium bromide_pulmonary disease, chronic obstructive", "label": "completedplacebo, ipratropium bromide_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "omega-3-acid ethyl esters", "label": "omega-3-acid ethyl esters", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "liraglutide, liraglutide, placebo", "label": "liraglutide, liraglutide, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "label": "[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedamd3100_leukemia, myeloid, acute, leukemia, myelogenous, chronic, leukemia, lymphoblastic, acute, lymphocytic leukemia, chronic, myelodysplastic syndromes, multiple myeloma, lymphoma, non-hodgkin, hodgkin disease", "label": "completedamd3100_leukemia, myeloid, acute, leukemia, myelogenous, chronic, leukemia, lymphoblastic, acute, lymphocytic leukemia, chronic, myelodysplastic syndromes, multiple myeloma, lymphoma, non-hodgkin, hodgkin disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedspironolactone_heart failure, congestive", "label": "terminatedspironolactone_heart failure, congestive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbotulinum toxin type a, normal saline_benign prostatic hyperplasia", "label": "completedbotulinum toxin type a, normal saline_benign prostatic hyperplasia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCN(CC)CC(=O)NC1=C(C)C=CC=C1C, [Na+].[Cl-]", "label": "CCN(CC)CC(=O)NC1=C(C)C=CC=C1C, [Na+].[Cl-]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [Na+].CC([O-])=O", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [Na+].CC([O-])=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]", "label": "CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]", "shape": "dot", "size": 10}, {"color": "red", "id": " timolol maleate ophthalmic solution 0.5%", "label": " timolol maleate ophthalmic solution 0.5%", "shape": "dot", "size": 10}, {"color": "red", "id": "rgn-259", "label": "rgn-259", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hiv-1 infection, aids", "label": "hiv-1 infection, aids", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "depressive disorder, treatment-resistant", "label": "depressive disorder, treatment-resistant", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dose escalation of cetuximab, standard first line treatment with cetuximab + folfiri", "label": "dose escalation of cetuximab, standard first line treatment with cetuximab + folfiri", "shape": "dot", "size": 10}, {"color": "green", "id": "oral contraceptive", "label": "oral contraceptive", "shape": "dot", "size": 10}, {"color": "red", "id": "e7820", "label": "e7820", "shape": "dot", "size": 10}, {"color": "blue", "id": " O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1", "label": " O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedkarenitecin, valproic acid_malignant melanoma", "label": "terminatedkarenitecin, valproic acid_malignant melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "peg -intron, colchicine", "label": "peg -intron, colchicine", "shape": "dot", "size": 10}, {"color": "blue", "id": " C[C@]12C[C@H](C3=CC=C(C=C3)S(C)(=O)=O)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F", "label": " C[C@]12C[C@H](C3=CC=C(C=C3)S(C)(=O)=O)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "green", "id": "gastritis", "label": "gastritis", "shape": "dot", "size": 10}, {"color": "green", "id": " fatigue", "label": " fatigue", "shape": "dot", "size": 10}, {"color": "green", "id": "hematopoietic/lymphoid cancer", "label": "hematopoietic/lymphoid cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "non-small cell lung cancer, malignant pleural effusion", "label": "non-small cell lung cancer, malignant pleural effusion", "shape": "dot", "size": 10}, {"color": "red", "id": " betaseron", "label": " betaseron", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCCOCCOC1=CC=C(C=C1)C1=CC=C2N(CC(C)C)CCC\\C(=C/C2=C1)C(=O)NC1=CC=C(C=C1)[S@@+]([O-])CC1=CN=CN1CCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCCCOCCOC1=CC=C(C=C1)C1=CC=C2N(CC(C)C)CCC\\C(=C/C2=C1)C(=O)NC1=CC=C(C=C1)[S@@+]([O-])CC1=CN=CN1CCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "mk0653a", "label": "mk0653a", "shape": "dot", "size": 10}, {"color": "green", "id": " allogeneic", "label": " allogeneic", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1", "label": "CN(C)C1CCN(CC1)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C2=NC(=NC(=N2)N2CCOCC2)N2CCOCC2)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "elotuzumab, lenalidomide, dexamethasone", "label": "elotuzumab, lenalidomide, dexamethasone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "colorectal cancer, depression, esophageal cancer, extrahepatic bile duct cancer, fatigue, gallbladder cancer, gastric cancer, liver cancer, lung cancer, pancreatic cancer", "label": "colorectal cancer, depression, esophageal cancer, extrahepatic bile duct cancer, fatigue, gallbladder cancer, gastric cancer, liver cancer, lung cancer, pancreatic cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "vx-001", "label": "vx-001", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcarbon c 14 oxaliplatin, oxaliplatin_colon adenocarcinoma", "label": "active, not recruitingcarbon c 14 oxaliplatin, oxaliplatin_colon adenocarcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " nacl solution", "label": " nacl solution", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, COC1=C(C\\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C", "label": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, COC1=C(C\\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazacytidine, vorinostat_lymphoma", "label": "completedazacytidine, vorinostat_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " mp-214 middle dose", "label": " mp-214 middle dose", "shape": "dot", "size": 10}, {"color": "red", "id": "insulin or placebo", "label": "insulin or placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "rdea3170 2.5 mg", "label": "rdea3170 2.5 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "amg 386, amg 386 placebo, paclitaxel, paclitaxel", "label": "amg 386, amg 386 placebo, paclitaxel, paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "infection, human immunodeficiency virus, hiv infections", "label": "infection, human immunodeficiency virus, hiv infections", "shape": "dot", "size": 10}, {"color": "red", "id": "sertraline/[s", "label": "sertraline/[s", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mupirocin calcium, mupirocin calcium", "label": "mupirocin calcium, mupirocin calcium", "shape": "dot", "size": 10}, {"color": "red", "id": " sorafenib plus tegafur-uracil", "label": " sorafenib plus tegafur-uracil", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "seliciclib, placebo", "label": "seliciclib, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedoral nicotine, placebo_smoking dependence, smoking", "label": "completedoral nicotine, placebo_smoking dependence, smoking", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "xaliproden (sr57746a), placebo, oxaliplatin, 5-fluorouracil, leucovorin", "label": "xaliproden (sr57746a), placebo, oxaliplatin, 5-fluorouracil, leucovorin", "shape": "dot", "size": 10}, {"color": "green", "id": " partial response", "label": " partial response", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpegvisomant treatment_acromegaly", "label": "completedpegvisomant treatment_acromegaly", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "300 ir grass pollen allergen extract tablet", "label": "300 ir grass pollen allergen extract tablet", "shape": "dot", "size": 10}, {"color": "red", "id": " levonorgestrel patch with bmi 32 kg/m2 to \u003c40 kg/m2", "label": " levonorgestrel patch with bmi 32 kg/m2 to \u003c40 kg/m2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "doxorubicin-eluting beads, everolimus", "label": "doxorubicin-eluting beads, everolimus", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adult acute megakaryoblastic leukemia (m7), adult acute minimally differentiated myeloid leukemia (m0), adult acute monoblastic leukemia (m5a), adult acute monocytic leukemia (m5b), adult acute myeloblastic leukemia with maturation (m2), adult acute myeloblastic leukemia without maturation (m1), adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myelomonocytic leukemia (m4), adult erythroleukemia (m6a), adult pure erythroid leukemia (m6b), recurrent adult acute myeloid leukemia, untreated adult acute myeloid leukemia", "label": "adult acute megakaryoblastic leukemia (m7), adult acute minimally differentiated myeloid leukemia (m0), adult acute monoblastic leukemia (m5a), adult acute monocytic leukemia (m5b), adult acute myeloblastic leukemia with maturation (m2), adult acute myeloblastic leukemia without maturation (m1), adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myelomonocytic leukemia (m4), adult erythroleukemia (m6a), adult pure erythroid leukemia (m6b), recurrent adult acute myeloid leukemia, untreated adult acute myeloid leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "n-acetylcystine, 0.9% saline", "label": "n-acetylcystine, 0.9% saline", "shape": "dot", "size": 10}, {"color": "red", "id": " high dose cytarabine", "label": " high dose cytarabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedenvarsus\u00ae, prograf\u00ae, advagraf\u00ae_end stage renal disease", "label": "completedenvarsus\u00ae, prograf\u00ae, advagraf\u00ae_end stage renal disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " insulin therapy", "label": " insulin therapy", "shape": "dot", "size": 10}, {"color": "red", "id": "crenezumab", "label": "crenezumab", "shape": "dot", "size": 10}, {"color": "red", "id": "docetaxel + oxaliplatin", "label": "docetaxel + oxaliplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ticagrelor + asa + bivalirudin, clopidogrel + asa + bivalirudin", "label": "ticagrelor + asa + bivalirudin, clopidogrel + asa + bivalirudin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusdaily intranasal administration of insulin_type 1 diabetes", "label": "unknown statusdaily intranasal administration of insulin_type 1 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "fluoropyrimidine (capecitabine or 5-fluorouracil)", "label": "fluoropyrimidine (capecitabine or 5-fluorouracil)", "shape": "dot", "size": 10}, {"color": "green", "id": "sleep", "label": "sleep", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fosfomycin-trometamol, sulfamethoxazole trimethoprim", "label": "fosfomycin-trometamol, sulfamethoxazole trimethoprim", "shape": "dot", "size": 10}, {"color": "green", "id": " estrogen receptor breast cancer", "label": " estrogen receptor breast cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedliraglutide, placebo_diabetes mellitus, type 1, overweight", "label": "completedliraglutide, placebo_diabetes mellitus, type 1, overweight", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedasp8825_restless legs syndrome", "label": "completedasp8825_restless legs syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "lennox-gastaut syndrome", "label": "lennox-gastaut syndrome", "shape": "dot", "size": 10}, {"color": "green", "id": "type2 diabetes", "label": "type2 diabetes", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "epirubicin, cisplatin, paclitaxel", "label": "epirubicin, cisplatin, paclitaxel", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=NC=C(NC(=O)NC2=C(OC[C@@H]3CNCCO3)C=C(C)C(Br)=C2)N=C1", "label": "CC1=NC=C(NC(=O)NC2=C(OC[C@@H]3CNCCO3)C=C(C)C(Br)=C2)N=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1", "label": "CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo comparator: placebo", "label": " placebo comparator: placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " ltx-315 + pembrolizumab", "label": " ltx-315 + pembrolizumab", "shape": "dot", "size": 10}, {"color": "red", "id": "rob 803", "label": "rob 803", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "metformin, simvastatin", "label": "metformin, simvastatin", "shape": "dot", "size": 10}, {"color": "red", "id": " timolol maleate ophthalmic solution 0.5% bid", "label": " timolol maleate ophthalmic solution 0.5% bid", "shape": "dot", "size": 10}, {"color": "red", "id": "pumosetrag", "label": "pumosetrag", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo_influenza", "label": "completedplacebo_influenza", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " nipent", "label": " nipent", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oxaliplatin, leucovorin calcium, fluorouracil, capecitabine", "label": "oxaliplatin, leucovorin calcium, fluorouracil, capecitabine", "shape": "dot", "size": 10}, {"color": "red", "id": " ivacaftor placebo", "label": " ivacaftor placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " marginal zone b-cell lymphoma", "label": " marginal zone b-cell lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ar-12286 ophthalmic solution 0.7%, ar-12286 ophthalmic solution 0.5%, timolol maleate ophthalmic solution 0.5%", "label": "ar-12286 ophthalmic solution 0.7%, ar-12286 ophthalmic solution 0.5%, timolol maleate ophthalmic solution 0.5%", "shape": "dot", "size": 10}, {"color": "green", "id": "recurrent b acute lymphoblastic leukemia", "label": "recurrent b acute lymphoblastic leukemia", "shape": "dot", "size": 10}, {"color": "red", "id": "4\u0027-dithiobis (3-aminobutane-1-sulfonic acid)]", "label": "4\u0027-dithiobis (3-aminobutane-1-sulfonic acid)]", "shape": "dot", "size": 10}, {"color": "red", "id": "technosphere insulin", "label": "technosphere insulin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsunitinib, pemetrexed, cisplatin, carboplatin_neoplasms", "label": "completedsunitinib, pemetrexed, cisplatin, carboplatin_neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "delayed graft function", "label": "delayed graft function", "shape": "dot", "size": 10}, {"color": "red", "id": "brinzolamide/timolol", "label": "brinzolamide/timolol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsaquinavir/ritonavir, atazanavir/ritonavir_hiv infections", "label": "completedsaquinavir/ritonavir, atazanavir/ritonavir_hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " fcm", "label": " fcm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsemaglutide, canagliflozin, placebo (canagliflozin), placebo (semaglutide)_diabetes, diabetes mellitus, type 2", "label": "completedsemaglutide, canagliflozin, placebo (canagliflozin), placebo (semaglutide)_diabetes, diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedbortezomib, dexamethasone, thalidomide_multiple myeloma", "label": "terminatedbortezomib, dexamethasone, thalidomide_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "edoxaban 60 mg", "label": "edoxaban 60 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtopotecan + cisplatin, etoposide + carboplatin_extensive disease, first-line, small cell lung cancer", "label": "terminatedtopotecan + cisplatin, etoposide + carboplatin_extensive disease, first-line, small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic kidney disease, renal insufficiency, hyperphosphatemia", "label": "chronic kidney disease, renal insufficiency, hyperphosphatemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NCCO.CCCCCCCC\\C=C/CCCCCCCC(O)=O, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O, O", "label": "NCCO.CCCCCCCC\\C=C/CCCCCCCC(O)=O, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O, O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dravet syndrome, seizure disorder", "label": "dravet syndrome, seizure disorder", "shape": "dot", "size": 10}, {"color": "green", "id": " pure autonomic failure", "label": " pure autonomic failure", "shape": "dot", "size": 10}, {"color": "red", "id": "hm10460a (45 \u03bcg/kg)", "label": "hm10460a (45 \u03bcg/kg)", "shape": "dot", "size": 10}, {"color": "red", "id": " tenofovir/emtricitabine and atazanavir and ritonavir", "label": " tenofovir/emtricitabine and atazanavir and ritonavir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC(=O)C1=C(O)C2=C(C[C@H]3N(CC4CC4)CC[C@@]22CC(=O)CC[C@@]32O)C=C1, NC(=O)C1=C(O)C2=C(C[C@H]3N(CC4CC4)CC[C@@]22CC(=O)CC[C@@]32O)C=C1, NC(=O)C1=C(O)C2=C(C[C@H]3N(CC4CC4)CC[C@@]22CC(=O)CC[C@@]32O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1", "label": "NC(=O)C1=C(O)C2=C(C[C@H]3N(CC4CC4)CC[C@@]22CC(=O)CC[C@@]32O)C=C1, NC(=O)C1=C(O)C2=C(C[C@H]3N(CC4CC4)CC[C@@]22CC(=O)CC[C@@]32O)C=C1, NC(=O)C1=C(O)C2=C(C[C@H]3N(CC4CC4)CC[C@@]22CC(=O)CC[C@@]32O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glioblastoma, malignant glioma", "label": "glioblastoma, malignant glioma", "shape": "dot", "size": 10}, {"color": "green", "id": " malignant pleural effusions", "label": " malignant pleural effusions", "shape": "dot", "size": 10}, {"color": "green", "id": " unresectable hepatocellular carcinoma", "label": " unresectable hepatocellular carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nintedanib, pemetrexed, cisplatin, cisplatin, pemetrexed, placebo", "label": "nintedanib, pemetrexed, cisplatin, cisplatin, pemetrexed, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo and docetaxel", "label": " placebo and docetaxel", "shape": "dot", "size": 10}, {"color": "green", "id": "advanced solid tumor", "label": "advanced solid tumor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitinglapatinib_neoplasms, breast", "label": "active, not recruitinglapatinib_neoplasms, breast", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "peg-interferon alpha-2a", "label": "peg-interferon alpha-2a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acute, uncomplicated human influenza", "label": "acute, uncomplicated human influenza", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completederibulin mesylate_soft tissue sarcoma", "label": "completederibulin mesylate_soft tissue sarcoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ranibizumab + laser", "label": " ranibizumab + laser", "shape": "dot", "size": 10}, {"color": "green", "id": " adult acute myeloid leukemia with del(5q)", "label": " adult acute myeloid leukemia with del(5q)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbms-790052 (daclatasvir), bms-650032 (asunaprevir)_hepatitis c", "label": "completedbms-790052 (daclatasvir), bms-650032 (asunaprevir)_hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CN(C)CCOC1=CC=C(C=C1)C(=C(\\CCCl)C1=CC=CC=C1)\\C1=CC=CC=C1", "label": " CN(C)CCOC1=CC=C(C=C1)C(=C(\\CCCl)C1=CC=CC=C1)\\C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "platinum-based chemotherapy alone (up to six cycles)", "label": "platinum-based chemotherapy alone (up to six cycles)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvildagliptin, thiazolidinedione (tzd)_diabetes mellitus, type 2", "label": "completedvildagliptin, thiazolidinedione (tzd)_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vascular disease, hypertension, angina, cardiac disease", "label": "vascular disease, hypertension, angina, cardiac disease", "shape": "dot", "size": 10}, {"color": "red", "id": "acetazolamide", "label": "acetazolamide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "schizophrenia, bipolar 1 disorder, major depressive disorder", "label": "schizophrenia, bipolar 1 disorder, major depressive disorder", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedrituximab_graft versus host disease", "label": "terminatedrituximab_graft versus host disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "leo90100 cutaneous spray, ointment, leo 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate, leo 90100 cutaneous spray, ointment, vehicle, daivobet\u00ae ointment", "label": "leo90100 cutaneous spray, ointment, leo 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate, leo 90100 cutaneous spray, ointment, vehicle, daivobet\u00ae ointment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "zidovudine (zdv), lamivudine (3tc), efavirenz (efv), ritonavir (nrv), indinavir (idv)", "label": "zidovudine (zdv), lamivudine (3tc), efavirenz (efv), ritonavir (nrv), indinavir (idv)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "canagliflozin 100 mg, canagliflozin 300 mg, placebo", "label": "canagliflozin 100 mg, canagliflozin 300 mg, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddepot leuprolide plus estrogen/progestin replacement, pioglitazone_polycystic ovary syndrome, obstructive sleep apnea", "label": "terminateddepot leuprolide plus estrogen/progestin replacement, pioglitazone_polycystic ovary syndrome, obstructive sleep apnea", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedplacebo_allergic rhinoconjunctivitis, healthy volunteers", "label": "terminatedplacebo_allergic rhinoconjunctivitis, healthy volunteers", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinhaled mannitol, inhaled placebo_cystic fibrosis", "label": "completedinhaled mannitol, inhaled placebo_cystic fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin like growth factor, type 1, placebo_amyotrophic lateral sclerosis", "label": "completedinsulin like growth factor, type 1, placebo_amyotrophic lateral sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N1C=CN=C1, [Na+].[Cl-]", "label": "N1C=CN=C1, [Na+].[Cl-]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcetuximab, cisplatin, cisplatin_breast neoplasm", "label": "completedcetuximab, cisplatin, cisplatin_breast neoplasm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2", "label": "[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2", "shape": "dot", "size": 10}, {"color": "red", "id": "guanfacine hydrochloride xr", "label": "guanfacine hydrochloride xr", "shape": "dot", "size": 10}, {"color": "red", "id": " continuation of backbone 2 nucleoside reverse transcriptase inhibitor (nrtis)", "label": " continuation of backbone 2 nucleoside reverse transcriptase inhibitor (nrtis)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlidocaine 5% medicated plaster, placebo topical plaster_pain, chronic pain, neuropathic pain, postoperative pain", "label": "terminatedlidocaine 5% medicated plaster, placebo topical plaster_pain, chronic pain, neuropathic pain, postoperative pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " localized malignant mesothelioma", "label": " localized malignant mesothelioma", "shape": "dot", "size": 10}, {"color": "green", "id": " death", "label": " death", "shape": "dot", "size": 10}, {"color": "red", "id": " gabapentin higher dose", "label": " gabapentin higher dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarboplatin, docetaxel_lung cancer", "label": "completedcarboplatin, docetaxel_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " lx4211 placebo", "label": " lx4211 placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "inx-08189, inx-08189, inx-08189, placebo matching with inx-08189, ribavirin, inx-08189, daclatasvir", "label": "inx-08189, inx-08189, inx-08189, placebo matching with inx-08189, ribavirin, inx-08189, daclatasvir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)CCC=C1C2=CC=CC=C2COC2=CC=CC=C12, CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN(C)CCC=C1C2=CC=CC=C2COC2=CC=CC=C12, CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "liraglutide, placebo, insulin", "label": "liraglutide, placebo, insulin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "red", "id": " detrusitol 2mg tablet", "label": " detrusitol 2mg tablet", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsaracatinib_adenocarcinoma of the gastroesophageal junction, adenocarcinoma of the stomach, recurrent gastric cancer, stage iii gastric cancer, stage iii esophageal cancer, stage iv esophageal cancer, stage iv gastric cancer", "label": "completedsaracatinib_adenocarcinoma of the gastroesophageal junction, adenocarcinoma of the stomach, recurrent gastric cancer, stage iii gastric cancer, stage iii esophageal cancer, stage iv esophageal cancer, stage iv gastric cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hiv infections, hepatitis b, hepatitis c", "label": "hiv infections, hepatitis b, hepatitis c", "shape": "dot", "size": 10}, {"color": "red", "id": "fe 999049", "label": "fe 999049", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "metronidazole, ceftriaxone sodium", "label": "metronidazole, ceftriaxone sodium", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtivozanib hydrochloride, paclitaxel, placebo_triple negative breast cancer", "label": "terminatedtivozanib hydrochloride, paclitaxel, placebo_triple negative breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfinasteride 5mg oral daily_non-small cell lung cancer", "label": "terminatedfinasteride 5mg oral daily_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbudesonide / formoterol, fluticasone/salmeterol_chronic obstructive pulmonary disease", "label": "completedbudesonide / formoterol, fluticasone/salmeterol_chronic obstructive pulmonary disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ace inhibition", "label": "ace inhibition", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsildenafil, placebo_portopulmonary hypertension", "label": "terminatedsildenafil, placebo_portopulmonary hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "fosbretabulin disodium", "label": "fosbretabulin disodium", "shape": "dot", "size": 10}, {"color": "green", "id": " hodgkin\u0027s lymphoma", "label": " hodgkin\u0027s lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedspironolactone, placebo_heart failure", "label": "completedspironolactone, placebo_heart failure", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedbi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, placebo_pain, healthy", "label": "terminatedbi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, bi 660848, placebo_pain, healthy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "drug/agent toxicity by tissue/organ", "label": "drug/agent toxicity by tissue/organ", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2", "label": "CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2", "shape": "dot", "size": 10}, {"color": "red", "id": " varenicline (cp-526", "label": " varenicline (cp-526", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sunitinib malate, paclitaxel, doxorubicin hydrochloride, cyclophosphamide", "label": "sunitinib malate, paclitaxel, doxorubicin hydrochloride, cyclophosphamide", "shape": "dot", "size": 10}, {"color": "green", "id": " experimental", "label": " experimental", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@H](NC(=O)C(C)(C)OC1=CC=C(C=N1)C(F)(F)F)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC=CC(=C1)C#N, CN(C)C(=N)NC(N)=N", "label": "C[C@H](NC(=O)C(C)(C)OC1=CC=C(C=N1)C(F)(F)F)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC=CC(=C1)C#N, CN(C)C(=N)NC(N)=N", "shape": "dot", "size": 10}, {"color": "red", "id": "cerc-301", "label": "cerc-301", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmetformin_metastatic prostate cancer", "label": "completedmetformin_metastatic prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "budesonide/formoterol easyhaler 320/9 ug/inhalation 4 inh, budesonide/formoterol easyhaler 320/9 ug/inhalation 1 inh, symbicort turbuhaler 320/9 ug/inhalation 4 inh, symbicort turbuhaler 320/9 ug/inhalation 1inh, placebo symbicort turbuhaler 320/9 ug/inhalation 4 inh, placebo budesonide/formoterol easyhaler 320/9 ug/inhalation 4 inh, placebo budesonide/formoterol easyhaler 320/9 ug/inhalation 1 inh, placebo symbicort turbuhaler 320/9 ug/inhalation 1 inh", "label": "budesonide/formoterol easyhaler 320/9 ug/inhalation 4 inh, budesonide/formoterol easyhaler 320/9 ug/inhalation 1 inh, symbicort turbuhaler 320/9 ug/inhalation 4 inh, symbicort turbuhaler 320/9 ug/inhalation 1inh, placebo symbicort turbuhaler 320/9 ug/inhalation 4 inh, placebo budesonide/formoterol easyhaler 320/9 ug/inhalation 4 inh, placebo budesonide/formoterol easyhaler 320/9 ug/inhalation 1 inh, placebo symbicort turbuhaler 320/9 ug/inhalation 1 inh", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarboplatin, gm-csf (sargramostim), interferon gamma_ovarian cancer, fallopian tube cancer, peritoneal cancer", "label": "completedcarboplatin, gm-csf (sargramostim), interferon gamma_ovarian cancer, fallopian tube cancer, peritoneal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcep-18770_multiple myeloma", "label": "terminatedcep-18770_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iii mantle cell lymphoma", "label": " stage iii mantle cell lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsar113945, placebo_knee osteoarthritis", "label": "completedsar113945, placebo_knee osteoarthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " ureteral neoplasms", "label": " ureteral neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlevetiracetam, topiramate_epilepsy", "label": "completedlevetiracetam, topiramate_epilepsy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": " glucose", "label": " glucose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnrituximab, urelumab_leukemia", "label": "withdrawnrituximab, urelumab_leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " kidney", "label": " kidney", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsgm-1019, placebo_nonalcoholic steatohepatitis", "label": "terminatedsgm-1019, placebo_nonalcoholic steatohepatitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedliothyronine sodium_prostate cancer", "label": "terminatedliothyronine sodium_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "bl-1020", "label": "bl-1020", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gemcitabine, capecitabine and bevacizumab", "label": "gemcitabine, capecitabine and bevacizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, placebo, placebo, placebo, placebo, placebo, liraglutide, liraglutide", "label": "semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, placebo, placebo, placebo, placebo, placebo, liraglutide, liraglutide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "green", "id": "advanced metastatic breast cancer", "label": "advanced metastatic breast cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtiotropium inhalation solution_pulmonary disease, chronic obstructive", "label": "completedtiotropium inhalation solution_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "lactin-v", "label": "lactin-v", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlidocaine_pain, unspecified adult solid tumor, protocol specific", "label": "completedlidocaine_pain, unspecified adult solid tumor, protocol specific", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ropinirole ir 1 mg placebo", "label": " ropinirole ir 1 mg placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedliposomal cytarabine_primary disease", "label": "completedliposomal cytarabine_primary disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine, docetaxel, capecitabine_breast cancer, breast neoplasms, cancer of the breast", "label": "completedgemcitabine, docetaxel, capecitabine_breast cancer, breast neoplasms, cancer of the breast", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pentostatin, alemtuzumab", "label": "pentostatin, alemtuzumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "finerenone (bay94-8862), placebo, inspra (eplerenone)", "label": "finerenone (bay94-8862), placebo, inspra (eplerenone)", "shape": "dot", "size": 10}, {"color": "red", "id": "dapagliflozin 10 mg", "label": "dapagliflozin 10 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddabigatran etexilate mesylate, odalasvir (odv), simeprevir (smv)_healthy", "label": "completeddabigatran etexilate mesylate, odalasvir (odv), simeprevir (smv)_healthy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " sandimmun optoral", "label": " sandimmun optoral", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrx-0201 plus gemcitabine_metastatic pancreatic cancer", "label": "completedrx-0201 plus gemcitabine_metastatic pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]1([C@@H](NC(C)=O)C(CC)CC)[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O", "label": " [H][C@@]1([C@@H](NC(C)=O)C(CC)CC)[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedduloxetine_major depressive disorder", "label": "completedduloxetine_major depressive disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedroxadustat, placebo_anemia", "label": "completedroxadustat, placebo_anemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "bi 10773", "label": "bi 10773", "shape": "dot", "size": 10}, {"color": "red", "id": " bi 10773 placebo", "label": " bi 10773 placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "xolair", "label": "xolair", "shape": "dot", "size": 10}, {"color": "red", "id": " boosted protease inhibitor (bpi)", "label": " boosted protease inhibitor (bpi)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3", "label": "COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pimasertib, dacarbazine", "label": "pimasertib, dacarbazine", "shape": "dot", "size": 10}, {"color": "green", "id": " bone resorption", "label": " bone resorption", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingpantoprazole_prostate cancer", "label": "active, not recruitingpantoprazole_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtiotropium 2.5 \u00b5g b.i.d, placebo, tiotropium 5 \u00b5g q.d._asthma", "label": "completedtiotropium 2.5 \u00b5g b.i.d, placebo, tiotropium 5 \u00b5g q.d._asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " imo-8400 regimen 3", "label": " imo-8400 regimen 3", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lidocaine, saline", "label": "lidocaine, saline", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcangrelor, prasugrel_coronary artery disease", "label": "completedcangrelor, prasugrel_coronary artery disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpaclitaxel, carboplatin_squamous cell carcinoma", "label": "completedpaclitaxel, carboplatin_squamous cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " cyclophosphamide as part of lymphodepletion", "label": " cyclophosphamide as part of lymphodepletion", "shape": "dot", "size": 10}, {"color": "red", "id": " and capecitabine", "label": " and capecitabine", "shape": "dot", "size": 10}, {"color": "red", "id": " cvt-301", "label": " cvt-301", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "erlotinib, sunitinib, erlotinib, placebo", "label": "erlotinib, sunitinib, erlotinib, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "label": "CNC(=O)C1=C(SC2=CC=C3C(NN=C3\\C=C\\C3=CC=CC=N3)=C2)C=CC=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " methotrexate (arm with bortezomib)", "label": " methotrexate (arm with bortezomib)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "malignant ascites, gastrointestinal cancers", "label": "malignant ascites, gastrointestinal cancers", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo for glimepiride", "label": " placebo for glimepiride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingfolfiri.3, nab-paclitaxel+ gemcitabine_metastatic pancreatic cancer", "label": "active, not recruitingfolfiri.3, nab-paclitaxel+ gemcitabine_metastatic pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "green", "id": " localized", "label": " localized", "shape": "dot", "size": 10}, {"color": "red", "id": "grazoprevir/elbasvir 100mg/50mg", "label": "grazoprevir/elbasvir 100mg/50mg", "shape": "dot", "size": 10}, {"color": "green", "id": " alcoholism", "label": " alcoholism", "shape": "dot", "size": 10}, {"color": "red", "id": " ar-13324 ophthalmic solution 0.02%", "label": " ar-13324 ophthalmic solution 0.02%", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvildagliptin, \"usual care\"_type 2 diabetes mellitus, elderly", "label": "completedvildagliptin, \"usual care\"_type 2 diabetes mellitus, elderly", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " carbidopa", "label": " carbidopa", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2", "label": "CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2", "shape": "dot", "size": 10}, {"color": "red", "id": "cg5503 ir; tapentadol", "label": "cg5503 ir; tapentadol", "shape": "dot", "size": 10}, {"color": "red", "id": "azd1419", "label": "azd1419", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "renal cell carcinoma, nonclear cell, temsirolimus resistance", "label": "renal cell carcinoma, nonclear cell, temsirolimus resistance", "shape": "dot", "size": 10}, {"color": "green", "id": " dyslipidemias", "label": " dyslipidemias", "shape": "dot", "size": 10}, {"color": "red", "id": " aflibercept (ziv-aflibercept", "label": " aflibercept (ziv-aflibercept", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azd2624, olanzapine, placebo", "label": "azd2624, olanzapine, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpegylated liposomal doxorubicin hydrochloride_lymphoma", "label": "completedpegylated liposomal doxorubicin hydrochloride_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " testim 1%", "label": " testim 1%", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, doxorubicin hydrochloride, fludarabine phosphate, paclitaxel, mesna", "label": "cyclophosphamide, doxorubicin hydrochloride, fludarabine phosphate, paclitaxel, mesna", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O", "label": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O", "label": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbevacizumab, doxorubicin, cyclophosphamide, capecitabine, docetaxel_breast cancer", "label": "completedbevacizumab, doxorubicin, cyclophosphamide, capecitabine, docetaxel_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " refractory visual pathway glioma", "label": " refractory visual pathway glioma", "shape": "dot", "size": 10}, {"color": "red", "id": " ceftriaxone sodium", "label": " ceftriaxone sodium", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dimiracetam, sugar pill", "label": "dimiracetam, sugar pill", "shape": "dot", "size": 10}, {"color": "red", "id": " darunavir", "label": " darunavir", "shape": "dot", "size": 10}, {"color": "green", "id": " unresectable renal pelvis urothelial carcinoma", "label": " unresectable renal pelvis urothelial carcinoma", "shape": "dot", "size": 10}, {"color": "red", "id": "octreotide lar", "label": "octreotide lar", "shape": "dot", "size": 10}, {"color": "blue", "id": " FC(F)(F)OC1=CC=C(C=C1)C1=CC=C2OCCN(CC3=NC=CC=N3)C(=O)C2=C1", "label": " FC(F)(F)OC1=CC=C(C=C1)C1=CC=C2OCCN(CC3=NC=CC=N3)C(=O)C2=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " vrc-srsdna015-00-vp", "label": " vrc-srsdna015-00-vp", "shape": "dot", "size": 10}, {"color": "red", "id": "syb d-0701", "label": "syb d-0701", "shape": "dot", "size": 10}, {"color": "red", "id": "ad-4833 15 mg", "label": "ad-4833 15 mg", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1", "label": "CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]12C[C@@]1([H])OC(O)=N[C@]([H])(C(=O)N1C[C@@]([H])(C[C@@]1([H])C(O)=N[C@@]1(C[C@@]1([H])C=C)C(O)=NS(=O)(=O)C1CC1)OC1=C(CCCCC2)N=C2C=CC(OC)=CC2=N1)C(C)(C)C", "label": " [H][C@@]12C[C@@]1([H])OC(O)=N[C@]([H])(C(=O)N1C[C@@]([H])(C[C@@]1([H])C(O)=N[C@@]1(C[C@@]1([H])C=C)C(O)=NS(=O)(=O)C1CC1)OC1=C(CCCCC2)N=C2C=CC(OC)=CC2=N1)C(C)(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bi10773, placebo, placebo, placebo, bi10773", "label": "bi10773, placebo, placebo, placebo, bi10773", "shape": "dot", "size": 10}, {"color": "red", "id": "mk0683", "label": "mk0683", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, gwp42003_schizophrenia, schizophrenia-related psychotic disorder", "label": "completedplacebo, gwp42003_schizophrenia, schizophrenia-related psychotic disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ranibizumab 0.5 mg", "label": "ranibizumab 0.5 mg", "shape": "dot", "size": 10}, {"color": "red", "id": "smc021 oral calcitonin", "label": "smc021 oral calcitonin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, doxorubicin", "label": "cyclophosphamide, doxorubicin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(C=N3)N3CCNCC3)N=C2N1C1CCCC1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H], CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(C=N3)N3CCNCC3)N=C2N1C1CCCC1", "label": "CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(C=N3)N3CCNCC3)N=C2N1C1CCCC1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H], CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(C=N3)N3CCNCC3)N=C2N1C1CCCC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusdocetaxel and epirubicin, docetaxel and epirubicin plus endostatin_breast cancer", "label": "unknown statusdocetaxel and epirubicin, docetaxel and epirubicin plus endostatin_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage 2 hypertension", "label": " stage 2 hypertension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrabeprazole 20mg, placebo dinner and bedtime, rabeprazole 20 mg two times, placebo at bedtime, rabeprazole 20mg,placebo dinner ,low dose tricyclic antidepressant_gastroesophageal reflux disease", "label": "completedrabeprazole 20mg, placebo dinner and bedtime, rabeprazole 20 mg two times, placebo at bedtime, rabeprazole 20mg,placebo dinner ,low dose tricyclic antidepressant_gastroesophageal reflux disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O", "label": "CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedquetiapine fumarate, ssri/clomipramine_obsessive compulsive disorder", "label": "completedquetiapine fumarate, ssri/clomipramine_obsessive compulsive disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bone cancer, metastasis", "label": "bone cancer, metastasis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC, CC1=CC(O)=CC(C)=C1Cl", "label": "O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1", "label": " CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpiribedil, pramipexole or ropinirole_idiopathic parkinson\u0027s disease", "label": "completedpiribedil, pramipexole or ropinirole_idiopathic parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C", "label": "OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C", "shape": "dot", "size": 10}, {"color": "red", "id": "alirocumab", "label": "alirocumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl", "label": "O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H]N=C(N([H])[H])N([H])CCC[C@H](N([H])C(=O)[C@H](CCCN([H])C(=N[H])N([H])[H])N([H])C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@H](CCCN([H])C(=N[H])N([H])[H])N([H])C(=O)[C@H](CC(C)C)N([H])C(=O)[C@@H](N([H])[H])[C@@H](C)CC)C(=O)N([H])[C@@H](CCCCN([H])[H])C(=O)N([H])[H], CC1=CC(O)=CC(C)=C1Cl", "label": "[H]N=C(N([H])[H])N([H])CCC[C@H](N([H])C(=O)[C@H](CCCN([H])C(=N[H])N([H])[H])N([H])C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@H](CCCN([H])C(=N[H])N([H])[H])N([H])C(=O)[C@H](CC(C)C)N([H])C(=O)[C@@H](N([H])[H])[C@@H](C)CC)C(=O)N([H])[C@@H](CCCCN([H])[H])C(=O)N([H])[H], CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedarmodafinil, placebo_sleep disorders, obstructive sleep apnea, major depressive disorder, dysthymic disorder", "label": "completedarmodafinil, placebo_sleep disorders, obstructive sleep apnea, major depressive disorder, dysthymic disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo-matched-to-ivacaftor tablet", "label": " placebo-matched-to-ivacaftor tablet", "shape": "dot", "size": 10}, {"color": "green", "id": " undifferentiated ovarian carcinoma", "label": " undifferentiated ovarian carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedthalidomide, placebo_multiple myeloma", "label": "completedthalidomide, placebo_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "locally advanced breast cancer, metastatic breast cancer", "label": "locally advanced breast cancer, metastatic breast cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddalfampridine-er 5mg, dalfampridine-er 10mg_multiple sclerosis", "label": "completeddalfampridine-er 5mg, dalfampridine-er 10mg_multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "label": " C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "ofatumumab 500mg", "label": "ofatumumab 500mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitinglapatinib, docetaxel, trastuzumab, docetaxel, trastuzumab_neoplasms, breast", "label": "active, not recruitinglapatinib, docetaxel, trastuzumab, docetaxel, trastuzumab_neoplasms, breast", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " nasal polyposis", "label": " nasal polyposis", "shape": "dot", "size": 10}, {"color": "red", "id": " bay43-9006) plus doxorubicin", "label": " bay43-9006) plus doxorubicin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddetemir + aspart insulin before meals, nph insulin + regular insulin_type 2 diabetes", "label": "completeddetemir + aspart insulin before meals, nph insulin + regular insulin_type 2 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " salmeterol 50mcg", "label": " salmeterol 50mcg", "shape": "dot", "size": 10}, {"color": "red", "id": "taxotere (docetaxel)", "label": "taxotere (docetaxel)", "shape": "dot", "size": 10}, {"color": "red", "id": " salmeterol 50 \u03bcg", "label": " salmeterol 50 \u03bcg", "shape": "dot", "size": 10}, {"color": "red", "id": " abc/3tc placebo", "label": " abc/3tc placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " metastatic carcinoid tumor", "label": " metastatic carcinoid tumor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfulvestrant_prostate cancer", "label": "completedfulvestrant_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " arm 2 boosted protease inhibitors and maraviroc", "label": " arm 2 boosted protease inhibitors and maraviroc", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcombination of temsirolimus and sunitinib_renal cell carcinoma", "label": "terminatedcombination of temsirolimus and sunitinib_renal cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "heavy uterine bleeding", "label": "heavy uterine bleeding", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedspd489 (lisdexamfetamine dimesylate ), placebo_major depressive disorder", "label": "completedspd489 (lisdexamfetamine dimesylate ), placebo_major depressive disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[C@H]1C[C@H](O)[C@H](O)CO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][C@@]1(C[C@@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[C@H]1C[C@H](O)[C@H](O)CO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnliposomal bupivicaine_pain", "label": "withdrawnliposomal bupivicaine_pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvx-659/tez/iva, iva, placebo_cystic fibrosis", "label": "completedvx-659/tez/iva, iva, placebo_cystic fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawniressa (gefitinib)_head and neck cancer, carcinoma, squamous cell", "label": "withdrawniressa (gefitinib)_head and neck cancer, carcinoma, squamous cell", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "apathy, alzheimer\u0027s disease", "label": "apathy, alzheimer\u0027s disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completed5 mg serlopitant tablets, matching placebo tablets_refractory chronic cough", "label": "completed5 mg serlopitant tablets, matching placebo tablets_refractory chronic cough", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " orthopedic surgery", "label": " orthopedic surgery", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtanezumab 10 mg iv, iv placebo for tanezumab_neoplasm metastasis, palliative care", "label": "completedtanezumab 10 mg iv, iv placebo for tanezumab_neoplasm metastasis, palliative care", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " fostamatinib disodium (r935788)", "label": " fostamatinib disodium (r935788)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine hydrochloride, triapine_lung cancer", "label": "completedgemcitabine hydrochloride, triapine_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sotrastaurin (dose 1) + tacrolimus + standard of care medications, sotrastaurin (dose 2) + tacrolimus + standard of care medications, sotrastaurin (dose 3) + tacrolimus + standard of care medications, mycophenolic acid + tacrolimus + standard of care medications", "label": "sotrastaurin (dose 1) + tacrolimus + standard of care medications, sotrastaurin (dose 2) + tacrolimus + standard of care medications, sotrastaurin (dose 3) + tacrolimus + standard of care medications, mycophenolic acid + tacrolimus + standard of care medications", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hypertension, cardiovascular risk factors", "label": "hypertension, cardiovascular risk factors", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedstandard dose (once daily) ppi plus low-dose antidepressant, double dose ppi plus evening placebo, rabeprazole , placebo, placebo_gastroesophageal reflux disease", "label": "completedstandard dose (once daily) ppi plus low-dose antidepressant, double dose ppi plus evening placebo, rabeprazole , placebo, placebo_gastroesophageal reflux disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "tiotropium bromide", "label": "tiotropium bromide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcarboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat_breast cancer", "label": "active, not recruitingcarboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC(=O)C1=CC(=C(I)C=C1)[N+]([O-])=O", "label": "NC(=O)C1=CC(=C(I)C=C1)[N+]([O-])=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completederlotinib, gemcitabine_pancreatic cancer", "label": "completederlotinib, gemcitabine_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " 7.5 mg", "label": " 7.5 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "type 2 diabetes, coronary artery disease", "label": "type 2 diabetes, coronary artery disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtanespimycin, bortezomib_adult grade iii lymphomatoid granulomatosis, aids-related peripheral/systemic lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone b-cell lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, stage iii adult burkitt lymphoma, stage iii adult diffuse large cell lymphoma, stage iii adult diffuse mixed cell lymphoma, stage iii adult diffuse small cleaved cell lymphoma, stage iii adult hodgkin lymphoma, stage iii adult immunoblastic large cell lymphoma, stage iii adult lymphoblastic lymphoma, stage iii adult t-cell leukemia/lymphoma, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iii marginal zone lymphoma, stage iii mycosis fungoides/sezary syndrome, stage iii small lymphocytic lymphoma, stage iv adult burkitt lymphoma, stage iv adult diffuse large cell lymphoma, stage iv adult diffuse mixed cell lymphoma, stage iv adult diffuse small cleaved cell lymphoma, stage iv adult hodgkin lymphoma, stage iv adult immunoblastic large cell lymphoma, stage iv adult lymphoblastic lymphoma, stage iv adult t-cell leukemia/lymphoma, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma, stage iv marginal zone lymphoma, stage iv mycosis fungoides/sezary syndrome, stage iv small lymphocytic lymphoma, unspecified adult solid tumor, protocol specific, waldenstr\u00f6m macroglobulinemia", "label": "terminatedtanespimycin, bortezomib_adult grade iii lymphomatoid granulomatosis, aids-related peripheral/systemic lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone b-cell lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, stage iii adult burkitt lymphoma, stage iii adult diffuse large cell lymphoma, stage iii adult diffuse mixed cell lymphoma, stage iii adult diffuse small cleaved cell lymphoma, stage iii adult hodgkin lymphoma, stage iii adult immunoblastic large cell lymphoma, stage iii adult lymphoblastic lymphoma, stage iii adult t-cell leukemia/lymphoma, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iii marginal zone lymphoma, stage iii mycosis fungoides/sezary syndrome, stage iii small lymphocytic lymphoma, stage iv adult burkitt lymphoma, stage iv adult diffuse large cell lymphoma, stage iv adult diffuse mixed cell lymphoma, stage iv adult diffuse small cleaved cell lymphoma, stage iv adult hodgkin lymphoma, stage iv adult immunoblastic large cell lymphoma, stage iv adult lymphoblastic lymphoma, stage iv adult t-cell leukemia/lymphoma, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma, stage iv marginal zone lymphoma, stage iv mycosis fungoides/sezary syndrome, stage iv small lymphocytic lymphoma, unspecified adult solid tumor, protocol specific, waldenstr\u00f6m macroglobulinemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " O=C1NC=CC(=O)N1.FC1=CN(C2CCCO2)C(=O)NC1=O", "label": " O=C1NC=CC(=O)N1.FC1=CN(C2CCCO2)C(=O)NC1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "transdermal nicotine patch", "label": "transdermal nicotine patch", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedly3154207, placebo, modafinil_healthy", "label": "completedly3154207, placebo, modafinil_healthy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, [H][C@@](N)(CC1=CC=CC=C1)[C@]([H])(O)C(O)=N[C@@]([H])(CC(C)C)C(O)=O", "label": "O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, [H][C@@](N)(CC1=CC=CC=C1)[C@]([H])(O)C(O)=N[C@@]([H])(CC(C)C)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddocetaxel and capecitabine_metastatic breast cancer", "label": "terminateddocetaxel and capecitabine_metastatic breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone furoate (ff) (100 mcg), vilanterol (vi) (25 mcg), placebo", "label": "fluticasone furoate (ff) (100 mcg), vilanterol (vi) (25 mcg), placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " follicular", "label": " follicular", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "risperidone, placebo, ly2140023", "label": "risperidone, placebo, ly2140023", "shape": "dot", "size": 10}, {"color": "green", "id": " anxiety states", "label": " anxiety states", "shape": "dot", "size": 10}, {"color": "red", "id": "ser-262", "label": "ser-262", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "esophageal, gastrooesophageal cancer, gastric cancer", "label": "esophageal, gastrooesophageal cancer, gastric cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alzheimer\u0027s disease, insomnia", "label": "alzheimer\u0027s disease, insomnia", "shape": "dot", "size": 10}, {"color": "red", "id": " ftc alone", "label": " ftc alone", "shape": "dot", "size": 10}, {"color": "red", "id": " low", "label": " low", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddasatinib_adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, recurrent adult brain neoplasm", "label": "completeddasatinib_adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, recurrent adult brain neoplasm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "panitumumab, doxycycline/placebo, panitumumab", "label": "panitumumab, doxycycline/placebo, panitumumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedranibizumab (lucentis), 0.5mg ranibizumab_age-related macular degeneration", "label": "terminatedranibizumab (lucentis), 0.5mg ranibizumab_age-related macular degeneration", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "volanesorsen", "label": "volanesorsen", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tez/iva, iva, placebo, placebo", "label": "tez/iva, iva, placebo, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1", "label": "CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddupilumab, placebo_atopic dermatitis (ad)", "label": "terminateddupilumab, placebo_atopic dermatitis (ad)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "community acquired pneumonia, severe", "label": "community acquired pneumonia, severe", "shape": "dot", "size": 10}, {"color": "red", "id": " tvp-1012 0.5mg", "label": " tvp-1012 0.5mg", "shape": "dot", "size": 10}, {"color": "red", "id": " oxaliplatin and 5fu combination", "label": " oxaliplatin and 5fu combination", "shape": "dot", "size": 10}, {"color": "blue", "id": " OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1", "label": " OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "mk0639", "label": "mk0639", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedatorvastatin_cardiovascular diseases", "label": "terminatedatorvastatin_cardiovascular diseases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "levosert-20, mirena", "label": "levosert-20, mirena", "shape": "dot", "size": 10}, {"color": "green", "id": " low-grade salivary gland carcinoma", "label": " low-grade salivary gland carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedribavirin, hiv antiretroviral therapy, hiv antiretroviral therapy_hiv infections, hepatitis c, chronic", "label": "completedribavirin, hiv antiretroviral therapy, hiv antiretroviral therapy_hiv infections, hepatitis c, chronic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azd1386, naproxen, placebo", "label": "azd1386, naproxen, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "nvc-422", "label": "nvc-422", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrituximab, anti-inflammatory drugs_rheumatoid arthritis", "label": "completedrituximab, anti-inflammatory drugs_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "udca", "label": "udca", "shape": "dot", "size": 10}, {"color": "red", "id": "combination product (sumatriptan succinate / naproxen sodium)", "label": "combination product (sumatriptan succinate / naproxen sodium)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ranibizumab 0.3 mg, aflibercept 2.0 mg", "label": "ranibizumab 0.3 mg, aflibercept 2.0 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtolterodine er, placebo_overactive bladder", "label": "terminatedtolterodine er, placebo_overactive bladder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, [H]\\C(=C(\\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC, [H][C@@]1(CC[C@@]([H])(CC1)N1CCN(CC2CC2)CC1)N=C(O)C1=CC(OC)=C(NC2=NC=C3N(C)C(=O)[C@@]([H])(CC)N(C(C)C)C3=N2)C=C1", "label": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, [H]\\C(=C(\\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC, [H][C@@]1(CC[C@@]([H])(CC1)N1CCN(CC2CC2)CC1)N=C(O)C1=CC(OC)=C(NC2=NC=C3N(C)C(=O)[C@@]([H])(CC)N(C(C)C)C3=N2)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)C(=N)NC(N)=N, [Na+].[Na+].[O-]P([O-])(F)=O", "label": "CN(C)C(=N)NC(N)=N, [Na+].[Na+].[O-]P([O-])(F)=O", "shape": "dot", "size": 10}, {"color": "green", "id": "exocrine pancreatic insufficiency", "label": "exocrine pancreatic insufficiency", "shape": "dot", "size": 10}, {"color": "red", "id": "aducanumab (recombinant", "label": "aducanumab (recombinant", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpafuramidine maleate (db289), trimethoprim-sulfamethoxazole (tmp-smx)_pneumonia, interstitial plasma cell, pneumocystis carinii pneumonia, pneumonia, pneumocystis carinii, hiv infections", "label": "terminatedpafuramidine maleate (db289), trimethoprim-sulfamethoxazole (tmp-smx)_pneumonia, interstitial plasma cell, pneumocystis carinii pneumonia, pneumonia, pneumocystis carinii, hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " itopride hci 100 mg", "label": " itopride hci 100 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpf-04958242, ketamine, placebo, ketamine_schizophrenia", "label": "completedpf-04958242, ketamine, placebo, ketamine_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "amg 386, amg 386, paclitaxel, amg 386 placebo", "label": "amg 386, amg 386, paclitaxel, amg 386 placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedatezolizumab_hodgkin lymphoma", "label": "terminatedatezolizumab_hodgkin lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedarbaclofen, baclofen, placebo_spasticity, multiple sclerosis", "label": "completedarbaclofen, baclofen, placebo_spasticity, multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "mp-424 (telaprevir)", "label": "mp-424 (telaprevir)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azd3355, azd3355, azd3355, azd3355, placebo", "label": "azd3355, azd3355, azd3355, azd3355, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedverteporfin, verteporfin, ranibizumab, dexamethasone_choroidal neovascularization, macular degeneration", "label": "completedverteporfin, verteporfin, ranibizumab, dexamethasone_choroidal neovascularization, macular degeneration", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedixempra (ixabepilone (bms-247550) )_cervical carcinoma, cervical adenocarcinoma, cervical adenosquamous carcinoma, cervical carcinoma, non-squamoustype", "label": "terminatedixempra (ixabepilone (bms-247550) )_cervical carcinoma, cervical adenocarcinoma, cervical adenosquamous carcinoma, cervical carcinoma, non-squamoustype", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbevacizumab, sb8, carboplatin, paclitaxel_lung cancer, non-small cell lung cancer", "label": "completedbevacizumab, sb8, carboplatin, paclitaxel_lung cancer, non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "polyethylene glycol 3350, movantik", "label": "polyethylene glycol 3350, movantik", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]1(CCC(C)=C[C@H]1C1=C(O)C=C(CCC)C=C1O)C(C)=C, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1", "label": "[H][C@]1(CCC(C)=C[C@H]1C1=C(O)C=C(CCC)C=C1O)C(C)=C, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "lisofylline", "label": "lisofylline", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazd9056, etanercept, placebo_rheumatoid arthritis", "label": "completedazd9056, etanercept, placebo_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlt-02, lt-02 placebo_ulcerative colitis", "label": "terminatedlt-02, lt-02 placebo_ulcerative colitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " childhood grade ii meningioma", "label": " childhood grade ii meningioma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtorcetrapib/atorvastatin, atorvastatin_hypercholesterolemia, familial, hyperlipidemia", "label": "completedtorcetrapib/atorvastatin, atorvastatin_hypercholesterolemia, familial, hyperlipidemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " folfox plus bevacizumab", "label": " folfox plus bevacizumab", "shape": "dot", "size": 10}, {"color": "green", "id": " hormone receptor positive tumor", "label": " hormone receptor positive tumor", "shape": "dot", "size": 10}, {"color": "green", "id": " adult acute monocytic leukemia (m5b)", "label": " adult acute monocytic leukemia (m5b)", "shape": "dot", "size": 10}, {"color": "green", "id": " unresectable extrahepatic bile duct carcinoma", "label": " unresectable extrahepatic bile duct carcinoma", "shape": "dot", "size": 10}, {"color": "red", "id": " atacicept", "label": " atacicept", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hepatitis b, chronic, hepatitis c, chronic", "label": "hepatitis b, chronic, hepatitis c, chronic", "shape": "dot", "size": 10}, {"color": "blue", "id": " CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1", "label": " CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtransdermal nicotine patch, lis-dexamphetamine (vyvanse), placebo_attention deficit hyperactivity disorder, nicotine dependence", "label": "completedtransdermal nicotine patch, lis-dexamphetamine (vyvanse), placebo_attention deficit hyperactivity disorder, nicotine dependence", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O[C@H](C[C@H](O)\\C=C\\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O, CC1=CC(O)=CC(C)=C1Cl", "label": "O[C@H](C[C@H](O)\\C=C\\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "red", "id": " msdc-0602 250 mg", "label": " msdc-0602 250 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " aprocitentan 25 mg", "label": " aprocitentan 25 mg", "shape": "dot", "size": 10}, {"color": "green", "id": "prolymphocytic leukemia", "label": "prolymphocytic leukemia", "shape": "dot", "size": 10}, {"color": "red", "id": "otamixaban (xrp0673)", "label": "otamixaban (xrp0673)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "FC1=CNC(=O)NC1=O, [H][C@](CNC(C)C)(C(=O)N1CCN(CC1)C1=NC=NC2=C1[C@]([H])(C)C[C@@]2([H])O)C1=CC=C(Cl)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "FC1=CNC(=O)NC1=O, [H][C@](CNC(C)C)(C(=O)N1CCN(CC1)C1=NC=NC2=C1[C@]([H])(C)C[C@@]2([H])O)C1=CC=C(Cl)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pioglitazone 15 mg, pioglitazone 45 mg, pioglitazone 30 mg, linagliptin 5mg / pioglitazone 45 mg fdc, linagliptin 5mg / pioglitazone 30 mg fdc, linagliptin 5mg, linagliptin 5mg / pioglitazone 15 mg fdc", "label": "pioglitazone 15 mg, pioglitazone 45 mg, pioglitazone 30 mg, linagliptin 5mg / pioglitazone 45 mg fdc, linagliptin 5mg / pioglitazone 30 mg fdc, linagliptin 5mg, linagliptin 5mg / pioglitazone 15 mg fdc", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, ustekinumab 45 mg, ustekinumab 90 mg_arthritis, psoriatic", "label": "completedplacebo, ustekinumab 45 mg, ustekinumab 90 mg_arthritis, psoriatic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acute and chronic inflammation, dyspepsia", "label": "acute and chronic inflammation, dyspepsia", "shape": "dot", "size": 10}, {"color": "red", "id": " msb0010841", "label": " msb0010841", "shape": "dot", "size": 10}, {"color": "green", "id": "phenylketonuria", "label": "phenylketonuria", "shape": "dot", "size": 10}, {"color": "red", "id": " bi 201335 (faldaprevir)", "label": " bi 201335 (faldaprevir)", "shape": "dot", "size": 10}, {"color": "red", "id": " azelastine hydrochloride 0.15% and placebo", "label": " azelastine hydrochloride 0.15% and placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " jnj-38518168 (3 mg)", "label": " jnj-38518168 (3 mg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedzanidip, felodipine sustained-release tablet_hypertension", "label": "completedzanidip, felodipine sustained-release tablet_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gsk2118436, dacarbazine (dtic)", "label": "gsk2118436, dacarbazine (dtic)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statustarceva (erlotinib)_non-small cell lung cancer", "label": "unknown statustarceva (erlotinib)_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "menatetranone", "label": "menatetranone", "shape": "dot", "size": 10}, {"color": "blue", "id": "OC(=O)CC(O)(CC(O)=O)C(O)=O", "label": "OC(=O)CC(O)(CC(O)=O)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "capecitabine, oxaliplatin, bevacizumab", "label": "capecitabine, oxaliplatin, bevacizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1, [H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1, [H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtd-9855 group 1, td-9855 group 2, placebo_fibromyalgia", "label": "completedtd-9855 group 1, td-9855 group 2, placebo_fibromyalgia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " nva237 25.0 \u00b5g once daily", "label": " nva237 25.0 \u00b5g once daily", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\\C(C)=C\\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\\C(C)=C\\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtmc435, placebo, peginterferon (pegifn\u03b1-2a), ribavirin_hepatitis c, chronic", "label": "completedtmc435, placebo, peginterferon (pegifn\u03b1-2a), ribavirin_hepatitis c, chronic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "indacaterol 300\u03bcg", "label": "indacaterol 300\u03bcg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(=O)OC1=CC=CC=C1C(O)=O, CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC(=O)OC1=CC=CC=C1C(O)=O, CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)C(=N)NC(N)=N, CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1, CN(C)C(=N)NC(N)=N", "label": "CN(C)C(=N)NC(N)=N, CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1, CN(C)C(=N)NC(N)=N", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo- sinemet", "label": " placebo- sinemet", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedenzastaurin hcl_colonic neoplasms", "label": "completedenzastaurin hcl_colonic neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine, docetaxel, doxorubicin_leiomyosarcoma, uterine neoplasm", "label": "completedgemcitabine, docetaxel, doxorubicin_leiomyosarcoma, uterine neoplasm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaripiprazole_autistic disorder, behavioral symptoms", "label": "completedaripiprazole_autistic disorder, behavioral symptoms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnaspirin (acetylsalicylic acid), placebo_episodic migraine, chronic migraine", "label": "withdrawnaspirin (acetylsalicylic acid), placebo_episodic migraine, chronic migraine", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "leukemia, pediatric cancer", "label": "leukemia, pediatric cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "qax576 placebo", "label": "qax576 placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "oxybutynin chloride", "label": "oxybutynin chloride", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(C)CNC(=O)[C@H]1C[C@](F)(C1)C1=CC(F)=C(CN2CCCC2)C=C1", "label": "CC(C)CNC(=O)[C@H]1C[C@](F)(C1)C1=CC(F)=C(CN2CCCC2)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "clear cell renal cell carcinoma, recurrent renal cell cancer, stage iii renal cell cancer, stage iv renal cell cancer", "label": "clear cell renal cell carcinoma, recurrent renal cell cancer, stage iii renal cell cancer, stage iv renal cell cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " verubecestat 40 mg (parts 1 and 2)", "label": " verubecestat 40 mg (parts 1 and 2)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, ClCCN(CCCl)P1(=O)NCCCO1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [O-][N+]1=C(S)C=CC=C1, N[C@@H](CC(O)=O)C(O)=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, S=C1N=CNC2=C1NC=N2, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "label": "ClCCN(CCCl)P1(=O)NCCCO1, ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, ClCCN(CCCl)P1(=O)NCCCO1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [O-][N+]1=C(S)C=CC=C1, N[C@@H](CC(O)=O)C(O)=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, S=C1N=CNC2=C1NC=N2, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusypl-001 low dose, ypl-001 high dose, placebo_chronic obstructive pulmonary disease", "label": "unknown statusypl-001 low dose, ypl-001 high dose, placebo_chronic obstructive pulmonary disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "dtg + 3tc", "label": "dtg + 3tc", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddoripenem_urinary tract infections, pyelonephritis", "label": "completeddoripenem_urinary tract infections, pyelonephritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adalimumab (up to 9 months exposure), methotrexate", "label": "adalimumab (up to 9 months exposure), methotrexate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1", "label": "[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iva squamous cell carcinoma of the paranasal sinus and nasal cavity", "label": " stage iva squamous cell carcinoma of the paranasal sinus and nasal cavity", "shape": "dot", "size": 10}, {"color": "red", "id": " insulin glargine- new formulation (hoe901)", "label": " insulin glargine- new formulation (hoe901)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "urinary bladder, overactive, parkinson disease", "label": "urinary bladder, overactive, parkinson disease", "shape": "dot", "size": 10}, {"color": "red", "id": " bepotastine besilate nasal spray 3% twice a day", "label": " bepotastine besilate nasal spray 3% twice a day", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedot329 (combination of fluticasone propionate and salmeterol xinafoate), advair diskus (combination of fluticasone propionate and salmeterol xinafoate), placebo_asthma", "label": "completedot329 (combination of fluticasone propionate and salmeterol xinafoate), advair diskus (combination of fluticasone propionate and salmeterol xinafoate), placebo_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " glpg1972 multiple ascending doses", "label": " glpg1972 multiple ascending doses", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddecitabine, arsenic trioxide and ascorbic acid_myelodysplastic syndrome", "label": "completeddecitabine, arsenic trioxide and ascorbic acid_myelodysplastic syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo matching vibegron", "label": " placebo matching vibegron", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C=C(C[C@@H](N)C(O)=O)C2=CC=CC=C12, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "CN1C=C(C[C@@H](N)C(O)=O)C2=CC=CC=C12, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsemuloparin sodium, placebo (for semuloparin)_venous thromboembolism, cancer", "label": "completedsemuloparin sodium, placebo (for semuloparin)_venous thromboembolism, cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " fluorine f 18 sodium fluoride", "label": " fluorine f 18 sodium fluoride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "label": "ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "grazoprevir 100mg / elbasvir 50 mg fdc, placebo to grazoprevir / elbasvir 50 mg fdc", "label": "grazoprevir 100mg / elbasvir 50 mg fdc, placebo to grazoprevir / elbasvir 50 mg fdc", "shape": "dot", "size": 10}, {"color": "red", "id": "hf0220", "label": "hf0220", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedruxolitinib_breast cancer", "label": "terminatedruxolitinib_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgr-md-02, placebo_nonalcoholic steatohepatitis", "label": "completedgr-md-02, placebo_nonalcoholic steatohepatitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " concor 5mg 2t and crestor 20 mg 1tab", "label": " concor 5mg 2t and crestor 20 mg 1tab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtacrolimus ointment, placebo ointment_dermatitis, atopic", "label": "completedtacrolimus ointment, placebo ointment_dermatitis, atopic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1", "label": " COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlosartan 50 mg, losartan 100 mg_copd, chronic bronchitis", "label": "terminatedlosartan 50 mg, losartan 100 mg_copd, chronic bronchitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " 2 mg nicotine polacrilex", "label": " 2 mg nicotine polacrilex", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpembrolizumab and high dose interferon alfa-2b (hdi)_melanoma", "label": "completedpembrolizumab and high dose interferon alfa-2b (hdi)_melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcetrorelix acetate, cetrorelix acetate, recombinant human choriogonadotropin (r-hcg), recombinant human follicle stimulating hormone (r-hfsh)_polycystic ovarian syndrome", "label": "completedcetrorelix acetate, cetrorelix acetate, recombinant human choriogonadotropin (r-hcg), recombinant human follicle stimulating hormone (r-hfsh)_polycystic ovarian syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glpg0492, placebo, glpg0492, glpg0492", "label": "glpg0492, placebo, glpg0492, glpg0492", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcyclosporin a, belatacept less intensive regimen (li), belatacept more intensive regimen (mi)_renal transplantation", "label": "completedcyclosporin a, belatacept less intensive regimen (li), belatacept more intensive regimen (mi)_renal transplantation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsyl1001 ophthalmic solution, vehicle opthalmic solution_dry eye disease", "label": "completedsyl1001 ophthalmic solution, vehicle opthalmic solution_dry eye disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "gsk1265744 10 mg", "label": "gsk1265744 10 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carboplatin, abi-007", "label": "carboplatin, abi-007", "shape": "dot", "size": 10}, {"color": "red", "id": " glycopyrronium mdi 14.4 micrograms", "label": " glycopyrronium mdi 14.4 micrograms", "shape": "dot", "size": 10}, {"color": "red", "id": " cnto 136 50 mg", "label": " cnto 136 50 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1, OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1, [H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C", "label": "CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1, OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1, [H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "valsartan 320 mg, amlodipine 10 mg, hydrochlorothiazide", "label": "valsartan 320 mg, amlodipine 10 mg, hydrochlorothiazide", "shape": "dot", "size": 10}, {"color": "red", "id": " flovent 100mcg", "label": " flovent 100mcg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\\C=C\\[C@H](C)C(C)(C)O, [H][C@@]1(CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\\C=C\\[C@H](C)C(C)(C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]1(CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\\C=C\\[C@H](C)C(C)(C)O, [H][C@@]1(CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\\C=C\\[C@H](C)C(C)(C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "green", "id": " transfusional hemosiderosis", "label": " transfusional hemosiderosis", "shape": "dot", "size": 10}, {"color": "red", "id": "radium-223 dichloride (bay88-8223)", "label": "radium-223 dichloride (bay88-8223)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vorinostat, comparator: bexarotene", "label": "vorinostat, comparator: bexarotene", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "urinary bladder diseases, urinary bladder overactive, urologic diseases", "label": "urinary bladder diseases, urinary bladder overactive, urologic diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedticagrelor 60 mg, ticagrelor placebo_diabetes mellitus, type 2", "label": "completedticagrelor 60 mg, ticagrelor placebo_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "prc-063 25 mg", "label": "prc-063 25 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedipilimumab, placebo_high risk stage iii melanoma", "label": "completedipilimumab, placebo_high risk stage iii melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ribavirin (sch 018908)", "label": "ribavirin (sch 018908)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClCCN(CCCl)P1(=O)NCCCO1", "label": "[H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClCCN(CCCl)P1(=O)NCCCO1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsagopilone (bay86-5302, zk 219477), sagopilone (bay86-5302, zk 219477), sagopilone (bay86-5302, zk 219477)_carcinoma, non small cell lung", "label": "completedsagopilone (bay86-5302, zk 219477), sagopilone (bay86-5302, zk 219477), sagopilone (bay86-5302, zk 219477)_carcinoma, non small cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedinsulin glargine, metformin, taspoglutide, taspoglutide_diabetes mellitus type 2", "label": "terminatedinsulin glargine, metformin, taspoglutide, taspoglutide_diabetes mellitus type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1, CN1N=CC(Cl)=C1C1=C(Cl)OC(=C1)C(=O)N[C@H](CN)CC1=CC=C(F)C(F)=C1", "label": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1, CN1N=CC(Cl)=C1C1=C(Cl)OC(=C1)C(=O)N[C@H](CN)CC1=CC=C(F)C(F)=C1", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1", "label": " CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo for enzalutamide", "label": " placebo for enzalutamide", "shape": "dot", "size": 10}, {"color": "red", "id": "insulin glargine/lixisenatide", "label": "insulin glargine/lixisenatide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O", "label": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O", "shape": "dot", "size": 10}, {"color": "blue", "id": " [O-][N+]1=CC(=CC=C1)C#CC1=CC(=CC=C1)N1C=C(C(=O)NC2CC2)C(=O)C2=CC=CN=C12", "label": " [O-][N+]1=CC(=CC=C1)C#CC1=CC(=CC=C1)N1C=C(C(=O)NC2CC2)C(=O)C2=CC=CN=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rituximab, cyclophosphamide, doxorubicin, prednisone, vincristine", "label": "rituximab, cyclophosphamide, doxorubicin, prednisone, vincristine", "shape": "dot", "size": 10}, {"color": "red", "id": " bevacizumab-eu", "label": " bevacizumab-eu", "shape": "dot", "size": 10}, {"color": "green", "id": "non-alcoholic fatty liver disease (nafld", "label": "non-alcoholic fatty liver disease (nafld", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1, CC(=O)OC1=CC=CC=C1C(O)=O", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1, CC(=O)OC1=CC=CC=C1C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedplerixafor_refractory multiple myeloma", "label": "terminatedplerixafor_refractory multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, [Ca++].[O-]C([O-])=O, [Ca++].[O-]C([O-])=O", "label": "CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, [Ca++].[O-]C([O-])=O, [Ca++].[O-]C([O-])=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddoxorubicin, rituxan, cyclophosphamide, vincristine and prednisone_non-hodgkin\u0027s lymphoma", "label": "completeddoxorubicin, rituxan, cyclophosphamide, vincristine and prednisone_non-hodgkin\u0027s lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCOC(=O)C(C)(C)NP(=O)(NC(C)(C)C(=O)OCC)C1=CC=C(O1)C1=C(SC(N)=N1)C(=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCOC(=O)C(C)(C)NP(=O)(NC(C)(C)C(=O)OCC)C1=CC=C(O1)C1=C(SC(N)=N1)C(=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, placebo, bms-936557 (anti-ip-10 antibody), bms-936557 (anti-ip-10 antibody), bms-936557 (anti-ip-10 antibody), bms-936557 (anti-ip-10 antibody), bms-936557 (anti-ip-10 antibody)_crohn\u0027s disease", "label": "completedplacebo, placebo, bms-936557 (anti-ip-10 antibody), bms-936557 (anti-ip-10 antibody), bms-936557 (anti-ip-10 antibody), bms-936557 (anti-ip-10 antibody), bms-936557 (anti-ip-10 antibody)_crohn\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo matching with bms-955176", "label": " placebo matching with bms-955176", "shape": "dot", "size": 10}, {"color": "blue", "id": "OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1", "label": "OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C", "label": "[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaggrenox, aggrenox, clopidogrel placebo, clopidogrel placebo, micardis, micardis, aggrenox placebo, aggrenox placebo, clopidogrel, clopidogrel, micardis placebo, micardis placebo_stroke", "label": "completedaggrenox, aggrenox, clopidogrel placebo, clopidogrel placebo, micardis, micardis, aggrenox placebo, aggrenox placebo, clopidogrel, clopidogrel, micardis placebo, micardis placebo_stroke", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlosartan potassium (+) hydrochlorothiazide_hypertension", "label": "completedlosartan potassium (+) hydrochlorothiazide_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " impulse-control disorders", "label": " impulse-control disorders", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gcs-100, placebo, saline", "label": "gcs-100, placebo, saline", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbevacizumab and erlotinib_cancer", "label": "completedbevacizumab and erlotinib_cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfirsocostat, placebo_nonalcoholic steatohepatitis (nash)", "label": "completedfirsocostat, placebo_nonalcoholic steatohepatitis (nash)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2", "label": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedabt-126, abt-126, placebo_alzheimer\u0027s disease", "label": "completedabt-126, abt-126, placebo_alzheimer\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlapatinib, paclitaxel_neoplasms, breast", "label": "completedlapatinib, paclitaxel_neoplasms, breast", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedchlorambucil, fludarabine phosphate_lymphoma", "label": "completedchlorambucil, fludarabine phosphate_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1, CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1, CCNC(=O)[C@H]1C[C@](F)(C1)C1=CC(F)=C(CN2CCCC2)C=C1", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1, CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1, CCNC(=O)[C@H]1C[C@](F)(C1)C1=CC(F)=C(CN2CCCC2)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtreatment, treatment_non squamous lung cancer", "label": "completedtreatment, treatment_non squamous lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " disease-modifying antirheumatic drugs (dmards)", "label": " disease-modifying antirheumatic drugs (dmards)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvitamin d_asthma, vitamin d deficiency", "label": "completedvitamin d_asthma, vitamin d deficiency", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "non-small cell lung cancer stage iiib, non-small cell lung cancer stage iv, non-small cell lung cancer metastatic", "label": "non-small cell lung cancer stage iiib, non-small cell lung cancer stage iv, non-small cell lung cancer metastatic", "shape": "dot", "size": 10}, {"color": "red", "id": " matching placebo to omarigliptin", "label": " matching placebo to omarigliptin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmetyrosine, placebo_velo-cardio-facial syndrome, psychosis", "label": "terminatedmetyrosine, placebo_velo-cardio-facial syndrome, psychosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedliraglutide or placebo_diabetes mellitus, non-insulin-dependent, hypertensive disease", "label": "completedliraglutide or placebo_diabetes mellitus, non-insulin-dependent, hypertensive disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " primary effusion lymphomas", "label": " primary effusion lymphomas", "shape": "dot", "size": 10}, {"color": "red", "id": " clenil\u00ae modulite\u00ae via aerochamber plus\u2122 plus charcoal block", "label": " clenil\u00ae modulite\u00ae via aerochamber plus\u2122 plus charcoal block", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]1(NC(=O)C2(CCN(CC3=CC=C(OC4=CC=C(C=C4)C(O)=O)C=C3)CC2)N(CCCC)C1=O)[C@H](O)C1CCCCC1", "label": "[H][C@@]1(NC(=O)C2(CCN(CC3=CC=C(OC4=CC=C(C=C4)C(O)=O)C=C3)CC2)N(CCCC)C1=O)[C@H](O)C1CCCCC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddocetaxel, mitoxantrone, prednisone_prostatic neoplasms", "label": "completeddocetaxel, mitoxantrone, prednisone_prostatic neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "bekinda", "label": "bekinda", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtacrolimus, mycophenolate mofetil_non-hodgkin\u0027s lymphoma, leukemia, multiple myeloma, acute myeloid leukemia, hodgkin lymphoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, myelodysplastic syndrome", "label": "completedtacrolimus, mycophenolate mofetil_non-hodgkin\u0027s lymphoma, leukemia, multiple myeloma, acute myeloid leukemia, hodgkin lymphoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, myelodysplastic syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "label": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "shape": "dot", "size": 10}, {"color": "red", "id": "pp1420", "label": "pp1420", "shape": "dot", "size": 10}, {"color": "red", "id": " act-128800 dose 3", "label": " act-128800 dose 3", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedorg 34517_major depressive disorder, psychotic disorders", "label": "completedorg 34517_major depressive disorder, psychotic disorders", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedldk378_cholangiocarcinoma", "label": "terminatedldk378_cholangiocarcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " glucagon hydrochloride solution", "label": " glucagon hydrochloride solution", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1(C)CCC(=CC1)C1=C(NC(=O)C2=NC=C(N2)C#N)C=CC(=N1)C1CC(C)(C)OC(C)(C)C1", "label": "CC1(C)CCC(=CC1)C1=C(NC(=O)C2=NC=C(N2)C#N)C=CC(=N1)C1CC(C)(C)OC(C)(C)C1", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1(C)OC(=C(C1=O)C1=CC=CC(F)=C1)C1=CC=C(C=C1)S(N)(=O)=O", "label": "CC1(C)OC(=C(C1=O)C1=CC=CC(F)=C1)C1=CC=C(C=C1)S(N)(=O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "end stage renal disease, renal transplant", "label": "end stage renal disease, renal transplant", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawncapecitabine and cetuximab_metastatic colorectal cancer", "label": "withdrawncapecitabine and cetuximab_metastatic colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedliraglutide 3 mg (saxenda), liraglutide 3 mg placebo_osteoarthritis, obesity", "label": "completedliraglutide 3 mg (saxenda), liraglutide 3 mg placebo_osteoarthritis, obesity", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "epicept-np-1 cream", "label": "epicept-np-1 cream", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Na+].OC([O-])=O, COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C", "label": "[Na+].OC([O-])=O, COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCN1N=CN=C1COC1=NN2C(C=C1C(C)(C)C)=NN=C2C1=CC=CC=C1F", "label": "CCN1N=CN=C1COC1=NN2C(C=C1C(C)(C)C)=NN=C2C1=CC=CC=C1F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]1(CCCN1C(O)=NC1=NC(C)=C(S1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F)C(O)=N, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "label": "[H][C@]1(CCCN1C(O)=NC1=NC(C)=C(S1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F)C(O)=N, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "shape": "dot", "size": 10}, {"color": "red", "id": "src kinase inhibitor kx2-391", "label": "src kinase inhibitor kx2-391", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N12, CC1=CC(\\C=C\\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1, C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N12, CC1=CC(\\C=C\\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1", "label": "C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N12, CC1=CC(\\C=C\\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1, C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N12, CC1=CC(\\C=C\\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1", "shape": "dot", "size": 10}, {"color": "red", "id": " crushed alo-02 60 mg/7.2 mg", "label": " crushed alo-02 60 mg/7.2 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCOC1=NC=C(C=C1C1=NC2=C(CC)N(CCOC)N=C2C(=O)N1)S(=O)(=O)N1CCN(CC)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCOC1=NC=C(C=C1C1=NC2=C(CC)N(CCOC)N=C2C(=O)N1)S(=O)(=O)N1CCN(CC)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": " calcitriol", "label": " calcitriol", "shape": "dot", "size": 10}, {"color": "red", "id": "leuprorelin acetate", "label": "leuprorelin acetate", "shape": "dot", "size": 10}, {"color": "red", "id": "part i - etoricoxib 60 mg", "label": "part i - etoricoxib 60 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C", "shape": "dot", "size": 10}, {"color": "green", "id": " proximal urethral cancer", "label": " proximal urethral cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " 0.5mg ranibizumab", "label": " 0.5mg ranibizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedregorafenib, ophthalmic oily suspension (bay73-4506), ranibizumab, placebo_macular degeneration", "label": "terminatedregorafenib, ophthalmic oily suspension (bay73-4506), ranibizumab, placebo_macular degeneration", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "bortezomib + rituximab", "label": "bortezomib + rituximab", "shape": "dot", "size": 10}, {"color": "red", "id": " granisetron", "label": " granisetron", "shape": "dot", "size": 10}, {"color": "red", "id": " docetaxel and trastuzumab", "label": " docetaxel and trastuzumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednilotinib_gastrointestinal stromal tumors", "label": "completednilotinib_gastrointestinal stromal tumors", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsorafenib, sir-sphere_liver carcinoma", "label": "completedsorafenib, sir-sphere_liver carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " drug: sch 900518 drug: ritonavir (rtv) biologic: peginterferon alfa-2b (pegintron)", "label": " drug: sch 900518 drug: ritonavir (rtv) biologic: peginterferon alfa-2b (pegintron)", "shape": "dot", "size": 10}, {"color": "red", "id": "raltegravir and atazanavir and ritonavir", "label": "raltegravir and atazanavir and ritonavir", "shape": "dot", "size": 10}, {"color": "red", "id": " first-line chemotherapy agents", "label": " first-line chemotherapy agents", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1", "label": "NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fludarabine, cyclophosphamide, acetaminophen, diphenhydramine, methylprednisolone, mesna, mycophenolate mofetil, prednisone, filgrastim", "label": "fludarabine, cyclophosphamide, acetaminophen, diphenhydramine, methylprednisolone, mesna, mycophenolate mofetil, prednisone, filgrastim", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12, CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12", "label": "CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12, CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "metastatic colorectal cancer, colon cancer, colorectal cancer, rectal cancer", "label": "metastatic colorectal cancer, colon cancer, colorectal cancer, rectal cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " ibandronate [bonviva/boniva]", "label": " ibandronate [bonviva/boniva]", "shape": "dot", "size": 10}, {"color": "red", "id": " empagliflozin high dose bid", "label": " empagliflozin high dose bid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedhuman biphasic insulin, human biphasic insulin, reference_diabetes mellitus", "label": "completedhuman biphasic insulin, human biphasic insulin, reference_diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "darunavir/ritonavir (drv/r)", "label": "darunavir/ritonavir (drv/r)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ly2409021, sitagliptin, placebo, metformin, sulfonylurea", "label": "ly2409021, sitagliptin, placebo, metformin, sulfonylurea", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1, CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1", "label": "CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1, CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1", "shape": "dot", "size": 10}, {"color": "green", "id": "brain metastases", "label": "brain metastases", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@]([H])(O)C[C@]3(C)[C@@]1(N=C(C)O2)C(=O)COC(C)=O", "label": "[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@]([H])(O)C[C@]3(C)[C@@]1(N=C(C)O2)C(=O)COC(C)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedglucosamine, chondroitin sulfate, glucosamine and chondroitin sulfate combined, celecoxib_osteoarthritis", "label": "completedglucosamine, chondroitin sulfate, glucosamine and chondroitin sulfate combined, celecoxib_osteoarthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuspasireotide lar 60 mg, pegvisomant_acromegaly", "label": "unknown statuspasireotide lar 60 mg, pegvisomant_acromegaly", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcebranopadol 100 \u00b5g, cebranopadol 300 \u00b5g, cebranopadol 600 \u00b5g, pregabalin, matching placebo_chronic pain, diabetic neuropathies, diabetes mellitus", "label": "completedcebranopadol 100 \u00b5g, cebranopadol 300 \u00b5g, cebranopadol 600 \u00b5g, pregabalin, matching placebo_chronic pain, diabetic neuropathies, diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=CC=C1OCC(O)CO, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [O-][N+]1=C(S)C=CC=C1, [H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H]\\C(=C(\\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC", "label": "COC1=CC=CC=C1OCC(O)CO, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [O-][N+]1=C(S)C=CC=C1, [H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H]\\C(=C(\\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "coronary disease, ultrasonography, interventional, hydroxymethylglutaryl-coa reductase inhibitors", "label": "coronary disease, ultrasonography, interventional, hydroxymethylglutaryl-coa reductase inhibitors", "shape": "dot", "size": 10}, {"color": "green", "id": " ewing", "label": " ewing", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rituximab, cyclophosphamide, fludarabine phosphate", "label": "rituximab, cyclophosphamide, fludarabine phosphate", "shape": "dot", "size": 10}, {"color": "red", "id": " 5-fluorouracil ( in folfox)", "label": " 5-fluorouracil ( in folfox)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine, carboplatin, sorafenib_bladder cancer", "label": "completedgemcitabine, carboplatin, sorafenib_bladder cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic kidney disease, type 2 diabetes mellitus", "label": "chronic kidney disease, type 2 diabetes mellitus", "shape": "dot", "size": 10}, {"color": "red", "id": " tiotropium respimat\u00ae high dose", "label": " tiotropium respimat\u00ae high dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfg-4592, epoetin alfa_anemia", "label": "completedfg-4592, epoetin alfa_anemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "rvx000222", "label": "rvx000222", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsumatriptan succinate_migraine disorders", "label": "completedsumatriptan succinate_migraine disorders", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " metastatic parathyroid cancer", "label": " metastatic parathyroid cancer", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1", "label": " CCCC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "ixazomib citrate", "label": "ixazomib citrate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsgi-110 (guadecitabine), treatment choice_leukemia, myeloid, acute", "label": "completedsgi-110 (guadecitabine), treatment choice_leukemia, myeloid, acute", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=CN([C@@H]2O[C@](CO)(C=C2)C#C)C(=O)NC1=O", "label": "CC1=CN([C@@H]2O[C@](CO)(C=C2)C#C)C(=O)NC1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbrentuximab vedotin_disease, hodgkin, lymphoma, large-cell, anaplastic, lymphoma, non-hodgkin", "label": "completedbrentuximab vedotin_disease, hodgkin, lymphoma, large-cell, anaplastic, lymphoma, non-hodgkin", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "zonisamide", "label": "zonisamide", "shape": "dot", "size": 10}, {"color": "red", "id": "granix", "label": "granix", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to nva237", "label": " placebo to nva237", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgdc-0853, adalimumab, folic acid, mtx, placebo_rheumatoid arthritis", "label": "completedgdc-0853, adalimumab, folic acid, mtx, placebo_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]1(CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\\C=C\\[C@H](C)C(C)C", "label": "[H][C@@]1(CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\\C=C\\[C@H](C)C(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pain, hiv infections, peripheral nervous system diseases", "label": "pain, hiv infections, peripheral nervous system diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1", "label": "[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "blue", "id": " O[Bi]1OC(=O)C2=CC=CC=C2O1", "label": " O[Bi]1OC(=O)C2=CC=CC=C2O1", "shape": "dot", "size": 10}, {"color": "red", "id": " infliximab (inf) + mtx", "label": " infliximab (inf) + mtx", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recurrence of solid tumor, glioblastoma multiforme, melanoma", "label": "recurrence of solid tumor, glioblastoma multiforme, melanoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsaccharomyces boulardii oral tablet, metronidazole_systemic sclerosis, small intestinal bacterial overgrowth", "label": "completedsaccharomyces boulardii oral tablet, metronidazole_systemic sclerosis, small intestinal bacterial overgrowth", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, bleomycin, brentuximab vedotin", "label": "brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, bleomycin, brentuximab vedotin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completede/c/f/taf_hiv, hiv infections", "label": "completede/c/f/taf_hiv, hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " 350 \u00b5g dexamethasone", "label": " 350 \u00b5g dexamethasone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedoxycodone hcl controlled-release tablets_pain", "label": "completedoxycodone hcl controlled-release tablets_pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "sertindole", "label": "sertindole", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbevacizumab, carboplatin, paclitaxel, placebo_melanoma", "label": "completedbevacizumab, carboplatin, paclitaxel, placebo_melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "celgosivir", "label": "celgosivir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin glargine, metformin, forxiga_type 2 diabetes mellitus", "label": "completedinsulin glargine, metformin, forxiga_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedumec/vi, placebo_pulmonary disease, chronic obstructive", "label": "completedumec/vi, placebo_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmk8141, comparator: placebo (unspecified), enalapril_hypertension", "label": "completedmk8141, comparator: placebo (unspecified), enalapril_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "cutaneous melanoma", "label": "cutaneous melanoma", "shape": "dot", "size": 10}, {"color": "red", "id": " part ii- naproxen 1000 mg", "label": " part ii- naproxen 1000 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedroflumilast_obesity", "label": "completedroflumilast_obesity", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "paliperidone extended-release, risperidone immediate-release", "label": "paliperidone extended-release, risperidone immediate-release", "shape": "dot", "size": 10}, {"color": "red", "id": " tenofovir/emtricitabine", "label": " tenofovir/emtricitabine", "shape": "dot", "size": 10}, {"color": "red", "id": "low dose asenapine maleate transdermal patch", "label": "low dose asenapine maleate transdermal patch", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bay80-6946, bay80-6946", "label": "bay80-6946, bay80-6946", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "5-fluorouracil, bevacizumab, leucovorin, oxaliplatin", "label": "5-fluorouracil, bevacizumab, leucovorin, oxaliplatin", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]12O[C@@]3([H])CCC4CC(=O)C[C@H]5[C@H](C[C@H]6O[C@H](C[C@@H](C)C6=C)CC[C@@H]6O[C@H](CC6=C)CC[C@@]67C[C@@H](O[C@H]1[C@@H](O6)[C@@]3([H])O4)[C@@H]2O7)O[C@H](C[C@H](O)CN)[C@@H]5OC", "label": "[H][C@@]12O[C@@]3([H])CCC4CC(=O)C[C@H]5[C@H](C[C@H]6O[C@H](C[C@@H](C)C6=C)CC[C@@H]6O[C@H](CC6=C)CC[C@@]67C[C@@H](O[C@H]1[C@@H](O6)[C@@]3([H])O4)[C@@H]2O7)O[C@H](C[C@H](O)CN)[C@@H]5OC", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1C=C(C[C@@H](N)C(O)=O)C2=CC=CC=C12", "label": "CN1C=C(C[C@@H](N)C(O)=O)C2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O", "label": "CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O", "shape": "dot", "size": 10}, {"color": "blue", "id": "FC(F)(F)C1=NC(NC2=C(Cl)C=C(Cl)C=C2)=NC=C1C(=O)NCC1CCOCC1", "label": "FC(F)(F)C1=NC(NC2=C(Cl)C=C(Cl)C=C2)=NC=C1C(=O)NCC1CCOCC1", "shape": "dot", "size": 10}, {"color": "red", "id": "normal saline (placebo)", "label": "normal saline (placebo)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, 2% rebamipide liquid, 4% rebamipide liquid", "label": "placebo, 2% rebamipide liquid, 4% rebamipide liquid", "shape": "dot", "size": 10}, {"color": "red", "id": "rebetol (ribavirin; sch 18908)", "label": "rebetol (ribavirin; sch 18908)", "shape": "dot", "size": 10}, {"color": "green", "id": " meibomian gland dysfunction", "label": " meibomian gland dysfunction", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "divalproex sodium er, risperidone", "label": "divalproex sodium er, risperidone", "shape": "dot", "size": 10}, {"color": "red", "id": " sp-8203 low dose", "label": " sp-8203 low dose", "shape": "dot", "size": 10}, {"color": "blue", "id": " CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1", "label": " CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " mitomycin (mmc)", "label": " mitomycin (mmc)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, bi 10773, placebo, bi 10773, placebo, placebo_diabetes mellitus, type 2, hypertension", "label": "completedplacebo, bi 10773, placebo, bi 10773, placebo, placebo_diabetes mellitus, type 2, hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedadvair 100/50mcg, advair 250/50mcg, flovent 100mcg, flovent 250mcg_asthma", "label": "completedadvair 100/50mcg, advair 250/50mcg, flovent 100mcg, flovent 250mcg_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsofosbuvir, rbv, peg_hepatitis c, chronic", "label": "completedsofosbuvir, rbv, peg_hepatitis c, chronic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "colorectal neoplasms, metastatic disease", "label": "colorectal neoplasms, metastatic disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O, OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O", "label": "OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O, OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": " non-oral corticosteroid (non-ocs) asthma medication", "label": " non-oral corticosteroid (non-ocs) asthma medication", "shape": "dot", "size": 10}, {"color": "red", "id": "nva237 12.5 \u00b5g once daily", "label": "nva237 12.5 \u00b5g once daily", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedantipsychotic_schizophrenia", "label": "terminatedantipsychotic_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "1st line chemotherapy", "label": "1st line chemotherapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bendamustine, bortezomib, dexamethasone", "label": "bendamustine, bortezomib, dexamethasone", "shape": "dot", "size": 10}, {"color": "red", "id": "telmisartan (micardis\u00ae) vs. placebo", "label": "telmisartan (micardis\u00ae) vs. placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpf-00489791, pf-00489791, pf-00489791, placebo_hypertension", "label": "completedpf-00489791, pf-00489791, pf-00489791, placebo_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ar-13324 ophthalmic solution 0.02% bid", "label": " ar-13324 ophthalmic solution 0.02% bid", "shape": "dot", "size": 10}, {"color": "red", "id": " brimonidine mono therapy", "label": " brimonidine mono therapy", "shape": "dot", "size": 10}, {"color": "red", "id": " clonidine lauriad\u00ae 100\u00b5g", "label": " clonidine lauriad\u00ae 100\u00b5g", "shape": "dot", "size": 10}, {"color": "red", "id": " \u0026 plerixafor", "label": " \u0026 plerixafor", "shape": "dot", "size": 10}, {"color": "green", "id": "pulmonary", "label": "pulmonary", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, vincristine, prednisone", "label": "cyclophosphamide, vincristine, prednisone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gastroesophageal junction adenocarcinoma, gastric cancer", "label": "gastroesophageal junction adenocarcinoma, gastric cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingdaratumumab, dexamethasone_multiple myeloma", "label": "active, not recruitingdaratumumab, dexamethasone_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedg-csf, leukapheresis, busulfan_acute myeloid leukemia (aml)", "label": "terminatedg-csf, leukapheresis, busulfan_acute myeloid leukemia (aml)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC(=O)\\C=C\\C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1, CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O, CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1", "label": "COC(=O)\\C=C\\C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1, CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O, CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1", "shape": "dot", "size": 10}, {"color": "green", "id": " adult anaplastic oligodendroglioma", "label": " adult anaplastic oligodendroglioma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "intravenous colimycin, intravenous placebo, nebulized colimycin, nebulized placebo", "label": "intravenous colimycin, intravenous placebo, nebulized colimycin, nebulized placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic lymphocytic leukemia, small lymphocytic leukemia", "label": "chronic lymphocytic leukemia, small lymphocytic leukemia", "shape": "dot", "size": 10}, {"color": "red", "id": "myelo001", "label": "myelo001", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent anal cancer", "label": " recurrent anal cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "revefenacin", "label": "revefenacin", "shape": "dot", "size": 10}, {"color": "green", "id": "locally advanced or metastatic medullary thyroid cancer", "label": "locally advanced or metastatic medullary thyroid cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dyskinesia, parkinson\u0027s disease", "label": "dyskinesia, parkinson\u0027s disease", "shape": "dot", "size": 10}, {"color": "red", "id": " stavudine", "label": " stavudine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "warfarin, dabigatran etexilate 150mg", "label": "warfarin, dabigatran etexilate 150mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedadefovir, lamivudine_chronic hepatitis b", "label": "completedadefovir, lamivudine_chronic hepatitis b", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O, [H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3", "label": "[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O, [H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo/sugar pill", "label": " placebo/sugar pill", "shape": "dot", "size": 10}, {"color": "red", "id": " quetiapine or risperidone + placebo", "label": " quetiapine or risperidone + placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "red", "id": "ym060", "label": "ym060", "shape": "dot", "size": 10}, {"color": "red", "id": "zolpidem sl800750", "label": "zolpidem sl800750", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to match budesonide/formoterol combination", "label": " placebo to match budesonide/formoterol combination", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsildenafil_duchenne muscular dystrophy, becker muscular dystrophy", "label": "terminatedsildenafil_duchenne muscular dystrophy, becker muscular dystrophy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " sleep disordered breathing", "label": " sleep disordered breathing", "shape": "dot", "size": 10}, {"color": "green", "id": " inflammatory arthritis", "label": " inflammatory arthritis", "shape": "dot", "size": 10}, {"color": "red", "id": "vorinostat (suberoylanilide hydroxamic acid)", "label": "vorinostat (suberoylanilide hydroxamic acid)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O, CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2, NNC(=O)C1=CC=NC=C1", "label": "CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O, CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2, NNC(=O)C1=CC=NC=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " adjustment disorder", "label": " adjustment disorder", "shape": "dot", "size": 10}, {"color": "red", "id": "z-360", "label": "z-360", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "certoparin, unfractionated heparin", "label": "certoparin, unfractionated heparin", "shape": "dot", "size": 10}, {"color": "red", "id": " erythropoietin", "label": " erythropoietin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "standard treatment, incretin-based treatment", "label": "standard treatment, incretin-based treatment", "shape": "dot", "size": 10}, {"color": "red", "id": "pym50028", "label": "pym50028", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCNC(=O)N(CCCl)N=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O", "label": "ClCCNC(=O)N(CCCl)N=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlaquinimod, mycophenolate mofetil, prednisolone/prednisone, placebo_lupus nephritis", "label": "completedlaquinimod, mycophenolate mofetil, prednisolone/prednisone, placebo_lupus nephritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rosiglitazone xr (extended release) oral tablets, placebo", "label": "rosiglitazone xr (extended release) oral tablets, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sgn-40, placebo, rituximab, etoposide, carboplatin, ifosfamide", "label": "sgn-40, placebo, rituximab, etoposide, carboplatin, ifosfamide", "shape": "dot", "size": 10}, {"color": "red", "id": "vicriviroc maleate 20 mg", "label": "vicriviroc maleate 20 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuscarboplatin, chemotherapy, cisplatin, paclitaxel_lung cancer", "label": "unknown statuscarboplatin, chemotherapy, cisplatin, paclitaxel_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedselinexor, hydroxyurea, ara-c_acute myeloid leukemia (aml)", "label": "completedselinexor, hydroxyurea, ara-c_acute myeloid leukemia (aml)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " advagraf", "label": " advagraf", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lupus nephritis, lupus erythematosus, systemic", "label": "lupus nephritis, lupus erythematosus, systemic", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "esophageal adenocarcinoma, gastric adenocarcinoma", "label": "esophageal adenocarcinoma, gastric adenocarcinoma", "shape": "dot", "size": 10}, {"color": "red", "id": "871", "label": "871", "shape": "dot", "size": 10}, {"color": "red", "id": " erenumab", "label": " erenumab", "shape": "dot", "size": 10}, {"color": "blue", "id": " CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1", "label": " CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " ischemic heart disease", "label": " ischemic heart disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcapecitabine, trastuzumab emtansine (t-dm1), trastuzumab emtansine (t-dm1), capecitabine_breast cancer, gastric cancer", "label": "terminatedcapecitabine, trastuzumab emtansine (t-dm1), trastuzumab emtansine (t-dm1), capecitabine_breast cancer, gastric cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " short bowel syndrome", "label": " short bowel syndrome", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone/formoterol, fluticasone/salmeterol", "label": "fluticasone/formoterol, fluticasone/salmeterol", "shape": "dot", "size": 10}, {"color": "green", "id": " diffuse large b-cell lymphoma", "label": " diffuse large b-cell lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": "tenofovir disoproxil fumarate (tenofovir df; tdf)", "label": "tenofovir disoproxil fumarate (tenofovir df; tdf)", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCN(CC)CCN1CCC2=C(C(C)=C(N2)\\C=C2/C(=O)NC3=CC=C(F)C=C23)C1=O", "label": "CCN(CC)CCN1CCC2=C(C(C)=C(N2)\\C=C2/C(=O)NC3=CC=C(F)C=C23)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "methylnaltrexone", "label": "methylnaltrexone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlx4211, lx4211 placebo_type 2 diabetes mellitus, renal impairment", "label": "completedlx4211, lx4211 placebo_type 2 diabetes mellitus, renal impairment", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage ii rectal cancer", "label": " stage ii rectal cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "bevacizumab + erlotinib hydrochloride", "label": "bevacizumab + erlotinib hydrochloride", "shape": "dot", "size": 10}, {"color": "red", "id": "fampridine", "label": "fampridine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "geographic atrophy, dry age related macular degeneration", "label": "geographic atrophy, dry age related macular degeneration", "shape": "dot", "size": 10}, {"color": "blue", "id": "FC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1", "label": "FC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo iv, placebo sc, ustekinumab iv, ustekinumab sc", "label": "placebo iv, placebo sc, ustekinumab iv, ustekinumab sc", "shape": "dot", "size": 10}, {"color": "red", "id": "standard of care", "label": "standard of care", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "stage iii squamous cell carcinoma of the hypopharynx, stage iii squamous cell carcinoma of the larynx, stage iii squamous cell carcinoma of the oropharynx, stage iii verrucous carcinoma of the larynx, stage iv squamous cell carcinoma of the hypopharynx, stage iva squamous cell carcinoma of the larynx, stage iva squamous cell carcinoma of the oropharynx, stage iva verrucous carcinoma of the larynx, stage ivb squamous cell carcinoma of the larynx, stage ivb squamous cell carcinoma of the oropharynx, stage ivb verrucous carcinoma of the larynx, tongue cancer", "label": "stage iii squamous cell carcinoma of the hypopharynx, stage iii squamous cell carcinoma of the larynx, stage iii squamous cell carcinoma of the oropharynx, stage iii verrucous carcinoma of the larynx, stage iv squamous cell carcinoma of the hypopharynx, stage iva squamous cell carcinoma of the larynx, stage iva squamous cell carcinoma of the oropharynx, stage iva verrucous carcinoma of the larynx, stage ivb squamous cell carcinoma of the larynx, stage ivb squamous cell carcinoma of the oropharynx, stage ivb verrucous carcinoma of the larynx, tongue cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " sinemet (comparator)", "label": " sinemet (comparator)", "shape": "dot", "size": 10}, {"color": "red", "id": "tc-6499", "label": "tc-6499", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedticagrelor, clopidogrel_coronary artery disease", "label": "completedticagrelor, clopidogrel_coronary artery disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedurg101, placebo_painful bladder syndrome, interstitial cystitis", "label": "completedurg101, placebo_painful bladder syndrome, interstitial cystitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmemantine_amyotrophic lateral sclerosis", "label": "completedmemantine_amyotrophic lateral sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedanti spasmodic agents, alverine citrate, simeticone_irritable bowel syndrome", "label": "completedanti spasmodic agents, alverine citrate, simeticone_irritable bowel syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedipx056 20 mg, ipx056 40 mg, encapsulated baclofen 20 mg, placebo baclofen tablet, ipx056 10 mg, ipx056 30 mg, ipx056 35 mg, placebo ipx056 20 mg, placebo ipx056 40 mg_multiple sclerosis", "label": "completedipx056 20 mg, ipx056 40 mg, encapsulated baclofen 20 mg, placebo baclofen tablet, ipx056 10 mg, ipx056 30 mg, ipx056 35 mg, placebo ipx056 20 mg, placebo ipx056 40 mg_multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuscapecitabine, fluorouracil, irinotecan hydrochloride_colorectal cancer", "label": "unknown statuscapecitabine, fluorouracil, irinotecan hydrochloride_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "rubeosis iridis", "label": "rubeosis iridis", "shape": "dot", "size": 10}, {"color": "red", "id": "folfox-4", "label": "folfox-4", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedged-0507-34-levo 80 mg, ged-0507-34-levo 160 mg, placebo_ulcerative colitis", "label": "terminatedged-0507-34-levo 80 mg, ged-0507-34-levo 160 mg, placebo_ulcerative colitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1", "label": " CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedneoadjuvant chemotherapy (cisplatin, 5-fluorouracil)_esophageal neoplasms, squamous cell cancer", "label": "terminatedneoadjuvant chemotherapy (cisplatin, 5-fluorouracil)_esophageal neoplasms, squamous cell cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmelatonin, placebo_gastrointestinal cancer, lung cancer", "label": "completedmelatonin, placebo_gastrointestinal cancer, lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedatorvastatin, placebo_heart failure, congestive", "label": "completedatorvastatin, placebo_heart failure, congestive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gsk1120212, chemotherapy", "label": "gsk1120212, chemotherapy", "shape": "dot", "size": 10}, {"color": "red", "id": " claritin\u00ae", "label": " claritin\u00ae", "shape": "dot", "size": 10}, {"color": "blue", "id": "OC(=O)C(CC(=C)C(O)=O)NC(=O)C1=CC=C(CCC2=CC3=C(NC(=N)NC3=N)C=C2)C=C1", "label": "OC(=O)C(CC(=C)C(O)=O)NC(=O)C1=CC=C(CCC2=CC3=C(NC(=N)NC3=N)C=C2)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " valproic acid (vpa)", "label": " valproic acid (vpa)", "shape": "dot", "size": 10}, {"color": "green", "id": "colorectal", "label": "colorectal", "shape": "dot", "size": 10}, {"color": "red", "id": "melatonin", "label": "melatonin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg", "label": "fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN(C)CC1=C(OC2=CC=CC=C12)C(=O)NCCOC1=CC=C(C=C1)C(=O)NO", "label": "CN(C)CC1=C(OC2=CC=CC=C12)C(=O)NCCOC1=CC=C(C=C1)C(=O)NO", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completed100 mg amg 162, 60 mg amg 162, 14 mg amg 162, placebo_osteoporosis", "label": "completed100 mg amg 162, 60 mg amg 162, 14 mg amg 162, placebo_osteoporosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ides", "label": "ides", "shape": "dot", "size": 10}, {"color": "red", "id": " bevacizumab maintenance therapy", "label": " bevacizumab maintenance therapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedftc/rpv/tdf, efv/ftc/tdf_hiv-1 infection", "label": "completedftc/rpv/tdf, efv/ftc/tdf_hiv-1 infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlong acting oxycodone, extra strength acetaminophen_arthritis, pain, cognitive impairment", "label": "terminatedlong acting oxycodone, extra strength acetaminophen_arthritis, pain, cognitive impairment", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N", "label": "COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo plus prevacid", "label": " placebo plus prevacid", "shape": "dot", "size": 10}, {"color": "red", "id": " r-etodolac + chlorambucil", "label": " r-etodolac + chlorambucil", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12, CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12, CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12, CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12, CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gsk548470 300 mg tablet, etv 0.5 mg capsule", "label": "gsk548470 300 mg tablet, etv 0.5 mg capsule", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NCC1(CC(O)=O)CCCCC1, [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O", "label": "NCC1(CC(O)=O)CCCCC1, [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lpv/r, peg-ifna 2a, ribavirin, nucs", "label": "lpv/r, peg-ifna 2a, ribavirin, nucs", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ruxolitinib, prednisone or methylprednisolone", "label": "ruxolitinib, prednisone or methylprednisolone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "shape": "dot", "size": 10}, {"color": "blue", "id": " OC1=NC2=C(OC1)C=CC(OCCCCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl)=C2", "label": " OC1=NC2=C(OC1)C=CC(OCCCCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl)=C2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcp-945,598, sibutramine_obesity", "label": "completedcp-945,598, sibutramine_obesity", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ly2886721, placebo", "label": "ly2886721, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCC1=CN=C(C=C1)C(=O)COC1=CC=C(CC2SC(=O)NC2=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCC1=CN=C(C=C1)C(=O)COC1=CC=C(CC2SC(=O)NC2=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "blue", "id": "ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1", "label": "ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gonadotropins plus gnrh antagonists, ganirelix", "label": "gonadotropins plus gnrh antagonists, ganirelix", "shape": "dot", "size": 10}, {"color": "green", "id": " foregut carcinoid tumor", "label": " foregut carcinoid tumor", "shape": "dot", "size": 10}, {"color": "red", "id": "mk0736", "label": "mk0736", "shape": "dot", "size": 10}, {"color": "red", "id": "bepotastine besilate formulation", "label": "bepotastine besilate formulation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedftc/rpv/taf, ftc/rpv/tdf placebo, ftc/rpv/tdf, ftc/rpv/taf placebo_hiv-1 infection", "label": "completedftc/rpv/taf, ftc/rpv/tdf placebo, ftc/rpv/tdf, ftc/rpv/taf placebo_hiv-1 infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nebulized arformoterol, salmeterol", "label": "nebulized arformoterol, salmeterol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedplacebo, denosumab_breast cancer", "label": "terminatedplacebo, denosumab_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "alendronate 70-mg/vitamin d3 5600 iu combination tablet (fosamax plus)", "label": "alendronate 70-mg/vitamin d3 5600 iu combination tablet (fosamax plus)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "FC1=CNC(=O)NC1=O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "label": "FC1=CNC(=O)NC1=O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "poly iclc", "label": "poly iclc", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "kaletra + current dual nrti backbone, current regimen", "label": "kaletra + current dual nrti backbone, current regimen", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgsk2894512 1% cream, gsk2894512 0.5% cream, vehicle cream_dermatitis, atopic", "label": "completedgsk2894512 1% cream, gsk2894512 0.5% cream, vehicle cream_dermatitis, atopic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " postpartum disorder", "label": " postpartum disorder", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednilotinib, imatinib_chronic myeloid leukemia", "label": "completednilotinib, imatinib_chronic myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsemuloparin sodium, enoxaparin, placebo_venous thromboembolism", "label": "completedsemuloparin sodium, enoxaparin, placebo_venous thromboembolism", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingibrutinib_metastatic melanoma, recurrent cutaneous melanoma, stage iv cutaneous melanoma ajcc v6 and v7", "label": "active, not recruitingibrutinib_metastatic melanoma, recurrent cutaneous melanoma, stage iv cutaneous melanoma ajcc v6 and v7", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedatorvastatin_hyperlipidemia", "label": "completedatorvastatin_hyperlipidemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2, CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2", "label": "CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2, CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2", "shape": "dot", "size": 10}, {"color": "red", "id": " 5-fu and cisplatin", "label": " 5-fu and cisplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpf-03187207 and latanoprost vehicle, latanoprost 0.005% and pf-03187207 vehicle_primary open angle glaucoma, ocular hypertension, pigmentary glaucoma, pseudoexfoliative glaucoma", "label": "completedpf-03187207 and latanoprost vehicle, latanoprost 0.005% and pf-03187207 vehicle_primary open angle glaucoma, ocular hypertension, pigmentary glaucoma, pseudoexfoliative glaucoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " ureter cancer", "label": " ureter cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "stroke, post stroke fatigue", "label": "stroke, post stroke fatigue", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, obe2109_endometriosis", "label": "completedplacebo, obe2109_endometriosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F, OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O", "label": "CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F, OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpemetrexed, carboplatin_esophageal neoplasms", "label": "terminatedpemetrexed, carboplatin_esophageal neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "qva149, tiotropium", "label": "qva149, tiotropium", "shape": "dot", "size": 10}, {"color": "red", "id": "ficlatuzumab", "label": "ficlatuzumab", "shape": "dot", "size": 10}, {"color": "red", "id": " pf-04217329 - low dose", "label": " pf-04217329 - low dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminated5 fluorouracyl, acide folinique, irinotecan, oxaliplatin, cap\u00e9citabine, bevacizumab_colorectal neoplasms", "label": "terminated5 fluorouracyl, acide folinique, irinotecan, oxaliplatin, cap\u00e9citabine, bevacizumab_colorectal neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "inc280", "label": "inc280", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedagomelatine, placebo_major depressive disorder (mdd)", "label": "completedagomelatine, placebo_major depressive disorder (mdd)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtamoxifen, ralimetinib (ly2228820 dimesylate)_postmenopausal, metastatic breast cancer", "label": "terminatedtamoxifen, ralimetinib (ly2228820 dimesylate)_postmenopausal, metastatic breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "osteoarthritis of the knee, chronic lower back pain", "label": "osteoarthritis of the knee, chronic lower back pain", "shape": "dot", "size": 10}, {"color": "green", "id": " heavy menstrual bleeding", "label": " heavy menstrual bleeding", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aripiprazole, risperidone long acting injectable (lai), quetiapine", "label": "aripiprazole, risperidone long acting injectable (lai), quetiapine", "shape": "dot", "size": 10}, {"color": "green", "id": " deleterious brca2 gene mutation", "label": " deleterious brca2 gene mutation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedamg 827, placebo, amg 827, amg 827_asthma", "label": "completedamg 827, placebo, amg 827, amg 827_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " vitamin e 800iu", "label": " vitamin e 800iu", "shape": "dot", "size": 10}, {"color": "red", "id": " 2=clobetasol propionate foam", "label": " 2=clobetasol propionate foam", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedotx-tpa ~4\u00b5g/day over 2 mos. with natural tears drops, otx-tpb ~3\u00b5g/day over 3 months with natural tears drops, timolol maleate (0.5%) dosed twice daily with punctum plug without drug_glaucoma", "label": "completedotx-tpa ~4\u00b5g/day over 2 mos. with natural tears drops, otx-tpb ~3\u00b5g/day over 3 months with natural tears drops, timolol maleate (0.5%) dosed twice daily with punctum plug without drug_glaucoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hematologic diseases, acute-graft-versus-host disease, leukemia, non-hodgkin lymphoma (nhl), hodgkin lymphoma", "label": "hematologic diseases, acute-graft-versus-host disease, leukemia, non-hodgkin lymphoma (nhl), hodgkin lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": "selepressin", "label": "selepressin", "shape": "dot", "size": 10}, {"color": "red", "id": "mycophenolate sodium", "label": "mycophenolate sodium", "shape": "dot", "size": 10}, {"color": "green", "id": " diffuse large cell lymphoma", "label": " diffuse large cell lymphoma", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent lung non-small cell carcinoma", "label": " recurrent lung non-small cell carcinoma", "shape": "dot", "size": 10}, {"color": "green", "id": " mature t-cell and nk-cell non-hodgkin lymphoma", "label": " mature t-cell and nk-cell non-hodgkin lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": " alogliptin and glyburide", "label": " alogliptin and glyburide", "shape": "dot", "size": 10}, {"color": "red", "id": " indirubin 50 \u03bcg/g", "label": " indirubin 50 \u03bcg/g", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "solid tumor, non-small cell lung cancer metastatic", "label": "solid tumor, non-small cell lung cancer metastatic", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedribociclib, ceritinib_non-small cell lung cancer", "label": "completedribociclib, ceritinib_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazacitidine_acute myeloid leukemia, myelodysplastic syndrome", "label": "completedazacitidine_acute myeloid leukemia, myelodysplastic syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "topotecan hydrochloride, topotecan hydrochloride, acetylcysteine", "label": "topotecan hydrochloride, topotecan hydrochloride, acetylcysteine", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(C)[C@]1(CC(=NO1)C1=NC=CC2=CC=CC=C12)C(=O)N[C@H]1CC(=O)O[C@]1(O)CF", "label": "CC(C)[C@]1(CC(=NO1)C1=NC=CC2=CC=CC=C12)C(=O)N[C@H]1CC(=O)O[C@]1(O)CF", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(CC[C@@]([H])(CC1)N1CCN(CC2CC2)CC1)N=C(O)C1=CC(OC)=C(NC2=NC=C3N(C)C(=O)[C@@]([H])(CC)N(C(C)C)C3=N2)C=C1, COC(=O)C1=CC=C2C(NC(=O)\\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1", "label": "[H][C@@]1(CC[C@@]([H])(CC1)N1CCN(CC2CC2)CC1)N=C(O)C1=CC(OC)=C(NC2=NC=C3N(C)C(=O)[C@@]([H])(CC)N(C(C)C)C3=N2)C=C1, COC(=O)C1=CC=C2C(NC(=O)\\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfosaprepitant, dexamethasone, 5ht3_chemotherapy-induced nausea and vomiting", "label": "completedfosaprepitant, dexamethasone, 5ht3_chemotherapy-induced nausea and vomiting", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedvandetanib_advanced clear cell renal carcinoma", "label": "terminatedvandetanib_advanced clear cell renal carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cp-675,206 and gemcitabine", "label": "cp-675,206 and gemcitabine", "shape": "dot", "size": 10}, {"color": "red", "id": "nebivolol and valsartan 1", "label": "nebivolol and valsartan 1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "epinastine nasal spray, low concentration, low dose volume, epinastine nasal spray, low concentration, high dose volume, epinastine nasal spray, high concentration, low dose volume, epinastine nasal spray, high concentration, high dose volume", "label": "epinastine nasal spray, low concentration, low dose volume, epinastine nasal spray, low concentration, high dose volume, epinastine nasal spray, high concentration, low dose volume, epinastine nasal spray, high concentration, high dose volume", "shape": "dot", "size": 10}, {"color": "red", "id": " brivaracetam 10 mg", "label": " brivaracetam 10 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedly3023414, enzalutamide, placebo_prostate cancer metastatic", "label": "completedly3023414, enzalutamide, placebo_prostate cancer metastatic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, canagliflozin 300mg/placebo, canagliflozin 300mg/canagliflozin 150mg, canagliflozin 300mg_diabetes mellitus, type 2", "label": "completedplacebo, canagliflozin 300mg/placebo, canagliflozin 300mg/canagliflozin 150mg, canagliflozin 300mg_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CNC(=O)CC[C@@H](NC(=O)C1=CC=C(NCC2=CNC3=NC=NC(=O)C3=N2)C=C1)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O", "label": "[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CNC(=O)CC[C@@H](NC(=O)C1=CC=C(NCC2=CNC3=NC=NC(=O)C3=N2)C=C1)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfluorouracil, leucovorin, oxaliplatin_colorectal cancer", "label": "completedfluorouracil, leucovorin, oxaliplatin_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "e10030, ranibizumab, e10030 sham intravitreal injection", "label": "e10030, ranibizumab, e10030 sham intravitreal injection", "shape": "dot", "size": 10}, {"color": "red", "id": "f8il10", "label": "f8il10", "shape": "dot", "size": 10}, {"color": "red", "id": " linagliptine 5 mg and pioglitazone 30 mg", "label": " linagliptine 5 mg and pioglitazone 30 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sillymarin, placebo", "label": "sillymarin, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, C#CCN[C@@H]1CCC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, C#CCN[C@@H]1CCC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "varespladib (a-002), placebo", "label": "varespladib (a-002), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcobi, rtv, atv, ftc/tdf, cobi placebo, rtv placebo_hiv, hiv infections", "label": "completedcobi, rtv, atv, ftc/tdf, cobi placebo, rtv placebo_hiv, hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedniacin/ laropiprant_hyperlipoproteinemia, metabolic syndrome", "label": "terminatedniacin/ laropiprant_hyperlipoproteinemia, metabolic syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " [18F-]", "label": " [18F-]", "shape": "dot", "size": 10}, {"color": "blue", "id": " NC12CC3CC(CC(C3)C1)C2", "label": " NC12CC3CC(CC(C3)C1)C2", "shape": "dot", "size": 10}, {"color": "green", "id": " adult anaplastic ependymoma", "label": " adult anaplastic ependymoma", "shape": "dot", "size": 10}, {"color": "red", "id": " vitamin d3 5000 iu", "label": " vitamin d3 5000 iu", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnrivaroxaban oral tablet_spinal cord injuries, thromboembolism", "label": "withdrawnrivaroxaban oral tablet_spinal cord injuries, thromboembolism", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedospemifene 60 mg, placebo_atrophy, vaginal diseases", "label": "completedospemifene 60 mg, placebo_atrophy, vaginal diseases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " apixaban + placebo", "label": " apixaban + placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "nadolol", "label": "nadolol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfulvestrant, mk-0646, dasatinib_breast cancer", "label": "terminatedfulvestrant, mk-0646, dasatinib_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " yh12852 dr1 2mg", "label": " yh12852 dr1 2mg", "shape": "dot", "size": 10}, {"color": "red", "id": " supportive treatment", "label": " supportive treatment", "shape": "dot", "size": 10}, {"color": "red", "id": "non-coumadin oral anticoagulant", "label": "non-coumadin oral anticoagulant", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]1(O)N=C(O)C2=C3C4=CC=CC=C4N4C3=C3N(C5=CC=CC=C5C3=C12)[C@@]1(C)O[C@]4([H])C[C@@]([H])(NC)[C@@]1([H])OC, CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1", "label": "[H][C@]1(O)N=C(O)C2=C3C4=CC=CC=C4N4C3=C3N(C5=CC=CC=C5C3=C12)[C@@]1(C)O[C@]4([H])C[C@@]([H])(NC)[C@@]1([H])OC, CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1", "shape": "dot", "size": 10}, {"color": "red", "id": " epa-e 300 mg capsule", "label": " epa-e 300 mg capsule", "shape": "dot", "size": 10}, {"color": "red", "id": " and leucovorin)", "label": " and leucovorin)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "quetiapine fumarate, risperidone", "label": "quetiapine fumarate, risperidone", "shape": "dot", "size": 10}, {"color": "red", "id": " carboxymethylcellulose based lubricant eye drops", "label": " carboxymethylcellulose based lubricant eye drops", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedromosozumab, placebo_postmenopausal, osteopenia", "label": "completedromosozumab, placebo_postmenopausal, osteopenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completed5-fu_basal cell nevus syndrome, skin neoplasm, nodular basal cell carcinoma of skin", "label": "completed5-fu_basal cell nevus syndrome, skin neoplasm, nodular basal cell carcinoma of skin", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarboplatin, gemcitabine, bevacizumab, placebo_ovarian cancer", "label": "completedcarboplatin, gemcitabine, bevacizumab, placebo_ovarian cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " rivaroxaban", "label": " rivaroxaban", "shape": "dot", "size": 10}, {"color": "red", "id": "samarium 153", "label": "samarium 153", "shape": "dot", "size": 10}, {"color": "red", "id": "antibiotic treatment", "label": "antibiotic treatment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel, docetaxel, placebo, nintedanib", "label": "docetaxel, docetaxel, placebo, nintedanib", "shape": "dot", "size": 10}, {"color": "red", "id": "risperidone implant", "label": "risperidone implant", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrotigotine_idiopathic parkinson\u0027s disease", "label": "completedrotigotine_idiopathic parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsolifenacin succinate_overactive bladder", "label": "completedsolifenacin succinate_overactive bladder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "aslan001", "label": "aslan001", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chlorthalidone, hydrochlorothiazide", "label": "chlorthalidone, hydrochlorothiazide", "shape": "dot", "size": 10}, {"color": "green", "id": " peripheral vascular disease", "label": " peripheral vascular disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpixantrone, cyclophosphamide, vincristine, rituximab, prednisone, vinorelbine, oxalplatin, ifosfasmide, etoposide, mitoxatrone, gemcitabine or rituximab_lymphoma, non-hodgkin", "label": "completedpixantrone, cyclophosphamide, vincristine, rituximab, prednisone, vinorelbine, oxalplatin, ifosfasmide, etoposide, mitoxatrone, gemcitabine or rituximab_lymphoma, non-hodgkin", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedatazanavir (atv) + ritonavir (rtv), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (nrtis), continuation of current haart (boosted protease inhibitor [pi] combination + 2 nrtis)_hiv-associated lipodystrophy syndrome", "label": "completedatazanavir (atv) + ritonavir (rtv), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (nrtis), continuation of current haart (boosted protease inhibitor [pi] combination + 2 nrtis)_hiv-associated lipodystrophy syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "citicoline, placebo", "label": "citicoline, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddulaglutide, placebo, sglt2 inhibitor, metformin_type 2 diabetes mellitus", "label": "completeddulaglutide, placebo, sglt2 inhibitor, metformin_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gemcitabine, etanercept", "label": "gemcitabine, etanercept", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carvedilol, placebo", "label": "carvedilol, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "degarelix mid-luteal", "label": "degarelix mid-luteal", "shape": "dot", "size": 10}, {"color": "red", "id": "carboxymethylcellulose and glycerin based artificial tear", "label": "carboxymethylcellulose and glycerin based artificial tear", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glioma, brain neoplasms, brain metastasis", "label": "glioma, brain neoplasms, brain metastasis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtorsemide, placebo_preeclampsia", "label": "completedtorsemide, placebo_preeclampsia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " eye drops", "label": " eye drops", "shape": "dot", "size": 10}, {"color": "red", "id": " bms-986142", "label": " bms-986142", "shape": "dot", "size": 10}, {"color": "green", "id": "mucositis", "label": "mucositis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddasatinib_gastrointestinal stromal tumor", "label": "completeddasatinib_gastrointestinal stromal tumor", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedly2605541, insulin glargine, insulin lispro_diabetes mellitus, type 2", "label": "completedly2605541, insulin glargine, insulin lispro_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@@H]1O[C@@H]1P(O)(O)=O, [Na+].[Cl-]", "label": "C[C@@H]1O[C@@H]1P(O)(O)=O, [Na+].[Cl-]", "shape": "dot", "size": 10}, {"color": "red", "id": " pegylated-interferon-alfa-2a", "label": " pegylated-interferon-alfa-2a", "shape": "dot", "size": 10}, {"color": "red", "id": " benralizumab placebo", "label": " benralizumab placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " first line chemotherapy", "label": " first line chemotherapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddaclatasvir, placebo_chronic hepatitis c", "label": "completeddaclatasvir, placebo_chronic hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbortezomib, placebo, dexamethasone_multiple myeloma", "label": "completedbortezomib, placebo, dexamethasone_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "prediabetic state", "label": "prediabetic state", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpramipexol extended release, pramipexol immediate release, placebo_parkinson disease", "label": "completedpramipexol extended release, pramipexol immediate release, placebo_parkinson disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedeverolimus_glioblastoma multiforme", "label": "terminatedeverolimus_glioblastoma multiforme", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "olanzapine, chemotherapy (cisplatin or cyclophosphamide and doxorubicin), antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)", "label": "olanzapine, chemotherapy (cisplatin or cyclophosphamide and doxorubicin), antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvia-2291, placebo_coronary artery disease", "label": "completedvia-2291, placebo_coronary artery disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " OCC(=O)COP(O)(O)=O", "label": " OCC(=O)COP(O)(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active comparator, ena713", "label": "active comparator, ena713", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawniloprost inhalation solution (ventavis)_pulmonary arterial hypertension", "label": "withdrawniloprost inhalation solution (ventavis)_pulmonary arterial hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O", "label": "CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "drospirenone/17\u00df-estradiol (angeliq, bay86-4891), drospirenone/17\u00df-estradiol (angeliq, bay86-4891), sh k 00641 c - medroxyprogesterone acetate / conjugated equine (prempro tm)", "label": "drospirenone/17\u00df-estradiol (angeliq, bay86-4891), drospirenone/17\u00df-estradiol (angeliq, bay86-4891), sh k 00641 c - medroxyprogesterone acetate / conjugated equine (prempro tm)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsimvastatin, placebo_pneumonia", "label": "terminatedsimvastatin, placebo_pneumonia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "nephrolithiasis", "label": "nephrolithiasis", "shape": "dot", "size": 10}, {"color": "red", "id": "pro-067", "label": "pro-067", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvorinostat, ifosfamide, carboplatin, etoposide_adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, contiguous stage ii mantle cell lymphoma, cutaneous b-cell non-hodgkin lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone b-cell lymphoma, noncontiguous stage ii mantle cell lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, splenic marginal zone lymphoma, stage i cutaneous t-cell non-hodgkin lymphoma, stage i mantle cell lymphoma, stage i mycosis fungoides/sezary syndrome, stage ii cutaneous t-cell non-hodgkin lymphoma, stage ii mycosis fungoides/sezary syndrome, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii mantle cell lymphoma, stage iii mycosis fungoides/sezary syndrome, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv mantle cell lymphoma, stage iv mycosis fungoides/sezary syndrome, waldenstr\u00f6m macroglobulinemia", "label": "completedvorinostat, ifosfamide, carboplatin, etoposide_adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, contiguous stage ii mantle cell lymphoma, cutaneous b-cell non-hodgkin lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone b-cell lymphoma, noncontiguous stage ii mantle cell lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, splenic marginal zone lymphoma, stage i cutaneous t-cell non-hodgkin lymphoma, stage i mantle cell lymphoma, stage i mycosis fungoides/sezary syndrome, stage ii cutaneous t-cell non-hodgkin lymphoma, stage ii mycosis fungoides/sezary syndrome, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii mantle cell lymphoma, stage iii mycosis fungoides/sezary syndrome, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv mantle cell lymphoma, stage iv mycosis fungoides/sezary syndrome, waldenstr\u00f6m macroglobulinemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbyl719, gemcitabine, (nab)-paclitaxel_pancreatic cancer", "label": "completedbyl719, gemcitabine, (nab)-paclitaxel_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo respimat\u00ae inhaler", "label": " placebo respimat\u00ae inhaler", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedocv-501, placebo_acute myeloid leukemia", "label": "completedocv-501, placebo_acute myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chop regimen, epoch regimen, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate", "label": "chop regimen, epoch regimen, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hepatitis b virus, hbv", "label": "hepatitis b virus, hbv", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "osmotic-release methylphenidate, placebo", "label": "osmotic-release methylphenidate, placebo", "shape": "dot", "size": 10}, {"color": "green", "id": "spinal muscular atrophy", "label": "spinal muscular atrophy", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to bi 1034020", "label": " placebo to bi 1034020", "shape": "dot", "size": 10}, {"color": "red", "id": "adefovir dipivoxil and hepatitis b vaccination", "label": "adefovir dipivoxil and hepatitis b vaccination", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, doxorubicin hydrochloride, paclitaxel", "label": "cyclophosphamide, doxorubicin hydrochloride, paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfidaxomicin_inflammatory bowel disease (ibd), clostridium difficile infection (cdi)", "label": "completedfidaxomicin_inflammatory bowel disease (ibd), clostridium difficile infection (cdi)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN(C\\C=C\\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12", "label": "CN(C\\C=C\\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "green", "id": " postherpetic neuralgia (phn)", "label": " postherpetic neuralgia (phn)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "paliperidone extended release (er), aripiprazole", "label": "paliperidone extended release (er), aripiprazole", "shape": "dot", "size": 10}, {"color": "green", "id": " adult pineoblastoma", "label": " adult pineoblastoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gastroesophageal reflux, heartburn", "label": "gastroesophageal reflux, heartburn", "shape": "dot", "size": 10}, {"color": "red", "id": "azd2014 3 on/4 off \u0026 weekly paclitaxel", "label": "azd2014 3 on/4 off \u0026 weekly paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "stage iii prostate adenocarcinoma ajcc v7, stage iii prostate cancer ajcc v7, stage iv prostate adenocarcinoma ajcc v7, stage iv prostate cancer ajcc v7", "label": "stage iii prostate adenocarcinoma ajcc v7, stage iii prostate cancer ajcc v7, stage iv prostate adenocarcinoma ajcc v7, stage iv prostate cancer ajcc v7", "shape": "dot", "size": 10}, {"color": "red", "id": "nnc0114-0000-0005", "label": "nnc0114-0000-0005", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "insulin lispro, human insulin isophane suspension (nph), insulin glargine, human insulin isophane suspension, human insulin 30/70", "label": "insulin lispro, human insulin isophane suspension (nph), insulin glargine, human insulin isophane suspension, human insulin 30/70", "shape": "dot", "size": 10}, {"color": "red", "id": "selinexor", "label": "selinexor", "shape": "dot", "size": 10}, {"color": "green", "id": " overactive", "label": " overactive", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cariprazine, antidepressant therapy (adt)", "label": "cariprazine, antidepressant therapy (adt)", "shape": "dot", "size": 10}, {"color": "red", "id": " proton pump inhibitor", "label": " proton pump inhibitor", "shape": "dot", "size": 10}, {"color": "red", "id": "355", "label": "355", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O, CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1", "label": "[Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O, CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "neurogenic bladder, voiding dysfunction", "label": "neurogenic bladder, voiding dysfunction", "shape": "dot", "size": 10}, {"color": "red", "id": " erwinia l-asparaginase", "label": " erwinia l-asparaginase", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcontrol systolic blood pressure less than 120 mmhg, control systolic blood pressure less than 140 mmhg_coronary artery disease, hypertension", "label": "terminatedcontrol systolic blood pressure less than 120 mmhg, control systolic blood pressure less than 140 mmhg_coronary artery disease, hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carmustine, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, vinblastine", "label": "carmustine, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, vinblastine", "shape": "dot", "size": 10}, {"color": "red", "id": "pharmacotherapy", "label": "pharmacotherapy", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1", "label": "CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC1=C2OC(=O)C=CC2=CC2=C1OC=C2", "label": "COC1=C2OC(=O)C=CC2=CC2=C1OC=C2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nausea and vomiting, ovarian brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian mucinous cystadenocarcinoma, ovarian seromucinous carcinoma, ovarian serous cystadenocarcinoma, stage ii ovarian cancer, stage iia fallopian tube cancer, stage iia ovarian cancer, stage iib fallopian tube cancer, stage iib ovarian cancer, stage iic fallopian tube cancer, stage iic ovarian cancer, stage iiia fallopian tube cancer, stage iiia ovarian cancer, stage iiia primary peritoneal cancer, stage iiib fallopian tube cancer, stage iiib ovarian cancer, stage iiib primary peritoneal cancer, stage iiic fallopian tube cancer, stage iiic ovarian cancer, stage iiic primary peritoneal cancer, stage iv fallopian tube cancer, stage iv ovarian cancer, stage iv primary peritoneal cancer, undifferentiated ovarian carcinoma", "label": "nausea and vomiting, ovarian brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian mucinous cystadenocarcinoma, ovarian seromucinous carcinoma, ovarian serous cystadenocarcinoma, stage ii ovarian cancer, stage iia fallopian tube cancer, stage iia ovarian cancer, stage iib fallopian tube cancer, stage iib ovarian cancer, stage iic fallopian tube cancer, stage iic ovarian cancer, stage iiia fallopian tube cancer, stage iiia ovarian cancer, stage iiia primary peritoneal cancer, stage iiib fallopian tube cancer, stage iiib ovarian cancer, stage iiib primary peritoneal cancer, stage iiic fallopian tube cancer, stage iiic ovarian cancer, stage iiic primary peritoneal cancer, stage iv fallopian tube cancer, stage iv ovarian cancer, stage iv primary peritoneal cancer, undifferentiated ovarian carcinoma", "shape": "dot", "size": 10}, {"color": "red", "id": " gw642444 50mcg", "label": " gw642444 50mcg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuspre-radiotherapy commencement of arimidex, post radiotherapy commencement of arimidex_breast cancer", "label": "unknown statuspre-radiotherapy commencement of arimidex, post radiotherapy commencement of arimidex_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpazopanib eye drops_macular degeneration", "label": "terminatedpazopanib eye drops_macular degeneration", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaripiprazole, placebo_irritability associated with autistic disorder", "label": "completedaripiprazole, placebo_irritability associated with autistic disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " ann arbor stage iv indolent adult non-hodgkin lymphoma", "label": " ann arbor stage iv indolent adult non-hodgkin lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsgx942, placebo_oral mucositis", "label": "completedsgx942, placebo_oral mucositis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmycophenolate mofetil, prednisone_lupus nephritis", "label": "terminatedmycophenolate mofetil, prednisone_lupus nephritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C, [Na+].[Cl-]", "label": "CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C, [Na+].[Cl-]", "shape": "dot", "size": 10}, {"color": "green", "id": "chemotherapy associated neutropenia", "label": "chemotherapy associated neutropenia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sitagliptin phosphate, comparator: sitagliptin phosphate (mk0431), comparator: pioglitazone, comparator: placebo (unspecified)", "label": "sitagliptin phosphate, comparator: sitagliptin phosphate (mk0431), comparator: pioglitazone, comparator: placebo (unspecified)", "shape": "dot", "size": 10}, {"color": "green", "id": "primary peritoneal cavity cancer", "label": "primary peritoneal cavity cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfluorouracil_extrahepatic bile duct cancer, liver cancer", "label": "terminatedfluorouracil_extrahepatic bile duct cancer, liver cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "s-1+leucovorin", "label": "s-1+leucovorin", "shape": "dot", "size": 10}, {"color": "green", "id": "atherosclerotic cardiovascular disease", "label": "atherosclerotic cardiovascular disease", "shape": "dot", "size": 10}, {"color": "red", "id": "pbi4050", "label": "pbi4050", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent rectal carcinoma", "label": " recurrent rectal carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "myocet\u00ae plus cyclophosphamide and trastuzumab, 4 cycles, followed by docetaxel plus trastuzumab, 4 cycles, free doxorubicin plus cyclophosphamide, 4 cycles, followed by docetaxel plus trastuzumab, 4 cycles", "label": "myocet\u00ae plus cyclophosphamide and trastuzumab, 4 cycles, followed by docetaxel plus trastuzumab, 4 cycles, free doxorubicin plus cyclophosphamide, 4 cycles, followed by docetaxel plus trastuzumab, 4 cycles", "shape": "dot", "size": 10}, {"color": "red", "id": " keppra xr", "label": " keppra xr", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "duloxetine hydrochloride, venlafaxine extended release", "label": "duloxetine hydrochloride, venlafaxine extended release", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, O", "label": "CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, O", "shape": "dot", "size": 10}, {"color": "red", "id": "sb-742457", "label": "sb-742457", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedprograf, lcp-tacro_renal failure, tremors", "label": "completedprograf, lcp-tacro_renal failure, tremors", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "zoledronic acid, sm-153", "label": "zoledronic acid, sm-153", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(=O)OC1=CC=CC=C1C(O)=O, [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC, NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1", "label": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(=O)OC1=CC=CC=C1C(O)=O, [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC, NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1", "shape": "dot", "size": 10}, {"color": "red", "id": "sgn-40", "label": "sgn-40", "shape": "dot", "size": 10}, {"color": "green", "id": " myelodysplastic/myeloproliferative diseases", "label": " myelodysplastic/myeloproliferative diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "depression, hypertension", "label": "depression, hypertension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedamg 386, paclitaxel and carboplatin_carcinoma, fallopian tube cancer, ovarian cancer, primary peritoneal cancer", "label": "completedamg 386, paclitaxel and carboplatin_carcinoma, fallopian tube cancer, ovarian cancer, primary peritoneal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " adult medulloblastoma", "label": " adult medulloblastoma", "shape": "dot", "size": 10}, {"color": "red", "id": " pledox (5 \u00b5mol/kg)", "label": " pledox (5 \u00b5mol/kg)", "shape": "dot", "size": 10}, {"color": "red", "id": "efavirenz (efv)", "label": "efavirenz (efv)", "shape": "dot", "size": 10}, {"color": "green", "id": " metabolic acidosis", "label": " metabolic acidosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgrazoprevir, elbasvir, mk-5172a_chronic hepatitis c", "label": "completedgrazoprevir, elbasvir, mk-5172a_chronic hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "prucalopride", "label": "prucalopride", "shape": "dot", "size": 10}, {"color": "red", "id": " clopidogrel tapering", "label": " clopidogrel tapering", "shape": "dot", "size": 10}, {"color": "green", "id": " stage i adult immunoblastic large cell lymphoma", "label": " stage i adult immunoblastic large cell lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine, cisplatin_non-small cell lung cancer", "label": "completedgemcitabine, cisplatin_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedidp-118 vehicle lotion, idp-118 vehicle cream, idp-118 lotion, ultravate cream_psoriasis", "label": "completedidp-118 vehicle lotion, idp-118 vehicle cream, idp-118 lotion, ultravate cream_psoriasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " bay43-9006)", "label": " bay43-9006)", "shape": "dot", "size": 10}, {"color": "green", "id": "non small cell lung cancer (nsclc)", "label": "non small cell lung cancer (nsclc)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo-p", "label": " placebo-p", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "levalbuterol hfa mdi followed by racemic albuterol hfa mdi, racemic albuterol followed by levalbuterol hfa mdi", "label": "levalbuterol hfa mdi followed by racemic albuterol hfa mdi, racemic albuterol followed by levalbuterol hfa mdi", "shape": "dot", "size": 10}, {"color": "red", "id": "pre-radiotherapy commencement of arimidex", "label": "pre-radiotherapy commencement of arimidex", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " radiation fibrosis", "label": " radiation fibrosis", "shape": "dot", "size": 10}, {"color": "green", "id": "carcinoma of the appendix", "label": "carcinoma of the appendix", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedeverolimus, myfortic, sandimmun optoral, simulect\u00ae_kidney transplantation", "label": "completedeverolimus, myfortic, sandimmun optoral, simulect\u00ae_kidney transplantation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, lumacaftor plus ivacaftor combination, ivacaftor_cystic fibrosis, homozygous for the f508del cftr mutation", "label": "completedplacebo, lumacaftor plus ivacaftor combination, ivacaftor_cystic fibrosis, homozygous for the f508del cftr mutation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "tivozanib (av-951) plus folfox6", "label": "tivozanib (av-951) plus folfox6", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalogliptin, alogliptin, placebo_diabetes mellitus", "label": "completedalogliptin, alogliptin, placebo_diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmaxalt 10mg mlt plus caffeine 75mg, maxalt 10mg mlt plus placebo, placebo + placebo_migraine with aura, migraine without aura", "label": "completedmaxalt 10mg mlt plus caffeine 75mg, maxalt 10mg mlt plus placebo, placebo + placebo_migraine with aura, migraine without aura", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddeferasirox_hemoglobinopathies, myelodysplastic syndromes, other inherited or acquired anaemia, mpd syndrome, diamond-blackfan anemia, other rare anaemias, transfusional iron overload", "label": "completeddeferasirox_hemoglobinopathies, myelodysplastic syndromes, other inherited or acquired anaemia, mpd syndrome, diamond-blackfan anemia, other rare anaemias, transfusional iron overload", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1", "label": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedzonisamide, placebo_alcohol use disorders, bipolar disorder", "label": "terminatedzonisamide, placebo_alcohol use disorders, bipolar disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " tofacitinib ointment 20 mg/g", "label": " tofacitinib ointment 20 mg/g", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pain, osteoarthritis of the knee", "label": "pain, osteoarthritis of the knee", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednuc-1031 and carboplatin_recurrent ovarian cancer", "label": "completednuc-1031 and carboplatin_recurrent ovarian cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " formoterol (12 \u00b5g b.i.d.)", "label": " formoterol (12 \u00b5g b.i.d.)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "blue", "id": "C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2", "label": "C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2", "shape": "dot", "size": 10}, {"color": "red", "id": "stalevo (levodopa/carbidopa/entacapone)", "label": "stalevo (levodopa/carbidopa/entacapone)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "clostridium difficile infection, diarrhea", "label": "clostridium difficile infection, diarrhea", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]1(CNCCO1)[C@@](O)(CC1=C(OC)C=CC(F)=C1)C1CCOCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1", "label": "[H][C@]1(CNCCO1)[C@@](O)(CC1=C(OC)C=CC(F)=C1)C1CCOCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawncinacalcet hcl_secondary hyperparathyroidism, hypercalcemia", "label": "withdrawncinacalcet hcl_secondary hyperparathyroidism, hypercalcemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Na+].[Na+].[O-]P([O-])(F)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[Na+].[Na+].[O-]P([O-])(F)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "bacillus clausii", "label": "bacillus clausii", "shape": "dot", "size": 10}, {"color": "red", "id": " obe2109", "label": " obe2109", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "montelukast sodium, inhaled corticosteroid", "label": "montelukast sodium, inhaled corticosteroid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "label": "N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "shape": "dot", "size": 10}, {"color": "red", "id": "diprivan", "label": "diprivan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "label": "ClCCN(CCCl)P1(=O)NCCCO1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo (for mn-166), mn-166, riluzole", "label": "placebo (for mn-166), mn-166, riluzole", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone furoate/vilanterol inhalation powder, fluticasone furoate inhalation powder, fluticasone propionate inhalation powder", "label": "fluticasone furoate/vilanterol inhalation powder, fluticasone furoate inhalation powder, fluticasone propionate inhalation powder", "shape": "dot", "size": 10}, {"color": "green", "id": " kit positive", "label": " kit positive", "shape": "dot", "size": 10}, {"color": "red", "id": "trv130 1.5 mg", "label": "trv130 1.5 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " glucagon", "label": " glucagon", "shape": "dot", "size": 10}, {"color": "red", "id": " proair hfa inhaler", "label": " proair hfa inhaler", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedazd2014_stomach neoplasms", "label": "terminatedazd2014_stomach neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pertuzumab, erlotinib", "label": "pertuzumab, erlotinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnleucovorin calcium, irinotecan hydrochloride, fluorouracil_recurrent colon cancer, recurrent rectal cancer, stage iva colon cancer, stage iva rectal cancer, stage ivb colon cancer, stage ivb rectal cancer", "label": "withdrawnleucovorin calcium, irinotecan hydrochloride, fluorouracil_recurrent colon cancer, recurrent rectal cancer, stage iva colon cancer, stage iva rectal cancer, stage ivb colon cancer, stage ivb rectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " fec-doc adjuvant chemotherapy", "label": " fec-doc adjuvant chemotherapy", "shape": "dot", "size": 10}, {"color": "red", "id": "pegylated interferon-alpha-2a", "label": "pegylated interferon-alpha-2a", "shape": "dot", "size": 10}, {"color": "red", "id": " biphasic human insulin", "label": " biphasic human insulin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Mg++].[O-]S([O-])(=O)=O, [Na+].[Cl-]", "label": "[Mg++].[O-]S([O-])(=O)=O, [Na+].[Cl-]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusenbrel, lbec0101_arthritis, rheumatoid", "label": "unknown statusenbrel, lbec0101_arthritis, rheumatoid", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F", "shape": "dot", "size": 10}, {"color": "blue", "id": " CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O", "label": " CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedroniciclib (bay 1000394), etoposide, cisplatin, carboplatin_small cell lung carcinoma", "label": "terminatedroniciclib (bay 1000394), etoposide, cisplatin, carboplatin_small cell lung carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "100 micrograms fluticasone propionate, 500 micrograms fluticasone propionate, lactose powder", "label": "100 micrograms fluticasone propionate, 500 micrograms fluticasone propionate, lactose powder", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpembrolizumab, acp-196 in combination with pembrolizumab_metastatic urothelial carcinoma", "label": "completedpembrolizumab, acp-196 in combination with pembrolizumab_metastatic urothelial carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " childhood diffuse large cell lymphoma", "label": " childhood diffuse large cell lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": " open-label denosumab", "label": " open-label denosumab", "shape": "dot", "size": 10}, {"color": "red", "id": " januvia\u00ae", "label": " januvia\u00ae", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCOC1=NC=C(C=C1C1=NC2=C(CC)N(CCOC)N=C2C(=O)N1)S(=O)(=O)N1CCN(CC)CC1", "label": "CCOC1=NC=C(C=C1C1=NC2=C(CC)N(CCOC)N=C2C(=O)N1)S(=O)(=O)N1CCN(CC)CC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "triamcinolone acetonide + laser, ranibizumab + laser, sham injection + laser, ranibizumab + deferred laser", "label": "triamcinolone acetonide + laser, ranibizumab + laser, sham injection + laser, ranibizumab + deferred laser", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CC(=O)OC1=CC=CC=C1C(O)=O", "label": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CC(=O)OC1=CC=CC=C1C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma", "label": "relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": "amg 655", "label": "amg 655", "shape": "dot", "size": 10}, {"color": "red", "id": "capsaicin 8%", "label": "capsaicin 8%", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "zd6126, placebo, 5-fluorouracil, leucovorin, oxaliplatin", "label": "zd6126, placebo, 5-fluorouracil, leucovorin, oxaliplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fenoverine, timebutine", "label": "fenoverine, timebutine", "shape": "dot", "size": 10}, {"color": "red", "id": " aromatase inhibition", "label": " aromatase inhibition", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "infliximab, methylprednisolone, methotrexate", "label": "infliximab, methylprednisolone, methotrexate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedasenapine 5 mg, asenapine 10 mg, placebo_schizophrenia", "label": "completedasenapine 5 mg, asenapine 10 mg, placebo_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedoxaliplatin, capecitabine, trastuzumab_metastatic breast cancer, liver metastases", "label": "completedoxaliplatin, capecitabine, trastuzumab_metastatic breast cancer, liver metastases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iiib mycosis fungoides/sezary syndrome", "label": " stage iiib mycosis fungoides/sezary syndrome", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "label": "ClCCN(CCCl)P1(=O)NCCCO1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "shape": "dot", "size": 10}, {"color": "red", "id": " immediate release carbidopa/levodopa", "label": " immediate release carbidopa/levodopa", "shape": "dot", "size": 10}, {"color": "green", "id": "recurrent head and neck squamous cell carcinoma", "label": "recurrent head and neck squamous cell carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1, OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1", "label": "CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1, OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC(=O)C1=NC=CN=C1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1", "label": "NC(=O)C1=NC=CN=C1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedranibizumab, ranibizumab_diabetic retinopathy, macular edema", "label": "completedranibizumab, ranibizumab_diabetic retinopathy, macular edema", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "psoriasis, skin diseases, skin diseases, papulosquamous", "label": "psoriasis, skin diseases, skin diseases, papulosquamous", "shape": "dot", "size": 10}, {"color": "red", "id": "syb l-0501", "label": "syb l-0501", "shape": "dot", "size": 10}, {"color": "green", "id": "papillary thyroid cancer", "label": "papillary thyroid cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtandutinib_metastatic cancer, pain, prostate cancer", "label": "completedtandutinib_metastatic cancer, pain, prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ceftaroline", "label": " ceftaroline", "shape": "dot", "size": 10}, {"color": "red", "id": " inhaled insulin (exubera)", "label": " inhaled insulin (exubera)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "non-hodgkin\u0027s lymphoma, marginal zone lymphoma", "label": "non-hodgkin\u0027s lymphoma, marginal zone lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Na+].[Na+].[O-]P([O-])(F)=O", "label": "[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Na+].[Na+].[O-]P([O-])(F)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedindomethacin, placebo_post-ercp acute pancreatitis", "label": "terminatedindomethacin, placebo_post-ercp acute pancreatitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "standard chemotherapy (pemetrexed and cisplatin), standard chemotherapy (pemetrexed and cisplatin) + bevacizumab", "label": "standard chemotherapy (pemetrexed and cisplatin), standard chemotherapy (pemetrexed and cisplatin) + bevacizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedasacol 800 mg (mesalamine), asacol 400 mg (mesalamine)_ulcerative colitis", "label": "completedasacol 800 mg (mesalamine), asacol 400 mg (mesalamine)_ulcerative colitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrituximab_diffuse large b-cell lymphoma (dlbcl), follicular nhl grade 3b", "label": "completedrituximab_diffuse large b-cell lymphoma (dlbcl), follicular nhl grade 3b", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "lymphoid hematological malignancies", "label": "lymphoid hematological malignancies", "shape": "dot", "size": 10}, {"color": "red", "id": "fluticasone/formoterol bai", "label": "fluticasone/formoterol bai", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "label": "[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcreatine_parkinson\u0027s disease", "label": "terminatedcreatine_parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " pervasive developmental disorder not otherwise specified (pdd-nos)", "label": " pervasive developmental disorder not otherwise specified (pdd-nos)", "shape": "dot", "size": 10}, {"color": "red", "id": " doxorubicin hydrochloride (doxil/caelyx)", "label": " doxorubicin hydrochloride (doxil/caelyx)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedduloxetine, placebo_multiple sclerosis", "label": "completedduloxetine, placebo_multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "cl-108 (hydrodocone 7.5 mg", "label": "cl-108 (hydrodocone 7.5 mg", "shape": "dot", "size": 10}, {"color": "red", "id": "suramin drug:docetaxel drug: carboplatin", "label": "suramin drug:docetaxel drug: carboplatin", "shape": "dot", "size": 10}, {"color": "red", "id": " bi 207127: 24-week treatment", "label": " bi 207127: 24-week treatment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hypertension,, hyperlipidemia", "label": "hypertension,, hyperlipidemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedatazanavir/ritonavir, lopinavir/ritonavir_hiv infections", "label": "completedatazanavir/ritonavir, lopinavir/ritonavir_hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbortezomib, cyclophosphamide, prednisone, vincristine sulfate_lymphoma", "label": "completedbortezomib, cyclophosphamide, prednisone, vincristine sulfate_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedolodaterol (bi 1744), olodaterol (bi 1744), placebo, olodaterol (bi 1744), olodaterol (bi 1744) placebo_pulmonary disease, chronic obstructive", "label": "completedolodaterol (bi 1744), olodaterol (bi 1744), placebo, olodaterol (bi 1744), olodaterol (bi 1744) placebo_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " deferiprone (l1)", "label": " deferiprone (l1)", "shape": "dot", "size": 10}, {"color": "red", "id": "itopride hci 50 mg", "label": "itopride hci 50 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ischemic stroke, malignant edema", "label": "ischemic stroke, malignant edema", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbemiparin sodium, enoxaparin sodium_deep vein thrombosis", "label": "completedbemiparin sodium, enoxaparin sodium_deep vein thrombosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@](CS)(N=C(O)C(C)(C)S)C(O)=O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O", "label": "[H][C@@](CS)(N=C(O)C(C)(C)S)C(O)=O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O", "shape": "dot", "size": 10}, {"color": "green", "id": "diabetes complications", "label": "diabetes complications", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "human immunodeficiency virus, hepatitis c, chronic", "label": "human immunodeficiency virus, hepatitis c, chronic", "shape": "dot", "size": 10}, {"color": "red", "id": " 100 mg + lenalidomide", "label": " 100 mg + lenalidomide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedramucirumab, capecitabine, cisplatin, placebo, fluorouracil_metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma", "label": "completedramucirumab, capecitabine, cisplatin, placebo, fluorouracil_metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "label": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "er niacin/laropiprant, comparator : placebo (unspecified)", "label": "er niacin/laropiprant, comparator : placebo (unspecified)", "shape": "dot", "size": 10}, {"color": "red", "id": "atazanavir/ritonavir", "label": "atazanavir/ritonavir", "shape": "dot", "size": 10}, {"color": "blue", "id": "COCC(=O)NC\\C=C\\C1=CC=C2N=CN=C(NC3=CC=C(OC4=CC=C(C)N=C4)C(C)=C3)C2=C1", "label": "COCC(=O)NC\\C=C\\C1=CC=C2N=CN=C(NC3=CC=C(OC4=CC=C(C)N=C4)C(C)=C3)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mk3207- 2.5 mg, mk3207- 5 mg, mk3207- 10 mg, mk3207- 20 mg, mk3207- 50 mg, mk3207- 100 mg, comparator: placebo (unspecified)", "label": "mk3207- 2.5 mg, mk3207- 5 mg, mk3207- 10 mg, mk3207- 20 mg, mk3207- 50 mg, mk3207- 100 mg, comparator: placebo (unspecified)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CN1C=NC2=C1C=C(C(O)=NOCCO)C(NC1=C(Cl)C=C(Br)C=C1)=C2F", "label": "CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CN1C=NC2=C1C=C(C(O)=NOCCO)C(NC1=C(Cl)C=C(Br)C=C1)=C2F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddarunavir (drv, tmc114), darunavir (drv, tmc114)_hiv infections, aids virus, human immunodeficiency virus, acquired immunodeficiency syndrome virus", "label": "completeddarunavir (drv, tmc114), darunavir (drv, tmc114)_hiv infections, aids virus, human immunodeficiency virus, acquired immunodeficiency syndrome virus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "diabetes mellitus, type 1, diabetes mellitus, type 2", "label": "diabetes mellitus, type 1, diabetes mellitus, type 2", "shape": "dot", "size": 10}, {"color": "green", "id": " hepatic cirrhosis", "label": " hepatic cirrhosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedgm-csf, chop, rituximab_lymphoma, non-hodgkin, lymphoma, b-cell, lymphoma, diffuse", "label": "terminatedgm-csf, chop, rituximab_lymphoma, non-hodgkin, lymphoma, b-cell, lymphoma, diffuse", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "breast cancer, iron overload, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, neuroblastoma, ovarian cancer", "label": "breast cancer, iron overload, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, neuroblastoma, ovarian cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "testicular cancer, germ cell cancer", "label": "testicular cancer, germ cell cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN\\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CN\\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CC1=CC(O)=CC(C)=C1Cl", "label": "CN\\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CN\\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "red", "id": "comparator: taranabant", "label": "comparator: taranabant", "shape": "dot", "size": 10}, {"color": "red", "id": "nifedipine (adalat", "label": "nifedipine (adalat", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "label": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo matching with metformin ir", "label": " placebo matching with metformin ir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingfludarabine, cyclophosphamide, rituximab, lenalidomide_chronic lymphocytic leukemia (cll)", "label": "active, not recruitingfludarabine, cyclophosphamide, rituximab, lenalidomide_chronic lymphocytic leukemia (cll)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "metastatic colorectal cancer, colon cancer, rectal cancer", "label": "metastatic colorectal cancer, colon cancer, rectal cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)[C@]1(CC[C@@]2(CC1)OCCC1=C2NC2=CC=C(F)C=C12)C1=CC=CC=C1, CN(C)[C@]1(CC[C@@]2(CC1)OCCC1=C2NC2=CC=C(F)C=C12)C1=CC=CC=C1, CN(C)[C@]1(CC[C@@]2(CC1)OCCC1=C2NC2=CC=C(F)C=C12)C1=CC=CC=C1, NCC1(CC(O)=O)CCCCC1, CC1=CC(O)=CC(C)=C1Cl", "label": "CN(C)[C@]1(CC[C@@]2(CC1)OCCC1=C2NC2=CC=C(F)C=C12)C1=CC=CC=C1, CN(C)[C@]1(CC[C@@]2(CC1)OCCC1=C2NC2=CC=C(F)C=C12)C1=CC=CC=C1, CN(C)[C@]1(CC[C@@]2(CC1)OCCC1=C2NC2=CC=C(F)C=C12)C1=CC=CC=C1, NCC1(CC(O)=O)CCCCC1, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sarcoma, chemotherapy-induced nausea and vomiting, effects of chemotherapy, adverse effects of medical drugs", "label": "sarcoma, chemotherapy-induced nausea and vomiting, effects of chemotherapy, adverse effects of medical drugs", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "thrombosis, venous", "label": "thrombosis, venous", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "anemia, renal failure, chronic renal failure", "label": "anemia, renal failure, chronic renal failure", "shape": "dot", "size": 10}, {"color": "red", "id": " rasagiline mesylate plus mirapex", "label": " rasagiline mesylate plus mirapex", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dabigatran etexilate 110mg, warfarin 3mg, aspirin, dabigatran etexilate 150mg, clopidogrel or ticagrelor, clopidogrel or ticagrelor, warfarin 5mg, clopidogrel or ticagrelor, warfarin 1mg", "label": "dabigatran etexilate 110mg, warfarin 3mg, aspirin, dabigatran etexilate 150mg, clopidogrel or ticagrelor, clopidogrel or ticagrelor, warfarin 5mg, clopidogrel or ticagrelor, warfarin 1mg", "shape": "dot", "size": 10}, {"color": "red", "id": "telbivudine (ldt)", "label": "telbivudine (ldt)", "shape": "dot", "size": 10}, {"color": "green", "id": " breast cancer female", "label": " breast cancer female", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O", "label": "[H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O", "shape": "dot", "size": 10}, {"color": "red", "id": "montelukast placebo", "label": "montelukast placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedeverolimus, mycophenolic acid (mpa), cyclosporine a (csa), basiliximab, corticosteroids_kidney transplantation, graft rejection", "label": "completedeverolimus, mycophenolic acid (mpa), cyclosporine a (csa), basiliximab, corticosteroids_kidney transplantation, graft rejection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcadazolid, vancomycin, cadazolid-matching placebo, vancomycin-matching placebo_clostridium difficile infection", "label": "completedcadazolid, vancomycin, cadazolid-matching placebo, vancomycin-matching placebo_clostridium difficile infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "z160", "label": "z160", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cisplatin, capecitabine, gemcitabine, nab-paclitaxel", "label": "cisplatin, capecitabine, gemcitabine, nab-paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adenocarcinoma of the prostate, hormone-refractory prostate cancer, recurrent prostate cancer, stage iv prostate cancer", "label": "adenocarcinoma of the prostate, hormone-refractory prostate cancer, recurrent prostate cancer, stage iv prostate cancer", "shape": "dot", "size": 10}, {"color": "blue", "id": "OC1=CC=C(C=C1)C1=COC2=C(C(O)=CC(O)=C2)C1=O", "label": "OC1=CC=C(C=C1)C1=COC2=C(C(O)=CC(O)=C2)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "cnto 1959 (5 mg)", "label": "cnto 1959 (5 mg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "everolimus, everolimus, everolimus, exemestane, bi 836845, bi 836845, exemestane, exemestane", "label": "everolimus, everolimus, everolimus, exemestane, bi 836845, bi 836845, exemestane, exemestane", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "td-4208", "label": "td-4208", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carboplatin, etoposide, ibrutinib, ifosfamide", "label": "carboplatin, etoposide, ibrutinib, ifosfamide", "shape": "dot", "size": 10}, {"color": "red", "id": " alprostadil", "label": " alprostadil", "shape": "dot", "size": 10}, {"color": "red", "id": " doxorubicin 50 mg/m^2", "label": " doxorubicin 50 mg/m^2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedimatinib mesylate, placebo (for imatinib mesylate)_diabetes mellitus, type i, diabetes mellitus, insulin-dependent, 1, type 1 diabetes mellitus, insulin-dependent diabetes mellitus 1, iddm", "label": "completedimatinib mesylate, placebo (for imatinib mesylate)_diabetes mellitus, type i, diabetes mellitus, insulin-dependent, 1, type 1 diabetes mellitus, insulin-dependent diabetes mellitus 1, iddm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ramucirumab, placebo, erlotinib, gefitinib, osimertinib", "label": "ramucirumab, placebo, erlotinib, gefitinib, osimertinib", "shape": "dot", "size": 10}, {"color": "red", "id": "aripiprazole+ adt", "label": "aripiprazole+ adt", "shape": "dot", "size": 10}, {"color": "red", "id": " tiotropium+olodaterol", "label": " tiotropium+olodaterol", "shape": "dot", "size": 10}, {"color": "red", "id": " ral placebo", "label": " ral placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsolifenacin succinate, solifenacin succinate, oxybutynin hydrochloride, placebo_multiple sclerosis, neurogenic bladder, spinal cord diseases", "label": "completedsolifenacin succinate, solifenacin succinate, oxybutynin hydrochloride, placebo_multiple sclerosis, neurogenic bladder, spinal cord diseases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcandesartan/hct, rosuvastatin_cardiovascular disease, stroke", "label": "completedcandesartan/hct, rosuvastatin_cardiovascular disease, stroke", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O", "label": "COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "single dose polycap, double dose polycap", "label": "single dose polycap, double dose polycap", "shape": "dot", "size": 10}, {"color": "red", "id": "telapristone acetate", "label": "telapristone acetate", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to reformulated raltegravir", "label": " placebo to reformulated raltegravir", "shape": "dot", "size": 10}, {"color": "green", "id": " metastatic malignant neoplasm", "label": " metastatic malignant neoplasm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tiotropium, indacaterol", "label": "tiotropium, indacaterol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, non-steroidal aromatase inhibitor therapy, zoledronic acid", "label": "placebo, non-steroidal aromatase inhibitor therapy, zoledronic acid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "obsessive-compulsive disorder, ocd", "label": "obsessive-compulsive disorder, ocd", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cardiac surgery, cardiopulmonary bypass", "label": "cardiac surgery, cardiopulmonary bypass", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC2=C3OC4=CC=C(C=C4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]4C(C=C2OC2=C(Cl)C=C(C=C2)[C@@H](O)[C@@H]2NC(=O)[C@H](NC4=O)C4=CC(=C(O)C=C4)C4=C(O)C(CNCP(O)(O)=O)=C(O)C=C4[C@H](NC2=O)C(O)=O)=C3)O[C@@H](C)[C@H]1O", "label": "CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC2=C3OC4=CC=C(C=C4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]4C(C=C2OC2=C(Cl)C=C(C=C2)[C@@H](O)[C@@H]2NC(=O)[C@H](NC4=O)C4=CC(=C(O)C=C4)C4=C(O)C(CNCP(O)(O)=O)=C(O)C=C4[C@H](NC2=O)C(O)=O)=C3)O[C@@H](C)[C@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "red", "id": " ckd-828 40/5mg", "label": " ckd-828 40/5mg", "shape": "dot", "size": 10}, {"color": "red", "id": "exenatide once weekly (bydureon\u2122)", "label": "exenatide once weekly (bydureon\u2122)", "shape": "dot", "size": 10}, {"color": "green", "id": " myofascial pain syndromes", "label": " myofascial pain syndromes", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "macitentan (act-064992), macitentan (act-064992), placebo", "label": "macitentan (act-064992), macitentan (act-064992), placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "ocv-501", "label": "ocv-501", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "sb010", "label": "sb010", "shape": "dot", "size": 10}, {"color": "red", "id": "treximet\u00ae", "label": "treximet\u00ae", "shape": "dot", "size": 10}, {"color": "red", "id": " 1000 mg/m^2", "label": " 1000 mg/m^2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedepoetin alfa_anemia, aging", "label": "terminatedepoetin alfa_anemia, aging", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedro5185426_malignant melanoma", "label": "completedro5185426_malignant melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iv adult burkitt lymphoma", "label": " stage iv adult burkitt lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": " dhap", "label": " dhap", "shape": "dot", "size": 10}, {"color": "blue", "id": " [C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO", "label": " [C@H]1([C@@H]2[C@H]([C@@H](N3C4=CC(=C(C)C=C4[N+]([Co-3]456(N7C8=C(C9=[N+]4C(C([C@@H]9CCC(N)=O)(C)C)=CC4=[N+]5C(=C(C5=[N+]6[C@@]([C@]7([C@@H]([C@@]8(C)CCC(=O)NC[C@@]([H])(C)OP([O-])(=O)O2)CC(N)=O)[H])([C@@]([C@@H]5CCC(N)=O)(C)CC(N)=O)C)C)[C@@]([C@@H]4CCC(N)=O)(C)CC(N)=O)C)C#N)=C3)C)O1)O)CO", "shape": "dot", "size": 10}, {"color": "red", "id": "abt-288", "label": "abt-288", "shape": "dot", "size": 10}, {"color": "green", "id": "peripheral arterial occlusive disease", "label": "peripheral arterial occlusive disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine/carboplatin, iniparib_breast cancer", "label": "completedgemcitabine/carboplatin, iniparib_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "albiglutide, sulfonylurea, biguanide, glinide, thiazolidinedione, alpha-glucosidase inhibitor", "label": "albiglutide, sulfonylurea, biguanide, glinide, thiazolidinedione, alpha-glucosidase inhibitor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednateglinide, acarbose_diabetes mellitus, type 2 diabetes mellitus", "label": "completednateglinide, acarbose_diabetes mellitus, type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "flucloxacillin, placebo (for flucloxacillin)", "label": "flucloxacillin, placebo (for flucloxacillin)", "shape": "dot", "size": 10}, {"color": "red", "id": " granulocyte colony stimulating factor (gcsf)", "label": " granulocyte colony stimulating factor (gcsf)", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to nva237 and indacaterol 150 \u00b5g", "label": " placebo to nva237 and indacaterol 150 \u00b5g", "shape": "dot", "size": 10}, {"color": "red", "id": " heparin lock", "label": " heparin lock", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcytarabine, idarubicin, all-trans retinoic acid, mitoxantrone, etoposid_acute myeloid leukemia", "label": "completedcytarabine, idarubicin, all-trans retinoic acid, mitoxantrone, etoposid_acute myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "budesonide/formoterol \u0027as needed\u0027 + budesonide placebo bid, budesonode bid + terbutaline \u0027as needed\u0027", "label": "budesonide/formoterol \u0027as needed\u0027 + budesonide placebo bid, budesonode bid + terbutaline \u0027as needed\u0027", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aprepitant, comparator: placebo (unspecified)", "label": "aprepitant, comparator: placebo (unspecified)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O", "label": "CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCC1=C(O[C@@H]2CCN(C2)C(=O)C=C)N=C(NC2=CC=C(C=C2)N2CCC(CC2)N2CCN(C)CC2)C(=N1)C(N)=O", "label": "CCC1=C(O[C@@H]2CCN(C2)C(=O)C=C)N=C(NC2=CC=C(C=C2)N2CCC(CC2)N2CCN(C)CC2)C(=N1)C(N)=O", "shape": "dot", "size": 10}, {"color": "green", "id": "metastatic hepatocellular carcinoma", "label": "metastatic hepatocellular carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gastric carcinoma, gastroesophageal junction carcinoma", "label": "gastric carcinoma, gastroesophageal junction carcinoma", "shape": "dot", "size": 10}, {"color": "red", "id": "sarilumab sar153191 (regn88)", "label": "sarilumab sar153191 (regn88)", "shape": "dot", "size": 10}, {"color": "red", "id": "investigational treatment", "label": "investigational treatment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedetoposide, cyclophosphamide, doxorubicin hydrochloride, lamivudine, prednisone, vincristine sulfate, zidovudine_lymphoma", "label": "completedetoposide, cyclophosphamide, doxorubicin hydrochloride, lamivudine, prednisone, vincristine sulfate, zidovudine_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedclevudine_chronic hepatitis b", "label": "terminatedclevudine_chronic hepatitis b", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednomac-e2, levonorgestrel and ethinyl estradiol_contraception", "label": "completednomac-e2, levonorgestrel and ethinyl estradiol_contraception", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "adjuvant chemotherapy with paclitaxel and nedaplatin", "label": "adjuvant chemotherapy with paclitaxel and nedaplatin", "shape": "dot", "size": 10}, {"color": "red", "id": " tafamidis", "label": " tafamidis", "shape": "dot", "size": 10}, {"color": "green", "id": " dme", "label": " dme", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "infectious skin diseases, bacterial skin diseases, staphylococcal skin infections, streptococcal infections, abscess", "label": "infectious skin diseases, bacterial skin diseases, staphylococcal skin infections, streptococcal infections, abscess", "shape": "dot", "size": 10}, {"color": "red", "id": " pf-04217329 - high dose", "label": " pf-04217329 - high dose", "shape": "dot", "size": 10}, {"color": "red", "id": " non-biologic disease modifying anti-rheumatic drug (dmard)", "label": " non-biologic disease modifying anti-rheumatic drug (dmard)", "shape": "dot", "size": 10}, {"color": "red", "id": " prc-063 100 mg", "label": " prc-063 100 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo iv, placebo sc", "label": "placebo iv, placebo sc", "shape": "dot", "size": 10}, {"color": "green", "id": "human immunodeficiency virus infection", "label": "human immunodeficiency virus infection", "shape": "dot", "size": 10}, {"color": "green", "id": "adult acute erythroid leukemia (m6)", "label": "adult acute erythroid leukemia (m6)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "wx-671, placebo", "label": "wx-671, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinotuzumab ozogamicin (cmc-544), rituximab (rituxan)_lymphoma, b-cell", "label": "completedinotuzumab ozogamicin (cmc-544), rituximab (rituxan)_lymphoma, b-cell", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N1CCN(CC1)C1CCCC1)=C2O, NNC(=O)C1=CC=NC=C1", "label": "CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\\C=N\\N1CCN(CC1)C1CCCC1)=C2O, NNC(=O)C1=CC=NC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCNC(=O)N(CCCl)N=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C", "label": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCNC(=O)N(CCCl)N=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmenopur, synarel, hcg trigger, clomiphene citrate, letrozole_infertility", "label": "completedmenopur, synarel, hcg trigger, clomiphene citrate, letrozole_infertility", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " salbutamol mdi", "label": " salbutamol mdi", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "leukemia, lymphoma, myeloma", "label": "leukemia, lymphoma, myeloma", "shape": "dot", "size": 10}, {"color": "red", "id": " valsartan + amlodipine 80/2.5 mg", "label": " valsartan + amlodipine 80/2.5 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedenzalutamide_metastatic prostate cancer", "label": "completedenzalutamide_metastatic prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, N[C@@H](CCCNC(N)=N)C(O)=O, FC1=CNC(=O)NC1=O, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, ClCCN(CCCl)P1(=O)NCCCO1", "label": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, N[C@@H](CCCNC(N)=N)C(O)=O, FC1=CNC(=O)NC1=O, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, ClCCN(CCCl)P1(=O)NCCCO1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcnp520, placebo_alzheimer\u0027s disease", "label": "completedcnp520, placebo_alzheimer\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iva oral cavity squamous cell carcinoma ajcc v6 and v7", "label": " stage iva oral cavity squamous cell carcinoma ajcc v6 and v7", "shape": "dot", "size": 10}, {"color": "red", "id": " rasagiline 1 mg capsule", "label": " rasagiline 1 mg capsule", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O, COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC", "label": "ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O, COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC", "shape": "dot", "size": 10}, {"color": "red", "id": "febuxostat ir", "label": "febuxostat ir", "shape": "dot", "size": 10}, {"color": "red", "id": "cal02 low-dose", "label": "cal02 low-dose", "shape": "dot", "size": 10}, {"color": "red", "id": "mk3207- 2.5 mg", "label": "mk3207- 2.5 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " alogliptin 25 mg", "label": " alogliptin 25 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1", "label": "CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iva rectal cancer ajcc v7", "label": " stage iva rectal cancer ajcc v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedly2495655, placebo, standard of care chemotherapy_pancreatic cancer", "label": "completedly2495655, placebo, standard of care chemotherapy_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "osteoarthritis, arthritis, rheumatoid", "label": "osteoarthritis, arthritis, rheumatoid", "shape": "dot", "size": 10}, {"color": "red", "id": " b12", "label": " b12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "doxorubicin-eluting beads, sorafenib tosylate", "label": "doxorubicin-eluting beads, sorafenib tosylate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvivitrol 380 mg, placebo_alcohol dependence", "label": "completedvivitrol 380 mg, placebo_alcohol dependence", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC1=CC=C(C[C@@H](O)C2=CC(OC)=C(OC)C(OC)=C2)C=C1O", "label": "COC1=CC=C(C[C@@H](O)C2=CC(OC)=C(OC)C(OC)=C2)C=C1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1", "label": "NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nifedipine (adalat, baya1040) and valsartan, nifedipine (adalat, baya1040), valsartan", "label": "nifedipine (adalat, baya1040) and valsartan, nifedipine (adalat, baya1040), valsartan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(=O)C1=CC=C2OC(C)(C)[C@@H](O)[C@@H](NC(=O)C3=CC=C(F)C(Cl)=C3)C2=C1, CC(=O)C1=CC=C2OC(C)(C)[C@@H](O)[C@@H](NC(=O)C3=CC=C(F)C(Cl)=C3)C2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC(=O)C1=CC=C2OC(C)(C)[C@@H](O)[C@@H](NC(=O)C3=CC=C(F)C(Cl)=C3)C2=C1, CC(=O)C1=CC=C2OC(C)(C)[C@@H](O)[C@@H](NC(=O)C3=CC=C(F)C(Cl)=C3)C2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedstandard-dose lopinavir/ritonavir, double-dose lopinavir/ritonavir, raltegravir, isoniazid, pyridoxine, pyrazinamide, ethambutol, rifabutin, rifampin_hiv infection, tuberculosis", "label": "terminatedstandard-dose lopinavir/ritonavir, double-dose lopinavir/ritonavir, raltegravir, isoniazid, pyridoxine, pyrazinamide, ethambutol, rifabutin, rifampin_hiv infection, tuberculosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "coronary artery disease, decreased left ventricular function", "label": "coronary artery disease, decreased left ventricular function", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusdovitinib_clear cell renal cell carcinoma", "label": "unknown statusdovitinib_clear cell renal cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "leukemia, precursor-b acute lymphoblastic leukemia, lymphoblastic lymphoma, lymphoma", "label": "leukemia, precursor-b acute lymphoblastic leukemia, lymphoblastic lymphoma, lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmirabegron, solifenacin succinate, placebo_urologic diseases, urinary bladder diseases, urological manifestations, signs and symptoms, urinary bladder, overactive", "label": "completedmirabegron, solifenacin succinate, placebo_urologic diseases, urinary bladder diseases, urological manifestations, signs and symptoms, urinary bladder, overactive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " contiguous stage ii adult diffuse large cell lymphoma", "label": " contiguous stage ii adult diffuse large cell lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "continue na treatment, discontinue na treatment", "label": "continue na treatment, discontinue na treatment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedly573636-sodium_ovarian cancer, fallopian tube cancer, primary peritoneal cancer", "label": "completedly573636-sodium_ovarian cancer, fallopian tube cancer, primary peritoneal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedglivec, gleevec_cancer", "label": "terminatedglivec, gleevec_cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "axial spondyloarthritis", "label": "axial spondyloarthritis", "shape": "dot", "size": 10}, {"color": "red", "id": "cy", "label": "cy", "shape": "dot", "size": 10}, {"color": "green", "id": " prodromal alzheimer\u0027s disease", "label": " prodromal alzheimer\u0027s disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedacei or arb, lisinopril_type 2 diabetes", "label": "terminatedacei or arb, lisinopril_type 2 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsunitinib_ascites", "label": "terminatedsunitinib_ascites", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " dexchlorpheniramine or diphenhydramine", "label": " dexchlorpheniramine or diphenhydramine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "milrinone, dobutamine", "label": "milrinone, dobutamine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "label": "CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "mecasermin", "label": "mecasermin", "shape": "dot", "size": 10}, {"color": "red", "id": " other ppi marketed in sweden", "label": " other ppi marketed in sweden", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hepatitis c virus infection, chronic hepatitis c, compensated cirrhosis", "label": "hepatitis c virus infection, chronic hepatitis c, compensated cirrhosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ertugliflozin 5 mg, ertugliflozin 10 mg, glimerpiride, placebo to ertugliflozin, placebo to glimepiride, metformin, sitagliptin", "label": "ertugliflozin 5 mg, ertugliflozin 10 mg, glimerpiride, placebo to ertugliflozin, placebo to glimepiride, metformin, sitagliptin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedobinutuzumab, bendamustine_non-hodgkin\u0027s lymphoma", "label": "completedobinutuzumab, bendamustine_non-hodgkin\u0027s lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCN(CC)CCN1C(=O)C2=C(C1=O)C1=C(N([C@@H]3O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]3O)C3=C(Cl)C=CC=C13)C1=C2C2=C(N1)C(Cl)=CC=C2, FC1=CNC(=O)NC1=O", "label": "CCN(CC)CCN1C(=O)C2=C(C1=O)C1=C(N([C@@H]3O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]3O)C3=C(Cl)C=CC=C13)C1=C2C2=C(N1)C(Cl)=CC=C2, FC1=CNC(=O)NC1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmycophenolate mofetil [cellcept], tacrolimus, cyclosporine, sirolimus_liver transplantation", "label": "completedmycophenolate mofetil [cellcept], tacrolimus, cyclosporine, sirolimus_liver transplantation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " with or without liver decompensation", "label": " with or without liver decompensation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glaucoma, open-angle, ocular hypertension", "label": "glaucoma, open-angle, ocular hypertension", "shape": "dot", "size": 10}, {"color": "red", "id": "300 ir house dust mites allergen extract tablet", "label": "300 ir house dust mites allergen extract tablet", "shape": "dot", "size": 10}, {"color": "red", "id": " mycophenolic plus tacrolimus", "label": " mycophenolic plus tacrolimus", "shape": "dot", "size": 10}, {"color": "red", "id": " ritonavir (nrv)", "label": " ritonavir (nrv)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedclofarabine, cytarabine, thymoglobulin_myelodysplastic syndromes, acute myeloid leukemia", "label": "terminatedclofarabine, cytarabine, thymoglobulin_myelodysplastic syndromes, acute myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbevacizumab [avastin], capecitabine, irinotecan_colorectal cancer", "label": "completedbevacizumab [avastin], capecitabine, irinotecan_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " unresectable thyroid gland carcinoma", "label": " unresectable thyroid gland carcinoma", "shape": "dot", "size": 10}, {"color": "green", "id": " cardiovascular death", "label": " cardiovascular death", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pioglitazone, placebo, nitroglycerin", "label": "pioglitazone, placebo, nitroglycerin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaclidinium bromide, tiotropium, placebo_chronic obstructive pulmonary disease (copd)", "label": "completedaclidinium bromide, tiotropium, placebo_chronic obstructive pulmonary disease (copd)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedasparaginase, methotrexate, dexamethasone, leucovorin calcium, mercaptopurine, vincristine_recurrent adult acute lymphoblastic leukemia", "label": "terminatedasparaginase, methotrexate, dexamethasone, leucovorin calcium, mercaptopurine, vincristine_recurrent adult acute lymphoblastic leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "floxuridine, dexamethasone, gemcitabine, oxaliplatin", "label": "floxuridine, dexamethasone, gemcitabine, oxaliplatin", "shape": "dot", "size": 10}, {"color": "green", "id": " chemotherapy effect", "label": " chemotherapy effect", "shape": "dot", "size": 10}, {"color": "red", "id": "argatroban", "label": "argatroban", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedeluxadoline, placebo_irritable bowel syndrome with diarrhea", "label": "completedeluxadoline, placebo_irritable bowel syndrome with diarrhea", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedhtx-011, placebo_analgesia", "label": "completedhtx-011, placebo_analgesia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusvortioxetine, placebo_social anxiety disorder, major depressive disorder", "label": "unknown statusvortioxetine, placebo_social anxiety disorder, major depressive disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N", "label": "OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N", "shape": "dot", "size": 10}, {"color": "red", "id": "concomitant radiochemotherapy - radiotherapy 66 gy", "label": "concomitant radiochemotherapy - radiotherapy 66 gy", "shape": "dot", "size": 10}, {"color": "blue", "id": " C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1", "label": " C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsonazoid_cutaneous melanoma, melanoma", "label": "terminatedsonazoid_cutaneous melanoma, melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CO\\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1", "label": "CO\\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CC(O)=O, CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1", "label": "CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CC(O)=O, CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedquizartinib_leukemia, myeloid, acute", "label": "completedquizartinib_leukemia, myeloid, acute", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "switch to myfortic", "label": "switch to myfortic", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fosrenol (lanthanum carbonate), sevelamer hydrochloride", "label": "fosrenol (lanthanum carbonate), sevelamer hydrochloride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ogx-427, abiraterone acetate, prednisone", "label": "ogx-427, abiraterone acetate, prednisone", "shape": "dot", "size": 10}, {"color": "red", "id": "placebo (sham inhaler)", "label": "placebo (sham inhaler)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazacitidine (aza), tyrosine kinase inhibitor (tki), azacitidine_leukemia", "label": "completedazacitidine (aza), tyrosine kinase inhibitor (tki), azacitidine_leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN(C)C(=O)[C@@H]1CCCN1C(=O)NCC1=CC=C(C=C1C)C(=O)N1CCCCC2=C1C=CC=C2", "label": "CN(C)C(=O)[C@@H]1CCCN1C(=O)NCC1=CC=C(C=C1C)C(=O)N1CCCCC2=C1C=CC=C2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, CSCC[C@H](N)C(O)=O, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, CSCC[C@H](N)C(O)=O, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclosporine a, tacrolimus, basiliximab, methylprednisolone, prednisone", "label": "cyclosporine a, tacrolimus, basiliximab, methylprednisolone, prednisone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtiotropium plus salmeterol, fluticasone/salmeterol_pulmonary disease, chronic obstructive", "label": "completedtiotropium plus salmeterol, fluticasone/salmeterol_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " C#CCN[C@@H]1CCC2=CC=CC=C12", "label": " C#CCN[C@@H]1CCC2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic constipation, constipation", "label": "chronic constipation, constipation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedipi 504 plus docetaxel, placebo plus docetaxel_non small cell lung cancer", "label": "completedipi 504 plus docetaxel, placebo plus docetaxel_non small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "carboxymethylcellulose based eye drop formulation a", "label": "carboxymethylcellulose based eye drop formulation a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedly2189265, placebo, liraglutide_type 2 diabetes mellitus", "label": "completedly2189265, placebo, liraglutide_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " emtricitabine/tenofovir disoproxil fumarate (ftc/tdf)", "label": " emtricitabine/tenofovir disoproxil fumarate (ftc/tdf)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fpns, ffns, placebo ffns, placebo fpns", "label": "fpns, ffns, placebo ffns, placebo fpns", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone furoate/gw642444, fluticasone propionate", "label": "fluticasone furoate/gw642444, fluticasone propionate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcediranib, olaparib_ovarian cancer", "label": "active, not recruitingcediranib, olaparib_ovarian cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "anthracycline-based", "label": "anthracycline-based", "shape": "dot", "size": 10}, {"color": "green", "id": " skin fibrosis", "label": " skin fibrosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfulvestrant, sorafenib tosylate_breast cancer", "label": "terminatedfulvestrant, sorafenib tosylate_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "triferic", "label": "triferic", "shape": "dot", "size": 10}, {"color": "red", "id": "regn475", "label": "regn475", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "geographic atrophy, age related macular degeneration", "label": "geographic atrophy, age related macular degeneration", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iv prostate cancer ajcc v7", "label": " stage iv prostate cancer ajcc v7", "shape": "dot", "size": 10}, {"color": "red", "id": " ombitasvir/paritaprevir/ritonavir", "label": " ombitasvir/paritaprevir/ritonavir", "shape": "dot", "size": 10}, {"color": "red", "id": "bdp", "label": "bdp", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rituximab, placebo", "label": "rituximab, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "tamsulosin hydrochloride", "label": "tamsulosin hydrochloride", "shape": "dot", "size": 10}, {"color": "red", "id": " etoposide phosphate", "label": " etoposide phosphate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, [Na+].[Cl-]", "label": "OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, [Na+].[Cl-]", "shape": "dot", "size": 10}, {"color": "red", "id": " ciprofloxacin (bayq3939) dry powder for inhalation", "label": " ciprofloxacin (bayq3939) dry powder for inhalation", "shape": "dot", "size": 10}, {"color": "red", "id": " clopidogrel or prasugrel)", "label": " clopidogrel or prasugrel)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cardiac allograft vasculopathy, heart transplant recipients", "label": "cardiac allograft vasculopathy, heart transplant recipients", "shape": "dot", "size": 10}, {"color": "red", "id": "nitrofurantoin monohydrate/macrocrystalline capsules", "label": "nitrofurantoin monohydrate/macrocrystalline capsules", "shape": "dot", "size": 10}, {"color": "red", "id": "surinabant (sr147778)", "label": "surinabant (sr147778)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrotigotine_advanced idiopathic parkinson\u0027s disease", "label": "completedrotigotine_advanced idiopathic parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CO[C@@H]1C[C@@H](CC[C@H]1O)\\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\\C(C)=C\\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2, N[C@@H](CCCNC(N)=N)C(O)=O, COC(=O)\\C=C\\C(O)=O", "label": "CO[C@@H]1C[C@@H](CC[C@H]1O)\\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\\C(C)=C\\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2, N[C@@H](CCCNC(N)=N)C(O)=O, COC(=O)\\C=C\\C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(=O)OC1=CC=CC=C1C(O)=O, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl, CC(=O)OC1=CC=CC=C1C(O)=O, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl", "label": "CC(=O)OC1=CC=CC=C1C(O)=O, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl, CC(=O)OC1=CC=CC=C1C(O)=O, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "loperamide, placebo", "label": "loperamide, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "rovalpituzumab tesirine", "label": "rovalpituzumab tesirine", "shape": "dot", "size": 10}, {"color": "green", "id": " mantle cell lymphoma", "label": " mantle cell lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O, [H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C", "label": "[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O, [H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gwp42003-p 20 mg/kg/day dose, placebo", "label": "gwp42003-p 20 mg/kg/day dose, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "aromatase inhibitor", "label": "aromatase inhibitor", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent non-small cell lung cancer", "label": " recurrent non-small cell lung cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "glipizide", "label": "glipizide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedplacebo ellipta, nemiralisib ellipta 50 \u00b5g, nemiralisib ellipta 100 \u00b5g, nemiralisib ellipta 250 \u00b5g, nemiralisib ellipta 500 \u00b5g, nemiralisib ellipta 750 \u00b5g, albuterol (salbutamol) mdi or nebules, standard of care therapy_pulmonary disease, chronic obstructive", "label": "terminatedplacebo ellipta, nemiralisib ellipta 50 \u00b5g, nemiralisib ellipta 100 \u00b5g, nemiralisib ellipta 250 \u00b5g, nemiralisib ellipta 500 \u00b5g, nemiralisib ellipta 750 \u00b5g, albuterol (salbutamol) mdi or nebules, standard of care therapy_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " attempted", "label": " attempted", "shape": "dot", "size": 10}, {"color": "green", "id": " non small cell lung", "label": " non small cell lung", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddaptomycin, vancomycin_staphylococcal infections, methicillin-resistant staphylococcus aureus", "label": "terminateddaptomycin, vancomycin_staphylococcal infections, methicillin-resistant staphylococcus aureus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pertuzumab, placebo, trastuzumab, docetaxel", "label": "pertuzumab, placebo, trastuzumab, docetaxel", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo (ga-0034)", "label": " placebo (ga-0034)", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1", "label": " CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " trisomy 8", "label": " trisomy 8", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N", "label": " CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlapatinib, paclitaxel, fluorouracil, epidoxorubicin, cyclophosphamide_neoplasms, breast", "label": "completedlapatinib, paclitaxel, fluorouracil, epidoxorubicin, cyclophosphamide_neoplasms, breast", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpalbociclib, anastrozole, letrozole, exemestane, fulvestrant_breast cancer", "label": "completedpalbociclib, anastrozole, letrozole, exemestane, fulvestrant_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbortezomib, acyclovir_non-small cell lung cancer", "label": "completedbortezomib, acyclovir_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C", "label": " CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CNNCC1=CC=C(C=C1)C(=O)NC(C)C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "label": "ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CNNCC1=CC=C(C=C1)C(=O)NC(C)C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " fluticasone propionate 250mcg/ salmeterol 50mcg", "label": " fluticasone propionate 250mcg/ salmeterol 50mcg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]", "label": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]", "shape": "dot", "size": 10}, {"color": "blue", "id": " CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1", "label": " CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "label": "CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": " tmc649128.", "label": " tmc649128.", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvalproic acid_head and neck cancer, oral cavity cancer, oropharyngeal cancer", "label": "completedvalproic acid_head and neck cancer, oral cavity cancer, oropharyngeal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lapatinib oral tablets, placebo", "label": "lapatinib oral tablets, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "taribavirin, taribavirin, taribavirin, ribavirin", "label": "taribavirin, taribavirin, taribavirin, ribavirin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN(C)C(=N)NC(N)=N, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN(C)C(=N)NC(N)=N, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddocetaxel, oxaliplatin, capecitabine_stomach neoplasms", "label": "completeddocetaxel, oxaliplatin, capecitabine_stomach neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlamotrigine (lamictal) extended-release, placebo_epilepsy, tonic-clonic", "label": "completedlamotrigine (lamictal) extended-release, placebo_epilepsy, tonic-clonic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alendronate, denosumab", "label": "alendronate, denosumab", "shape": "dot", "size": 10}, {"color": "red", "id": "bvt.115959", "label": "bvt.115959", "shape": "dot", "size": 10}, {"color": "blue", "id": " NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1", "label": " NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedofatumumab + bendamustine_chronic lymphocytic leukemia (cll)", "label": "terminatedofatumumab + bendamustine_chronic lymphocytic leukemia (cll)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "incb013739", "label": "incb013739", "shape": "dot", "size": 10}, {"color": "red", "id": "sildenafil 100mg single oral dose", "label": "sildenafil 100mg single oral dose", "shape": "dot", "size": 10}, {"color": "red", "id": " mometasone 200 mcg", "label": " mometasone 200 mcg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvalsartan, placebo_carotid artery diseases, atherosclerosis", "label": "completedvalsartan, placebo_carotid artery diseases, atherosclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaliskiren_hypertension", "label": "completedaliskiren_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "mesalazine (mesalamine)", "label": "mesalazine (mesalamine)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "indacaterol, formoterol (12 \u00b5g b.i.d.), tiotropium (18 \u00b5g o.d.), placebo to indacaterol, placebo to formoterol", "label": "indacaterol, formoterol (12 \u00b5g b.i.d.), tiotropium (18 \u00b5g o.d.), placebo to indacaterol, placebo to formoterol", "shape": "dot", "size": 10}, {"color": "red", "id": " sch 619734 dose 3", "label": " sch 619734 dose 3", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgranulocyte-colony stimulating factor (g-csf), fixed dose plerixafor, weight-based plerixafor_non-hodgkin\u0027s lymphoma", "label": "completedgranulocyte-colony stimulating factor (g-csf), fixed dose plerixafor, weight-based plerixafor_non-hodgkin\u0027s lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chemotherapy (induction period), rituximab", "label": "chemotherapy (induction period), rituximab", "shape": "dot", "size": 10}, {"color": "red", "id": " concurrent brimonidine 0.2% and 0.5% timolol", "label": " concurrent brimonidine 0.2% and 0.5% timolol", "shape": "dot", "size": 10}, {"color": "red", "id": "placebo matched to atacicept", "label": "placebo matched to atacicept", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsom230, placebo_cluster headache - episodic and chronic", "label": "terminatedsom230, placebo_cluster headache - episodic and chronic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawndasatinib_advanced lymphoma, advanced malignant solid neoplasm, hematopoietic and lymphoid cell neoplasm, refractory lymphoma, refractory malignant solid neoplasm, refractory plasma cell myeloma", "label": "withdrawndasatinib_advanced lymphoma, advanced malignant solid neoplasm, hematopoietic and lymphoid cell neoplasm, refractory lymphoma, refractory malignant solid neoplasm, refractory plasma cell myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "malignant neoplasm", "label": "malignant neoplasm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalisertib_advanced solid tumors, lymphomas", "label": "completedalisertib_advanced solid tumors, lymphomas", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedflutiform 250/10, skp-fluticasone, flovent fluticasone hfa_asthma", "label": "completedflutiform 250/10, skp-fluticasone, flovent fluticasone hfa_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " oncology patients", "label": " oncology patients", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mycophenolate sodium, cyclophosphamide", "label": "mycophenolate sodium, cyclophosphamide", "shape": "dot", "size": 10}, {"color": "red", "id": " intravenous immunoglobulin", "label": " intravenous immunoglobulin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[O-][N+]1=CC(Cl)=C(NC(=O)C2=CC=C(OC(F)F)C3=C2C2=C(O3)C=CN=C2)C(Cl)=C1, [O-][N+]1=CC(Cl)=C(NC(=O)C2=CC=C(OC(F)F)C3=C2C2=C(O3)C=CN=C2)C(Cl)=C1, [O-][N+]1=CC(Cl)=C(NC(=O)C2=CC=C(OC(F)F)C3=C2C2=C(O3)C=CN=C2)C(Cl)=C1, [Na+].[Cl-]", "label": "[O-][N+]1=CC(Cl)=C(NC(=O)C2=CC=C(OC(F)F)C3=C2C2=C(O3)C=CN=C2)C(Cl)=C1, [O-][N+]1=CC(Cl)=C(NC(=O)C2=CC=C(OC(F)F)C3=C2C2=C(O3)C=CN=C2)C(Cl)=C1, [O-][N+]1=CC(Cl)=C(NC(=O)C2=CC=C(OC(F)F)C3=C2C2=C(O3)C=CN=C2)C(Cl)=C1, [Na+].[Cl-]", "shape": "dot", "size": 10}, {"color": "red", "id": " teriflunomide", "label": " teriflunomide", "shape": "dot", "size": 10}, {"color": "red", "id": " sm-13496 (lurasidone hcl)", "label": " sm-13496 (lurasidone hcl)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbenralizumab arm a, benralizumab arm b, benralizumab arm c, placebo_moderate to very severe chronic obstructive pulmonary disease", "label": "completedbenralizumab arm a, benralizumab arm b, benralizumab arm c, placebo_moderate to very severe chronic obstructive pulmonary disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel plus doxercalciferol, docetaxel plus placebo", "label": "docetaxel plus doxercalciferol, docetaxel plus placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "mb07803", "label": "mb07803", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedofatumumab subcutaneous injection, teriflunomide-matching placebo capsules, teriflunomide capsule, matching placebo of ofatumumab subcutaneous injections_relapsing multiple scelrosis", "label": "completedofatumumab subcutaneous injection, teriflunomide-matching placebo capsules, teriflunomide capsule, matching placebo of ofatumumab subcutaneous injections_relapsing multiple scelrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnvoriconazole (topical), topical sterile water placebo group_pain, thermal injury, burns, hyperalgesia", "label": "withdrawnvoriconazole (topical), topical sterile water placebo group_pain, thermal injury, burns, hyperalgesia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rosiglitazone, gliclazide (comparison drug)", "label": "rosiglitazone, gliclazide (comparison drug)", "shape": "dot", "size": 10}, {"color": "green", "id": " moderate chronic obstructive pulmonary disease", "label": " moderate chronic obstructive pulmonary disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedctap101 30 \u03bcg capsules_chronic kidney disease, hyperparathyroidism, secondary, vitamin d deficiency", "label": "completedctap101 30 \u03bcg capsules_chronic kidney disease, hyperparathyroidism, secondary, vitamin d deficiency", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuscisplatin_head and neck cancer", "label": "unknown statuscisplatin_head and neck cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "pvc suppression using flecainide", "label": "pvc suppression using flecainide", "shape": "dot", "size": 10}, {"color": "green", "id": " painful neuropathy", "label": " painful neuropathy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingfluoruracil, oxaliplatin, irinotecan, bevacizumab_metastatic colorectal cancer", "label": "active, not recruitingfluoruracil, oxaliplatin, irinotecan, bevacizumab_metastatic colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "roche", "label": "roche", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedint-747, placebo_diabetes mellitus, type ii, fatty liver", "label": "completedint-747, placebo_diabetes mellitus, type ii, fatty liver", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "sovaprevir", "label": "sovaprevir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC[C@H]1CC[C@@H](CC1)C(O)=O", "label": "ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC[C@H]1CC[C@@H](CC1)C(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": " minimal residual disease", "label": " minimal residual disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completederlotinib, satraplatin_lung cancer", "label": "completederlotinib, satraplatin_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcabazitaxel plus bavituximab_prostate cancer, prostatic neoplasms", "label": "terminatedcabazitaxel plus bavituximab_prostate cancer, prostatic neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " adult lymphocyte predominant hodgkin lymphoma", "label": " adult lymphocyte predominant hodgkin lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": " 1%", "label": " 1%", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalvocidib, irinotecan hydrochloride_liver cancer", "label": "completedalvocidib, irinotecan hydrochloride_liver cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedadc3680, placebo, montelukast_asthma", "label": "completedadc3680, placebo, montelukast_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gemcitabine, trastuzumab", "label": "gemcitabine, trastuzumab", "shape": "dot", "size": 10}, {"color": "red", "id": "budesonide/formoterol turbuhaler", "label": "budesonide/formoterol turbuhaler", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcisplatin, etoposide_drug/agent toxicity by tissue/organ, testicular germ cell tumor", "label": "completedcisplatin, etoposide_drug/agent toxicity by tissue/organ, testicular germ cell tumor", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, prucalopride", "label": "placebo, prucalopride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtheramine, theramine- like placebo_knee pain, knee chondroplasty", "label": "terminatedtheramine, theramine- like placebo_knee pain, knee chondroplasty", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "gemcabene 150 mg", "label": "gemcabene 150 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " cpt-11", "label": " cpt-11", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "odm-201 tablet a, odm-201 tablet b, odm-201 capsule formulation", "label": "odm-201 tablet a, odm-201 tablet b, odm-201 capsule formulation", "shape": "dot", "size": 10}, {"color": "red", "id": " atomoxetine", "label": " atomoxetine", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "label": " CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebos, formoterol inhalant powder, budesonide powder, budesonide and formoterol product", "label": "placebos, formoterol inhalant powder, budesonide powder, budesonide and formoterol product", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusdocetaxel, liposomal doxorubicine and cyclophosphamide_breast cancer", "label": "unknown statusdocetaxel, liposomal doxorubicine and cyclophosphamide_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1, COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1, CC(C)NCC(O)COC1=CC=CC2=C1C=CN2, NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1", "label": "COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1, COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1, CC(C)NCC(O)COC1=CC=CC2=C1C=CN2, NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedasenapine_psychosis", "label": "completedasenapine_psychosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedradium-223 dichloride (xofigo, bay88-8223), radium-223 dichloride (xofigo, bay88-8223), radium-223 dichloride (xofigo, bay88-8223)_prostatic neoplasms", "label": "completedradium-223 dichloride (xofigo, bay88-8223), radium-223 dichloride (xofigo, bay88-8223), radium-223 dichloride (xofigo, bay88-8223)_prostatic neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " fluticasone 100 mcg", "label": " fluticasone 100 mcg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic hepatitis c, genotype 4 chronic hepatitis c", "label": "chronic hepatitis c, genotype 4 chronic hepatitis c", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, milnacipran", "label": "placebo, milnacipran", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedrp101, gemcitabine (1000 mg/m2)_pancreatic cancer", "label": "terminatedrp101, gemcitabine (1000 mg/m2)_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rituximab [mabthera/rituxan], methotrexate", "label": "rituximab [mabthera/rituxan], methotrexate", "shape": "dot", "size": 10}, {"color": "red", "id": "leo 90100", "label": "leo 90100", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carcinoma, non-small-cell lung, lung neoplasms", "label": "carcinoma, non-small-cell lung, lung neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmontelukast sodium, comparator: placebo, comparator: fluticasone, comparator: placebo_asthma", "label": "completedmontelukast sodium, comparator: placebo, comparator: fluticasone, comparator: placebo_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "inhaled nitric oxide - 30 mcg/kg ibw/hr, inhaled nitric oxide 5,10,15 mcg/kg ibw/hr, inhaled nitric oxide 75 mcg/kg ibw/hr", "label": "inhaled nitric oxide - 30 mcg/kg ibw/hr, inhaled nitric oxide 5,10,15 mcg/kg ibw/hr, inhaled nitric oxide 75 mcg/kg ibw/hr", "shape": "dot", "size": 10}, {"color": "red", "id": " pp3m 263 mg eq.", "label": " pp3m 263 mg eq.", "shape": "dot", "size": 10}, {"color": "red", "id": "glimepiride/ metformin", "label": "glimepiride/ metformin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NCCS, CC1=CC(O)=CC(C)=C1Cl", "label": "NCCS, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusphotrex (rostaporfin)_macular degeneration", "label": "unknown statusphotrex (rostaporfin)_macular degeneration", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedranibizumab, sham to ranibizumab_diabetic macular edema", "label": "completedranibizumab, sham to ranibizumab_diabetic macular edema", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate", "label": "cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmycophenolate mofetil withdrawal, cyclosporione a withdrawal_renal transplantation", "label": "terminatedmycophenolate mofetil withdrawal, cyclosporione a withdrawal_renal transplantation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " unipolar", "label": " unipolar", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "plinabulin, pegfilgrastim", "label": "plinabulin, pegfilgrastim", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1, CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1, CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1", "label": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1, CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1, CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nonmetastatic castration-resistant prostate cancer, prostate cancer, cancer of the prostate", "label": "nonmetastatic castration-resistant prostate cancer, prostate cancer, cancer of the prostate", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo amlodipine", "label": " placebo amlodipine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "green", "id": " pineal region neoplasm", "label": " pineal region neoplasm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo_refractory generalized myasthenia gravis", "label": "completedplacebo_refractory generalized myasthenia gravis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "testosterone gel, placebo", "label": "testosterone gel, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsirolimus_chronic graft-versus-host-disease, oral mucosal disease due to graft-versus-host disease", "label": "terminatedsirolimus_chronic graft-versus-host-disease, oral mucosal disease due to graft-versus-host disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(C=C3CC[C@@]21[H])=NO", "label": "[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(C=C3CC[C@@]21[H])=NO", "shape": "dot", "size": 10}, {"color": "blue", "id": "S1SSSSSSS1", "label": "S1SSSSSSS1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azacitidine, azacitidine + lenalidomide", "label": "azacitidine, azacitidine + lenalidomide", "shape": "dot", "size": 10}, {"color": "green", "id": " surgical site infection", "label": " surgical site infection", "shape": "dot", "size": 10}, {"color": "red", "id": "atripla (r)", "label": "atripla (r)", "shape": "dot", "size": 10}, {"color": "red", "id": "zytiga\u00ae (abiraterone acetate)", "label": "zytiga\u00ae (abiraterone acetate)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcisplatin, docetaxel, fluorouracil, paclitaxel_head and neck cancer", "label": "terminatedcisplatin, docetaxel, fluorouracil, paclitaxel_head and neck cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedchampix_smoking", "label": "completedchampix_smoking", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpaliperidone, placebo_schizophrenia", "label": "completedpaliperidone, placebo_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo (part b)", "label": " placebo (part b)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "paclitaxel, docetaxel", "label": "paclitaxel, docetaxel", "shape": "dot", "size": 10}, {"color": "red", "id": " hctz 12.5 mg tablet", "label": " hctz 12.5 mg tablet", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "inhaled fluticasone propionate, salmeterol, montelukast", "label": "inhaled fluticasone propionate, salmeterol, montelukast", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iiic cutaneous melanoma ajcc v7", "label": " stage iiic cutaneous melanoma ajcc v7", "shape": "dot", "size": 10}, {"color": "red", "id": " lx7101 (0.25%)", "label": " lx7101 (0.25%)", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo (for enzalutamide)", "label": " placebo (for enzalutamide)", "shape": "dot", "size": 10}, {"color": "red", "id": " fluoropyrimidine-based chemotherapy", "label": " fluoropyrimidine-based chemotherapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completederlotinib hydrochloride, tivantinib_recurrent renal cell carcinoma, stage iii renal cell cancer, stage iv renal cell cancer, type 1 papillary renal cell carcinoma, type 2 papillary renal cell carcinoma", "label": "completederlotinib hydrochloride, tivantinib_recurrent renal cell carcinoma, stage iii renal cell cancer, stage iv renal cell cancer, type 1 papillary renal cell carcinoma, type 2 papillary renal cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent disease", "label": " recurrent disease", "shape": "dot", "size": 10}, {"color": "red", "id": " duration of treatment - during each treatment cycle", "label": " duration of treatment - during each treatment cycle", "shape": "dot", "size": 10}, {"color": "red", "id": "lifitegrast", "label": "lifitegrast", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent adult soft tissue sarcoma", "label": " recurrent adult soft tissue sarcoma", "shape": "dot", "size": 10}, {"color": "red", "id": " dexmedetomidine", "label": " dexmedetomidine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1, CC1=CC(O)=CC(C)=C1Cl", "label": "O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "red", "id": "uk-369", "label": "uk-369", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbatefenterol, umeclidinium/ vilanterol, placebo_pulmonary disease, chronic obstructive", "label": "completedbatefenterol, umeclidinium/ vilanterol, placebo_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "gantenerumab", "label": "gantenerumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "red", "id": "bdp nasal aerosol", "label": "bdp nasal aerosol", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo (pbo) oral capsules", "label": " placebo (pbo) oral capsules", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bevacizumab, capecitabine", "label": "bevacizumab, capecitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "herceptin, taxol, fluorouracil, cytoxan, epirubicin", "label": "herceptin, taxol, fluorouracil, cytoxan, epirubicin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(CN(CC(O)=O)CC(O)=O)CN(CC(O)=O)CC(O)=O, OC(CN(CC(O)=O)CC(O)=O)CN(CC(O)=O)CC(O)=O", "label": "OC(CN(CC(O)=O)CC(O)=O)CN(CC(O)=O)CC(O)=O, OC(CN(CC(O)=O)CC(O)=O)CN(CC(O)=O)CC(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gsk233705 12.5mcg, gsk233705 25mcg, gsk233705 50mcg, gsk233705 100mcg, gsk233705 200mcg, placebo", "label": "gsk233705 12.5mcg, gsk233705 25mcg, gsk233705 50mcg, gsk233705 100mcg, gsk233705 200mcg, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "non-alcoholic fatty liver disease (nafld, hypertriglyceridemia", "label": "non-alcoholic fatty liver disease (nafld, hypertriglyceridemia", "shape": "dot", "size": 10}, {"color": "green", "id": " non-hodgkins lymphoma", "label": " non-hodgkins lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": " best standard of care", "label": " best standard of care", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "coronary artery disease, angina, unstable", "label": "coronary artery disease, angina, unstable", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cytarabine, etoposide, leucovorin calcium, methotrexate, temozolomide", "label": "cytarabine, etoposide, leucovorin calcium, methotrexate, temozolomide", "shape": "dot", "size": 10}, {"color": "red", "id": "taranabant", "label": "taranabant", "shape": "dot", "size": 10}, {"color": "red", "id": "vildagliptin 100 mg qd", "label": "vildagliptin 100 mg qd", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusplacebo, rozerem 8mg_insomnia", "label": "unknown statusplacebo, rozerem 8mg_insomnia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "comparator: sitagliptin phosphate (sitagliptin)", "label": "comparator: sitagliptin phosphate (sitagliptin)", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)CC[C@]12C", "label": "[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)CC[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Ca], [Ca]", "label": "[Ca], [Ca]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bipolar disorder, depression, depressive disorder", "label": "bipolar disorder, depression, depressive disorder", "shape": "dot", "size": 10}, {"color": "red", "id": "combination of pegylated interferon alfa-2b (peg) and ribavirin (rbv)", "label": "combination of pegylated interferon alfa-2b (peg) and ribavirin (rbv)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbay1142524, bay1142524, bay1142524, bay1142524, placebo_heart failure", "label": "completedbay1142524, bay1142524, bay1142524, bay1142524, placebo_heart failure", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlaquinimod, placebo_huntington\u0027s disease", "label": "completedlaquinimod, placebo_huntington\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " aerosolized placebo", "label": " aerosolized placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "peginterferon alfa-2a [pegasys], copegus", "label": "peginterferon alfa-2a [pegasys], copegus", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, ba058 80 mcg, teriparatide_osteoporosis, postmenopausal osteoporosis", "label": "completedplacebo, ba058 80 mcg, teriparatide_osteoporosis, postmenopausal osteoporosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1, CN1N=CC(Cl)=C1C1=C(Cl)SC(=C1)C(=O)N[C@H](CN)CC1=CC=CC(F)=C1", "label": "CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1, CN1N=CC(Cl)=C1C1=C(Cl)SC(=C1)C(=O)N[C@H](CN)CC1=CC=CC(F)=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingceftriaxone, flucloxacillin_cellulitis", "label": "active, not recruitingceftriaxone, flucloxacillin_cellulitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "lha510 ophthalmic suspension", "label": "lha510 ophthalmic suspension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpradigastat (lcq908), placebo_coronary artery disease, hypertriglyceridemia", "label": "terminatedpradigastat (lcq908), placebo_coronary artery disease, hypertriglyceridemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednaltrexone sr 32 mg/ bupropion sr 360 mg/ day, placebo_obesity, overweight", "label": "completednaltrexone sr 32 mg/ bupropion sr 360 mg/ day, placebo_obesity, overweight", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "testicular neoplasms, neoplasms, germ cell and embryonal, neoplasms, testicular diseases, gonadal disorders, antineoplastic agents, molecular mechanisms of pharmacological action", "label": "testicular neoplasms, neoplasms, germ cell and embryonal, neoplasms, testicular diseases, gonadal disorders, antineoplastic agents, molecular mechanisms of pharmacological action", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "locally advance breast cancer (labc), metastatic breast cancer (mbc)", "label": "locally advance breast cancer (labc), metastatic breast cancer (mbc)", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo identical to bi10773 low dose", "label": " placebo identical to bi10773 low dose", "shape": "dot", "size": 10}, {"color": "red", "id": " idp-122 vehicle lotion", "label": " idp-122 vehicle lotion", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CSCC[C@H](N)C(O)=O", "label": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CSCC[C@H](N)C(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": " fluid overload", "label": " fluid overload", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingselumetinib, docetaxel, placebo, pegylated g-csf_locally advanced or metastatic non small cell lung cancer stage iiib - iv", "label": "active, not recruitingselumetinib, docetaxel, placebo, pegylated g-csf_locally advanced or metastatic non small cell lung cancer stage iiib - iv", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedenzalutamide_bladder cancer", "label": "terminatedenzalutamide_bladder cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ldv/sof", "label": "ldv/sof", "shape": "dot", "size": 10}, {"color": "green", "id": " polyneuropathy", "label": " polyneuropathy", "shape": "dot", "size": 10}, {"color": "red", "id": " morphine prolonged release", "label": " morphine prolonged release", "shape": "dot", "size": 10}, {"color": "blue", "id": "NCCC1=CNC=N1", "label": "NCCC1=CNC=N1", "shape": "dot", "size": 10}, {"color": "green", "id": " congestive heart failure", "label": " congestive heart failure", "shape": "dot", "size": 10}, {"color": "red", "id": " ro5083945", "label": " ro5083945", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)OC1=CC=C(C=C1C#N)C1=NC(=NO1)C1=CC=CC2=C1CC[C@@H]2NCCO, [Na+].[Cl-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC(C)OC1=CC=C(C=C1C#N)C1=NC(=NO1)C1=CC=CC2=C1CC[C@@H]2NCCO, [Na+].[Cl-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": " ypl-001 high dose", "label": " ypl-001 high dose", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC1=NC(=O)C2=C(N1)N(COCCO)C=N2", "label": "NC1=NC(=O)C2=C(N1)N(COCCO)C=N2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedamifostine_head and neck cancer", "label": "terminatedamifostine_head and neck cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " rotigotine", "label": " rotigotine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsunitinib malate (sutent)_renal cell carcinoma", "label": "terminatedsunitinib malate (sutent)_renal cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " rdea806 600 mg", "label": " rdea806 600 mg", "shape": "dot", "size": 10}, {"color": "green", "id": " colorectal tumors", "label": " colorectal tumors", "shape": "dot", "size": 10}, {"color": "red", "id": " aegr-733", "label": " aegr-733", "shape": "dot", "size": 10}, {"color": "red", "id": " e. coli asparaginase", "label": " e. coli asparaginase", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nasopharyngeal neoplasms, stomatitis", "label": "nasopharyngeal neoplasms, stomatitis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawniloprost_persistent pulmonary hypertension, respiratory distress syndrome", "label": "withdrawniloprost_persistent pulmonary hypertension, respiratory distress syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " amlodipine 2.5mg/atorvastatin 10mg", "label": " amlodipine 2.5mg/atorvastatin 10mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddabigatran, phenprocoumon_coronary heart disease, atrial fibrillation, acute coronary syndrome, atherosclerosis", "label": "terminateddabigatran, phenprocoumon_coronary heart disease, atrial fibrillation, acute coronary syndrome, atherosclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1", "label": " CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(=O)\\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, OC(=O)\\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "OC(=O)\\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, OC(=O)\\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, lapatinib", "label": "doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, lapatinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedhyalgan (sodium hyaluronate)_osteoarthritis", "label": "completedhyalgan (sodium hyaluronate)_osteoarthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " bevacizumab or aflibercept", "label": " bevacizumab or aflibercept", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "asenapine, placebo", "label": "asenapine, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " formoterol 12 mcg", "label": " formoterol 12 mcg", "shape": "dot", "size": 10}, {"color": "red", "id": " rapid-acting insulin secretagogue", "label": " rapid-acting insulin secretagogue", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "anetumab ravtansine (bay94-9343), vinorelbine", "label": "anetumab ravtansine (bay94-9343), vinorelbine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtimolol maleate ophthalmic solution 0.5% bid, ar-13324 ophthalmic solution 0.02%_ocular hypertension, open-angle glaucoma", "label": "completedtimolol maleate ophthalmic solution 0.5% bid, ar-13324 ophthalmic solution 0.02%_ocular hypertension, open-angle glaucoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " moxifloxacin placebo", "label": " moxifloxacin placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " folinic acid 200 mg/m\u00b2", "label": " folinic acid 200 mg/m\u00b2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "irinotecan hydrochloride, leucovorin calcium, fluorouracil", "label": "irinotecan hydrochloride, leucovorin calcium, fluorouracil", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedindacaterol maleate_asthma", "label": "completedindacaterol maleate_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " triamcinolone acetonide", "label": " triamcinolone acetonide", "shape": "dot", "size": 10}, {"color": "green", "id": " urological manifestations", "label": " urological manifestations", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatednordihydroguaiaretic acid (ndga)_prostate cancer", "label": "terminatednordihydroguaiaretic acid (ndga)_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " maraviroc + fosamprenavir/ritonavir", "label": " maraviroc + fosamprenavir/ritonavir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "xp19986 sr3, 20 mg qd, xp19986 sr3, 40 mg qd, xp19986 sr3, 60 mg qd, xp19986 sr3, 30 mg bid, placebo", "label": "xp19986 sr3, 20 mg qd, xp19986 sr3, 40 mg qd, xp19986 sr3, 60 mg qd, xp19986 sr3, 30 mg bid, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbendamustine, bortezomib, rituximab_lymphoma", "label": "completedbendamustine, bortezomib, rituximab_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " previously untreated childhood rhabdomyosarcoma", "label": " previously untreated childhood rhabdomyosarcoma", "shape": "dot", "size": 10}, {"color": "green", "id": "myelodysplastic and myeloproliferative disorders", "label": "myelodysplastic and myeloproliferative disorders", "shape": "dot", "size": 10}, {"color": "red", "id": " pf-04937319 - 20mg", "label": " pf-04937319 - 20mg", "shape": "dot", "size": 10}, {"color": "red", "id": "pd 0332991 (pre-surgery)", "label": "pd 0332991 (pre-surgery)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, multistem low dose, placebo, multistem low dose, placebo, multistem high dose, placebo, multistem high dose, placebo, multistem high dose, placebo, multistem high dose", "label": "placebo, multistem low dose, placebo, multistem low dose, placebo, multistem high dose, placebo, multistem high dose, placebo, multistem high dose, placebo, multistem high dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvortioxetine 10-20 mg, placebo, ssri_major depressive disorder", "label": "completedvortioxetine 10-20 mg, placebo, ssri_major depressive disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingibrutinib, placebo_chronic lymphocytic leukemia", "label": "active, not recruitingibrutinib, placebo_chronic lymphocytic leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrivaroxaban (xarelto, bay59-7939), enoxaparin, rivaroxaban placebo, enoxaparin placebo_venous thromboembolism", "label": "completedrivaroxaban (xarelto, bay59-7939), enoxaparin, rivaroxaban placebo, enoxaparin placebo_venous thromboembolism", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1", "label": "CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "syr-472, alogliptin 25 mg, placebo", "label": "syr-472, alogliptin 25 mg, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "peginterferon alfa-2a [pegasys], ribavirin [copegus], pioglitazone", "label": "peginterferon alfa-2a [pegasys], ribavirin [copegus], pioglitazone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": " peginterferon alfa-2a 90\u03bcg", "label": " peginterferon alfa-2a 90\u03bcg", "shape": "dot", "size": 10}, {"color": "green", "id": " plexiform neurofibroma", "label": " plexiform neurofibroma", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(=O)NC1=NN=C(S1)S(N)(=O)=O", "label": "CC(=O)NC1=NN=C(S1)S(N)(=O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "FC1=CC=C(C=C1)C(OCCN1CCN(CCCC2=CC=CC=C2)CC1)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "FC1=CC=C(C=C1)C(OCCN1CCN(CCCC2=CC=CC=C2)CC1)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "green", "id": "acute heart failure", "label": "acute heart failure", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iii breast cancer ajcc v7", "label": " stage iii breast cancer ajcc v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpracinostat, azacitidine_acute myeloid leukemia", "label": "completedpracinostat, azacitidine_acute myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acute myeloid leukemia, acute myelogenous leukemia", "label": "acute myeloid leukemia, acute myelogenous leukemia", "shape": "dot", "size": 10}, {"color": "green", "id": " malignant mesothelioma", "label": " malignant mesothelioma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glpg0259 oral capsule, placebo, glpg0259 (part b), placebo (part b)", "label": "glpg0259 oral capsule, placebo, glpg0259 (part b), placebo (part b)", "shape": "dot", "size": 10}, {"color": "red", "id": " oral risperidone", "label": " oral risperidone", "shape": "dot", "size": 10}, {"color": "red", "id": " 300 units per milliliter (u/ml)", "label": " 300 units per milliliter (u/ml)", "shape": "dot", "size": 10}, {"color": "green", "id": " adult papillary meningioma", "label": " adult papillary meningioma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "diffuse large b-cell lymphoma, lymphoma, diffuse large-cell, diffuse large-cell lymphoma, lymphoma", "label": "diffuse large b-cell lymphoma, lymphoma, diffuse large-cell, diffuse large-cell lymphoma, lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddapagliflozin, placebo for dapagliflozin, saxagliptin, placebo for saxagliptin_type 2 diabetes mellitus, inadequate glycaemic control", "label": "completeddapagliflozin, placebo for dapagliflozin, saxagliptin, placebo for saxagliptin_type 2 diabetes mellitus, inadequate glycaemic control", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "15 mg e4/3 mg drsp", "label": "15 mg e4/3 mg drsp", "shape": "dot", "size": 10}, {"color": "green", "id": " poor sleep quality", "label": " poor sleep quality", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvx-702_rheumatoid arthritis", "label": "completedvx-702_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ombrabulin (ave8062)", "label": "ombrabulin (ave8062)", "shape": "dot", "size": 10}, {"color": "red", "id": " bococizumab (pf-04950615;rn316)", "label": " bococizumab (pf-04950615;rn316)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F, CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O", "label": "CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F, CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "idelalisib, rituximab, ifosfamide, carboplatin, etoposide", "label": "idelalisib, rituximab, ifosfamide, carboplatin, etoposide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bepotastine besilate nasal spray 2% twice a day, bepotastine besilate nasal spray 3% twice a day, bepotastine besilate nasal spray 4% twice a day, placebo nasal spray", "label": "bepotastine besilate nasal spray 2% twice a day, bepotastine besilate nasal spray 3% twice a day, bepotastine besilate nasal spray 4% twice a day, placebo nasal spray", "shape": "dot", "size": 10}, {"color": "red", "id": "ozanimod", "label": "ozanimod", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "abacavir/lamivudine + raltegravir, abacavir/lamivudine + darunavir/ritonavir", "label": "abacavir/lamivudine + raltegravir, abacavir/lamivudine + darunavir/ritonavir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingalectinib, crizotinib_non-small cell lung cancer", "label": "active, not recruitingalectinib, crizotinib_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtrimethoprim-sulfamethoxazole, placebo_vesicoureteral reflux, urinary tract infections", "label": "completedtrimethoprim-sulfamethoxazole, placebo_vesicoureteral reflux, urinary tract infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vargatef, placebo", "label": "vargatef, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " azd3480", "label": " azd3480", "shape": "dot", "size": 10}, {"color": "red", "id": " palonosetron hydrochloride", "label": " palonosetron hydrochloride", "shape": "dot", "size": 10}, {"color": "red", "id": " clobetasol 0.05% ointment", "label": " clobetasol 0.05% ointment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmelatonin, atenolol, ibuprofen_advanced cancer, cachexia", "label": "terminatedmelatonin, atenolol, ibuprofen_advanced cancer, cachexia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "triple negative locally advanced non-resectable breast cancer", "label": "triple negative locally advanced non-resectable breast cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bupropion, transdermal nicotine patch, nicotine polacrilex, nicotine lozenge", "label": "bupropion, transdermal nicotine patch, nicotine polacrilex, nicotine lozenge", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednrt (nicoderm cq)_smoking, nicotine addiction, surgery", "label": "completednrt (nicoderm cq)_smoking, nicotine addiction, surgery", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrimegepant, placebo, sumatriptan_migraine, acute treatment of migraine", "label": "completedrimegepant, placebo, sumatriptan_migraine, acute treatment of migraine", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedchemotherapy_adenocarcinoma pancreas", "label": "terminatedchemotherapy_adenocarcinoma pancreas", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage ivc squamous cell carcinoma of the lip and oral cavity", "label": " stage ivc squamous cell carcinoma of the lip and oral cavity", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mp-376 (levofloxacin solution for inhalation), tis (tobramycin inhalation solution)", "label": "mp-376 (levofloxacin solution for inhalation), tis (tobramycin inhalation solution)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "brentuximab vedotin, doxorubicin hydrochloride, vinblastine, dacarbazine", "label": "brentuximab vedotin, doxorubicin hydrochloride, vinblastine, dacarbazine", "shape": "dot", "size": 10}, {"color": "red", "id": " zp4207 (dasiglucagon)", "label": " zp4207 (dasiglucagon)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedruxolitinib_thalassemia major", "label": "completedruxolitinib_thalassemia major", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1, CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C", "label": "CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1, CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "label": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cep-1347 10mg, cep1347 25mg, cep-1347 50mg", "label": "cep-1347 10mg, cep1347 25mg, cep-1347 50mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingafatinib dimaleate_recurrent non-small cell lung carcinoma, stage iv non-small cell lung cancer", "label": "active, not recruitingafatinib dimaleate_recurrent non-small cell lung carcinoma, stage iv non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine hydrochloride, topotecan hydrochloride_fallopian tube cancer, ovarian cancer, peritoneal cavity cancer", "label": "completedgemcitabine hydrochloride, topotecan hydrochloride_fallopian tube cancer, ovarian cancer, peritoneal cavity cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " vehicle without active", "label": " vehicle without active", "shape": "dot", "size": 10}, {"color": "green", "id": " adult brain stem glioma", "label": " adult brain stem glioma", "shape": "dot", "size": 10}, {"color": "green", "id": " proctosigmoiditis", "label": " proctosigmoiditis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CS(=O)(=O)OCCCCOS(C)(=O)=O, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "label": "CS(=O)(=O)OCCCCOS(C)(=O)=O, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": " implantable", "label": " implantable", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gastroparesis, gastroesophageal reflux disease", "label": "gastroparesis, gastroesophageal reflux disease", "shape": "dot", "size": 10}, {"color": "red", "id": " solabegron immediate release tablets", "label": " solabegron immediate release tablets", "shape": "dot", "size": 10}, {"color": "red", "id": " dexamethasone (standard retreatment)", "label": " dexamethasone (standard retreatment)", "shape": "dot", "size": 10}, {"color": "red", "id": " biguanides (bg)", "label": " biguanides (bg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)C(=N)NC(N)=N, O=C1CSC(=O)N1", "label": "CN(C)C(=N)NC(N)=N, O=C1CSC(=O)N1", "shape": "dot", "size": 10}, {"color": "red", "id": " 0.1% azelastine hydrochloride 1096 mcg daily", "label": " 0.1% azelastine hydrochloride 1096 mcg daily", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent adult diffuse mixed cell lymphoma", "label": " recurrent adult diffuse mixed cell lymphoma", "shape": "dot", "size": 10}, {"color": "green", "id": " germ cell and embryonal", "label": " germ cell and embryonal", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedticagrelor, aspirin, placebo - ticagrelor, placebo - aspirin_coronary artery disease, stable angina, acute coronary syndrome", "label": "terminatedticagrelor, aspirin, placebo - ticagrelor, placebo - aspirin_coronary artery disease, stable angina, acute coronary syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgw685698x (fluticasone furoate) 100mcg morning, gw685698x (fluticasone furoate) 100mcg evening, gw685698x (fluticasone furoate) 250mcg evening, placebo_asthma", "label": "completedgw685698x (fluticasone furoate) 100mcg morning, gw685698x (fluticasone furoate) 100mcg evening, gw685698x (fluticasone furoate) 250mcg evening, placebo_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcarboplatin, paclitaxel_breast carcinoma, recurrent breast carcinoma, stage iv breast cancer", "label": "terminatedcarboplatin, paclitaxel_breast carcinoma, recurrent breast carcinoma, stage iv breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1", "label": "[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1", "shape": "dot", "size": 10}, {"color": "red", "id": "metformin placebo", "label": "metformin placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "label": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": " epoch regimen", "label": " epoch regimen", "shape": "dot", "size": 10}, {"color": "red", "id": "e7107", "label": "e7107", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC[C@H]1OB(O)C2=C1C=CC=C2OCCCO", "label": "NC[C@H]1OB(O)C2=C1C=CC=C2OCCCO", "shape": "dot", "size": 10}, {"color": "red", "id": " pt005", "label": " pt005", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawncarboplatin, gemcitabine hydrochloride, paclitaxel_lung cancer", "label": "withdrawncarboplatin, gemcitabine hydrochloride, paclitaxel_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalefacept, tacrolimus, basiliximab, mycophenolate mofetil, corticosteroids_kidney transplantation", "label": "completedalefacept, tacrolimus, basiliximab, mycophenolate mofetil, corticosteroids_kidney transplantation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrence", "label": " recurrence", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "montelukast placebo, salmeterol, montelukast", "label": "montelukast placebo, salmeterol, montelukast", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfinafloxacin 800 mg i.v. once daily, finafloxacin placebo i.v. once daily, finafloxacin 800 mg tablets once daily, finafloxacin placebo tablets once daily, ciprofloxacin 400 mg i.v. twice daily, ciprofloxacin placebo i.v. twice daily, ciprofloxacin 500 mg oral twice daily, ciprofloxacin placebo oral twice daily_urinary tract infections, acute pyelonephritis", "label": "completedfinafloxacin 800 mg i.v. once daily, finafloxacin placebo i.v. once daily, finafloxacin 800 mg tablets once daily, finafloxacin placebo tablets once daily, ciprofloxacin 400 mg i.v. twice daily, ciprofloxacin placebo i.v. twice daily, ciprofloxacin 500 mg oral twice daily, ciprofloxacin placebo oral twice daily_urinary tract infections, acute pyelonephritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC(=N)SCCCC#N, NC(=N)SCCCC#N", "label": "NC(=N)SCCCC#N, NC(=N)SCCCC#N", "shape": "dot", "size": 10}, {"color": "red", "id": "dolutegravir 50 mg oad", "label": "dolutegravir 50 mg oad", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddelafloxacin, moxifloxacin, linezolid_community acquired bacterial pneumonia", "label": "completeddelafloxacin, moxifloxacin, linezolid_community acquired bacterial pneumonia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " heregulin", "label": " heregulin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "teriparatide, alendronate", "label": "teriparatide, alendronate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone furoate (ff), placebo", "label": "fluticasone furoate (ff), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedslv320_congestive heart failure", "label": "completedslv320_congestive heart failure", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCN(CC)CCNC(=O)C1=CC=C(N)C=C1", "label": " CCN(CC)CCNC(=O)C1=CC=C(N)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedexparel, placebo_distal radius fracture", "label": "terminatedexparel, placebo_distal radius fracture", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednaltrexone_depression", "label": "completednaltrexone_depression", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " O", "label": " O", "shape": "dot", "size": 10}, {"color": "blue", "id": "C[C@](O)(COC1=CC=C(C=C1)C#N)C(O)=NC1=CC(=C(C=C1)C#N)C(F)(F)F", "label": "C[C@](O)(COC1=CC=C(C=C1)C#N)C(O)=NC1=CC(=C(C=C1)C#N)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gastroesophageal reflux disease, heartburn, regurgitation", "label": "gastroesophageal reflux disease, heartburn, regurgitation", "shape": "dot", "size": 10}, {"color": "red", "id": " moxifloxacin 400 mg", "label": " moxifloxacin 400 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glaucoma, primary open angle (poag), ocular hypertension", "label": "glaucoma, primary open angle (poag), ocular hypertension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedimatinib mesylate, cyclophosphamide (dosing level 1 ), imatinib mesylate, cyclophosphamide (dosing level 2), imatinib mesylate, cyclophosphamide (dosing level 3)_cancer", "label": "completedimatinib mesylate, cyclophosphamide (dosing level 1 ), imatinib mesylate, cyclophosphamide (dosing level 2), imatinib mesylate, cyclophosphamide (dosing level 3)_cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent mycosis fungoides/sezary syndrome, stage i cutaneous t-cell non-hodgkin lymphoma, stage ia mycosis fungoides/sezary syndrome, stage ib mycosis fungoides/sezary syndrome, stage ii cutaneous t-cell non-hodgkin lymphoma, stage iia mycosis fungoides/sezary syndrome, stage iib mycosis fungoides/sezary syndrome, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iiia mycosis fungoides/sezary syndrome, stage iiib mycosis fungoides/sezary syndrome, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iva mycosis fungoides/sezary syndrome, stage ivb mycosis fungoides/sezary syndrome", "label": "recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent mycosis fungoides/sezary syndrome, stage i cutaneous t-cell non-hodgkin lymphoma, stage ia mycosis fungoides/sezary syndrome, stage ib mycosis fungoides/sezary syndrome, stage ii cutaneous t-cell non-hodgkin lymphoma, stage iia mycosis fungoides/sezary syndrome, stage iib mycosis fungoides/sezary syndrome, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iiia mycosis fungoides/sezary syndrome, stage iiib mycosis fungoides/sezary syndrome, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iva mycosis fungoides/sezary syndrome, stage ivb mycosis fungoides/sezary syndrome", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1", "label": "CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " advair 500/50mcg", "label": " advair 500/50mcg", "shape": "dot", "size": 10}, {"color": "red", "id": " org 25935", "label": " org 25935", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ibrutinib, gemcitabine, nab-paclitaxel", "label": "ibrutinib, gemcitabine, nab-paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ldv/sof, vdv, rbv", "label": "ldv/sof, vdv, rbv", "shape": "dot", "size": 10}, {"color": "red", "id": " cabotegravir injectable suspension", "label": " cabotegravir injectable suspension", "shape": "dot", "size": 10}, {"color": "red", "id": " gnrha with tamoxifen", "label": " gnrha with tamoxifen", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddarunavir, ritonavir, tenofovir disoproxil fumarate, emtricitabine, placebo for tenofovir disoproxil fumarate, placebo for maraviroc, maraviroc_hiv-1 infection", "label": "completeddarunavir, ritonavir, tenofovir disoproxil fumarate, emtricitabine, placebo for tenofovir disoproxil fumarate, placebo for maraviroc, maraviroc_hiv-1 infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "early rheumatoid arthritis", "label": "early rheumatoid arthritis", "shape": "dot", "size": 10}, {"color": "red", "id": "rdx5791", "label": "rdx5791", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedhigh dose methotrexate, high dose cytarabine_lymphoma, b cell", "label": "completedhigh dose methotrexate, high dose cytarabine_lymphoma, b cell", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "disulfiram, arsenic trioxide", "label": "disulfiram, arsenic trioxide", "shape": "dot", "size": 10}, {"color": "red", "id": " biphasic insulin aspart 50", "label": " biphasic insulin aspart 50", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine, cisplatin_endometrial cancer", "label": "completedgemcitabine, cisplatin_endometrial cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ziv-aflibercept", "label": "ziv-aflibercept", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedser100, placebo_isolated systolic hypertension", "label": "completedser100, placebo_isolated systolic hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedemixustat hydrochloride_proliferative diabetic retinopathy", "label": "completedemixustat hydrochloride_proliferative diabetic retinopathy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iv verrucous carcinoma of the larynx", "label": " stage iv verrucous carcinoma of the larynx", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcommercial hylenex\u00ae recombinant (hyaluronidase human injection), precommercial hylenex recombinant (hyaluronidase human injection), insulin lispro, insulin aspart, insulin glulisine_type 1 diabetes mellitus", "label": "completedcommercial hylenex\u00ae recombinant (hyaluronidase human injection), precommercial hylenex recombinant (hyaluronidase human injection), insulin lispro, insulin aspart, insulin glulisine_type 1 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl", "label": "CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1, OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O", "label": "COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1, OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@]1([H])OC(O)=N[C@]([H])(C(=O)N1C[C@@]([H])(C[C@@]1([H])C(O)=N[C@@]1(C[C@@]1([H])C=C)C(O)=NS(=O)(=O)C1CC1)OC1=C(CCCCC2)N=C2C=CC(OC)=CC2=N1)C(C)(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CNC(=N3)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1, [H][C@@]12C[C@@]1([H])OC(O)=N[C@]([H])(C(=O)N1C[C@@]([H])(C[C@@]1([H])C(O)=N[C@@]1(C[C@@]1([H])C=C)C(O)=NS(=O)(=O)C1CC1)OC1=C(CCCCC2)N=C2C=CC(OC)=CC2=N1)C(C)(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CNC(=N3)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1", "label": "[H][C@@]12C[C@@]1([H])OC(O)=N[C@]([H])(C(=O)N1C[C@@]([H])(C[C@@]1([H])C(O)=N[C@@]1(C[C@@]1([H])C=C)C(O)=NS(=O)(=O)C1CC1)OC1=C(CCCCC2)N=C2C=CC(OC)=CC2=N1)C(C)(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CNC(=N3)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1, [H][C@@]12C[C@@]1([H])OC(O)=N[C@]([H])(C(=O)N1C[C@@]([H])(C[C@@]1([H])C(O)=N[C@@]1(C[C@@]1([H])C=C)C(O)=NS(=O)(=O)C1CC1)OC1=C(CCCCC2)N=C2C=CC(OC)=CC2=N1)C(C)(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(=CN1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CNC(=N3)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcore study: deferasirox, core study: deferoxamine, extension: deferoxamine to deferasirox, extension: deferasirox to deferoxamine, deferasirox, deferoxamine_transfusional iron overload, transfusional hemosiderosis", "label": "completedcore study: deferasirox, core study: deferoxamine, extension: deferoxamine to deferasirox, extension: deferasirox to deferoxamine, deferasirox, deferoxamine_transfusional iron overload, transfusional hemosiderosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrituximab_lymphoma, follicular", "label": "completedrituximab_lymphoma, follicular", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, cyclosporine, etoposide, methotrexate, busulfan, mesna", "label": "cyclophosphamide, cyclosporine, etoposide, methotrexate, busulfan, mesna", "shape": "dot", "size": 10}, {"color": "green", "id": " cp-b liver cirrhosis", "label": " cp-b liver cirrhosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=NC=C(N1CCO)[N+]([O-])=O, CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1", "label": "CC1=NC=C(N1CCO)[N+]([O-])=O, CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1", "shape": "dot", "size": 10}, {"color": "green", "id": " castrate resistant prostate cancer", "label": " castrate resistant prostate cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "epirubicin hydrochloride, mitomycin c", "label": "epirubicin hydrochloride, mitomycin c", "shape": "dot", "size": 10}, {"color": "red", "id": " tranexamic acid tablets", "label": " tranexamic acid tablets", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2", "label": " [H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2", "shape": "dot", "size": 10}, {"color": "red", "id": " ne-58095 ir placebo", "label": " ne-58095 ir placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acute heart failure, acute decompensation of chronic heart failure, new onset of heart failure", "label": "acute heart failure, acute decompensation of chronic heart failure, new onset of heart failure", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cardiomyopathy, heart failure", "label": "cardiomyopathy, heart failure", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "xeloda,, oxaliplatin, tki258", "label": "xeloda,, oxaliplatin, tki258", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pregabalin, diphenhydramine", "label": "pregabalin, diphenhydramine", "shape": "dot", "size": 10}, {"color": "red", "id": "rolofylline", "label": "rolofylline", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O", "label": " [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fdc of tiotropium + olodaterol, placebo, tiotropium, olodaterol", "label": "fdc of tiotropium + olodaterol, placebo, tiotropium, olodaterol", "shape": "dot", "size": 10}, {"color": "green", "id": " severe motor fluctuations", "label": " severe motor fluctuations", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute basophilic leukemia, adult acute eosinophilic leukemia, adult acute megakaryoblastic leukemia, adult acute monoblastic leukemia, adult acute monocytic leukemia, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with maturation, adult acute myeloid leukemia with minimal differentiation, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll, adult acute myeloid leukemia without maturation, adult acute myelomonocytic leukemia, adult erythroleukemia, adult pure erythroid leukemia, alkylating agent-related acute myeloid leukemia, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia, untreated adult acute myeloid leukemia", "label": "acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute basophilic leukemia, adult acute eosinophilic leukemia, adult acute megakaryoblastic leukemia, adult acute monoblastic leukemia, adult acute monocytic leukemia, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with maturation, adult acute myeloid leukemia with minimal differentiation, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll, adult acute myeloid leukemia without maturation, adult acute myelomonocytic leukemia, adult erythroleukemia, adult pure erythroid leukemia, alkylating agent-related acute myeloid leukemia, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia, untreated adult acute myeloid leukemia", "shape": "dot", "size": 10}, {"color": "red", "id": "cisplatinum", "label": "cisplatinum", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rapastinel, placebo", "label": "rapastinel, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " concurrent nimotuzumab during radiotherapy", "label": " concurrent nimotuzumab during radiotherapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "diabetic neuropathic pain, chronic low back pain", "label": "diabetic neuropathic pain, chronic low back pain", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "furosemide injection solution for subcutaneous administration (80 mg), oral furosemide tablets (80 mg)", "label": "furosemide injection solution for subcutaneous administration (80 mg), oral furosemide tablets (80 mg)", "shape": "dot", "size": 10}, {"color": "red", "id": " ranibizumab", "label": " ranibizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carcinoma, hepatocellular, liver neoplasms", "label": "carcinoma, hepatocellular, liver neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "solifenacin, oxybutynin immediate release", "label": "solifenacin, oxybutynin immediate release", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN(C)CCO\\N=C(\\C=C\\C1=CC=C(O)C=C1)/C1=CC=CC=C1F", "label": "CN(C)CCO\\N=C(\\C=C\\C1=CC=C(O)C=C1)/C1=CC=CC=C1F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "label": "[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpegylated liposomal doxorubicin (sch 200746), capecitabine_breast cancer", "label": "completedpegylated liposomal doxorubicin (sch 200746), capecitabine_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmetformin, doxorubicin_breast cancer, breast tumors", "label": "terminatedmetformin, doxorubicin_breast cancer, breast tumors", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "patiromer, patiromer, patiromer, patiromer, patiromer, patiromer, losartan, spironolactone", "label": "patiromer, patiromer, patiromer, patiromer, patiromer, patiromer, losartan, spironolactone", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iv cutaneous melanoma ajcc v6 and v7", "label": " stage iv cutaneous melanoma ajcc v6 and v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "uveitis, juvenile arthritis", "label": "uveitis, juvenile arthritis", "shape": "dot", "size": 10}, {"color": "green", "id": " stage i oropharyngeal squamous cell carcinoma ajcc v6 and v7", "label": " stage i oropharyngeal squamous cell carcinoma ajcc v6 and v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NCC1(CC(O)=O)CCCCC1, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "NCC1(CC(O)=O)CCCCC1, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acute leukemias of ambiguous lineage, bacterial infection, diarrhea, fungal infection, musculoskeletal complications, neutropenia, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, secondary acute myeloid leukemia, untreated childhood acute myeloid leukemia and other myeloid malignancies", "label": "acute leukemias of ambiguous lineage, bacterial infection, diarrhea, fungal infection, musculoskeletal complications, neutropenia, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, secondary acute myeloid leukemia, untreated childhood acute myeloid leukemia and other myeloid malignancies", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C1CN(CCO1)C1=CC=C(C=C1)N=C1NC(=CN2C=CN=C12)C1=CC2=NNC=C2C=C1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "label": "C1CN(CCO1)C1=CC=C(C=C1)N=C1NC(=CN2C=CN=C12)C1=CC2=NNC=C2C=C1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O", "label": "[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O", "shape": "dot", "size": 10}, {"color": "red", "id": " selinexor", "label": " selinexor", "shape": "dot", "size": 10}, {"color": "red", "id": " ezalutamide", "label": " ezalutamide", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iii intrahepatic cholangiocarcinoma", "label": " stage iii intrahepatic cholangiocarcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lapatinib, vinorelbine", "label": "lapatinib, vinorelbine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "g-csf, saline", "label": "g-csf, saline", "shape": "dot", "size": 10}, {"color": "green", "id": " malignant", "label": " malignant", "shape": "dot", "size": 10}, {"color": "green", "id": " discoid", "label": " discoid", "shape": "dot", "size": 10}, {"color": "red", "id": " metformin + glimepiride", "label": " metformin + glimepiride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel, gemcitabine, docetaxel, docetaxel", "label": "docetaxel, gemcitabine, docetaxel, docetaxel", "shape": "dot", "size": 10}, {"color": "red", "id": " olopatadine", "label": " olopatadine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "canagliflozin, placebo, sitagliptin", "label": "canagliflozin, placebo, sitagliptin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, oxaliplatin, leucovorin, 5-fluorouracil_stomach cancer, esophageal cancer", "label": "completedplacebo, oxaliplatin, leucovorin, 5-fluorouracil_stomach cancer, esophageal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " dabigatran dose 1", "label": " dabigatran dose 1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "everolimus (rad001), tacrolimus, basiliximab, corticosteroids", "label": "everolimus (rad001), tacrolimus, basiliximab, corticosteroids", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carcinoma, squamous cell, carcinoma, adenosquamous, carcinoma, large cell, carcinoma, non-small-cell lung", "label": "carcinoma, squamous cell, carcinoma, adenosquamous, carcinoma, large cell, carcinoma, non-small-cell lung", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent inverted papilloma of the paranasal sinus and nasal cavity", "label": " recurrent inverted papilloma of the paranasal sinus and nasal cavity", "shape": "dot", "size": 10}, {"color": "red", "id": "mannitol challenge test \u0026 reversibility test", "label": "mannitol challenge test \u0026 reversibility test", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hypertension, pure autonomic failure, multiple system atrophy", "label": "hypertension, pure autonomic failure, multiple system atrophy", "shape": "dot", "size": 10}, {"color": "green", "id": "pulmonary disease", "label": "pulmonary disease", "shape": "dot", "size": 10}, {"color": "green", "id": " venous thromboembolism", "label": " venous thromboembolism", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin glargine /lixisenatide fixed ratio combination, insulin glargine, metformin (background drug)_type 2 diabetes mellitus", "label": "completedinsulin glargine /lixisenatide fixed ratio combination, insulin glargine, metformin (background drug)_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvorapaxar, placebo_atherosclerosis, ischemia, myocardial infarction, cerebrovascular accident, peripheral arterial disease", "label": "completedvorapaxar, placebo_atherosclerosis, ischemia, myocardial infarction, cerebrovascular accident, peripheral arterial disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "O=C(N1CCCCC1)C1=CC2=C(C=C1)N=CC=N2", "label": "O=C(N1CCCCC1)C1=CC2=C(C=C1)N=CC=N2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "coronary artery disease, angina, metabolic syndrome", "label": "coronary artery disease, angina, metabolic syndrome", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, bibw 2992_carcinoma, non-small-cell lung", "label": "completedplacebo, bibw 2992_carcinoma, non-small-cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcytarabine, daunorubicin hydrochloride, gemtuzumab ozogamicin_leukemia, myelodysplastic syndromes", "label": "completedcytarabine, daunorubicin hydrochloride, gemtuzumab ozogamicin_leukemia, myelodysplastic syndromes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " statin therapy", "label": " statin therapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tariquidar + vinorelbine, placebo + vinorelbine", "label": "tariquidar + vinorelbine, placebo + vinorelbine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ibrutinib, obinutuzumab, chlorambucil", "label": "ibrutinib, obinutuzumab, chlorambucil", "shape": "dot", "size": 10}, {"color": "red", "id": "pegylated interferon alpha-2b", "label": "pegylated interferon alpha-2b", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmirtazapine treatment_depression, excessive daytime sleepiness", "label": "completedmirtazapine treatment_depression, excessive daytime sleepiness", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gemcitabine, dasatinib, gemcitabine, dasatinib", "label": "gemcitabine, dasatinib, gemcitabine, dasatinib", "shape": "dot", "size": 10}, {"color": "red", "id": " canagliflozin (jnj-28431754) 100 mg", "label": " canagliflozin (jnj-28431754) 100 mg", "shape": "dot", "size": 10}, {"color": "red", "id": "wf10", "label": "wf10", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedoxaliplatin (oxa), levofolinate calcium (l-lv), 5-fu, panitumumab, oxaliplatin (oxa), levofolinate calcium (l-lv), 5-fu, panitumumab_colorectal carcinoma", "label": "completedoxaliplatin (oxa), levofolinate calcium (l-lv), 5-fu, panitumumab, oxaliplatin (oxa), levofolinate calcium (l-lv), 5-fu, panitumumab_colorectal carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcisplatin, cetuximab_head and neck squamous cell cancer", "label": "terminatedcisplatin, cetuximab_head and neck squamous cell cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "lyophilized albiglutide dcc pen injector", "label": "lyophilized albiglutide dcc pen injector", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to mk0893", "label": " placebo to mk0893", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recurrent ovarian cancer, platinum sensitive ovarian cancer", "label": "recurrent ovarian cancer, platinum sensitive ovarian cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpx-12_pancreatic neoplasms", "label": "terminatedpx-12_pancreatic neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O", "label": " CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2, CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2, CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dapagliflozin, dapagliflozin, placebo matching dapagliflozin, thiazolidinedione (pioglitazone)", "label": "dapagliflozin, dapagliflozin, placebo matching dapagliflozin, thiazolidinedione (pioglitazone)", "shape": "dot", "size": 10}, {"color": "red", "id": "probucol 250mg/day", "label": "probucol 250mg/day", "shape": "dot", "size": 10}, {"color": "green", "id": " hairy cell leukemia", "label": " hairy cell leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo for sitagliptin 25 mg, placebo for sitagliptin 50 mg, sitagliptin 25 mg, sitagliptin 50 mg_glucose intolerance", "label": "completedplacebo for sitagliptin 25 mg, placebo for sitagliptin 50 mg, sitagliptin 25 mg, sitagliptin 50 mg_glucose intolerance", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ace inhibition, intensified blood pressure control, add-on angiotensin receptor blockade", "label": "ace inhibition, intensified blood pressure control, add-on angiotensin receptor blockade", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O", "label": " [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O", "shape": "dot", "size": 10}, {"color": "red", "id": " emtricitabine-tenofovir(ftc/tdf)", "label": " emtricitabine-tenofovir(ftc/tdf)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcisplatin, docetaxel, wee1 inhibitor azd1775_head and neck squamous cell carcinoma", "label": "completedcisplatin, docetaxel, wee1 inhibitor azd1775_head and neck squamous cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "intensive control of sbp", "label": "intensive control of sbp", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O", "label": " [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedaprepitant, granisetron_nausea, vomiting", "label": "terminatedaprepitant, granisetron_nausea, vomiting", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " disease progression", "label": " disease progression", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtmc435, tvr_hepatitis c", "label": "completedtmc435, tvr_hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtemozolomide, velban, cisplatin, interleukin-2, intron-a, thalidomide_melanoma", "label": "terminatedtemozolomide, velban, cisplatin, interleukin-2, intron-a, thalidomide_melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedbicalutamide and cp-675,206 (tremelimumab), bicalutamide, cp-675,206 (tremelimumab), bicalutamide, cp-675,206 (tremelimumab), bicalutamide, cp-675,206 (tremelimumab), bicalutamide, cp-675,206_prostate cancer", "label": "terminatedbicalutamide and cp-675,206 (tremelimumab), bicalutamide, cp-675,206 (tremelimumab), bicalutamide, cp-675,206 (tremelimumab), bicalutamide, cp-675,206 (tremelimumab), bicalutamide, cp-675,206_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " standard of care therapy", "label": " standard of care therapy", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]1(O)CS[C@@]([H])(OC2=CC3=C(C=C2)C(C)=CC(=O)O3)[C@]([H])(O)[C@@]1([H])O", "label": "[H][C@@]1(O)CS[C@@]([H])(OC2=CC3=C(C=C2)C(C)=CC(=O)O3)[C@]([H])(O)[C@@]1([H])O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gwp42003, placebo", "label": "gwp42003, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " bay63-2521) 2.5 mg", "label": " bay63-2521) 2.5 mg", "shape": "dot", "size": 10}, {"color": "green", "id": " high level of sugar (glucose) in the blood", "label": " high level of sugar (glucose) in the blood", "shape": "dot", "size": 10}, {"color": "green", "id": " impaired cognition", "label": " impaired cognition", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel, cisplatin, cetuximab", "label": "docetaxel, cisplatin, cetuximab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatednilotinib, pegylated interferon \u03b1-2b_chronic myeloid leukemia", "label": "terminatednilotinib, pegylated interferon \u03b1-2b_chronic myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "nasapaque nasal solution", "label": "nasapaque nasal solution", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazasite\u00ae_blepharitis", "label": "completedazasite\u00ae_blepharitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " gcsf", "label": " gcsf", "shape": "dot", "size": 10}, {"color": "green", "id": " glioblastoma with oligodendroglial component", "label": " glioblastoma with oligodendroglial component", "shape": "dot", "size": 10}, {"color": "red", "id": "mefloquine", "label": "mefloquine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, C#CCN[C@@H]1CCC2=CC=CC=C12, C#CCN[C@@H]1CCC2=CC=CC=C12", "label": "COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, C#CCN[C@@H]1CCC2=CC=CC=C12, C#CCN[C@@H]1CCC2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "melanoma, soft tissue sarcoma, parathyroid carcinoma, small cell carcinoma of the lung, carcinoid tumors", "label": "melanoma, soft tissue sarcoma, parathyroid carcinoma, small cell carcinoma of the lung, carcinoid tumors", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedstrontium chloride hexahydrate, placebo_amputation stumps, pain", "label": "completedstrontium chloride hexahydrate, placebo_amputation stumps, pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " serevent\u2122", "label": " serevent\u2122", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1", "label": "ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmethylphenidate hydrochloride extended release capsules_attention deficit hyperactivity disorder, adhd", "label": "completedmethylphenidate hydrochloride extended release capsules_attention deficit hyperactivity disorder, adhd", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "embolism", "label": "embolism", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawncisplatin, erlotinib hydrochloride_cervical cancer", "label": "withdrawncisplatin, erlotinib hydrochloride_cervical cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1", "label": "CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "map0004, iv placebo (saline), placebo inhaler, iv dihydroergotamine mesylate (dhe)", "label": "map0004, iv placebo (saline), placebo inhaler, iv dihydroergotamine mesylate (dhe)", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1", "label": " CCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "degarelix, degarelix", "label": "degarelix, degarelix", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O", "label": "[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statussimvastatin, placebo_optic neuritis, multiple sclerosis", "label": "unknown statussimvastatin, placebo_optic neuritis, multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "diminished ovarian reserve, infertility, in vitro fertilization", "label": "diminished ovarian reserve, infertility, in vitro fertilization", "shape": "dot", "size": 10}, {"color": "red", "id": " pf-04217329 - high middle dose", "label": " pf-04217329 - high middle dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedeverolimus, fulvestrant_breast cancer", "label": "completedeverolimus, fulvestrant_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedibrutinib_marginal zone lymphoma, b-cell lymphoma", "label": "completedibrutinib_marginal zone lymphoma, b-cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " jnj-54861911", "label": " jnj-54861911", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedescitalopram, aripiprazole_major depressive disorder", "label": "completedescitalopram, aripiprazole_major depressive disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cangrelor p2y12 (platelet) inhibitor, clopidogrel - 300 or 600 mg (study arm), clopidogrel 600 mg post cangrelor", "label": "cangrelor p2y12 (platelet) inhibitor, clopidogrel - 300 or 600 mg (study arm), clopidogrel 600 mg post cangrelor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nitazoxanide, vancomycin", "label": "nitazoxanide, vancomycin", "shape": "dot", "size": 10}, {"color": "red", "id": "imipramine hydrochloride", "label": "imipramine hydrochloride", "shape": "dot", "size": 10}, {"color": "green", "id": "advanced metastatic gastric cancer", "label": "advanced metastatic gastric cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedexenatide_hyperglycemia, acute coronary syndromes, myocardial infarction", "label": "completedexenatide_hyperglycemia, acute coronary syndromes, myocardial infarction", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hiv infections, hepatitis c, liver disease", "label": "hiv infections, hepatitis c, liver disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmexiletine, placebo_sporadic amyotrophic lateral sclerosis", "label": "completedmexiletine, placebo_sporadic amyotrophic lateral sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlenalidomide, pembrolizumab_relapsed or refractory solid tumors, nonsmall cell lung cancer", "label": "terminatedlenalidomide, pembrolizumab_relapsed or refractory solid tumors, nonsmall cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)NC1=CC=C(O)C=C1, COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC", "label": "C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)NC1=CC=C(O)C=C1, COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC", "shape": "dot", "size": 10}, {"color": "red", "id": " pregabalin capsule", "label": " pregabalin capsule", "shape": "dot", "size": 10}, {"color": "red", "id": "dalbavancin", "label": "dalbavancin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gad-alum, vitamin d, etanercept", "label": "gad-alum, vitamin d, etanercept", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "capecitabine, cisplatin, imatinib mesylate", "label": "capecitabine, cisplatin, imatinib mesylate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O=[As]O[As]=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "label": "O=[As]O[As]=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "deferoxamine, deferiprone (l1)", "label": "deferoxamine, deferiprone (l1)", "shape": "dot", "size": 10}, {"color": "red", "id": " trametinib (multiple tablet)", "label": " trametinib (multiple tablet)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N", "label": "CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N", "shape": "dot", "size": 10}, {"color": "red", "id": " zolpidem", "label": " zolpidem", "shape": "dot", "size": 10}, {"color": "green", "id": " blood disease", "label": " blood disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddocetaxel, oxaliplatin, bevacizumab_non-small cell lung cancer", "label": "completeddocetaxel, oxaliplatin, bevacizumab_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1", "label": "[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1", "shape": "dot", "size": 10}, {"color": "green", "id": " otorhinolaryngologic neoplasms", "label": " otorhinolaryngologic neoplasms", "shape": "dot", "size": 10}, {"color": "red", "id": " vehicle saline as placebo", "label": " vehicle saline as placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iv grade 3 follicular lymphoma", "label": " stage iv grade 3 follicular lymphoma", "shape": "dot", "size": 10}, {"color": "blue", "id": " COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2", "label": " COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2", "shape": "dot", "size": 10}, {"color": "red", "id": " rebif new formulation + ibuprofen prn", "label": " rebif new formulation + ibuprofen prn", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine hydrochloride_bladder cancer", "label": "completedgemcitabine hydrochloride_bladder cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "red", "id": "pamrevlumab", "label": "pamrevlumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "interferon-alfa, su011248", "label": "interferon-alfa, su011248", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "filgrastim, bortezomib, carfilzomib, dexamethasone, cyclophosphamide, thalidomide, lenalidomide, pomalidomide", "label": "filgrastim, bortezomib, carfilzomib, dexamethasone, cyclophosphamide, thalidomide, lenalidomide, pomalidomide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedabi-007 (abraxane\u00ae)_urothelial cancer, bladder cancer", "label": "terminatedabi-007 (abraxane\u00ae)_urothelial cancer, bladder cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " multiple ascending doses", "label": " multiple ascending doses", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iii childhood large cell lymphoma", "label": " stage iii childhood large cell lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": " 5-fu infusion", "label": " 5-fu infusion", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O", "label": "OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O", "label": "CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O", "shape": "dot", "size": 10}, {"color": "red", "id": "cisplatin+capecitabine", "label": "cisplatin+capecitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpf-05180999, placebo, 120 mg mr pf-05180999, 360 mg mr pf-05180999, 10 mg cetirizine, placebo_migraine", "label": "terminatedpf-05180999, placebo, 120 mg mr pf-05180999, 360 mg mr pf-05180999, 10 mg cetirizine, placebo_migraine", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1, CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1", "label": "CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1, CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bacterial infections, skin structures and soft tissue infections", "label": "bacterial infections, skin structures and soft tissue infections", "shape": "dot", "size": 10}, {"color": "red", "id": " saline solution", "label": " saline solution", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlevetiracetam, placebo_essential tremor", "label": "completedlevetiracetam, placebo_essential tremor", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active comparator: a, placebo comparator b, active comparator b, placebo comparator a", "label": "active comparator: a, placebo comparator b, active comparator b, placebo comparator a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "colchicine, placebo", "label": "colchicine, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, pregabalin, pregabalin_diabetic neuropathy, painful", "label": "completedplacebo, pregabalin, pregabalin_diabetic neuropathy, painful", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmfns and antibiotic, matching placebo nasal spray plus antibiotic_sinusitis", "label": "terminatedmfns and antibiotic, matching placebo nasal spray plus antibiotic_sinusitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfluticasone furoate nasal spray, placebo_rhinitis, allergic, perennial, allergic rhinitis", "label": "completedfluticasone furoate nasal spray, placebo_rhinitis, allergic, perennial, allergic rhinitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedoxaliplatin, folinic acid, 5-fluoro-uracil, irinotecan, bevacizumab, cetuximab_colorectal cancer", "label": "completedoxaliplatin, folinic acid, 5-fluoro-uracil, irinotecan, bevacizumab, cetuximab_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "type 2 diabetes mellitus, high hba1c level, inadequate glycaemic control", "label": "type 2 diabetes mellitus, high hba1c level, inadequate glycaemic control", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlenalidomide_acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute myeloid leukemia in remission", "label": "terminatedlenalidomide_acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute myeloid leukemia in remission", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " fallopian tube serous adenocarcinoma", "label": " fallopian tube serous adenocarcinoma", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2", "label": "[H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "iv insulin to maintain target glucose concentration of 80-130 mg/dl, standard care control - sliding scale insulin to keep glucose less than 180 mg/dl", "label": "iv insulin to maintain target glucose concentration of 80-130 mg/dl, standard care control - sliding scale insulin to keep glucose less than 180 mg/dl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1", "label": "CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " tia (transient ischemic attack)", "label": " tia (transient ischemic attack)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedbeeam_follicular lymphoma", "label": "terminatedbeeam_follicular lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "corifollitropin alfa, placebo corifollitropin alfa, placebo recfsh / follitropin beta, ganirelix", "label": "corifollitropin alfa, placebo corifollitropin alfa, placebo recfsh / follitropin beta, ganirelix", "shape": "dot", "size": 10}, {"color": "red", "id": " flibanserin 50mg", "label": " flibanserin 50mg", "shape": "dot", "size": 10}, {"color": "red", "id": "mcn36 (nutritional supplement)", "label": "mcn36 (nutritional supplement)", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC", "label": "CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedht-100_duchenne muscular dystrophy", "label": "terminatedht-100_duchenne muscular dystrophy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "kaletra tablets", "label": "kaletra tablets", "shape": "dot", "size": 10}, {"color": "red", "id": "21-dipropionate", "label": "21-dipropionate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcandesartan_type 2 diabetes", "label": "completedcandesartan_type 2 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "merkel cell carcinoma, skin cancer", "label": "merkel cell carcinoma, skin cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddacarbazine, fotemustine, interferon alfa-2b_malignant melanoma, recurrent melanoma", "label": "completeddacarbazine, fotemustine, interferon alfa-2b_malignant melanoma, recurrent melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "filgrastim, pegfilgrastim", "label": "filgrastim, pegfilgrastim", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcapecitabine, exemestane, everolimus_breast cancer", "label": "completedcapecitabine, exemestane, everolimus_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "leo 29102", "label": "leo 29102", "shape": "dot", "size": 10}, {"color": "red", "id": "milrinone", "label": "milrinone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedex1000, biphasic human insulin_diabetes, diabetes mellitus, type 2", "label": "completedex1000, biphasic human insulin_diabetes, diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pain, diabetic neuropathy", "label": "pain, diabetic neuropathy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=C(Cl)C2=NC(=CC(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCCCC[C@@H]3C[C@]3(NC4=O)P(O)(=O)CC3=C(F)C=CC=C3F)NC(=O)OC3CCCC3)=C2C=C1)C1=CSC(NC(C)C)=N1, FC1=CC=CC=C1C1=NC2=CN(CC3=CC=C(N=N3)C3=CC=C(C=C3C(F)(F)F)C(F)(F)F)C=CC2=N1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "COC1=C(Cl)C2=NC(=CC(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCCCC[C@@H]3C[C@]3(NC4=O)P(O)(=O)CC3=C(F)C=CC=C3F)NC(=O)OC3CCCC3)=C2C=C1)C1=CSC(NC(C)C)=N1, FC1=CC=CC=C1C1=NC2=CN(CC3=CC=C(N=N3)C3=CC=C(C=C3C(F)(F)F)C(F)(F)F)C=CC2=N1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "red", "id": "intrathecal baclofen bolus", "label": "intrathecal baclofen bolus", "shape": "dot", "size": 10}, {"color": "green", "id": "bunion", "label": "bunion", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedselinexor, sorafenib_leukemia, acute myeloid leukemia", "label": "completedselinexor, sorafenib_leukemia, acute myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " loteprednol", "label": " loteprednol", "shape": "dot", "size": 10}, {"color": "red", "id": " oxaliplatin (eloxatin\u00ae)", "label": " oxaliplatin (eloxatin\u00ae)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lenalidomide 5 mg, lenalidomide 10 mg, placebo", "label": "lenalidomide 5 mg, lenalidomide 10 mg, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtadalafil_pulmonary hypertension", "label": "completedtadalafil_pulmonary hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawngax - gemcitabine, abraxane and xeloda_pancreatic cancer", "label": "withdrawngax - gemcitabine, abraxane and xeloda_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completede/c/f/taf, drv, baseline drv- containing arv regimen_hiv-1, hiv infections, acquired immunodeficiency syndrome", "label": "completede/c/f/taf, drv, baseline drv- containing arv regimen_hiv-1, hiv infections, acquired immunodeficiency syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=C(C=C(C=C1F)C(=O)NC1CC1)C1=CC=C(C=N1)C(=O)NCC(C)(C)C, NC[C@H]1CC[C@@H](CC1)C(O)=O, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1", "label": "CC1=C(C=C(C=C1F)C(=O)NC1CC1)C1=CC=C(C=N1)C(=O)NCC(C)(C)C, NC[C@H]1CC[C@@H](CC1)C(O)=O, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " oligo-astrocytoma", "label": " oligo-astrocytoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ovarian cancer, neoplasms, carcinoma", "label": "ovarian cancer, neoplasms, carcinoma", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1", "label": "CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1", "shape": "dot", "size": 10}, {"color": "red", "id": " reproxalap ophthalmic solution (0.1%)", "label": " reproxalap ophthalmic solution (0.1%)", "shape": "dot", "size": 10}, {"color": "green", "id": " pigmentary glaucoma", "label": " pigmentary glaucoma", "shape": "dot", "size": 10}, {"color": "green", "id": " untreated childhood rhabdomyosarcoma", "label": " untreated childhood rhabdomyosarcoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CSCC[C@H](N)C(O)=O, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CSCC[C@H](N)C(O)=O, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "desvenlafaxine succinate sustained-release (dvs sr)", "label": "desvenlafaxine succinate sustained-release (dvs sr)", "shape": "dot", "size": 10}, {"color": "green", "id": "visual impairment", "label": "visual impairment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aripiprazole, aripiprazole", "label": "aripiprazole, aripiprazole", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rad001, xelox, carboplatin", "label": "rad001, xelox, carboplatin", "shape": "dot", "size": 10}, {"color": "red", "id": "reformulated raltegravir", "label": "reformulated raltegravir", "shape": "dot", "size": 10}, {"color": "red", "id": " fluticasone/formoterol pmdi with spacer", "label": " fluticasone/formoterol pmdi with spacer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednitazoxanide, nitazoxanide, placebo_influenza", "label": "completednitazoxanide, nitazoxanide, placebo_influenza", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo for mitiglinide, mitiglinide, mitiglinide_diabetes mellitus, type 2", "label": "completedplacebo for mitiglinide, mitiglinide, mitiglinide_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "locally advanced renal cell carcinoma, metastatic renal cell carcinoma", "label": "locally advanced renal cell carcinoma, metastatic renal cell carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bol-303259-x, timolol maleate", "label": "bol-303259-x, timolol maleate", "shape": "dot", "size": 10}, {"color": "red", "id": "nvr 3-778", "label": "nvr 3-778", "shape": "dot", "size": 10}, {"color": "green", "id": " adult glioblastoma", "label": " adult glioblastoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedact-541468, placebo_insomnia disorder", "label": "completedact-541468, placebo_insomnia disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " progressive breast cancer", "label": " progressive breast cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " recombinant fsh", "label": " recombinant fsh", "shape": "dot", "size": 10}, {"color": "red", "id": " herceptin", "label": " herceptin", "shape": "dot", "size": 10}, {"color": "red", "id": "immune globulin intravenous [human]", "label": "immune globulin intravenous [human]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "enfuvirtide, highly active antiretroviral treatment (haart)", "label": "enfuvirtide, highly active antiretroviral treatment (haart)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tenofovir disoproxil fumarate/emtricitabine, lopinavir/ritonavir", "label": "tenofovir disoproxil fumarate/emtricitabine, lopinavir/ritonavir", "shape": "dot", "size": 10}, {"color": "red", "id": " ertugliflozin 4 mg split into twice daily", "label": " ertugliflozin 4 mg split into twice daily", "shape": "dot", "size": 10}, {"color": "green", "id": " urogenital neoplasms", "label": " urogenital neoplasms", "shape": "dot", "size": 10}, {"color": "red", "id": "mupirocin calcium ointment", "label": "mupirocin calcium ointment", "shape": "dot", "size": 10}, {"color": "green", "id": "tonsillitis", "label": "tonsillitis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedevp-6124, placebo_alzheimer\u0027s disease, central nervous system diseases, cognition", "label": "completedevp-6124, placebo_alzheimer\u0027s disease, central nervous system diseases, cognition", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaliskiren, aliskiren, aliskiren, aliskiren_diabetes mellitus, type 2", "label": "completedaliskiren, aliskiren, aliskiren, aliskiren_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrad001, folfox, bevacizumab_colorectal cancer", "label": "completedrad001, folfox, bevacizumab_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(O)=NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN1C(O)=NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1", "shape": "dot", "size": 10}, {"color": "red", "id": " comparator : rosuvastatin calcium", "label": " comparator : rosuvastatin calcium", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pain, polyneuropathies", "label": "pain, polyneuropathies", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bivalirudin, heparin", "label": "bivalirudin, heparin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedgs-1101_waldenstrom\u0027s macroglobulinemia", "label": "terminatedgs-1101_waldenstrom\u0027s macroglobulinemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCC(=O)NS(=O)(=O)C1=CC(NC2=NC=C(F)C(NC3=CC=C(OCC#C)C=C3)=N2)=CC=C1C", "label": "CCC(=O)NS(=O)(=O)C1=CC(NC2=NC=C(F)C(NC3=CC=C(OCC#C)C=C3)=N2)=CC=C1C", "shape": "dot", "size": 10}, {"color": "red", "id": "mp513", "label": "mp513", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azithromycin, atovaquone, sulfamethoxazole-trimethoprim", "label": "azithromycin, atovaquone, sulfamethoxazole-trimethoprim", "shape": "dot", "size": 10}, {"color": "red", "id": "placebo for sch 900962", "label": "placebo for sch 900962", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COCCOC1C(O)C(COP(O)(=S)OC2C(COP(O)(=S)OC3C(COP(O)(=S)OC4C(COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5C(COP(O)(=S)OC6C(COP(O)(=S)OC7C(COP(O)(=S)OC8C(CO)OC(C8OCCOC)N8C=NC9=C8NC(=N)N=C9O)OC(C7OCCOC)N7C=NC8=C7NC(=N)N=C8O)OC(C6OCCOC)N6C=NC7=C6NC(=N)N=C7O)OC(C5OCCOC)N5C=NC6=C(N)N=CN=C56)N5C=C(C)C(=N)N=C5O)N5C=NC6=C5NC(=N)N=C6O)N5C=C(C)C(=N)N=C5O)N5C=NC6=C5NC(=N)N=C6O)N5C=NC6=C5NC(=N)N=C6O)N5C=C(C)C(=N)N=C5O)N5C=NC6=C5NC(=N)N=C6O)N5C=C(C)C(=N)N=C5O)N5C=C(C)C(O)=NC5=O)N5C=C(C)C(=N)N=C5O)N5C=NC6=C5NC(=N)N=C6O)N5C=NC6=C5NC(=N)N=C6O)OC(C4OCCOC)N4C=C(C)C(O)=NC4=O)OC(C3OCCOC)N3C=C(C)C(=N)N=C3O)OC(C2OCCOC)N2C=NC3=C(N)N=CN=C23)OC1N1C=C(C)C(O)=NC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "COCCOC1C(O)C(COP(O)(=S)OC2C(COP(O)(=S)OC3C(COP(O)(=S)OC4C(COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5CC(OC5COP(O)(=S)OC5C(COP(O)(=S)OC6C(COP(O)(=S)OC7C(COP(O)(=S)OC8C(CO)OC(C8OCCOC)N8C=NC9=C8NC(=N)N=C9O)OC(C7OCCOC)N7C=NC8=C7NC(=N)N=C8O)OC(C6OCCOC)N6C=NC7=C6NC(=N)N=C7O)OC(C5OCCOC)N5C=NC6=C(N)N=CN=C56)N5C=C(C)C(=N)N=C5O)N5C=NC6=C5NC(=N)N=C6O)N5C=C(C)C(=N)N=C5O)N5C=NC6=C5NC(=N)N=C6O)N5C=NC6=C5NC(=N)N=C6O)N5C=C(C)C(=N)N=C5O)N5C=NC6=C5NC(=N)N=C6O)N5C=C(C)C(=N)N=C5O)N5C=C(C)C(O)=NC5=O)N5C=C(C)C(=N)N=C5O)N5C=NC6=C5NC(=N)N=C6O)N5C=NC6=C5NC(=N)N=C6O)OC(C4OCCOC)N4C=C(C)C(O)=NC4=O)OC(C3OCCOC)N3C=C(C)C(=N)N=C3O)OC(C2OCCOC)N2C=NC3=C(N)N=CN=C23)OC1N1C=C(C)C(O)=NC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate", "label": "cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate", "shape": "dot", "size": 10}, {"color": "red", "id": " gsk573719", "label": " gsk573719", "shape": "dot", "size": 10}, {"color": "green", "id": " chemotherapeutic agent toxicity", "label": " chemotherapeutic agent toxicity", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(=O)NC1=CC=CC(=C1)N1CCN(CCCCNS(=O)(=O)CC2CCCCC2)CC1", "label": "CC(=O)NC1=CC=CC(=C1)N1CCN(CCCCNS(=O)(=O)CC2CCCCC2)CC1", "shape": "dot", "size": 10}, {"color": "red", "id": "ji-101", "label": "ji-101", "shape": "dot", "size": 10}, {"color": "green", "id": " pyelonephritis", "label": " pyelonephritis", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo every 2 weeks", "label": " placebo every 2 weeks", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC2=NC(=CC(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](CC(=O)N3CCCCC3)C(C)(C)C)C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)=C2C=C1)C1=CC=CC=C1, COC1=CC2=NC(=CC(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](CC(=O)N3CCCCC3)C(C)(C)C)C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)=C2C=C1)C1=CC=CC=C1, COC1=CC2=NC(=CC(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](CC(=O)N3CCCCC3)C(C)(C)C)C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)=C2C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "COC1=CC2=NC(=CC(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](CC(=O)N3CCCCC3)C(C)(C)C)C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)=C2C=C1)C1=CC=CC=C1, COC1=CC2=NC(=CC(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](CC(=O)N3CCCCC3)C(C)(C)C)C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)=C2C=C1)C1=CC=CC=C1, COC1=CC2=NC(=CC(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](CC(=O)N3CCCCC3)C(C)(C)C)C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C3CC3)=C2C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "imetelstat", "label": "imetelstat", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dmard, methotrexate, tocilizumab [roactemra/actemra], tocilizumab [roactemra/actemra], tocilizumab [roactemra/actemra]", "label": "dmard, methotrexate, tocilizumab [roactemra/actemra], tocilizumab [roactemra/actemra], tocilizumab [roactemra/actemra]", "shape": "dot", "size": 10}, {"color": "green", "id": " proliferative diabetic retinopathy", "label": " proliferative diabetic retinopathy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cardiac surgery, coronary artery bypass, aortic aneurysm, valve surgery, kidney diseases", "label": "cardiac surgery, coronary artery bypass, aortic aneurysm, valve surgery, kidney diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nilotinib, placebo to nilotinib", "label": "nilotinib, placebo to nilotinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednd0612 (levodopa/carbidopa solution)_parkinson\u0027s disease", "label": "completednd0612 (levodopa/carbidopa solution)_parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "gwp42003", "label": "gwp42003", "shape": "dot", "size": 10}, {"color": "red", "id": "tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)", "label": "tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedidn-6556_acute on chronic hepatic failure, acute liver failure, liver cirrhosis, acute alcoholic hepatitis", "label": "terminatedidn-6556_acute on chronic hepatic failure, acute liver failure, liver cirrhosis, acute alcoholic hepatitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " dimebon", "label": " dimebon", "shape": "dot", "size": 10}, {"color": "red", "id": "basal-bolus detemir-aspart insulin regimen", "label": "basal-bolus detemir-aspart insulin regimen", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statussarpogrelate_chronic kidney disease", "label": "unknown statussarpogrelate_chronic kidney disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "prucalopride, polyethylene glycol (peg), lactulose", "label": "prucalopride, polyethylene glycol (peg), lactulose", "shape": "dot", "size": 10}, {"color": "red", "id": "antithymocyte globulin (atg)", "label": "antithymocyte globulin (atg)", "shape": "dot", "size": 10}, {"color": "green", "id": " adult mixed cellularity hodgkin lymphoma", "label": " adult mixed cellularity hodgkin lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "diabetic retinopathy, retinal neovascularisation", "label": "diabetic retinopathy, retinal neovascularisation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedranibizumab 0.5mg, ranibizumab 0.5mg_age-related macular degeneration, choroidal neovascularization", "label": "completedranibizumab 0.5mg, ranibizumab 0.5mg_age-related macular degeneration, choroidal neovascularization", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedalogliptin+pioglitazone, alogliptin, pioglitazone_diabetes mellitus, type 2", "label": "terminatedalogliptin+pioglitazone, alogliptin, pioglitazone_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsodium oxybate_schizophrenia, insomnia related to schizophrenia (307.42)", "label": "completedsodium oxybate_schizophrenia, insomnia related to schizophrenia (307.42)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fampridine-sr, placebo", "label": "fampridine-sr, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedraltegravir film-coated tablet, raltegravir chewable tablet, other anti-retroviral therapy_hiv infection", "label": "completedraltegravir film-coated tablet, raltegravir chewable tablet, other anti-retroviral therapy_hiv infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "amitriptyline hydrochloride", "label": "amitriptyline hydrochloride", "shape": "dot", "size": 10}, {"color": "red", "id": " aprocitentan 50 mg", "label": " aprocitentan 50 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " tramadol", "label": " tramadol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CC1=CC(O)=CC(C)=C1Cl", "label": "CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CC(=O)OC1=CC=CC=C1C(O)=O, CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1", "label": "CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CC(=O)OC1=CC=CC=C1C(O)=O, CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " pf-06835919 high dose", "label": " pf-06835919 high dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmethotrexate_rheumatoid arthritis", "label": "completedmethotrexate_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1, CC(O)=O", "label": "CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1, CC(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedadalimumab_rheumatoid arthritis", "label": "completedadalimumab_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@]1(CCC(C)=C[C@H]1C1=C(O)C=C(CCC)C=C1O)C(C)=C", "label": "[H][C@]1(CCC(C)=C[C@H]1C1=C(O)C=C(CCC)C=C1O)C(C)=C", "shape": "dot", "size": 10}, {"color": "red", "id": " fluticasone/salmeterol (advair diskus)", "label": " fluticasone/salmeterol (advair diskus)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsorafenib + paclitaxel + carboplatin, placebo + paclitaxel + carboplatin_carcinoma, non-small-cell lung", "label": "terminatedsorafenib + paclitaxel + carboplatin, placebo + paclitaxel + carboplatin_carcinoma, non-small-cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatednivolumab, azacitidine, fludarabine, cyclophosphamide, cytarabine, all trans retinoic acid, sildenafil, melphalan_myelodysplastic syndromes", "label": "terminatednivolumab, azacitidine, fludarabine, cyclophosphamide, cytarabine, all trans retinoic acid, sildenafil, melphalan_myelodysplastic syndromes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "apatorsen (ogx-427)", "label": "apatorsen (ogx-427)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbimatoprost_primary open-angle glaucoma, ocular hypertension", "label": "completedbimatoprost_primary open-angle glaucoma, ocular hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " carcinoma of breast", "label": " carcinoma of breast", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bevacizumab, gemcitabine, docetaxel and valproic acid", "label": "bevacizumab, gemcitabine, docetaxel and valproic acid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedarmodafinil (nuvigil), placebo_schizophrenia, schizoaffective disorder", "label": "completedarmodafinil (nuvigil), placebo_schizophrenia, schizoaffective disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " teduglutide 0.05 mg/kg/d", "label": " teduglutide 0.05 mg/kg/d", "shape": "dot", "size": 10}, {"color": "red", "id": " gemcabene 300 mg", "label": " gemcabene 300 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddepocyt, temozolomide_neoplastic meningitis", "label": "terminateddepocyt, temozolomide_neoplastic meningitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1", "label": "NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfsh-gex(tm), gonal-f(r)_infertility", "label": "completedfsh-gex(tm), gonal-f(r)_infertility", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "rdea119", "label": "rdea119", "shape": "dot", "size": 10}, {"color": "green", "id": " ampullary cancer", "label": " ampullary cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvismodegib 150 mg, placebo to vismodegib, bevacizumab, modified folfox, folfiri_metastatic colorectal cancer", "label": "completedvismodegib 150 mg, placebo to vismodegib, bevacizumab, modified folfox, folfiri_metastatic colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iva mycosis fungoides and sezary syndrome", "label": " stage iva mycosis fungoides and sezary syndrome", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1, NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N", "label": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1, NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cisplatin, gemcitabine hydrochloride", "label": "cisplatin, gemcitabine hydrochloride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1", "label": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vorinostat, vorinostat, vorinostat, vorinostat, erlotinib", "label": "vorinostat, vorinostat, vorinostat, vorinostat, erlotinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "shape": "dot", "size": 10}, {"color": "blue", "id": "OC(=O)C1=CC=CC=C1O", "label": "OC(=O)C1=CC=CC=C1O", "shape": "dot", "size": 10}, {"color": "red", "id": "group a: valsartan plus chlorthalidone", "label": "group a: valsartan plus chlorthalidone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vorinostat, bevacizumab, carboplatin, paclitaxel, vorinostat, bevacizumab, carboplatin, paclitaxel", "label": "vorinostat, bevacizumab, carboplatin, paclitaxel, vorinostat, bevacizumab, carboplatin, paclitaxel", "shape": "dot", "size": 10}, {"color": "red", "id": " oxaliplatine", "label": " oxaliplatine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "velcade, alimta", "label": "velcade, alimta", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "CC(C)C(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, prasugrel", "label": "placebo, prasugrel", "shape": "dot", "size": 10}, {"color": "red", "id": "td-9855", "label": "td-9855", "shape": "dot", "size": 10}, {"color": "green", "id": "metabolic diseases", "label": "metabolic diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic hepatitis c infection, chronic hepatitis c", "label": "chronic hepatitis c infection, chronic hepatitis c", "shape": "dot", "size": 10}, {"color": "red", "id": "paclitaxel (genexol\u00ae)", "label": "paclitaxel (genexol\u00ae)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bendamustine + rituximab + pixantrone, pegfilgrastim", "label": "bendamustine + rituximab + pixantrone, pegfilgrastim", "shape": "dot", "size": 10}, {"color": "red", "id": "inositol", "label": "inositol", "shape": "dot", "size": 10}, {"color": "green", "id": " rupture of intracranial aneurysm", "label": " rupture of intracranial aneurysm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rivaroxaban (xarelto, bay59-7939), warfarin, rivaroxaban placebo, warfarin placebo", "label": "rivaroxaban (xarelto, bay59-7939), warfarin, rivaroxaban placebo, warfarin placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " respiratory infection", "label": " respiratory infection", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedroniciclib (bay1000394), placebo_small cell lung carcinoma", "label": "terminatedroniciclib (bay1000394), placebo_small cell lung carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, paliperidone palmitate", "label": "placebo, paliperidone palmitate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfulvestrant, mln9708_breast cancer", "label": "terminatedfulvestrant, mln9708_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " steroids (methylprednisone or prednisone)", "label": " steroids (methylprednisone or prednisone)", "shape": "dot", "size": 10}, {"color": "red", "id": " tolterodine er", "label": " tolterodine er", "shape": "dot", "size": 10}, {"color": "blue", "id": "COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1", "label": "COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " adhd", "label": " adhd", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adalimumab, methotrexate, folic acid, prednisolone", "label": "adalimumab, methotrexate, folic acid, prednisolone", "shape": "dot", "size": 10}, {"color": "red", "id": "glpg0634", "label": "glpg0634", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": " dalteparin", "label": " dalteparin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedandrographolides, capecitabine_colorectal neoplasms", "label": "terminatedandrographolides, capecitabine_colorectal neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " goserelin (zoladex)", "label": " goserelin (zoladex)", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iiia ovarian epithelial cancer", "label": " stage iiia ovarian epithelial cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCN(CC)C(=S)SSC(=S)N(CC)CC, CN1N=NC2=C(N=CN2C1=O)C(N)=O", "label": "CCN(CC)C(=S)SSC(=S)N(CC)CC, CN1N=NC2=C(N=CN2C1=O)C(N)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone furoate, ff/vilanterol (vi; gw642444m), placebo", "label": "fluticasone furoate, ff/vilanterol (vi; gw642444m), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusfebuxostat_tumor lysis syndrome", "label": "unknown statusfebuxostat_tumor lysis syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednnz-2566, placebo_rett syndrome", "label": "completednnz-2566, placebo_rett syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=NC(NNC(=O)[C@H](CC2CCCC2)CN(O)C=O)=C(F)C(=N1)N1CCN2CCOC[C@@H]2C1, [Ne], CC1=NC(NNC(=O)[C@H](CC2CCCC2)CN(O)C=O)=C(F)C(=N1)N1CCN2CCOC[C@@H]2C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC1=NC(NNC(=O)[C@H](CC2CCCC2)CN(O)C=O)=C(F)C(=N1)N1CCN2CCOC[C@@H]2C1, [Ne], CC1=NC(NNC(=O)[C@H](CC2CCCC2)CN(O)C=O)=C(F)C(=N1)N1CCN2CCOC[C@@H]2C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "green", "id": " adult acute myeloblastic leukemia without maturation (m1)", "label": " adult acute myeloblastic leukemia without maturation (m1)", "shape": "dot", "size": 10}, {"color": "red", "id": " alogliptin and voglibose", "label": " alogliptin and voglibose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "esophageal cancer, precancerous condition", "label": "esophageal cancer, precancerous condition", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cariprazine (rgh-188), placebo", "label": "cariprazine (rgh-188), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaprepitant, aprepitant placebo, ondansetron, dexamethasone, ondansetron placebo, rescue therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride)._nausea, vomiting", "label": "completedaprepitant, aprepitant placebo, ondansetron, dexamethasone, ondansetron placebo, rescue therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride)._nausea, vomiting", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "casopitant, dexamethasone, placebo, ondansetron", "label": "casopitant, dexamethasone, placebo, ondansetron", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel (taxotere\u00ae) chemotherapy, leuprolide acetate ( eligard\u00ae) hormonal therapy, docetaxel (taxotere\u00ae) chemotherapy, leuprolide acetate ( eligard\u00ae) hormonal therapy, leuprolide acetate ( eligard\u00ae) hormonal therapy", "label": "docetaxel (taxotere\u00ae) chemotherapy, leuprolide acetate ( eligard\u00ae) hormonal therapy, docetaxel (taxotere\u00ae) chemotherapy, leuprolide acetate ( eligard\u00ae) hormonal therapy, leuprolide acetate ( eligard\u00ae) hormonal therapy", "shape": "dot", "size": 10}, {"color": "red", "id": " anastrazole", "label": " anastrazole", "shape": "dot", "size": 10}, {"color": "green", "id": "urologic neoplasms", "label": "urologic neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpioglitazone, placebo_bone metabolism", "label": "completedpioglitazone, placebo_bone metabolism", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oral vancomycin, moviprep, prilosec", "label": "oral vancomycin, moviprep, prilosec", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "risankizumab, ustekinumab, placebo for risankizumab, placebo for ustekinumab", "label": "risankizumab, ustekinumab, placebo for risankizumab, placebo for ustekinumab", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iii adenoid cystic carcinoma of the oral cavity", "label": " stage iii adenoid cystic carcinoma of the oral cavity", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin_colorectal cancer", "label": "terminatedfluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, obeticholic acid (oca)_liver cirrhosis, biliary", "label": "completedplacebo, obeticholic acid (oca)_liver cirrhosis, biliary", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ccrt arm without consolidation chemotherapy", "label": " ccrt arm without consolidation chemotherapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(N=O)C(=O)NC1CCCCC1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(N=O)C(=O)NC1CCCCC1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddocetaxel and cisplatin_non-small cell lung cancer", "label": "terminateddocetaxel and cisplatin_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtelmisartan, telmisartan/hctz_hypertension", "label": "completedtelmisartan, telmisartan/hctz_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, tiotropium + olodaterol, tiotropium + olodaterol, tiotropium, olodaterol_pulmonary disease, chronic obstructive", "label": "completedplacebo, tiotropium + olodaterol, tiotropium + olodaterol, tiotropium, olodaterol_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "iron sucrose, oxandrolone, iv iron placebo, oxandrolone placebo", "label": "iron sucrose, oxandrolone, iv iron placebo, oxandrolone placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcositecan_primary peritoneal carcinoma, recurrent ovarian carcinoma", "label": "completedcositecan_primary peritoneal carcinoma, recurrent ovarian carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(CCCl)P1(=O)NCCCO1", "label": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(CCCl)P1(=O)NCCCO1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC, CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O", "label": "CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC, CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbbi608, placebo_colorectal carcinoma", "label": "completedbbi608, placebo_colorectal carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ly2189265, exenatide, placebo, metformin, pioglitazone", "label": "ly2189265, exenatide, placebo, metformin, pioglitazone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatednaloxegol, placebo_cancer, constipation, pain", "label": "terminatednaloxegol, placebo_cancer, constipation, pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "nelotanserin", "label": "nelotanserin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, ac-201, febuxostat", "label": "placebo, ac-201, febuxostat", "shape": "dot", "size": 10}, {"color": "red", "id": " 5-fu and radiotherapy", "label": " 5-fu and radiotherapy", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo (pbo)", "label": " placebo (pbo)", "shape": "dot", "size": 10}, {"color": "red", "id": "[f-18]-5-fluoro-2\u0027-deoxycytidine", "label": "[f-18]-5-fluoro-2\u0027-deoxycytidine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedexenatide, placebo_obesity, impaired glucose tolerance", "label": "completedexenatide, placebo_obesity, impaired glucose tolerance", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "g-csf", "label": "g-csf", "shape": "dot", "size": 10}, {"color": "green", "id": " metastatic squamous cell carcinoma of the larynx", "label": " metastatic squamous cell carcinoma of the larynx", "shape": "dot", "size": 10}, {"color": "red", "id": " protease inhibitor/ritonavir", "label": " protease inhibitor/ritonavir", "shape": "dot", "size": 10}, {"color": "green", "id": "acute ulcerative colitis", "label": "acute ulcerative colitis", "shape": "dot", "size": 10}, {"color": "green", "id": " acute decompensated heart failure (adhf)", "label": " acute decompensated heart failure (adhf)", "shape": "dot", "size": 10}, {"color": "red", "id": "ui05msp015ct", "label": "ui05msp015ct", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedparitaprevir/ritonavir/ombitasvir (ptv/r/obt), dasabuvir (dsv), ribavirin (rbv)_hiv infections, hepatitis c", "label": "terminatedparitaprevir/ritonavir/ombitasvir (ptv/r/obt), dasabuvir (dsv), ribavirin (rbv)_hiv infections, hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mediastinal cancer, metastatic cancer, testicular germ cell tumor", "label": "mediastinal cancer, metastatic cancer, testicular germ cell tumor", "shape": "dot", "size": 10}, {"color": "red", "id": " aromatase inhibitors", "label": " aromatase inhibitors", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "linagliptin, empagliflozin + linagliptin, empagliflozin + linagliptin, empagliflozin + linagliptin, empaglifozin placebo + linagliptin placebo, empagliflozin + linagliptin", "label": "linagliptin, empagliflozin + linagliptin, empagliflozin + linagliptin, empagliflozin + linagliptin, empaglifozin placebo + linagliptin placebo, empagliflozin + linagliptin", "shape": "dot", "size": 10}, {"color": "red", "id": "laba", "label": "laba", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazilsartan medoxomil/placebo, azilsartan medoxomil - chlorthalidone_essential hypertension", "label": "completedazilsartan medoxomil/placebo, azilsartan medoxomil - chlorthalidone_essential hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " [Na+].OCCCC([O-])=O", "label": " [Na+].OCCCC([O-])=O", "shape": "dot", "size": 10}, {"color": "red", "id": " aricept (donepezil ir 10 mg)", "label": " aricept (donepezil ir 10 mg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "peg-intron, rebetol, hcv 796, peg-intron, rebetol, hcv 796, peg-intron, rebetol", "label": "peg-intron, rebetol, hcv 796, peg-intron, rebetol, hcv 796, peg-intron, rebetol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C=C(CNCC2CCN(CC2)C2=NC=C(C=N2)C(=O)NO)C2=CC=CC=C12, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "CN1C=C(CNCC2CCN(CC2)C2=NC=C(C=N2)C(=O)NO)C2=CC=CC=C12, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1", "label": " [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " followed by docetaxel plus trastuzumab", "label": " followed by docetaxel plus trastuzumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtemozolomide_lymphoma", "label": "terminatedtemozolomide_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "yh12852 ir 0.05mg", "label": "yh12852 ir 0.05mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12, CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1, CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12, CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1, CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bortezomib, chop, rituximab", "label": "bortezomib, chop, rituximab", "shape": "dot", "size": 10}, {"color": "red", "id": "clopidogrel 75mg", "label": "clopidogrel 75mg", "shape": "dot", "size": 10}, {"color": "red", "id": " ranibizumab 0.5mg", "label": " ranibizumab 0.5mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "label": "ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dabrafenib, vemurafenib, trametinib", "label": "dabrafenib, vemurafenib, trametinib", "shape": "dot", "size": 10}, {"color": "green", "id": " rad51 gene mutation", "label": " rad51 gene mutation", "shape": "dot", "size": 10}, {"color": "green", "id": " stomatitis", "label": " stomatitis", "shape": "dot", "size": 10}, {"color": "green", "id": " hyperlipoproteinemias", "label": " hyperlipoproteinemias", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpseudoephedrine/paracetamol_common cold, headache, nasal congestion", "label": "completedpseudoephedrine/paracetamol_common cold, headache, nasal congestion", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gen 1200mg/day, gen 2400mg/day, gen 3600mg/day, placebo", "label": "gen 1200mg/day, gen 2400mg/day, gen 3600mg/day, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddronedarone (sr33589), placebo_atrial fibrillation, atrial flutter", "label": "completeddronedarone (sr33589), placebo_atrial fibrillation, atrial flutter", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCC1=C(\\C=C\\C(=O)N[C@H](C)C2=CC(F)=C(NS(C)(=O)=O)C(F)=C2)C=CC(=N1)C(F)(F)F", "label": "CCCC1=C(\\C=C\\C(=O)N[C@H](C)C2=CC(F)=C(NS(C)(=O)=O)C(F)=C2)C=CC(=N1)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pain, acute pain", "label": "pain, acute pain", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedbupropion sr_tobacco use disorder", "label": "terminatedbupropion sr_tobacco use disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " myelodysplasia", "label": " myelodysplasia", "shape": "dot", "size": 10}, {"color": "red", "id": " vehicle opthalmic solution", "label": " vehicle opthalmic solution", "shape": "dot", "size": 10}, {"color": "red", "id": "folotyn and leucovorin", "label": "folotyn and leucovorin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbevacizumab [avastin], fotemustine_malignant melanoma", "label": "completedbevacizumab [avastin], fotemustine_malignant melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "vx-661", "label": "vx-661", "shape": "dot", "size": 10}, {"color": "red", "id": "cp-866", "label": "cp-866", "shape": "dot", "size": 10}, {"color": "green", "id": " stage ivc sinonasal squamous cell carcinoma ajcc v7", "label": " stage ivc sinonasal squamous cell carcinoma ajcc v7", "shape": "dot", "size": 10}, {"color": "green", "id": " acute heart failure", "label": " acute heart failure", "shape": "dot", "size": 10}, {"color": "red", "id": "vesatolimod", "label": "vesatolimod", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "campath 1h\u00ae, rituximab, mycophenolate mofetil", "label": "campath 1h\u00ae, rituximab, mycophenolate mofetil", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedas mdi, proventil_asthma", "label": "completedas mdi, proventil_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, afatinib", "label": "placebo, afatinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hiv, pregnancy", "label": "hiv, pregnancy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "methotrexate, vinblastine, doxorubicin, cisplatin, cisplatin, gemcitabine", "label": "methotrexate, vinblastine, doxorubicin, cisplatin, cisplatin, gemcitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "obesity type 2 diabetes mellitus, type 2 diabetes mellitus", "label": "obesity type 2 diabetes mellitus, type 2 diabetes mellitus", "shape": "dot", "size": 10}, {"color": "green", "id": " bacterial skin diseases", "label": " bacterial skin diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvildagliptin (laf237), voglibose, vildagliptin and voglibose_type 2 diabetes", "label": "completedvildagliptin (laf237), voglibose, vildagliptin and voglibose_type 2 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcetuximab, dasatinib, cisplatin_head and neck cancer", "label": "terminatedcetuximab, dasatinib, cisplatin_head and neck cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedliraglutide, metformin, sulphonylurea_diabetes, diabetes mellitus, type 2", "label": "completedliraglutide, metformin, sulphonylurea_diabetes, diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCC[C@H](NC(=O)[C@@H](CCCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O", "label": "CCCC[C@H](NC(=O)[C@@H](CCCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCCC1=NC2=CC(\\C=C\\C(=O)NO)=CC=C2N1CCN(CC)CC, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "label": "CCCCC1=NC2=CC(\\C=C\\C(=O)NO)=CC=C2N1CCN(CC)CC, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "shape": "dot", "size": 10}, {"color": "red", "id": " golimumab (placebo group)", "label": " golimumab (placebo group)", "shape": "dot", "size": 10}, {"color": "red", "id": " epidoxorubicin", "label": " epidoxorubicin", "shape": "dot", "size": 10}, {"color": "green", "id": " poor quality sleep", "label": " poor quality sleep", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin glargine, metformin, dpp-4 inhibitor, sulphonylurea_diabetes mellitus, type 2", "label": "completedinsulin glargine, metformin, dpp-4 inhibitor, sulphonylurea_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " post-stroke", "label": " post-stroke", "shape": "dot", "size": 10}, {"color": "red", "id": " 100 mg", "label": " 100 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic lymphocytic leukemia, leukemia", "label": "chronic lymphocytic leukemia, leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlenvatinib_biliary tract cancer", "label": "completedlenvatinib_biliary tract cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcf101, placebo_rheumatoid arthritis", "label": "completedcf101, placebo_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsimulect\u00ae, neoral\u00ae, certican\u00ae, myfortic\u00ae, corticosteroids_renal transplantation", "label": "completedsimulect\u00ae, neoral\u00ae, certican\u00ae, myfortic\u00ae, corticosteroids_renal transplantation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo fluticasone furoate", "label": " placebo fluticasone furoate", "shape": "dot", "size": 10}, {"color": "red", "id": " baricitinib placebo", "label": " baricitinib placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmercaptopurine, methotrexate, tretinoin_leukemia", "label": "completedmercaptopurine, methotrexate, tretinoin_leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedthalidomide_carcinoma of the appendix, colorectal cancer", "label": "completedthalidomide_carcinoma of the appendix, colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ramucirumab, placebo, s-1, oxaliplatin, paclitaxel", "label": "ramucirumab, placebo, s-1, oxaliplatin, paclitaxel", "shape": "dot", "size": 10}, {"color": "red", "id": "per977", "label": "per977", "shape": "dot", "size": 10}, {"color": "red", "id": "bicillin l-a", "label": "bicillin l-a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrelugolix, estradiol/norethindrone acetate, relugolix placebo, estradiol/norethindrone acetate placebo_heavy menstrual bleeding, uterine fibroid", "label": "completedrelugolix, estradiol/norethindrone acetate, relugolix placebo, estradiol/norethindrone acetate placebo_heavy menstrual bleeding, uterine fibroid", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnepidural steroid injection_lumbar spinal stenosis", "label": "withdrawnepidural steroid injection_lumbar spinal stenosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "fesoterodine 8mg", "label": "fesoterodine 8mg", "shape": "dot", "size": 10}, {"color": "green", "id": " progesterone receptor-negative breast cancer", "label": " progesterone receptor-negative breast cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingavelumab (msb0010718c), axitinib (ag-013736), sunitinib_renal cell cancer", "label": "active, not recruitingavelumab (msb0010718c), axitinib (ag-013736), sunitinib_renal cell cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " cinaciguat (bay58-2667)", "label": " cinaciguat (bay58-2667)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone furoate, matching placebo", "label": "fluticasone furoate, matching placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcabozantinib_differentiated thyroid cancer (dtc), poorly differentiated thyroid cancer", "label": "active, not recruitingcabozantinib_differentiated thyroid cancer (dtc), poorly differentiated thyroid cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Na+].[Na+].[O-]P([O-])(F)=O, [H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O", "label": "[Na+].[Na+].[O-]P([O-])(F)=O, [H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin degludec/insulin aspart, insulin degludec, insulin aspart_diabetes, diabetes mellitus, type 2", "label": "completedinsulin degludec/insulin aspart, insulin degludec, insulin aspart_diabetes, diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O", "label": " CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O", "shape": "dot", "size": 10}, {"color": "red", "id": " abiraterone acetate mtd", "label": " abiraterone acetate mtd", "shape": "dot", "size": 10}, {"color": "green", "id": " hospital acquired pneumonia (hap)", "label": " hospital acquired pneumonia (hap)", "shape": "dot", "size": 10}, {"color": "red", "id": "azd2281", "label": "azd2281", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsingle low dose cyclophosphamide, multiple low dose cyclophosphamide_multiple myeloma", "label": "completedsingle low dose cyclophosphamide, multiple low dose cyclophosphamide_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gemcitabine, docetaxel", "label": "gemcitabine, docetaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adult acute megakaryoblastic leukemia (m7), adult acute minimally differentiated myeloid leukemia (m0), adult acute monoblastic leukemia (m5a), adult acute monocytic leukemia (m5b), adult acute myeloblastic leukemia with maturation (m2), adult acute myeloblastic leukemia without maturation (m1), adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myelomonocytic leukemia (m4), adult erythroleukemia (m6a), adult pure erythroid leukemia (m6b), recurrent adult acute myeloid leukemia", "label": "adult acute megakaryoblastic leukemia (m7), adult acute minimally differentiated myeloid leukemia (m0), adult acute monoblastic leukemia (m5a), adult acute monocytic leukemia (m5b), adult acute myeloblastic leukemia with maturation (m2), adult acute myeloblastic leukemia without maturation (m1), adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myelomonocytic leukemia (m4), adult erythroleukemia (m6a), adult pure erythroid leukemia (m6b), recurrent adult acute myeloid leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "atrial fibrillation, quality of life", "label": "atrial fibrillation, quality of life", "shape": "dot", "size": 10}, {"color": "red", "id": "tmc278la", "label": "tmc278la", "shape": "dot", "size": 10}, {"color": "green", "id": "chronic low back pain with a neuropathic component", "label": "chronic low back pain with a neuropathic component", "shape": "dot", "size": 10}, {"color": "red", "id": " naproxen sodium 440 mg (bayh6689)", "label": " naproxen sodium 440 mg (bayh6689)", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo juice", "label": " placebo juice", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddocetaxel, erlotinib_carcinoma, non-small cell lung", "label": "terminateddocetaxel, erlotinib_carcinoma, non-small cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O.O.[Na+].[Na+].O[Si](O)(O)O.O[Si](O)(O)O.O[Si](O)(O)O.O[Zr](O)(O)(O)([O-])[O-]", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O.O.[Na+].[Na+].O[Si](O)(O)O.O[Si](O)(O)O.O[Si](O)(O)O.O[Zr](O)(O)(O)([O-])[O-]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedregorafenib_ovarian cancer, primary peritoneal cancer, fallopian tube cancer", "label": "terminatedregorafenib_ovarian cancer, primary peritoneal cancer, fallopian tube cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "naltrexone-hcl, placebo", "label": "naltrexone-hcl, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo 10 mg", "label": " placebo 10 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " pac-14028 cream vehicle", "label": " pac-14028 cream vehicle", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaripiprazole im depot, aripiprazole tablets_schizophrenia", "label": "completedaripiprazole im depot, aripiprazole tablets_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedganaxolone, placebo_depressive disorder, depression, depression, postpartum, behavioral symptoms, mood disorders, mental disorder, pregnancy complications, postpartum blues, ppd, postpartum disorder", "label": "completedganaxolone, placebo_depressive disorder, depression, depression, postpartum, behavioral symptoms, mood disorders, mental disorder, pregnancy complications, postpartum blues, ppd, postpartum disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " nps 1776 (400 mg)", "label": " nps 1776 (400 mg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "abscess, wound infection, surgical site infection, cellulitis", "label": "abscess, wound infection, surgical site infection, cellulitis", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]1(O)CS[C@@]([H])(OC2=CC3=C(C=C2)C(C)=CC(=O)O3)[C@]([H])(O)[C@@]1([H])O", "label": " [H][C@@]1(O)CS[C@@]([H])(OC2=CC3=C(C=C2)C(C)=CC(=O)O3)[C@]([H])(O)[C@@]1([H])O", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC(N)=O", "label": "NC(N)=O", "shape": "dot", "size": 10}, {"color": "green", "id": "wobenzym", "label": "wobenzym", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H]\\C1=C([H])\\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1", "label": "[H]\\C1=C([H])\\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1", "shape": "dot", "size": 10}, {"color": "red", "id": " 671800 ed placebo", "label": " 671800 ed placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddcv/asv/bms-791325, ribavirin, sofosbuvir, peginterferon \u03b1-2a_hepatitis c", "label": "completeddcv/asv/bms-791325, ribavirin, sofosbuvir, peginterferon \u03b1-2a_hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " gemcis", "label": " gemcis", "shape": "dot", "size": 10}, {"color": "green", "id": " jnc 7 stage i hypertension", "label": " jnc 7 stage i hypertension", "shape": "dot", "size": 10}, {"color": "green", "id": " cachexia", "label": " cachexia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, [H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2", "label": "CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, [H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2", "shape": "dot", "size": 10}, {"color": "blue", "id": " OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO", "label": " OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lung cancer, pancreatic cancer, esophageal cancer", "label": "lung cancer, pancreatic cancer, esophageal cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "mitoxantrone", "label": "mitoxantrone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "secondary hyperparathyroidism, dialysis", "label": "secondary hyperparathyroidism, dialysis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfludarabine monophosphate, melphalan, bortezomib_multiple myeloma", "label": "completedfludarabine monophosphate, melphalan, bortezomib_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O, [Na+].[Na+].[O-]P([O-])(F)=O", "label": "CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O, [Na+].[Na+].[O-]P([O-])(F)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nsclc, neutropenia, febrile neutropenia", "label": "nsclc, neutropenia, febrile neutropenia", "shape": "dot", "size": 10}, {"color": "red", "id": "tedizolid phophate", "label": "tedizolid phophate", "shape": "dot", "size": 10}, {"color": "red", "id": "intravitreal aflibercept injection (iai; eylea\u00ae; bay86-5321)", "label": "intravitreal aflibercept injection (iai; eylea\u00ae; bay86-5321)", "shape": "dot", "size": 10}, {"color": "red", "id": "aricept", "label": "aricept", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "metastatic melanoma, stage iii melanoma, stage iv melanoma", "label": "metastatic melanoma, stage iii melanoma, stage iv melanoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusgemcitabine, capecitabine, erlotinib_pancreatic cancer", "label": "unknown statusgemcitabine, capecitabine, erlotinib_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "triple-negative breast neoplasms, carcinoma, non-small-cell lung, head and neck carcinoma, squamous cell, advanced solid tumors", "label": "triple-negative breast neoplasms, carcinoma, non-small-cell lung, head and neck carcinoma, squamous cell, advanced solid tumors", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedzoster vaccine live_hepatitis c", "label": "terminatedzoster vaccine live_hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tiotropium, placebo to tiotropium, salmeterol, placebo to salmeterol", "label": "tiotropium, placebo to tiotropium, salmeterol, placebo to salmeterol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Ta], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[Ta], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "red", "id": " syn-010 42 mg", "label": " syn-010 42 mg", "shape": "dot", "size": 10}, {"color": "red", "id": "sodium hyaluronate", "label": "sodium hyaluronate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedjnj-2641585 / velcade / dexamethasone_multiple myeloma", "label": "completedjnj-2641585 / velcade / dexamethasone_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "roflumilast escalation dosage", "label": "roflumilast escalation dosage", "shape": "dot", "size": 10}, {"color": "red", "id": "neoadjuvant cisplatin and gemcitabine", "label": "neoadjuvant cisplatin and gemcitabine", "shape": "dot", "size": 10}, {"color": "blue", "id": " N[C@@H](CNC(=O)CC[C@@H](NC(=O)C1=CC=C(NCC2=CNC3=NC=NC(=O)C3=N2)C=C1)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O", "label": " N[C@@H](CNC(=O)CC[C@@H](NC(=O)C1=CC=C(NCC2=CNC3=NC=NC(=O)C3=N2)C=C1)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusgcb, gemox_advanced urothelial carcinoma", "label": "unknown statusgcb, gemox_advanced urothelial carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vorinostat oral capsule group 1, vorinostat oral capsule group 2", "label": "vorinostat oral capsule group 1, vorinostat oral capsule group 2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alogliptin and pioglitazone, alogliptin and pioglitazone", "label": "alogliptin and pioglitazone, alogliptin and pioglitazone", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC", "label": " CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC", "shape": "dot", "size": 10}, {"color": "red", "id": " 15 \u00b5g ethinylestradiol and 60 \u00b5g gestodene", "label": " 15 \u00b5g ethinylestradiol and 60 \u00b5g gestodene", "shape": "dot", "size": 10}, {"color": "red", "id": " insulin lispro", "label": " insulin lispro", "shape": "dot", "size": 10}, {"color": "red", "id": "lopinavir-rtv (kaletra): 3 capsules (600 mg)/12 h", "label": "lopinavir-rtv (kaletra): 3 capsules (600 mg)/12 h", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvinorelbine_non-small cell lung cancer stage iiib, non-small cell lung cancer stage iv", "label": "completedvinorelbine_non-small cell lung cancer stage iiib, non-small cell lung cancer stage iv", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "seliciclib", "label": "seliciclib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F, CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F", "label": "CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F, CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "label": "[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": " srt2104", "label": " srt2104", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "breast cancer, brain metastases", "label": "breast cancer, brain metastases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalendronate, placebo to romosozumab, placebo to alendronate_postmenopausal women with osteoporosis", "label": "completedalendronate, placebo to romosozumab, placebo to alendronate_postmenopausal women with osteoporosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " zoladex", "label": " zoladex", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcaffeine 100-200 mg bid, placebo_parkinson\u0027s disease, excessive daytime somnolence", "label": "completedcaffeine 100-200 mg bid, placebo_parkinson\u0027s disease, excessive daytime somnolence", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedrosuvastatin_coronary arteriosclerosis", "label": "terminatedrosuvastatin_coronary arteriosclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gastroesophageal reflux, asthma", "label": "gastroesophageal reflux, asthma", "shape": "dot", "size": 10}, {"color": "red", "id": " peg-interferon-alfa 2b", "label": " peg-interferon-alfa 2b", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ly2189265, insulin glargine, sulfonylureas (su), biguanide (bg)", "label": "ly2189265, insulin glargine, sulfonylureas (su), biguanide (bg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ferric citrate, placebo", "label": "ferric citrate, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedenzalutamide_hormone-refractory prostate cancer", "label": "completedenzalutamide_hormone-refractory prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " beclomethasone hfa", "label": " beclomethasone hfa", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuspioglitazone plus exenatide, insulin glargine and insulin aspart_type 2 diabetes", "label": "unknown statuspioglitazone plus exenatide, insulin glargine and insulin aspart_type 2 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "naloxegol", "label": "naloxegol", "shape": "dot", "size": 10}, {"color": "red", "id": "bi 207127 na", "label": "bi 207127 na", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedipragliflozin, placebo, sitagliptin_type 2 diabetes mellitus", "label": "completedipragliflozin, placebo, sitagliptin_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedberodual\u00ae via respimat\u00ae, high dose, berodual\u00ae via respimat\u00ae, low dose, berodual\u00ae via mdi, high dose, placebo respimat\u00ae, placebo mdi_asthma", "label": "completedberodual\u00ae via respimat\u00ae, high dose, berodual\u00ae via respimat\u00ae, low dose, berodual\u00ae via mdi, high dose, placebo respimat\u00ae, placebo mdi_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " asa", "label": " asa", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedteneligliptin/canagliflozin_type 2 diabetes mellitus", "label": "completedteneligliptin/canagliflozin_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acr16 10 mg, acr16 22.5 mg, acr16 45 mg", "label": "acr16 10 mg, acr16 22.5 mg, acr16 45 mg", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O", "label": "CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1", "label": "COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " sp2086 50 mg b.i.d.", "label": " sp2086 50 mg b.i.d.", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatededoxaban, warfarin_atrial fibrillation", "label": "terminatededoxaban, warfarin_atrial fibrillation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " salmeterol high dose", "label": " salmeterol high dose", "shape": "dot", "size": 10}, {"color": "red", "id": "5 fluorouracyl", "label": "5 fluorouracyl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12", "label": "FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmethylphenidate hydrochloride_brain and central nervous system tumors, cognitive/functional effects, depression, fatigue, quality of life", "label": "terminatedmethylphenidate hydrochloride_brain and central nervous system tumors, cognitive/functional effects, depression, fatigue, quality of life", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " oncology", "label": " oncology", "shape": "dot", "size": 10}, {"color": "red", "id": " iv sildenafil", "label": " iv sildenafil", "shape": "dot", "size": 10}, {"color": "red", "id": "vec-162 20 mg", "label": "vec-162 20 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "schizophrenia, bipolar i disorder", "label": "schizophrenia, bipolar i disorder", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sitagliptin phosphate, comparator: voglibose", "label": "sitagliptin phosphate, comparator: voglibose", "shape": "dot", "size": 10}, {"color": "red", "id": "kamada-aat for inhalation", "label": "kamada-aat for inhalation", "shape": "dot", "size": 10}, {"color": "blue", "id": "[Gd+3].OC(=O)CN(CCN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)CC([O-])=O", "label": "[Gd+3].OC(=O)CN(CCN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)CC([O-])=O", "shape": "dot", "size": 10}, {"color": "red", "id": "extended-release exenatide", "label": "extended-release exenatide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedetanercept, etanercept, placebo, placebo_rheumatoid arthritis", "label": "terminatedetanercept, etanercept, placebo, placebo_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "lr-eshap (lenalidomide 5 mg)", "label": "lr-eshap (lenalidomide 5 mg)", "shape": "dot", "size": 10}, {"color": "green", "id": " cancer of the fallopian tube", "label": " cancer of the fallopian tube", "shape": "dot", "size": 10}, {"color": "blue", "id": "C1C[C@H]2CN3CCNCC4=C3C(=CC=C4)[C@H]2C1", "label": "C1C[C@H]2CN3CCNCC4=C3C(=CC=C4)[C@H]2C1", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1", "label": "CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CNC(=O)CC[C@@H](NC(=O)C1=CC=C(NCC2=CNC3=NC=NC(=O)C3=N2)C=C1)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O", "label": "[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CNC(=O)CC[C@@H](NC(=O)C1=CC=C(NCC2=CNC3=NC=NC(=O)C3=N2)C=C1)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": " htx-011a", "label": " htx-011a", "shape": "dot", "size": 10}, {"color": "red", "id": " pf-4217329 - highest dose", "label": " pf-4217329 - highest dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "primary myelofibrosis (mf), post-polycythemia vera (pv) mf, post-essential thrombocythemia (et) mf", "label": "primary myelofibrosis (mf), post-polycythemia vera (pv) mf, post-essential thrombocythemia (et) mf", "shape": "dot", "size": 10}, {"color": "red", "id": " mk-3475 (phase ii)", "label": " mk-3475 (phase ii)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "ast-726 low dose", "label": "ast-726 low dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "amg 479 or placebo administered with either exemestane or fulvestrant, amg 479 or placebo administered with either exemestane or fulvestrant, amg 479 or placebo administered with either exemestane or fulvestrant", "label": "amg 479 or placebo administered with either exemestane or fulvestrant, amg 479 or placebo administered with either exemestane or fulvestrant, amg 479 or placebo administered with either exemestane or fulvestrant", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddoxorubicin, cyclophosphamide, paclitaxel, bevacizumab_breast cancer", "label": "completeddoxorubicin, cyclophosphamide, paclitaxel, bevacizumab_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1", "label": "COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1", "shape": "dot", "size": 10}, {"color": "blue", "id": "OC(CN1C=CN=C1[N+]([O-])=O)CN1CCCCC1", "label": "OC(CN1C=CN=C1[N+]([O-])=O)CN1CCCCC1", "shape": "dot", "size": 10}, {"color": "green", "id": " diffuse large-cell", "label": " diffuse large-cell", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnfluoxetine, placebo_stroke", "label": "withdrawnfluoxetine, placebo_stroke", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ridaforolimus + dalotuzumab", "label": "ridaforolimus + dalotuzumab", "shape": "dot", "size": 10}, {"color": "green", "id": " hernia", "label": " hernia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cisplatin, etoposide, sorafenib tosylate", "label": "cisplatin, etoposide, sorafenib tosylate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbms-986165, placebo for bms-986165_psoriasis", "label": "completedbms-986165, placebo for bms-986165_psoriasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lung diseases, obstructive, blood eosinophil count, glucocorticoids, copd, pulmonary disease, chronic obstructive", "label": "lung diseases, obstructive, blood eosinophil count, glucocorticoids, copd, pulmonary disease, chronic obstructive", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "preservative-free tafluprost, comparator: timolol", "label": "preservative-free tafluprost, comparator: timolol", "shape": "dot", "size": 10}, {"color": "red", "id": "ciclesonide", "label": "ciclesonide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfimasartan/hctz combination, fimasartan_essential hypertension", "label": "completedfimasartan/hctz combination, fimasartan_essential hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "transient ischemic attack", "label": "transient ischemic attack", "shape": "dot", "size": 10}, {"color": "red", "id": "ar11", "label": "ar11", "shape": "dot", "size": 10}, {"color": "green", "id": "dyspepsia", "label": "dyspepsia", "shape": "dot", "size": 10}, {"color": "red", "id": " pirfenidone", "label": " pirfenidone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ronacaleret, teriparatide, alendronate", "label": "ronacaleret, teriparatide, alendronate", "shape": "dot", "size": 10}, {"color": "red", "id": "vinorelbine oral formulation", "label": "vinorelbine oral formulation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "multiple myeloma, newly diagnosed patients", "label": "multiple myeloma, newly diagnosed patients", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedneu-p11, neu-p11 placebo_insomnia", "label": "completedneu-p11, neu-p11 placebo_insomnia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " mdco 3", "label": " mdco 3", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ondansetron + cognitive behavioral therapy, placebo + cognitive behavioral therapy", "label": "ondansetron + cognitive behavioral therapy, placebo + cognitive behavioral therapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, linaclotide", "label": "placebo, linaclotide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H], CC(=O)OC1=CC=CC=C1C(O)=O", "label": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H], CC(=O)OC1=CC=CC=C1C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, hepatosplenic t-cell lymphoma, nodal marginal zone b-cell lymphoma, peripheral t-cell lymphoma, post-transplant lymphoproliferative disorder, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult hodgkin lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent mycosis fungoides/sezary syndrome, splenic marginal zone lymphoma, waldenstrom macroglobulinemia", "label": "adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, hepatosplenic t-cell lymphoma, nodal marginal zone b-cell lymphoma, peripheral t-cell lymphoma, post-transplant lymphoproliferative disorder, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult hodgkin lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent mycosis fungoides/sezary syndrome, splenic marginal zone lymphoma, waldenstrom macroglobulinemia", "shape": "dot", "size": 10}, {"color": "red", "id": "amoxicillin", "label": "amoxicillin", "shape": "dot", "size": 10}, {"color": "red", "id": " cmf", "label": " cmf", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C)C2=CC(=CC=C12)[N+]([O-])=O", "label": "CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C)C2=CC(=CC=C12)[N+]([O-])=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1", "label": "NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone furoate/vilanterol, placebo", "label": "fluticasone furoate/vilanterol, placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " non-metastatic childhood soft tissue sarcoma", "label": " non-metastatic childhood soft tissue sarcoma", "shape": "dot", "size": 10}, {"color": "red", "id": "131-i-tm-601", "label": "131-i-tm-601", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo sitagliptin", "label": " placebo sitagliptin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedanastrozole, azd0530 (saracatinib), placebo_breast cancer", "label": "completedanastrozole, azd0530 (saracatinib), placebo_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "osteoarthritis knee pain", "label": "osteoarthritis knee pain", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "transitional cell carcinoma, bladder carcinoma, urothelial carcinoma", "label": "transitional cell carcinoma, bladder carcinoma, urothelial carcinoma", "shape": "dot", "size": 10}, {"color": "green", "id": " metastatic cancer", "label": " metastatic cancer", "shape": "dot", "size": 10}, {"color": "blue", "id": " [Mg++].[Cl-].[Cl-]", "label": " [Mg++].[Cl-].[Cl-]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlovastatin_breast cancer", "label": "terminatedlovastatin_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ribavirin-placebo", "label": " ribavirin-placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcapecitabine, oxaliplatin, folfox_colorectal cancer", "label": "completedcapecitabine, oxaliplatin, folfox_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sarcoma, desmoplastic small round cell tumor (dsrct)", "label": "sarcoma, desmoplastic small round cell tumor (dsrct)", "shape": "dot", "size": 10}, {"color": "red", "id": " palbociclib 125mg", "label": " palbociclib 125mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbi 655064 medium dose, bi 655064 high dose, bi 655064 high dose, placebo, bi 655064 low dose, placebo, bi 655064 medium dose_arthritis, rheumatoid, healthy", "label": "completedbi 655064 medium dose, bi 655064 high dose, bi 655064 high dose, placebo, bi 655064 low dose, placebo, bi 655064 medium dose_arthritis, rheumatoid, healthy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel, phenelzine sulfate", "label": "docetaxel, phenelzine sulfate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution, latanoprost 0.005% ophthalmic solution", "label": "bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution, latanoprost 0.005% ophthalmic solution", "shape": "dot", "size": 10}, {"color": "green", "id": "post-menopausal osteoporosis", "label": "post-menopausal osteoporosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedampyra first, then placebo, placebo first, then ampyra_parkinson\u0027s disease", "label": "completedampyra first, then placebo, placebo first, then ampyra_parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1", "label": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=CC(O)=CC(C)=C1Cl, CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1", "label": "CC1=CC(O)=CC(C)=C1Cl, CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " peg-ifn\u03b12a", "label": " peg-ifn\u03b12a", "shape": "dot", "size": 10}, {"color": "red", "id": "gkt137831", "label": "gkt137831", "shape": "dot", "size": 10}, {"color": "red", "id": "exisulind", "label": "exisulind", "shape": "dot", "size": 10}, {"color": "red", "id": " 250 mg ck-2017357", "label": " 250 mg ck-2017357", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "crizotinib, pemetrexed/cisplatin, pemetrexed/carboplatin", "label": "crizotinib, pemetrexed/cisplatin, pemetrexed/carboplatin", "shape": "dot", "size": 10}, {"color": "green", "id": "hormone refractory prostate cancer", "label": "hormone refractory prostate cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpci-32765_b-cell chronic lymphocytic leukemia, small lymphocytic lymphoma", "label": "completedpci-32765_b-cell chronic lymphocytic leukemia, small lymphocytic lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " vinflunine", "label": " vinflunine", "shape": "dot", "size": 10}, {"color": "green", "id": " gastroesophageal reflux disease", "label": " gastroesophageal reflux disease", "shape": "dot", "size": 10}, {"color": "red", "id": " poly i:poly c12u 200 ug", "label": " poly i:poly c12u 200 ug", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gliadel, avastin, temodar", "label": "gliadel, avastin, temodar", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sumatriptan, placebo", "label": "sumatriptan, placebo", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]12CC(=CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC)C(O)=O", "label": "[H][C@@]12CC(=CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC)C(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": "neural tube defects", "label": "neural tube defects", "shape": "dot", "size": 10}, {"color": "green", "id": " musculoskeletal diseases", "label": " musculoskeletal diseases", "shape": "dot", "size": 10}, {"color": "red", "id": " \u00272-0453", "label": " \u00272-0453", "shape": "dot", "size": 10}, {"color": "red", "id": "brilacidin", "label": "brilacidin", "shape": "dot", "size": 10}, {"color": "red", "id": "xp23829 400 mg qd", "label": "xp23829 400 mg qd", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completederlotinib hydrochloride_recurrent renal cell cancer, stage iii renal cell cancer, stage iv renal cell cancer", "label": "completederlotinib hydrochloride_recurrent renal cell cancer, stage iii renal cell cancer, stage iv renal cell cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedbifeprunox, placebo, quetiapine_schizophrenia", "label": "terminatedbifeprunox, placebo, quetiapine_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " uterine carcinosarcoma", "label": " uterine carcinosarcoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcyclosporine a microemulsion, placebo_chronic plaque psoriasis", "label": "completedcyclosporine a microemulsion, placebo_chronic plaque psoriasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedeplivanserin (sr46349), placebo_fibromyalgia, sleep, chronic pain", "label": "completedeplivanserin (sr46349), placebo_fibromyalgia, sleep, chronic pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "epinephrine", "label": "epinephrine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CSCC[C@H](N)C(O)=O", "label": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CSCC[C@H](N)C(O)=O", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C", "label": "COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C", "shape": "dot", "size": 10}, {"color": "blue", "id": "N.[Cl-].[Cl-].[Pt+4].CC([O-])=O.CC([O-])=O.NC1CCCCC1", "label": "N.[Cl-].[Cl-].[Pt+4].CC([O-])=O.CC([O-])=O.NC1CCCCC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtacrolimus od, mycophenolic acid, prednisolone_renal insufficiency, kidney transplantation", "label": "completedtacrolimus od, mycophenolic acid, prednisolone_renal insufficiency, kidney transplantation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " fluticasone propionate 250mcg/salmeterol 50mcg", "label": " fluticasone propionate 250mcg/salmeterol 50mcg", "shape": "dot", "size": 10}, {"color": "green", "id": " relapsed/refractory", "label": " relapsed/refractory", "shape": "dot", "size": 10}, {"color": "red", "id": " amisulpride", "label": " amisulpride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pf-04991532, pf-04991532, pf-04991532, pf-0499132, placebo", "label": "pf-04991532, pf-04991532, pf-04991532, pf-0499132, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " protease inhibitor", "label": " protease inhibitor", "shape": "dot", "size": 10}, {"color": "red", "id": "oxycodone/naloxone controlled-release", "label": "oxycodone/naloxone controlled-release", "shape": "dot", "size": 10}, {"color": "blue", "id": "NCCNC1=CC=C(NCCN)C2=C1C(=O)C1=C(C=NC=C1)C2=O", "label": "NCCNC1=CC=C(NCCN)C2=C1C(=O)C1=C(C=NC=C1)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rivoglitazone, pioglitazone, placebo", "label": "rivoglitazone, pioglitazone, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C", "label": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddocetaxel, vandetanib_gastric cancer", "label": "terminateddocetaxel, vandetanib_gastric cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo matching with duloxetine", "label": " placebo matching with duloxetine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedldk378_non-small cell lung cancer", "label": "completedldk378_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=CC=CC=C23)C=C1", "label": "ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=CC=CC=C23)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvildagliptin, placebo_diabetes mellitus, type 2", "label": "completedvildagliptin, placebo_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsym004 (12 mg/kg), sym004 (9/6 mg/kg), fluorouracil (5-fu), capecitabine_metastatic colorectal cancer", "label": "completedsym004 (12 mg/kg), sym004 (9/6 mg/kg), fluorouracil (5-fu), capecitabine_metastatic colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "taxol, campt, topotesin", "label": "taxol, campt, topotesin", "shape": "dot", "size": 10}, {"color": "green", "id": " small cell glioblastoma", "label": " small cell glioblastoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfebuxostat_coronary artery disease", "label": "terminatedfebuxostat_coronary artery disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "interferon-beta-1a", "label": "interferon-beta-1a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlubiprostone, placebo_chronic idiopathic constipation", "label": "completedlubiprostone, placebo_chronic idiopathic constipation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1", "label": "[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "zolpidem-mr (modified release)", "label": "zolpidem-mr (modified release)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O", "label": "[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": " combivent respimat (20 mcg/100 mcg)", "label": " combivent respimat (20 mcg/100 mcg)", "shape": "dot", "size": 10}, {"color": "green", "id": " brain necrosis", "label": " brain necrosis", "shape": "dot", "size": 10}, {"color": "red", "id": "epratuzumab", "label": "epratuzumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlubiprostone_constipation, cystic fibrosis", "label": "completedlubiprostone_constipation, cystic fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo mdi without spacer", "label": " placebo mdi without spacer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma", "label": "recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": " kaletra (lopinavir/ritonavir) + combivir (zidovudine/lamivudine)", "label": " kaletra (lopinavir/ritonavir) + combivir (zidovudine/lamivudine)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedads-5102_walking impairment, multiple sclerosis", "label": "completedads-5102_walking impairment, multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "hdv insulin lispro", "label": "hdv insulin lispro", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dexamethasone, asparaginase, asparaginase, cyclophosphamide, cytarabine, daunorubicin, doxorubicin, etoposide, ifosfamide, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine, vindesine", "label": "dexamethasone, asparaginase, asparaginase, cyclophosphamide, cytarabine, daunorubicin, doxorubicin, etoposide, ifosfamide, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine, vindesine", "shape": "dot", "size": 10}, {"color": "red", "id": "dm-1992", "label": "dm-1992", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bladder cancer, pancreas cancer, cholangiocellular carcinoma", "label": "bladder cancer, pancreas cancer, cholangiocellular carcinoma", "shape": "dot", "size": 10}, {"color": "green", "id": " low cardiac output syndrome", "label": " low cardiac output syndrome", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mometasone, placebo, albuterol/salbutamol", "label": "mometasone, placebo, albuterol/salbutamol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mepolizumab iv, mepolizumab sc, iv placebo, sc placebo", "label": "mepolizumab iv, mepolizumab sc, iv placebo, sc placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " tourette syndrome", "label": " tourette syndrome", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic myeloproliferative disorders, graft versus host disease, leukemia, myelodysplastic syndromes, myelodysplastic/myeloproliferative diseases", "label": "chronic myeloproliferative disorders, graft versus host disease, leukemia, myelodysplastic syndromes, myelodysplastic/myeloproliferative diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completederlotinib (aka tarceva or osi-774), bevacizumab (aka avastin or rhu mab vegf)_colorectal cancer", "label": "completederlotinib (aka tarceva or osi-774), bevacizumab (aka avastin or rhu mab vegf)_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "dyslipidemias", "label": "dyslipidemias", "shape": "dot", "size": 10}, {"color": "red", "id": " a pi3k inhibitor", "label": " a pi3k inhibitor", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo as capsules", "label": " placebo as capsules", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bipolar disorder, depression, bipolar", "label": "bipolar disorder, depression, bipolar", "shape": "dot", "size": 10}, {"color": "red", "id": "lx4211", "label": "lx4211", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnirinotecan_lung cancer", "label": "withdrawnirinotecan_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "vilanterol", "label": "vilanterol", "shape": "dot", "size": 10}, {"color": "red", "id": "nifedipine (adalat gits", "label": "nifedipine (adalat gits", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedkpi-121 1% ophthalmic suspension dosed bid, vehicle of kpi-121 ophthalmic suspension dosed bid_post surgical ocular inflammation and pain", "label": "completedkpi-121 1% ophthalmic suspension dosed bid, vehicle of kpi-121 ophthalmic suspension dosed bid_post surgical ocular inflammation and pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completederlotinib_non small cell lung cancer", "label": "completederlotinib_non small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dalteparin ( fragmin), unfractionated heparin", "label": "dalteparin ( fragmin), unfractionated heparin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CCCNC(N)=N)C(O)=O, FC1=CNC(=O)NC1=O, FC1=CNC(=O)NC1=O", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CCCNC(N)=N)C(O)=O, FC1=CNC(=O)NC1=O, FC1=CNC(=O)NC1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ranolazine, matching placebo", "label": "ranolazine, matching placebo", "shape": "dot", "size": 10}, {"color": "blue", "id": "C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O", "label": "C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1N=CC(Cl)=C1C1=C(Cl)SC(=C1)C(=O)N[C@H](CN)CC1=CC=CC(F)=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "label": "CN1N=CC(Cl)=C1C1=C(Cl)SC(=C1)C(=O)N[C@H](CN)CC1=CC=CC(F)=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "shape": "dot", "size": 10}, {"color": "red", "id": "tapentadol extended release", "label": "tapentadol extended release", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcyclophosphamide, capecitabine, methotrexate, celecoxib, pamidronate (or zoledronate)_chemotherapy, breast cancer, metastatic", "label": "terminatedcyclophosphamide, capecitabine, methotrexate, celecoxib, pamidronate (or zoledronate)_chemotherapy, breast cancer, metastatic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaripiprazole_tourette\u0027s syndrome, tic disorders", "label": "completedaripiprazole_tourette\u0027s syndrome, tic disorders", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(=N)NCCSCC[C@H](N)C(O)=O", "label": "CC(=N)NCCSCC[C@H](N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlinaclotide acetate, matching placebo_chronic constipation", "label": "completedlinaclotide acetate, matching placebo_chronic constipation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lmt (atorvastatin, simvastatin, or rosuvastatin), alirocumab, placebo", "label": "lmt (atorvastatin, simvastatin, or rosuvastatin), alirocumab, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedavp-786, paroxetine, duloxetine_drug-drug interaction", "label": "completedavp-786, paroxetine, duloxetine_drug-drug interaction", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage ii rectal cancer ajcc v7", "label": " stage ii rectal cancer ajcc v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalogliptin, alogliptin, alogliptin, alogliptin, voglibose, placebo_diabetes mellitus, type 2", "label": "completedalogliptin, alogliptin, alogliptin, alogliptin, voglibose, placebo_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " cdmard", "label": " cdmard", "shape": "dot", "size": 10}, {"color": "red", "id": " irinotecan", "label": " irinotecan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ps433540, placebo, ps433540", "label": "ps433540, placebo, ps433540", "shape": "dot", "size": 10}, {"color": "blue", "id": " NCCNC1=CC=C(NCCN)C2=C1C(=O)C1=C(C=NC=C1)C2=O", "label": " NCCNC1=CC=C(NCCN)C2=C1C(=O)C1=C(C=NC=C1)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1", "label": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2, CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2, CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2, CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2, CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "kidney disease, nephropathy, type 2 diabetes", "label": "kidney disease, nephropathy, type 2 diabetes", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "uft (uracil, tegafur)", "label": "uft (uracil, tegafur)", "shape": "dot", "size": 10}, {"color": "red", "id": " third agent", "label": " third agent", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsl fentanyl_pain", "label": "terminatedsl fentanyl_pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lapatinib ditosylate, doxil", "label": "lapatinib ditosylate, doxil", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvx-770, placebo_cystic fibrosis", "label": "completedvx-770, placebo_cystic fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "tiotropium/salmeterol qd", "label": "tiotropium/salmeterol qd", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "irinotecan, cisplatin, sunitinib (sutent)", "label": "irinotecan, cisplatin, sunitinib (sutent)", "shape": "dot", "size": 10}, {"color": "red", "id": "hld200", "label": "hld200", "shape": "dot", "size": 10}, {"color": "green", "id": " tic disorders", "label": " tic disorders", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsaline solution_degenerative arthritis, knee osteoarthritis", "label": "completedsaline solution_degenerative arthritis, knee osteoarthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedstatin_ischemic stroke", "label": "completedstatin_ischemic stroke", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C#CCN[C@@H]1CCC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C#CCN[C@@H]1CCC2=CC=CC=C12", "label": "C#CCN[C@@H]1CCC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C#CCN[C@@H]1CCC2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "red", "id": "low dose aut00206 800mg", "label": "low dose aut00206 800mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pazopanib (gw786034), carboplatin, paclitaxel", "label": "pazopanib (gw786034), carboplatin, paclitaxel", "shape": "dot", "size": 10}, {"color": "green", "id": " pancreatic insufficiency", "label": " pancreatic insufficiency", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1, CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1, CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": " rituximab (us)", "label": " rituximab (us)", "shape": "dot", "size": 10}, {"color": "red", "id": " filgrastim (g-csf)", "label": " filgrastim (g-csf)", "shape": "dot", "size": 10}, {"color": "green", "id": " stage 0 oral cavity squamous cell carcinoma ajcc v6 and v7", "label": " stage 0 oral cavity squamous cell carcinoma ajcc v6 and v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "teriparatide, risedronate", "label": "teriparatide, risedronate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=NC(C)=NC(Cl)=C1NC1=NCCN1, CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1", "label": "COC1=NC(C)=NC(Cl)=C1NC1=NCCN1, CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " myelocytic", "label": " myelocytic", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo_active systemic lupus erythematosus", "label": "completedplacebo_active systemic lupus erythematosus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gabapentin lower dose, donepezil, gabapentin higher dose", "label": "gabapentin lower dose, donepezil, gabapentin higher dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcyclophosphamide, placebo, doxorubicin, paclitaxel, carboplatin, veliparib, placebo_triple negative breast cancer", "label": "completedcyclophosphamide, placebo, doxorubicin, paclitaxel, carboplatin, veliparib, placebo_triple negative breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCOC1=C2N=CN([C@@H]3O[C@@H]4CO[P@@](=O)(OC(C)C)O[C@H]4[C@@]3(C)F)C2=NC(N)=N1", "label": " CCOC1=C2N=CN([C@@H]3O[C@@H]4CO[P@@](=O)(OC(C)C)O[C@H]4[C@@]3(C)F)C2=NC(N)=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtopotecan hydrochloride_fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer", "label": "completedtopotecan hydrochloride_fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgsk1325756 (danirixin), placebo to match gsk1325756, oseltamivir phosphate, placebo to match oseltamivir phosphate_virus diseases", "label": "completedgsk1325756 (danirixin), placebo to match gsk1325756, oseltamivir phosphate, placebo to match oseltamivir phosphate_virus diseases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1, [Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1", "label": "[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1, [Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbrivanib alaninate_colorectal cancer", "label": "completedbrivanib alaninate_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O", "label": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "metastatic pancreatic adenocarcinoma, recurrent pancreatic carcinoma, stage iv pancreatic cancer ajcc v6 and v7", "label": "metastatic pancreatic adenocarcinoma, recurrent pancreatic carcinoma, stage iv pancreatic cancer ajcc v6 and v7", "shape": "dot", "size": 10}, {"color": "blue", "id": "[Nb]", "label": "[Nb]", "shape": "dot", "size": 10}, {"color": "red", "id": "qutenza", "label": "qutenza", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel, asa404", "label": "docetaxel, asa404", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcapecitabine, cyclophosphamide, epirubicin hydrochloride, fluorouracil, methotrexate_breast cancer", "label": "active, not recruitingcapecitabine, cyclophosphamide, epirubicin hydrochloride, fluorouracil, methotrexate_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O", "label": "COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": " post-traumatic", "label": " post-traumatic", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "stomach neoplasms, neoplasms metastasis, erbb2 gene amplification", "label": "stomach neoplasms, neoplasms metastasis, erbb2 gene amplification", "shape": "dot", "size": 10}, {"color": "red", "id": "erythropoetin beta", "label": "erythropoetin beta", "shape": "dot", "size": 10}, {"color": "red", "id": "inclisiran", "label": "inclisiran", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hiv, tuberculosis", "label": "hiv, tuberculosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "ubenimex", "label": "ubenimex", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "abt-335, simvastatin, placebo", "label": "abt-335, simvastatin, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedb/f/taf_hiv-1 infection", "label": "completedb/f/taf_hiv-1 infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "clear cell renal cell carcinoma, recurrent renal cell carcinoma, stage iv renal cell cancer ajcc v7", "label": "clear cell renal cell carcinoma, recurrent renal cell carcinoma, stage iv renal cell cancer ajcc v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingbrentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide_anaplastic large-cell lymphoma, non-hodgkin lymphoma, t-cell lymphoma", "label": "active, not recruitingbrentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide_anaplastic large-cell lymphoma, non-hodgkin lymphoma, t-cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " pancreas neoplasms", "label": " pancreas neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtestosterone gel 2%_prostatic hyperplasia, lower urinary tract symptoms, hypogonadism", "label": "completedtestosterone gel 2%_prostatic hyperplasia, lower urinary tract symptoms, hypogonadism", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "cp-4055 (elacyt)", "label": "cp-4055 (elacyt)", "shape": "dot", "size": 10}, {"color": "red", "id": "travoprost 0.004% ophthalmic solution", "label": "travoprost 0.004% ophthalmic solution", "shape": "dot", "size": 10}, {"color": "red", "id": "vch 916", "label": "vch 916", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F, CN(C)\\N=N\\C1=C(N=CN1)C(N)=O", "label": "CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F, CN(C)\\N=N\\C1=C(N=CN1)C(N)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC(=O)C1=CC=C2C(NC(=O)\\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "COC(=O)C1=CC=C2C(NC(=O)\\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfluticasone propionate_1.5, fluticasone propionate_3, fluticasone propionate_6, fp from active 250 ug mdi inhaler_healthy, asthma", "label": "completedfluticasone propionate_1.5, fluticasone propionate_3, fluticasone propionate_6, fp from active 250 ug mdi inhaler_healthy, asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClC1=CC=CC(Cl)=C1NC1=NCCN1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "ClC1=CC=CC(Cl)=C1NC1=NCCN1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2", "label": "CC(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C2OC(N)=NC2=C1, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo capsules - end of pci", "label": " placebo capsules - end of pci", "shape": "dot", "size": 10}, {"color": "red", "id": "tremelimumab", "label": "tremelimumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnonly 1 arm: treatment with msc-afp_perianal fistula", "label": "withdrawnonly 1 arm: treatment with msc-afp_perianal fistula", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC", "label": "CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC", "shape": "dot", "size": 10}, {"color": "green", "id": " contiguous stage ii small lymphocytic lymphoma", "label": " contiguous stage ii small lymphocytic lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclosporine a, placebo", "label": "cyclosporine a, placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iib rectal cancer", "label": " stage iib rectal cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bortezomib, dexamethasone, rituximab", "label": "bortezomib, dexamethasone, rituximab", "shape": "dot", "size": 10}, {"color": "red", "id": " oral prednisone", "label": " oral prednisone", "shape": "dot", "size": 10}, {"color": "green", "id": "advanced", "label": "advanced", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic myeloproliferative disorders, graft versus host disease, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes", "label": "chronic myeloproliferative disorders, graft versus host disease, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "green", "id": " leukaemia", "label": " leukaemia", "shape": "dot", "size": 10}, {"color": "green", "id": " small lymphocytic lymphoma (sll)", "label": " small lymphocytic lymphoma (sll)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpaclitaxel, ricolinostat, bevacizumab_ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma", "label": "terminatedpaclitaxel, ricolinostat, bevacizumab_ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azd1722 (in-patient), placebo (in-patient), azd1722 (out-patient), placebo", "label": "azd1722 (in-patient), placebo (in-patient), azd1722 (out-patient), placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " 200 mg lx4211", "label": " 200 mg lx4211", "shape": "dot", "size": 10}, {"color": "red", "id": " pegylated g-csf", "label": " pegylated g-csf", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "label": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedroxadustat, placebo_anemia in chronic kidney disease in non-dialysis patients", "label": "completedroxadustat, placebo_anemia in chronic kidney disease in non-dialysis patients", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedadl5859, duloxetine, placebo_peripheral neuropathy, neuropathic pain", "label": "completedadl5859, duloxetine, placebo_peripheral neuropathy, neuropathic pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " high cholesterol", "label": " high cholesterol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedhydroxyurea_sickle cell disease, pulmonary hypertension", "label": "terminatedhydroxyurea_sickle cell disease, pulmonary hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "mdma", "label": "mdma", "shape": "dot", "size": 10}, {"color": "red", "id": " mitoxatrone", "label": " mitoxatrone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcelecoxib_breast cancer", "label": "terminatedcelecoxib_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedag-013736_carcinoma, renal cell", "label": "completedag-013736_carcinoma, renal cell", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedamg 557, amg 557 placebo_cutaneous lupus, lupus", "label": "terminatedamg 557, amg 557 placebo_cutaneous lupus, lupus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recurrent glioblastoma multiforme, malignant glioma, adult brain tumor", "label": "recurrent glioblastoma multiforme, malignant glioma, adult brain tumor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H]\\C(=C(\\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO, CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "[H]\\C(=C(\\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO, CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpalonosetron_neoplasms, nausea, vomiting", "label": "completedpalonosetron_neoplasms, nausea, vomiting", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "60mg edoxaban, 180mg edoxaban, 50 iu/kg beriplex p/n, 25 iu/kg beriplex p/n, 10 iu/kg beriplex p/n", "label": "60mg edoxaban, 180mg edoxaban, 50 iu/kg beriplex p/n, 25 iu/kg beriplex p/n, 10 iu/kg beriplex p/n", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgw685698/gw642444_pulmonary disease, chronic obstructive", "label": "completedgw685698/gw642444_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " hematologic neoplasms", "label": " hematologic neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedesketamine (intranasal spray), duloxetine (oral antidepressant), escitalopram (oral antidepressant), sertraline (oral antidepressant), venlafaxine extended release (xr) (oral antidepressant)_treatment-resistant depression", "label": "completedesketamine (intranasal spray), duloxetine (oral antidepressant), escitalopram (oral antidepressant), sertraline (oral antidepressant), venlafaxine extended release (xr) (oral antidepressant)_treatment-resistant depression", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cobimetinib, vemurafenib", "label": "cobimetinib, vemurafenib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "ono-2506", "label": "ono-2506", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glaucoma, ocular hypertension, ocular surface disease", "label": "glaucoma, ocular hypertension, ocular surface disease", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O", "label": "[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddaptomycin, vancomycin_cellulitis", "label": "completeddaptomycin, vancomycin_cellulitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " maxalt 10mg mlt plus placebo", "label": " maxalt 10mg mlt plus placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " hb/apap", "label": " hb/apap", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedirl790, placebo_parkinson disease", "label": "completedirl790, placebo_parkinson disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " baricitinib", "label": " baricitinib", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iiia breast cancer", "label": " stage iiia breast cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "oral zinc and vitamin c supplements", "label": "oral zinc and vitamin c supplements", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statustaxotere, jevtana_metastatic castration-resistant prostate cancer", "label": "unknown statustaxotere, jevtana_metastatic castration-resistant prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1", "label": "CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo 20", "label": " placebo 20", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hyperlipidemia, hypercholesterolemia, hypertriglyceridemia", "label": "hyperlipidemia, hypercholesterolemia, hypertriglyceridemia", "shape": "dot", "size": 10}, {"color": "red", "id": " probucol", "label": " probucol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O=C(N[C@H]1CN2CCC1CC2)C1=CNC2=C(SC=C2)C1=O, O=C(N[C@H]1CN2CCC1CC2)C1=CNC2=C(SC=C2)C1=O, O=C(N[C@H]1CN2CCC1CC2)C1=CNC2=C(SC=C2)C1=O", "label": "O=C(N[C@H]1CN2CCC1CC2)C1=CNC2=C(SC=C2)C1=O, O=C(N[C@H]1CN2CCC1CC2)C1=CNC2=C(SC=C2)C1=O, O=C(N[C@H]1CN2CCC1CC2)C1=CNC2=C(SC=C2)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\\C(C)=C\\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\\C(C)=C\\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "multiple myeloma, waldenstrom macroglobulinemia", "label": "multiple myeloma, waldenstrom macroglobulinemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg_pulmonary disease, chronic obstructive", "label": "completedfluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcci-779, bortezomib_multiple myeloma", "label": "completedcci-779, bortezomib_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gemcitabine, gemcitabine, cisplatin", "label": "gemcitabine, gemcitabine, cisplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarboplatin, paclitaxel, bevacizumab_epithelial ovarian cancer, primary peritoneal cancer, fallopian tube cancer", "label": "completedcarboplatin, paclitaxel, bevacizumab_epithelial ovarian cancer, primary peritoneal cancer, fallopian tube cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ferric citrate, ferric citrate, ferric citrate", "label": "ferric citrate, ferric citrate, ferric citrate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "interferon beta-1a placebo, daclizumab high yield process placebo", "label": "interferon beta-1a placebo, daclizumab high yield process placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC2=CC=C(C=C2C=C1)C1=CC(=NN1[C@@H](C)C1=CC=C(C=C1)C(=O)NCCC(O)=O)C1=CC(Cl)=CC(Cl)=C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "COC1=CC2=CC=C(C=C2C=C1)C1=CC(=NN1[C@@H](C)C1=CC=C(C=C1)C(=O)NCCC(O)=O)C1=CC(Cl)=CC(Cl)=C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "skyla (levonorgestrel, bay86-5028)", "label": "skyla (levonorgestrel, bay86-5028)", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo(metformin)", "label": " placebo(metformin)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpramipexole_parkinson disease", "label": "completedpramipexole_parkinson disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "romosozumab, placebo, denosumab", "label": "romosozumab, placebo, denosumab", "shape": "dot", "size": 10}, {"color": "red", "id": " human insulin isophane suspension", "label": " human insulin isophane suspension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbrentuximab vedotin_recurrent hodgkin lymphoma, refractory hodgkin lymphoma", "label": "completedbrentuximab vedotin_recurrent hodgkin lymphoma, refractory hodgkin lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedertapenem_endometritis", "label": "terminatedertapenem_endometritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2, COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "label": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2, COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcreatine monohydrate, placebo_huntington disease", "label": "completedcreatine monohydrate, placebo_huntington disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pharmacological cardioversion - flecainide, metoprolol, verapamil, digoxin, pharmacological cardioversion - amiodarone", "label": "pharmacological cardioversion - flecainide, metoprolol, verapamil, digoxin, pharmacological cardioversion - amiodarone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcombination pill of losartan and hydrochlorothiazide_hypertension", "label": "completedcombination pill of losartan and hydrochlorothiazide_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)", "label": " tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsaracatinib_recurrent melanoma, stage iia melanoma, stage iib melanoma, stage iic melanoma, stage iv melanoma", "label": "completedsaracatinib_recurrent melanoma, stage iia melanoma, stage iib melanoma, stage iic melanoma, stage iv melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedinc424, bkm120_myelofibrosis", "label": "terminatedinc424, bkm120_myelofibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCCOC1=NC(N)=C2NC(=O)CN(CC3=CC=CC(CN4CCCC4)=C3)C2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCO", "label": "CCCCOC1=NC(N)=C2NC(=O)CN(CC3=CC=CC(CN4CCCC4)=C3)C2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCO", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedledipasvir/sofosbuvir, ribavirin_hiv-1 infection, hepatitis c", "label": "terminatedledipasvir/sofosbuvir, ribavirin_hiv-1 infection, hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "label": "[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "shape": "dot", "size": 10}, {"color": "red", "id": "top1288", "label": "top1288", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedetanercept, placebo_juvenile rheumatoid arthritis", "label": "terminatedetanercept, placebo_juvenile rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carbidopa/levodopa/entacapone, immediate release carbidopa/levodopa", "label": "carbidopa/levodopa/entacapone, immediate release carbidopa/levodopa", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CS(=O)(=O)OCCCCOS(C)(=O)=O, NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "label": "CS(=O)(=O)OCCCCOS(C)(=O)=O, NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": "neutrolin", "label": "neutrolin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpregabalin, pregabalin_abdominal pain, surgical adhesions", "label": "terminatedpregabalin, pregabalin_abdominal pain, surgical adhesions", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " armodafinil", "label": " armodafinil", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnisotonic hydration fluid and recombinant human hyaluronidase_dehydration", "label": "withdrawnisotonic hydration fluid and recombinant human hyaluronidase_dehydration", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " vancomycin iv", "label": " vancomycin iv", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1", "label": " CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1", "shape": "dot", "size": 10}, {"color": "green", "id": "recurrence of solid tumor", "label": "recurrence of solid tumor", "shape": "dot", "size": 10}, {"color": "red", "id": " povidone-iodine 10%", "label": " povidone-iodine 10%", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtolvaptan, placebo of tolvaptan_heart failure", "label": "completedtolvaptan, placebo of tolvaptan_heart failure", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusliraglutide_non-alcoholic fatty liver disease (nafld), weight loss, non-alcoholic steatohepatitis (nash)", "label": "unknown statusliraglutide_non-alcoholic fatty liver disease (nafld), weight loss, non-alcoholic steatohepatitis (nash)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " lh-rh agonist", "label": " lh-rh agonist", "shape": "dot", "size": 10}, {"color": "red", "id": "zonegran", "label": "zonegran", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedumeclidinium, umeclidinium matching placebo, tiotropium, tiotropium matching placebo_pulmonary disease, chronic obstructive", "label": "completedumeclidinium, umeclidinium matching placebo, tiotropium, tiotropium matching placebo_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " puva (8-mop + uva)", "label": " puva (8-mop + uva)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpemetrexed, topotecan_ovarian cancer, endometrial cancer, cervical cancer, lung cancer", "label": "completedpemetrexed, topotecan_ovarian cancer, endometrial cancer, cervical cancer, lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O", "label": "CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "atrial fibrillation, inflammation", "label": "atrial fibrillation, inflammation", "shape": "dot", "size": 10}, {"color": "green", "id": " undifferentiated gallbladder carcinoma", "label": " undifferentiated gallbladder carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "label": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuscannabidiol, methylprednisolone, calcineurin inhibitor_acute-graft-versus-host disease", "label": "unknown statuscannabidiol, methylprednisolone, calcineurin inhibitor_acute-graft-versus-host disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " 0.005% calcipotriol", "label": " 0.005% calcipotriol", "shape": "dot", "size": 10}, {"color": "blue", "id": " NC1=NC(N)=C2N=CN([C@H]3CO[C@@H](CO)O3)C2=N1", "label": " NC1=NC(N)=C2N=CN([C@H]3CO[C@@H](CO)O3)C2=N1", "shape": "dot", "size": 10}, {"color": "red", "id": " nitazoxanide", "label": " nitazoxanide", "shape": "dot", "size": 10}, {"color": "blue", "id": " ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1", "label": " ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, thalidomide, vincristine sulfate", "label": "cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, thalidomide, vincristine sulfate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tivantinib, placebo, cetuximab, irinotecan", "label": "tivantinib, placebo, cetuximab, irinotecan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfpns, ffns, placebo fpns, placebo ffns_rhinitis, allergic, perennial", "label": "completedfpns, ffns, placebo fpns, placebo ffns_rhinitis, allergic, perennial", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "childhood cancer, aplastic anemia, metabolic disorders", "label": "childhood cancer, aplastic anemia, metabolic disorders", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CS(=O)(=O)OCCCCOS(C)(=O)=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1", "label": "CS(=O)(=O)OCCCCOS(C)(=O)=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completediw-3718, matching placebo, ppi_gastroesophageal reflux disease", "label": "completediw-3718, matching placebo, ppi_gastroesophageal reflux disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Na+].[Na+].[O-]P([O-])(F)=O, COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1", "label": "[Na+].[Na+].[O-]P([O-])(F)=O, COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1", "shape": "dot", "size": 10}, {"color": "red", "id": " prasugrel)", "label": " prasugrel)", "shape": "dot", "size": 10}, {"color": "red", "id": "carvedilol phosphate", "label": "carvedilol phosphate", "shape": "dot", "size": 10}, {"color": "red", "id": "nab-paclitaxel", "label": "nab-paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chemotherapy, chemotherapy", "label": "chemotherapy, chemotherapy", "shape": "dot", "size": 10}, {"color": "red", "id": "otx-101 0.05%", "label": "otx-101 0.05%", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedeculizumab, placebo_myasthenia gravis", "label": "terminatedeculizumab, placebo_myasthenia gravis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "quisinostat, paclitaxel, carboplatin, gemcitabine, cisplatin", "label": "quisinostat, paclitaxel, carboplatin, gemcitabine, cisplatin", "shape": "dot", "size": 10}, {"color": "red", "id": " and thalidomide", "label": " and thalidomide", "shape": "dot", "size": 10}, {"color": "red", "id": "erythropoietin", "label": "erythropoietin", "shape": "dot", "size": 10}, {"color": "red", "id": "oseltamivir", "label": "oseltamivir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmacitentan 10 mg, placebo_pulmonary arterial hypertension", "label": "completedmacitentan 10 mg, placebo_pulmonary arterial hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC[C@H]1OB(O)C2=C1C=CC=C2OCCCO, CC1(C)C[C@@H]1C(=O)N\\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O", "label": "NC[C@H]1OB(O)C2=C1C=CC=C2OCCCO, CC1(C)C[C@@H]1C(=O)N\\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedneod001, placebo_al amyloidosis", "label": "completedneod001, placebo_al amyloidosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "advanced cancers", "label": "advanced cancers", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvalsartan plus hydrochlorothiazide_hypertension", "label": "completedvalsartan plus hydrochlorothiazide_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "asunaprevir (asv), daclatasvir (dcv), pegylated-interferon alfa 2a (pegifn), ribavirin (rbv)", "label": "asunaprevir (asv), daclatasvir (dcv), pegylated-interferon alfa 2a (pegifn), ribavirin (rbv)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ly2623091, eplerenone", "label": "ly2623091, eplerenone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazilsartan medoxomil and chlorthalidone, olmesartan medoxomil and hydrochlorothiazide_safety", "label": "completedazilsartan medoxomil and chlorthalidone, olmesartan medoxomil and hydrochlorothiazide_safety", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iii papillary thyroid cancer", "label": " stage iii papillary thyroid cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcopanlisib, trastuzumab emtansine_her2-positive breast cancer, metastatic breast cancer, locally advanced breast cancer, unresectable breast cancer", "label": "terminatedcopanlisib, trastuzumab emtansine_her2-positive breast cancer, metastatic breast cancer, locally advanced breast cancer, unresectable breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedibandronate sodium_metastatic cancer, pain, prostate cancer", "label": "completedibandronate sodium_metastatic cancer, pain, prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1", "label": "CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1", "shape": "dot", "size": 10}, {"color": "red", "id": "glucosamine sulfate /chondroitin sulfate - capsules", "label": "glucosamine sulfate /chondroitin sulfate - capsules", "shape": "dot", "size": 10}, {"color": "red", "id": " metoprolol succinate + doxazosin", "label": " metoprolol succinate + doxazosin", "shape": "dot", "size": 10}, {"color": "red", "id": "bendamustine hcl", "label": "bendamustine hcl", "shape": "dot", "size": 10}, {"color": "red", "id": "abbv-553", "label": "abbv-553", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "vx-371", "label": "vx-371", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, hepatosplenic t-cell lymphoma, peripheral t-cell lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma", "label": "anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, hepatosplenic t-cell lymphoma, peripheral t-cell lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": " imatinib", "label": " imatinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingibrutinib, nivolumab_hematologic neoplasms", "label": "active, not recruitingibrutinib, nivolumab_hematologic neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 500 mg bid, placebo", "label": "naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 500 mg bid, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@](C)(OC)[C@]([H])(N=C(O)OC)C(=O)N1CCC[C@@]1([H])C1=NC2=C(N1)C=C(F)C(=C2)[C@@]1([H])CC[C@@]([H])(N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@]2([H])CCCN2C(=O)[C@@]([H])(N=C(O)OC)[C@@]([H])(C)OC)C=C1F, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "[H][C@](C)(OC)[C@]([H])(N=C(O)OC)C(=O)N1CCC[C@@]1([H])C1=NC2=C(N1)C=C(F)C(=C2)[C@@]1([H])CC[C@@]([H])(N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@]2([H])CCCN2C(=O)[C@@]([H])(N=C(O)OC)[C@@]([H])(C)OC)C=C1F, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "red", "id": "biphasic insulin aspart", "label": "biphasic insulin aspart", "shape": "dot", "size": 10}, {"color": "red", "id": "cov155", "label": "cov155", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "parkinson\u0027s disease, parkinson disease, dyskinesias", "label": "parkinson\u0027s disease, parkinson disease, dyskinesias", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvandetanib_pancreatic cancer", "label": "completedvandetanib_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H], [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H], [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3", "label": "[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H], [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H], [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12", "label": "CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C", "label": " CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C", "shape": "dot", "size": 10}, {"color": "red", "id": " rtv)", "label": " rtv)", "shape": "dot", "size": 10}, {"color": "red", "id": "prednisone", "label": "prednisone", "shape": "dot", "size": 10}, {"color": "red", "id": "tirzepatide", "label": "tirzepatide", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\\C)=C\\C1=CSC(C)=N1", "label": " [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\\C)=C\\C1=CSC(C)=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1, CC1=CC(O)=CC(C)=C1Cl, CC1=CC(O)=CC(C)=C1Cl, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1, CC1=CC(O)=CC(C)=C1Cl, CC1=CC(O)=CC(C)=C1Cl, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmupirocin (bactroban) 2%; hexachlorophene (phisohex) 3%, placebo_hiv infections, staphylococcal infections", "label": "completedmupirocin (bactroban) 2%; hexachlorophene (phisohex) 3%, placebo_hiv infections, staphylococcal infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvinorelbine, gemcitabine, cisplatin_non small cell lung carcinoma", "label": "completedvinorelbine, gemcitabine, cisplatin_non small cell lung carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedym178, placebo, tolterodine er_urinary bladder, overactive", "label": "completedym178, placebo, tolterodine er_urinary bladder, overactive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedidelalisib_follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma", "label": "completedidelalisib_follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1", "label": "CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1", "shape": "dot", "size": 10}, {"color": "red", "id": " low dose cytarabine", "label": " low dose cytarabine", "shape": "dot", "size": 10}, {"color": "red", "id": "ag-519", "label": "ag-519", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "S1SSSSSSS1, CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1", "label": "S1SSSSSSS1, CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " empagliflozin 25 mg + linagliptin 5 mg", "label": " empagliflozin 25 mg + linagliptin 5 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo comparator: cd07223 vehicle gel bid", "label": " placebo comparator: cd07223 vehicle gel bid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedhydroxychloroquine, placebo_primary sj\u00f6gren\u0027s syndrome", "label": "completedhydroxychloroquine, placebo_primary sj\u00f6gren\u0027s syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, leucovorin calcium, oxaliplatin_pancreatic cancer", "label": "completedfluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, leucovorin calcium, oxaliplatin_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "triptorelin (decapeptyl\u00ae) - treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)", "label": "triptorelin (decapeptyl\u00ae) - treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)", "shape": "dot", "size": 10}, {"color": "red", "id": " chemotherapy + chemoradiotherapy", "label": " chemotherapy + chemoradiotherapy", "shape": "dot", "size": 10}, {"color": "blue", "id": " C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\\C(O)=O", "label": " C\\C(\\C=C\\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\\C(O)=O", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC[C@@]1(C)CCCN2CCC3=C(OC4=CC=CC=C34)[C@H]12", "label": "COC[C@@]1(C)CCCN2CCC3=C(OC4=CC=CC=C34)[C@H]12", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=CN2N=C(C=C2N=C1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)C1=CC(Cl)=CC=C1NS(C)(=O)=O", "label": "CC1=CN2N=C(C=C2N=C1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)C1=CC(Cl)=CC=C1NS(C)(=O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "coronary artery disease, pain, postoperative", "label": "coronary artery disease, pain, postoperative", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "degarelix 80 mg / degarelix 80 mg, degarelix 160 mg / degarelix 160 mg, leuprolide 7.5 mg / degarelix 80 mg, leuprolide 7.5 mg / degarelix 160 mg", "label": "degarelix 80 mg / degarelix 80 mg, degarelix 160 mg / degarelix 160 mg, leuprolide 7.5 mg / degarelix 80 mg, leuprolide 7.5 mg / degarelix 160 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedee20/drsp (bay86-5300), ee20/drsp (bay86-5300), ee20/drsp (yaz, bay86-5300)_contraception, ovulation inhibition, contraceptives, oral", "label": "completedee20/drsp (bay86-5300), ee20/drsp (bay86-5300), ee20/drsp (yaz, bay86-5300)_contraception, ovulation inhibition, contraceptives, oral", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedziprasidone_bipolar ii disorder, major depressive episode", "label": "completedziprasidone_bipolar ii disorder, major depressive episode", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcysteamine bitartrate_mitochondrial diseases", "label": "terminatedcysteamine bitartrate_mitochondrial diseases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "brca1 mutation carrier", "label": "brca1 mutation carrier", "shape": "dot", "size": 10}, {"color": "red", "id": "gsk2798745", "label": "gsk2798745", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedimiquimod_non-melanomatous skin cancer", "label": "completedimiquimod_non-melanomatous skin cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " dexamethasone intravenous", "label": " dexamethasone intravenous", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": " gsk1265744 30 mg", "label": " gsk1265744 30 mg", "shape": "dot", "size": 10}, {"color": "green", "id": " lung large cell carcinoma", "label": " lung large cell carcinoma", "shape": "dot", "size": 10}, {"color": "red", "id": "10% metronidazole ointment", "label": "10% metronidazole ointment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlevetiracetam_alcoholism", "label": "completedlevetiracetam_alcoholism", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo identical to bi 1356 5mg, placebo identical to glimepiride 1mg or 2mg or 3mg or 4 mg, bi 1356, glimepiride", "label": "placebo identical to bi 1356 5mg, placebo identical to glimepiride 1mg or 2mg or 3mg or 4 mg, bi 1356, glimepiride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtacrolimus_kidney transplantation", "label": "terminatedtacrolimus_kidney transplantation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "vascular dementia", "label": "vascular dementia", "shape": "dot", "size": 10}, {"color": "red", "id": "fosamprenavir", "label": "fosamprenavir", "shape": "dot", "size": 10}, {"color": "red", "id": " vintafolide iv infusion", "label": " vintafolide iv infusion", "shape": "dot", "size": 10}, {"color": "green", "id": "end-stage renal disease (esrd)", "label": "end-stage renal disease (esrd)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dronedarone, placebo (for dronedarone)", "label": "dronedarone, placebo (for dronedarone)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O", "label": "CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsuvorexant high dose (hd), suvorexant low dose (ld), comparator: placebo_primary insomnia", "label": "completedsuvorexant high dose (hd), suvorexant low dose (ld), comparator: placebo_primary insomnia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " OC[C@H]1CN(CC2=CNC3=C2N=CNC3=O)C[C@@H]1O", "label": " OC[C@H]1CN(CC2=CNC3=C2N=CNC3=O)C[C@@H]1O", "shape": "dot", "size": 10}, {"color": "red", "id": "raltegravir potassium", "label": "raltegravir potassium", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "standard dose bevacizumab, low dose bevacizumab, lomustine", "label": "standard dose bevacizumab, low dose bevacizumab, lomustine", "shape": "dot", "size": 10}, {"color": "green", "id": "complex regional pain syndrome i (crps i)", "label": "complex regional pain syndrome i (crps i)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "e2007 (perampanel), placebo", "label": "e2007 (perampanel), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedatazanavir, ritonavir, lamivudine_human immunodeficiency virus", "label": "completedatazanavir, ritonavir, lamivudine_human immunodeficiency virus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "gff mdi (pt 003)", "label": "gff mdi (pt 003)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsildenafil, placebo_cystic fibrosis", "label": "completedsildenafil, placebo_cystic fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "emtricitabine/tenofovir disoproxil fumarate", "label": "emtricitabine/tenofovir disoproxil fumarate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbifidobacterium lactis (bb-12), placebo_healthy", "label": "completedbifidobacterium lactis (bb-12), placebo_healthy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " irinotecan based chemotherapy", "label": " irinotecan based chemotherapy", "shape": "dot", "size": 10}, {"color": "green", "id": " follicular lymphoma", "label": " follicular lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cubicin, vancomycin", "label": "cubicin, vancomycin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrepaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet_diabetes, diabetes mellitus, type 2", "label": "completedrepaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet_diabetes, diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " 20 mcg ee/3 mg drsp", "label": " 20 mcg ee/3 mg drsp", "shape": "dot", "size": 10}, {"color": "red", "id": " alvimopan 0.5 mg/day", "label": " alvimopan 0.5 mg/day", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, CN\\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, CN\\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "red", "id": "ac-1204", "label": "ac-1204", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedepirubicin, docetaxel, capecitabine, trastuzumab_breast cancer", "label": "completedepirubicin, docetaxel, capecitabine, trastuzumab_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " lung disease", "label": " lung disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedafatinib 20mg, afatinib 40mg, vinorelbine iv 25 or 20mg/m2_neoplasms", "label": "completedafatinib 20mg, afatinib 40mg, vinorelbine iv 25 or 20mg/m2_neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\\C=N\\N4CCN(C)CC4)=C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CO[C@H]1\\C=C\\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\\C=N\\N4CCN(C)CC4)=C(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "aplindore", "label": "aplindore", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcediranib maleate_b-cell chronic lymphocytic leukemia, refractory chronic lymphocytic leukemia", "label": "completedcediranib maleate_b-cell chronic lymphocytic leukemia, refractory chronic lymphocytic leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedoctreotide capsules_acromegaly", "label": "completedoctreotide capsules_acromegaly", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "esophageal neoplasms, stomach neoplasms", "label": "esophageal neoplasms, stomach neoplasms", "shape": "dot", "size": 10}, {"color": "red", "id": " usual care as prescribed by the ed physicians.", "label": " usual care as prescribed by the ed physicians.", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alpelisib, buparlisib, placebo", "label": "alpelisib, buparlisib, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "utd1 injection plus capecitabine, capecitabine", "label": "utd1 injection plus capecitabine, capecitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "durvalumab, rituximab, doxorubicin, vincristine, cyclophosphamide, prednisone, lenalidomide", "label": "durvalumab, rituximab, doxorubicin, vincristine, cyclophosphamide, prednisone, lenalidomide", "shape": "dot", "size": 10}, {"color": "red", "id": " prednisone 5 mg once daily", "label": " prednisone 5 mg once daily", "shape": "dot", "size": 10}, {"color": "red", "id": " tiotropium 18 mcg", "label": " tiotropium 18 mcg", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1C#N", "label": " CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1C#N", "shape": "dot", "size": 10}, {"color": "red", "id": "23 mg eribulin", "label": "23 mg eribulin", "shape": "dot", "size": 10}, {"color": "red", "id": " arikayce\u2122 140 mg", "label": " arikayce\u2122 140 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "abvd + fdg-pet/ct scan treatment adaptation, beacoppesc", "label": "abvd + fdg-pet/ct scan treatment adaptation, beacoppesc", "shape": "dot", "size": 10}, {"color": "red", "id": " budesonide mmx\u00ae 9 mg", "label": " budesonide mmx\u00ae 9 mg", "shape": "dot", "size": 10}, {"color": "green", "id": "hodgkin\u0027s lymphoma", "label": "hodgkin\u0027s lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2", "label": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2", "shape": "dot", "size": 10}, {"color": "green", "id": "symptomatic atrial fibrillation", "label": "symptomatic atrial fibrillation", "shape": "dot", "size": 10}, {"color": "red", "id": "aee788", "label": "aee788", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "combination product (sumatriptan succinate / naproxen sodium), placebo", "label": "combination product (sumatriptan succinate / naproxen sodium), placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " 2%", "label": " 2%", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedemtricitabine/tenofovir, abacavir/lamivudine_hiv infection", "label": "completedemtricitabine/tenofovir, abacavir/lamivudine_hiv infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cg5503, placebo", "label": "cg5503, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlenalidomide_mantle cell lymphoma", "label": "completedlenalidomide_mantle cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azd6244, capecitabine", "label": "azd6244, capecitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtobramycin inhalation powder, tobramycin inhalation solution, colistimethate_cystic fibrosis", "label": "completedtobramycin inhalation powder, tobramycin inhalation solution, colistimethate_cystic fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " uterine neoplasm", "label": " uterine neoplasm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine hydrochloride_adenocarcinoma of the pancreas, recurrent pancreatic cancer, stage ii pancreatic cancer, stage iii pancreatic cancer, stage iv pancreatic cancer", "label": "completedgemcitabine hydrochloride_adenocarcinoma of the pancreas, recurrent pancreatic cancer, stage ii pancreatic cancer, stage iii pancreatic cancer, stage iv pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " met ir", "label": " met ir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "preladenant, l-dopa, other parkinson\u0027s disease treatments", "label": "preladenant, l-dopa, other parkinson\u0027s disease treatments", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcarboplatin, nab-paclitaxel_carcinoma, non-small cell lung", "label": "terminatedcarboplatin, nab-paclitaxel_carcinoma, non-small cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " oxaliplatin (oxa)", "label": " oxaliplatin (oxa)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "egfr exon 19 deletion mutation, egfr np_005219.2:p.l858r, lung non-squamous non-small cell carcinoma, stage iv lung non-small cell cancer ajcc v7", "label": "egfr exon 19 deletion mutation, egfr np_005219.2:p.l858r, lung non-squamous non-small cell carcinoma, stage iv lung non-small cell cancer ajcc v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsalmeterol 50mcg/ fluticasone propionate 500mcg_pulmonary disease, chronic obstructive", "label": "completedsalmeterol 50mcg/ fluticasone propionate 500mcg_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1", "label": "CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvarlitinib, capecitabine_biliary tract cancer", "label": "completedvarlitinib, capecitabine_biliary tract cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CN1C2=CC(O)=CC(O)=C2NC2=C(C=CC=C2O)C1=O", "label": "CC(C)=CCC\\C(C)=C\\CC\\C(C)=C\\CN1C2=CC(O)=CC(O)=C2NC2=C(C=CC=C2O)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnsirolimus, sirolimus, sirolimus, sirolimus, sirolimus_cardiac allograft vasculopathy", "label": "withdrawnsirolimus, sirolimus, sirolimus, sirolimus, sirolimus_cardiac allograft vasculopathy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "levalbuterol hfa mdi, racemic albuterol", "label": "levalbuterol hfa mdi, racemic albuterol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rhinitis, allergic, seasonal, conjunctivitis, allergic", "label": "rhinitis, allergic, seasonal, conjunctivitis, allergic", "shape": "dot", "size": 10}, {"color": "green", "id": " neovascular", "label": " neovascular", "shape": "dot", "size": 10}, {"color": "green", "id": "diabetic neuralgia", "label": "diabetic neuralgia", "shape": "dot", "size": 10}, {"color": "red", "id": " insulin degludec", "label": " insulin degludec", "shape": "dot", "size": 10}, {"color": "red", "id": " oral antidiabetic drug (glimepiride and metformin)", "label": " oral antidiabetic drug (glimepiride and metformin)", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC(C)[C@@H](C)\\C=C\\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C", "label": " CC(C)[C@@H](C)\\C=C\\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ulipristal acetate (upa), placebo", "label": "ulipristal acetate (upa), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpemetrexed, gemcitabine_metastatic colorectal cancer", "label": "terminatedpemetrexed, gemcitabine_metastatic colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "propranolol hydrochloride", "label": "propranolol hydrochloride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "temozolomide, bevacizumab, lithium carbonate", "label": "temozolomide, bevacizumab, lithium carbonate", "shape": "dot", "size": 10}, {"color": "red", "id": " lamivudine", "label": " lamivudine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dapagliflozin 10mg qd, gliclazide 30mg qd", "label": "dapagliflozin 10mg qd, gliclazide 30mg qd", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tolvaptan, furosemide", "label": "tolvaptan, furosemide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "atamestane, toremifene, letrozole, aromatase inhibition, estrogen receptor blocker", "label": "atamestane, toremifene, letrozole, aromatase inhibition, estrogen receptor blocker", "shape": "dot", "size": 10}, {"color": "red", "id": " apremilast 20 mg", "label": " apremilast 20 mg", "shape": "dot", "size": 10}, {"color": "red", "id": "bay 43-9006", "label": "bay 43-9006", "shape": "dot", "size": 10}, {"color": "green", "id": "hbv", "label": "hbv", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "inhaled snsp113, inhaled placebo", "label": "inhaled snsp113, inhaled placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "spi-2012, pegfilgrastim, docetaxel, cyclophosphamide", "label": "spi-2012, pegfilgrastim, docetaxel, cyclophosphamide", "shape": "dot", "size": 10}, {"color": "green", "id": " platelet function and reactivity tests", "label": " platelet function and reactivity tests", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpyruvate (13c)_prostate cancer", "label": "terminatedpyruvate (13c)_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]1(CC2=CC=CN=C2)N2CCC(CC2)[C@@]1([H])NC(=O)C1=CC2=C(O1)C=CC=C2", "label": " [H][C@@]1(CC2=CC=CN=C2)N2CCC(CC2)[C@@]1([H])NC(=O)C1=CC2=C(O1)C=CC=C2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dolutegravir 50 mg twice daily, dolutegravir placebo twice daily", "label": "dolutegravir 50 mg twice daily, dolutegravir placebo twice daily", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F, CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F, CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F, CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F, CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F, CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F, CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F", "shape": "dot", "size": 10}, {"color": "green", "id": " severe aplastic anemia", "label": " severe aplastic anemia", "shape": "dot", "size": 10}, {"color": "red", "id": "oglemilast", "label": "oglemilast", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "semaglutide, sitagliptin", "label": "semaglutide, sitagliptin", "shape": "dot", "size": 10}, {"color": "red", "id": "suboxone", "label": "suboxone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rebetol (ribavirin; sch 18908), copegus (ribavirin)", "label": "rebetol (ribavirin; sch 18908), copegus (ribavirin)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=C(F)C(=CC=C1)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3", "label": "COC1=C(F)C(=CC=C1)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3", "shape": "dot", "size": 10}, {"color": "green", "id": " leukemia", "label": " leukemia", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo: tablet of rivaroxaban", "label": " placebo: tablet of rivaroxaban", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazacitidine combined to lenalidomide_myelodysplastic syndromes", "label": "completedazacitidine combined to lenalidomide_myelodysplastic syndromes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " budesonide hfa pmdi", "label": " budesonide hfa pmdi", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedombitasvir/abt-450/ritonavir, dasabuvir, ribavirin (rbv)_chronic hepatitis c, hepatitis c (hcv), hepatitis c genotype 1a", "label": "completedombitasvir/abt-450/ritonavir, dasabuvir, ribavirin (rbv)_chronic hepatitis c, hepatitis c (hcv), hepatitis c genotype 1a", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedixabepilone, ixabepilone + cetuximab_triple negative locally advanced non-resectable breast cancer, metastatic breast cancer", "label": "completedixabepilone, ixabepilone + cetuximab_triple negative locally advanced non-resectable breast cancer, metastatic breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "1=etanercept, 2=clobetasol propionate foam", "label": "1=etanercept, 2=clobetasol propionate foam", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedqax576 placebo, qax576_eosinophilic esophagitis", "label": "completedqax576 placebo, qax576_eosinophilic esophagitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC(=O)C1=CC=C2C(NC(=O)\\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1", "label": "COC(=O)C1=CC=C2C(NC(=O)\\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalemtuzumab, tacrolimus, alemtuzumab_kidney transplantation", "label": "completedalemtuzumab, tacrolimus, alemtuzumab_kidney transplantation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "label": "[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iii salivary gland cancer", "label": " stage iii salivary gland cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeds-1, lv_gastric cancer", "label": "completeds-1, lv_gastric cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dry eye disease, keratoconjunctivitis sicca", "label": "dry eye disease, keratoconjunctivitis sicca", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "l-arginine, placebo", "label": "l-arginine, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fulvestrant, fulvestrant", "label": "fulvestrant, fulvestrant", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtargretin\u00ae (bexarotene), pegylated liposomal doxorubicin hydrochloride_lymphoma", "label": "completedtargretin\u00ae (bexarotene), pegylated liposomal doxorubicin hydrochloride_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " tocotrinol", "label": " tocotrinol", "shape": "dot", "size": 10}, {"color": "blue", "id": "FC1=C(N=CC=C1C(=O)N1CCC(CC1)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1)C(F)(F)F", "label": "FC1=C(N=CC=C1C(=O)N1CCC(CC1)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bevacizumab, oxaliplatin, capecitabine", "label": "bevacizumab, oxaliplatin, capecitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lymphoma, sarcoma, wilmstumor, neuroblastoma", "label": "lymphoma, sarcoma, wilmstumor, neuroblastoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmetformin_lung neoplasms, carcinoma, non-small-cell lung", "label": "terminatedmetformin_lung neoplasms, carcinoma, non-small-cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "primary renal allograft candidate", "label": "primary renal allograft candidate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O=C1N=CN=C2NNC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "O=C1N=CN=C2NNC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "metformin, insulin", "label": "metformin, insulin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CNC[C@H](O)C1=CC(O)=C(O)C=C1, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CNC[C@H](O)C1=CC(O)=C(O)C=C1, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "red", "id": " depending on dose interval", "label": " depending on dose interval", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "neuroendocrine tumors, pancreatic neoplasms", "label": "neuroendocrine tumors, pancreatic neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C", "label": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusplacebo, furosemide_heart failure", "label": "unknown statusplacebo, furosemide_heart failure", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " bay80-6946)", "label": " bay80-6946)", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC1=NC(C#CC2=CC=NC(Cl)=C2)=C(C)N1C1=CC=C(F)C=C1", "label": " CC1=NC(C#CC2=CC=NC(Cl)=C2)=C(C)N1C1=CC=C(F)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O=[Zn], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, FC1=CNC(=O)NC1=O", "label": "O=[Zn], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, FC1=CNC(=O)NC1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC", "label": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC", "shape": "dot", "size": 10}, {"color": "red", "id": " rabbit antithymocyte globulin", "label": " rabbit antithymocyte globulin", "shape": "dot", "size": 10}, {"color": "red", "id": "l-glutamine", "label": "l-glutamine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "etanercept, methotrexate, sulfasalazine, hydroxychloroquine, placebo, triple, placebo, etanercept", "label": "etanercept, methotrexate, sulfasalazine, hydroxychloroquine, placebo, triple, placebo, etanercept", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "raloxifene, clomiphene", "label": "raloxifene, clomiphene", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcabazitaxel_ovarian cancer", "label": "terminatedcabazitaxel_ovarian cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedglpg1972 single ascending doses, placebo single dose, glpg1972 multiple ascending doses, placebo multiple doses_healthy", "label": "completedglpg1972 single ascending doses, placebo single dose, glpg1972 multiple ascending doses, placebo multiple doses_healthy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "chemotherapy ( folfiri regimen", "label": "chemotherapy ( folfiri regimen", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvalsartan_hypertension, left ventricular hypertrophy", "label": "completedvalsartan_hypertension, left ventricular hypertrophy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " lfg316 lower dose", "label": " lfg316 lower dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin degludec, insulin aspart, liraglutide_diabetes, diabetes mellitus, type 2", "label": "completedinsulin degludec, insulin aspart, liraglutide_diabetes, diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gedatolisib, paclitaxel, carboplatin", "label": "gedatolisib, paclitaxel, carboplatin", "shape": "dot", "size": 10}, {"color": "red", "id": " rivastigmine 15 cm^2", "label": " rivastigmine 15 cm^2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CC1=CC(O)=CC(C)=C1Cl", "label": "OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcisplatin, docetaxel, etoposide_lung cancer", "label": "completedcisplatin, docetaxel, etoposide_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " migraine headache", "label": " migraine headache", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "3% de-089 ophthalmic solution, 0.1% sodium hyaluronate ophthalmic solution", "label": "3% de-089 ophthalmic solution, 0.1% sodium hyaluronate ophthalmic solution", "shape": "dot", "size": 10}, {"color": "red", "id": " ibandronate", "label": " ibandronate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O=C1NC(=O)[C@H]([C@@H]1C1=CNC2=CC=CC=C12)C1=CN2CCCC3=C2C1=CC=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "label": "O=C1NC(=O)[C@H]([C@@H]1C1=CNC2=CC=CC=C12)C1=CN2CCCC3=C2C1=CC=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "shape": "dot", "size": 10}, {"color": "green", "id": " cystic fibrosis with exacerbation", "label": " cystic fibrosis with exacerbation", "shape": "dot", "size": 10}, {"color": "green", "id": "postmenopausal osteoporosis (pmo)", "label": "postmenopausal osteoporosis (pmo)", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo-matching cadazolid", "label": " placebo-matching cadazolid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpegylated interferon alfa-2a and ribavirin, pegylated interferon alfa-2a and ribavirin, pegylated interferon alfa-2a and ribavirin_chronic hepatitis c", "label": "terminatedpegylated interferon alfa-2a and ribavirin, pegylated interferon alfa-2a and ribavirin, pegylated interferon alfa-2a and ribavirin_chronic hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ave1642", "label": "ave1642", "shape": "dot", "size": 10}, {"color": "red", "id": " ribavirin (rbv) tablet", "label": " ribavirin (rbv) tablet", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "label": "[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "shape": "dot", "size": 10}, {"color": "red", "id": " adl5945 0.1 mg", "label": " adl5945 0.1 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedropivacaine, lidocaine/ketamine_pain, nausea", "label": "terminatedropivacaine, lidocaine/ketamine_pain, nausea", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "her-2 gene amplification", "label": "her-2 gene amplification", "shape": "dot", "size": 10}, {"color": "red", "id": " azd3241 600 mg bid", "label": " azd3241 600 mg bid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusdocetaxel, prednisone, enzalutamide_prostatic neoplasms", "label": "unknown statusdocetaxel, prednisone, enzalutamide_prostatic neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "linaclotide, matching placebo", "label": "linaclotide, matching placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " carvedilol", "label": " carvedilol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedraltegravir_hiv-1 infection, chronic renal insufficiency", "label": "completedraltegravir_hiv-1 infection, chronic renal insufficiency", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " pegvisomant", "label": " pegvisomant", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lapatinib ditosylate, paclitaxel albumin-stabilized nanoparticle formulation", "label": "lapatinib ditosylate, paclitaxel albumin-stabilized nanoparticle formulation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tongue cancer, chemotherapy effect, surgery", "label": "tongue cancer, chemotherapy effect, surgery", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddonepezil_parkinson\u0027s disease", "label": "terminateddonepezil_parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, prednisone, methylprednisolone, diphenhydramine, acetaminophen, cyclophosphamide, prednisone, methylprednisolone, diphenhydramine, acetaminophen", "label": "cyclophosphamide, prednisone, methylprednisolone, diphenhydramine, acetaminophen, cyclophosphamide, prednisone, methylprednisolone, diphenhydramine, acetaminophen", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vortioxetine (lu aa21004), placebo", "label": "vortioxetine (lu aa21004), placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo for risankizumab", "label": " placebo for risankizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rituximab + standard chop, rituximab + bi-weekly chop", "label": "rituximab + standard chop, rituximab + bi-weekly chop", "shape": "dot", "size": 10}, {"color": "red", "id": "grazoprevir/elbasvir", "label": "grazoprevir/elbasvir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedclarithromycin, glucocorticoid_chronic rhinosinusitis, endoscopic sinus surgery", "label": "completedclarithromycin, glucocorticoid_chronic rhinosinusitis, endoscopic sinus surgery", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "zegerid", "label": "zegerid", "shape": "dot", "size": 10}, {"color": "red", "id": " ff/vi (100/25) mcg", "label": " ff/vi (100/25) mcg", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(=O)C(O)=O", "label": "CC(=O)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsodium oxybate_parkinson disease", "label": "completedsodium oxybate_parkinson disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " single dose of 10 mcg", "label": " single dose of 10 mcg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glioblastoma, gliosarcoma, anaplastic astrocytoma", "label": "glioblastoma, gliosarcoma, anaplastic astrocytoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedramosetron, aprepitant, dexamethasone, palonosetron, aprepitant, dexamethasone_cancer, tumors", "label": "completedramosetron, aprepitant, dexamethasone, palonosetron, aprepitant, dexamethasone_cancer, tumors", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " optimized background arv", "label": " optimized background arv", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedvorinostat_pancreatic cancer", "label": "terminatedvorinostat_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfluorouracil, oxaliplatin_esophageal cancer", "label": "completedfluorouracil, oxaliplatin_esophageal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedteriflunomide, placebo (for teriflunomide), interferon-\u03b2_multiple sclerosis", "label": "completedteriflunomide, placebo (for teriflunomide), interferon-\u03b2_multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, NC1=CC(C(O)=O)=C(O)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1", "label": "COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, NC1=CC(C(O)=O)=C(O)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " neoral", "label": " neoral", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcetuximab_carcinoma, non-small-cell lung", "label": "completedcetuximab_carcinoma, non-small-cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1", "label": "C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pf-06650833, placebo, tofacitinib", "label": "pf-06650833, placebo, tofacitinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "advanced, metastatic breast cancer", "label": "advanced, metastatic breast cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chemotherapy-induced neutropenia, myelosuppression, breast cancer", "label": "chemotherapy-induced neutropenia, myelosuppression, breast cancer", "shape": "dot", "size": 10}, {"color": "green", "id": " vulvovaginal atrophy", "label": " vulvovaginal atrophy", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent gastric cancer", "label": " recurrent gastric cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, FC1=CNC(=O)NC1=O, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, ClCCN(CCCl)P1(=O)NCCCO1", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, FC1=CNC(=O)NC1=O, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, ClCCN(CCCl)P1(=O)NCCCO1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "atherosclerosis, ldl-hypercholesterolemia", "label": "atherosclerosis, ldl-hypercholesterolemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedamrubicin hydrochloride, etoposide-cisplatin combined chemotherapy_lung cancer", "label": "completedamrubicin hydrochloride, etoposide-cisplatin combined chemotherapy_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "brivanib", "label": "brivanib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmetformin xl, placebo_left ventricular hypertrophy, insulin resistance, coronary artery disease, prediabetes", "label": "completedmetformin xl, placebo_left ventricular hypertrophy, insulin resistance, coronary artery disease, prediabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "fludarabine", "label": "fludarabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedexenatide once weekly, placebo_type 2 diabetes", "label": "completedexenatide once weekly, placebo_type 2 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpregabalin, pregabalin, placebo_pain", "label": "completedpregabalin, pregabalin, placebo_pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvinflunine plus capecitabine, capecitabine_breast cancer", "label": "completedvinflunine plus capecitabine, capecitabine_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "docetaxel + trastuzumab sc + pertuzumab", "label": "docetaxel + trastuzumab sc + pertuzumab", "shape": "dot", "size": 10}, {"color": "red", "id": " ethanol", "label": " ethanol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlenalidomide and r-chop_follicular lymphoma", "label": "completedlenalidomide and r-chop_follicular lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " uk-369", "label": " uk-369", "shape": "dot", "size": 10}, {"color": "green", "id": " behavioral symptoms", "label": " behavioral symptoms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedselinexor, dexamethasone_multiple myeloma", "label": "completedselinexor, dexamethasone_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "atrial fibrillation, persistent atrial fibrillation", "label": "atrial fibrillation, persistent atrial fibrillation", "shape": "dot", "size": 10}, {"color": "green", "id": " diabetic foot", "label": " diabetic foot", "shape": "dot", "size": 10}, {"color": "red", "id": " lapatinib plus capecitabine", "label": " lapatinib plus capecitabine", "shape": "dot", "size": 10}, {"color": "red", "id": " clobex shampoo placebo", "label": " clobex shampoo placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " age-related", "label": " age-related", "shape": "dot", "size": 10}, {"color": "red", "id": "pazopanib 400 mg qd - gemcitabine and docetaxel in combination", "label": "pazopanib 400 mg qd - gemcitabine and docetaxel in combination", "shape": "dot", "size": 10}, {"color": "red", "id": " sorafenib standard dose", "label": " sorafenib standard dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfluorouracil, leucovorin calcium_colorectal cancer", "label": "terminatedfluorouracil, leucovorin calcium_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl, CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1", "label": "OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl, CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "a: placebo to match donepezil and mk-3134 + placebo to match scopolamine", "label": "a: placebo to match donepezil and mk-3134 + placebo to match scopolamine", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo for apixaban", "label": " placebo for apixaban", "shape": "dot", "size": 10}, {"color": "green", "id": " adult supratentorial primitive neuroectodermal tumor", "label": " adult supratentorial primitive neuroectodermal tumor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusvelcade, thalidomide, dexamethasone_multiple myeloma", "label": "unknown statusvelcade, thalidomide, dexamethasone_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "intravitreal triamcinolone injection, intravitreal triamcinolone injection", "label": "intravitreal triamcinolone injection, intravitreal triamcinolone injection", "shape": "dot", "size": 10}, {"color": "red", "id": "microflare protocol for ivf", "label": "microflare protocol for ivf", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpemetrexed, erlotinib_metastatic colorectal cancer", "label": "completedpemetrexed, erlotinib_metastatic colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, O", "label": "[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, O", "shape": "dot", "size": 10}, {"color": "red", "id": "aln-pcssc", "label": "aln-pcssc", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbosentan (tracleer)_systemic scleroderma, skin fibrosis, hand functionality", "label": "completedbosentan (tracleer)_systemic scleroderma, skin fibrosis, hand functionality", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completede7389_prostate cancer", "label": "completede7389_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\\C=C\\C1=CC=C(OCCN(C)C)C=C1, O", "label": "CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\\C=C\\C1=CC=C(OCCN(C)C)C=C1, O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil", "label": "oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "breast cancer, her2-negative breast cancer", "label": "breast cancer, her2-negative breast cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalbuterol/salbutamol, ipratropium_pulmonary disease, chronic obstructive", "label": "completedalbuterol/salbutamol, ipratropium_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " salmeterol/fluticasone propionate inhalation powder (50/100mcg bid)", "label": " salmeterol/fluticasone propionate inhalation powder (50/100mcg bid)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatednaproxen, ce-224535, placebo_osteoarthritis", "label": "terminatednaproxen, ce-224535, placebo_osteoarthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " autologous stem cell transplantation", "label": " autologous stem cell transplantation", "shape": "dot", "size": 10}, {"color": "red", "id": "pv-10 (10% rose bengal disodium)", "label": "pv-10 (10% rose bengal disodium)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC1=CC(O)=CC(C)=C1Cl, CC1=CC(O)=CC(C)=C1Cl", "label": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC1=CC(O)=CC(C)=C1Cl, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtrazodone, sentra pm and trazodone (copack kit trazamine), placebo trazodone and placebo sentra pm_sleep disorder", "label": "completedtrazodone, sentra pm and trazodone (copack kit trazamine), placebo trazodone and placebo sentra pm_sleep disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "umeclidinium bromide", "label": "umeclidinium bromide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completede5555, e5555, e5555, placebo_acute coronary syndrome", "label": "completede5555, e5555, e5555, placebo_acute coronary syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " biliary", "label": " biliary", "shape": "dot", "size": 10}, {"color": "red", "id": " nilotinib (tasigna \u00ae) and pegylated interferon alfa 2a (pegasys\u00ae)", "label": " nilotinib (tasigna \u00ae) and pegylated interferon alfa 2a (pegasys\u00ae)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, COC1=C(OC)C=C2C(OC3=CC(Cl)=C(C=C3)N=C(O)N=C3NOC(C)=C3)=CC=NC2=C1", "label": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, COC1=C(OC)C=C2C(OC3=CC(Cl)=C(C=C3)N=C(O)N=C3NOC(C)=C3)=CC=NC2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Na+].CC12CC(O)C3C(CCC4=CC(=O)C=CC34C)C1CCC2(O)C(=O)COC(=O)C1=CC(=CC=C1)S([O-])(=O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "[Na+].CC12CC(O)C3C(CCC4=CC(=O)C=CC34C)C1CCC2(O)C(=O)COC(=O)C1=CC(=CC=C1)S([O-])(=O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "green", "id": " egfr gene mutations", "label": " egfr gene mutations", "shape": "dot", "size": 10}, {"color": "red", "id": "lapatinib + 1", "label": "lapatinib + 1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedam 5 + dm 0, am 5 + dm 2.5, am 5 + dm 7.5, am 5 + dm 30_hypertension", "label": "completedam 5 + dm 0, am 5 + dm 2.5, am 5 + dm 7.5, am 5 + dm 30_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2, CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2", "label": "CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2, CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2", "shape": "dot", "size": 10}, {"color": "green", "id": " transient ischemic attack", "label": " transient ischemic attack", "shape": "dot", "size": 10}, {"color": "red", "id": "albiglutide (gsk716155) or exenatide", "label": "albiglutide (gsk716155) or exenatide", "shape": "dot", "size": 10}, {"color": "green", "id": " tubular breast cancer stage iii", "label": " tubular breast cancer stage iii", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedliraglutide, metformin_type 2 diabetes, overweight, obesity", "label": "completedliraglutide, metformin_type 2 diabetes, overweight, obesity", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "lopinavir/ritonavir simplification strategy", "label": "lopinavir/ritonavir simplification strategy", "shape": "dot", "size": 10}, {"color": "green", "id": " solid neoplasm", "label": " solid neoplasm", "shape": "dot", "size": 10}, {"color": "blue", "id": "CS(=O)(=O)OCCN(CCBr)C1=C(C=C(C=C1[N+]([O-])=O)[N+]([O-])=O)C(=O)NCCOP(O)(O)=O", "label": "CS(=O)(=O)OCCN(CCBr)C1=C(C=C(C=C1[N+]([O-])=O)[N+]([O-])=O)C(=O)NCCOP(O)(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pregabalin, pregabalin, pregabalin, pregabalin, pregabalin, pregabalin, placebo", "label": "pregabalin, pregabalin, pregabalin, pregabalin, pregabalin, pregabalin, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "silymarin 700 mg", "label": "silymarin 700 mg", "shape": "dot", "size": 10}, {"color": "red", "id": "cystadane", "label": "cystadane", "shape": "dot", "size": 10}, {"color": "red", "id": " cee ", "label": " cee ", "shape": "dot", "size": 10}, {"color": "green", "id": " osteoarthritis of the knee", "label": " osteoarthritis of the knee", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedipragliflozin, placebo_type 1 diabetes mellitus", "label": "completedipragliflozin, placebo_type 1 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " insulin glargine 1.0 u/kg body wt sc", "label": " insulin glargine 1.0 u/kg body wt sc", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedqva149, placebo_chronic obstructive pulmonary disease", "label": "completedqva149, placebo_chronic obstructive pulmonary disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusaxs-02 (oral zoledronate), placebo_complex regional pain syndrome, reflex sympathetic dystrophy", "label": "unknown statusaxs-02 (oral zoledronate), placebo_complex regional pain syndrome, reflex sympathetic dystrophy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tepotinib, gefitinib, pemetrexed, cisplatin, carboplatin", "label": "tepotinib, gefitinib, pemetrexed, cisplatin, carboplatin", "shape": "dot", "size": 10}, {"color": "green", "id": " paratonia", "label": " paratonia", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C", "label": " CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "epo906 (patupilone), doxorubicin", "label": "epo906 (patupilone), doxorubicin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alogliptin, pioglitazone, placebo", "label": "alogliptin, pioglitazone, placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " human papilloma virus", "label": " human papilloma virus", "shape": "dot", "size": 10}, {"color": "red", "id": "bay85-8501", "label": "bay85-8501", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgtx-024, gtx-024, placebo_cachexia", "label": "completedgtx-024, gtx-024, placebo_cachexia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C", "label": "COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C", "shape": "dot", "size": 10}, {"color": "red", "id": "meclizine oral tablet", "label": "meclizine oral tablet", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarfilzomib, lenalidomide, dexamethasone, lenalidomide, lenalidomide_multiple myeloma", "label": "completedcarfilzomib, lenalidomide, dexamethasone, lenalidomide, lenalidomide_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to match adalimumab", "label": " placebo to match adalimumab", "shape": "dot", "size": 10}, {"color": "green", "id": " metabolic disease", "label": " metabolic disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recruitingbortezomib, melphalan, prednisone (vmp), 1 or 2 cycle(s) hdm (high dose melphalan), 2 cycles of bortezomib, lenalidomide, dexamethasone (vrd)_multiple myeloma", "label": "recruitingbortezomib, melphalan, prednisone (vmp), 1 or 2 cycle(s) hdm (high dose melphalan), 2 cycles of bortezomib, lenalidomide, dexamethasone (vrd)_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrlx030 (serelaxin), placebo_chronic heart failure", "label": "completedrlx030 (serelaxin), placebo_chronic heart failure", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "linezolid, vancomycin", "label": "linezolid, vancomycin", "shape": "dot", "size": 10}, {"color": "red", "id": " 50 mg etanercept", "label": " 50 mg etanercept", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedranibizumab_diabetic retinopathy, macular oedema", "label": "completedranibizumab_diabetic retinopathy, macular oedema", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlopinavir/ritonavir, lopinavir/ritonavir, raltegravir, emtricitabine/tenofovir disoproxil fumarate, abacavir/lamivudine/zidovudine, abacavir/lamivudine, lamivudine/zidovudine, abacavir, zidovudine, lamivudine_hiv-1 infection", "label": "completedlopinavir/ritonavir, lopinavir/ritonavir, raltegravir, emtricitabine/tenofovir disoproxil fumarate, abacavir/lamivudine/zidovudine, abacavir/lamivudine, lamivudine/zidovudine, abacavir, zidovudine, lamivudine_hiv-1 infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "trastuzumab, other chemotherapy in association with trastuzumab", "label": "trastuzumab, other chemotherapy in association with trastuzumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedflibanserin_sexual dysfunctions, psychological", "label": "completedflibanserin_sexual dysfunctions, psychological", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CS(=O)(=O)OCCCCOS(C)(=O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "CS(=O)(=O)OCCCCOS(C)(=O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ondansetron, ibuprofen, paracetamol, ondansetron, ibuprofen, paracetamol, metoclopramide, ibuprofen, paracetamol, metoclopramide, codeine phosphate, ibuprofen, paracetamol", "label": "ondansetron, ibuprofen, paracetamol, ondansetron, ibuprofen, paracetamol, metoclopramide, ibuprofen, paracetamol, metoclopramide, codeine phosphate, ibuprofen, paracetamol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedatorvastatin, atorvastatin, placebo for atorvastin_hiv-1 infection", "label": "completedatorvastatin, atorvastatin, placebo for atorvastin_hiv-1 infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1", "shape": "dot", "size": 10}, {"color": "red", "id": "clonidine mbt 50\u00b5g", "label": "clonidine mbt 50\u00b5g", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedibodutant, ibodutant, ibodutant, placebo_irritable bowel syndrome with diarrhea", "label": "completedibodutant, ibodutant, ibodutant, placebo_irritable bowel syndrome with diarrhea", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, ziprasidone, ziprasidone_bipolar disorder", "label": "completedplacebo, ziprasidone, ziprasidone_bipolar disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedplacebo, paracetamol_pain", "label": "terminatedplacebo, paracetamol_pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedentospletinib, idelalisib_chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large b-cell lymphoma, indolent non-hodgkin\u0027s lymphoma", "label": "terminatedentospletinib, idelalisib_chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large b-cell lymphoma, indolent non-hodgkin\u0027s lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, OC(=O)[C@@H]1CCCN1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "label": "CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, OC(=O)[C@@H]1CCCN1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "shape": "dot", "size": 10}, {"color": "green", "id": " non-squamous non-small cell lung", "label": " non-squamous non-small cell lung", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC12CC3CC(CC(C3)C1)C2", "label": "NC12CC3CC(CC(C3)C1)C2", "shape": "dot", "size": 10}, {"color": "red", "id": " gemcitabine/carboplatin plus iniparib", "label": " gemcitabine/carboplatin plus iniparib", "shape": "dot", "size": 10}, {"color": "blue", "id": " CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1", "label": " CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "tak-580", "label": "tak-580", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tranexamic acid tablets, tranexamic acid tablets, placebo tablets", "label": "tranexamic acid tablets, tranexamic acid tablets, placebo tablets", "shape": "dot", "size": 10}, {"color": "blue", "id": " ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1", "label": " ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcapecitabine, eribulin, gemcitabine, vinorelbine_metastatic triple negative breast cancer", "label": "completedcapecitabine, eribulin, gemcitabine, vinorelbine_metastatic triple negative breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12, OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12, OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12, CC1=CC(O)=CC(C)=C1Cl", "label": "OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12, OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12, OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpl2200 aspirin capsules, enteric-coated aspirin caplets_diabetes mellitus, type 2", "label": "completedpl2200 aspirin capsules, enteric-coated aspirin caplets_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ns1209", "label": "ns1209", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedeltrombopag, placebo_non-alcoholic steatohepatitis, chronic liver disease, hcv, nash - nonalcoholic steatohepatitis, hiv infection, thrombocytopenia, hepatitis c virus, hbv, human immunodeficiency virus, liver diseases, hepatitis b virus", "label": "terminatedeltrombopag, placebo_non-alcoholic steatohepatitis, chronic liver disease, hcv, nash - nonalcoholic steatohepatitis, hiv infection, thrombocytopenia, hepatitis c virus, hbv, human immunodeficiency virus, liver diseases, hepatitis b virus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cetuximab, folfox", "label": "cetuximab, folfox", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iiic primary peritoneal cancer ajcc v7", "label": " stage iiic primary peritoneal cancer ajcc v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vak694; alutard avanz sq, vak694 placebo infusion; alutard avanz sq, vak694 placebo infusion; saline", "label": "vak694; alutard avanz sq, vak694 placebo infusion; alutard avanz sq, vak694 placebo infusion; saline", "shape": "dot", "size": 10}, {"color": "green", "id": " high blood sugar", "label": " high blood sugar", "shape": "dot", "size": 10}, {"color": "red", "id": " concerta (methylphenidate)", "label": " concerta (methylphenidate)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1, CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1, COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C", "label": "CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1, CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1, COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmmf(1000mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (300 mg bid) + tacrolimus + standard of care medications_liver transplantation", "label": "completedmmf(1000mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (300 mg bid) + tacrolimus + standard of care medications_liver transplantation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "shape": "dot", "size": 10}, {"color": "red", "id": "agn-150998", "label": "agn-150998", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O", "label": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\\C=C\\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": "propafenone; flecainide; sotalol; dofetilide", "label": "propafenone; flecainide; sotalol; dofetilide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "comparator: placebo, rolofylline", "label": "comparator: placebo, rolofylline", "shape": "dot", "size": 10}, {"color": "blue", "id": "C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1C)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1C)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmicronized progesterone_infertility", "label": "completedmicronized progesterone_infertility", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarfilzomib, bortezomib, dexamethasone_multiple myeloma", "label": "completedcarfilzomib, bortezomib, dexamethasone_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=CC=C1OCC(O)CO, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C", "label": "COC1=CC=CC=C1OCC(O)CO, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfluticasone furoate, vilanterol, fluticasone propionate, salmeterol, budesonide, formoterol fumarate_asthma", "label": "completedfluticasone furoate, vilanterol, fluticasone propionate, salmeterol, budesonide, formoterol fumarate_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo_ulcerative colitis", "label": "completedplacebo_ulcerative colitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": " micardis", "label": " micardis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbendamustine hydrochloride_non-hodgkin\u0027s lymphoma, mantle cell lymphoma", "label": "completedbendamustine hydrochloride_non-hodgkin\u0027s lymphoma, mantle cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "metformin, ly2189265, placebo (oral), placebo (subcutaneous)", "label": "metformin, ly2189265, placebo (oral), placebo (subcutaneous)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "abt-869, bevacizumab, oxaliplatin, folinic acid, fluorouracil, abt-869", "label": "abt-869, bevacizumab, oxaliplatin, folinic acid, fluorouracil, abt-869", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazd0530 100mg daily, azd0530 125mg daily, placebo_alzheimer\u0027s disease", "label": "completedazd0530 100mg daily, azd0530 125mg daily, placebo_alzheimer\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " antibody mediated rejection", "label": " antibody mediated rejection", "shape": "dot", "size": 10}, {"color": "red", "id": "mln9708", "label": "mln9708", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "kidney failure, chronic, catheter-related infections", "label": "kidney failure, chronic, catheter-related infections", "shape": "dot", "size": 10}, {"color": "red", "id": " tiotropium bromide 1.25\u00b5g once daily", "label": " tiotropium bromide 1.25\u00b5g once daily", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "peritonitis, postoperative complications", "label": "peritonitis, postoperative complications", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrn624 (pf-04383119), rn624 (pf-04383119), rn624 (pf-04383119), rn624 (pf-04383119), rn624 (pf-04383119), placebo_osteoarthritis", "label": "completedrn624 (pf-04383119), rn624 (pf-04383119), rn624 (pf-04383119), rn624 (pf-04383119), rn624 (pf-04383119), placebo_osteoarthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "idarubicin, cytarabine, bortezomib, etoposide", "label": "idarubicin, cytarabine, bortezomib, etoposide", "shape": "dot", "size": 10}, {"color": "green", "id": " localized unresectable adult primary liver cancer", "label": " localized unresectable adult primary liver cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedglimepiride + metformin_diabetes mellitus, type 2", "label": "completedglimepiride + metformin_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnhyaluronic acid_urinary tract infection", "label": "withdrawnhyaluronic acid_urinary tract infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnmodafinil, methylphenidate_parkinson\u0027s disease", "label": "withdrawnmodafinil, methylphenidate_parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " durlaza\u2122", "label": " durlaza\u2122", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsodium valproate_neuralgia, neuropathic peripheral pain", "label": "terminatedsodium valproate_neuralgia, neuropathic peripheral pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=CC(O)=CC(C)=C1Cl, [H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "CC1=CC(O)=CC(C)=C1Cl, [H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=NC2=C(C=C(C=C2N1CC1=C(C)C(=CC=C1)C(F)(F)F)N1CCOCC1)C(O)=O", "label": "CC1=NC2=C(C=C(C=C2N1CC1=C(C)C(=CC=C1)C(F)(F)F)N1CCOCC1)C(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent grade 1 follicular lymphoma", "label": " recurrent grade 1 follicular lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "brain tumor, central nervous system tumors, cachexia, leukemia, lymphoma, myelodysplastic syndromes, myelodysplastic/myeloproliferative diseases, unspecified childhood solid tumor, protocol specific", "label": "brain tumor, central nervous system tumors, cachexia, leukemia, lymphoma, myelodysplastic syndromes, myelodysplastic/myeloproliferative diseases, unspecified childhood solid tumor, protocol specific", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N+]([O-])=O", "label": "CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N+]([O-])=O", "shape": "dot", "size": 10}, {"color": "green", "id": "myxofibrosarcoma", "label": "myxofibrosarcoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "breast cancer, lung cancer", "label": "breast cancer, lung cancer", "shape": "dot", "size": 10}, {"color": "green", "id": " mucinous adenocarcinoma of the rectum", "label": " mucinous adenocarcinoma of the rectum", "shape": "dot", "size": 10}, {"color": "red", "id": " etoricoxib 90 mg", "label": " etoricoxib 90 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "salmeterol xinafoate, serevent\u00ae diskus\u00ae, placebo (handihaler\u00ae), placebo (diskus\u00ae)", "label": "salmeterol xinafoate, serevent\u00ae diskus\u00ae, placebo (handihaler\u00ae), placebo (diskus\u00ae)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel, vinorelbine, carboplatin, gemcitabine", "label": "docetaxel, vinorelbine, carboplatin, gemcitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carmustine, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, melphalan, prednisolone, vincristine sulfate", "label": "carmustine, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, melphalan, prednisolone, vincristine sulfate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O=C(CC(C1=CC=CC=C1)C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "O=C(CC(C1=CC=CC=C1)C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "cr845 tablet 1 mg", "label": "cr845 tablet 1 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "kw-2478, bortezomib", "label": "kw-2478, bortezomib", "shape": "dot", "size": 10}, {"color": "red", "id": " yh4808 200mg (repeat dose)", "label": " yh4808 200mg (repeat dose)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpeginterferon beta-1a_relapsing multiple sclerosis", "label": "completedpeginterferon beta-1a_relapsing multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "levofloxacin, piperacillin/tazobactam", "label": "levofloxacin, piperacillin/tazobactam", "shape": "dot", "size": 10}, {"color": "red", "id": " docetaxel + oxaliplatin + 5-fu", "label": " docetaxel + oxaliplatin + 5-fu", "shape": "dot", "size": 10}, {"color": "red", "id": " aq nasal spray placebo", "label": " aq nasal spray placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfludarabine, cyclophosphamide, aldesleukin, mart-1 reactive cd8+ pbl_metastatic melanoma, skin cancer", "label": "terminatedfludarabine, cyclophosphamide, aldesleukin, mart-1 reactive cd8+ pbl_metastatic melanoma, skin cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " ovarian mucinous adenocarcinoma", "label": " ovarian mucinous adenocarcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtigecycline_skin diseases, infectious", "label": "completedtigecycline_skin diseases, infectious", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsta-5326_crohn\u0027s disease", "label": "completedsta-5326_crohn\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "ovarian hyperstimulation syndrome", "label": "ovarian hyperstimulation syndrome", "shape": "dot", "size": 10}, {"color": "green", "id": "relapsed or refractory solid tumors", "label": "relapsed or refractory solid tumors", "shape": "dot", "size": 10}, {"color": "red", "id": " tac + mmf + corticosteroids", "label": " tac + mmf + corticosteroids", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tiotropium, aclidinium", "label": "tiotropium, aclidinium", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCN(C1CCN(CC[C@H](C2=CC=C(C=C2)S(C)(=O)=O)C2=CC(F)=CC(F)=C2)CC1)C(=O)CC1=CC=C(C=C1)S(C)(=O)=O", "label": " CCN(C1CCN(CC[C@H](C2=CC=C(C=C2)S(C)(=O)=O)C2=CC(F)=CC(F)=C2)CC1)C(=O)CC1=CC=C(C=C1)S(C)(=O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": " ascorbic acid and bortezomib", "label": " ascorbic acid and bortezomib", "shape": "dot", "size": 10}, {"color": "green", "id": " progesterone receptor-positive breast cancer", "label": " progesterone receptor-positive breast cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nifedipine (adalat, baya1040)", "label": "nifedipine (adalat, baya1040)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedreduced glutathione sodium salt, 0.9% normal saline (control)_cystic fibrosis", "label": "completedreduced glutathione sodium salt, 0.9% normal saline (control)_cystic fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlai (liposomal amikacin for inhalation) 590 mg_mycobacterium infections, nontuberculous", "label": "completedlai (liposomal amikacin for inhalation) 590 mg_mycobacterium infections, nontuberculous", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "regorafenib + panitumumab", "label": "regorafenib + panitumumab", "shape": "dot", "size": 10}, {"color": "red", "id": " treatment 360 days dapt", "label": " treatment 360 days dapt", "shape": "dot", "size": 10}, {"color": "blue", "id": "CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(NCC3=CC(I)=CC=C3)N=CN=C12", "label": "CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(NCC3=CC(I)=CC=C3)N=CN=C12", "shape": "dot", "size": 10}, {"color": "red", "id": " dexketoprofen-multiple doses", "label": " dexketoprofen-multiple doses", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedentecavir, telbivudine_hepatitis b, chronic hepatitis b", "label": "completedentecavir, telbivudine_hepatitis b, chronic hepatitis b", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbms-914392, bms-914392, bms-914392, placebo_atrial fibrillation", "label": "completedbms-914392, bms-914392, bms-914392, placebo_atrial fibrillation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddenosumab, zoledronic acid_postmenopausal osteoporosis", "label": "completeddenosumab, zoledronic acid_postmenopausal osteoporosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, ziprasidone oral capsule", "label": "placebo, ziprasidone oral capsule", "shape": "dot", "size": 10}, {"color": "green", "id": " colonic diseases", "label": " colonic diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1", "label": "NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatederlotinib_head and neck cancer, carcinoma, squamous cell", "label": "terminatederlotinib_head and neck cancer, carcinoma, squamous cell", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " risankizumab sc", "label": " risankizumab sc", "shape": "dot", "size": 10}, {"color": "red", "id": "bimatoprost/timolol fixed combination", "label": "bimatoprost/timolol fixed combination", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "mk0557, comparator: placebo (unspecified)", "label": "mk0557, comparator: placebo (unspecified)", "shape": "dot", "size": 10}, {"color": "green", "id": " paroxysmal nocturnal hemoglobinuria", "label": " paroxysmal nocturnal hemoglobinuria", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "anemia, renal insufficiency, chronic", "label": "anemia, renal insufficiency, chronic", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "red", "id": "ormd-0801", "label": "ormd-0801", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "label": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "shape": "dot", "size": 10}, {"color": "red", "id": " (lipid microspheres) intravenous suspension", "label": " (lipid microspheres) intravenous suspension", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iv squamous cell carcinoma of the hypopharynx", "label": " stage iv squamous cell carcinoma of the hypopharynx", "shape": "dot", "size": 10}, {"color": "green", "id": " brca 2 gene mutation", "label": " brca 2 gene mutation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedly900003_carcinoma, non-small-cell lung", "label": "completedly900003_carcinoma, non-small-cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvapendavir, vapendavir, placebo_asthma", "label": "completedvapendavir, vapendavir, placebo_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " N[C@@H](CO)C(O)=O", "label": " N[C@@H](CO)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "colorectal cancer, familial adenomatous polyposis", "label": "colorectal cancer, familial adenomatous polyposis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcyclophosphamide, fludarabine phosphate, mycophenolate mofetil, sirolimus, tacrolimus_immunodeficiency syndrome, severe aplastic anemia, genetic disorder", "label": "terminatedcyclophosphamide, fludarabine phosphate, mycophenolate mofetil, sirolimus, tacrolimus_immunodeficiency syndrome, severe aplastic anemia, genetic disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " quinapril 10 mg and amlodipine 5 mg", "label": " quinapril 10 mg and amlodipine 5 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " carboplatin/paclitaxel (cp)", "label": " carboplatin/paclitaxel (cp)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "suspendedalisertib, fulvestrant_estrogen receptor status, her2/neu negative, invasive breast carcinoma, postmenopausal, stage iii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer", "label": "suspendedalisertib, fulvestrant_estrogen receptor status, her2/neu negative, invasive breast carcinoma, postmenopausal, stage iii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "8iu intranasal oxytocin", "label": "8iu intranasal oxytocin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "high-dose atorvastatin, low-dose atorvastatin", "label": "high-dose atorvastatin, low-dose atorvastatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bacteremia, healthcare-associated pneumonia, ventilator-associated pneumonia", "label": "bacteremia, healthcare-associated pneumonia, ventilator-associated pneumonia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmontelukast (high feno group), prednisolon, montelukast (high feno), montelukast (low feno group)_cough", "label": "completedmontelukast (high feno group), prednisolon, montelukast (high feno), montelukast (low feno group)_cough", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aromatase inhibitor, growth hormone, aromatase inhibitor and growth hormone", "label": "aromatase inhibitor, growth hormone, aromatase inhibitor and growth hormone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddapagliflozin, dapagliflozin, dapagliflozin, metformin, placebo_type 2 diabetes", "label": "completeddapagliflozin, dapagliflozin, dapagliflozin, metformin, placebo_type 2 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo_herpes zoster", "label": "completedplacebo_herpes zoster", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN(C)C(=N)NC(N)=N, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN(C)C(=N)NC(N)=N", "label": "[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN(C)C(=N)NC(N)=N, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN(C)C(=N)NC(N)=N", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(C)C\\C=C\\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(C)C\\C=C\\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "loteprednol etabonate gel (bid), loteprednol etabonate gel (tid), vehicle (bid), vehicle (tid)", "label": "loteprednol etabonate gel (bid), loteprednol etabonate gel (tid), vehicle (bid), vehicle (tid)", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iia prostate cancer ajcc v8", "label": " stage iia prostate cancer ajcc v8", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtipranavir, ritonavir_hiv infections", "label": "completedtipranavir, ritonavir_hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1", "label": "CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "non-pegylated liposomal doxorubicon (myocet\u2122), lapatinib (tyverb\u2122)", "label": "non-pegylated liposomal doxorubicon (myocet\u2122), lapatinib (tyverb\u2122)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hypercholesterolemia, coronary arteriosclerosis", "label": "hypercholesterolemia, coronary arteriosclerosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmr prednisone, placebo_rheumatoid arthritis", "label": "completedmr prednisone, placebo_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "urg101", "label": "urg101", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarboplatin, erlotinib hydrochloride, paclitaxel_lung cancer", "label": "completedcarboplatin, erlotinib hydrochloride, paclitaxel_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcaduet_hypertension, dyslipidemia", "label": "completedcaduet_hypertension, dyslipidemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC(=N\\C1=C/C1=C(C)C=C(C)N1)C1=CC2=CC=CC=C2N1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "label": "COC1=CC(=N\\C1=C/C1=C(C)C=C(C)N1)C1=CC2=CC=CC=C2N1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtrastuzumab [herceptin]_breast cancer", "label": "terminatedtrastuzumab [herceptin]_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ophthalmic oily suspension (bay73-4506)", "label": " ophthalmic oily suspension (bay73-4506)", "shape": "dot", "size": 10}, {"color": "red", "id": "nnc0142-0002", "label": "nnc0142-0002", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfp mdpi, flovent diskus, albuterol/salbutamol_asthma", "label": "completedfp mdpi, flovent diskus, albuterol/salbutamol_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " gemcitabine (1000 mg/m2)", "label": " gemcitabine (1000 mg/m2)", "shape": "dot", "size": 10}, {"color": "red", "id": " metformin 500 mg (ttd)", "label": " metformin 500 mg (ttd)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "label": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtopotecan, lapatinib_cancer, ovarian, relapse, chemotherapy", "label": "terminatedtopotecan, lapatinib_cancer, ovarian, relapse, chemotherapy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "non squamous", "label": "non squamous", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsatraplatin, prednisone_prostate cancer, hormone refractory prostate cancer", "label": "completedsatraplatin, prednisone_prostate cancer, hormone refractory prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO, CSCC[C@H](N)C(O)=O", "label": "[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO, CSCC[C@H](N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "secukinumab 150mg, secukinumab 10mg/kg i.v. regimen", "label": "secukinumab 150mg, secukinumab 10mg/kg i.v. regimen", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNC1=NC=C(C=C1C)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1C)C(O)=O, [H][C@]12CC[C@]([H])(C[C@]([H])(C1)SCC(=O)O[C@]1([H])C[C@@](C)(C=C)[C@@]([H])(O)[C@]([H])(C)[C@]34CCC(=O)[C@@]3([H])[C@@]1(C)[C@]([H])(C)CC4)N2C, CNC1=NC=C(C=C1C)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1C)C(O)=O", "label": "CNC1=NC=C(C=C1C)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1C)C(O)=O, [H][C@]12CC[C@]([H])(C[C@]([H])(C1)SCC(=O)O[C@]1([H])C[C@@](C)(C=C)[C@@]([H])(O)[C@]([H])(C)[C@]34CCC(=O)[C@@]3([H])[C@@]1(C)[C@]([H])(C)CC4)N2C, CNC1=NC=C(C=C1C)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1C)C(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": " nicotine dependence", "label": " nicotine dependence", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "zotepine, risperidone", "label": "zotepine, risperidone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "migraine, migraine disorders, headache", "label": "migraine, migraine disorders, headache", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlbh589_renal cell carcinoma", "label": "completedlbh589_renal cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " symbicort pmdi", "label": " symbicort pmdi", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "green", "id": "skin infections", "label": "skin infections", "shape": "dot", "size": 10}, {"color": "red", "id": " dolutegravir placebo", "label": " dolutegravir placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "psi-7977", "label": "psi-7977", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedribavirin, hydroxychloroquine_hepatitis c", "label": "terminatedribavirin, hydroxychloroquine_hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "depression, relapsing-remitting multiple sclerosis", "label": "depression, relapsing-remitting multiple sclerosis", "shape": "dot", "size": 10}, {"color": "red", "id": " lopinavir/r", "label": " lopinavir/r", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo (for tiotropium)", "label": " placebo (for tiotropium)", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent head and neck carcinoma", "label": " recurrent head and neck carcinoma", "shape": "dot", "size": 10}, {"color": "blue", "id": " C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C", "label": " C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C", "shape": "dot", "size": 10}, {"color": "green", "id": "neoplasms malignant", "label": "neoplasms malignant", "shape": "dot", "size": 10}, {"color": "green", "id": " schizophreniform", "label": " schizophreniform", "shape": "dot", "size": 10}, {"color": "red", "id": "oligog cf-5/20", "label": "oligog cf-5/20", "shape": "dot", "size": 10}, {"color": "red", "id": " org 34517", "label": " org 34517", "shape": "dot", "size": 10}, {"color": "blue", "id": " O=C(\\C=C\\C=C\\C1=CC2=C(OCO2)C=C1)N1CCCCC1", "label": " O=C(\\C=C\\C=C\\C1=CC2=C(OCO2)C=C1)N1CCCCC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "biliary tract cancer, biliary tract neoplasms", "label": "biliary tract cancer, biliary tract neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedliraglutide, placebo_hyperglycemia, chronic heart failure", "label": "completedliraglutide, placebo_hyperglycemia, chronic heart failure", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Gd+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)C(COCC1=CC=CC=C1)C(O)=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, FC1=CNC(=O)NC1=O, CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "label": "[Gd+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)C(COCC1=CC=CC=C1)C(O)=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, FC1=CNC(=O)NC1=O, CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "shape": "dot", "size": 10}, {"color": "red", "id": "iloperidone", "label": "iloperidone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmifepristone oral tablet [korlym], placebo oral tablet_stress disorders, post-traumatic", "label": "completedmifepristone oral tablet [korlym], placebo oral tablet_stress disorders, post-traumatic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcarduus marianus 6ch, carduus marianus 12ch, carduus marianus 30ch, placebo_dyslipidemia, menopause, obesity", "label": "terminatedcarduus marianus 6ch, carduus marianus 12ch, carduus marianus 30ch, placebo_dyslipidemia, menopause, obesity", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rosiglitazone, theophylline, beclomethasone, inhaled beclomethasone and oral theophylline", "label": "rosiglitazone, theophylline, beclomethasone, inhaled beclomethasone and oral theophylline", "shape": "dot", "size": 10}, {"color": "red", "id": " bupivacaine liposome injectable suspension", "label": " bupivacaine liposome injectable suspension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "baclofen 30mg/day, baclofen 75mg/day, placebo", "label": "baclofen 30mg/day, baclofen 75mg/day, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C2=CC=CC=C2)C2=CC=CC=C2)=N1, NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl, COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C2=CC=CC=C2)C2=CC=CC=C2)=N1", "label": "COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C2=CC=CC=C2)C2=CC=CC=C2)=N1, NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl, COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C2=CC=CC=C2)C2=CC=CC=C2)=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "major depressive disorder, mdd, depression", "label": "major depressive disorder, mdd, depression", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pembrolizumab + epacadostat, pembrolizumab + placebo", "label": "pembrolizumab + epacadostat, pembrolizumab + placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CCCC(CCC)C(O)=O", "label": "OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CCCC(CCC)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H]\\C(=C(\\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO, ClCCN(CCCl)P1(=O)NCCCO1", "label": "[H]\\C(=C(\\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO, ClCCN(CCCl)P1(=O)NCCCO1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpasireotide, everolimus_castrate resistant prostate cancer, chemotherapy naive prostate cancer, prostate cancer", "label": "terminatedpasireotide, everolimus_castrate resistant prostate cancer, chemotherapy naive prostate cancer, prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "pregabalin (lyrica)", "label": "pregabalin (lyrica)", "shape": "dot", "size": 10}, {"color": "red", "id": "immu-107", "label": "immu-107", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingnivolumab, doxorubicin, vinblastine, dacarbazine_hodgkin disease", "label": "active, not recruitingnivolumab, doxorubicin, vinblastine, dacarbazine_hodgkin disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "pomalidomide (cc-4047)", "label": "pomalidomide (cc-4047)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recurrent adult acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, ph1 positive cml", "label": "recurrent adult acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, ph1 positive cml", "shape": "dot", "size": 10}, {"color": "red", "id": "ibudilast", "label": "ibudilast", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, cp-690,550, cp-690,550_crohn\u0027s disease", "label": "completedplacebo, cp-690,550, cp-690,550_crohn\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CSCC[C@H](N)C(O)=O, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O, CSCC[C@H](N)C(O)=O, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N", "label": "CSCC[C@H](N)C(O)=O, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O, CSCC[C@H](N)C(O)=O, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N", "shape": "dot", "size": 10}, {"color": "green", "id": " metastatic digestive system neuroendocrine tumor g1", "label": " metastatic digestive system neuroendocrine tumor g1", "shape": "dot", "size": 10}, {"color": "red", "id": " corticosteroid: dexamethasone", "label": " corticosteroid: dexamethasone", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo of lcz696", "label": " placebo of lcz696", "shape": "dot", "size": 10}, {"color": "red", "id": " nucleoside reverse transcriptase inhibitors", "label": " nucleoside reverse transcriptase inhibitors", "shape": "dot", "size": 10}, {"color": "green", "id": " persistent atrial fibrillation", "label": " persistent atrial fibrillation", "shape": "dot", "size": 10}, {"color": "red", "id": " cotrimoxazole placebo", "label": " cotrimoxazole placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "depot leuprolide plus estrogen/progestin replacement", "label": "depot leuprolide plus estrogen/progestin replacement", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Li+], CC1=CC(O)=CC(C)=C1Cl", "label": "[Li+], CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ipragliflozin, placebo, pioglitazone", "label": "ipragliflozin, placebo, pioglitazone", "shape": "dot", "size": 10}, {"color": "red", "id": "atazanavir/ritonavir +2 nrtis (immediate switch group)", "label": "atazanavir/ritonavir +2 nrtis (immediate switch group)", "shape": "dot", "size": 10}, {"color": "red", "id": " mesalamine 1200 mg", "label": " mesalamine 1200 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, N[C@@H](CCCNC(N)=N)C(O)=O, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, S=C1N=CNC2=C1NC=N2, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, N[C@@H](CC1=CN=CN1)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "label": "N[C@@H](CC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, N[C@@H](CCCNC(N)=N)C(O)=O, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, S=C1N=CNC2=C1NC=N2, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, N[C@@H](CC1=CN=CN1)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminated33a, placebo, azacitidine, decitabine_acute myeloid leukemia", "label": "terminated33a, placebo, azacitidine, decitabine_acute myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "risedronate sodium", "label": "risedronate sodium", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnbendamustine, rituximab_chronic lymphocytic leukemia", "label": "withdrawnbendamustine, rituximab_chronic lymphocytic leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lenalidomide, dacarbazine", "label": "lenalidomide, dacarbazine", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent adult brain neoplasm", "label": " recurrent adult brain neoplasm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedad-4833 15 mg, ad-4833 30 mg, placebo_diabetes mellitus", "label": "completedad-4833 15 mg, ad-4833 30 mg, placebo_diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddocetaxel, cisplatin, 5-fluorouracil_nasopharyngeal neoplasms, carcinoma", "label": "completeddocetaxel, cisplatin, 5-fluorouracil_nasopharyngeal neoplasms, carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvorinostat_breast cancer, stage i breast cancer, stage ii breast cancer, stage iii breast cancer", "label": "completedvorinostat_breast cancer, stage i breast cancer, stage ii breast cancer, stage iii breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, acurox 5/30 mg, acurox 7.5/30", "label": "placebo, acurox 5/30 mg, acurox 7.5/30", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgsk573719, tiotropium_pulmonary disease, chronic obstructive", "label": "completedgsk573719, tiotropium_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oliceridine, placebo, morphine", "label": "oliceridine, placebo, morphine", "shape": "dot", "size": 10}, {"color": "red", "id": "arzoxifene", "label": "arzoxifene", "shape": "dot", "size": 10}, {"color": "green", "id": "stage i chronic lymphocytic leukemia", "label": "stage i chronic lymphocytic leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddalotuzumab, erlotinib_carcinoma, non-small-cell lung", "label": "completeddalotuzumab, erlotinib_carcinoma, non-small-cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "folfiri regimen, capecitabine, celecoxib, fluorouracil, irinotecan hydrochloride, leucovorin calcium", "label": "folfiri regimen, capecitabine, celecoxib, fluorouracil, irinotecan hydrochloride, leucovorin calcium", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgroup a: carfilzomib \u0026 non-imid regimen, group b: carfilzomib \u0026 imid containing regimen._multiple myeloma", "label": "completedgroup a: carfilzomib \u0026 non-imid regimen, group b: carfilzomib \u0026 imid containing regimen._multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1", "label": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carcinoma, renal cell, non clear cell renal carcinoma, papillary cell renal carcinoma, adenocarcinoma", "label": "carcinoma, renal cell, non clear cell renal carcinoma, papillary cell renal carcinoma, adenocarcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrm-493, placebo_prader-willi syndrome", "label": "completedrm-493, placebo_prader-willi syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=C(C[C@@H](O)C2=CC(OC)=C(OC)C(OC)=C2)C=C1O", "label": "ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=C(C[C@@H](O)C2=CC(OC)=C(OC)C(OC)=C2)C=C1O", "shape": "dot", "size": 10}, {"color": "red", "id": "dexlansoprazole mr", "label": "dexlansoprazole mr", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedamuvatinib_small cell lung carcinoma", "label": "completedamuvatinib_small cell lung carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O", "label": "CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1", "label": " CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "furosemide injection solution for subcutaneous administration (80 mg)", "label": "furosemide injection solution for subcutaneous administration (80 mg)", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=CC=C(C=C1)N1N=C(C=C1NC(=O)NC1=CC=C(OCCN2CCOCC2)C2=C1C=CC=C2)C(C)(C)C", "label": "CC1=CC=C(C=C1)N1N=C(C=C1NC(=O)NC1=CC=C(OCCN2CCOCC2)C2=C1C=CC=C2)C(C)(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuscyclophosphamide, epirubicin hydrochloride, gemcitabine hydrochloride, paclitaxel_breast cancer", "label": "unknown statuscyclophosphamide, epirubicin hydrochloride, gemcitabine hydrochloride, paclitaxel_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "lfg316", "label": "lfg316", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent small cell lung cancer", "label": " recurrent small cell lung cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " chlorthalidone", "label": " chlorthalidone", "shape": "dot", "size": 10}, {"color": "red", "id": "cannabidiol oral solution", "label": "cannabidiol oral solution", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "telmisartan and amlodipine, telmisartan", "label": "telmisartan and amlodipine, telmisartan", "shape": "dot", "size": 10}, {"color": "blue", "id": "COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1", "label": "COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " small intestine lymphoma", "label": " small intestine lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "abrupt clopidogrel interruption, clopidogrel tapering", "label": "abrupt clopidogrel interruption, clopidogrel tapering", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusranibizumab_macular degeneration", "label": "unknown statusranibizumab_macular degeneration", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lung cancer, non-small cell, non-small-cell lung cancer", "label": "lung cancer, non-small cell, non-small-cell lung cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "indacaterol, salmeterol", "label": "indacaterol, salmeterol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "crx-102 (2.7/90), prednisolone, placebo, crx-102 (2.7/180), crx-102 (2.7/360)", "label": "crx-102 (2.7/90), prednisolone, placebo, crx-102 (2.7/180), crx-102 (2.7/360)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "postmenopausal women, locally advanced metastatic breast cancer, metastatic breast cancer", "label": "postmenopausal women, locally advanced metastatic breast cancer, metastatic breast cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "telbivudine", "label": "telbivudine", "shape": "dot", "size": 10}, {"color": "green", "id": " chronic kidney disease.", "label": " chronic kidney disease.", "shape": "dot", "size": 10}, {"color": "red", "id": "birinapant (tl32711)", "label": "birinapant (tl32711)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpegylated liposomal doxorubicin, docetaxel, trastuzumab_breast neoplasm", "label": "completedpegylated liposomal doxorubicin, docetaxel, trastuzumab_breast neoplasm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "topotecan, cyclophosphamide, melphalan", "label": "topotecan, cyclophosphamide, melphalan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCO, COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1", "label": "CCO, COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "glycopyrronium mdi 28.8 micrograms", "label": "glycopyrronium mdi 28.8 micrograms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "decitabine, temozolomide", "label": "decitabine, temozolomide", "shape": "dot", "size": 10}, {"color": "blue", "id": "CNC(C)CC1=CC2=C(OCO2)C=C1", "label": "CNC(C)CC1=CC2=C(OCO2)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " cetuximab and folfox", "label": " cetuximab and folfox", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H]\\C(=C(\\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H]\\C(=C(\\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "blue", "id": "[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1", "label": "[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@@H](O[C@H]1CC[C@@H]2CN(C[C@H]2[C@@H]1C1=CC=C(F)C=C1)C1=CC(=O)CC1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "C[C@@H](O[C@H]1CC[C@@H]2CN(C[C@H]2[C@@H]1C1=CC=C(F)C=C1)C1=CC(=O)CC1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmetformin er_colorectal carcinoma", "label": "terminatedmetformin er_colorectal carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcyclophosphamide, doxorubicin hydrochloride, lenalidomide, prednisone, vincristine sulfate_lymphoma", "label": "active, not recruitingcyclophosphamide, doxorubicin hydrochloride, lenalidomide, prednisone, vincristine sulfate_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "cyclosporine vs infliximab", "label": "cyclosporine vs infliximab", "shape": "dot", "size": 10}, {"color": "red", "id": " divalproex sodium er", "label": " divalproex sodium er", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplerixafor_related donors donating pbsc to a family member, acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, non-hodgkin\u0027s lymphoma, hodgkin\u0027s disease, chronic lymphocytic leukemia", "label": "completedplerixafor_related donors donating pbsc to a family member, acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, non-hodgkin\u0027s lymphoma, hodgkin\u0027s disease, chronic lymphocytic leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@@]3([H])[C@@](C)([C@@H](O)C[C@@]4([H])OC[C@@]34OC(=O)C)C(=O)[C@H](OC(=O)C)C(=C1C)C2(C)C)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1", "label": "CC\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/C\\C=C/CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@@]3([H])[C@@](C)([C@@H](O)C[C@@]4([H])OC[C@@]34OC(=O)C)C(=O)[C@H](OC(=O)C)C(=C1C)C2(C)C)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " noncontiguous stage ii adult diffuse mixed cell lymphoma", "label": " noncontiguous stage ii adult diffuse mixed cell lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": " induction paclitaxel", "label": " induction paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "botox, saline", "label": "botox, saline", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bicifadine, bicifadine, bicifadine", "label": "bicifadine, bicifadine, bicifadine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcetuximab, cisplatin, capecitabine_gastric cancer", "label": "completedcetuximab, cisplatin, capecitabine_gastric cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " complex regional pain syndromes (crps)", "label": " complex regional pain syndromes (crps)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, oros-methylphenidate_attention deficit hyperactivity disorder", "label": "completedplacebo, oros-methylphenidate_attention deficit hyperactivity disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlapatinib, metformin_metastatic breast cancer", "label": "terminatedlapatinib, metformin_metastatic breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatednivolumab_solid tumors induced by prior radiation exposure", "label": "terminatednivolumab_solid tumors induced by prior radiation exposure", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1", "label": "CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawntemsirolimus (torisel)_brain neoplasms", "label": "withdrawntemsirolimus (torisel)_brain neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "chemotherapy (capecitabine", "label": "chemotherapy (capecitabine", "shape": "dot", "size": 10}, {"color": "red", "id": "insulin peglispro", "label": "insulin peglispro", "shape": "dot", "size": 10}, {"color": "red", "id": " bayg5421)", "label": " bayg5421)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtemozolomide, sorafenib_glioblastoma multiforme", "label": "completedtemozolomide, sorafenib_glioblastoma multiforme", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "intranasal ketamine", "label": "intranasal ketamine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1", "label": "COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgw870086x, placebo_asthma", "label": "completedgw870086x, placebo_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "bezafibrate + diflunisal", "label": "bezafibrate + diflunisal", "shape": "dot", "size": 10}, {"color": "red", "id": "perindopril + amlodipine + if necessary", "label": "perindopril + amlodipine + if necessary", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnepoetin alfa_hiv infections, neuropathy", "label": "withdrawnepoetin alfa_hiv infections, neuropathy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(C1)N=C(N=C2C(F)(F)F)C(F)(F)F, N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(C1)N=C(N=C2C(F)(F)F)C(F)(F)F, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F", "label": "N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(C1)N=C(N=C2C(F)(F)F)C(F)(F)F, N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(C1)N=C(N=C2C(F)(F)F)C(F)(F)F, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F", "shape": "dot", "size": 10}, {"color": "red", "id": " gsk1838262 300 mg", "label": " gsk1838262 300 mg", "shape": "dot", "size": 10}, {"color": "green", "id": " interventional", "label": " interventional", "shape": "dot", "size": 10}, {"color": "red", "id": " amg 386 3mg/kg", "label": " amg 386 3mg/kg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalogliptin and pioglitazone, alogliptin and pioglitazone, pioglitazone_type 2 diabetes mellitus", "label": "completedalogliptin and pioglitazone, alogliptin and pioglitazone, pioglitazone_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " combivent respimat 20/100 mcg", "label": " combivent respimat 20/100 mcg", "shape": "dot", "size": 10}, {"color": "red", "id": " exentide", "label": " exentide", "shape": "dot", "size": 10}, {"color": "green", "id": "sunburn", "label": "sunburn", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iii nasopharyngeal carcinoma", "label": " stage iii nasopharyngeal carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedirbesartan, placebo_atrial fibrillation, cardiovascular disease", "label": "completedirbesartan, placebo_atrial fibrillation, cardiovascular disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo plus dexamethasone hfa", "label": " placebo plus dexamethasone hfa", "shape": "dot", "size": 10}, {"color": "red", "id": "gsk962040 (25 mg tablet)", "label": "gsk962040 (25 mg tablet)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iiib breast cancer", "label": " stage iiib breast cancer", "shape": "dot", "size": 10}, {"color": "green", "id": " non-small-cell lung cancer stage iv", "label": " non-small-cell lung cancer stage iv", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "certolizumab pegol, certolizumab pegol", "label": "certolizumab pegol, certolizumab pegol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtopiramate (drug)_parkinson\u0027s disease", "label": "terminatedtopiramate (drug)_parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpaclitaxel, carboplatin_gynecologic malignancies", "label": "terminatedpaclitaxel, carboplatin_gynecologic malignancies", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " angiotensin ii type 1 receptor blocker", "label": " angiotensin ii type 1 receptor blocker", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completederlotinib_non-small cell lung cancer", "label": "completederlotinib_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "t138067 intravenous", "label": "t138067 intravenous", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1", "shape": "dot", "size": 10}, {"color": "red", "id": "desogestrel/ethinyl estradiol and ethinyl estradiol", "label": "desogestrel/ethinyl estradiol and ethinyl estradiol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O", "label": "ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawneverolimus_breast cancer", "label": "withdrawneverolimus_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedarq197_cancer", "label": "completedarq197_cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " telcagepant potassium 300 mg", "label": " telcagepant potassium 300 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " nucs", "label": " nucs", "shape": "dot", "size": 10}, {"color": "red", "id": " ibandronat", "label": " ibandronat", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ertugliflozin 5 mg, ertugliflozin 10 mg, placebo to ertugliflozin, metformin, placebo to metformin, glimepiride", "label": "ertugliflozin 5 mg, ertugliflozin 10 mg, placebo to ertugliflozin, metformin, placebo to metformin, glimepiride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazd2014 3 on/4 off \u0026 weekly paclitaxel, azd2014 2 on/5 off \u0026 weekly paclitaxel_advanced cancer", "label": "completedazd2014 3 on/4 off \u0026 weekly paclitaxel, azd2014 2 on/5 off \u0026 weekly paclitaxel_advanced cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ozanimod, ozanimod placebo, interferon beta-1a, interferon beta-1a placebo", "label": "ozanimod, ozanimod placebo, interferon beta-1a, interferon beta-1a placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "circadin 2/5/10 mg", "label": "circadin 2/5/10 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " benserazide", "label": " benserazide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtobramycin inhalation powder, tobramycin solution for inhalation_cystic fibrosis", "label": "completedtobramycin inhalation powder, tobramycin solution for inhalation_cystic fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvx-659/tez/iva, tez/iva, iva, placebo, placebo_cystic fibrosis", "label": "completedvx-659/tez/iva, tez/iva, iva, placebo, placebo_cystic fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfluorouracil (5fu), leucovorin, bevacizumab [avastin], capecitabine [xeloda], oxaliplatin_colorectal cancer", "label": "completedfluorouracil (5fu), leucovorin, bevacizumab [avastin], capecitabine [xeloda], oxaliplatin_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedefalizumab, placebo_psoriasis", "label": "completedefalizumab, placebo_psoriasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oral azacitidine, oral azacitidine", "label": "oral azacitidine, oral azacitidine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C, [H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "label": "[H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C, [H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acetylsalicylic acid at 1st visit, then placebo at 2nd visit, placebo at 1st visit, then acetylsalicylic acid at 2nd visit", "label": "acetylsalicylic acid at 1st visit, then placebo at 2nd visit, placebo at 1st visit, then acetylsalicylic acid at 2nd visit", "shape": "dot", "size": 10}, {"color": "blue", "id": "C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1", "label": "C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C1=C(C#N)C(=NC(SCC2=CSC(=N2)C2=CC=C(Cl)C=C2)=C1C#N)N1CCCC1", "shape": "dot", "size": 10}, {"color": "green", "id": " dyslipidemia", "label": " dyslipidemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1", "label": "OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddesvenlafaxine succinate sustained-release, placebo_major depressive disorder", "label": "completeddesvenlafaxine succinate sustained-release, placebo_major depressive disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "555)", "label": "555)", "shape": "dot", "size": 10}, {"color": "green", "id": " chronic obstructive pulmonary disease (copd)", "label": " chronic obstructive pulmonary disease (copd)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rituximab, gemcitabine", "label": "rituximab, gemcitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, azelastine hcl, azelastinehcl / fluticasone propionate, fluticasone propionate_seasonal allergic rhinitis", "label": "completedplacebo, azelastine hcl, azelastinehcl / fluticasone propionate, fluticasone propionate_seasonal allergic rhinitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "label": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iv ovarian cancer ajcc v6 and v7", "label": " stage iv ovarian cancer ajcc v6 and v7", "shape": "dot", "size": 10}, {"color": "red", "id": "dl-alpha-tocopherol", "label": "dl-alpha-tocopherol", "shape": "dot", "size": 10}, {"color": "red", "id": "oxycodone naloxone", "label": "oxycodone naloxone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlenalidomide, paclitaxel_prostate cancer", "label": "terminatedlenalidomide, paclitaxel_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " secondary hyperparathyroidism", "label": " secondary hyperparathyroidism", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedenzalutamide_metastatic castration-resistant prostate cancer", "label": "completedenzalutamide_metastatic castration-resistant prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedamg 386 placebo, amg 386 10mg/kg, amg 386 3mg/kg, cisplatin, capecitabine, cisplatin, capecitabine, cisplatin, capecitabine_gastrointestinal cancer", "label": "completedamg 386 placebo, amg 386 10mg/kg, amg 386 3mg/kg, cisplatin, capecitabine, cisplatin, capecitabine, cisplatin, capecitabine_gastrointestinal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsorafenib tosylate, vorinostat_liver cancer", "label": "completedsorafenib tosylate, vorinostat_liver cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pemetrexed, placebo", "label": "pemetrexed, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " paclitaxel", "label": " paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recruitingibrutinib_t-cell lymphoma, relapsed and refractory t-cell lymphoma", "label": "recruitingibrutinib_t-cell lymphoma, relapsed and refractory t-cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedatorvastatin_diabetes mellitus, type 2, hydroxymethylglutaryl-coa reductase inhibitors", "label": "completedatorvastatin_diabetes mellitus, type 2, hydroxymethylglutaryl-coa reductase inhibitors", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " mycophenolate mofetil (mmf/mpa)", "label": " mycophenolate mofetil (mmf/mpa)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednedaplatin, cisplatin, docetaxel_squamous cell carcinoma", "label": "completednedaplatin, cisplatin, docetaxel_squamous cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, gemcitabine, pertuzumab_ovarian cancer, peritoneal cancer, fallopian tube cancer", "label": "completedplacebo, gemcitabine, pertuzumab_ovarian cancer, peritoneal cancer, fallopian tube cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "adl5859", "label": "adl5859", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, active comparator, low dose pf-03635659, mid dose pf-03635659, high dose pf-03635659_pulmonary disease, chronic obstructive, lung diseases, respiratory tract diseases, chronic obstructive airway disease, copd", "label": "completedplacebo, active comparator, low dose pf-03635659, mid dose pf-03635659, high dose pf-03635659_pulmonary disease, chronic obstructive, lung diseases, respiratory tract diseases, chronic obstructive airway disease, copd", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatednew formulation phenylephrine hcl, marketed phenylephrine hcl, placebo_common cold", "label": "terminatednew formulation phenylephrine hcl, marketed phenylephrine hcl, placebo_common cold", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma", "label": "glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedparacetamol, placebo_osteoarthritis, knee", "label": "completedparacetamol, placebo_osteoarthritis, knee", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C", "label": " [H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "epirubicin, cyclophosphamide, docetaxel, trastuzumab", "label": "epirubicin, cyclophosphamide, docetaxel, trastuzumab", "shape": "dot", "size": 10}, {"color": "green", "id": " metastatic childhood soft tissue sarcoma", "label": " metastatic childhood soft tissue sarcoma", "shape": "dot", "size": 10}, {"color": "red", "id": "azacytidine", "label": "azacytidine", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2", "label": "CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, ro4917838, antipshychotics (standard of care)_schizophrenia", "label": "completedplacebo, ro4917838, antipshychotics (standard of care)_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedamlodipine, lisinopril_type 1 diabetes, diabetic retinopathy, eye diseases, diabetes complications", "label": "completedamlodipine, lisinopril_type 1 diabetes, diabetic retinopathy, eye diseases, diabetes complications", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedabt-888, temozolomide_prostate cancer", "label": "completedabt-888, temozolomide_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "ClCCNC(=O)N(CCCl)N=O", "label": "ClCCNC(=O)N(CCCl)N=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfazaclo_schizophrenia, schizoaffective disorder", "label": "completedfazaclo_schizophrenia, schizoaffective disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " acute myeloid leukemia", "label": " acute myeloid leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddaptomycin, standard of care (soc)_skin diseases, infectious", "label": "completeddaptomycin, standard of care (soc)_skin diseases, infectious", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recruitingcyclophosphamide and jx-594 dose escalation, cyclophosphamide and jx-594, cyclophosphamide, avelumab and jx-594 and cyclophosphamide_solid tumors, soft-tissue sarcoma, breast cancer", "label": "recruitingcyclophosphamide and jx-594 dose escalation, cyclophosphamide and jx-594, cyclophosphamide, avelumab and jx-594 and cyclophosphamide_solid tumors, soft-tissue sarcoma, breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " bi 207127: 16-week treatment", "label": " bi 207127: 16-week treatment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsofosbuvir, ledipasvir_hepatitis c", "label": "completedsofosbuvir, ledipasvir_hepatitis c", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " parkinson\u0027s disease", "label": " parkinson\u0027s disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(=O)C(CC(=C)C(O)=O)NC(=O)C1=CC=C(CCC2=CC3=C(NC(=N)NC3=N)C=C2)C=C1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "label": "OC(=O)C(CC(=C)C(O)=O)NC(=O)C1=CC=C(CCC2=CC3=C(NC(=N)NC3=N)C=C2)C=C1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedferric carboxymaltose_iron-deficiency anemia", "label": "terminatedferric carboxymaltose_iron-deficiency anemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "liposarcoma, myxoid, sarcoma, soft tissue, leiomyosarcoma, liposarcoma, pleomorphic liposarcoma", "label": "liposarcoma, myxoid, sarcoma, soft tissue, leiomyosarcoma, liposarcoma, pleomorphic liposarcoma", "shape": "dot", "size": 10}, {"color": "red", "id": " other intravenous chemotherapy drugs", "label": " other intravenous chemotherapy drugs", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "testosterone gel (androgel), placebo", "label": "testosterone gel (androgel), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawntriptan, doxycycline_migraine disorders, headache, migraine, migraine, migraine headache, migraine with aura, migraine without aura, headache disorders, primary", "label": "withdrawntriptan, doxycycline_migraine disorders, headache, migraine, migraine, migraine headache, migraine with aura, migraine without aura, headache disorders, primary", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpaclitaxel and carboplatin regimen_non-small cell lung cancer", "label": "terminatedpaclitaxel and carboplatin regimen_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lenalidomide, melphalan, plerixafor", "label": "lenalidomide, melphalan, plerixafor", "shape": "dot", "size": 10}, {"color": "green", "id": " myelodysplastic syndromes (mds)", "label": " myelodysplastic syndromes (mds)", "shape": "dot", "size": 10}, {"color": "green", "id": " papillary thyroid cancer", "label": " papillary thyroid cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmp-214 low dose, mp-214 middle dose, mp-214 high dose_schizophrenia", "label": "completedmp-214 low dose, mp-214 middle dose, mp-214 high dose_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsildenafil, placebo_hypertension, pulmonary, diseases of mitral valve", "label": "terminatedsildenafil, placebo_hypertension, pulmonary, diseases of mitral valve", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " small lymphocytic leukemia", "label": " small lymphocytic leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C, CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C", "label": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C, CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo + 30 mg apremilast", "label": " placebo + 30 mg apremilast", "shape": "dot", "size": 10}, {"color": "red", "id": " carboplatin (standard of care)", "label": " carboplatin (standard of care)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "label": "CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adenocarcinoma, metastasis, pancreas neoplasms", "label": "adenocarcinoma, metastasis, pancreas neoplasms", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcyclophosphamide, lenalidomide, dexamethasone, melphalan_multiple myeloma", "label": "active, not recruitingcyclophosphamide, lenalidomide, dexamethasone, melphalan_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedquetiapine fumarate (seroquel)_schizophrenia", "label": "completedquetiapine fumarate (seroquel)_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "dp001 softgel capsules", "label": "dp001 softgel capsules", "shape": "dot", "size": 10}, {"color": "green", "id": " stage ivc inverted papilloma of the paranasal sinus and nasal cavity", "label": " stage ivc inverted papilloma of the paranasal sinus and nasal cavity", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "heavy uterine bleeding, uterine fibroids", "label": "heavy uterine bleeding, uterine fibroids", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtradipitant, placebo_atopic dermatitis, eczema, chronic pruritus", "label": "completedtradipitant, placebo_atopic dermatitis, eczema, chronic pruritus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpregabalin dose level 1, pregabalin dose level 2, placebo_generalized tonic clonic seizures", "label": "completedpregabalin dose level 1, pregabalin dose level 2, placebo_generalized tonic clonic seizures", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "detrusor muscle hyperactivity", "label": "detrusor muscle hyperactivity", "shape": "dot", "size": 10}, {"color": "red", "id": "placebo (for ramucirumab)", "label": "placebo (for ramucirumab)", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCC[C@@H](C)C[C@H](N)CC(O)=O", "label": "CCC[C@@H](C)C[C@H](N)CC(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": " splenomegaly", "label": " splenomegaly", "shape": "dot", "size": 10}, {"color": "red", "id": "docetaxel (taxotere)", "label": "docetaxel (taxotere)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C2=C1C=CC=C2, CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2", "label": "CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C2=C1C=CC=C2, CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedhll1-dox (the doxorubicin conjugate of milatuzumab)_multiple myeloma", "label": "terminatedhll1-dox (the doxorubicin conjugate of milatuzumab)_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, [H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, [H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsildenafil 100 mg, placebo_female sexual arousal disorder", "label": "completedsildenafil 100 mg, placebo_female sexual arousal disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "icotinib, gefitinib", "label": "icotinib, gefitinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedradotinib_leukemia, leukemia, myeloid, leukemia, myelogenous, chronic, bcr-abl positive, philadelphia chromosome, hematologic diseases", "label": "completedradotinib_leukemia, leukemia, myeloid, leukemia, myelogenous, chronic, bcr-abl positive, philadelphia chromosome, hematologic diseases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "clopidogrel + aspirin", "label": "clopidogrel + aspirin", "shape": "dot", "size": 10}, {"color": "red", "id": " paclitaxel 175mg/m\u00b2 q21d", "label": " paclitaxel 175mg/m\u00b2 q21d", "shape": "dot", "size": 10}, {"color": "green", "id": "adenocarcinoma of the colon", "label": "adenocarcinoma of the colon", "shape": "dot", "size": 10}, {"color": "green", "id": "gram-positive", "label": "gram-positive", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcapecitabine, vorinostat_paranasal sinus squamous cell carcinoma, recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent oral cavity squamous cell carcinoma, recurrent oropharyngeal squamous cell carcinoma, stage iva hypopharyngeal squamous cell carcinoma, stage iva laryngeal squamous cell carcinoma, stage iva oral cavity squamous cell carcinoma, stage iva oropharyngeal squamous cell carcinoma, stage ivb hypopharyngeal squamous cell carcinoma, stage ivb laryngeal squamous cell carcinoma, stage ivb oral cavity squamous cell carcinoma, stage ivb oropharyngeal squamous cell carcinoma, stage ivc hypopharyngeal squamous cell carcinoma, stage ivc laryngeal squamous cell carcinoma, stage ivc oral cavity squamous cell carcinoma, stage ivc oropharyngeal squamous cell carcinoma", "label": "terminatedcapecitabine, vorinostat_paranasal sinus squamous cell carcinoma, recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent oral cavity squamous cell carcinoma, recurrent oropharyngeal squamous cell carcinoma, stage iva hypopharyngeal squamous cell carcinoma, stage iva laryngeal squamous cell carcinoma, stage iva oral cavity squamous cell carcinoma, stage iva oropharyngeal squamous cell carcinoma, stage ivb hypopharyngeal squamous cell carcinoma, stage ivb laryngeal squamous cell carcinoma, stage ivb oral cavity squamous cell carcinoma, stage ivb oropharyngeal squamous cell carcinoma, stage ivc hypopharyngeal squamous cell carcinoma, stage ivc laryngeal squamous cell carcinoma, stage ivc oral cavity squamous cell carcinoma, stage ivc oropharyngeal squamous cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "elvitegravir", "label": "elvitegravir", "shape": "dot", "size": 10}, {"color": "green", "id": " branch retinal vein occlusion", "label": " branch retinal vein occlusion", "shape": "dot", "size": 10}, {"color": "red", "id": "empagliflozin medium placebo", "label": "empagliflozin medium placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " hydrocodone/apap", "label": " hydrocodone/apap", "shape": "dot", "size": 10}, {"color": "red", "id": " 5 mg/ml", "label": " 5 mg/ml", "shape": "dot", "size": 10}, {"color": "red", "id": " alpha1 blocker", "label": " alpha1 blocker", "shape": "dot", "size": 10}, {"color": "red", "id": " topical treatments or phototherapy", "label": " topical treatments or phototherapy", "shape": "dot", "size": 10}, {"color": "green", "id": "her2+ metastatic breast cancer (mbc)", "label": "her2+ metastatic breast cancer (mbc)", "shape": "dot", "size": 10}, {"color": "red", "id": "nktr-181", "label": "nktr-181", "shape": "dot", "size": 10}, {"color": "red", "id": " temodar\u00ae (temozolomide)", "label": " temodar\u00ae (temozolomide)", "shape": "dot", "size": 10}, {"color": "red", "id": "isradipine", "label": "isradipine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCNC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)CCC1=CC=CC=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCNC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)CCC1=CC=CC=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlevomilnacipran, placebo_tobacco use disorder", "label": "completedlevomilnacipran, placebo_tobacco use disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " universal hec placebo gel formulation", "label": " universal hec placebo gel formulation", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=NC=CN1CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1", "label": "CC1=NC=CN1CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "leuprolide acetate - formulation a", "label": "leuprolide acetate - formulation a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC(=O)NO", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC(=O)NO", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "budesonide mmx\u00ae, placebo, 5-asa", "label": "budesonide mmx\u00ae, placebo, 5-asa", "shape": "dot", "size": 10}, {"color": "red", "id": "viaject\u00ae25", "label": "viaject\u00ae25", "shape": "dot", "size": 10}, {"color": "green", "id": "infections", "label": "infections", "shape": "dot", "size": 10}, {"color": "red", "id": "cetrorelix 78 mg + 78 mg", "label": "cetrorelix 78 mg + 78 mg", "shape": "dot", "size": 10}, {"color": "green", "id": " urinary bladder disorder", "label": " urinary bladder disorder", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgft505 80mg, placebo_impaired glucose tolerance, abdominal obesity", "label": "completedgft505 80mg, placebo_impaired glucose tolerance, abdominal obesity", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "pd-0332991", "label": "pd-0332991", "shape": "dot", "size": 10}, {"color": "red", "id": "ch-4051", "label": "ch-4051", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedquetiapine_mood disorders", "label": "completedquetiapine_mood disorders", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "narcolepsy with cataplexy", "label": "narcolepsy with cataplexy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dasotraline, placebo", "label": "dasotraline, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " peginterferon alpha-2a ", "label": " peginterferon alpha-2a ", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusfolfiri + cetuximab_colorectal cancer metastatic", "label": "unknown statusfolfiri + cetuximab_colorectal cancer metastatic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "tmc125", "label": "tmc125", "shape": "dot", "size": 10}, {"color": "green", "id": " glioblastoma", "label": " glioblastoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fallopian tube cancer, malignant tumor of peritoneum, recurrent ovarian epithelial cancer", "label": "fallopian tube cancer, malignant tumor of peritoneum, recurrent ovarian epithelial cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "safinamide + levodopa", "label": "safinamide + levodopa", "shape": "dot", "size": 10}, {"color": "red", "id": " dalbavancin-matching placebo", "label": " dalbavancin-matching placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedly450139, placebo_alzheimer\u0027s disease", "label": "completedly450139, placebo_alzheimer\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "psoriasis, metabolic syndrome, hyperlipidemia, obesity, hypertension", "label": "psoriasis, metabolic syndrome, hyperlipidemia, obesity, hypertension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingpaclitaxel, trastuzumab_breast cancer, carcinoma of the breast", "label": "active, not recruitingpaclitaxel, trastuzumab_breast cancer, carcinoma of the breast", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "benign prostatic hyperplasia, lower urinary tract symptoms", "label": "benign prostatic hyperplasia, lower urinary tract symptoms", "shape": "dot", "size": 10}, {"color": "green", "id": " flt3 gene mutation", "label": " flt3 gene mutation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "shape": "dot", "size": 10}, {"color": "red", "id": " 0.04% capsaicin patch", "label": " 0.04% capsaicin patch", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "calcium gluconate, magnesium sulfate, oxaliplatin", "label": "calcium gluconate, magnesium sulfate, oxaliplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbcd-063, copaxone-teva, placebo_relapsing-remitting multiple sclerosis", "label": "completedbcd-063, copaxone-teva, placebo_relapsing-remitting multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H]\\C(COC1=NC=CC(CN2CCCCC2)=C1)=C(/[H])CN=C(O)CS(=O)CC1=CC=CO1", "label": "[H]\\C(COC1=NC=CC(CN2CCCCC2)=C1)=C(/[H])CN=C(O)CS(=O)CC1=CC=CO1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedatazanavir + ritonavir_human immunodeficiency virus (hiv) infections", "label": "completedatazanavir + ritonavir_human immunodeficiency virus (hiv) infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsitagliptin, sulfonylurea, metformin_type 2 diabetes mellitus", "label": "completedsitagliptin, sulfonylurea, metformin_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " zpl389", "label": " zpl389", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmbs2320, placebo_rheumatoid arthritis", "label": "completedmbs2320, placebo_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dementia, paratonia", "label": "dementia, paratonia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmethadone hydrochloride_nausea and vomiting, pain, sleep disorders, unspecified adult solid tumor, protocol specific", "label": "terminatedmethadone hydrochloride_nausea and vomiting, pain, sleep disorders, unspecified adult solid tumor, protocol specific", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedirbesartan, placebo, ps433540, ps433540, ps433540_hypertension", "label": "completedirbesartan, placebo, ps433540, ps433540, ps433540_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " dyspareunia", "label": " dyspareunia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alvocidib, mitoxantrone hydrochloride, carboplatin, cytarabine, sirolimus, etoposide, topotecan hydrochloride", "label": "alvocidib, mitoxantrone hydrochloride, carboplatin, cytarabine, sirolimus, etoposide, topotecan hydrochloride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "binge eating disorder, obesity", "label": "binge eating disorder, obesity", "shape": "dot", "size": 10}, {"color": "red", "id": "phx1149t", "label": "phx1149t", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle, capecitabine orally days 1 -21, erlotinib 100 mg orally days 1-28, bevacizumab 5 mg/kg intravenously every 2 weeks_pancreatic cancer", "label": "completedgemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle, capecitabine orally days 1 -21, erlotinib 100 mg orally days 1-28, bevacizumab 5 mg/kg intravenously every 2 weeks_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "mucinous adenocarcinoma of the colon", "label": "mucinous adenocarcinoma of the colon", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcisplatin (or alternative)_carcinoma, squamous cell, head and neck neoplasms, oropharyngeal neoplasms", "label": "active, not recruitingcisplatin (or alternative)_carcinoma, squamous cell, head and neck neoplasms, oropharyngeal neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "b-cell adult acute lymphoblastic leukemia, b-cell chronic lymphocytic leukemia, cutaneous b-cell non-hodgkin lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, intraocular lymphoma, nodal marginal zone b-cell lymphoma, recurrent adult acute lymphoblastic leukemia, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, refractory hairy cell leukemia, small intestine lymphoma, splenic marginal zone lymphoma, testicular lymphoma, waldenstr\u00f6m macroglobulinemia", "label": "b-cell adult acute lymphoblastic leukemia, b-cell chronic lymphocytic leukemia, cutaneous b-cell non-hodgkin lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, intraocular lymphoma, nodal marginal zone b-cell lymphoma, recurrent adult acute lymphoblastic leukemia, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, refractory hairy cell leukemia, small intestine lymphoma, splenic marginal zone lymphoma, testicular lymphoma, waldenstr\u00f6m macroglobulinemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddocetaxel, doxorubicin hydrochloride_breast cancer", "label": "completeddocetaxel, doxorubicin hydrochloride_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hepatitis b, chronic, cirrhosis, fibrosis, chronic hepatitis b", "label": "hepatitis b, chronic, cirrhosis, fibrosis, chronic hepatitis b", "shape": "dot", "size": 10}, {"color": "red", "id": "nicorandil", "label": "nicorandil", "shape": "dot", "size": 10}, {"color": "red", "id": " sulfonylurea or pioglitazone", "label": " sulfonylurea or pioglitazone", "shape": "dot", "size": 10}, {"color": "red", "id": " viread (300 mg tenofovir disoproxil fumarate) once daily", "label": " viread (300 mg tenofovir disoproxil fumarate) once daily", "shape": "dot", "size": 10}, {"color": "red", "id": "1 mg/kg cnto 136", "label": "1 mg/kg cnto 136", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnfloxuridine (fudr), irinotecan (cpt-11), fluorouracil, panitumumab, dexamethasone, leucovorin_colorectal adenocarcinoma metastatic to the liver", "label": "withdrawnfloxuridine (fudr), irinotecan (cpt-11), fluorouracil, panitumumab, dexamethasone, leucovorin_colorectal adenocarcinoma metastatic to the liver", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "brentuximab vedotin, adriamycin, vinblastine, and dacarbazine", "label": "brentuximab vedotin, adriamycin, vinblastine, and dacarbazine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, COC1=C(C\\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, COC1=C(C\\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carboplatin, pegylated liposomal doxorubicin hydrochloride", "label": "carboplatin, pegylated liposomal doxorubicin hydrochloride", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent adult t-cell leukemia/lymphoma", "label": " recurrent adult t-cell leukemia/lymphoma", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1", "label": "COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo+ adt", "label": " placebo+ adt", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completediva337, placebo_scleroderma, diffuse, diffuse cutaneous systemic sclerosis", "label": "completediva337, placebo_scleroderma, diffuse, diffuse cutaneous systemic sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedfluticasone propionate_bronchiolitis", "label": "terminatedfluticasone propionate_bronchiolitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "breast cancer, hypercalcemia of malignancy, metastatic cancer", "label": "breast cancer, hypercalcemia of malignancy, metastatic cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " ciprofloxacin 500 mg oral twice daily", "label": " ciprofloxacin 500 mg oral twice daily", "shape": "dot", "size": 10}, {"color": "green", "id": "chronic sinusitis", "label": "chronic sinusitis", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo", "label": " placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pledox (2 \u00b5mol/kg), pledox (5 \u00b5mol/kg), pledox (10 \u00b5mol/kg), placebo (0,9% nacl)", "label": "pledox (2 \u00b5mol/kg), pledox (5 \u00b5mol/kg), pledox (10 \u00b5mol/kg), placebo (0,9% nacl)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "diabetic nephropathy, type 2 diabetes mellitus, proteinuria", "label": "diabetic nephropathy, type 2 diabetes mellitus, proteinuria", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedave8112, placebo_parkinson\u0027s disease", "label": "terminatedave8112, placebo_parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtak-442, tak-442, tak-442, tak-442, tak-442, tak-442, enoxaparin_venous thromboembolism", "label": "completedtak-442, tak-442, tak-442, tak-442, tak-442, tak-442, enoxaparin_venous thromboembolism", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hiv infection, hyperlipidemia", "label": "hiv infection, hyperlipidemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsunitinib and rapamycin (drug will be held)_non-small cell lung cancer", "label": "completedsunitinib and rapamycin (drug will be held)_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedonabotulinumtoxina, saline_chronic migraine", "label": "completedonabotulinumtoxina, saline_chronic migraine", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "breast neoplasms, metastases", "label": "breast neoplasms, metastases", "shape": "dot", "size": 10}, {"color": "red", "id": "insulin glulisine", "label": "insulin glulisine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "risperidone, ziprasidone", "label": "risperidone, ziprasidone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedf17464, placebo_schizophrenia", "label": "completedf17464, placebo_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddasatinib, letrozole_metastatic breast cancer", "label": "completeddasatinib, letrozole_metastatic breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsb939_leukemia, solid tumours", "label": "completedsb939_leukemia, solid tumours", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "niacin extended release and lovastatin tablets", "label": "niacin extended release and lovastatin tablets", "shape": "dot", "size": 10}, {"color": "green", "id": " b cell", "label": " b cell", "shape": "dot", "size": 10}, {"color": "red", "id": "laromustine", "label": "laromustine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O)N=[N+]=[N-]", "label": "NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O)N=[N+]=[N-]", "shape": "dot", "size": 10}, {"color": "green", "id": " small for gestational age", "label": " small for gestational age", "shape": "dot", "size": 10}, {"color": "blue", "id": " N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O", "label": " N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O", "shape": "dot", "size": 10}, {"color": "red", "id": "0.12% chlorhexidine solution", "label": "0.12% chlorhexidine solution", "shape": "dot", "size": 10}, {"color": "green", "id": " psychotic disorder", "label": " psychotic disorder", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcotrimoxazole prophylaxis, cotrimoxazole placebo_hiv infections, neutropenia, anemia", "label": "completedcotrimoxazole prophylaxis, cotrimoxazole placebo_hiv infections, neutropenia, anemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "label": " CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, cutaneous b-cell non-hodgkin lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, hepatosplenic t-cell lymphoma, intraocular lymphoma, nodal marginal zone b-cell lymphoma, noncutaneous extranodal lymphoma, peripheral t-cell lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, small intestine lymphoma, splenic marginal zone lymphoma, testicular lymphoma, waldenstrom macroglobulinemia", "label": "adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, cutaneous b-cell non-hodgkin lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, hepatosplenic t-cell lymphoma, intraocular lymphoma, nodal marginal zone b-cell lymphoma, noncutaneous extranodal lymphoma, peripheral t-cell lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, small intestine lymphoma, splenic marginal zone lymphoma, testicular lymphoma, waldenstrom macroglobulinemia", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iva cervical cancer", "label": " stage iva cervical cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcyclophosphamide, fludarabine, sargramostim, rituximab_chronic lymphocytic leukemia", "label": "completedcyclophosphamide, fludarabine, sargramostim, rituximab_chronic lymphocytic leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedvemurafenib, leflunomide_melanoma", "label": "terminatedvemurafenib, leflunomide_melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bevacizumab, temsirolimus, bevacizumab, interferon-alfa 9mu", "label": "bevacizumab, temsirolimus, bevacizumab, interferon-alfa 9mu", "shape": "dot", "size": 10}, {"color": "red", "id": " fesoterodine 4mg", "label": " fesoterodine 4mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "small lymphocytic lymphoma, chronic lymphocytic leukemia", "label": "small lymphocytic lymphoma, chronic lymphocytic leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedspm 962, ropinirole, placebo_parkinson\u0027s disease", "label": "completedspm 962, ropinirole, placebo_parkinson\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " regular insulin u-100", "label": " regular insulin u-100", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sc12267 (4sc-101), placebo, methotrexate, folic acid", "label": "sc12267 (4sc-101), placebo, methotrexate, folic acid", "shape": "dot", "size": 10}, {"color": "blue", "id": " NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1", "label": " NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "nasal carbon dioxide", "label": "nasal carbon dioxide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oxaliplatin, mitomycin + gemcitabine", "label": "oxaliplatin, mitomycin + gemcitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtechnosphere\u00ae insulin, technosphere powder_type 2 diabetes", "label": "completedtechnosphere\u00ae insulin, technosphere powder_type 2 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "methotrexate (stable dose)", "label": "methotrexate (stable dose)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCOC(=O)C1=CC=C(N)C=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "label": "CCOC(=O)C1=CC=C(N)C=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo for sar440340", "label": " placebo for sar440340", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedolodaterol (bi 1744) low, low tiotropium bromide, olodaterol (bi 1744) high, medium tiotropium bromide, high tiotropium bromide, placebo_pulmonary disease, chronic obstructive", "label": "completedolodaterol (bi 1744) low, low tiotropium bromide, olodaterol (bi 1744) high, medium tiotropium bromide, high tiotropium bromide, placebo_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "head and neck cancer, carcinoma, squamous cell, head and neck cancers", "label": "head and neck cancer, carcinoma, squamous cell, head and neck cancers", "shape": "dot", "size": 10}, {"color": "green", "id": "advanced solid tumor cancers", "label": "advanced solid tumor cancers", "shape": "dot", "size": 10}, {"color": "red", "id": " ta-7284-high-middle", "label": " ta-7284-high-middle", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedocriplasmin 0.0625mg, ocriplasmin 0.125mg, sham injection_diabetic retinopathy, posterior vitreous detachment, disease progression", "label": "terminatedocriplasmin 0.0625mg, ocriplasmin 0.125mg, sham injection_diabetic retinopathy, posterior vitreous detachment, disease progression", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " increased iron storage / disturbed distribution", "label": " increased iron storage / disturbed distribution", "shape": "dot", "size": 10}, {"color": "red", "id": " lhrha", "label": " lhrha", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbusulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin (go), daunorubicin_leukemia", "label": "completedbusulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin (go), daunorubicin_leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " 60", "label": " 60", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlenalidomide: double-blind induction, melphalan, prednisone, aspirin, placebo, lenalidomide: double-blind maintenance, lenalidomide: open-label_newly diagnosed multiple myeloma", "label": "completedlenalidomide: double-blind induction, melphalan, prednisone, aspirin, placebo, lenalidomide: double-blind maintenance, lenalidomide: open-label_newly diagnosed multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azilsartan medoxomil and amlodipine, azilsartan medoxomil and amlodipine, amlodipine", "label": "azilsartan medoxomil and amlodipine, azilsartan medoxomil and amlodipine, amlodipine", "shape": "dot", "size": 10}, {"color": "red", "id": " nifedipine", "label": " nifedipine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H]\\C(=C(\\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC, [H]\\C(=C(\\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC", "label": "[H]\\C(=C(\\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC, [H]\\C(=C(\\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "type 2 diabetes, chronic kidney disease", "label": "type 2 diabetes, chronic kidney disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "red", "id": "chf1535 200/6 \u00b5g", "label": "chf1535 200/6 \u00b5g", "shape": "dot", "size": 10}, {"color": "green", "id": " inborn", "label": " inborn", "shape": "dot", "size": 10}, {"color": "red", "id": "evogliptin", "label": "evogliptin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingpembrolizumab, mfolfox6_colorectal cancer", "label": "active, not recruitingpembrolizumab, mfolfox6_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "label": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": " vinorelbine injection", "label": " vinorelbine injection", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeda: fludarabine + busulphan, b: fludarabine + thiotepa_myelofibrosis", "label": "completeda: fludarabine + busulphan, b: fludarabine + thiotepa_myelofibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddovitinib_advanced malignant pleural mesothelioma, mpm", "label": "terminateddovitinib_advanced malignant pleural mesothelioma, mpm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " behavioral insomnia of childhood", "label": " behavioral insomnia of childhood", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingdoxorubicin, cytarabine, methotrexate, vincristine, cyclophosphamide, methylprednisone, hydrocortisone sodium succinate, dexamethasone, 6-mp, peg-asparaginase, imatinib, etoposide, e. coli asparaginase_acute lymphoblastic leukemia", "label": "active, not recruitingdoxorubicin, cytarabine, methotrexate, vincristine, cyclophosphamide, methylprednisone, hydrocortisone sodium succinate, dexamethasone, 6-mp, peg-asparaginase, imatinib, etoposide, e. coli asparaginase_acute lymphoblastic leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " testicular lymphoma", "label": " testicular lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": " adalat", "label": " adalat", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "docetaxel, capecitabine", "label": "docetaxel, capecitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedbifeprunox, quetiapine, bifeprunox_schizophrenia", "label": "terminatedbifeprunox, quetiapine, bifeprunox_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpramipexole_restless legs syndrome", "label": "completedpramipexole_restless legs syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@](C)(C(O)=NS(C)(=O)=O)C1=CC=C(CC(C)C)C=C1, [H][C@](C)(C(O)=NS(C)(=O)=O)C1=CC=C(CC(C)C)C=C1", "label": "[H][C@](C)(C(O)=NS(C)(=O)=O)C1=CC=C(CC(C)C)C=C1, [H][C@](C)(C(O)=NS(C)(=O)=O)C1=CC=C(CC(C)C)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " alogliptin and metformin fdc placebo", "label": " alogliptin and metformin fdc placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCCC1=NC(=CN1C1=CC=C(OC2=CC=C(Cl)C=C2)C=C1)C1=CC=C(OCCCN(CC)CC)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCCCC1=NC(=CN1C1=CC=C(OC2=CC=C(Cl)C=C2)C=C1)C1=CC=C(OCCCN(CC)CC)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iiic2 uterine corpus cancer", "label": " stage iiic2 uterine corpus cancer", "shape": "dot", "size": 10}, {"color": "green", "id": " hemoglobin ss disease with crisis", "label": " hemoglobin ss disease with crisis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedazeliragon 5mg_alzheimer\u0027s disease", "label": "terminatedazeliragon 5mg_alzheimer\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "levonorgestrel (mirena, bay86-5028), cytotec, placebo", "label": "levonorgestrel (mirena, bay86-5028), cytotec, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawn95% pure ecgc capsules 200mg, placebo comparator:_multiple sclerosis", "label": "withdrawn95% pure ecgc capsules 200mg, placebo comparator:_multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmurepavadin, two anti-pseudomonal antibiotics_pneumonia", "label": "terminatedmurepavadin, two anti-pseudomonal antibiotics_pneumonia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=C(O)C=CC2=C1OC=C(C2=O)C1=CC=C(O)C=C1", "label": "OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=C(O)C=CC2=C1OC=C(C2=O)C1=CC=C(O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCNC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)CCC1=CC=CC=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1", "label": "CCNC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)CCC1=CC=CC=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedara-c, bl-8040_acute myeloid leukemia", "label": "completedara-c, bl-8040_acute myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=C(CC(O)=O)C2=CC(F)=CC=C2\\C1=C/C1=CC=C(C=C1)S(C)=O", "label": "CC1=C(CC(O)=O)C2=CC(F)=CC=C2\\C1=C/C1=CC=C(C=C1)S(C)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedan2728 ointment, 2%, an2898 ointment, 1%, an2898 ointment vehicle, an2728 ointment vehicle_dermatitis, atopic", "label": "completedan2728 ointment, 2%, an2898 ointment, 1%, an2898 ointment vehicle, an2728 ointment vehicle_dermatitis, atopic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " maintain dual therapy (sulf/pio) as comparator to liraglutide", "label": " maintain dual therapy (sulf/pio) as comparator to liraglutide", "shape": "dot", "size": 10}, {"color": "blue", "id": " [Li+]", "label": " [Li+]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedasenapine, olanzapine_schizophrenia", "label": "completedasenapine, olanzapine_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=CC=C1OCC(O)CO, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "COC1=CC=CC=C1OCC(O)CO, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "red", "id": "nktr-102", "label": "nktr-102", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingcisplatin_stage iii oropharyngeal squamous cell carcinoma, stage iva oropharyngeal squamous cell carcinoma, stage ivb oropharyngeal squamous cell carcinoma, stage ivc oropharyngeal squamous cell carcinoma, tongue carcinoma", "label": "active, not recruitingcisplatin_stage iii oropharyngeal squamous cell carcinoma, stage iva oropharyngeal squamous cell carcinoma, stage ivb oropharyngeal squamous cell carcinoma, stage ivc oropharyngeal squamous cell carcinoma, tongue carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ged-0507-34-levo 160 mg", "label": " ged-0507-34-levo 160 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "leukemia, lymphoma, neuroblastoma, immunodeficiencies, anemia", "label": "leukemia, lymphoma, neuroblastoma, immunodeficiencies, anemia", "shape": "dot", "size": 10}, {"color": "red", "id": "palbociclib + taselisib / pictilisib", "label": "palbociclib + taselisib / pictilisib", "shape": "dot", "size": 10}, {"color": "green", "id": "hepatic metastases", "label": "hepatic metastases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cancer, thromboembolism", "label": "cancer, thromboembolism", "shape": "dot", "size": 10}, {"color": "red", "id": "gemcitabine alone", "label": "gemcitabine alone", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O", "label": " CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O", "shape": "dot", "size": 10}, {"color": "green", "id": " congenital adrenal hyperplasia (cah)", "label": " congenital adrenal hyperplasia (cah)", "shape": "dot", "size": 10}, {"color": "blue", "id": " CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1", "label": " CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo for risankizumab, risankizumab_ankylosing spondylitis (as)", "label": "completedplacebo for risankizumab, risankizumab_ankylosing spondylitis (as)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " squalamine lactate ophthalmic solution", "label": " squalamine lactate ophthalmic solution", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedbusulfan, clofarabine, fludarabine, melphalan, carmustine, etoposide, cytarabine_acute myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hodgkins disease, non-hodgkins lymphoma, aplastic anemia, multiple myeloma, myelodysplastic syndrome", "label": "terminatedbusulfan, clofarabine, fludarabine, melphalan, carmustine, etoposide, cytarabine_acute myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hodgkins disease, non-hodgkins lymphoma, aplastic anemia, multiple myeloma, myelodysplastic syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ttp273", "label": "ttp273", "shape": "dot", "size": 10}, {"color": "red", "id": " aprepitant placebo", "label": " aprepitant placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "label": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "shape": "dot", "size": 10}, {"color": "red", "id": " ta-7284 high", "label": " ta-7284 high", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completed5-ala-sfc, placebo_diabetes mellitus, type 2", "label": "completed5-ala-sfc, placebo_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo bi 10773 low dose", "label": " placebo bi 10773 low dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "saredutant (sr48968), placebo, escitalopram", "label": "saredutant (sr48968), placebo, escitalopram", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "saxagliptin, vildagliptin, sitagliptin", "label": "saxagliptin, vildagliptin, sitagliptin", "shape": "dot", "size": 10}, {"color": "red", "id": " omalizumab", "label": " omalizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcisplatin, etoposide, gemcitabine, methylprednisolone_lymphoma", "label": "completedcisplatin, etoposide, gemcitabine, methylprednisolone_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "botulinum toxin", "label": "botulinum toxin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1", "label": "CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "abt-450/r/abt-267, abt-333, ribavirin, telaprevir, pegylated interferon alpha 2-a (pegifn)", "label": "abt-450/r/abt-267, abt-333, ribavirin, telaprevir, pegylated interferon alpha 2-a (pegifn)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeditca 650 osmotic mini pump 20/60 mcg/day, itca 650 osmotic mini pump 60 mcg/day, metformin, liraglutide_diabetes mellitus, type 2", "label": "completeditca 650 osmotic mini pump 20/60 mcg/day, itca 650 osmotic mini pump 60 mcg/day, metformin, liraglutide_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acute myeloid leukemia (aml), myelodysplastic syndrome (mds)", "label": "acute myeloid leukemia (aml), myelodysplastic syndrome (mds)", "shape": "dot", "size": 10}, {"color": "red", "id": " 50 mcg", "label": " 50 mcg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recurrent ovarian epithelial cancer, recurrent ovarian germ cell tumor, malignant tumor of peritoneum, stage iv ovarian epithelial cancer, stage iv ovarian germ cell tumor", "label": "recurrent ovarian epithelial cancer, recurrent ovarian germ cell tumor, malignant tumor of peritoneum, stage iv ovarian epithelial cancer, stage iv ovarian germ cell tumor", "shape": "dot", "size": 10}, {"color": "green", "id": " metastatic lung cancer", "label": " metastatic lung cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "insulin degludec/insulin aspart, insulin degludec/insulin aspart", "label": "insulin degludec/insulin aspart, insulin degludec/insulin aspart", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "htx-011, bupivacaine hcl without epinephrine, saline placebo", "label": "htx-011, bupivacaine hcl without epinephrine, saline placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " advanced lung disease", "label": " advanced lung disease", "shape": "dot", "size": 10}, {"color": "green", "id": "hypothyroidism", "label": "hypothyroidism", "shape": "dot", "size": 10}, {"color": "blue", "id": " N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F", "label": " N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F", "shape": "dot", "size": 10}, {"color": "red", "id": "empagliflozin 10 mg + linagliptin 5 mg", "label": "empagliflozin 10 mg + linagliptin 5 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcapecitabine, erlotinib hydrochloride, gemcitabine hydrochloride_pancreatic cancer", "label": "completedcapecitabine, erlotinib hydrochloride, gemcitabine hydrochloride_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingrituximab, lenalidomide, placebo_lymphoma, non-hodgkin", "label": "active, not recruitingrituximab, lenalidomide, placebo_lymphoma, non-hodgkin", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "amlexanox", "label": "amlexanox", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iiia ovarian cancer ajcc v6 and v7", "label": " stage iiia ovarian cancer ajcc v6 and v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sorafenib, bibf 1120", "label": "sorafenib, bibf 1120", "shape": "dot", "size": 10}, {"color": "green", "id": " adenosquamous cell", "label": " adenosquamous cell", "shape": "dot", "size": 10}, {"color": "blue", "id": " COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1", "label": " COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1", "shape": "dot", "size": 10}, {"color": "green", "id": "advanced prostate cancer", "label": "advanced prostate cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingramucirumab, docetaxel, placebo_urothelial carcinoma", "label": "active, not recruitingramucirumab, docetaxel, placebo_urothelial carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "relebactam 250 mg", "label": "relebactam 250 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alogliptin and insulin, alogliptin and insulin, insulin", "label": "alogliptin and insulin, alogliptin and insulin, insulin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "capecitabine, vinorelbine tartrate", "label": "capecitabine, vinorelbine tartrate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedgemcitabine, placebo_bladder neoplasms", "label": "terminatedgemcitabine, placebo_bladder neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "neurogenic detrusor overactivity", "label": "neurogenic detrusor overactivity", "shape": "dot", "size": 10}, {"color": "green", "id": " refractory b-cell non-hodgkin lymphoma", "label": " refractory b-cell non-hodgkin lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "telithromycin", "label": "telithromycin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "heart failure, cardiac failure, acute decompensated heart failure (adhf)", "label": "heart failure, cardiac failure, acute decompensated heart failure (adhf)", "shape": "dot", "size": 10}, {"color": "red", "id": " fulvestrant or tamoxifen or aromatase inhibitor", "label": " fulvestrant or tamoxifen or aromatase inhibitor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcediranib maleate_recurrent non-small cell lung cancer", "label": "completedcediranib maleate_recurrent non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " tocosol paclitaxel", "label": " tocosol paclitaxel", "shape": "dot", "size": 10}, {"color": "red", "id": "tirasemtiv", "label": "tirasemtiv", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmetformin, erlotinib_breast cancer", "label": "completedmetformin, erlotinib_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "sbr759", "label": "sbr759", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "insulin degludec/liraglutide, insulin glargine, insulin aspart", "label": "insulin degludec/liraglutide, insulin glargine, insulin aspart", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinterferon-beta-1a (avonex) plus methylprednisolone_relapsing-remitting multiple sclerosis", "label": "completedinterferon-beta-1a (avonex) plus methylprednisolone_relapsing-remitting multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rheumatoid arthritis, influenza, methotrexate", "label": "rheumatoid arthritis, influenza, methotrexate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcarboplatin, irinotecan_lung cancer", "label": "completedcarboplatin, irinotecan_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dyslipidemia, hypertension", "label": "dyslipidemia, hypertension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbevacizumab, capecitabine, oxaliplatin_cancer", "label": "completedbevacizumab, capecitabine, oxaliplatin_cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedazd 2014, rituximab_diffuse large b-cell lymphoma", "label": "completedazd 2014, rituximab_diffuse large b-cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azacitidine, oxaliplatin, epirubicin, capecitabine", "label": "azacitidine, oxaliplatin, epirubicin, capecitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O", "label": "[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "suspendedzd6126, placebo_carcinoma, renal cell, kidney neoplasms", "label": "suspendedzd6126, placebo_carcinoma, renal cell, kidney neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1", "label": "CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "atopic dermatitis, eczema", "label": "atopic dermatitis, eczema", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "huntington\u0027s disease, chorea", "label": "huntington\u0027s disease, chorea", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lfg316, sham, lfg316 lower dose", "label": "lfg316, sham, lfg316 lower dose", "shape": "dot", "size": 10}, {"color": "blue", "id": " C[C@H]1CN(CC2=CC=C(CC(=O)N3CCC(CC3)NC3=CC=CC(F)=C3)C=C2)CCN1", "label": " C[C@H]1CN(CC2=CC=C(CC(=O)N3CCC(CC3)NC3=CC=CC(F)=C3)C=C2)CCN1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bendamustine, chlorambucil, cyclophosphamide, fludarabine, obinutuzumab", "label": "bendamustine, chlorambucil, cyclophosphamide, fludarabine, obinutuzumab", "shape": "dot", "size": 10}, {"color": "red", "id": " [18-f] fluorodeoxyglucose (fdg)", "label": " [18-f] fluorodeoxyglucose (fdg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedezatiostat hydrochloride, lenalidomide (revlimid\u00ae)_myelodysplastic syndrome", "label": "completedezatiostat hydrochloride, lenalidomide (revlimid\u00ae)_myelodysplastic syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "vx-445/tez/iva", "label": "vx-445/tez/iva", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine+cisplatin, bibw 2992_carcinoma, non-small-cell lung, adenocarcinoma", "label": "completedgemcitabine+cisplatin, bibw 2992_carcinoma, non-small-cell lung, adenocarcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpirfenidone_idiopathic pulmonary fibrosis, pulmonary fibrosis", "label": "completedpirfenidone_idiopathic pulmonary fibrosis, pulmonary fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "staccato\u00ae alprazolam", "label": "staccato\u00ae alprazolam", "shape": "dot", "size": 10}, {"color": "red", "id": "cp 751", "label": "cp 751", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "androgen ablation, cabazitaxel, salvage therapy, neoadjuvant treatment - hormonal therapy, neoadjuvant treatment - cabazitaxel", "label": "androgen ablation, cabazitaxel, salvage therapy, neoadjuvant treatment - hormonal therapy, neoadjuvant treatment - cabazitaxel", "shape": "dot", "size": 10}, {"color": "green", "id": " parkinson disease", "label": " parkinson disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, CC(C)CC1=CC=C(C=C1)C(C)C(O)=O, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2", "label": "NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, CC(C)CC1=CC=C(C=C1)C(C)C(O)=O, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2", "shape": "dot", "size": 10}, {"color": "red", "id": " phosphate-buffered saline", "label": " phosphate-buffered saline", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCCOCCOC(=O)C1=CN=CC=C1", "label": "CCCCOCCOC(=O)C1=CN=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " hm10460a (270 \u03bcg/kg)", "label": " hm10460a (270 \u03bcg/kg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedhm10460a (45 \u03bcg/kg), hm10460a (135 \u03bcg/kg), hm10460a (270 \u03bcg/kg), pegfilgrastim 6mg, docetaxel, cyclophosphamide_neutropenia", "label": "completedhm10460a (45 \u03bcg/kg), hm10460a (135 \u03bcg/kg), hm10460a (270 \u03bcg/kg), pegfilgrastim 6mg, docetaxel, cyclophosphamide_neutropenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " lymphoid malignancies", "label": " lymphoid malignancies", "shape": "dot", "size": 10}, {"color": "green", "id": "bone pain in stage i - iii breast cancer", "label": "bone pain in stage i - iii breast cancer", "shape": "dot", "size": 10}, {"color": "green", "id": " hepatocellular adenocarcinoma", "label": " hepatocellular adenocarcinoma", "shape": "dot", "size": 10}, {"color": "red", "id": "moxonidine", "label": "moxonidine", "shape": "dot", "size": 10}, {"color": "red", "id": " mirtazapine", "label": " mirtazapine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "apixaban, clarithromycin", "label": "apixaban, clarithromycin", "shape": "dot", "size": 10}, {"color": "red", "id": " gsk2190915 placebo", "label": " gsk2190915 placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "label": "CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedenoxaparin sodium, semuloparin sodium, placebo_venous thromboembolism", "label": "completedenoxaparin sodium, semuloparin sodium, placebo_venous thromboembolism", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fentanyl, morphine, ticagrelor, aspirin, unfractioned heparin", "label": "fentanyl, morphine, ticagrelor, aspirin, unfractioned heparin", "shape": "dot", "size": 10}, {"color": "green", "id": " gastrointestinal neoplasms", "label": " gastrointestinal neoplasms", "shape": "dot", "size": 10}, {"color": "red", "id": " liposomal cytarabine", "label": " liposomal cytarabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C12, N[C@@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "N[C@@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C12, N[C@@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalendronate sodium_osteopenia, osteoporosis", "label": "completedalendronate sodium_osteopenia, osteoporosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "mild alzheimer\u0027s disease", "label": "mild alzheimer\u0027s disease", "shape": "dot", "size": 10}, {"color": "blue", "id": " C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1C)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": " C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1C)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[O-][N+](=O)C1=CC=C(O1)\\C=N\\N1CC(=O)NC1=O, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O, CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O, [H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "label": "[O-][N+](=O)C1=CC=C(O1)\\C=N\\N1CC(=O)NC1=O, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O, CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O, [H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": "travoprost ophthalmic solution", "label": "travoprost ophthalmic solution", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "arzoxifene, raloxifene", "label": "arzoxifene, raloxifene", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddefinity, (lipid microspheres) intravenous suspension_breast cancer", "label": "terminateddefinity, (lipid microspheres) intravenous suspension_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnremodulin_congenital heart disease", "label": "withdrawnremodulin_congenital heart disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " silrolimus", "label": " silrolimus", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpimavanserin tartrate, placebo_alzheimer\u0027s disease psychosis", "label": "completedpimavanserin tartrate, placebo_alzheimer\u0027s disease psychosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " comparator: pioglitazone", "label": " comparator: pioglitazone", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC1=C2C(=CN(COP(O)(O)=O)C2=C(N=C1)N1C=NC(C)=N1)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1", "label": "COC1=C2C(=CN(COP(O)(O)=O)C2=C(N=C1)N1C=NC(C)=N1)C(=O)C(=O)N1CCN(CC1)C(=O)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "green", "id": "anorexia", "label": "anorexia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lipitor, placebo", "label": "lipitor, placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " large b-cell", "label": " large b-cell", "shape": "dot", "size": 10}, {"color": "green", "id": " ph1 positive cml", "label": " ph1 positive cml", "shape": "dot", "size": 10}, {"color": "red", "id": " biosynthetic human insulin injection", "label": " biosynthetic human insulin injection", "shape": "dot", "size": 10}, {"color": "red", "id": "ec1456 and ec20", "label": "ec1456 and ec20", "shape": "dot", "size": 10}, {"color": "green", "id": " adenocarcinoma of the rectum", "label": " adenocarcinoma of the rectum", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeda3309_constipation, chronic constipation", "label": "completeda3309_constipation, chronic constipation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "label": "ClCCN(CCCl)P1(=O)NCCCO1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpf-04494700, pf-04494700, placebo_alzheimer\u0027s disease", "label": "completedpf-04494700, pf-04494700, placebo_alzheimer\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O", "label": " [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O", "shape": "dot", "size": 10}, {"color": "blue", "id": "OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1", "label": "OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "green", "id": "recurrent adenoid cystic carcinoma of the oral cavity", "label": "recurrent adenoid cystic carcinoma of the oral cavity", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1", "label": "CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " er niacin", "label": " er niacin", "shape": "dot", "size": 10}, {"color": "blue", "id": " O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1", "label": " O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1", "shape": "dot", "size": 10}, {"color": "blue", "id": " COC1=C(OC)C=C2C(OC3=CC(Cl)=C(C=C3)N=C(O)N=C3NOC(C)=C3)=CC=NC2=C1", "label": " COC1=C(OC)C=C2C(OC3=CC(Cl)=C(C=C3)N=C(O)N=C3NOC(C)=C3)=CC=NC2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC(=O)[C@H](CC1=CC(=CC=C1)C(N)=N)[C@@H](C)NC(=O)C1=CC=C(C=C1)C1=CC=[N+]([O-])C=C1, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O", "label": "COC(=O)[C@H](CC1=CC(=CC=C1)C(N)=N)[C@@H](C)NC(=O)C1=CC=C(C=C1)C1=CC=[N+]([O-])C=C1, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O", "label": "[Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "low back pain, chronic pain", "label": "low back pain, chronic pain", "shape": "dot", "size": 10}, {"color": "red", "id": "tlc599 ld group", "label": "tlc599 ld group", "shape": "dot", "size": 10}, {"color": "red", "id": "inecalcitol", "label": "inecalcitol", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcabazitaxel xrp6258, abiraterone acetate, prednisone 5 mg_prostate cancer", "label": "completedcabazitaxel xrp6258, abiraterone acetate, prednisone 5 mg_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCOC1=NC=C(C=C1C1=NC2=C(CC)N(CCOC)N=C2C(=O)N1)S(=O)(=O)N1CCN(CC)CC1", "label": " CCOC1=NC=C(C=C1C1=NC2=C(CC)N(CCOC)N=C2C(=O)N1)S(=O)(=O)N1CCN(CC)CC1", "shape": "dot", "size": 10}, {"color": "red", "id": "incobotulinum toxin a", "label": "incobotulinum toxin a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O", "label": "CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, melatonin_schizophrenia, schizoaffective disorder, bipolar affective disorder", "label": "completedplacebo, melatonin_schizophrenia, schizoaffective disorder, bipolar affective disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " vp-16", "label": " vp-16", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "abt-267, pegylated interferon (pegifn), ribavirin (rbv)", "label": "abt-267, pegylated interferon (pegifn), ribavirin (rbv)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcisplatin, paclitaxel_ovarian cancer, primary peritoneal cavity cancer", "label": "completedcisplatin, paclitaxel_ovarian cancer, primary peritoneal cavity cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcisplatin_head and neck cancer", "label": "terminatedcisplatin_head and neck cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "xylitol syrup", "label": "xylitol syrup", "shape": "dot", "size": 10}, {"color": "red", "id": "alks 37", "label": "alks 37", "shape": "dot", "size": 10}, {"color": "red", "id": " ast-726 placebo", "label": " ast-726 placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ceritinib, pemetrexed, docetaxel", "label": "ceritinib, pemetrexed, docetaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gw786034, placebo", "label": "gw786034, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(=O)OC1=CC=CC=C1C(O)=O, CN(C)C(=N)NC(N)=N", "label": "CC(=O)OC1=CC=CC=C1C(O)=O, CN(C)C(=N)NC(N)=N", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gastro-oesophageal junction cancer, gastric cancer", "label": "gastro-oesophageal junction cancer, gastric cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " ccrt with ip chemotherapy (irinotecan + cisplatin)", "label": " ccrt with ip chemotherapy (irinotecan + cisplatin)", "shape": "dot", "size": 10}, {"color": "red", "id": "cobitolimod", "label": "cobitolimod", "shape": "dot", "size": 10}, {"color": "red", "id": "acetylsalicylic acid", "label": "acetylsalicylic acid", "shape": "dot", "size": 10}, {"color": "blue", "id": "OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1", "label": "OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " 300 u/ml", "label": " 300 u/ml", "shape": "dot", "size": 10}, {"color": "red", "id": " cnto 6785 100 mg", "label": " cnto 6785 100 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gemtuzumab ozogamicin, vorinostat", "label": "gemtuzumab ozogamicin, vorinostat", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "belinostat, paclitaxel, carboplatin", "label": "belinostat, paclitaxel, carboplatin", "shape": "dot", "size": 10}, {"color": "red", "id": "comparator: sitagliptin phosphate", "label": "comparator: sitagliptin phosphate", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O", "label": " CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsorafenib and gemcitabine_carcinoma, hepatocellular", "label": "completedsorafenib and gemcitabine_carcinoma, hepatocellular", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1", "label": "CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "palbociclib 200mg, palbociclib 125mg", "label": "palbociclib 200mg, palbociclib 125mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsublingual methadone_cancer, pain", "label": "terminatedsublingual methadone_cancer, pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedintravitreal aflibercept injection_cystoid macular edema, diabetic macular edema", "label": "completedintravitreal aflibercept injection_cystoid macular edema, diabetic macular edema", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsimvastatin, placebo_bipolar disorder", "label": "terminatedsimvastatin, placebo_bipolar disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " sativex", "label": " sativex", "shape": "dot", "size": 10}, {"color": "red", "id": "sr141716 (rimonabant)", "label": "sr141716 (rimonabant)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgsk2336805, pegylated interferon alfa-2a, ribavirin, gsk2336805 matching placebo_hepatitis c, chronic", "label": "completedgsk2336805, pegylated interferon alfa-2a, ribavirin, gsk2336805 matching placebo_hepatitis c, chronic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "risperidone, sertindole", "label": "risperidone, sertindole", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgalantamine cr, memantine, placebo_alzheimer\u0027s disease", "label": "completedgalantamine cr, memantine, placebo_alzheimer\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " vehicle of kpi-121 ophthalmic suspension dosed bid", "label": " vehicle of kpi-121 ophthalmic suspension dosed bid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingfaslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy_hormone receptor positive breast cancer", "label": "active, not recruitingfaslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy_hormone receptor positive breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedgemcitabine neoadjuvant, gemcitabine adjuvant_pancreatic cancer", "label": "terminatedgemcitabine neoadjuvant, gemcitabine adjuvant_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcalcitriol ointment, clobetasol spray_psoriasis", "label": "completedcalcitriol ointment, clobetasol spray_psoriasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ldmtx", "label": "ldmtx", "shape": "dot", "size": 10}, {"color": "red", "id": "rifaximin eir", "label": "rifaximin eir", "shape": "dot", "size": 10}, {"color": "red", "id": " oral capsules", "label": " oral capsules", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "esophageal cancer, adenocarcinoma", "label": "esophageal cancer, adenocarcinoma", "shape": "dot", "size": 10}, {"color": "red", "id": " glpg1972 cohort 3", "label": " glpg1972 cohort 3", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rituximab, chlorambucil", "label": "rituximab, chlorambucil", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O", "label": " CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ast-120, celphere\u00ae cp-305", "label": "ast-120, celphere\u00ae cp-305", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lapatinib, docetaxel", "label": "lapatinib, docetaxel", "shape": "dot", "size": 10}, {"color": "red", "id": " zoledronate", "label": " zoledronate", "shape": "dot", "size": 10}, {"color": "red", "id": " triple it therapy", "label": " triple it therapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "biphasic insulin aspart 30, biphasic insulin aspart 30, metformin", "label": "biphasic insulin aspart 30, biphasic insulin aspart 30, metformin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "urinary bladder, neurogenic", "label": "urinary bladder, neurogenic", "shape": "dot", "size": 10}, {"color": "red", "id": " truvada\u2122", "label": " truvada\u2122", "shape": "dot", "size": 10}, {"color": "red", "id": "ombitasvir/paritaprevir/ritonavir", "label": "ombitasvir/paritaprevir/ritonavir", "shape": "dot", "size": 10}, {"color": "red", "id": "al-794", "label": "al-794", "shape": "dot", "size": 10}, {"color": "red", "id": "voraxaze (glucarpidase)", "label": "voraxaze (glucarpidase)", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(C)(N)CC1=CC=CC=C1", "label": "CC(C)(N)CC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lenalidomide, placebo, rituximab, cyclophosphamide, doxorubicin, prednisone, vincristine", "label": "lenalidomide, placebo, rituximab, cyclophosphamide, doxorubicin, prednisone, vincristine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedasc-01, placebo_major depressive disorder", "label": "completedasc-01, placebo_major depressive disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo(for thvd-201)", "label": " placebo(for thvd-201)", "shape": "dot", "size": 10}, {"color": "red", "id": " saline 0.9%", "label": " saline 0.9%", "shape": "dot", "size": 10}, {"color": "red", "id": " iv doxapram", "label": " iv doxapram", "shape": "dot", "size": 10}, {"color": "red", "id": " vildagliptin 50 mg bid", "label": " vildagliptin 50 mg bid", "shape": "dot", "size": 10}, {"color": "red", "id": " 250 mg/day", "label": " 250 mg/day", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcombination of low ics and montelukast, monotherapy of medium dose ics_persistent asthma, elderly", "label": "completedcombination of low ics and montelukast, monotherapy of medium dose ics_persistent asthma, elderly", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalisertib_adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, hepatosplenic t-cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, recurrent adult non-hodgkin lymphoma, recurrent adult t-cell leukemia/lymphoma", "label": "completedalisertib_adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, hepatosplenic t-cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, recurrent adult non-hodgkin lymphoma, recurrent adult t-cell leukemia/lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "O[C@@H]1[C@@H](CC2=CC=CC=C2)COC2=CC(=CC=C12)C1=CC(=CC=C1C(O)=O)C(F)(F)F", "label": "O[C@@H]1[C@@H](CC2=CC=CC=C2)COC2=CC(=CC=C12)C1=CC(=CC=C1C(O)=O)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "red", "id": "org 24448", "label": "org 24448", "shape": "dot", "size": 10}, {"color": "green", "id": " ventilator-associated pneumonia", "label": " ventilator-associated pneumonia", "shape": "dot", "size": 10}, {"color": "red", "id": "pneumococcal protein vaccine", "label": "pneumococcal protein vaccine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedrituximab_leukemia, lymphocytic, chronic, lymphoma, small lymphocytic", "label": "terminatedrituximab_leukemia, lymphocytic, chronic, lymphoma, small lymphocytic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " retinal vein occlusion", "label": " retinal vein occlusion", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent thyroid cancer", "label": " recurrent thyroid cancer", "shape": "dot", "size": 10}, {"color": "green", "id": "borderline ovarian mucinous tumor", "label": "borderline ovarian mucinous tumor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NCC=C.ClCC1CO1, CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1", "label": "NCC=C.ClCC1CO1, CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1", "shape": "dot", "size": 10}, {"color": "red", "id": "budesonide / formoterol fumarate (symbicort)", "label": "budesonide / formoterol fumarate (symbicort)", "shape": "dot", "size": 10}, {"color": "red", "id": "mdx-1100", "label": "mdx-1100", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "defactinib (vs-6063), placebo", "label": "defactinib (vs-6063), placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C", "label": "CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1", "label": "CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC(C)OC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "esophageal neoplasms, esophageal diseases", "label": "esophageal neoplasms, esophageal diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "embolism, thrombosis", "label": "embolism, thrombosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ceritinib, pemetrexed, cisplatin, carboplatin", "label": "ceritinib, pemetrexed, cisplatin, carboplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=NC2=CC=CC(=C2C(=O)N1C1=CC=C(OCCCN2CCCC2)C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC1=NC2=CC=CC(=C2C(=O)N1C1=CC=C(OCCCN2CCCC2)C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "blue", "id": "OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1", "label": "OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " 100 mg or 200 mg (dose escalation period 3)", "label": " 100 mg or 200 mg (dose escalation period 3)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2", "label": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2", "shape": "dot", "size": 10}, {"color": "green", "id": "hemorrhage", "label": "hemorrhage", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusfimasartan, valsartan, atenolol_blood pressure, ischemic stroke", "label": "unknown statusfimasartan, valsartan, atenolol_blood pressure, ischemic stroke", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedecp methoxsalen, standard of care_chronic graft versus host disease", "label": "completedecp methoxsalen, standard of care_chronic graft versus host disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcediranib maleate_neurofibromatosis type 1, plexiform neurofibroma, spinal cord neurofibroma", "label": "terminatedcediranib maleate_neurofibromatosis type 1, plexiform neurofibroma, spinal cord neurofibroma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "axitinib, sunitinib", "label": "axitinib, sunitinib", "shape": "dot", "size": 10}, {"color": "green", "id": " delayed graft function", "label": " delayed graft function", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddesvenlafaxine sr, desipramine, paroxetine_depression", "label": "completeddesvenlafaxine sr, desipramine, paroxetine_depression", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedreparixin continuous infusion, reparixin intermittent infusion_ischemia-reperfusion injury, kidney diseases", "label": "completedreparixin continuous infusion, reparixin intermittent infusion_ischemia-reperfusion injury, kidney diseases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "genotype 1 chronic hepatitis c", "label": "genotype 1 chronic hepatitis c", "shape": "dot", "size": 10}, {"color": "red", "id": "dsc127", "label": "dsc127", "shape": "dot", "size": 10}, {"color": "red", "id": "xalacom (kp2035)", "label": "xalacom (kp2035)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, FC1=CNC(=O)NC1=O", "label": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, FC1=CNC(=O)NC1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=CC(O[C@@H](CCC(F)(F)F)C2=CC=C(C=C2)C(=O)NCCC(O)=O)=CC(C)=C1C1=CC=C(C=C1)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "CC1=CC(O[C@@H](CCC(F)(F)F)C2=CC=C(C=C2)C(=O)NCCC(O)=O)=CC(C)=C1C1=CC=C(C=C1)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": " joint diseases", "label": " joint diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvalacyclovir, placebo_schizophrenia, schizoaffective disorder", "label": "completedvalacyclovir, placebo_schizophrenia, schizoaffective disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@](C)(O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@](C)(O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "green", "id": " high risk prostate cancer", "label": " high risk prostate cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " pramipexole", "label": " pramipexole", "shape": "dot", "size": 10}, {"color": "green", "id": "estrogen receptor positive", "label": "estrogen receptor positive", "shape": "dot", "size": 10}, {"color": "green", "id": " dopamine beta hydroxylase deficiency", "label": " dopamine beta hydroxylase deficiency", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": " prasugrel 60mg", "label": " prasugrel 60mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1", "label": "CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatednitroprusside_myocardial infarction", "label": "terminatednitroprusside_myocardial infarction", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vemurafenib, bevacizumab, cobimetinib", "label": "vemurafenib, bevacizumab, cobimetinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmethadone hydrochloride, morphine sulfate, oxycodone hydrochloride_brain and central nervous system tumors, chronic myeloproliferative disorders, leukemia, lymphoma, lymphoproliferative disorder, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, pain, precancerous condition, unspecified adult solid tumor, protocol specific", "label": "terminatedmethadone hydrochloride, morphine sulfate, oxycodone hydrochloride_brain and central nervous system tumors, chronic myeloproliferative disorders, leukemia, lymphoma, lymphoproliferative disorder, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, pain, precancerous condition, unspecified adult solid tumor, protocol specific", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednab-paclitaxel, gemcitabine_pancreatic cancer", "label": "completednab-paclitaxel, gemcitabine_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedgsk2248761 100 mg once daily, gsk2248761 200 mg once daily, etravirine_infection, human immunodeficiency virus", "label": "terminatedgsk2248761 100 mg once daily, gsk2248761 200 mg once daily, etravirine_infection, human immunodeficiency virus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedibrutinib_adult b acute lymphoblastic leukemia, adult b acute lymphoblastic leukemia with t(9;22)(q34;q11.2); bcr-abl1, recurrent adult acute lymphoblastic leukemia", "label": "terminatedibrutinib_adult b acute lymphoblastic leukemia, adult b acute lymphoblastic leukemia with t(9;22)(q34;q11.2); bcr-abl1, recurrent adult acute lymphoblastic leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedeltrombopag_thrombocytopenia, multiple myeloma", "label": "terminatedeltrombopag_thrombocytopenia, multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedgemcitabine, oxaliplatin_cancer of the head and neck", "label": "terminatedgemcitabine, oxaliplatin_cancer of the head and neck", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "heartburn", "label": "heartburn", "shape": "dot", "size": 10}, {"color": "green", "id": "recurrent ovarian epithelial cancer", "label": "recurrent ovarian epithelial cancer", "shape": "dot", "size": 10}, {"color": "red", "id": " triapine", "label": " triapine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tacrolimus capsule, tacrolimus placebo, leflunomide tablet, leflunomide placebo, prednisone", "label": "tacrolimus capsule, tacrolimus placebo, leflunomide tablet, leflunomide placebo, prednisone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lenalidomide, placebo", "label": "lenalidomide, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dupilumab sar231893 (regn668), placebo, mometasone furoate nasal spray", "label": "dupilumab sar231893 (regn668), placebo, mometasone furoate nasal spray", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "apatinib, placebo", "label": "apatinib, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=CC(=O)C=C2CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]3[C@@]12C, CN(C)CCOC1=CC=C(C=C1)C(=C(\\CCCl)C1=CC=CC=C1)\\C1=CC=CC=C1, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N", "label": "CC1=CC(=O)C=C2CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]3[C@@]12C, CN(C)CCOC1=CC=C(C=C1)C(=C(\\CCCl)C1=CC=CC=C1)\\C1=CC=CC=C1, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfesoterodine 8 mg, placebo_urinary bladder, overactive", "label": "completedfesoterodine 8 mg, placebo_urinary bladder, overactive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " amoxicillin/clavulanate", "label": " amoxicillin/clavulanate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "meloxicam suppository, meloxicam tablet, indomethacin", "label": "meloxicam suppository, meloxicam tablet, indomethacin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@](CCO)(N=C(O)C1(N)CCN(CC1)C1=NC=NC2=C1C=CN2)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]", "label": "[H][C@@](CCO)(N=C(O)C1(N)CCN(CC1)C1=NC=NC2=C1C=CN2)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlis-dexamphetamine_attention deficit hyperactivity disorder, glucose intolerance, obesity", "label": "terminatedlis-dexamphetamine_attention deficit hyperactivity disorder, glucose intolerance, obesity", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "palliative care", "label": "palliative care", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "propofol, ketamine", "label": "propofol, ketamine", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=CC=C2C(NC[C@](O)(CC(C)(C)C3=CC(F)=CC4=C3OCC4)C(F)(F)F)=CC=CC2=N1", "label": "CC1=CC=C2C(NC[C@](O)(CC(C)(C)C3=CC(F)=CC4=C3OCC4)C(F)(F)F)=CC=CC2=N1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rituximab, bendamustine, medi-551", "label": "rituximab, bendamustine, medi-551", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sch 727965, capecitabine, erlotinib", "label": "sch 727965, capecitabine, erlotinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ketamine, morphine", "label": "ketamine, morphine", "shape": "dot", "size": 10}, {"color": "red", "id": "snx-5422 plus ibrutinib", "label": "snx-5422 plus ibrutinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1", "label": "[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2, NC[C@H]1CC[C@@H](CC1)C(O)=O", "label": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2, NC[C@H]1CC[C@@H](CC1)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": " peginterferon alpha 2a", "label": " peginterferon alpha 2a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedraltegravir poloxamer film coated tablet, raltegravir chewable tablet, raltegravir oral granules for suspension (20 mg/ml), raltegravir poloxamer film coated tablet_hiv infections", "label": "completedraltegravir poloxamer film coated tablet, raltegravir chewable tablet, raltegravir oral granules for suspension (20 mg/ml), raltegravir poloxamer film coated tablet_hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " tdf/ftc", "label": " tdf/ftc", "shape": "dot", "size": 10}, {"color": "red", "id": " cisplatin and sti571", "label": " cisplatin and sti571", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "accelerated phase chronic myelogenous leukemia, blastic phase chronic myelogenous leukemia, childhood chronic myelogenous leukemia, chronic myelogenous leukemia, bcr-abl1 positive, meningeal chronic myelogenous leukemia, recurrent childhood acute lymphoblastic leukemia, relapsing chronic myelogenous leukemia, unspecified childhood solid tumor, protocol specific", "label": "accelerated phase chronic myelogenous leukemia, blastic phase chronic myelogenous leukemia, childhood chronic myelogenous leukemia, chronic myelogenous leukemia, bcr-abl1 positive, meningeal chronic myelogenous leukemia, recurrent childhood acute lymphoblastic leukemia, relapsing chronic myelogenous leukemia, unspecified childhood solid tumor, protocol specific", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpemetrexed, cisplatin and cbp501, pemetrexed and cisplatin_malignant pleural mesothelioma, solid tumors", "label": "completedpemetrexed, cisplatin and cbp501, pemetrexed and cisplatin_malignant pleural mesothelioma, solid tumors", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ds stage i plasma cell myeloma, ds stage ii plasma cell myeloma, ds stage iii plasma cell myeloma, refractory plasma cell myeloma, smoldering plasma cell myeloma", "label": "ds stage i plasma cell myeloma, ds stage ii plasma cell myeloma, ds stage iii plasma cell myeloma, refractory plasma cell myeloma, smoldering plasma cell myeloma", "shape": "dot", "size": 10}, {"color": "red", "id": "cl-108 (hydrocodone 7.5 mg", "label": "cl-108 (hydrocodone 7.5 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "affective psychosis, bipolar, bipolar disorder, mania", "label": "affective psychosis, bipolar, bipolar disorder, mania", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alendronate 70-mg/vitamin d3 5600 iu combination tablet (fosamax plus), calcitriol", "label": "alendronate 70-mg/vitamin d3 5600 iu combination tablet (fosamax plus), calcitriol", "shape": "dot", "size": 10}, {"color": "red", "id": " rdea806 800 mg", "label": " rdea806 800 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingoxaliplatin, leucovorin calcium, fluorouracil, carboplatin, paclitaxel_adenocarcinoma of the gastroesophageal junction, esophageal cancer", "label": "active, not recruitingoxaliplatin, leucovorin calcium, fluorouracil, carboplatin, paclitaxel_adenocarcinoma of the gastroesophageal junction, esophageal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedly2062430, placebo_alzheimer\u0027s disease", "label": "completedly2062430, placebo_alzheimer\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddexamethasone, sham injection_diabetic macular edema", "label": "completeddexamethasone, sham injection_diabetic macular edema", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbi 409306 100 mg qd, bi 498306 50 mg qd, placebo, bi 498306 25 mg qd, bi 409306 10 mg qd_schizophrenia", "label": "completedbi 409306 100 mg qd, bi 498306 50 mg qd, placebo, bi 498306 25 mg qd, bi 409306 10 mg qd_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " brinzolamide/brimonidine vehicle", "label": " brinzolamide/brimonidine vehicle", "shape": "dot", "size": 10}, {"color": "blue", "id": " COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1", "label": " COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)NCCCNCCCCN)OS(O)(=O)=O", "label": "CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)NCCCNCCCCN)OS(O)(=O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "advagraf\u00ae, prograf\u00ae", "label": "advagraf\u00ae, prograf\u00ae", "shape": "dot", "size": 10}, {"color": "red", "id": " cyclophosphamide and mesna", "label": " cyclophosphamide and mesna", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusapatinib (250 mg/d) + docetaxel (60 mg/m2), apatinib (500 mg/d) + docetaxel (60 mg/m2), apatinib (750 mg/d) + docetaxel (60 mg/m2)_lung adenocarcinoma", "label": "unknown statusapatinib (250 mg/d) + docetaxel (60 mg/m2), apatinib (500 mg/d) + docetaxel (60 mg/m2), apatinib (750 mg/d) + docetaxel (60 mg/m2)_lung adenocarcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "risankizumab", "label": "risankizumab", "shape": "dot", "size": 10}, {"color": "green", "id": " bone tumor", "label": " bone tumor", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hepatitis c, hcv", "label": "hepatitis c, hcv", "shape": "dot", "size": 10}, {"color": "red", "id": "dn-101 (calcitriol)", "label": "dn-101 (calcitriol)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcobitolimod, placebo_ulcerative colitis", "label": "completedcobitolimod, placebo_ulcerative colitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1C(COC2=CC=C(CC3SC(=O)NC3=O)C=C2)=NC2=CC=CC=C2C1=O", "label": "CN1C(COC2=CC=C(CC3SC(=O)NC3=O)C=C2)=NC2=CC=CC=C2C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1", "label": "CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OS(=O)(=O)CCS, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "ClCCN(CCCl)P1(=O)NCCCO1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OS(=O)(=O)CCS, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin degludec_diabetes, diabetes mellitus, type 2", "label": "completedinsulin degludec_diabetes, diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgw274150_migraine disorders, migraine", "label": "completedgw274150_migraine disorders, migraine", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " raltegravir chewable tablet", "label": " raltegravir chewable tablet", "shape": "dot", "size": 10}, {"color": "green", "id": " neurofibromatosis 1", "label": " neurofibromatosis 1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedqaw039, montelukast, placebo_allergic rhinitis", "label": "completedqaw039, montelukast, placebo_allergic rhinitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO", "label": "CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ixazomib, thalidomide, dexamethasone", "label": "ixazomib, thalidomide, dexamethasone", "shape": "dot", "size": 10}, {"color": "red", "id": "trv130", "label": "trv130", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "ClCCN(CCCl)P1(=O)NCCCO1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC", "label": "[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "budesonide/formoterol (symbicort), budesonide (pulmicort), terbutaline sulfate (bricasol)", "label": "budesonide/formoterol (symbicort), budesonide (pulmicort), terbutaline sulfate (bricasol)", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O", "label": "CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "red", "id": " platinum-based chemotherapy", "label": " platinum-based chemotherapy", "shape": "dot", "size": 10}, {"color": "red", "id": "jnj-56136379", "label": "jnj-56136379", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "act-129968, placebo, cetirizine", "label": "act-129968, placebo, cetirizine", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iva mycosis fungoides/sezary syndrome", "label": " stage iva mycosis fungoides/sezary syndrome", "shape": "dot", "size": 10}, {"color": "red", "id": " rostafuroxin", "label": " rostafuroxin", "shape": "dot", "size": 10}, {"color": "red", "id": "dlbs1033", "label": "dlbs1033", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsildenafil, sildenafil_chronic obstructive pulmonary disease, pulmonary hypertension", "label": "completedsildenafil, sildenafil_chronic obstructive pulmonary disease, pulmonary hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusadriamycin+cyclophosphamide\u003edocetaxel, gnrha with tamoxifen_breast cancer", "label": "unknown statusadriamycin+cyclophosphamide\u003edocetaxel, gnrha with tamoxifen_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " tazorac\u00ae (tazarotene) cream 0.05%", "label": " tazorac\u00ae (tazarotene) cream 0.05%", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tapentadol prolonged release, tapentadol prolonged release with pregabalin, tapentadol prolonged release open label maintenance", "label": "tapentadol prolonged release, tapentadol prolonged release with pregabalin, tapentadol prolonged release open label maintenance", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hiv infection, gastrointestinal symptoms", "label": "hiv infection, gastrointestinal symptoms", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iiia skin melanoma", "label": " stage iiia skin melanoma", "shape": "dot", "size": 10}, {"color": "red", "id": "seroquel (quetiapine)", "label": "seroquel (quetiapine)", "shape": "dot", "size": 10}, {"color": "red", "id": "mdco-216", "label": "mdco-216", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iii melanoma", "label": " stage iii melanoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, FC1=CNC(=O)NC1=O", "label": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, FC1=CNC(=O)NC1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "red", "id": "pf-06282999", "label": "pf-06282999", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "intensive insulin, routine care", "label": "intensive insulin, routine care", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hiv infections, gonorrhea, chlamydial infections, genital herpes", "label": "hiv infections, gonorrhea, chlamydial infections, genital herpes", "shape": "dot", "size": 10}, {"color": "red", "id": "cilnidipine", "label": "cilnidipine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuspolyphenon e_hiv infection", "label": "unknown statuspolyphenon e_hiv infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCC\\N=C1/S\\C(=C/C2=CC=C(OC[C@H](O)CO)C(Cl)=C2)C(=O)N1C1=CC=CC=C1C", "label": "CCC\\N=C1/S\\C(=C/C2=CC=C(OC[C@H](O)CO)C(Cl)=C2)C(=O)N1C1=CC=CC=C1C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "major cutaneous abscess, cellulitis, erysipelas", "label": "major cutaneous abscess, cellulitis, erysipelas", "shape": "dot", "size": 10}, {"color": "red", "id": " goserelin with bicalutamide and dutasteride", "label": " goserelin with bicalutamide and dutasteride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedazd7762, irinotecan_advanced solid tumors, cancer, advanced solid malignancies", "label": "terminatedazd7762, irinotecan_advanced solid tumors, cancer, advanced solid malignancies", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " n-acetylcysteine", "label": " n-acetylcysteine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "b-cell adult acute lymphoblastic leukemia, blastic phase chronic myelogenous leukemia, chronic myelogenous leukemia, bcr-abl1 positive, philadelphia chromosome positive adult precursor acute lymphoblastic leukemia, untreated adult acute lymphoblastic leukemia", "label": "b-cell adult acute lymphoblastic leukemia, blastic phase chronic myelogenous leukemia, chronic myelogenous leukemia, bcr-abl1 positive, philadelphia chromosome positive adult precursor acute lymphoblastic leukemia, untreated adult acute lymphoblastic leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtipifarnib;zarnestra; r115777_acute myeloid leukemia", "label": "completedtipifarnib;zarnestra; r115777_acute myeloid leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dalteparin (fragmin), unfractionated heparin", "label": "dalteparin (fragmin), unfractionated heparin", "shape": "dot", "size": 10}, {"color": "red", "id": "tivozanib (av-951) plus temsirolimus", "label": "tivozanib (av-951) plus temsirolimus", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gsk1322322 initial fit for purpose tablets, gsk1322322 over granulated tablets, gsk1322322 intended commercial tablets, placebo tablets, 13c-gsk1322322 stable isotope powder, gsk1322322 for injection, placebo injection", "label": "gsk1322322 initial fit for purpose tablets, gsk1322322 over granulated tablets, gsk1322322 intended commercial tablets, placebo tablets, 13c-gsk1322322 stable isotope powder, gsk1322322 for injection, placebo injection", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "antithymocyte globulin (atg), prednisone", "label": "antithymocyte globulin (atg), prednisone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "label": "N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " mfolfox6+placebo", "label": " mfolfox6+placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "medi4736 (durvalumab)", "label": "medi4736 (durvalumab)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "colesevelam hcl, sitagliptin", "label": "colesevelam hcl, sitagliptin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlixisenatide (ave0010), placebo, basal insulin, metformin_diabetes mellitus, type 2", "label": "completedlixisenatide (ave0010), placebo, basal insulin, metformin_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage ib mycosis fungoides/sezary syndrome", "label": " stage ib mycosis fungoides/sezary syndrome", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsulfonylurea, liraglutide, liraglutide_diabetes, diabetes mellitus, type 2", "label": "completedsulfonylurea, liraglutide, liraglutide_diabetes, diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bimosiamose, placebo", "label": "bimosiamose, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "squalamine lactate ophthalmic solution, 0.2%, placebo ophthalmic solution, ranibizumab", "label": "squalamine lactate ophthalmic solution, 0.2%, placebo ophthalmic solution, ranibizumab", "shape": "dot", "size": 10}, {"color": "red", "id": " matched placebo - sugar pill", "label": " matched placebo - sugar pill", "shape": "dot", "size": 10}, {"color": "red", "id": "zinc", "label": "zinc", "shape": "dot", "size": 10}, {"color": "red", "id": "hycamtin", "label": "hycamtin", "shape": "dot", "size": 10}, {"color": "red", "id": "sofosbuvir and daclatasvir", "label": "sofosbuvir and daclatasvir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12, [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C", "label": "CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12, [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lapatinib, topotecan", "label": "lapatinib, topotecan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hepatitis c, hcv, chronic hepatitis c infection, hepatitis c genotype 1", "label": "hepatitis c, hcv, chronic hepatitis c infection, hepatitis c genotype 1", "shape": "dot", "size": 10}, {"color": "red", "id": "bbi608", "label": "bbi608", "shape": "dot", "size": 10}, {"color": "red", "id": "pd-0325901", "label": "pd-0325901", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedatomoxetine_attention deficit hyperactivity disorder, cannabis abuse", "label": "terminatedatomoxetine_attention deficit hyperactivity disorder, cannabis abuse", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, placebo, placebo, bi 187004, placebo, bi 187004, bi 187004, bi 187004_diabetes mellitus, type 2", "label": "completedplacebo, placebo, placebo, bi 187004, placebo, bi 187004, bi 187004, bi 187004_diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedbotulinum toxin type a, placebo_chronic prostatitis with chronic pelvic pain syndrome, prostatitis", "label": "terminatedbotulinum toxin type a, placebo_chronic prostatitis with chronic pelvic pain syndrome, prostatitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCNC(=O)C1=NOC(=C1C1=CC=C(CN2CCOCC2)C=C1)C1=CC(=C(O)C=C1O)C(C)(C)C, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "label": "CCNC(=O)C1=NOC(=C1C1=CC=C(CN2CCOCC2)C=C1)C1=CC(=C(O)C=C1O)C(C)(C)C, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": " allograft rejection", "label": " allograft rejection", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmemantine, placebo oral tablet_parkinson\u0027s disease, cognitive impairment, dementia", "label": "completedmemantine, placebo oral tablet_parkinson\u0027s disease, cognitive impairment, dementia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " tesetaxel once weekly", "label": " tesetaxel once weekly", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O, CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F", "label": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O, CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeds-adenosyl methionine_abdominal pain", "label": "completeds-adenosyl methionine_abdominal pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "sch 530348", "label": "sch 530348", "shape": "dot", "size": 10}, {"color": "green", "id": "small cell carcinoma", "label": "small cell carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbudesonide mmx\u00ae 6 mg, budesonide mmx\u00ae 9 mg, entocort ec\u00ae 3 mg, placebo_ulcerative colitis", "label": "completedbudesonide mmx\u00ae 6 mg, budesonide mmx\u00ae 9 mg, entocort ec\u00ae 3 mg, placebo_ulcerative colitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCNC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)CCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCNC(=O)CCC\\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\\C=C\\[C@@H](O)CCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedc31g, nonoxynol-9 (n-9)_pregnancy", "label": "completedc31g, nonoxynol-9 (n-9)_pregnancy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dexamethasone based mouthwash, everolimus, exemestane", "label": "dexamethasone based mouthwash, everolimus, exemestane", "shape": "dot", "size": 10}, {"color": "blue", "id": "N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2", "label": "N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H]", "label": "[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedamlodipine_hypertension", "label": "completedamlodipine_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "pelvic organ prolapse", "label": "pelvic organ prolapse", "shape": "dot", "size": 10}, {"color": "red", "id": "cabazitaxel xrp6258", "label": "cabazitaxel xrp6258", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "label": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1", "label": "COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "grazoprevir and elbasvir", "label": "grazoprevir and elbasvir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsta-9090_breast cancer", "label": "completedsta-9090_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitinglenalidomide_lymphoma", "label": "active, not recruitinglenalidomide_lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "regorafenib (bay73-4506) - sequential / cisplatin / pemetrexed", "label": "regorafenib (bay73-4506) - sequential / cisplatin / pemetrexed", "shape": "dot", "size": 10}, {"color": "red", "id": " arsenic trioxide", "label": " arsenic trioxide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "neurogenic orthostatic hypotension, non-diabetic autonomic neuropathy, multiple system atrophy, dopamine beta hydroxylase deficiency", "label": "neurogenic orthostatic hypotension, non-diabetic autonomic neuropathy, multiple system atrophy, dopamine beta hydroxylase deficiency", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlovaza\u00ae, the placebo contained 1 gram of corn oil in each capsule._myocardial infarction", "label": "terminatedlovaza\u00ae, the placebo contained 1 gram of corn oil in each capsule._myocardial infarction", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " micardis plus 80/12.5", "label": " micardis plus 80/12.5", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedstb, tvd, atr, rtv, atv, abc/3tc, iohexol_hiv-1 infection", "label": "completedstb, tvd, atr, rtv, atv, abc/3tc, iohexol_hiv-1 infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ac regimen", "label": "ac regimen", "shape": "dot", "size": 10}, {"color": "red", "id": "oxybutynin chloride oros", "label": "oxybutynin chloride oros", "shape": "dot", "size": 10}, {"color": "red", "id": "ticagrelor + asa + bivalirudin", "label": "ticagrelor + asa + bivalirudin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedaspirin_thrombocytopenia, myocardial infarction", "label": "terminatedaspirin_thrombocytopenia, myocardial infarction", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " alteplase placebo", "label": " alteplase placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " histone deacetylase inhibitor", "label": " histone deacetylase inhibitor", "shape": "dot", "size": 10}, {"color": "red", "id": "modified folfox6 + bevacizumab", "label": "modified folfox6 + bevacizumab", "shape": "dot", "size": 10}, {"color": "red", "id": " experimental: cd07223 1.5% topical gel tid", "label": " experimental: cd07223 1.5% topical gel tid", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C", "label": "[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "red", "id": "polyphenon e (egcg)", "label": "polyphenon e (egcg)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pemetrexed plus carboplatin, gefitinib", "label": "pemetrexed plus carboplatin, gefitinib", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ranibizumab 0.3 mg - 3 times monthly, then quarterly, ranibizumab 0.5 mg - 3 times monthly, then quarterly, ranibizumab 0.3 mg monthly", "label": "ranibizumab 0.3 mg - 3 times monthly, then quarterly, ranibizumab 0.5 mg - 3 times monthly, then quarterly, ranibizumab 0.3 mg monthly", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lurbinectedin (pm01183), pegylated liposomal doxorubicin (pld), topotecan", "label": "lurbinectedin (pm01183), pegylated liposomal doxorubicin (pld), topotecan", "shape": "dot", "size": 10}, {"color": "red", "id": "pertuzumab", "label": "pertuzumab", "shape": "dot", "size": 10}, {"color": "red", "id": "tesofensine", "label": "tesofensine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(=O)\\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1", "label": "OC(=O)\\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to 17-\u03b2 estradiol", "label": " placebo to 17-\u03b2 estradiol", "shape": "dot", "size": 10}, {"color": "green", "id": " refractory adult acute lymphoblastic leukemia", "label": " refractory adult acute lymphoblastic leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedjaungo, placebo_dermatitis, atopic", "label": "completedjaungo, placebo_dermatitis, atopic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpatritumab, erlotinib, placebo_lung cancer, non-small cell lung cancer", "label": "terminatedpatritumab, erlotinib, placebo_lung cancer, non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpaclitaxel, carboplatin_non-small cell lung cancer", "label": "completedpaclitaxel, carboplatin_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateddexamethasone, panobinostat, liposomal vincristine, mitoxantrone, peg-asparaginase, bortezomib, intrathecal triples, high-dose methotrexate, 6-mercaptopurine, high-dose cytarabine, nelarabine, cyclophosphamide, etoposide, clofarabine_acute lymphoblastic leukemia, lymphoma, non-hodgkin\u0027s, leukemia, t-cell, leukemia, b-cell", "label": "terminateddexamethasone, panobinostat, liposomal vincristine, mitoxantrone, peg-asparaginase, bortezomib, intrathecal triples, high-dose methotrexate, 6-mercaptopurine, high-dose cytarabine, nelarabine, cyclophosphamide, etoposide, clofarabine_acute lymphoblastic leukemia, lymphoma, non-hodgkin\u0027s, leukemia, t-cell, leukemia, b-cell", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent oral cavity squamous cell carcinoma", "label": " recurrent oral cavity squamous cell carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "non-squamous non-small cell lung cancer, squamous non-small cell lung cancer", "label": "non-squamous non-small cell lung cancer, squamous non-small cell lung cancer", "shape": "dot", "size": 10}, {"color": "blue", "id": " CCCNC(C)C(=O)NC1=CC=CC=C1C", "label": " CCCNC(C)C(=O)NC1=CC=CC=C1C", "shape": "dot", "size": 10}, {"color": "red", "id": " polymyxin b + doripenem", "label": " polymyxin b + doripenem", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedentecavir, entecavir, peginterferon alfa-2a [pegasys], peginterferon alfa-2a [pegasys]_hepatitis b, chronic", "label": "completedentecavir, entecavir, peginterferon alfa-2a [pegasys], peginterferon alfa-2a [pegasys]_hepatitis b, chronic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H], CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F, OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "label": "[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H], CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F, OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1, OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1, OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1", "label": "OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1, OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1, OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtofogliflozin csg452, insulin, placebo_type 2 diabetes mellitus", "label": "completedtofogliflozin csg452, insulin, placebo_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "vonoprazan", "label": "vonoprazan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnnicotine inhaler_tobacco use disorder", "label": "withdrawnnicotine inhaler_tobacco use disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "uveitis, posterior, glaucoma", "label": "uveitis, posterior, glaucoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedamrubicin hydrocloride, docetaxel_lung cancer", "label": "completedamrubicin hydrocloride, docetaxel_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgw842166_osteoarthritis, knee", "label": "completedgw842166_osteoarthritis, knee", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedquetiapine extended release, risperidone_schizophrenia, depression", "label": "completedquetiapine extended release, risperidone_schizophrenia, depression", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": " fiasp\u00ae", "label": " fiasp\u00ae", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "gemcitabine, uft", "label": "gemcitabine, uft", "shape": "dot", "size": 10}, {"color": "red", "id": "sp-304 0.3 mg", "label": "sp-304 0.3 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " dexrazoxane hydrochloride", "label": " dexrazoxane hydrochloride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbortezomib, dexamethasone, and thalidomide, bortezomib, dexamethasone, thalidomide, and cyclophosphamide_multiple myeloma", "label": "completedbortezomib, dexamethasone, and thalidomide, bortezomib, dexamethasone, thalidomide, and cyclophosphamide_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsb-773812, olanzapine_schizophrenia", "label": "completedsb-773812, olanzapine_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " prednisone or equivalent", "label": " prednisone or equivalent", "shape": "dot", "size": 10}, {"color": "red", "id": " emtricitabine /tenofovir df", "label": " emtricitabine /tenofovir df", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "p-ifn alfa 2a, p-ifn alfa 2b, ribavirin, boceprevir", "label": "p-ifn alfa 2a, p-ifn alfa 2b, ribavirin, boceprevir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "adalimumab, methotrexate", "label": "adalimumab, methotrexate", "shape": "dot", "size": 10}, {"color": "red", "id": " lesinurad", "label": " lesinurad", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "5-fu continuous infusion, mtx + 5-fu sequential therapy", "label": "5-fu continuous infusion, mtx + 5-fu sequential therapy", "shape": "dot", "size": 10}, {"color": "red", "id": "benazepril", "label": "benazepril", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rosuvastatin, placebo", "label": "rosuvastatin, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "lenalidomide and low-dose dexamethasone", "label": "lenalidomide and low-dose dexamethasone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedplacebo, azilsartan medoxomil, azilsartan medoxomil_hypertension, diabetes", "label": "terminatedplacebo, azilsartan medoxomil, azilsartan medoxomil_hypertension, diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "label": "C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2", "label": "CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawncelecoxib_breast carcinoma", "label": "withdrawncelecoxib_breast carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alisertib, placebo, paclitaxel", "label": "alisertib, placebo, paclitaxel", "shape": "dot", "size": 10}, {"color": "red", "id": "capecitabine (xeloda)", "label": "capecitabine (xeloda)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "simvastatin, aspirin, placebo", "label": "simvastatin, aspirin, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1", "label": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " heparin", "label": " heparin", "shape": "dot", "size": 10}, {"color": "red", "id": " losartan potassium", "label": " losartan potassium", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O=[Zn], CC1=CC(O)=CC(C)=C1Cl", "label": "O=[Zn], CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "red", "id": " ropinirole cr 2 mg placebo", "label": " ropinirole cr 2 mg placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo for rosuvastatin", "label": " placebo for rosuvastatin", "shape": "dot", "size": 10}, {"color": "red", "id": "cc-5103 (lenalidomide)", "label": "cc-5103 (lenalidomide)", "shape": "dot", "size": 10}, {"color": "green", "id": " stage ivc papillary thyroid cancer", "label": " stage ivc papillary thyroid cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingdoxorubicin hydrochloride, sorafenib tosylate_advanced adult hepatocellular carcinoma, recurrent hepatocellular carcinoma, stage iii hepatocellular carcinoma ajcc v7, stage iiia hepatocellular carcinoma ajcc v7, stage iiib hepatocellular carcinoma ajcc v7, stage iiic hepatocellular carcinoma ajcc v7, stage iv hepatocellular carcinoma ajcc v7, stage iva hepatocellular carcinoma ajcc v7, stage ivb hepatocellular carcinoma ajcc v7, unresectable hepatocellular carcinoma", "label": "active, not recruitingdoxorubicin hydrochloride, sorafenib tosylate_advanced adult hepatocellular carcinoma, recurrent hepatocellular carcinoma, stage iii hepatocellular carcinoma ajcc v7, stage iiia hepatocellular carcinoma ajcc v7, stage iiib hepatocellular carcinoma ajcc v7, stage iiic hepatocellular carcinoma ajcc v7, stage iv hepatocellular carcinoma ajcc v7, stage iva hepatocellular carcinoma ajcc v7, stage ivb hepatocellular carcinoma ajcc v7, unresectable hepatocellular carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "obesity, oligospermia", "label": "obesity, oligospermia", "shape": "dot", "size": 10}, {"color": "red", "id": " 90y-hpam4", "label": " 90y-hpam4", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, tozadenant", "label": "placebo, tozadenant", "shape": "dot", "size": 10}, {"color": "green", "id": " juvenile idiopathic arthritis", "label": " juvenile idiopathic arthritis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedescitalopram_postpartum depression", "label": "completedescitalopram_postpartum depression", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ertugliflozin, sitagliptin, placebo to ertugliflozin, placebo to sitagliptin, glimepiride", "label": "ertugliflozin, sitagliptin, placebo to ertugliflozin, placebo to sitagliptin, glimepiride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpn400 (vimovo), diclofenac/misoprostol_gastric ulcer", "label": "terminatedpn400 (vimovo), diclofenac/misoprostol_gastric ulcer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedexenatide once weekly, metformin, sitagliptin, pioglitazone_type 2 diabetes mellitus", "label": "completedexenatide once weekly, metformin, sitagliptin, pioglitazone_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cp 751,871 (figitumumab), erlotinib, erlotinib", "label": "cp 751,871 (figitumumab), erlotinib, erlotinib", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo equivalent", "label": " placebo equivalent", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "shape": "dot", "size": 10}, {"color": "blue", "id": "FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12", "label": "FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsyn-010 21 mg, syn-010 42 mg, placebo_irritable bowel syndrome with constipation (ibs-c)", "label": "completedsyn-010 21 mg, syn-010 42 mg, placebo_irritable bowel syndrome with constipation (ibs-c)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "eyp001a", "label": "eyp001a", "shape": "dot", "size": 10}, {"color": "red", "id": "sildenafil vaginal suppositories", "label": "sildenafil vaginal suppositories", "shape": "dot", "size": 10}, {"color": "blue", "id": " FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1", "label": " FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1", "shape": "dot", "size": 10}, {"color": "green", "id": "adult giant cell glioblastoma", "label": "adult giant cell glioblastoma", "shape": "dot", "size": 10}, {"color": "red", "id": " umeclidinium/vilanterol", "label": " umeclidinium/vilanterol", "shape": "dot", "size": 10}, {"color": "red", "id": "amg 479", "label": "amg 479", "shape": "dot", "size": 10}, {"color": "blue", "id": " COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl", "label": " COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl", "shape": "dot", "size": 10}, {"color": "red", "id": "apalutamide", "label": "apalutamide", "shape": "dot", "size": 10}, {"color": "green", "id": "dyslipidemia", "label": "dyslipidemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "avastin, preservative-free triamcinolone acetonide (tac-pf)", "label": "avastin, preservative-free triamcinolone acetonide (tac-pf)", "shape": "dot", "size": 10}, {"color": "red", "id": " gliclazide (comparison drug)", "label": " gliclazide (comparison drug)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=CC(\\C=C\\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "label": "CC1=CC(\\C=C\\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statussunitinib_glioblastoma multiforme", "label": "unknown statussunitinib_glioblastoma multiforme", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " nonspecific interstitial pneumonia", "label": " nonspecific interstitial pneumonia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedepoetin alfa_anemia, breast neoplasms, quality of life", "label": "completedepoetin alfa_anemia, breast neoplasms, quality of life", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " thryoid gland nonmedullary carcinoma", "label": " thryoid gland nonmedullary carcinoma", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1", "label": "NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " post polycythemia vera myelofibrosis", "label": " post polycythemia vera myelofibrosis", "shape": "dot", "size": 10}, {"color": "green", "id": " pseudomyxoma peritonei", "label": " pseudomyxoma peritonei", "shape": "dot", "size": 10}, {"color": "green", "id": " small cell carcinoma of the lung", "label": " small cell carcinoma of the lung", "shape": "dot", "size": 10}, {"color": "green", "id": " in vitro fertilization", "label": " in vitro fertilization", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)[C@]([H])(CC)[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C", "label": "[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)[C@]([H])(CC)[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hiv infections, tuberculosis", "label": "hiv infections, tuberculosis", "shape": "dot", "size": 10}, {"color": "red", "id": " pro re nata (prn) ranibizumab", "label": " pro re nata (prn) ranibizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtamibarotene, placebo_stage iiib non-small cell lung cancer with pleural effusion, stage iv non-small cell lung cancer", "label": "terminatedtamibarotene, placebo_stage iiib non-small cell lung cancer with pleural effusion, stage iv non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ssp-002358 (0.5 mg) + ppi", "label": " ssp-002358 (0.5 mg) + ppi", "shape": "dot", "size": 10}, {"color": "red", "id": " docetaxel and cisplatin", "label": " docetaxel and cisplatin", "shape": "dot", "size": 10}, {"color": "red", "id": "concor 5mg(bisoprolol hemifumarate 5mg) 2tab", "label": "concor 5mg(bisoprolol hemifumarate 5mg) 2tab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rapamycin, methotrexate", "label": "rapamycin, methotrexate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedirbesartan/hydrochlorothiazide_hypertension", "label": "completedirbesartan/hydrochlorothiazide_hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "nilotinib (tasigna \u00ae)", "label": "nilotinib (tasigna \u00ae)", "shape": "dot", "size": 10}, {"color": "red", "id": " menatetrenone", "label": " menatetrenone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "infliximab, mercaptopurine, azathioprine, infliximab", "label": "infliximab, mercaptopurine, azathioprine, infliximab", "shape": "dot", "size": 10}, {"color": "red", "id": " suberoylanilide hydroxamic acid (saha) / duration of treatment 6 months", "label": " suberoylanilide hydroxamic acid (saha) / duration of treatment 6 months", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1", "label": "[Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "travoprost/timolol fixed combination", "label": "travoprost/timolol fixed combination", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtibolone, estradiol-norethisterone_sexual dysfunction", "label": "completedtibolone, estradiol-norethisterone_sexual dysfunction", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " gs-0938", "label": " gs-0938", "shape": "dot", "size": 10}, {"color": "green", "id": "adjunctive treatment of major depressive disorder", "label": "adjunctive treatment of major depressive disorder", "shape": "dot", "size": 10}, {"color": "red", "id": " dofetilide", "label": " dofetilide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC", "label": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC", "shape": "dot", "size": 10}, {"color": "red", "id": " aprepitant powder for suspension (pfs)", "label": " aprepitant powder for suspension (pfs)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cyclophosphamide, fludarabine phosphate, lenalidomide", "label": "cyclophosphamide, fludarabine phosphate, lenalidomide", "shape": "dot", "size": 10}, {"color": "red", "id": "mucinex", "label": "mucinex", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmk-0893 10 mg, mk-0893 40 mg, mk-0893 200 mg, mk-0893 1000 mg, placebo_type 2 diabetes mellitus", "label": "completedmk-0893 10 mg, mk-0893 40 mg, mk-0893 200 mg, mk-0893 1000 mg, placebo_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "abrilumab", "label": "abrilumab", "shape": "dot", "size": 10}, {"color": "green", "id": " adverse drug event", "label": " adverse drug event", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpropiverine hydrochloride, tolterodine extended-release tablet_overactive bladder", "label": "completedpropiverine hydrochloride, tolterodine extended-release tablet_overactive bladder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " thiamine deficiency", "label": " thiamine deficiency", "shape": "dot", "size": 10}, {"color": "green", "id": "hiv-1 and hepatitis c co-infection", "label": "hiv-1 and hepatitis c co-infection", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1, COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1", "label": "COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1, COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " fancf gene mutation", "label": " fancf gene mutation", "shape": "dot", "size": 10}, {"color": "red", "id": "placebo for mitiglinide", "label": "placebo for mitiglinide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedivig_cutaneous lupus erythematosus", "label": "completedivig_cutaneous lupus erythematosus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcenicriviroc, placebo_nonalcoholic steatohepatitis", "label": "completedcenicriviroc, placebo_nonalcoholic steatohepatitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcabazitaxel (xrp6258) (rpr116258), mitoxantrone, prednisone_neoplasms, prostatic neoplasms", "label": "completedcabazitaxel (xrp6258) (rpr116258), mitoxantrone, prednisone_neoplasms, prostatic neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " vx-659", "label": " vx-659", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ly2140023, placebo, standard of care", "label": "ly2140023, placebo, standard of care", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcetuximab +/- dexamethasone_multiple myeloma", "label": "terminatedcetuximab +/- dexamethasone_multiple myeloma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "blood loss, bone tumour", "label": "blood loss, bone tumour", "shape": "dot", "size": 10}, {"color": "red", "id": "indacaterol 27.5 mcg", "label": "indacaterol 27.5 mcg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCC(CCC)C(O)=O", "label": "CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCC(CCC)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtedizolid (bay119-2631), placebo tedizolid (bay119-2631), linezolid, placebo linezolid_bacterial infections", "label": "completedtedizolid (bay119-2631), placebo tedizolid (bay119-2631), linezolid, placebo linezolid_bacterial infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recurrent uterine corpus carcinoma, stage iiia uterine corpus cancer ajcc v7, stage iiib uterine corpus cancer ajcc v7, stage iiic uterine corpus cancer ajcc v7, stage iva uterine corpus cancer ajcc v7, stage ivb uterine corpus cancer ajcc v7", "label": "recurrent uterine corpus carcinoma, stage iiia uterine corpus cancer ajcc v7, stage iiib uterine corpus cancer ajcc v7, stage iiic uterine corpus cancer ajcc v7, stage iva uterine corpus cancer ajcc v7, stage ivb uterine corpus cancer ajcc v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedduloxetine hydrochloride_neurotoxicity, pain, peripheral neuropathy, unspecified adult solid tumor, protocol specific", "label": "completedduloxetine hydrochloride_neurotoxicity, pain, peripheral neuropathy, unspecified adult solid tumor, protocol specific", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "abediterol 0.156 \u03bcg", "label": "abediterol 0.156 \u03bcg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F, [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O", "label": "CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F, [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": "sar302503", "label": "sar302503", "shape": "dot", "size": 10}, {"color": "red", "id": " part ii- placebo to etoricoxib 60 mg", "label": " part ii- placebo to etoricoxib 60 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedexenatide once weekly, liraglutide_type 2 diabetes mellitus", "label": "completedexenatide once weekly, liraglutide_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedxpf-002, placebo_postherpetic neuralgia", "label": "completedxpf-002, placebo_postherpetic neuralgia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " chronic kidney disease stage 5", "label": " chronic kidney disease stage 5", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtipranavir capsules, ritonavir capsules_hiv infections", "label": "terminatedtipranavir capsules, ritonavir capsules_hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedl-folinic acid, 5 fu, oxaliplatin_biliary tract cancer, gallbladder cancer, cholangiocarcinoma, ampullary cancer", "label": "completedl-folinic acid, 5 fu, oxaliplatin_biliary tract cancer, gallbladder cancer, cholangiocarcinoma, ampullary cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " 80 mg ixekizumab", "label": " 80 mg ixekizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12CC(SCC\\N=C\\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O, [H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O", "label": "[H][C@]12CC(SCC\\N=C\\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O, [H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddexanabinol_brain cancer", "label": "completeddexanabinol_brain cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=C(N1)C=C(C=C3)C#N)C2=O, C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl", "label": "CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=C(N1)C=C(C=C3)C#N)C2=O, C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl", "shape": "dot", "size": 10}, {"color": "red", "id": "kaletra + current dual nrti backbone", "label": "kaletra + current dual nrti backbone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tacrolimus, methotrexate, sirolimus", "label": "tacrolimus, methotrexate, sirolimus", "shape": "dot", "size": 10}, {"color": "blue", "id": "COCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(O)(O)=O", "label": "COCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(O)(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "male breast cancer, recurrent breast cancer, stage iv breast cancer, unspecified adult solid tumor, protocol specific", "label": "male breast cancer, recurrent breast cancer, stage iv breast cancer, unspecified adult solid tumor, protocol specific", "shape": "dot", "size": 10}, {"color": "green", "id": " adult choroid plexus neoplasm", "label": " adult choroid plexus neoplasm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedabi-007, carboplatin, gemcitabine_bladder cancer", "label": "completedabi-007, carboplatin, gemcitabine_bladder cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "label": "CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]", "label": "[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]", "shape": "dot", "size": 10}, {"color": "red", "id": "gsk962040 50 mg", "label": "gsk962040 50 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedprucalopride, prucalopride_constipation", "label": "completedprucalopride, prucalopride_constipation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "secukinumab 150 mg", "label": "secukinumab 150 mg", "shape": "dot", "size": 10}, {"color": "red", "id": "an2728 ointment", "label": "an2728 ointment", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ixabepilone, anticonvulsant", "label": "ixabepilone, anticonvulsant", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedam1030-cream or placebo_atopic dermatitis", "label": "completedam1030-cream or placebo_atopic dermatitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " sporadic thyroid gland medullary carcinoma", "label": " sporadic thyroid gland medullary carcinoma", "shape": "dot", "size": 10}, {"color": "red", "id": " insulin glargine 1.5 u/kg body wt sc", "label": " insulin glargine 1.5 u/kg body wt sc", "shape": "dot", "size": 10}, {"color": "red", "id": " diphenhydramine hydrochloride (hcl)", "label": " diphenhydramine hydrochloride (hcl)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, COC1=C2N(C=C(C(O)=O)C(=O)C2=CC=C1N1C[C@@H](C)C[C@H](N)C1)C1CC1", "label": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, COC1=C2N(C=C(C(O)=O)C(=O)C2=CC=C1N1C[C@@H](C)C[C@H](N)C1)C1CC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsage-547, placebo_essential tremor", "label": "completedsage-547, placebo_essential tremor", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " large-cell", "label": " large-cell", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pegylated interferon alfa 2b, ribavirin", "label": "pegylated interferon alfa 2b, ribavirin", "shape": "dot", "size": 10}, {"color": "red", "id": " ropinirole ir 2 mg placebo", "label": " ropinirole ir 2 mg placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completed323u66 sr 150 mg tablet, 323u66 sr 150 mg placebo tablet_depressive disorder, major", "label": "completed323u66 sr 150 mg tablet, 323u66 sr 150 mg placebo tablet_depressive disorder, major", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmsdc-0160, placebo_alzheimer\u0027s disease", "label": "completedmsdc-0160, placebo_alzheimer\u0027s disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " abt-333", "label": " abt-333", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O, [H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O", "label": "[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O, [H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": " obinutuzumab", "label": " obinutuzumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpemetrexed, best supportive care_non small cell lung cancer", "label": "completedpemetrexed, best supportive care_non small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=CC(O)=CC(C)=C1Cl, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1", "label": "CC1=CC(O)=CC(C)=C1Cl, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedazacytidine, gm-csf_leukemia", "label": "terminatedazacytidine, gm-csf_leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sleep initiation and maintenance disorders, depression", "label": "sleep initiation and maintenance disorders, depression", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddoxorubicin hydrochloride, cyclophosphamide, methotrexate, rasburicase, leucovorin calcium, prednisone, methylprednisolone, cytarabine, etoposide, vincristine sulfate, hydrocortisone sodium succinate_childhood burkitt lymphoma, childhood diffuse large cell lymphoma, childhood immunoblastic large cell lymphoma, stage i childhood large cell lymphoma, stage i childhood small noncleaved cell lymphoma, stage ii childhood large cell lymphoma, stage ii childhood small noncleaved cell lymphoma, stage iii childhood large cell lymphoma, stage iii childhood small noncleaved cell lymphoma, stage iv childhood large cell lymphoma, stage iv childhood small noncleaved cell lymphoma, untreated childhood acute lymphoblastic leukemia", "label": "completeddoxorubicin hydrochloride, cyclophosphamide, methotrexate, rasburicase, leucovorin calcium, prednisone, methylprednisolone, cytarabine, etoposide, vincristine sulfate, hydrocortisone sodium succinate_childhood burkitt lymphoma, childhood diffuse large cell lymphoma, childhood immunoblastic large cell lymphoma, stage i childhood large cell lymphoma, stage i childhood small noncleaved cell lymphoma, stage ii childhood large cell lymphoma, stage ii childhood small noncleaved cell lymphoma, stage iii childhood large cell lymphoma, stage iii childhood small noncleaved cell lymphoma, stage iv childhood large cell lymphoma, stage iv childhood small noncleaved cell lymphoma, untreated childhood acute lymphoblastic leukemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completed5-fluorouracil, cisplatin, sunitinib malate_stomach neoplasms", "label": "completed5-fluorouracil, cisplatin, sunitinib malate_stomach neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cytomegalovirus (cmv)-positive recipients, allogeneic, hematopoietic cell transplant (hct)", "label": "cytomegalovirus (cmv)-positive recipients, allogeneic, hematopoietic cell transplant (hct)", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "label": " [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "atazanavir/ritonavir +2 nrtis (immediate switch group), lpv/r +2 nrtis (delayed/optional switch group)", "label": "atazanavir/ritonavir +2 nrtis (immediate switch group), lpv/r +2 nrtis (delayed/optional switch group)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbelinostat, azacitidine_accelerated phase of disease, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll, adult acute promyelocytic leukemia with t(15;17)(q22;q12); pml-rara, atypical chronic myeloid leukemia, bcr-abl1 negative, blastic phase, chronic myelogenous leukemia, bcr-abl1 positive, chronic myelomonocytic leukemia, de novo myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, unclassifiable, philadelphia chromosome negative, bcr-abl1 positive chronic myelogenous leukemia, previously treated myelodysplastic syndrome, primary myelofibrosis, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent disease, secondary acute myeloid leukemia, secondary myelodysplastic syndrome", "label": "completedbelinostat, azacitidine_accelerated phase of disease, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll, adult acute promyelocytic leukemia with t(15;17)(q22;q12); pml-rara, atypical chronic myeloid leukemia, bcr-abl1 negative, blastic phase, chronic myelogenous leukemia, bcr-abl1 positive, chronic myelomonocytic leukemia, de novo myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, unclassifiable, philadelphia chromosome negative, bcr-abl1 positive chronic myelogenous leukemia, previously treated myelodysplastic syndrome, primary myelofibrosis, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent disease, secondary acute myeloid leukemia, secondary myelodysplastic syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " anastrozole or letrozole)", "label": " anastrozole or letrozole)", "shape": "dot", "size": 10}, {"color": "red", "id": "tbr-652", "label": "tbr-652", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedozanimod, placebo_ulcerative colitis", "label": "completedozanimod, placebo_ulcerative colitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " standard of care: cyclophosphamide", "label": " standard of care: cyclophosphamide", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC1=C(OC)C(=O)[C@H](C)[C@@H](C\\C=C(/C)CC\\C=C(/C)CCC=C(C)C)[C@H]1O", "label": "COC1=C(OC)C(=O)[C@H](C)[C@@H](C\\C=C(/C)CC\\C=C(/C)CCC=C(C)C)[C@H]1O", "shape": "dot", "size": 10}, {"color": "red", "id": "extended release niacin", "label": "extended release niacin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "clofarabine, cyclophosphamide, etoposide", "label": "clofarabine, cyclophosphamide, etoposide", "shape": "dot", "size": 10}, {"color": "green", "id": " ibd", "label": " ibd", "shape": "dot", "size": 10}, {"color": "red", "id": "paclitaxel and carboplatin combination", "label": "paclitaxel and carboplatin combination", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1", "label": "NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedabatacept, methotrexate_rheumatoid arthritis", "label": "completedabatacept, methotrexate_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " aortic stenosis", "label": " aortic stenosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedetanercept, sulphasalazine (ssz)_ankylosing spondylitis", "label": "completedetanercept, sulphasalazine (ssz)_ankylosing spondylitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "zd6474", "label": "zd6474", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "akt inhibitor mk2206, anastrozole, goserelin acetate", "label": "akt inhibitor mk2206, anastrozole, goserelin acetate", "shape": "dot", "size": 10}, {"color": "green", "id": " catheter-related", "label": " catheter-related", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aliskiren, amlodipine", "label": "aliskiren, amlodipine", "shape": "dot", "size": 10}, {"color": "green", "id": "relapsed or refractory chronic lymphocytic leukemia", "label": "relapsed or refractory chronic lymphocytic leukemia", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC[C@@H](CO)NCCN[C@@H](CC)CO", "label": " CC[C@@H](CO)NCCN[C@@H](CC)CO", "shape": "dot", "size": 10}, {"color": "red", "id": " loestrin 1/20", "label": " loestrin 1/20", "shape": "dot", "size": 10}, {"color": "blue", "id": " CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F", "label": " CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "zgn-440 sterile diluent, zgn-440 for injectable suspension", "label": "zgn-440 sterile diluent, zgn-440 for injectable suspension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@H](NC(=O)C(C)(C)OC1=CC=C(C=N1)C(F)(F)F)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC=CC(=C1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "C[C@H](NC(=O)C(C)(C)OC1=CC=C(C=N1)C(F)(F)F)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC=CC(=C1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acute pain, bunion, abdominoplasty", "label": "acute pain, bunion, abdominoplasty", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedruxolitinib, placebo, pemetrexed, cisplatin_nsclc (non-small cell lung carcinoma)", "label": "terminatedruxolitinib, placebo, pemetrexed, cisplatin_nsclc (non-small cell lung carcinoma)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bibf 1120, sunitinib", "label": "bibf 1120, sunitinib", "shape": "dot", "size": 10}, {"color": "red", "id": "cyclophosphamide dose level 1", "label": "cyclophosphamide dose level 1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedabt-089, atomoxetine, placebo_attention-deficit/hyperactivity disorder", "label": "completedabt-089, atomoxetine, placebo_attention-deficit/hyperactivity disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplatinum-based chemotherapy alone (up to six cycles), platinum-based chemotherapy followed by maintenance therapy with gefitinib_lung cancer", "label": "completedplatinum-based chemotherapy alone (up to six cycles), platinum-based chemotherapy followed by maintenance therapy with gefitinib_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "emphysema", "label": "emphysema", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sorafenib (nexavar, bay43-9006), placebo, capecitabine", "label": "sorafenib (nexavar, bay43-9006), placebo, capecitabine", "shape": "dot", "size": 10}, {"color": "red", "id": "al-60371/al-817 otic suspension", "label": "al-60371/al-817 otic suspension", "shape": "dot", "size": 10}, {"color": "red", "id": "paclitaxel / carboplatin", "label": "paclitaxel / carboplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "lupron, casodex", "label": "lupron, casodex", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "epirubicin, cyclophosphamide, paclitaxel, carboplatin, g-csf", "label": "epirubicin, cyclophosphamide, paclitaxel, carboplatin, g-csf", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin aspart, glargine and detemir_type 1 diabetes", "label": "completedinsulin aspart, glargine and detemir_type 1 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "vernakalant injection", "label": "vernakalant injection", "shape": "dot", "size": 10}, {"color": "red", "id": "patidegib", "label": "patidegib", "shape": "dot", "size": 10}, {"color": "blue", "id": "O.O=O.[O-][Cl]=O.[O-][Cl]=O.[O-][Cl]=O.[O-][Cl]=O", "label": "O.O=O.[O-][Cl]=O.[O-][Cl]=O.[O-][Cl]=O.[O-][Cl]=O", "shape": "dot", "size": 10}, {"color": "red", "id": " tipranavir (tpv) high dose", "label": " tipranavir (tpv) high dose", "shape": "dot", "size": 10}, {"color": "red", "id": " canagliflozin 300mg", "label": " canagliflozin 300mg", "shape": "dot", "size": 10}, {"color": "green", "id": " advanced malignancy", "label": " advanced malignancy", "shape": "dot", "size": 10}, {"color": "red", "id": " fosamprenavir/ritonavir", "label": " fosamprenavir/ritonavir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ym150, warfarin", "label": "ym150, warfarin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ds-5565, pregabalin, placebo tablet, placebo capsule", "label": "ds-5565, pregabalin, placebo tablet, placebo capsule", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvinflunine, alkylating agent of physician choice registered in cancer_breast cancer, metastases", "label": "completedvinflunine, alkylating agent of physician choice registered in cancer_breast cancer, metastases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedadh-1, cisplatin, gemcitabine hydrochloride_ampulla of vater adenocarcinoma, gallbladder adenocarcinoma, metastatic pancreatic adenocarcinoma, pancreatic adenocarcinoma, stage iii ampulla of vater cancer, stage iii intrahepatic cholangiocarcinoma, stage iii pancreatic cancer, stage iiia gallbladder cancer, stage iiia hilar cholangiocarcinoma, stage iiib gallbladder cancer, stage iiib hilar cholangiocarcinoma, stage iv ampulla of vater cancer, stage iva gallbladder cancer, stage iva hilar cholangiocarcinoma, stage iva intrahepatic cholangiocarcinoma, stage iva pancreatic cancer, stage ivb gallbladder cancer, stage ivb hilar cholangiocarcinoma, stage ivb intrahepatic cholangiocarcinoma, stage ivb pancreatic cancer", "label": "completedadh-1, cisplatin, gemcitabine hydrochloride_ampulla of vater adenocarcinoma, gallbladder adenocarcinoma, metastatic pancreatic adenocarcinoma, pancreatic adenocarcinoma, stage iii ampulla of vater cancer, stage iii intrahepatic cholangiocarcinoma, stage iii pancreatic cancer, stage iiia gallbladder cancer, stage iiia hilar cholangiocarcinoma, stage iiib gallbladder cancer, stage iiib hilar cholangiocarcinoma, stage iv ampulla of vater cancer, stage iva gallbladder cancer, stage iva hilar cholangiocarcinoma, stage iva intrahepatic cholangiocarcinoma, stage iva pancreatic cancer, stage ivb gallbladder cancer, stage ivb hilar cholangiocarcinoma, stage ivb intrahepatic cholangiocarcinoma, stage ivb pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "postoperative pain, opioid induced constipation", "label": "postoperative pain, opioid induced constipation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rituximab, doxorubicin, vincristine, cyclophosphamide, prednisone", "label": "rituximab, doxorubicin, vincristine, cyclophosphamide, prednisone", "shape": "dot", "size": 10}, {"color": "red", "id": "(folpi) picoplatin with 5-fu and leucovorin", "label": "(folpi) picoplatin with 5-fu and leucovorin", "shape": "dot", "size": 10}, {"color": "green", "id": "anaplastic large-cell lymphoma", "label": "anaplastic large-cell lymphoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtas-303, placebo_stress urinary incontinence", "label": "completedtas-303, placebo_stress urinary incontinence", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "COC1=CC=C(Br)C=C1NC(=O)NC1=C2C=CN(CC3=CC=NC(N)=C3)C2=CC=C1", "label": "COC1=CC=C(Br)C=C1NC(=O)NC1=C2C=CN(CC3=CC=NC(N)=C3)C2=CC=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " pleural mesothelioma", "label": " pleural mesothelioma", "shape": "dot", "size": 10}, {"color": "red", "id": " lu af11167 (3-4 mg/day)", "label": " lu af11167 (3-4 mg/day)", "shape": "dot", "size": 10}, {"color": "red", "id": "deferasirox + azacitidine", "label": "deferasirox + azacitidine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "azilsartan medoxomil, azilsartan medoxomil, valsartan, olmesartan, placebo", "label": "azilsartan medoxomil, azilsartan medoxomil, valsartan, olmesartan, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedarm a: folfiri or folfox + bevacizumab, arm b: folfiri or folfox, arm d: folfiri or folfox plus cetuximab, arm f: folfiri or folfox plus bevacizumab and cetuximab_metastatic colorectal cancer", "label": "completedarm a: folfiri or folfox + bevacizumab, arm b: folfiri or folfox, arm d: folfiri or folfox plus cetuximab, arm f: folfiri or folfox plus bevacizumab and cetuximab_metastatic colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " rituximab", "label": " rituximab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgs-6615, placebo to match gs-6615, placebo to match dofetilide, dofetilide_long qt syndrome", "label": "completedgs-6615, placebo to match gs-6615, placebo to match dofetilide, dofetilide_long qt syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "interim/maintenance dexamethasone, induction/consolidation dexamethasone, induction/consolidation cisplatin, induction/consolidation adriamycin, inductionconsolidation cyclophosphamide, induction/consolidation etoposide, induction pegfilgrastim, transplant 1 dexamethasone, transplant 1 cisplatin, transplant 1 adriamycin, transplant 1 cyclophosphamide, transplant 1 etoposide, transplant 1 melphalan, transplant 1 and 2 pegfilgrastim, transplant 2 carmustine, transplant 2 etoposide, transplant 2 cytarabine, transplant 2 melphalan, transplant 2 dexamethasone, transplant 1 and 2 bortezomib, transplant 1 and 2 thalidomide", "label": "interim/maintenance dexamethasone, induction/consolidation dexamethasone, induction/consolidation cisplatin, induction/consolidation adriamycin, inductionconsolidation cyclophosphamide, induction/consolidation etoposide, induction pegfilgrastim, transplant 1 dexamethasone, transplant 1 cisplatin, transplant 1 adriamycin, transplant 1 cyclophosphamide, transplant 1 etoposide, transplant 1 melphalan, transplant 1 and 2 pegfilgrastim, transplant 2 carmustine, transplant 2 etoposide, transplant 2 cytarabine, transplant 2 melphalan, transplant 2 dexamethasone, transplant 1 and 2 bortezomib, transplant 1 and 2 thalidomide", "shape": "dot", "size": 10}, {"color": "red", "id": " peginterferon alfa-2b (peg2b)", "label": " peginterferon alfa-2b (peg2b)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "immunodeficiency virus type 1, human", "label": "immunodeficiency virus type 1, human", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaripiprazole lauroxil_schizophrenia", "label": "completedaripiprazole lauroxil_schizophrenia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "mmf", "label": "mmf", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "intensive insulin group, oral antidiabetic drug (glimepiride and metformin)", "label": "intensive insulin group, oral antidiabetic drug (glimepiride and metformin)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cenersen, idarubicin, cytarabine", "label": "cenersen, idarubicin, cytarabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "prostate adenocarcinoma, recurrent prostate carcinoma, stage iii prostate cancer, stage iv prostate cancer", "label": "prostate adenocarcinoma, recurrent prostate carcinoma, stage iii prostate cancer, stage iv prostate cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "end stage renal disease, antibody mediated rejection", "label": "end stage renal disease, antibody mediated rejection", "shape": "dot", "size": 10}, {"color": "green", "id": " brip1 gene mutation", "label": " brip1 gene mutation", "shape": "dot", "size": 10}, {"color": "red", "id": " carboplatin - phase 2", "label": " carboplatin - phase 2", "shape": "dot", "size": 10}, {"color": "red", "id": " vak694 placebo infusion; alutard avanz sq", "label": " vak694 placebo infusion; alutard avanz sq", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedempagliflozin medium dose, empagliflozin low dose, empagliflozin high dose, placebo_diabetes mellitus, type 1", "label": "completedempagliflozin medium dose, empagliflozin low dose, empagliflozin high dose, placebo_diabetes mellitus, type 1", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedreproxalap ophthalmic solution (0.25%), reproxalap ophthalmic solution (0.1%), vehicle ophthalmic solution_dry eye syndrome", "label": "completedreproxalap ophthalmic solution (0.25%), reproxalap ophthalmic solution (0.1%), vehicle ophthalmic solution_dry eye syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtamsulosin hydrochloride, solifenacin succinate, placebo_lower urinary tract symptoms, prostatic hyperplasia", "label": "completedtamsulosin hydrochloride, solifenacin succinate, placebo_lower urinary tract symptoms, prostatic hyperplasia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC(CC)CC1(CCCCC1)C(=O)NC1=CC=CC=C1SC(=O)C(C)C", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC(CC)CC1(CCCCC1)C(=O)NC1=CC=CC=C1SC(=O)C(C)C", "shape": "dot", "size": 10}, {"color": "green", "id": "oropharyngeal neoplasms", "label": "oropharyngeal neoplasms", "shape": "dot", "size": 10}, {"color": "blue", "id": " CN1CCN(CCOC2=CC3=C(C(NC4=C(Cl)C=CC5=C4OCO5)=NC=N3)C(OC3CCOCC3)=C2)CC1", "label": " CN1CCN(CCOC2=CC3=C(C(NC4=C(Cl)C=CC5=C4OCO5)=NC=N3)C(OC3CCOCC3)=C2)CC1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O", "label": "CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O", "shape": "dot", "size": 10}, {"color": "red", "id": " sm-13496", "label": " sm-13496", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "anatomic stage iv breast cancer ajcc v8, estrogen receptor positive, kit positive, pdgfr positive, postmenopausal, progesterone receptor positive, prognostic stage iv breast cancer ajcc v8", "label": "anatomic stage iv breast cancer ajcc v8, estrogen receptor positive, kit positive, pdgfr positive, postmenopausal, progesterone receptor positive, prognostic stage iv breast cancer ajcc v8", "shape": "dot", "size": 10}, {"color": "blue", "id": " COC1=CC(=CC(OC)=C1OC)[C@@H](O)CC1=CC(O)=C(OC)C=C1", "label": " COC1=CC(=CC(OC)=C1OC)[C@@H](O)CC1=CC(O)=C(OC)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": "oxymorphone extended release", "label": "oxymorphone extended release", "shape": "dot", "size": 10}, {"color": "blue", "id": "NC1=CC(O)=C(C=C1)C(O)=O", "label": "NC1=CC(O)=C(C=C1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedliraglutide, placebo_type 2 diabetes", "label": "completedliraglutide, placebo_type 2 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=C(C=C(C=C1F)C(=O)NC1CC1)C1=CC=C(C=N1)C(=O)NCC(C)(C)C", "label": "CC1=C(C=C(C=C1F)C(=O)NC1CC1)C1=CC=C(C=N1)C(=O)NCC(C)(C)C", "shape": "dot", "size": 10}, {"color": "red", "id": "php-201 0.25% ophthalmic solution", "label": "php-201 0.25% ophthalmic solution", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bevacizumab, bortezomib", "label": "bevacizumab, bortezomib", "shape": "dot", "size": 10}, {"color": "red", "id": " oral aminocaproic acid", "label": " oral aminocaproic acid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaripiprazole, opc-14597_schizophrenia, mental disorder, nervous system diseases", "label": "completedaripiprazole, opc-14597_schizophrenia, mental disorder, nervous system diseases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedniclosamide_colon cancer", "label": "terminatedniclosamide_colon cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCN1N=CN=C1COC1=NN2C(C=C1C(C)(C)C)=NN=C2C1=CC=CC=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCN1N=CN=C1COC1=NN2C(C=C1C(C)(C)C)=NN=C2C1=CC=CC=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "levetiracetam (add-on)", "label": "levetiracetam (add-on)", "shape": "dot", "size": 10}, {"color": "green", "id": " oral cancer", "label": " oral cancer", "shape": "dot", "size": 10}, {"color": "green", "id": " upper limb spasticity", "label": " upper limb spasticity", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, CN1N=NC2=C(N=CN2C1=O)C(N)=O", "label": "CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, CN1N=NC2=C(N=CN2C1=O)C(N)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedlive attenuated influenza vaccine_influenza", "label": "terminatedlive attenuated influenza vaccine_influenza", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC1=CC=C(C=C1)C12CC1CNC2", "label": "CC1=CC=C(C=C1)C12CC1CNC2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgsk1120212, docetaxel_lung cancer, non-small cell", "label": "completedgsk1120212, docetaxel_lung cancer, non-small cell", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "hemostasis", "label": "hemostasis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "conceptrol, amphora", "label": "conceptrol, amphora", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddegarelix_prostatic neoplasms", "label": "completeddegarelix_prostatic neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "bivalirudin", "label": "bivalirudin", "shape": "dot", "size": 10}, {"color": "red", "id": " azd8871 600 \u00b5g", "label": " azd8871 600 \u00b5g", "shape": "dot", "size": 10}, {"color": "red", "id": "asp9831", "label": "asp9831", "shape": "dot", "size": 10}, {"color": "green", "id": " stage ivc laryngeal verrucous carcinoma ajcc v7", "label": " stage ivc laryngeal verrucous carcinoma ajcc v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsunitinib, everolimus_metastatic renal cell carcinoma", "label": "terminatedsunitinib, everolimus_metastatic renal cell carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcisplatin, rucaparib, cisplatin_breast cancer", "label": "completedcisplatin, rucaparib, cisplatin_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo (for ramucirumab), docetaxel_non-small cell lung cancer", "label": "completedplacebo (for ramucirumab), docetaxel_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "mln8237 (alisertib)", "label": "mln8237 (alisertib)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "igf-1r inhibitor osi-906, erlotinib hydrochloride, goserelin, letrozole", "label": "igf-1r inhibitor osi-906, erlotinib hydrochloride, goserelin, letrozole", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfinerenone (bay 94-8862), placebo_diabetic nephropathies", "label": "completedfinerenone (bay 94-8862), placebo_diabetic nephropathies", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " 12-month clopidogrel therapy", "label": " 12-month clopidogrel therapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedchf6001, budesonide, placebo_chronic obstructive pulmonary disease", "label": "completedchf6001, budesonide, placebo_chronic obstructive pulmonary disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "ramelteon sl", "label": "ramelteon sl", "shape": "dot", "size": 10}, {"color": "green", "id": "dementia", "label": "dementia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ilaprazole, esomeprazole", "label": "ilaprazole, esomeprazole", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia", "label": "myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedambrisentan, placebo, sildenafil, tadalafil_pulmonary arterial hypertension", "label": "completedambrisentan, placebo, sildenafil, tadalafil_pulmonary arterial hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2, COC1=CC=CC=C1OCC(O)CO, CSCC[C@H](N)C(O)=O", "label": "[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2, COC1=CC=CC=C1OCC(O)CO, CSCC[C@H](N)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedatazanavir/ritonavir monotherapy_hiv-1 infection", "label": "completedatazanavir/ritonavir monotherapy_hiv-1 infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " progression", "label": " progression", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completede6011, placebo_rheumatoid arthritis", "label": "completede6011, placebo_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "stage i lymphoepithelioma of the nasopharynx", "label": "stage i lymphoepithelioma of the nasopharynx", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedliraglutide, metformin, placebo, nnc0090-2746_diabetes, diabetes mellitus type 2", "label": "completedliraglutide, metformin, placebo, nnc0090-2746_diabetes, diabetes mellitus type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aleglitazar, aspirin, placebo", "label": "aleglitazar, aspirin, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsfp_end stage renal disease, chronic kidney disease", "label": "completedsfp_end stage renal disease, chronic kidney disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "S1SSSSSSS1, CC(=O)OC1=CC=CC=C1C(O)=O, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl", "label": "S1SSSSSSS1, CC(=O)OC1=CC=CC=C1C(O)=O, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "green", "id": " herpes genitalis", "label": " herpes genitalis", "shape": "dot", "size": 10}, {"color": "red", "id": "ly2963016", "label": "ly2963016", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CCC[C@]1([H])[C@@]([H])(OC1=C2C=C(O)C=C1)C1=CC=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "[H][C@@]12CCC[C@]1([H])[C@@]([H])(OC1=C2C=C(O)C=C1)C1=CC=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcangrelor_st segment elevation myocardial infarction, percutaneous coronary intervention", "label": "completedcangrelor_st segment elevation myocardial infarction, percutaneous coronary intervention", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsalmeterol xinafoate/fluticasone propionate_asthma", "label": "terminatedsalmeterol xinafoate/fluticasone propionate_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " sumatriptan", "label": " sumatriptan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfexofenadine/allegra (m016455)_atopic dermatitis", "label": "completedfexofenadine/allegra (m016455)_atopic dermatitis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "vibegron, vibegron placebo, tolterodine tartrate er, tolterodine placebo", "label": "vibegron, vibegron placebo, tolterodine tartrate er, tolterodine placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to match gs-0938", "label": " placebo to match gs-0938", "shape": "dot", "size": 10}, {"color": "red", "id": "zushima plaster with high dose", "label": "zushima plaster with high dose", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "biphasic insulin aspart 50, biphasic human insulin 50", "label": "biphasic insulin aspart 50, biphasic human insulin 50", "shape": "dot", "size": 10}, {"color": "red", "id": " 10 mg/kg cnto 136", "label": " 10 mg/kg cnto 136", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpaclitaxel poliglumex, carboplatin_carcinoma, non-small-cell lung", "label": "terminatedpaclitaxel poliglumex, carboplatin_carcinoma, non-small-cell lung", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rituximab, chop, intrathecal methotrexate", "label": "rituximab, chop, intrathecal methotrexate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "relugolix, leuprorelin", "label": "relugolix, leuprorelin", "shape": "dot", "size": 10}, {"color": "red", "id": " azd4017", "label": " azd4017", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "OC(=O)[C@@H]1CCCN1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1", "label": "OC(=O)[C@@H]1CCCN1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " fludarabine phosphate", "label": " fludarabine phosphate", "shape": "dot", "size": 10}, {"color": "red", "id": " 0.5 mg isonep", "label": " 0.5 mg isonep", "shape": "dot", "size": 10}, {"color": "green", "id": " histiocytoma/undifferentiated pleomorphic sarcoma", "label": " histiocytoma/undifferentiated pleomorphic sarcoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedradiation plus erlotinib_cancer", "label": "terminatedradiation plus erlotinib_cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "OP(O)(=O)CCN1CCCNC2=C1C(=O)C2=O", "label": "OP(O)(=O)CCN1CCCNC2=C1C(=O)C2=O", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo treatment to blind study", "label": " placebo treatment to blind study", "shape": "dot", "size": 10}, {"color": "blue", "id": "CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12", "label": "CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedruboxistaurin, placebo_diabetic retinopathy", "label": "completedruboxistaurin, placebo_diabetic retinopathy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfk506e_heart transplantation, liver transplantation, kidney transplantation", "label": "completedfk506e_heart transplantation, liver transplantation, kidney transplantation", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ovarian cancer, fallopian tube cancer, malignant tumor of peritoneum", "label": "ovarian cancer, fallopian tube cancer, malignant tumor of peritoneum", "shape": "dot", "size": 10}, {"color": "red", "id": "mesalamine 2400 mg (5-asa)", "label": "mesalamine 2400 mg (5-asa)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1, COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC", "label": "CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1, COC1=C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C2CC[C@H](NC(C)=O)C3=CC(=O)C(SC)=CC=C3C2=C1OC", "shape": "dot", "size": 10}, {"color": "red", "id": "dolutegravir 50 mg (one tablet daily)", "label": "dolutegravir 50 mg (one tablet daily)", "shape": "dot", "size": 10}, {"color": "green", "id": "radiation necrosis", "label": "radiation necrosis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "capecitabine, cyclophosphamide, lapatinib ditosylate", "label": "capecitabine, cyclophosphamide, lapatinib ditosylate", "shape": "dot", "size": 10}, {"color": "red", "id": "ibandronate [bondronat]", "label": "ibandronate [bondronat]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrivaroxaban, placebo_heart failure, coronary artery disease", "label": "completedrivaroxaban, placebo_heart failure, coronary artery disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine, cisplatin_metastatic breast cancer", "label": "completedgemcitabine, cisplatin_metastatic breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2", "label": "CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2, NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2", "label": "NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2, NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2", "shape": "dot", "size": 10}, {"color": "green", "id": " respiratory insufficiency", "label": " respiratory insufficiency", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuscyclophosphamide_lupus nephritis", "label": "unknown statuscyclophosphamide_lupus nephritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "at13387", "label": "at13387", "shape": "dot", "size": 10}, {"color": "green", "id": " scleroderma spectrum of diseases", "label": " scleroderma spectrum of diseases", "shape": "dot", "size": 10}, {"color": "red", "id": " azd2014 2 on/5 off \u0026 weekly paclitaxel", "label": " azd2014 2 on/5 off \u0026 weekly paclitaxel", "shape": "dot", "size": 10}, {"color": "red", "id": " solifenacin placebo", "label": " solifenacin placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "aliskerin/valsartan and rampiril", "label": "aliskerin/valsartan and rampiril", "shape": "dot", "size": 10}, {"color": "red", "id": " dapagliflozin", "label": " dapagliflozin", "shape": "dot", "size": 10}, {"color": "red", "id": "6 mg ciprofloxacin", "label": "6 mg ciprofloxacin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "indinavir, lamivudine, ritonavir", "label": "indinavir, lamivudine, ritonavir", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgsk2849466, placebo_cachexia", "label": "completedgsk2849466, placebo_cachexia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to indacaterol and glycopyrronium (qva149)", "label": " placebo to indacaterol and glycopyrronium (qva149)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfluticasone propionate/formoterol fumarate_asthma", "label": "completedfluticasone propionate/formoterol fumarate_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddhap, everolimus_hodgkin lymphoma", "label": "completeddhap, everolimus_hodgkin lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusconjugated equine estrogens 0.45 mg/day, transdermal estradiol, 50 mcg/day, micronized progesterone, 200 mg/day x 12 d/month, cee , progesterone, estradiol patch or placebo for each, cee, progesterone, transdermal patch or the placebo_menopause, arteriosclerosis", "label": "unknown statusconjugated equine estrogens 0.45 mg/day, transdermal estradiol, 50 mcg/day, micronized progesterone, 200 mg/day x 12 d/month, cee , progesterone, estradiol patch or placebo for each, cee, progesterone, transdermal patch or the placebo_menopause, arteriosclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cisplatin, docetaxel, 5-fluorouracil", "label": "cisplatin, docetaxel, 5-fluorouracil", "shape": "dot", "size": 10}, {"color": "red", "id": "ff/levocabastine", "label": "ff/levocabastine", "shape": "dot", "size": 10}, {"color": "red", "id": " rituximab in combination with placebo", "label": " rituximab in combination with placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "decitabine, digoxin", "label": "decitabine, digoxin", "shape": "dot", "size": 10}, {"color": "green", "id": "chronic rhinosinusitis", "label": "chronic rhinosinusitis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fec chemotherapy, docetaxel, pertuzumab, placebo, trastuzumab", "label": "fec chemotherapy, docetaxel, pertuzumab, placebo, trastuzumab", "shape": "dot", "size": 10}, {"color": "red", "id": " epi/docetaxel", "label": " epi/docetaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CC1=CC(O)=CC(C)=C1Cl", "label": "C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "red", "id": "vedolizumab", "label": "vedolizumab", "shape": "dot", "size": 10}, {"color": "green", "id": "recurrent fallopian tube carcinoma", "label": "recurrent fallopian tube carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedamiloride solution for inhalation_cystic fibrosis", "label": "completedamiloride solution for inhalation_cystic fibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatediv amiodarone, iv procainamide_ventricular tachycardia, wide qrs tachycardia", "label": "terminatediv amiodarone, iv procainamide_ventricular tachycardia, wide qrs tachycardia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ranibizumab injection 0.5 mg", "label": " ranibizumab injection 0.5 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfaster-acting insulin aspart, insulin detemir, insulin aspart, faster-acting insulin aspart_diabetes, diabetes mellitus, type 1", "label": "completedfaster-acting insulin aspart, insulin detemir, insulin aspart, faster-acting insulin aspart_diabetes, diabetes mellitus, type 1", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "suspendedicotinib_non-small cell lung cancer", "label": "suspendedicotinib_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgsk1120212, gemcitabine, placebo_cancer", "label": "completedgsk1120212, gemcitabine, placebo_cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C", "label": "N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C", "shape": "dot", "size": 10}, {"color": "red", "id": "temocillin", "label": "temocillin", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iib lung non-small cell carcinoma ajcc v7", "label": " stage iib lung non-small cell carcinoma ajcc v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlopinavir/ritonavir (lpv/r), lamivudine (3tc)_hiv infections", "label": "completedlopinavir/ritonavir (lpv/r), lamivudine (3tc)_hiv infections", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to match momelotinib", "label": " placebo to match momelotinib", "shape": "dot", "size": 10}, {"color": "green", "id": " recurrent ewing sarcoma", "label": " recurrent ewing sarcoma", "shape": "dot", "size": 10}, {"color": "red", "id": "meloxicam", "label": "meloxicam", "shape": "dot", "size": 10}, {"color": "red", "id": " teriparatide", "label": " teriparatide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1", "label": "O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completed300 ir grass pollen allergen extract tablet, placebo tablet_allergy", "label": "completed300 ir grass pollen allergen extract tablet, placebo tablet_allergy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsirolimus_kidney diseases", "label": "completedsirolimus_kidney diseases", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpanobinostat, fluorouracil, leucovorin calcium_recurrent colon cancer, recurrent rectal cancer, stage iv colon cancer, stage iv rectal cancer", "label": "terminatedpanobinostat, fluorouracil, leucovorin calcium_recurrent colon cancer, recurrent rectal cancer, stage iv colon cancer, stage iv rectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " therapy-related acute myeloid leukemia", "label": " therapy-related acute myeloid leukemia", "shape": "dot", "size": 10}, {"color": "red", "id": "ar-12286 0.5% ophthalmic solution", "label": "ar-12286 0.5% ophthalmic solution", "shape": "dot", "size": 10}, {"color": "red", "id": "np001", "label": "np001", "shape": "dot", "size": 10}, {"color": "red", "id": "carvedilol mr", "label": "carvedilol mr", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aripiprazole+ adt, placebo+ adt", "label": "aripiprazole+ adt, placebo+ adt", "shape": "dot", "size": 10}, {"color": "red", "id": "avastin (bevacizumab", "label": "avastin (bevacizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sage-217, levodopa, antiparkinsonian agent(s)", "label": "sage-217, levodopa, antiparkinsonian agent(s)", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iii breast cancer", "label": " stage iii breast cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "prednisolone and mycophenolate mofetil", "label": "prednisolone and mycophenolate mofetil", "shape": "dot", "size": 10}, {"color": "red", "id": " bendamustine hydrochloride", "label": " bendamustine hydrochloride", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedcapecitabine, bevacizumab, irinotecan_metastatic colorectal cancer", "label": "terminatedcapecitabine, bevacizumab, irinotecan_metastatic colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmethotrexate (mtx)_rheumatoid arthritis", "label": "completedmethotrexate (mtx)_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "dose level 1", "label": "dose level 1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completednasal fentanyl_pain", "label": "completednasal fentanyl_pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "insulin detemir, insulin nph", "label": "insulin detemir, insulin nph", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbkm120_endometrial cancer", "label": "completedbkm120_endometrial cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpg-530742, placebo, 50 mg pg-530742, 100 mg pg-530742, 200 mg pg-530742_osteoarthritis, knee", "label": "completedpg-530742, placebo, 50 mg pg-530742, 100 mg pg-530742, 200 mg pg-530742_osteoarthritis, knee", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " ranibizumab 0.5 mg - 3 times monthly", "label": " ranibizumab 0.5 mg - 3 times monthly", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "oc000459, placebo", "label": "oc000459, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": " felodipine", "label": " felodipine", "shape": "dot", "size": 10}, {"color": "red", "id": "beta-blocker monotherapy", "label": "beta-blocker monotherapy", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC2=C(NC=C2CCNC(C)=O)C=C1, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1, CC1=CC(O)=CC(C)=C1Cl", "label": "COC1=CC2=C(NC=C2CCNC(C)=O)C=C1, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "0.05 ml/kg ddfpe", "label": "0.05 ml/kg ddfpe", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "paravertebral nerve block: 4 ml ropivacaine 0.5% at each of six levels, 10 cc of 0.375% ropivacaine pectoral nerve block", "label": "paravertebral nerve block: 4 ml ropivacaine 0.5% at each of six levels, 10 cc of 0.375% ropivacaine pectoral nerve block", "shape": "dot", "size": 10}, {"color": "red", "id": "inhaled nitric oxide 75 mcg/kg ibw/hr", "label": "inhaled nitric oxide 75 mcg/kg ibw/hr", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "locally advanced solid tumours, metastatic solid tumours, ovarian cancer", "label": "locally advanced solid tumours, metastatic solid tumours, ovarian cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "ac220", "label": "ac220", "shape": "dot", "size": 10}, {"color": "red", "id": " cholestyramine", "label": " cholestyramine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedgonal -f\u00ae [r-hfsh], ovitrelle\u00ae [r-hcg alfa], gonadotropin-releasing hormone (gnrh) agonist, gonadotropin-releasing hormone (gnrh) antagonist_in vitro fertilization", "label": "terminatedgonal -f\u00ae [r-hfsh], ovitrelle\u00ae [r-hcg alfa], gonadotropin-releasing hormone (gnrh) agonist, gonadotropin-releasing hormone (gnrh) antagonist_in vitro fertilization", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "metformin / placebo treatment for 4 months", "label": "metformin / placebo treatment for 4 months", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tic disorders, tourette syndrome", "label": "tic disorders, tourette syndrome", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H]\\C(=C(\\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC", "label": " [H]\\C(=C(\\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC", "shape": "dot", "size": 10}, {"color": "red", "id": "active", "label": "active", "shape": "dot", "size": 10}, {"color": "green", "id": "vitamin d deficiency", "label": "vitamin d deficiency", "shape": "dot", "size": 10}, {"color": "red", "id": " atorvastatin 40 mg", "label": " atorvastatin 40 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "celecoxib, celecoxib", "label": "celecoxib, celecoxib", "shape": "dot", "size": 10}, {"color": "red", "id": " iti-214 dose c", "label": " iti-214 dose c", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "label": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2", "shape": "dot", "size": 10}, {"color": "red", "id": " granisetron transdermal patch", "label": " granisetron transdermal patch", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinfliximab (ifx) placebo infusion; azathioprine (aza) caps_crohn disease", "label": "completedinfliximab (ifx) placebo infusion; azathioprine (aza) caps_crohn disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " N[C@@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C12", "label": " N[C@@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo via ellipta", "label": " placebo via ellipta", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedip chemotherapy_ovarian neoplasms", "label": "terminatedip chemotherapy_ovarian neoplasms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "adult brain glioblastoma", "label": "adult brain glioblastoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcholecalciferol_wheezing, allergy", "label": "completedcholecalciferol_wheezing, allergy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "group a: valsartan plus chlorthalidone, group b: valsartan, group c: chlorthalidone", "label": "group a: valsartan plus chlorthalidone, group b: valsartan, group c: chlorthalidone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nab-paclitaxel, trastuzumab", "label": "nab-paclitaxel, trastuzumab", "shape": "dot", "size": 10}, {"color": "green", "id": " benign prostate hyperplasia", "label": " benign prostate hyperplasia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbea 2180 br, tiotropium_pulmonary disease, chronic obstructive", "label": "completedbea 2180 br, tiotropium_pulmonary disease, chronic obstructive", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "4.0 mg isonep, 0.5 mg isonep, 0.5 mg lucentis or 1.25 mg avastin or 2 mg eylea, sham injection", "label": "4.0 mg isonep, 0.5 mg isonep, 0.5 mg lucentis or 1.25 mg avastin or 2 mg eylea, sham injection", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tenofovir disoproxil fumarate intravaginal ring, placebo intravaginal ring (ivr)", "label": "tenofovir disoproxil fumarate intravaginal ring, placebo intravaginal ring (ivr)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "green", "id": "combretastatin a4 phosphate", "label": "combretastatin a4 phosphate", "shape": "dot", "size": 10}, {"color": "green", "id": "stage ia breast cancer", "label": "stage ia breast cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "tranexamic acid tablets (xp12b)", "label": "tranexamic acid tablets (xp12b)", "shape": "dot", "size": 10}, {"color": "green", "id": " noncontiguous stage ii adult diffuse small cleaved cell lymphoma", "label": " noncontiguous stage ii adult diffuse small cleaved cell lymphoma", "shape": "dot", "size": 10}, {"color": "red", "id": " bevacizumab", "label": " bevacizumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CS(=O)(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COS(C)(=O)=O, [Na+].[Na+].[O-]P([O-])(F)=O", "label": "CS(=O)(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COS(C)(=O)=O, [Na+].[Na+].[O-]P([O-])(F)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "contiguous stage ii small lymphocytic lymphoma, noncontiguous stage ii small lymphocytic lymphoma, stage 0 chronic lymphocytic leukemia, stage i chronic lymphocytic leukemia, stage i small lymphocytic lymphoma, stage ii chronic lymphocytic leukemia", "label": "contiguous stage ii small lymphocytic lymphoma, noncontiguous stage ii small lymphocytic lymphoma, stage 0 chronic lymphocytic leukemia, stage i chronic lymphocytic leukemia, stage i small lymphocytic lymphoma, stage ii chronic lymphocytic leukemia", "shape": "dot", "size": 10}, {"color": "red", "id": "nedaplatin", "label": "nedaplatin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aromatase inhibition therapy, cyclophosphamide, docetaxel, doxorubicin hydrochloride, epirubicin hydrochloride, fluorouracil, paclitaxel, releasing hormone agonist therapy, tamoxifen citrate", "label": "aromatase inhibition therapy, cyclophosphamide, docetaxel, doxorubicin hydrochloride, epirubicin hydrochloride, fluorouracil, paclitaxel, releasing hormone agonist therapy, tamoxifen citrate", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingenzalutamide, metformin hydrochloride_prostate cancer", "label": "active, not recruitingenzalutamide, metformin hydrochloride_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedextended release oxycodone, immediate release oxycodone_chronic pain", "label": "terminatedextended release oxycodone, immediate release oxycodone_chronic pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": "CN1N=CN=C1[C@@H]1[C@H](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1", "label": "CN1N=CN=C1[C@@H]1[C@H](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " bendamustine at a dose of 120 mg/m2", "label": " bendamustine at a dose of 120 mg/m2", "shape": "dot", "size": 10}, {"color": "red", "id": " darunavir/ritonavir (prezista)", "label": " darunavir/ritonavir (prezista)", "shape": "dot", "size": 10}, {"color": "red", "id": " peg-interferon-alpha 2a (pegasys\u00ae)", "label": " peg-interferon-alpha 2a (pegasys\u00ae)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "label": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "shape": "dot", "size": 10}, {"color": "red", "id": "herbal treatment (sa100)", "label": "herbal treatment (sa100)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedbevacizumab [avastin]_colorectal cancer", "label": "completedbevacizumab [avastin]_colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chloroquine, carboplatin, gemcitabine", "label": "chloroquine, carboplatin, gemcitabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedeverolimus_estrogen receptor-positive breast cancer, gastrinoma, glucagonoma, her2-negative breast cancer, insulinoma, mucositis, oral complications, pancreatic polypeptide tumor, progesterone receptor-positive breast cancer, recurrent breast cancer, recurrent islet cell carcinoma, recurrent renal cell cancer, somatostatinoma, stage iii renal cell cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer, stage iv renal cell cancer", "label": "terminatedeverolimus_estrogen receptor-positive breast cancer, gastrinoma, glucagonoma, her2-negative breast cancer, insulinoma, mucositis, oral complications, pancreatic polypeptide tumor, progesterone receptor-positive breast cancer, recurrent breast cancer, recurrent islet cell carcinoma, recurrent renal cell cancer, somatostatinoma, stage iii renal cell cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer, stage iv renal cell cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O", "label": " [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatednitazoxanide, placebo_influenza", "label": "terminatednitazoxanide, placebo_influenza", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "locally advance breast cancer (labc)", "label": "locally advance breast cancer (labc)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "psoriasis, plaque psoriasis", "label": "psoriasis, plaque psoriasis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1", "label": "[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1", "shape": "dot", "size": 10}, {"color": "green", "id": " hyperkalemia", "label": " hyperkalemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ozenoxacin, placebo", "label": "ozenoxacin, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ckd-501 0.5mg, pioglitazone 15mg", "label": "ckd-501 0.5mg, pioglitazone 15mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo / teneli (teneligliptin) + pio (pioglitazone), teneli / teneli + pio_type 2 diabetes mellitus", "label": "completedplacebo / teneli (teneligliptin) + pio (pioglitazone), teneli / teneli + pio_type 2 diabetes mellitus", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpalonosetron_chemotherapy-induced nausea and vomiting, non hodgkin\u0027s lymphoma", "label": "completedpalonosetron_chemotherapy-induced nausea and vomiting, non hodgkin\u0027s lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "62.5/25mcg, 62.5mcg, 25mcg, placebo", "label": "62.5/25mcg, 62.5mcg, 25mcg, placebo", "shape": "dot", "size": 10}, {"color": "green", "id": " hodgkin\u0027s disease", "label": " hodgkin\u0027s disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlosartan 100mg, placebo_kidney disease, proteinuria", "label": "completedlosartan 100mg, placebo_kidney disease, proteinuria", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedlansoprazole, matching placebo_asthma", "label": "completedlansoprazole, matching placebo_asthma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedqgc001 [(3s,3\u0027s)-4,4\u0027-dithiobis (3-aminobutane-1-sulfonic acid)], placebo_essential hypertension", "label": "completedqgc001 [(3s,3\u0027s)-4,4\u0027-dithiobis (3-aminobutane-1-sulfonic acid)], placebo_essential hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo + adt, brexpiprazole +adt", "label": "placebo + adt, brexpiprazole +adt", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "crohn\u0027s disease, colitis, ibd, inflammatory bowel disease", "label": "crohn\u0027s disease, colitis, ibd, inflammatory bowel disease", "shape": "dot", "size": 10}, {"color": "red", "id": " gadolinium-chelate", "label": " gadolinium-chelate", "shape": "dot", "size": 10}, {"color": "green", "id": " oropharyngeal neoplasms", "label": " oropharyngeal neoplasms", "shape": "dot", "size": 10}, {"color": "green", "id": " heart diseases", "label": " heart diseases", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuserlotinib with neoadjuvant chemotherapy_breast cancer", "label": "unknown statuserlotinib with neoadjuvant chemotherapy_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ixabepilone, fluoropyrimidine, irinotecan", "label": "ixabepilone, fluoropyrimidine, irinotecan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuslenalidomide_myelodysplastic syndromes", "label": "unknown statuslenalidomide_myelodysplastic syndromes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]1(C[C@@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[C@H]1C[C@H](O)[C@H](O)CO1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CC(=O)OC1=CC=CC=C1C(O)=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1", "label": "[H][C@@]1(C[C@@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[C@H]1C[C@H](O)[C@H](O)CO1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CC(=O)OC1=CC=CC=C1C(O)=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " docetaxel (t) + bevacizumab", "label": " docetaxel (t) + bevacizumab", "shape": "dot", "size": 10}, {"color": "red", "id": "insulin lispro 6 day (6d)", "label": "insulin lispro 6 day (6d)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "large granular lymphocytic leukemia, lgl leukemia", "label": "large granular lymphocytic leukemia, lgl leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fentanyl, placebo", "label": "fentanyl, placebo", "shape": "dot", "size": 10}, {"color": "red", "id": "infusional 5-fluorouracil", "label": "infusional 5-fluorouracil", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "blue", "id": "[H][C@]1(CC=C(C)C)O[C@]1(C)[C@@]1([H])[C@]([H])(OC)[C@@]([H])(CC[C@]11CO1)OC(=O)NC(=O)CCl", "label": "[H][C@]1(CC=C(C)C)O[C@]1(C)[C@@]1([H])[C@]([H])(OC)[C@@]([H])(CC[C@]11CO1)OC(=O)NC(=O)CCl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "insulin degludec, insulin glargine, insulin aspart", "label": "insulin degludec, insulin glargine, insulin aspart", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@](O)(CNCCNC1=CC(=CC=C1)C1=CC(=CC=C1)C(O)=O)C1=CC=CC(Cl)=C1", "label": " [H][C@](O)(CNCCNC1=CC(=CC=C1)C1=CC(=CC=C1)C(O)=O)C1=CC=CC(Cl)=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedpeg-l-asparaginase, dexamethasone acetate_t-cell lymphoma, relapsed t-cell lymphoma, refractory t-cell lymphoma", "label": "terminatedpeg-l-asparaginase, dexamethasone acetate_t-cell lymphoma, relapsed t-cell lymphoma, refractory t-cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(O)=O, CC(O)=O", "label": "CC(O)=O, CC(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrepaglinide, gliclazide_diabetes, diabetes mellitus, type 2", "label": "completedrepaglinide, gliclazide_diabetes, diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "cdp323", "label": "cdp323", "shape": "dot", "size": 10}, {"color": "red", "id": " standard treatment (lidocaine viscous solution", "label": " standard treatment (lidocaine viscous solution", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCCCC1=NC(=CN1C1=CC=C(OC2=CC=C(Cl)C=C2)C=C1)C1=CC=C(OCCCN(CC)CC)C=C1", "label": "CCCCC1=NC(=CN1C1=CC=C(OC2=CC=C(Cl)C=C2)C=C1)C1=CC=C(OCCCN(CC)CC)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedciprofloxacin and amoxicillin, i.v. antibiotics_fever, neutropenia, cancer", "label": "terminatedciprofloxacin and amoxicillin, i.v. antibiotics_fever, neutropenia, cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O", "label": "CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completed17b estradiol (1mg) / (0.125 mg) tmg continuous combined (totelle), tibolone (livial)_vasomotor symptoms", "label": "completed17b estradiol (1mg) / (0.125 mg) tmg continuous combined (totelle), tibolone (livial)_vasomotor symptoms", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmacitentan, tadalafil_pulmonary arterial hypertension", "label": "terminatedmacitentan, tadalafil_pulmonary arterial hypertension", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "autism, pediatric autism", "label": "autism, pediatric autism", "shape": "dot", "size": 10}, {"color": "green", "id": "recurrent squamous cell carcinoma of the head or neck", "label": "recurrent squamous cell carcinoma of the head or neck", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvosaroxin_leukemia, acute disease, acute myeloid leukemia, nonlymphocytic leukemia, myelodysplastic syndromes", "label": "completedvosaroxin_leukemia, acute disease, acute myeloid leukemia, nonlymphocytic leukemia, myelodysplastic syndromes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " stage iv renal cell cancer", "label": " stage iv renal cell cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ambrisentan 5 mg, placebo", "label": "ambrisentan 5 mg, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@]1(O)N=C(O)C2=C3C4=CC=CC=C4N4C3=C3N(C5=CC=CC=C5C3=C12)[C@@]1(C)O[C@]4([H])C[C@@]([H])(NC)[C@@]1([H])OC, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "label": "[H][C@]1(O)N=C(O)C2=C3C4=CC=CC=C4N4C3=C3N(C5=CC=CC=C5C3=C12)[C@@]1(C)O[C@]4([H])C[C@@]([H])(NC)[C@@]1([H])OC, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "shape": "dot", "size": 10}, {"color": "red", "id": " sc cls-ta", "label": " sc cls-ta", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedruxolitinib pre- hematopoietic cell transplantation (hct)_primary myelofibrosis, post polycythemia vera myelofibrosis, post essential thrombocythemia myelofibrosis", "label": "terminatedruxolitinib pre- hematopoietic cell transplantation (hct)_primary myelofibrosis, post polycythemia vera myelofibrosis, post essential thrombocythemia myelofibrosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " gsk1605786a", "label": " gsk1605786a", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completeddexlansoprazole, placebo_heartburn, gastroesophageal reflux disease", "label": "completeddexlansoprazole, placebo_heartburn, gastroesophageal reflux disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " hemorrhage", "label": " hemorrhage", "shape": "dot", "size": 10}, {"color": "red", "id": " bi 671800 ed 100 mg", "label": " bi 671800 ed 100 mg", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrevlimid_waldenstrom macroglobulinemia", "label": "completedrevlimid_waldenstrom macroglobulinemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "desvenlafaxine succinate sustained-release (dvs sr), desvenlafaxine succinate sustained-release (dvs sr), placebo, duloxetine 60 mg/day", "label": "desvenlafaxine succinate sustained-release (dvs sr), desvenlafaxine succinate sustained-release (dvs sr), placebo, duloxetine 60 mg/day", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedvildagliptin_type 2 diabetes", "label": "completedvildagliptin_type 2 diabetes", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "liposomal doxorubicin, myocet / paclitaxel", "label": "liposomal doxorubicin, myocet / paclitaxel", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "pemetrexed, cisplatin, cixutumumab", "label": "pemetrexed, cisplatin, cixutumumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "glaucoma, cataract, wound heal", "label": "glaucoma, cataract, wound heal", "shape": "dot", "size": 10}, {"color": "red", "id": " pf-00547659 sc injection", "label": " pf-00547659 sc injection", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnd-cycloserine_obsessive compulsive disorder", "label": "withdrawnd-cycloserine_obsessive compulsive disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalo-01 (morphine sulfate plus naltrexone hydrochloride er)_pain", "label": "completedalo-01 (morphine sulfate plus naltrexone hydrochloride er)_pain", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " onartuzumab placebo", "label": " onartuzumab placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingtgr-1202, ibrutinib_chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma", "label": "active, not recruitingtgr-1202, ibrutinib_chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "advanced/metastatic non-small cell lung cancer", "label": "advanced/metastatic non-small cell lung cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedezetimibe (+) simvastatin_hyperlipidemia", "label": "completedezetimibe (+) simvastatin_hyperlipidemia", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": " postmenopausal", "label": " postmenopausal", "shape": "dot", "size": 10}, {"color": "red", "id": "diclofenac", "label": "diclofenac", "shape": "dot", "size": 10}, {"color": "green", "id": " endometrial undifferentiated carcinoma", "label": " endometrial undifferentiated carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O", "label": "[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O", "shape": "dot", "size": 10}, {"color": "green", "id": " stage ib breast cancer ajcc v7", "label": " stage ib breast cancer ajcc v7", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O", "label": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O", "label": "CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2", "label": " [H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tamoxifen, anastrozole, zoledronic acid", "label": "tamoxifen, anastrozole, zoledronic acid", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "rescue medication: self-injectable epinephrine, rescue medication: loratadine tablets, rescue medication: olopatadine ophthalmic drops, rescue medication: mometasone furoate nasal spray", "label": "rescue medication: self-injectable epinephrine, rescue medication: loratadine tablets, rescue medication: olopatadine ophthalmic drops, rescue medication: mometasone furoate nasal spray", "shape": "dot", "size": 10}, {"color": "red", "id": "fotemustine", "label": "fotemustine", "shape": "dot", "size": 10}, {"color": "green", "id": " hiv/aids", "label": " hiv/aids", "shape": "dot", "size": 10}, {"color": "red", "id": "placebo group(once daily)", "label": "placebo group(once daily)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tamoxifen, anastrazole (arimidex), goserelin acetate (zoladex)", "label": "tamoxifen, anastrazole (arimidex), goserelin acetate (zoladex)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedselonsertib, prednisolone, placebo_alcoholic hepatitis (ah)", "label": "completedselonsertib, prednisolone, placebo_alcoholic hepatitis (ah)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "8 international units (iu) of oxytocin", "label": "8 international units (iu) of oxytocin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawncapecitabine, gemcitabine hydrochloride_pancreatic cancer", "label": "withdrawncapecitabine, gemcitabine hydrochloride_pancreatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "acute graft versus host disease", "label": "acute graft versus host disease", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "delayed graft function, acute graft rejection", "label": "delayed graft function, acute graft rejection", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcam2038 q1w or q4w exposure to sl bpn/nx, cam2038 q1w or q4w new to bpn treatment_opioid use disorder", "label": "completedcam2038 q1w or q4w exposure to sl bpn/nx, cam2038 q1w or q4w new to bpn treatment_opioid use disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "ventilator associated pneumonia", "label": "ventilator associated pneumonia", "shape": "dot", "size": 10}, {"color": "blue", "id": "CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O", "label": "CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": " parenteral narcotic", "label": " parenteral narcotic", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedclopidogrel, aspirin 100mg_coronary artery disease (cad)", "label": "completedclopidogrel, aspirin 100mg_coronary artery disease (cad)", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2, N1C=CN=C1, CSCC[C@H](N)C(O)=O", "label": "COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2, N1C=CN=C1, CSCC[C@H](N)C(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": "gastroesophageal junction adenocarcinoma", "label": "gastroesophageal junction adenocarcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedgefitinib_bladder cancer", "label": "terminatedgefitinib_bladder cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma", "label": "recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "concurrent chemotherapy with cisplatin, concurrent chemotherapy with docetaxel, adjuvant chemotherapy with cisplatin and docetaxel", "label": "concurrent chemotherapy with cisplatin, concurrent chemotherapy with docetaxel, adjuvant chemotherapy with cisplatin and docetaxel", "shape": "dot", "size": 10}, {"color": "red", "id": "ataluren", "label": "ataluren", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, palifermin_head and neck cancer", "label": "completedplacebo, palifermin_head and neck cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "escitalopram, memantine, placebo", "label": "escitalopram, memantine, placebo", "shape": "dot", "size": 10}, {"color": "green", "id": "choroidal neovascularization", "label": "choroidal neovascularization", "shape": "dot", "size": 10}, {"color": "blue", "id": "C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "label": "C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, [H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O", "label": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, [H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "hiv infection, hypercholesterolemia", "label": "hiv infection, hypercholesterolemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1", "label": "CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedclopidogrel, prasugrel, commercially-available aspirin_acute coronary syndrome", "label": "completedclopidogrel, prasugrel, commercially-available aspirin_acute coronary syndrome", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O", "label": "ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "paclitaxel albumin nanoparticle for injectable suspension (abraxane), sorafenib (nexavar)", "label": "paclitaxel albumin nanoparticle for injectable suspension (abraxane), sorafenib (nexavar)", "shape": "dot", "size": 10}, {"color": "red", "id": " sibutramine", "label": " sibutramine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedtemsirolimus_fallopian tube cancer, primary peritoneal cavity cancer, recurrent ovarian epithelial cancer", "label": "completedtemsirolimus_fallopian tube cancer, primary peritoneal cavity cancer, recurrent ovarian epithelial cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "acute kidney injury, renal insufficiency", "label": "acute kidney injury, renal insufficiency", "shape": "dot", "size": 10}, {"color": "blue", "id": " [Na+].OC([O-])=O", "label": " [Na+].OC([O-])=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "biphasic insulin aspart 30, metformin, biphasic insulin aspart 50", "label": "biphasic insulin aspart 30, metformin, biphasic insulin aspart 50", "shape": "dot", "size": 10}, {"color": "red", "id": "placebo + adt", "label": "placebo + adt", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O", "label": "N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "tacrolimus (standard gvhd prophylaxis), mycophenolate (standard gvhd prophylaxis), etanercept, methoxsalen", "label": "tacrolimus (standard gvhd prophylaxis), mycophenolate (standard gvhd prophylaxis), etanercept, methoxsalen", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo for denosumab", "label": " placebo for denosumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedag-013736, gemcitabine, gemcitabine, placebo_carcinoma, pancreatic ductal", "label": "completedag-013736, gemcitabine, gemcitabine, placebo_carcinoma, pancreatic ductal", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "alogliptin and glyburide, alogliptin and glyburide, glyburide", "label": "alogliptin and glyburide, alogliptin and glyburide, glyburide", "shape": "dot", "size": 10}, {"color": "red", "id": " forsteo (teriparatide)", "label": " forsteo (teriparatide)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "active, not recruitingpemetrexed disodium_malignant mesothelioma", "label": "active, not recruitingpemetrexed disodium_malignant mesothelioma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsitagliptin, glimepiride, sitagliptin-placebo, glimepiride-placebo_diabetes mellitus type 2", "label": "terminatedsitagliptin, glimepiride, sitagliptin-placebo, glimepiride-placebo_diabetes mellitus type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "beclomethasone 100 \u00b5g plus formoterol 6 \u00b5g (chf1535) pmdi, budesonide 200 \u00b5g plus formoterol 6 \u00b5g dpi, formoterol 12 \u00b5g dpi", "label": "beclomethasone 100 \u00b5g plus formoterol 6 \u00b5g (chf1535) pmdi, budesonide 200 \u00b5g plus formoterol 6 \u00b5g dpi, formoterol 12 \u00b5g dpi", "shape": "dot", "size": 10}, {"color": "green", "id": " bone metastasis", "label": " bone metastasis", "shape": "dot", "size": 10}, {"color": "green", "id": " stage ivb esthesioneuroblastoma of the paranasal sinus and nasal cavity", "label": " stage ivb esthesioneuroblastoma of the paranasal sinus and nasal cavity", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedtemozolomide_melanoma (skin), metastatic cancer", "label": "terminatedtemozolomide_melanoma (skin), metastatic cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminateducn-01 (7-hydroxystaurosporine)_lymphoma, large-cell, ki-1, lymphoma, t-cell", "label": "terminateducn-01 (7-hydroxystaurosporine)_lymphoma, large-cell, ki-1, lymphoma, t-cell", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " aqx-1125 200 mg", "label": " aqx-1125 200 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " brimonidine tartrate 0.2% ophthalmic solution", "label": " brimonidine tartrate 0.2% ophthalmic solution", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "busulphan plus cyclophosphamide, busulphan plus fludarabine", "label": "busulphan plus cyclophosphamide, busulphan plus fludarabine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedrituximab, etoposide, carboplatine, ifosfamide + mesna, cisplatine, cytosine arabinoside, dexamethasone, bcnu, etoposide, cytarabine, melphalan_lymphoma, large-cell, diffuse", "label": "completedrituximab, etoposide, carboplatine, ifosfamide + mesna, cisplatine, cytosine arabinoside, dexamethasone, bcnu, etoposide, cytarabine, melphalan_lymphoma, large-cell, diffuse", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "high blood pressure", "label": "high blood pressure", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fluticasone, placebo inhalation, salmeterol, fluticasone/salmeterol", "label": "fluticasone, placebo inhalation, salmeterol, fluticasone/salmeterol", "shape": "dot", "size": 10}, {"color": "green", "id": " lung infection", "label": " lung infection", "shape": "dot", "size": 10}, {"color": "red", "id": " bevacizumab [avastin]", "label": " bevacizumab [avastin]", "shape": "dot", "size": 10}, {"color": "green", "id": " hilar cholangiocarcinoma", "label": " hilar cholangiocarcinoma", "shape": "dot", "size": 10}, {"color": "red", "id": " yh4808 400 mg (repeat doses)", "label": " yh4808 400 mg (repeat doses)", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC1=CC(O)=CC(C)=C1Cl, [H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "label": "CC1=CC(O)=CC(C)=C1Cl, [H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "piclozotan, 0.9% sodium chloride (normal saline)", "label": "piclozotan, 0.9% sodium chloride (normal saline)", "shape": "dot", "size": 10}, {"color": "red", "id": "methoxy polyethylene glycol-epoetin beta", "label": "methoxy polyethylene glycol-epoetin beta", "shape": "dot", "size": 10}, {"color": "green", "id": "eosinophilic esophagitis (eoe)", "label": "eosinophilic esophagitis (eoe)", "shape": "dot", "size": 10}, {"color": "red", "id": " oxandrolone 20 mg", "label": " oxandrolone 20 mg", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo - sugar pill", "label": " placebo - sugar pill", "shape": "dot", "size": 10}, {"color": "green", "id": " unresectable cancer", "label": " unresectable cancer", "shape": "dot", "size": 10}, {"color": "green", "id": " squamous cell cancer", "label": " squamous cell cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "bevacizumab, chemotherapy, placebo", "label": "bevacizumab, chemotherapy, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1, CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12", "label": "CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1, CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "NC(=O)[C@@H]1CC[C@@H](N1)C1=CC=C(OCC2=CC=CC=C2F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "NC(=O)[C@@H]1CC[C@@H](N1)C1=CC=C(OCC2=CC=CC=C2F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpemetrexed, gemcitabine, cisplatin_non small cell lung carcinoma", "label": "completedpemetrexed, gemcitabine, cisplatin_non small cell lung carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "estrace", "label": "estrace", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dexamethasone intravitreal implant, monthly ranibizumab", "label": "dexamethasone intravitreal implant, monthly ranibizumab", "shape": "dot", "size": 10}, {"color": "red", "id": " placebo to bevacizumab", "label": " placebo to bevacizumab", "shape": "dot", "size": 10}, {"color": "green", "id": " lgl leukemia", "label": " lgl leukemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedcd101, caspofungin, fluconazole, intravenous placebo, oral placebo_candidemia, mycoses, fungal infection, fungemia, invasive candidiasis", "label": "completedcd101, caspofungin, fluconazole, intravenous placebo, oral placebo_candidemia, mycoses, fungal infection, fungemia, invasive candidiasis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ospemifene, vaginal conjugated estrogens", "label": "ospemifene, vaginal conjugated estrogens", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ruxolitinib phosphate, danazol", "label": "ruxolitinib phosphate, danazol", "shape": "dot", "size": 10}, {"color": "red", "id": " trx0014", "label": " trx0014", "shape": "dot", "size": 10}, {"color": "green", "id": " familial primary pulmonary hypertension", "label": " familial primary pulmonary hypertension", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "sgi-110, ipilimumab", "label": "sgi-110, ipilimumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "label": "C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "shape": "dot", "size": 10}, {"color": "red", "id": "654-ii (anisodamine)", "label": "654-ii (anisodamine)", "shape": "dot", "size": 10}, {"color": "green", "id": " l1", "label": " l1", "shape": "dot", "size": 10}, {"color": "green", "id": " lung squamous cell carcinoma", "label": " lung squamous cell carcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "dsc127, placebo vehicle gel, standard of care gel, aquasite", "label": "dsc127, placebo vehicle gel, standard of care gel, aquasite", "shape": "dot", "size": 10}, {"color": "red", "id": "floxuridine (fudr)", "label": "floxuridine (fudr)", "shape": "dot", "size": 10}, {"color": "red", "id": " vehicle 1", "label": " vehicle 1", "shape": "dot", "size": 10}, {"color": "green", "id": " renal replacement therapy", "label": " renal replacement therapy", "shape": "dot", "size": 10}, {"color": "green", "id": " squamous cell head and neck cancer", "label": " squamous cell head and neck cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "type 2 diabetes, nonalcoholic steatohepatitis", "label": "type 2 diabetes, nonalcoholic steatohepatitis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedinsulin degludec, insulin degludec, insulin degludec_diabetes, diabetes mellitus, type 2", "label": "completedinsulin degludec, insulin degludec, insulin degludec_diabetes, diabetes mellitus, type 2", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedaripiprazole_schizophrenia, bipolar disorder", "label": "completedaripiprazole_schizophrenia, bipolar disorder", "node_type": "status", "shape": "dot", "size": 10}, {"color": "blue", "id": " CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4", "label": " CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "chronic sinusitis, nasal polyposis", "label": "chronic sinusitis, nasal polyposis", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "metastatic squamous neck cancer with occult primary squamous cell carcinoma, recurrent metastatic squamous neck cancer with occult primary, recurrent salivary gland cancer, recurrent squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the larynx, recurrent squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the nasopharynx, recurrent squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity, recurrent verrucous carcinoma of the larynx, recurrent verrucous carcinoma of the oral cavity, salivary gland squamous cell carcinoma, stage iv squamous cell carcinoma of the hypopharynx, stage iv squamous cell carcinoma of the nasopharynx, stage iva salivary gland cancer, stage iva squamous cell carcinoma of the larynx, stage iva squamous cell carcinoma of the lip and oral cavity, stage iva squamous cell carcinoma of the oropharynx, stage iva squamous cell carcinoma of the paranasal sinus and nasal cavity, stage iva verrucous carcinoma of the larynx, stage iva verrucous carcinoma of the oral cavity, stage ivb salivary gland cancer, stage ivb squamous cell carcinoma of the larynx, stage ivb squamous cell carcinoma of the lip and oral cavity, stage ivb squamous cell carcinoma of the oropharynx, stage ivb squamous cell carcinoma of the paranasal sinus and nasal cavity, stage ivb verrucous carcinoma of the larynx, stage ivb verrucous carcinoma of the oral cavity, stage ivc salivary gland cancer, stage ivc squamous cell carcinoma of the larynx, stage ivc squamous cell carcinoma of the lip and oral cavity, stage ivc squamous cell carcinoma of the oropharynx, stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity, stage ivc verrucous carcinoma of the larynx, stage ivc verrucous carcinoma of the oral cavity, tongue cancer", "label": "metastatic squamous neck cancer with occult primary squamous cell carcinoma, recurrent metastatic squamous neck cancer with occult primary, recurrent salivary gland cancer, recurrent squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the larynx, recurrent squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the nasopharynx, recurrent squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity, recurrent verrucous carcinoma of the larynx, recurrent verrucous carcinoma of the oral cavity, salivary gland squamous cell carcinoma, stage iv squamous cell carcinoma of the hypopharynx, stage iv squamous cell carcinoma of the nasopharynx, stage iva salivary gland cancer, stage iva squamous cell carcinoma of the larynx, stage iva squamous cell carcinoma of the lip and oral cavity, stage iva squamous cell carcinoma of the oropharynx, stage iva squamous cell carcinoma of the paranasal sinus and nasal cavity, stage iva verrucous carcinoma of the larynx, stage iva verrucous carcinoma of the oral cavity, stage ivb salivary gland cancer, stage ivb squamous cell carcinoma of the larynx, stage ivb squamous cell carcinoma of the lip and oral cavity, stage ivb squamous cell carcinoma of the oropharynx, stage ivb squamous cell carcinoma of the paranasal sinus and nasal cavity, stage ivb verrucous carcinoma of the larynx, stage ivb verrucous carcinoma of the oral cavity, stage ivc salivary gland cancer, stage ivc squamous cell carcinoma of the larynx, stage ivc squamous cell carcinoma of the lip and oral cavity, stage ivc squamous cell carcinoma of the oropharynx, stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity, stage ivc verrucous carcinoma of the larynx, stage ivc verrucous carcinoma of the oral cavity, tongue cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "gsk189075", "label": "gsk189075", "shape": "dot", "size": 10}, {"color": "red", "id": " levonorgestrel ius (mirena", "label": " levonorgestrel ius (mirena", "shape": "dot", "size": 10}, {"color": "red", "id": "de-117 ophthalmic solution", "label": "de-117 ophthalmic solution", "shape": "dot", "size": 10}, {"color": "red", "id": " docetaxel and irinotecan", "label": " docetaxel and irinotecan", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "aclidinium bromide 100 \u03bcg bid, aclidinium bromide 200 \u03bcg bid, aclidininum bromide 400 \u03bcg bid, placebo, formoterol 12 \u03bcg bid", "label": "aclidinium bromide 100 \u03bcg bid, aclidinium bromide 200 \u03bcg bid, aclidininum bromide 400 \u03bcg bid, placebo, formoterol 12 \u03bcg bid", "shape": "dot", "size": 10}, {"color": "green", "id": " rpa1 gene mutation", "label": " rpa1 gene mutation", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedsolumedrol_secondary progressive multiple sclerosis", "label": "terminatedsolumedrol_secondary progressive multiple sclerosis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "nivolumab, ipilimumab, placebo", "label": "nivolumab, ipilimumab, placebo", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedrituximab [mabthera/rituxan], placebo, methotrexate, rituximab [mabthera/rituxan]_rheumatoid arthritis", "label": "terminatedrituximab [mabthera/rituxan], placebo, methotrexate, rituximab [mabthera/rituxan]_rheumatoid arthritis", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgs-5885, gs-9451, ribavirin tablet, gs-9451 placebo_hepatitis c, chronic", "label": "completedgs-5885, gs-9451, ribavirin tablet, gs-9451 placebo_hepatitis c, chronic", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "prostate neoplasms, prostate cancer", "label": "prostate neoplasms, prostate cancer", "shape": "dot", "size": 10}, {"color": "red", "id": "panobinostat with rituximab", "label": "panobinostat with rituximab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgemcitabine hcl, pemetrexed disodium, gemcitabine hcl_lung cancer", "label": "completedgemcitabine hcl, pemetrexed disodium, gemcitabine hcl_lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedamg 706, placebo, paclitaxel, carboplatin_non-small cell lung cancer", "label": "terminatedamg 706, placebo, paclitaxel, carboplatin_non-small cell lung cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "paclitaxel, nanoparticle albumin-bound", "label": "paclitaxel, nanoparticle albumin-bound", "shape": "dot", "size": 10}, {"color": "red", "id": " docetaxel + cddp", "label": " docetaxel + cddp", "shape": "dot", "size": 10}, {"color": "green", "id": " giant cell glioblastoma", "label": " giant cell glioblastoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedpt001 mdi, ipratropium bromide hfa inhalation aerosol_chronic obstructive pulmonary disease", "label": "completedpt001 mdi, ipratropium bromide hfa inhalation aerosol_chronic obstructive pulmonary disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "relapsed / recurrent germ cell tumors", "label": "relapsed / recurrent germ cell tumors", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "panobinostat, fludarabine, cytarabine, intrathecal triples, leucovorin", "label": "panobinostat, fludarabine, cytarabine, intrathecal triples, leucovorin", "shape": "dot", "size": 10}, {"color": "red", "id": " td-9855", "label": " td-9855", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "fesoterodine, fesoterodine", "label": "fesoterodine, fesoterodine", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "terminatedmelatonin (n-acetyl-5-methoxytryptamine), placebo_breast cancer, depression", "label": "terminatedmelatonin (n-acetyl-5-methoxytryptamine), placebo_breast cancer, depression", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " 100 mg pg-530742", "label": " 100 mg pg-530742", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O", "label": "COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, COCCOC1=CC=C(C=C1)N1CCN(CCN2N=CC3=C2N=C(N)N2N=C(N=C32)C2=CC=CO2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O", "shape": "dot", "size": 10}, {"color": "green", "id": "hyperkalemia", "label": "hyperkalemia", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedfebuxostat, febuxostat, allopurinol_gout", "label": "completedfebuxostat, febuxostat, allopurinol_gout", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " formoterol 24ug", "label": " formoterol 24ug", "shape": "dot", "size": 10}, {"color": "red", "id": "ts-1", "label": "ts-1", "shape": "dot", "size": 10}, {"color": "red", "id": " cephalexin", "label": " cephalexin", "shape": "dot", "size": 10}, {"color": "red", "id": "cx-8998", "label": "cx-8998", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsof/vel, sof, rbv_hepatitis c virus infection", "label": "completedsof/vel, sof, rbv_hepatitis c virus infection", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedalisertib, paclitaxel_ovarian carcinoma, fallopian tube cancer, peritoneal cancer, breast carcinoma", "label": "completedalisertib, paclitaxel_ovarian carcinoma, fallopian tube cancer, peritoneal cancer, breast carcinoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(O)(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O", "label": "COCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(O)(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O", "shape": "dot", "size": 10}, {"color": "red", "id": "mk0954", "label": "mk0954", "shape": "dot", "size": 10}, {"color": "blue", "id": " O=C1N=CN=C2NNC=C12", "label": " O=C1N=CN=C2NNC=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "plecanatide, placebo, bisacodyl", "label": "plecanatide, placebo, bisacodyl", "shape": "dot", "size": 10}, {"color": "red", "id": "pt001 mdi", "label": "pt001 mdi", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "withdrawnimatinib mesylate_stage iiia skin melanoma, stage iiib skin melanoma, stage iiic skin melanoma, stage iv skin melanoma", "label": "withdrawnimatinib mesylate_stage iiia skin melanoma, stage iiib skin melanoma, stage iiic skin melanoma, stage iv skin melanoma", "node_type": "status", "shape": "dot", "size": 10}, {"color": "green", "id": "acute cough", "label": "acute cough", "shape": "dot", "size": 10}, {"color": "red", "id": "antibiotic prophylaxis", "label": "antibiotic prophylaxis", "shape": "dot", "size": 10}, {"color": "blue", "id": " [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1", "label": " [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1", "shape": "dot", "size": 10}, {"color": "red", "id": " etonogestrel-ethinyl estradiol vaginal ring", "label": " etonogestrel-ethinyl estradiol vaginal ring", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgenistein_colon cancer, rectal cancer, colorectal cancer", "label": "completedgenistein_colon cancer, rectal cancer, colorectal cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": " bivalirudin + clopidogrel + aspirin", "label": " bivalirudin + clopidogrel + aspirin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12, BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12", "label": "BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12, BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedgefitinib_tumors", "label": "completedgefitinib_tumors", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "escitalopram, sugar pill", "label": "escitalopram, sugar pill", "shape": "dot", "size": 10}, {"color": "red", "id": " sequential", "label": " sequential", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "open angle glaucoma, ocular hypertension", "label": "open angle glaucoma, ocular hypertension", "shape": "dot", "size": 10}, {"color": "green", "id": " stage ii enteropathy-associated t-cell lymphoma", "label": " stage ii enteropathy-associated t-cell lymphoma", "shape": "dot", "size": 10}, {"color": "green", "id": " stage ivb intrahepatic cholangiocarcinoma", "label": " stage ivb intrahepatic cholangiocarcinoma", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "heavy drinking, hiv, alcohol dependence", "label": "heavy drinking, hiv, alcohol dependence", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedplacebo, loratadine syrup 1 mg/ml rescue treatment, loratadine 10 mg rescue treatment, olopatadine 0.1% rescue treatment, mometasone furoate 50 mcg rescue treatment, albuterol 108 mcg rescue treatment, fluticasone 44 mcg rescue treatment, prednisone 5 mg rescue treatment_rhinoconjunctivitis, rhinitis, conjunctivitis, allergy", "label": "completedplacebo, loratadine syrup 1 mg/ml rescue treatment, loratadine 10 mg rescue treatment, olopatadine 0.1% rescue treatment, mometasone furoate 50 mcg rescue treatment, albuterol 108 mcg rescue treatment, fluticasone 44 mcg rescue treatment, prednisone 5 mg rescue treatment_rhinoconjunctivitis, rhinitis, conjunctivitis, allergy", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "rosiglitazone", "label": "rosiglitazone", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statusaccordion pill carbidopa/levodopa, sinemet cr 25mg-100mg extended-release tablet_parkinson disease", "label": "unknown statusaccordion pill carbidopa/levodopa, sinemet cr 25mg-100mg extended-release tablet_parkinson disease", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "ipilimumab, leuprolide, goserelin, degarelix", "label": "ipilimumab, leuprolide, goserelin, degarelix", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedmetformin_prostate cancer", "label": "completedmetformin_prostate cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "consensus interferon (interferon alfacon-1) and ribavirin", "label": "consensus interferon (interferon alfacon-1) and ribavirin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "FC1=CN(C2CCCO2)C(=O)NC1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "label": "FC1=CN(C2CCCO2)C(=O)NC1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "CC(=O)NC1=CC=C(O)C=C1, CC(=O)NC1=CC=C(O)C=C1", "label": "CC(=O)NC1=CC=C(O)C=C1, CC(=O)NC1=CC=C(O)C=C1", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C", "label": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, CC1=CC(O)=CC(C)=C1Cl", "label": "[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, CC1=CC(O)=CC(C)=C1Cl", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "unknown statuscyclophosphamide, docetaxel, doxorubicin hydrochloride, tamoxifen citrate_breast cancer", "label": "unknown statuscyclophosphamide, docetaxel, doxorubicin hydrochloride, tamoxifen citrate_breast cancer", "node_type": "status", "shape": "dot", "size": 10}, {"color": "red", "id": "dalotuzumab", "label": "dalotuzumab", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "experimental: empiric tb treatment, art only arm", "label": "experimental: empiric tb treatment, art only arm", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "carvedilol, metoprolol succinate, metoprolol succinate + doxazosin", "label": "carvedilol, metoprolol succinate, metoprolol succinate + doxazosin", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "completedsorafenib tosylate, temsirolimus_adult glioblastoma, adult gliosarcoma, recurrent adult brain neoplasm", "label": "completedsorafenib tosylate, temsirolimus_adult glioblastoma, adult gliosarcoma, recurrent adult brain neoplasm", "node_type": "status", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1, [H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "label": "COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1, [H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "anorexia, cachexia, fatigue, lung cancer", "label": "anorexia, cachexia, fatigue, lung cancer", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "cisplatin, cyclophosphamide", "label": "cisplatin, cyclophosphamide", "shape": "dot", "size": 10}, {"color": "#97c2fc", "id": "placebo, donepezil, donepezil", "label": "placebo, donepezil, donepezil", "shape": "dot", "size": 10}]);
                  edges = new vis.DataSet([{"arrows": "to", "edge_type": "builds", "from": "CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O", "to": "ibalizumab, optimized background regimen", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "nevirapine ir, nevirapine xr", "to": "completednevirapine ir, nevirapine xr_hiv infections", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedtrabectedin_sarcoma", "to": "sarcoma", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "qva149, umeclidinium/vilanterol, placebo (umeclidinium/vilanterol ), placebo (qva149)", "to": "completedqva149, umeclidinium/vilanterol, placebo (umeclidinium/vilanterol ), placebo (qva149)_chronic obstructive pulmonary disease", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatednexium, placebo_exercise triggered asthma, gastroesophageal reflux", "to": "exercise triggered asthma, gastroesophageal reflux", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "duloxetine, propranolol, placebo treatment", "to": "low back pain", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "udca, sitagliptin", "to": "unknown statusudca, sitagliptin_type 2 diabetes mellitus, chronic liver disease", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "capecitabine, oxaliplatin", "to": "unknown statuscapecitabine, oxaliplatin_colorectal neoplasms, liver metastases", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "capecitabine, oxaliplatin", "to": "completedcapecitabine, oxaliplatin_gastric cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "insulin glargine, inhaled insulin (exubera)", "to": "completedinsulin glargine, inhaled insulin (exubera)_diabetes mellitus, type 2", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "cbsst + oxytocin, cbsst + placebo", "to": "completedcbsst + oxytocin, cbsst + placebo_schizophrenia, schizoaffective disorder", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "g-csf plus plerixafor, g-csf plus plerixafor", "to": "completedg-csf plus plerixafor, g-csf plus plerixafor_non-hodgkin lymphoma, hodgkin disease", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "clopidogrel, cilostazol", "to": "cerebral infarction, atherosclerosis", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "hydroxychloroquine (hc)", "to": "terminatedhydroxychloroquine (hc)_renal cell carcinoma", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus", "to": "active, not recruitingcyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus_adult acute lymphoblastic leukemia in complete remission, acute myeloid leukemia in remission, previously treated myelodysplastic syndrome, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, childhood acute lymphoblastic leukemia in complete remission", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "eszopiclone, placebo", "to": "sleep initiation and maintenance disorders", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "hsp90 inhibitor sta-9090", "to": "adenocarcinoma of the prostate, hormone-resistant prostate cancer, recurrent prostate cancer, stage iv prostate cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "clofarabine, cytarabine", "to": "terminatedclofarabine, cytarabine_acute myelogenous leukemia", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "active, not recruitingcisplatin, fluorouracil_anal cancer", "to": "anal cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "etoposide, mitoxantrone hydrochloride, prednisone, vinorelbine tartrate", "to": "completedetoposide, mitoxantrone hydrochloride, prednisone, vinorelbine tartrate_prostate cancer", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "mycophenolate mofetil, mycofenolate mofetil (mmf), placebo", "to": "interstitial cystitis, painful bladder syndrome", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "umeclidinium/vilanterol 62.5/25 mcg, tiotropium 18 mcg", "to": "completedumeclidinium/vilanterol 62.5/25 mcg, tiotropium 18 mcg_pulmonary disease, chronic obstructive", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "tmc125, darunavir; ritonavir", "to": "hiv", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "oral azacitidine", "to": "terminatedoral azacitidine_myelodysplastic syndromes, chronic myelomonocytic leukemia, acute myeloid leukemia, multiple myeloma, non-hodgkin lymphoma, hodgkin lymphoma", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "zgn-440 for injectable suspension, zgn-440 placebo for injectable suspension", "to": "prader-willi syndrome, obesity", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "olaratumab, doxorubicin, placebo", "to": "active, not recruitingolaratumab, doxorubicin, placebo_soft tissue sarcoma", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "dasatinib, rituximab, fludarabine", "to": "chronic lymphocytic leukemia, small lymphocytic lymphoma", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "tipifarnib", "to": "adult acute megakaryoblastic leukemia, adult acute monoblastic leukemia, adult acute monocytic leukemia, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with maturation, adult acute myeloid leukemia with minimal differentiation, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll, adult acute myeloid leukemia without maturation, adult acute myelomonocytic leukemia, adult erythroleukemia, adult pure erythroid leukemia, alkylating agent-related acute myeloid leukemia, secondary acute myeloid leukemia, untreated adult acute myeloid leukemia", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "pazopanib and paclitaxel", "to": "ovarian neoplasm", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "hld200 methylphenidate hydrochloride (mph) capsules, placebo", "to": "completedhld200 methylphenidate hydrochloride (mph) capsules, placebo_attention deficit hyperactivity disorder", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO", "to": "ipragliflozin, alpha glucosidase inhibitor", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "letrozole; avastin", "to": "completedletrozole; avastin_breast cancer, cancer of the breast, breast neoplasm", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "pt001 mdi, tiotropium bromide, pt001 placebo mdi", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O, S1SSSSSSS1", "to": "edoxaban tosylate, enoxaparin/unfractionated heparin, warfarin", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "ClC1=CC(Cl)=C(C=C1)C(=O)NS(=O)(=O)C1=CC=C(Br)S1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "to": "tasisulam-sodium, paclitaxel", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "placebo, vanquix auto-injector (diazepam injection)", "to": "seizures, epilepsies, partial, epilepsy, complex partial, epilepsy, generalized, epilepsy", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "to": "topotecan and taxotere", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "opc-41061(tolvaptan)", "to": "heart failure, congestive, edema", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "to": "du-176b 15mg, du-176b 30mg, enoxaparin sodium 20 mg (=2000iu)", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "placebo + methotrexate (mtx) (group 1), ustekinumab + mtx (group 2), ustekinumab + mtx (group 3), cnto 1959 + mtx (group 4), cnto 1959 + mtx (group 5)", "to": "completedplacebo + methotrexate (mtx) (group 1), ustekinumab + mtx (group 2), ustekinumab + mtx (group 3), cnto 1959 + mtx (group 4), cnto 1959 + mtx (group 5)_arthritis, rheumatoid", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completeddoxorubicin hydrochloride_sarcoma", "to": "sarcoma", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "atomoxetine, other standard therapy for adhd", "to": "completedatomoxetine, other standard therapy for adhd_attention deficit hyperactivity disorder", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "active, not recruitingenzalutamide, bicalutamide, leuprolide acetate, goserelin acetate_adenocarcinoma of the prostate, recurrent prostate cancer, stage iv prostate cancer", "to": "adenocarcinoma of the prostate, recurrent prostate cancer, stage iv prostate cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "tozadenant", "to": "terminatedtozadenant_idiopathic parkinson disease", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "nemonoxacin, nemonoxacin, tavanic, tavanic, placebo (250 ml), placebo (100 ml)", "to": "completednemonoxacin, nemonoxacin, tavanic, tavanic, placebo (250 ml), placebo (100 ml)_pneumonia, bacterial", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "lidocaine hydrochloride, ketorolac tromethamine", "to": "unknown statuslidocaine hydrochloride, ketorolac tromethamine_anesthesia", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "anti-il-20, placebo", "to": "completedanti-il-20, placebo_inflammation, rheumatoid arthritis", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedvalganciclovir, ganciclovir_cytomegalovirus infections", "to": "cytomegalovirus infections", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[K+]", "to": "bexxar (tositumomab), potassium iodide (ki)", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "aspirin (acetylsalicylic acid, baye4465), placebo", "to": "completedaspirin (acetylsalicylic acid, baye4465), placebo_moderate risk of cvd", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "aspirin (acetylsalicylic acid, baye4465), placebo", "to": "completedaspirin (acetylsalicylic acid, baye4465), placebo_common cold", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "to": "5-fluorouracil, capecitabine, cyclophosphamide, docetaxel, epirubicin", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1", "to": "xl281, famotidine", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "gsk1363089 (foretinib)", "to": "neoplasms, head and neck", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedpf-04494700 - low dose arm, pf-04494700 - high dose arm, placebo comparator_alzheimer disease", "to": "alzheimer disease", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "intraventricular rituximab plus mtx", "to": "central nervous system lymphoma, intraocular lymphoma", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedbnc210, placebo_post-traumatic stress disorder", "to": "post-traumatic stress disorder", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "prasugrel, clopidogrel", "to": "terminatedprasugrel, clopidogrel_thrombosis, coronary artery disease", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "mometasone furoate, nortriptyline hcl, vehicle (placebo)", "to": "plaque psoriasis", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedbosentan_idiopathic pulmonary fibrosis", "to": "idiopathic pulmonary fibrosis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CSCC[C@H](N)C(O)=O", "to": "ertugliflozin 5 mg, ertugliflozin 15 mg, placebo to ertugliflozin, placebo to glimepiride, metformin", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "withdrawneverolimus_peutz-jeghers syndrome, neoplastic processes, neoplasm metastasis", "to": "peutz-jeghers syndrome, neoplastic processes, neoplasm metastasis", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "5 fluorouracil, irinotecan, levo- leucovorin, sunitinib, 5 fluorouracil, irinotecan, levo- leucovorin, placebo", "to": "completed5 fluorouracil, irinotecan, levo- leucovorin, sunitinib, 5 fluorouracil, irinotecan, levo- leucovorin, placebo_metastatic colorectal cancer", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedbrentuximab vedotin, methotrexate, bexarotene_primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, cutaneous t-cell lymphoma", "to": "primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, cutaneous t-cell lymphoma", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedbetrixaban, enoxaparin_venous thromboembolism (vte)", "to": "venous thromboembolism (vte)", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "oral vinorelbine, cisplatin, maintenance with metronomic oral vinorelbine, pemetrexed, cisplatin, maintenance with pemetrexed", "to": "carcinoma, non-small-cell lung, secondary, advanced stage iiib, high thymidylate synthase expression", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "neonatal morphine solution, methadone, phenobarbital", "to": "completedneonatal morphine solution, methadone, phenobarbital_neonatal abstinence syndrome, neonatal opioid withdrawal", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedplacebo, varenicline tartrate, bupropion hydrochloride, nicotine replacement therapy patch_smoking cessation", "to": "smoking cessation", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "tenofovir, placebo", "to": "chronic hepatitis b, hepatocellular carcinoma", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedoros hydromorphone hci sr (slow release)_low back pain", "to": "low back pain", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "abt-199", "to": "chronic lymphocytic leukemia, 17 p deletion, cancer of the blood and bone marrow", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completed100 mg sumatriptan tablet and optinose placebo delivered nasally, optinose sumatriptan delivered nasally and placebo tablet_migraine, headaches", "to": "migraine, headaches", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "busulfan, cytarabine, daunorubicin hydrochloride, decitabine, etoposide", "to": "acute myeloid leukemia, acute myeloid leukemia with myelodysplasia-related changes, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22.3;q23.3); mllt3-kmt2a, untreated adult acute myeloid leukemia", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "withdrawnsorafenib_medullary thyroid carcinoma", "to": "medullary thyroid carcinoma", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedivabradine, placebo_coronary disease, ventricular dysfunction, left", "to": "coronary disease, ventricular dysfunction, left", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "carvedilol controlled release/lisinopril, lisinopril + placebo", "to": "completedcarvedilol controlled release/lisinopril, lisinopril + placebo_hypertension", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedcariprazine_bipolar i disorder", "to": "bipolar i disorder", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "capecitabine", "to": "unknown statuscapecitabine_rectal carcinoma", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O", "to": "ar antagonist (bms-641988)", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O", "to": "r-hlh + r-hfsh, r-hfsh, recombinant human choriogonadotropin (r-hcg), gnrh antagonist", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "everolimus and intravesical gemcitabine", "to": "completedeverolimus and intravesical gemcitabine_bladder cancer", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completederlotinib hydrochloride, sorafenib tosylate_extrahepatic bile duct adenocarcinoma, gallbladder adenocarcinoma, gallbladder adenocarcinoma with squamous metaplasia, hilar cholangiocarcinoma, recurrent extrahepatic bile duct carcinoma, recurrent gallbladder carcinoma, undifferentiated gallbladder carcinoma, unresectable extrahepatic bile duct carcinoma, unresectable gallbladder carcinoma", "to": "extrahepatic bile duct adenocarcinoma, gallbladder adenocarcinoma, gallbladder adenocarcinoma with squamous metaplasia, hilar cholangiocarcinoma, recurrent extrahepatic bile duct carcinoma, recurrent gallbladder carcinoma, undifferentiated gallbladder carcinoma, unresectable extrahepatic bile duct carcinoma, unresectable gallbladder carcinoma", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "abiraterone acetate, placebo, prednisone", "to": "prostate neoplasms", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "abiraterone acetate, placebo, prednisone", "to": "completedabiraterone acetate, placebo, prednisone_prostate neoplasms", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C", "to": "fluticasone furoate/vilanterol 100/25 mcg via ellipta inhaler, placebo inhalation powders via ellipta inhaler, fluticasone propionate/salmeterol 250/50 mcg via accuhaler/diskus inhaler, placebo inhalation powder via accuhaler/diskus inhaler, fluticasone propionate 250 mcg via accuhaler/diskus inhaler", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "inhaled td139, placebo", "to": "idiopathic pulmonary fibrosis", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "perampanel", "to": "terminatedperampanel_parkinson\u0027s disease", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "umeclidinium bromide/vilanterol, placebo accuhaler/diskus, fluticasone propionate/salmeterol, placebo ndpi", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "ibrutinib, bendamustine hydrochloride, rituximab, placebo", "to": "chronic lymphocytic leukemia, small lymphocytic lymphoma", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN", "to": "ldx treatment", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedexparel 266 mg, placebo_posterolateral thoracotomy, postoperative pain", "to": "posterolateral thoracotomy, postoperative pain", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "e7080 capsule", "to": "thyroid cancer", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1", "to": "cyclophosphamide, fludarabine, alemtuzumab, rituximab", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1", "to": "fludarabine, cyclophosphamide, alemtuzumab, rituximab", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O, CC1=CC(O)=CC(C)=C1Cl", "to": "apixaban, placebo drug", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1", "to": "combination therapy using decitabine and midostaurin", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NC1=CC(C(O)=O)=C(O)C=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "to": "mesalazine, iv corticosteroid, oral corticosteroids", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "octreotide, dg3173", "to": "completedoctreotide, dg3173_acromegaly", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "bevacizumab, temsirolimus", "to": "kidney cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "ogx-427 600 mg, ogx-427 1000 mg, placebo, gemcitabine, cisplatin, carboplatin", "to": "completedogx-427 600 mg, ogx-427 1000 mg, placebo, gemcitabine, cisplatin, carboplatin_urologic neoplasms, metastatic bladder cancer, urinary tract neoplasms", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "brimonidine, brimonidine mono therapy, sodium carboxymethylcellulose, corticosteroid eye drop", "to": "completedbrimonidine, brimonidine mono therapy, sodium carboxymethylcellulose, corticosteroid eye drop_dry eye", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedallopurinol, placebo_pre-hypertension, jnc 7 stage i hypertension", "to": "pre-hypertension, jnc 7 stage i hypertension", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "unknown statustriptolide, cart, placebo_hiv", "to": "hiv", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "pm01183", "to": "completedpm01183_breast cancer", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1, [H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O, OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O, CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1", "to": "ceftazidime - avibactam ( caz-avi), doripenem, either switch to oral therapy: 500 mg of ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "somatropin, placebo", "to": "chronic kidney disease, end-stage renal disease", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "to": "pegylated interferon alpha2a", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "to": "gemcitabine, capecitabine and sorafenib (6 cycles)", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1", "to": "pegylated interferon alpha-2a", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "sorafenib, bavituximab", "to": "withdrawnsorafenib, bavituximab_hepatocellular carcinoma, unresectable hepatocellular carcinoma, liver cancer", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1", "to": "rosiglitazone therapy", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedsb-705498_irritable colon", "to": "irritable colon", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O", "to": "gnrh antagonist (cetrorelix), conventional gnrh agonist (triptorelin)", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O", "to": "iron isomaltoside/ferric derisomaltose, iron sucrose", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "doxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, vinblastine sulfate, vincristine sulfate", "to": "completeddoxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, vinblastine sulfate, vincristine sulfate_lymphoma", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedux007_glucose transporter type 1 deficiency syndrome", "to": "glucose transporter type 1 deficiency syndrome", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedamg 706_thyroid cancer", "to": "thyroid cancer", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "rivaroxaban (xarelto, bay59-7939), enoxaparin followed by vka", "to": "venous thrombosis", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedbortezomib_sarcoma", "to": "sarcoma", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "raltegravir (mk-0518), nevirapine, lamivudine, tenofovir, emtricitabine, lopinavir, ritonavir, atazanavir, darunavir", "to": "terminatedraltegravir (mk-0518), nevirapine, lamivudine, tenofovir, emtricitabine, lopinavir, ritonavir, atazanavir, darunavir_hiv infections", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "[f-18]-5-fluoro-2\u0027-deoxycytidine, tetrahydrouridine intravenous (iv), tetrahydrouridine (oral)", "to": "head and neck neoplasms, lung neoplasms, urinary bladder neoplasms, breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "bevacizumab, rad001", "to": "kidney cancer", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedescitalopram, placebo_generalized anxiety disorder", "to": "generalized anxiety disorder", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "placebo, buprenorphine transdermal system", "to": "low back pain", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "placebo, buprenorphine transdermal system", "to": "completedplacebo, buprenorphine transdermal system_low back pain", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedsuboxone, rbp-6000, placebo_opioid dependence, opioid related disorders", "to": "opioid dependence, opioid related disorders", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1", "to": "bisoprolol", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1", "to": "abt-199", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedsorafenib, tegafur/uracil (ufur\u00ae)_hepatocellular carcinoma", "to": "hepatocellular carcinoma", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "anb020, placebo", "to": "completedanb020, placebo_eosinophilic asthma", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "pf-04991532, placebo", "to": "completedpf-04991532, placebo_diabetes mellitus, diabetes mellitus, type 2, glucose metabolism disorders", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CCN(CC)CCNC(=O)C1=C(C)NC(\\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C", "to": "doxorubicin hydrochloride, sunitinib malate", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "roflumilast, pioglitazone, placebo, placebo", "to": "terminatedroflumilast, pioglitazone, placebo, placebo_nonalcoholic steatohapatitis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1", "to": "perifosine, imatinib mesylate", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedaprepitant, placebo_chemotherapy induced nausea and vomiting", "to": "chemotherapy induced nausea and vomiting", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "azd3480, donepezil", "to": "alzheimer disease", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "imexon", "to": "completedimexon_follicular lymphoma, small lymphocytic lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, diffuse large b cell lymphoma, mantle cell lymphoma, burkitt\u0027s lymphoma", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "lurasidone, placebo", "to": "bipolar i disorder", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "lurasidone, placebo", "to": "major depressive disorder with mixed features", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "irinotecan hydrochloride", "to": "adenocarcinoma of the colon, adenocarcinoma of the rectum, recurrent colon cancer, recurrent rectal cancer, stage iii colon cancer, stage iii rectal cancer, stage iv colon cancer, stage iv rectal cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "irinotecan hydrochloride", "to": "withdrawnirinotecan hydrochloride_central nervous system metastases, male breast cancer, recurrent breast cancer, stage iv breast cancer", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "goserelin acetate, letrozole, anastrozole, chemotherapy", "to": "estrogen receptor-positive breast cancer, her2-negative breast cancer, stage ii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1, [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "to": "fx006 32 mg, tca ir 40", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1", "to": "ganciclovir", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CNC(=O)C1=CC=C(C=C1F)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2N=C1, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "to": "inc280, gefitinib", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatediv meropenem, i.v. meropenem, parenteral aminoglycoside; tobramycin for injection usp or gentamicin sulfate injection solution concentrate 5mg.kg iv q24h; amikacin sulfate injection usp 20 mg/kg iv q24h, linezolid or vancomycin (per institutional guidelines) will be available for mrsa coverage._bacterial pneumonia", "to": "bacterial pneumonia", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedbest available therapy, ruxolitinib_polycythemia vera", "to": "polycythemia vera", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "ff inhalation powder, ff/gw642444 inhalation powder, gw642444 inhalation powder, placebo", "to": "completedff inhalation powder, ff/gw642444 inhalation powder, gw642444 inhalation powder, placebo_pulmonary disease, chronic obstructive", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "carboplatin, celecoxib, gemcitabine hydrochloride, pemetrexed disodium", "to": "terminatedcarboplatin, celecoxib, gemcitabine hydrochloride, pemetrexed disodium_lung cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "axs-05, bupropion sr", "to": "completedaxs-05, bupropion sr_smoking cessation, smoking, cigarette, nicotine dependence", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "inhaled fluticasone propionate", "to": "asthma, chronic obstructive pulmonary disease, obstructive sleep apnea", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "netupitant and palonosetron, palonosetron, dexamethasone", "to": "completednetupitant and palonosetron, palonosetron, dexamethasone_chemotherapy-induced nausea and vomiting", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "oral ftc/tdf (daily emtricitabine/tenofovir disoproxil fumarate tablet), rectal daily tfv rg 1% gel (rectally applied tenofovir reduced glycerin 1% gel), rectal rai-associated tfv rg 1% gel (receptive anal intercourse associated rectally applied tenofovir reduced glycerin 1% gel)", "to": "hiv", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "pemetrexed disodium, sunitinib malate", "to": "recurrent non-small cell lung carcinoma, stage iiib non-small cell lung cancer ajcc v7, stage iv non-small cell lung cancer ajcc v7", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedezetimibe + statin (simvastatin, atorvastatin, or pravastatin), double statin (simvastatin, atorvastatin, or pravastatin)_hypercholesterolemia", "to": "hypercholesterolemia", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "olanzapine", "to": "hematopoietic/lymphoid cancer, pain, unspecified adult solid tumor, protocol specific", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedmemantine, placebo pill_alzheimer disease", "to": "alzheimer disease", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "ly2940680", "to": "neoplasm metastasis", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "placebo capsule, 10 mg natura-alpha capsule and 10 mg placebo capsule, 2 x 10 mg natura-alpha capsules", "to": "unknown statusplacebo capsule, 10 mg natura-alpha capsule and 10 mg placebo capsule, 2 x 10 mg natura-alpha capsules_ulcerative colitis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=CC(F)=CC=C1F, CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=CC(F)=CC=C1F, CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1, CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1", "to": "omarigliptin, placebo to omarigliptin, glipizide, placebo to glipizide", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "alendronate, denosumab, placebo", "to": "completedalendronate, denosumab, placebo_postmenopausal osteoporosis", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "olaparib, physician\u0027s choice chemotherapy", "to": "breast cancer metastatic, brca 1 gene mutation, brca 2 gene mutation", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "bortezomib, rituximab", "to": "terminatedbortezomib, rituximab_lymphoma", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "sunitinib (sutent), taxotere", "to": "breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "cisplatin, panitumumab", "to": "head and neck cancer, squamous cell carcinoma", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "to": "budesonide and formoterol bid", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedgalantamine_schizophrenia, psychotic disorder", "to": "schizophrenia, psychotic disorder", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "hydromorphone er, sugar pill", "to": "low back pain", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "pioglitazone", "to": "depressive disorder, major, metabolic syndrome x", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "hsp90 inhibitor auy922", "to": "unspecified adult solid tumor, protocol specific", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedezetimibe, placebo_hypercholesterolemia, atherosclerosis", "to": "hypercholesterolemia, atherosclerosis", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "placebo, oros (methylphenidate hcl), ritalin (methylphenidate)", "to": "completedplacebo, oros (methylphenidate hcl), ritalin (methylphenidate)_attention deficit hyperactivity disorder", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "dacomitinib, pemetrexed", "to": "terminateddacomitinib, pemetrexed_non small cell lung cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "hqk-1001, placebo", "to": "terminatedhqk-1001, placebo_sickle cell disease, sickle cell anemia, sickle cell disorders, hemoglobin s disease, sickling disorder due to hemoglobin s", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "abiraterone acetate, prednisone, abiraterone acetate placebo, prednisone placebo", "to": "prostate neoplasms", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "corticosteroids, cyclophosphamide, mycophenolate mofetil, ocrelizumab, placebo, azathioprine", "to": "lupus nephritis, systemic lupus erythematosus", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedsecukinumab 150 mg s.c., secukinumab 300 mg s.c., placebo_plaque psoriasis", "to": "plaque psoriasis", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "chemotherapy, gemcitabine, irinotecan, leucovorin, 5-fluorouracil, pembrolizumab", "to": "pancreatic adenocarcinoma", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC(O)(P(O)(O)=O)P(O)(O)=O", "to": "iv bisphosphonate q 4 weeks", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedmilnacipran, placebo_autism spectrum disorder, asperger syndrome, aspergers syndrome", "to": "autism spectrum disorder, asperger syndrome, aspergers syndrome", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "tozadenant (syn115) 60 mg bid, placebo, levodopa (l-dopa), tozadenant (syn115) 120 mg bid, tozadenant (syn115) 180 mg bid, tozadenant (syn115) 240 mg bid", "to": "completedtozadenant (syn115) 60 mg bid, placebo, levodopa (l-dopa), tozadenant (syn115) 120 mg bid, tozadenant (syn115) 180 mg bid, tozadenant (syn115) 240 mg bid_parkinson\u0027s disease", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin", "to": "chronic hepatitis c, decompensated cirrhosis, hepatitis c virus", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H], CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O", "to": "at-101, topotecan", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedrivastigmine 5 cm^2, rivastigmine 10 cm^2, rivastigmine 15 cm^2, placebo to 15 cm^2 patch, placebo to 10 cm^2 patch_alzheimer disease", "to": "alzheimer disease", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedduloxetine, pregabalin, placebo_diabetic peripheral neuropathic pain", "to": "diabetic peripheral neuropathic pain", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O", "to": "corticosteroids, cyclophosphamide, mycophenolate mofetil, ocrelizumab, placebo, azathioprine", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "active, not recruitinghigh dose methylprednisolone (hdmp), ofatumumab, lenalidomide_chronic lymphocytic leukemia, small lymphocytic lymphoma", "to": "chronic lymphocytic leukemia, small lymphocytic lymphoma", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1", "to": "dasatinib, imatinib", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "vitamin d3 cholecalciferol", "to": "vitamin d deficiency, insulin resistance", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "captopril, enalapril, lisinopril, ramipril, trandolapril, bisoprolol, carvedilol, metoprolol succinate, candesartan, valsartan, eplerenone, spironolactone, diuretics, hf treatment according to swedish guidelines", "to": "heart failure, ventricular dysfunction, left", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedku-0059436 (azd2281)(parp inhibitor), ku-0059436 (azd2281)(parp inhibitor)_ovarian neoplasm", "to": "ovarian neoplasm", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedlenvatinib, placebo, lenvatinib_thyroid cancer", "to": "thyroid cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "insulin glulisine, insulin glargine", "to": "completedinsulin glulisine, insulin glargine_diabetes mellitus, type 1", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "ibudilast, placebo oral capsule", "to": "completedibudilast, placebo oral capsule_multiple sclerosis, primary progressive, multiple sclerosis, secondary progressive", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib", "to": "completedakt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib_pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma, recurrent pancreatic carcinoma, stage iv pancreatic cancer", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1", "to": "placebo, bi 10773, placebo, placebo, placebo, bi 10773", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "glimepiride and metformin hydrochloride combination (hoe490), glimepiride (hoe490)", "to": "completedglimepiride and metformin hydrochloride combination (hoe490), glimepiride (hoe490)_type 2 diabetes mellitus", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "quetiapine fumarate, escitalopram oxylate", "to": "generalized anxiety disorder", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(=O)OC1=CC=CC=C1C(O)=O", "to": "tapentadol er (100 to 250 mg twice daily), matching placebo (twice daily), oxycodone cr (20 to 50 mg twice daily)", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "cep-701, high-dose cytarabine, mitozantrone, etoposide, cytarabine (combination chemotherapy)", "to": "completedcep-701, high-dose cytarabine, mitozantrone, etoposide, cytarabine (combination chemotherapy)_acute myeloid leukemia", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedtemozolomide_colorectal neoplasm, head and neck neoplasm, carcinoma, non-small-cell lung, esophageal neoplasm", "to": "colorectal neoplasm, head and neck neoplasm, carcinoma, non-small-cell lung, esophageal neoplasm", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "rg7388, pegasys", "to": "completedrg7388, pegasys_polycythemia vera, essential thrombocythemia", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedgemcitabine hydrochloride, triapine_anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, intraocular lymphoma, nodal marginal zone b-cell lymphoma, primary central nervous system hodgkin lymphoma, primary central nervous system non-hodgkin lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, small intestine lymphoma, splenic marginal zone lymphoma, stage iii adult burkitt lymphoma, stage iii adult diffuse large cell lymphoma, stage iii adult diffuse mixed cell lymphoma, stage iii adult diffuse small cleaved cell lymphoma, stage iii adult hodgkin lymphoma, stage iii adult immunoblastic large cell lymphoma, stage iii adult lymphoblastic lymphoma, stage iii adult t-cell leukemia/lymphoma, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iii marginal zone lymphoma, stage iii mycosis fungoides/sezary syndrome, stage iii small lymphocytic lymphoma, stage iv adult burkitt lymphoma, stage iv adult diffuse large cell lymphoma, stage iv adult diffuse mixed cell lymphoma, stage iv adult diffuse small cleaved cell lymphoma, stage iv adult hodgkin lymphoma, stage iv adult immunoblastic large cell lymphoma, stage iv adult lymphoblastic lymphoma, stage iv adult t-cell leukemia/lymphoma, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma, stage iv marginal zone lymphoma, stage iv mycosis fungoides/sezary syndrome, stage iv small lymphocytic lymphoma, unspecified adult solid tumor, protocol specific, waldenstr\u00f6m macroglobulinemia", "to": "anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, intraocular lymphoma, nodal marginal zone b-cell lymphoma, primary central nervous system hodgkin lymphoma, primary central nervous system non-hodgkin lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, small intestine lymphoma, splenic marginal zone lymphoma, stage iii adult burkitt lymphoma, stage iii adult diffuse large cell lymphoma, stage iii adult diffuse mixed cell lymphoma, stage iii adult diffuse small cleaved cell lymphoma, stage iii adult hodgkin lymphoma, stage iii adult immunoblastic large cell lymphoma, stage iii adult lymphoblastic lymphoma, stage iii adult t-cell leukemia/lymphoma, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iii grade 1 follicular lymphoma, stage iii grade 2 follicular lymphoma, stage iii grade 3 follicular lymphoma, stage iii mantle cell lymphoma, stage iii marginal zone lymphoma, stage iii mycosis fungoides/sezary syndrome, stage iii small lymphocytic lymphoma, stage iv adult burkitt lymphoma, stage iv adult diffuse large cell lymphoma, stage iv adult diffuse mixed cell lymphoma, stage iv adult diffuse small cleaved cell lymphoma, stage iv adult hodgkin lymphoma, stage iv adult immunoblastic large cell lymphoma, stage iv adult lymphoblastic lymphoma, stage iv adult t-cell leukemia/lymphoma, stage iv cutaneous t-cell non-hodgkin lymphoma, stage iv grade 1 follicular lymphoma, stage iv grade 2 follicular lymphoma, stage iv grade 3 follicular lymphoma, stage iv mantle cell lymphoma, stage iv marginal zone lymphoma, stage iv mycosis fungoides/sezary syndrome, stage iv small lymphocytic lymphoma, unspecified adult solid tumor, protocol specific, waldenstr\u00f6m macroglobulinemia", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, placebo", "to": "completedtak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, placebo_acute coronary syndrome", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedmedi8897, placebo_respiratory syncytial virus infections", "to": "respiratory syncytial virus infections", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "ranibizumab 0.5mg, thr-317 8mg, sham injection", "to": "diabetes mellitus, diabetic retinopathy, macular edema", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "pn400 (vimovo), pn 400 (vimovo)", "to": "completedpn400 (vimovo), pn 400 (vimovo)_gastric ulcer", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "nivolumab, bevacizumab", "to": "hepatocellular carcinoma", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "systemic chemotherapy (folfox)", "to": "colorectal cancer, colorectal carcinoma, liver metastases", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "omarigliptin, sitagliptin, placebo to omarigliptin, placebo to sitagliptin, open-label metformin, open-label glimepiride", "to": "completedomarigliptin, sitagliptin, placebo to omarigliptin, placebo to sitagliptin, open-label metformin, open-label glimepiride_type 2 diabetes", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "oral glycopyrrolate liquid", "to": "completedoral glycopyrrolate liquid_cerebral palsy, neurological conditions, mental retardation, sialorrhea", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C=NC2=C1C=C(C(O)=NOCCO)C(NC1=C(Cl)C=C(Br)C=C1)=C2F, [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1", "to": "docetaxel and azd6244, docetaxel and placebo", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completednintedanib, placebo, sildenafil_idiopathic pulmonary fibrosis", "to": "idiopathic pulmonary fibrosis", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "azathioprine, infliximab, prednisolon", "to": "terminatedazathioprine, infliximab, prednisolon_crohn\u0027s disease", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completeddarunavir, ritonavir and rilpivirine_hiv", "to": "hiv", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedetc-1002, placebo_hypercholesterolemia", "to": "hypercholesterolemia", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "rvt-101 35 mg, placebo", "to": "alzheimer\u0027s disease, dementia with lewy bodies, parkinson\u0027s disease dementia", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "tocilizumab, adalimumab, placebo to tocilizumab, placebo to adalimumab", "to": "completedtocilizumab, adalimumab, placebo to tocilizumab, placebo to adalimumab_rheumatoid arthritis", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "fluticasone 250/formoterol 10, fluticasone 250/salmeterol 25, fluticasone 125/formoterol 5", "to": "completedfluticasone 250/formoterol 10, fluticasone 250/salmeterol 25, fluticasone 125/formoterol 5_asthma", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "iron (ferrous sulfate)", "to": "withdrawniron (ferrous sulfate)_anemia", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NC[C@H]1CC[C@@H](CC1)C(O)=O, NCCCCCC(O)=O", "to": "oral tranexamic acid, oral aminocaproic acid", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedtrastuzumab (9 weeks) + docetaxel, trastuzumab (9 weeks) + docetaxel + cef + trastuzumab (up to 51 weeks)_breast neoplasms", "to": "breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedcapecitabine, sunitinib malate_breast neoplasms", "to": "breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "withdrawngabapentin, placebo_fabry disease, neuropathic pain", "to": "fabry disease, neuropathic pain", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedbi 409306, placebo, bi 409306, placebo, placebo, bi 409306, bi 409306, placebo, placebo_alzheimer disease", "to": "alzheimer disease", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "firategrast 150 mg, firategrast 300 mg", "to": "completedfirategrast 150 mg, firategrast 300 mg_multiple sclerosis", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedplacebo, buprenorphine transdermal system_low back pain", "to": "low back pain", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedlatanoprost 0.005% eye drops and brimonidine 0.1% eye drops, latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops_glaucoma, ocular hypertension", "to": "glaucoma, ocular hypertension", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedpf-04457845, placebo_post-traumatic stress disorder", "to": "post-traumatic stress disorder", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1", "to": "abacavir sulfate", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N, N[C@@H](CCCNC(N)=N)C(O)=O", "to": "dapagliflozin, dapagliflozin, metformin, dapagliflozin placebo, pioglitazone", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "tocilizumab [roactemra/actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate", "to": "terminatedtocilizumab [roactemra/actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate_rheumatoid arthritis", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completeddocetaxel_breast neoplasms", "to": "breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12C[C@@]([H])(C=C1)[C@@H]([C@@H]2NC1=C(F)C=NC(NC2=CC=C(N3CCN(C)CC3)C(C)=C2)=N1)C(N)=O, [H][C@@]12C[C@@]([H])(C=C1)[C@@H]([C@@H]2NC1=C(F)C=NC(NC2=CC=C(N3CCN(C)CC3)C(C)=C2)=N1)C(N)=O", "to": "as703569/gemcitabine, as703569/gemcitabine", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completeddocetaxel, doxorubicin, carboplatin, cyclophosphamide, trastuzumab, bevacizumab_breast neoplasms", "to": "breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedlde225_advanced solid tumor cancers, medulloblastoma, basal cell carcinoma", "to": "advanced solid tumor cancers, medulloblastoma, basal cell carcinoma", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedpreladenant, placebo, anticholinergic agents or propanolol, haloperidol_akathisia, drug-induced, antipsychotic agents, movement disorders", "to": "akathisia, drug-induced, antipsychotic agents, movement disorders", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "bi 201335", "to": "completedbi 201335_hepatitis c, liver cirrhosis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1", "to": "[s,s]-reboxetine + pregabalin, pregabalin", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "pramipexole 0.125 mg tablet, pramipexole 0.5 mg tablet", "to": "idiopathic restless legs syndrome", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedabiraterone acetate, glucocorticoid_prostate neoplasms", "to": "prostate neoplasms", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "marcaine", "to": "femoral fractures, pain, postoperative", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "topiramate", "to": "completedtopiramate_obesity", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "topiramate", "to": "epilepsy, seizures, epilepsies, partial, epilepsy, generalized, seizures, tonic-clonic", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "ClCCN(CCCl)P1(=O)NCCCO1, NC(=O)NO", "to": "cytarabine, hydroxyurea", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completeddexamethasone, trabectedin_breast neoplasms", "to": "breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "niacin extended-release and simvastatin tablets", "to": "hypercholesterolemia", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "niacin extended-release and simvastatin tablets", "to": "completedniacin extended-release and simvastatin tablets_hypercholesterolemia", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedclarithromycin, placebo_cachexia, lung cancer", "to": "cachexia, lung cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "mometasone furoate nasal spray (mfns), placebo nasal spray", "to": "completedmometasone furoate nasal spray (mfns), placebo nasal spray_allergic rhinitis, asthma", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "poly-iclc, temozolomide", "to": "glioblastoma multiforme, astrocytoma, grade iv", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1, CC1=CC(O)=CC(C)=C1Cl", "to": "5-mg desloratadine, placebo tablet", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "cyclophosphamide, celecoxib", "to": "active, not recruitingcyclophosphamide, celecoxib_fallopian tube cancer, peritoneal cavity cancer, recurrent ovarian epithelial cancer", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "cyclophosphamide, celecoxib", "to": "sarcoma, melanoma, epithelial malignancies, pleural malignancies", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "arq-151 cream 0.3%, arq-151 cream 0.15%, arq-151 vehicle cream", "to": "plaque psoriasis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H]\\C(=C(\\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC, [H]\\C(=C(\\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "istradefylline, istradefylline, placebo", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "azd2820, placebo", "to": "terminatedazd2820, placebo_obesity", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "baclofen/amitriptyline/ketamine gel", "to": "chronic myeloproliferative disorders, leukemia, lymphoma, lymphoproliferative disorder, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, neurotoxicity, pain, unspecified adult solid tumor, protocol specific", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C", "to": "tolterodine er, placebo, fesoterodine", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "maraviroc", "to": "completedmaraviroc_acquired immunodeficiency syndrome, hiv infection", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "maraviroc", "to": "hiv", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "maraviroc", "to": "human immunodeficiency virus (hiv), hiv associated neurocognitive disorders (hand)", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "tg-873870 (nemonoxacin)", "to": "completedtg-873870 (nemonoxacin)_diabetic foot infections", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "haemocomplettan p, placebo", "to": "hemorrhage, thoracic aneurysm", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "haemocomplettan p, placebo", "to": "terminatedhaemocomplettan p, placebo_hemorrhage, thoracic aneurysm", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedpemetrexed_sarcoma", "to": "sarcoma", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedadalimumab, placebo_ulcerative colitis, pouchitis", "to": "ulcerative colitis, pouchitis", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "recombinant human growth hormone, recombinant human igf-1", "to": "growth hormone deficiency", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(NC2=CC(F)=CC=C12)C1=C(C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)C2=CC=C(F)C=C2N1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "birinapant, azacitidine, placebo", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "perifosine", "to": "endometrial cancer, sarcoma", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "perifosine", "to": "adenocarcinoma of the prostate, recurrent prostate cancer, stage iib prostate cancer, stage iii prostate cancer, stage iv prostate cancer", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "perifosine", "to": "kidney cancer", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completeddcvax-001, poly-iclc, placebo_hiv-1 infection, hiv infection, healthy volunteers", "to": "hiv-1 infection, hiv infection, healthy volunteers", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CCCC(=O)OCOC(=O)C(C)(C)C", "to": "pivanex", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedepirubicin, cyclophosphamide and docetaxel, docetaxel, cyclophosphamide_breast neoplasms", "to": "breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "erlotinib, bevacizumab, gemcitabine, cisplatin", "to": "completederlotinib, bevacizumab, gemcitabine, cisplatin_carcinoma, non-small-cell lung", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "raltegravir, tenofovir, emtricitabine", "to": "hiv", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "epacadostat, pembrolizumab", "to": "sarcoma", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "epacadostat, pembrolizumab", "to": "active, not recruitingepacadostat, pembrolizumab_sarcoma", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "desloratadine 5 mg, placebo", "to": "completeddesloratadine 5 mg, placebo_perennial allergic rhinitis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, [H][C@@](O)(CS(=O)(=O)C1=CC2=CC=C(Cl)C=C2C=C1)C(=O)N1CCC(CC1)N1CCCN=C1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, tak-442, placebo", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedibrutinib_lymphoma, mantle-cell", "to": "lymphoma, mantle-cell", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "decadron\u00ae, benadryl\u00ae, ativan\u00ae, ondansetron hydrochloride", "to": "terminateddecadron\u00ae, benadryl\u00ae, ativan\u00ae, ondansetron hydrochloride_nausea, vomiting, unspecified childhood solid tumor, protocol specific", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NS(=O)(=O)C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "to": "e7070, idarubicin, cytarabine, dexamethasone", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedixekizumab, guselkumab, placebo_plaque psoriasis", "to": "plaque psoriasis", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "triptorelin (decapeptyl\u00ae)", "to": "completedtriptorelin (decapeptyl\u00ae)_prostate cancer", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)CCC1=C, NC[C@H]1CC[C@@H](CC1)C(O)=O", "to": "vitamin d (cholecalciferol) and pba (sodium phenylbutyrate), placebo tablets", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "to": "cetuximab, cisplatin, docetaxel, cisplatin", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC", "to": "bevacizumab, rad001", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "nanoparticulate paclitaxel", "to": "completednanoparticulate paclitaxel_peritoneal neoplasms", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedpregabalin, placebo_generalized anxiety disorder", "to": "generalized anxiety disorder", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedintravenous ferric carboxymaltose_iron deficiency, anaemia", "to": "iron deficiency, anaemia", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "to": "oncaspar, doxil, decadron", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "to": "ramosetron, aprepitant, dexamethasone", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "to": "ozurdex implant", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "to": "vlx1570 and dexamethasone", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C", "to": "bcd chemotherapy (bendamustine, carboplatin, dexamethasone)", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "decitabine", "to": "completeddecitabine_acute myelogenous leukemia", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "decitabine", "to": "unspecified adult solid tumor, protocol specific", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "decitabine", "to": "terminateddecitabine_unspecified adult solid tumor, protocol specific", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "decitabine", "to": "unknown statusdecitabine_untreated adult acute myeloid leukemia, effect of drugs, drug safety", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "atezolizumab, topotecan, carboplatin, etoposide", "to": "completedatezolizumab, topotecan, carboplatin, etoposide_small cell lung cancer, small cell lung cancer limited stage, small cell lung cancer extensive stage", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "placebo, xolair", "to": "completedplacebo, xolair_asthma", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, N[C@@H](CCCNC(N)=N)C(O)=O", "to": "paclitaxel for injection\uff08albumin bound\uff09, carboplatin", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "gemcitabine, capecitabine and sorafenib (6 cycles)", "to": "completedgemcitabine, capecitabine and sorafenib (6 cycles)_carcinoma, renal cell", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1", "to": "linagliptin, linagliptin", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "etelcalcetide, placebo", "to": "hyperparathyroidism, secondary", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completeddasatinib_chronic myelogenous leukemia, philadelphia chromosome positive acute lymphoblastic leukemia", "to": "chronic myelogenous leukemia, philadelphia chromosome positive acute lymphoblastic leukemia", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedsta363, placebo_low back pain", "to": "low back pain", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC1=CNC(=O)NC1=O", "to": "gm1, placebo, mfolfox6 or xelox", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "erismodegib, placebo", "to": "breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedezetimibe + simvastatin, simvastatin, placebo_hypercholesterolemia, atherosclerosis", "to": "hypercholesterolemia, atherosclerosis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NCCCNCCSP(O)(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC", "to": "amifostine trihydrate, fluorouracil, cisplatin", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "gtx-024, placebo", "to": "muscle wasting, non-small cell lung cancer", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O", "to": "fondaparinux", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "oral casopitant (gw679769), iv casopitant (gw679769), iv ondansetron hydrochloride, oral dexamethasone", "to": "completedoral casopitant (gw679769), iv casopitant (gw679769), iv ondansetron hydrochloride, oral dexamethasone_nausea and vomiting, chemotherapy-induced", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O", "to": "irinotecan plus capecitabine", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "e7070, idarubicin, cytarabine, dexamethasone", "to": "completede7070, idarubicin, cytarabine, dexamethasone_leukemia", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedly2127399, placebo every 2 weeks, placebo every 4 weeks, standard of care_systemic lupus erythematosus, connective tissue disease, autoimmune disease", "to": "systemic lupus erythematosus, connective tissue disease, autoimmune disease", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "gm-csf", "to": "terminatedgm-csf_myeloma", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "topotecan and taxotere", "to": "completedtopotecan and taxotere_ovarian neoplasms, uterine neoplasms", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "mt-1303-low, mt-1303-middle, mt-1303-high, placebo", "to": "completedmt-1303-low, mt-1303-middle, mt-1303-high, placebo_relapsing-remitting multiple sclerosis", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedtamsulosin hcl controlled release capsules, matching placebo capsule_prostatic hyperplasia", "to": "prostatic hyperplasia", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC1=CC(O)=CC(C)=C1Cl, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1", "to": "ezetimibe (+) simvastatin, simvastatin, atorvastatin", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "everolimus, sunitinib", "to": "completedeverolimus, sunitinib_advanced non-clear cell renal cell carcinoma", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "everolimus, sunitinib", "to": "kidney cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "ombitasvir/paritaprevir/ritonavir, dasabuvir", "to": "completedombitasvir/paritaprevir/ritonavir, dasabuvir_chronic hepatitis c infection, compensated cirrhosis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "sm-13496 40mg, sm-13496 80mg, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "lurasidone 40 mg, lurasidone 80 mg, placebo 40 or 80 mg", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "gamma delta tocotrienols - low dose, gamma delta tocotrienols - high dose, sugar pill", "to": "hypercholesterolemia", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "to": "pemetrexed, gemcitabine, carboplatin, pemetrexed", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "gsk2118436", "to": "completedgsk2118436_cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "filgrastim, pegfilgrastim, etoposide, cisplatin", "to": "completedfilgrastim, pegfilgrastim, etoposide, cisplatin_lung cancer", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedgabapentin/b-complex, pregabalin_diabetic peripheral neuropathic pain", "to": "diabetic peripheral neuropathic pain", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "lapatinib oral tablets, radiotherapy, cisplatin chemotherapy", "to": "neoplasms, head and neck", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "volinanserin, placebo", "to": "sleep initiation and maintenance disorders", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, OC(=O)C1=CN=CC=C1, NC(N)=NC(=O)C1=C(N)N=C(N)C(Cl)=N1, CC(=O)OC1=CC=CC=C1C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "ezetimibe, niaspan, statin therapy, aspirin, clopidogrel, placebo niaspan, placebo ezetimibe", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completeddecitabine, fludarabine phosphate, busulfan, cyclophosphamide, tacrolimus, mycophenolate mofetil_acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia", "to": "acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "exemestane, everolimus (rad001)", "to": "completedexemestane, everolimus (rad001)_metastatic breast cancer", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedcisplatin, paclitaxel_ovarian cancer, peritoneal cancer, fallopian tube cancer, bowel obstruction", "to": "ovarian cancer, peritoneal cancer, fallopian tube cancer, bowel obstruction", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "risperidone", "to": "depressive disorder, depressive disorder, major, depression", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "nnc109-0012, placebo", "to": "completednnc109-0012, placebo_inflammation, rheumatoid arthritis", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedeviplera_hiv", "to": "hiv", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "pembrolizumab, azacitidine", "to": "completedpembrolizumab, azacitidine_metastatic colorectal cancer", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "bosentan", "to": "idiopathic pulmonary fibrosis", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "bosentan", "to": "completedbosentan_idiopathic pulmonary fibrosis", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "b/f/taf, f/taf, dtg, dtg placebo, f/taf placebo, b/f/taf placebo", "to": "active, not recruitingb/f/taf, f/taf, dtg, dtg placebo, f/taf placebo, b/f/taf placebo_hiv-1-infection", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "azathioprine (aza) or 6-mercaptopurine (6-mp)", "to": "completedazathioprine (aza) or 6-mercaptopurine (6-mp)_inflammatory bowel diseases, crohn disease, ulcerative colitis", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedacetyl-l-carnitine, placebo_carpal tunnel syndrome, compression neuropathy", "to": "carpal tunnel syndrome, compression neuropathy", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminateddecitabine_unspecified adult solid tumor, protocol specific", "to": "unspecified adult solid tumor, protocol specific", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "candesartan, placebo", "to": "terminatedcandesartan, placebo_glucose intolerance, obesity", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "unknown statusprednisone, vincristine, daunorubicin , cyclophosphamide , l.-asparaginase, cytosine-arabinoside, methotrexate, etoposide_lymphoblastic lymphoma", "to": "lymphoblastic lymphoma", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "r932333, placebo", "to": "completedr932333, placebo_lupus erythematosus, discoid, lupus erythematosus, systemic", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completednilotinib, imatinib_myelogenous leukemia, chronic", "to": "myelogenous leukemia, chronic", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "opk-88003, placebo", "to": "completedopk-88003, placebo_type 2 diabetes mellitus", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "dlbs1033, placebo", "to": "completeddlbs1033, placebo_healthy", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "dlbs1033, placebo", "to": "terminateddlbs1033, placebo_diabetes, peripheral arterial disease", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1", "to": "ombitasvir/paritaprevir/ritonavir, dasabuvir", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedgs-9450, gs-9450 placebo_hcv infection", "to": "hcv infection", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "pregabalin", "to": "post-herpetic neuralgia", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "pregabalin", "to": "completedpregabalin_epilepsy", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "pregabalin", "to": "herpes zoster, postherpetic neuralgia", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedfec-docgemzar adjuvant chemotherapy, fec-doc adjuvant chemotherapy, zoledronic acid i.v. 2 years, zoledronic acid i.v. 5 years_breast neoplasms", "to": "breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "dapagliflozin, placebo matching with dapagliflozin, saxagliptin, metformin immediate release (ir)", "to": "completeddapagliflozin, placebo matching with dapagliflozin, saxagliptin, metformin immediate release (ir)_type 2 diabetes", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)C1=C(C)N=CN=C1C)C1=CC=C(C=C1)C(F)(F)F, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "to": "vicriviroc, emtricitabine and tenofovir disoproxil fumarate", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "bhr-200 (0.36% transdermal 17\u03b2-estradiol gel), placebo", "to": "cancer of the prostate", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "pregabalin, placebo", "to": "generalized anxiety disorder", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "pregabalin, placebo", "to": "completedpregabalin, placebo_generalized anxiety disorder", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "pregabalin, placebo", "to": "completedpregabalin, placebo_neuropathic pain", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "pregabalin, placebo", "to": "completedpregabalin, placebo_dry eye", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1, CC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1, CC1=CC(O)=CC(C)=C1Cl", "to": "ot-551, ot-551, vehicle placebo", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "mitomycin -c", "to": "laryngeal stenosis, subglottic stenosis, tracheal stenosis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1", "to": "perampanel", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C", "to": "liposomal bupivacaine (lb)", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "bortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone", "to": "terminatedbortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone_non-hodgkin\u0027s lymphoma", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1", "to": "fimasartan , amlodipine, placebo", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "umec/vi, umec/vi matching placebo, tiotropium, tiotropium matching placebo, indacaterol, indacaterol matching placebo, albuterol/salbutamol metered dose inhaler (mdi)", "to": "completedumec/vi, umec/vi matching placebo, tiotropium, tiotropium matching placebo, indacaterol, indacaterol matching placebo, albuterol/salbutamol metered dose inhaler (mdi)_pulmonary disease, chronic obstructive", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "prednisone, cyclophosphamide, doxorubicin, vincristine", "to": "contiguous stage ii adult diffuse large cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone b-cell lymphoma, noncontiguous stage ii adult diffuse large cell lymphoma, splenic marginal zone lymphoma, stage i adult diffuse large cell lymphoma, testicular lymphoma, waldenstr\u00f6m macroglobulinemia", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "pro 140 (humanized monoclonal antibody to ccr5), placebo comparator", "to": "completedpro 140 (humanized monoclonal antibody to ccr5), placebo comparator_hiv -1 infection, hiv infections", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "aripiprazole, placebo, lithium, valproate", "to": "bipolar disorder mania", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "lenalidomide + plerixafor (+ rituximab)", "to": "leukemia, lymphocytic, chronic, b-cell", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "lcz696 (sacubitril/valsartan)", "to": "completedlcz696 (sacubitril/valsartan)_heart failure", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "escitalopram, pindolol, escitalopram, escitalopram", "to": "unipolar depression", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "ruxolitinib, hydroxyurea (hu), hu-placebo, ruxolitinib-placebo", "to": "polycythemia vera", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "ClCCN(CCCl)P1(=O)NCCCO1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "to": "bendamustin, bortezomib, lenalidomide", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "oregano extract cream, hydrocortisone", "to": "terminatedoregano extract cream, hydrocortisone_atopic dermatitis", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "ibalizumab, optimized background regimen", "to": "hiv", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "pitavastatin", "to": "completedpitavastatin_hypercholesterolemia, dyslipidemias", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "td-4208, tiotropium", "to": "completedtd-4208, tiotropium_chronic obstructive pulmonary disease (copd)", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "cyclosporine a versus mycophenolate mofetil for psoriasis", "to": "unknown statuscyclosporine a versus mycophenolate mofetil for psoriasis_psoriasis", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "placebo, combination product (sumatriptan succinate/naproxen sodium)", "to": "completedplacebo, combination product (sumatriptan succinate/naproxen sodium)_migraine disorders", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedduloxetine hydrochloride_major depressive disorder, idiopathic parkinson disease", "to": "major depressive disorder, idiopathic parkinson disease", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "cisplatin, fluorouracil, leucovorin calcium", "to": "adenocarcinoma of the gastroesophageal junction, gastric cancer", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[Fe++].NCC([O-])=O.NCC([O-])=O.OS(O)(=O)=O", "to": "ferrous bis-glycinate, ferrous glycine sulphate", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "enzalutamide, bicalutamide, leuprolide acetate, goserelin acetate", "to": "adenocarcinoma of the prostate, recurrent prostate cancer, stage iv prostate cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "enzalutamide, bicalutamide, leuprolide acetate, goserelin acetate", "to": "active, not recruitingenzalutamide, bicalutamide, leuprolide acetate, goserelin acetate_adenocarcinoma of the prostate, recurrent prostate cancer, stage iv prostate cancer", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "active, not recruitingepacadostat, pembrolizumab_sarcoma", "to": "sarcoma", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminateddesipramine hcl_small cell lung cancer (sclc), neuroendocrine tumors", "to": "small cell lung cancer (sclc), neuroendocrine tumors", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "insulin lispro, insulin aspart", "to": "completedinsulin lispro, insulin aspart_type 2 diabetes mellitus", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "to": "non pegylated liposomal doxorubicin and docetaxel", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O", "to": "liposomal doxorubicin", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "aprepitant 125 mg, aprepitant 80 mg, aprepitant powder for suspension (pfs), ondansetron, placebo for aprepitant 125 mg, placebo for aprepitant 80 mg, placebo for aprepitant pfs, emetogenic chemotherapy", "to": "chemotherapy induced nausea and vomiting", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "axitinib (ag-013736)", "to": "hepatocellular carcinoma", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1", "to": "gemcitabine, cisplatin, gefitinib", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedpeg-p-ifn-alpha-2b (aop2014), hydroxyurea_polycythemia vera", "to": "polycythemia vera", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "leukine, dexamethasone", "to": "withdrawnleukine, dexamethasone_renal cell carcinoma", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "COC(=O)C1=CC=C2C(NC(=O)\\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1", "to": "microgynon, nintedanib", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "cisplatin, ifosfamide, paclitaxel", "to": "completedcisplatin, ifosfamide, paclitaxel_bladder cancer, urethral cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "sbi-087, sbi-087, sbi-087, sbi-087, placebo", "to": "completedsbi-087, sbi-087, sbi-087, sbi-087, placebo_active rheumatoid arthritis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C", "to": "verteporfin photodynamic therapy (low fluence) and bevacizumab, verteporfin photodynamic therapy (very low fluence) and bevacizumab, verteporfin photodynamic therapy (sham) and bevacizumab", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedcelecoxib, doxorubicin hydrochloride_metastatic cancer, prostate cancer", "to": "metastatic cancer, prostate cancer", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12", "to": "irinotecan hydrochloride", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "ribavirin, ribavirin + pegylated interferon-alpha", "to": "terminatedribavirin, ribavirin + pegylated interferon-alpha_hepatitis c", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "ecf, ic, folfox", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedniacin extended-release and simvastatin tablets_hypercholesterolemia", "to": "hypercholesterolemia", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedsimvastatin_alzheimer disease", "to": "alzheimer disease", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "O", "to": "enbrel (etanercept)", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "O", "to": "recombinant human growth hormone, recombinant human igf-1", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "O", "to": "t0001, t0001, t0001, t0001, enbrel", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "O", "to": "tlc599 ld group, normal saline, tlc599 hd group", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1", "to": "budesonide/formoterol, fluticasone/salmeterol, albuterol", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminateditv depocyt + temozolomide_glioblastoma multiforme, glioma, astrocytoma, brain tumor", "to": "glioblastoma multiforme, glioma, astrocytoma, brain tumor", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedsimvastatin (+) ezetimibe, comparator: atorvastatin_hypercholesterolemia", "to": "hypercholesterolemia", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C=NC=C1[C@@](N)(C1=CC=C(Cl)C=C1)C1=CC2=C(C=C1)N(C)C(=O)C=C2C1=CC(Cl)=CC=C1", "to": "tipifarnib", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO, CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F", "to": "mek-162, nilotinib", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "gsk573719 125mcg, gsk573719 250mcg, gsk573719 500mcg, placebo", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "mgcd0103", "to": "completedmgcd0103_myelodysplastic syndrome, acute myelogenous leukemia", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1", "to": "mgcd0103", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "calcium sensing receptor agonist", "to": "hyperparathyroidism, secondary", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedromidepsin, poly iclc_cutaneous t-cell lymphoma", "to": "cutaneous t-cell lymphoma", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "to": "enoxaparin sodium", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "to": "paclitaxel, cisplatin, pegfilgrastim", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "to": "docetaxel, cisplatin, fluorouracil, bevacizumab, leucovorin", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "to": "chemotherapy following concurrent chemoradiotherapy", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "to": "gemcitabine and cisplatin (induction chemotherapy)", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "to": "bi 2536, pemetrexed", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]", "to": "enoxaparin sodium 40 mg/0.2 ml subcutaneous injectable, chemotherapeutic combinations", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "N[C@@H](CO)C(O)=O, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, CCO", "to": "dolutegravir, lamivudine, continue current antiretroviral regimen", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "valsartan + hctz, valsartan, hctz", "to": "completedvalsartan + hctz, valsartan, hctz_hypertension", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1, CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1", "to": "axs-05, bupropion sr", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedapo866_cutaneous t-cell lymphoma", "to": "cutaneous t-cell lymphoma", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "abiraterone acetate", "to": "completedabiraterone acetate_prostate cancer", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "efavirenz, tenofovir /emtricitabine, tenofovir/lamivudine, lamivudine/zidovudine", "to": "hiv", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "rvt-101 35 mg, placebo", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "re-021 (sparsentan), irbesartan", "to": "focal segmental glomerulosclerosis", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "carfilzomib, melphalan, prednisone", "to": "completedcarfilzomib, melphalan, prednisone_myeloma", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "active, not recruitingabemaciclib, fulvestrant, placebo_breast neoplasms", "to": "breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "COC1=CC(=CC=C1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1C1=CC=CC(Cl)=C1F)C1=CC=C(Cl)C=C1F)C(O)=O", "to": "rg7388, pegasys", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "tremelimumab, durvalumab", "to": "active, not recruitingtremelimumab, durvalumab_colorectal cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "irbesartan/hydrochlorothiazide, irbesartan", "to": "completedirbesartan/hydrochlorothiazide, irbesartan_hypertension", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedleuprolide acetate_alzheimer disease", "to": "alzheimer disease", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1, N[C@@H](CCCNC(N)=N)C(O)=O", "to": "prasugrel, clopidogrel", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedlebrikizumab, pirfenidone, placebo_idiopathic pulmonary fibrosis", "to": "idiopathic pulmonary fibrosis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "to": "efavirenz (efv), emtricitabine (ftc), tenofovir df (tdf)", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "to": "atripla (atr) consisting of efv 600 mg/ftc 200 mg/tdf 300 mg", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "to": "entecavir + tenofovir (mdr group)", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C", "to": "tenofovir/emtricitabine", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completeddocetaxel, vandetanib_non-small cell lung cancer, lung cancer", "to": "non-small cell lung cancer, lung cancer", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "to": "pazopanib and paclitaxel", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "to": "lapatinib in tandem with capecitabine", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "O[C@H](\\C=C\\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C)C1CC1, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C, O[C@H](\\C=C\\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C)C1CC1", "to": "calcipotriol plus hydrocortisone ointment vehicle, tacalcitol ointment, calcipotriol plus hydrocortisone ointment", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedcapecitabine, celecoxib_unspecified adult solid tumor, protocol specific", "to": "unspecified adult solid tumor, protocol specific", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1", "to": "lapatinib, trastuzumab, aromatase inhibitor, lapatinib", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedmipomersen sodium, placebo_heterozygous familial hypercholesterolemia, coronary artery disease", "to": "heterozygous familial hypercholesterolemia, coronary artery disease", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedminoxidil, hydralazine_treatment induced hypertension", "to": "treatment induced hypertension", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1, CC(C)CC1=CC=C(C=C1)C(C)C(O)=O", "to": "lacosamide, levetiracetam", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "pr-104, docetaxel, gemcitabine hydrochloride", "to": "unspecified adult solid tumor, protocol specific", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedhaemocomplettan p, placebo_hemorrhage, thoracic aneurysm", "to": "hemorrhage, thoracic aneurysm", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedtivantinib, placebo, erlotinib_non squamous, non-small-cell lung cancer", "to": "non squamous, non-small-cell lung cancer", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "rilpivirine", "to": "hiv", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "withdrawnmorphine sulfate, placebo_chronic obstructive pulmonary disease, dyspnea", "to": "chronic obstructive pulmonary disease, dyspnea", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "fluocinolone acetonide, fluocinolone acetonide", "to": "completedfluocinolone acetonide, fluocinolone acetonide_diabetic macular edema", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "capecitabine", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "rhumab-vegf, docetaxel", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "oxaliplatin + docetaxel", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "androgen-deprivation therapy, docetaxel", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "s-1", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "trastuzumab, pf03512676", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "trastuzumab qw, trastuzumab q3w", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "vb-111, bevacizumab", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "abt-888 and mfolfox-6", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "luteinizing hormone-releasing hormone (lhrh), docetaxel", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "capecitabine plus oxaliplatin", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "mk-3475, docetaxel", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "interferon-gamma and nivolumab", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1", "to": "tremelimumab, durvalumab", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedimo-8400 regimen 1, imo-8400 regimen 2, imo-8400 regimen 3, saline placebo, imo-8400 regimen 4_plaque psoriasis", "to": "plaque psoriasis", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedpegfilgrastim_breast cancer, chemotherapy, febrile neutropenia", "to": "breast cancer, chemotherapy, febrile neutropenia", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "to": "lenalidomide, bortezomib", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "to": "lenalidomide + plerixafor (+ rituximab)", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "to": "bendamustine, rituximab, lenalidomide", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "to": "lenalidomide, epoetin beta", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O", "to": "pembrolizumab, azacitidine", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completeddocetaxel, 5-fluorouracil, doxorubicin, cyclophosphamide_breast neoplasms", "to": "breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "ecc, folfiri", "to": "completedecc, folfiri_stomach cancer, neoplasm metastasis", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedly2127399, placebo_systemic lupus erythematosus, connective tissue disease, autoimmune disease", "to": "systemic lupus erythematosus, connective tissue disease, autoimmune disease", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1CCC[C@H]1C1=CN=CC=C1, [H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "nicotine nasal spray, varenicline, placebo nasal spray, placebo varenicline", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedhki-272, paclitaxel_advanced breast cancer, advanced malignant solid tumors, breast neoplasms", "to": "advanced breast cancer, advanced malignant solid tumors, breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=CSC(N)=N1)C(O)=O", "to": "cisplatin, docetaxel, fluorouracil, cetuximab", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "xyrem, xyrem placebo, modafinil at established dose, modafinil (placebo)", "to": "narcolepsy", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "tesetaxel", "to": "unknown statustesetaxel_adenocarcinoma of the stomach, adenocarcinoma of esophagogastric junction", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedpresatovir, presatovir placebo_respiratory syncytial virus infection", "to": "respiratory syncytial virus infection", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedetanercept, chs-0214_plaque psoriasis", "to": "plaque psoriasis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3", "to": "galantamine hydrobromide", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "gemcitabine hydrochloride, imatinib mesylate", "to": "kidney cancer", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedezetimibe (+) simvastatin_hypercholesterolemia", "to": "hypercholesterolemia", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "risperidone ism 75 mg, risperidone ism 100 mg, placebo of risperidone ism", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "ipilimumab", "to": "completedipilimumab_melanoma, brain metastases", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "ipilimumab", "to": "active, not recruitingipilimumab_malignant melanoma", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1N=NC2=C(N=CN2C1=O)C(N)=O", "to": "bevacizumab and temozolomide", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "carboplatin, nab-paclitaxel, mk-3475 (phase i), mk-3475 (phase ii)", "to": "active, not recruitingcarboplatin, nab-paclitaxel, mk-3475 (phase i), mk-3475 (phase ii)_non-small cell lung cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "neoadjuvant chemotherapy with gemcitabine/oxaliplatin, adjuvant chemotherapy with gemcitabine", "to": "terminatedneoadjuvant chemotherapy with gemcitabine/oxaliplatin, adjuvant chemotherapy with gemcitabine_pancreatic cancer", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3", "to": "esterified estrogens 1.25mg and methyltestosterone 2.5mg, esterified estrogens 1.25 mg", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "gsk2838232, placebo, ritonavir", "to": "terminatedgsk2838232, placebo, ritonavir_infection, human immunodeficiency virus", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "sunitinib, paclitaxel, bevacizumab, paclitaxel", "to": "breast neoplasms", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "aliskiren, amlodipine, placebo aliskiren, placebo amlodipine", "to": "high blood pressure, metabolic syndrome, insulin resistance, endothelial dysfunction", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CCNC(=O)C1=NOC(=C1C1=CC=C(CN2CCOCC2)C=C1)C1=CC(=C(O)C=C1O)C(C)(C)C", "to": "erlotinib hydrochloride, hsp90 inhibitor auy922", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "bevacizumab, irinotecan, oxaliplatin, 5-fluorouracil/leucovorin", "to": "completedbevacizumab, irinotecan, oxaliplatin, 5-fluorouracil/leucovorin_colorectal cancer metastatic", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1", "to": "angiotensin receptor blockers, \u03b2-blockers, thiazide diuretics", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "pitolisant, placebo", "to": "narcolepsy with cataplexy, excessive daytime sleepiness", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "oral tranexamic acid, oral aminocaproic acid", "to": "knee osteoarthritis, blood clot, transfusion related complication, blood loss", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedglargine insulin_diabetes", "to": "diabetes", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "withdrawndoxorubicin, cisplatin_hepatocellular carcinoma", "to": "hepatocellular carcinoma", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedbicalutamide, flutamide, goserelin acetate, ipilimumab, leuprolide acetate_prostate adenocarcinoma, prostate carcinoma, recurrent prostate carcinoma, stage iii prostate cancer, stage iv prostate cancer", "to": "prostate adenocarcinoma, prostate carcinoma, recurrent prostate carcinoma, stage iii prostate cancer, stage iv prostate cancer", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N", "to": "glimepiride/metformin fixed combination, metformin hcl", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N", "to": "dapagliflozin, placebo-matching dapagliflozin", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "adjunctive asenapine", "to": "posttraumatic stress disorder", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedcinacalcet_chronic kidney disease, end stage renal disease, coronary artery calcification, vascular calcification, calcification, cardiovascular disease, chronic renal failure, hyperparathyroidism, kidney disease, nephrology, secondary hyperparathyroidism", "to": "chronic kidney disease, end stage renal disease, coronary artery calcification, vascular calcification, calcification, cardiovascular disease, chronic renal failure, hyperparathyroidism, kidney disease, nephrology, secondary hyperparathyroidism", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "truvada qd, maraviroc 300 qd", "to": "hiv", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CC1=C(C)C2=C(C=C1)C(=O)C1=CC=CC(CC(O)=O)=C1O2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC", "to": "asa404, placebo, carboplatin, paclitaxel", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "terminatedil2, zoledronic acid_kidney cancer", "to": "kidney cancer", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "docetaxel, prednisone", "to": "adenocarcinoma of the prostate, hormone-resistant prostate cancer, recurrent prostate cancer, stage iv prostate cancer", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "docetaxel, prednisone", "to": "withdrawndocetaxel, prednisone_prostate cancer, adenocarcinoma of the prostate, stage i prostate cancer, stage ii prostate cancer", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedganaxolone, placebo_depression, depressive disorder, depression, postpartum, behavioral symptoms, mood disorders, mental disorders, puerperal disorders, pregnancy complications, postpartum, ppd", "to": "depression, depressive disorder, depression, postpartum, behavioral symptoms, mood disorders, mental disorders, puerperal disorders, pregnancy complications, postpartum, ppd", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F", "to": "netupitant and palonosetron, aprepitant, palonosetron, dexamethasone", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "terlipressin acetate continuous infusion", "to": "completedterlipressin acetate continuous infusion_cirrhosis, ascites hepatic", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "irinotecan plus capecitabine", "to": "completedirinotecan plus capecitabine_carcinoma, hepatocellular", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "latanoprostene bunod", "to": "glaucoma, ocular hypertension", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "carbamazepine er (equetro)", "to": "completedcarbamazepine er (equetro)_bipolar disorder, mania", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "avelumab, m9241, avelumab (once weekly), m9241 (mtd), avelumab (expansion cohort)", "to": "terminatedavelumab, m9241, avelumab (once weekly), m9241 (mtd), avelumab (expansion cohort)_advanced solid tumors", "width": 1}, {"arrows": "to", "edge_type": "has_status", "from": "reldesemtiv, placebo", "to": "completedreldesemtiv, placebo_amyotrophic lateral sclerosis", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CCN(CC)CC(=O)NC1=C(C)C=CC=C1C, OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1", "to": "lidocaine hydrochloride, ketorolac tromethamine", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "amg 162, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "cnto148, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "gi262570 0.5 mg, gi262570 1.0 mg, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "alogliptin", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "fermagate, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "omega-3 fatty acid administration, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "placebo, combination product (sumatriptan succinate/naproxen sodium)", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "canakinumab, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "atacicept, atacicept, atacicept, placebo matched to atacicept", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "pancrecarb\u00ae (pancrelipase), placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "palifermin before only, placebo, palifermin before and after", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "volinanserin, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "somatropin, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "mrx-801, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "tocilizumab, placebo, permitted dmards", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "0.135mg map0010, 0.25mg map0010, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "d9421-c, 9mg, d9421-c, 15mg, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "abciximab, abciximab placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "eptifibatide, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "bms-791325, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "1.5 mg or 2.0 mg cjc-1134-pc, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "placebo, xolair", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "azli 75 mg three times daily (tid), placebo three times daily (tid)", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "sun13834, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "sbi-087, sbi-087, sbi-087, sbi-087, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "anti-il-20, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "sarilumab, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "tbr-652, tbr-652 matching placebo, tbr-652 50 mg, tbr-652 75 mg, tbr-652 100 mg, tbr-652 150 mg", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "amg 827 350 mg, amg 827 210 mg, amg 827 700 mg, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "vedolizumab, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "nnc109-0012, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "namilumab (mt203), placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "pth analog, placebo, forsteo (teriparatide)", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "glpg0778, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "spd557, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "75 mg lx4211, 200 mg lx4211, 400 mg lx4211, 200 mg lx4211, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "blisibimod, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "ferrisat, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "azd2820, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "vr506, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "amg 827 140, placebo, amg 827 280, amg 827 210", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "octohydroaminoacridine succinate tablets, octohydroaminoacridine succinate tablets, octohydroaminoacridine succinate tablets, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "placebo, r940343 1mg, r940343 2mg", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "r932333, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "saf312, placebo to saf312", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "hqk-1001, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "placebo, mk-8237 6 du, mk-8237 12 du", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "ttp054, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "placebo, gevokizumab", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "dlbs1033, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "iw-9179, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "mt-1303-low, mt-1303-middle, mt-1303-high, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "cov155, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "syl1001, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "bay85-8501, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "chr-5154, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "pf-02545920, placebo, pf-02545920", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "cnto 6785, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "bococizumab (pf-04950615), placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "dp-b99, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "rikkunshito, rikkunshito placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "opa-15406, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "ain457 300 mg, ustekinumab 45/90 mg, placebo secukinumab", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "t-817ma-h, t-817ma-l, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "sb012, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "s -equol, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "vay736, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "cxl-1427, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "bi 1744 cl, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "chf 5259, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "r-verapamil 75 mg tablet, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "p-321 ophthalmic solution, p-321 ophthalmic solution placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "haemocomplettan p, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "tlpldc, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "placebo, alirocumab", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "qge031, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "cs-3150, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "erythropoietin, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "bms-986036, bms-986036, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "jkb-121: 5 mg twice daily, jkb-121: 10 mg twice daily, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "jnj-42847922, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "vis410, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "ipp-201101, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "guselkumab, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "reldesemtiv, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "mdco-216, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "risankizumab, placebo for risankizumab", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "miv-711, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "secukinumab and placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "gsk3179106, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "pf-04965842, pf-04965842, pf-04965842, pf-04965842, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "gsp 301 ns, gom-ns, gmm-2 ns, gsp 301 placebo ns", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "f-627, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "placebo, abbv-8e12", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "bhv-0223, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "broncho-vaxom, placebo - cap", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "php-201 0.25% ophthalmic solution, php-201 0.5% ophthalmic solution, placebo ophthalmic solution", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "sm04690, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "placebo, jnj-42847922", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "opk-88003, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "al-794, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "ppc-06 400 mg qd, ppc-06 400 mg bid, ppc-06 600 mg, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "anb020, placebo", "width": 1}, {"arrows": "to", "edge_type": "builds", "from": "CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O", "to": "placebo, e2730", "width": 1}, {"arrows": "to", "edge_type": "status_of", "from": "completedabiraterone acetate, placebo, prednisone_prostate neoplasms", "to": "prostate neoplasms", "width": 1}, {"arrows": "to", "edge_type": "heals", "from": "artemether/lumefantrine (al)", "to": "hiv infection, malaria", "width": 1}]);

                  nodeColors = {};
                  allNodes = nodes.get({ returnType: "Object" });
                  for (nodeId in allNodes) {
                    nodeColors[nodeId] = allNodes[nodeId].color;
                  }
                  allEdges = edges.get({ returnType: "Object" });
                  // adding nodes and edges to the graph
                  data = {nodes: nodes, edges: edges};

                  var options = {
    "configure": {
        "enabled": false
    },
    "edges": {
        "color": {
            "inherit": true
        },
        "smooth": {
            "enabled": true,
            "type": "dynamic"
        }
    },
    "interaction": {
        "dragNodes": true,
        "hideEdgesOnDrag": false,
        "hideNodesOnDrag": false
    },
    "physics": {
        "enabled": true,
        "stabilization": {
            "enabled": true,
            "fit": true,
            "iterations": 1000,
            "onlyDynamicEdges": false,
            "updateInterval": 50
        }
    }
};

                  


                  

                  network = new vis.Network(container, data, options);

                  

                  

                  


                  
                      network.on("stabilizationProgress", function(params) {
                          document.getElementById('loadingBar').removeAttribute("style");
                          var maxWidth = 496;
                          var minWidth = 20;
                          var widthFactor = params.iterations/params.total;
                          var width = Math.max(minWidth,maxWidth * widthFactor);
                          document.getElementById('bar').style.width = width + 'px';
                          document.getElementById('text').innerHTML = Math.round(widthFactor*100) + '%';
                      });
                      network.once("stabilizationIterationsDone", function() {
                          document.getElementById('text').innerHTML = '100%';
                          document.getElementById('bar').style.width = '496px';
                          document.getElementById('loadingBar').style.opacity = 0;
                          // really clean the dom element
                          setTimeout(function () {document.getElementById('loadingBar').style.display = 'none';}, 500);
                      });
                  

                  return network;

              }
              drawGraph();
        </script>
    </body>
</html>